<SEC-DOCUMENT>0001140361-24-045693.txt : 20241107
<SEC-HEADER>0001140361-24-045693.hdr.sgml : 20241107
<ACCEPTANCE-DATETIME>20241107170045
ACCESSION NUMBER:		0001140361-24-045693
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20241107
DATE AS OF CHANGE:		20241107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		241436890

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ef20034474_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:adma="http://admabiologics.com/20240930" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_bc34a0819aa14c55b88748319002a33f" contextRef="c20240101to20240930" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_c1f44fcffab749dda721d1e5b746ce94" contextRef="c20240101to20240930" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_a4839fbe616246d3a08857ac06e2e7d7" contextRef="c20240101to20240930">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_08a4081ba0214061a447aff0c26db396" contextRef="c20240101to20240930">Q3</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_9fd1153128b74fd7b74acd19d68737d3" contextRef="c20240101to20240930">0001368514</ix:nonNumeric><ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Fact_aabd598a3cab423c96bb46e0610cf636" contextRef="c20240930_RangeAxis_MinimumMember">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_e1bb617d16104c86ba85a63d93bd3935" contextRef="c20240930_RangeAxis_MinimumMember">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Fact_837d17e5cc4148dab6c5f12dca0a9d3b" contextRef="c20240101to20240930">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Fact_2d5d7cee97d843e6bdafc3e0cea93ecc" contextRef="c20230101to20231231">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" id="Fact_f94c3272e4024032bf1c8ec0500c05eb" contextRef="c20231218to20231218">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDays" id="Fact_8458c263b75e47d7a0c66a15b98f6079" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember">P2D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDays" id="Fact_8c7034ac2c65418ea392b4cb6da4a682" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember">P2D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="Fact_572da660a7754ce69aefce28a22367a6" contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">P3D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="Fact_b6b7fa74500a4b88b6db8be11e46fee6" contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">P3D</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="Fact_04c4d72102c94fdb82f3fcd93478e6fd" contextRef="c20230101to20231231_RangeAxis_MinimumMember">2028-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="Fact_ee510cd27e5248eea4877ba277c443e7" contextRef="c20230101to20231231_RangeAxis_MaximumMember">2043-12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adma-20240930.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240101to20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_TypeOfArrangementAxis_BiotestLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_CounterpartyNameAxis_AresCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240930_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20230930_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_StatementBusinessSegmentsAxis_CorporateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>adma:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>adma:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>adma:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>adma:Officer</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>adma:Term</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>adma:Segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
<div style="line-height: initial;">

  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
      <div>
        <div style="text-align: center; font-weight: bold;"><span style="font-size: 14pt;">UNITED STATES<br/>
          </span></div>

        <div style="text-align: center; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

        <div style="text-align: center; font-size: 12pt; font-weight: bold;">WASHINGTON, D.C. 20549</div>

        <div style="text-align: center; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_8838a0557939413aa4d1579953df83a0" contextRef="c20240101to20240930">10-Q</ix:nonNumeric></div>

        <div>(Mark One)</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentQuarterlyReport" id="Fact_3a3ef01f8157491cad9c9ad8e377e496" contextRef="c20240101to20240930" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top;">
                <div>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
<div>
        &#160;&#160;&#160; For the quarterly period ended <span style="text-decoration: underline;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_a73d7046e4a8407bae525f39de634c57" contextRef="c20240101to20240930" format="ixt:date-monthname-day-year-en">September 30, 2024</ix:nonNumeric></span></div>

        <div style="text-align: center;">OR</div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_4e37d04973334da79c233499264b6521" contextRef="c20240101to20240930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </td>

    <td style="width: auto; vertical-align: top;">
                <div>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
              </td>

  </tr>


</table>
<div><span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;</span>
        For the transition period from ________ to ________
        </div>
<div style="text-align: center;">Commission file number <span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_a582f70da2b545caabf21705bd560b2a" contextRef="c20240101to20240930">001-36728</ix:nonNumeric></span></div>

        <div style="text-align: center; color: rgb(0, 0, 0); font-size: 24pt; font-weight: bold;"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_66c888673190405084a95a15da08b4ea" contextRef="c20240101to20240930">ADMA BIOLOGICS, INC.</ix:nonNumeric><br/>
          </span></div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Exact Name of Registrant as Specified in Its Charter)</div>

        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_23bbfb9951c343a094cf661a0e13e89e" contextRef="c20240101to20240930" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
                  </span></div>
              </td>

    <td style="width: 2%; vertical-align: top;">
                <div style="margin-left: 9pt">&#160;</div>
              </td>

    <td style="width: 49%; vertical-align: bottom;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_53c9fd7c701d422d89a56c3831f77d33" contextRef="c20240101to20240930">56-2590442</ix:nonNumeric><br/>
                  </span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(State or Other Jurisdiction of Incorporation or Organization)</div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(I.R.S. Employer Identification No.)</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_e3a3adfd9f9e469fac63dd1b004d26ce" contextRef="c20240101to20240930">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_c200eb049f51448d8face15792f9555d" contextRef="c20240101to20240930">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_c95efbad89ac4b3cb3eb6b84c66f922f" contextRef="c20240101to20240930" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></span></div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_2eb3f31080d84ecf98d52ae9b7431a97" contextRef="c20240101to20240930">07446</ix:nonNumeric><br/>
                  </span></div>
              </td>

  </tr>

  <tr>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(Address of Principal Executive Offices)</div>
              </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 49%; vertical-align: top;">
                <div style="text-align: center; color: rgb(0, 0, 0);">(Zip Code)</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);"><span style="text-decoration: underline;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_72e89c8005ea4e4f84cb8460fdebc4ab" contextRef="c20240101to20240930">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_8f186fe0b6724826af2e6d6d22d2a822" contextRef="c20240101to20240930">478-5552</ix:nonNumeric></span></div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Registrant&#8217;s Telephone Number, Including Area Code)</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br/>
        </div>

        <div style="text-align: center; color: rgb(0, 0, 0);">Securities registered pursuant to Section 12(b) of the Act:</div>

        <div style="text-align: center; color: rgb(0, 0, 0);"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Title of each class</div>
              </td>

    <td style="width: 30%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Trading Symbol(s)</div>
              </td>

    <td style="width: 35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);">Name of each exchange on which registered</div>
              </td>

  </tr>

  <tr>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_69673173e3c9420c931b7611929ac609" contextRef="c20240101to20240930">Common Stock</ix:nonNumeric><br/>
                </div>
              </td>

    <td style="width: 30%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_07ec329ff92c43018f7bba1b424c723e" contextRef="c20240101to20240930">ADMA</ix:nonNumeric></div>
              </td>

    <td style="width: 35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: center; color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_49b1bc0b736b4a74be1935da670e8868" contextRef="c20240101to20240930" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Global Market<br/>
                </div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
          such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160; &#160; <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_b412f81e364e47518dd0b5629f2d4731" contextRef="c20240101to20240930">Yes</ix:nonNumeric> &#9746;&#160; &#160; No &#9744;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter)
          during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; &#160; <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_09b03c6f545340fc8318795d70f49675" contextRef="c20240101to20240930">Yes</ix:nonNumeric> &#9746;&#160; &#160; No &#9744;</div>

        <div style="text-align: justify;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the
          definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td colspan="1" style="width: 15%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);"><ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_cdcd47892b0646169803253de81b9ae2" contextRef="c20240101to20240930" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric>&#160; &#160; &#9746;</div>
              </td>

    <td style="width: 35%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Accelerated filer&#160; &#160; &#9744;</div>
              </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 15%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Non-accelerated filer&#160; &#160; </span>&#9744;</div>
              </td>

    <td style="width: 35%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Smaller reporting company&#160; &#160; </span><ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_9c4fa56f2045498ca2904c830d4cac3b" contextRef="c20240101to20240930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>
              </td>

  </tr>

  <tr>

    <td colspan="1" style="width: 15%; vertical-align: top;">&#160;</td>

    <td style="width: 50%; vertical-align: top;">&#160;</td>

    <td style="width: 35%; vertical-align: top;">
                <div><span style="color: rgb(0, 0, 0);">Emerging growth company&#160; &#160; </span><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_0d12894aec8d4f14b8decd8e86a3030f" contextRef="c20240101to20240930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>
              </td>

  </tr>


</table>
        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
          provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160; &#160; Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_d4880ec764e64a0387bb9fa8c124a63e" contextRef="c20240101to20240930" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160; &#160; No &#9746;</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;"><span style="font-size: 10pt;">As of <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">November 1, 2024</span></span>, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_2357357af3cf4d788b3f1a1f17c5d3a2" contextRef="c20241101" unitRef="U001" decimals="INF" scale="0" format="ixt:num-dot-decimal">236,390,253</ix:nonFraction> shares of the issuer&#8217;s common stock
          outstanding.</div>

        <div style="text-align: justify; text-indent: 36pt;"> <br/>
        </div>

        <div style="text-align: justify; text-indent: 36pt;">
          <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/></div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        </div>

        <!--PROfilePageNumberReset%LCR%1%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

      <div>&#160;</div>

      <!--Anchor-->
      <div style="text-align: center; font-weight: bold;"><!--Anchor--><a id="INDEX"><!--Anchor--></a>INDEX</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="vertical-align: top;" colspan="4">
              <div>PART I FINANCIAL INFORMATION</div>
            </td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="4" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 9%; vertical-align: top;">
              <div>Item 1.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom;">
              <div style="margin-right: 36pt;">Financial Statements</div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#BALANCESHEETS">Condensed Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and December 31, 2023</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">3</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);"><br/>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#OPERATIONS">Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months Ended September 30, 2024 and 2023</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">4</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#STOCKHOLDERSEQUITY">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity (Unaudited) for the Three and Nine Months Ended September 30, 2024 and 2023</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">5</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#CASHFLOWS">Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months Ended September 30, 2024 and 2023</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">7</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#NOTESTOCONDENSED">Notes to Unaudited Condensed Consolidated Financial Statements</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">8</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 2.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#ManagementsDiscussion">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">25</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 3.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">38</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 4.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#ControlsandProcedures.">Controls and Procedures.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">39</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" colspan="3">
              <div><a href="#PARTII">PART II OTHER INFORMATION</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">40</td>

  </tr>

  <tr>

    <td style="vertical-align: top;" colspan="3" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 1.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#LegalProceedings.">Legal Proceedings.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">40</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 1A.</div>
            </td>

    <td style="width: 83%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#RiskFactors.">Risk Factors.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">40<br/>
            </td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 2.</div>
            </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#UnregisteredSales">Unregistered Sales of Equity Securities and Use of Proceeds.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">71</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 3.</div>
            </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#DefaultsUponSeniorSecurit">Defaults Upon Senior Securities.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">71</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 4.</div>
            </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#MineSafetyDisclosures.">Mine Safety Disclosures.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">71</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: bottom; text-align: right;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 5.</div>
            </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#OtherInformation.">Other Information.</a></div>
            </td>

    <td style="width: 5%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">71</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 9%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div>Item 6.</div>
            </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
              <div style="margin-right: 36pt;"><a href="#Exhibits.">Exhibits.</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">71</td>

  </tr>

  <tr>

    <td style="width: 3%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 9%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 83%; vertical-align: top;" rowspan="1">&#160;</td>

    <td style="width: 5%; vertical-align: top;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; background-color: rgb(204, 238, 255);" colspan="3">
              <div><a href="#SIGNATURES">SIGNATURE</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255); text-align: right;">72</td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">This Quarterly Report on Form 10-Q includes our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup>,&#8221; &#8220;Nabi-HB<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>&#8221; and &#8220;BIVIGAM<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>,&#8221; which are protected under applicable intellectual property laws and
        are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#8482;</sup> or <sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup> symbols, but such references are not intended to
        indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217;
        trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or endorsement or sponsorship of us by, these other parties.</div>

      <div style="color: rgb(0, 0, 0);"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">i</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%1%%%-->
      <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Special Note Regarding Forward-Looking Statements</div>

      <div><br/>
      </div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Some of the information in this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of
        the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended.&#160;These statements include, among others, statements about:&#160;</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our ability to manufacture ASCENIV and BIVIGAM on a commercial scale and further commercialize these products as a result of their approval by the U.S. Food and
                Drug Administration (the &#8220;FDA&#8221;) in 2019;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of
                such efforts;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the
                labeling or nature of any such approvals;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product
                candidates;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our dependence upon our third-party customers, suppliers and vendors and their compliance with applicable regulatory requirements;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our belief that we have addressed the delays experienced with final drug product current Good Manufacturing Practices (&#8220;cGMP&#8221;) release testing by our third-party
                vendors by adding additional release testing laboratories to our FDA-approved consortium listed in our drug approval documents;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our plans to increase our supplies of source plasma (including source plasma containing certain levels of antibodies to Respiratory Syncytial Virus), our ability
                to obtain and maintain regulatory compliance and reliance on third-party supply agreements as well as any extensions to such agreements;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the potential indications for our products and product candidates;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">potential investigational new product applications;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the acceptability of any of our products, including ASCENIV, BIVIGAM and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or
                payers;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory
                submissions;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">concurrence by the FDA with our conclusions concerning our products and product candidates;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the comparability of results of our hyperimmune and immune globulin (&#8220;IG&#8221;) products to other comparably run hyperimmune and immune globulin clinical trials;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with <span style="font-size: 10pt; font-family: 'Times New Roman'; color: #000000;">Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity,</span> or other immune deficiencies or any other condition for which the products may
                be prescribed or evaluated;</div>
            </td>

  </tr>


</table>
      <div> <div><br/></div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate
                meaningful revenues from this product;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV or other
                future pipeline product candidates;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our ability to develop, manufacture, receive regulatory approval and commercialize our potential pipeline of any new hyperimmune globulins, including SG-001;<br/>
              </div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160;&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our plans related to the expansion and efficiencies of our manufacturing capacity, yield improvements, supply chain robustness, in-house fill-finish capabilities,
                distribution and other collaborative agreements and the success of such endeavors;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our estimates regarding revenues, net income, Adjusted EBITDA, expenses, capital requirements, ASCENIV&#8217;s growth, ability to maintain profitability and positive
                cash flows and the potential need for and availability of additional financing;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
              </td>

    <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our ability to realize our deferred tax assets or the need for a valuation allowance, or the effects of changes in tax laws on our deferred tax assets;</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
              </td>

    <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our estimates of future taxable income and the timing of a potential full or partial release of the valuation allowance against our net deferred tax assets,
                  which could have a material impact on our financial condition or financial results;</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
              </td>

    <td style="width: 92.31%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">our estimates of future effective tax rates and corresponding tax obligations, which could have a material impact on our financial condition or financial
                  results;</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">possible or likely reimbursement levels for our currently marketed products;</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations; and</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 3.85%; vertical-align: top;">&#160;</td>

    <td style="width: 3.85%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#8226;</div>
            </td>

    <td style="width: 92.31%; vertical-align: top;">
              <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">future domestic and global economic conditions including, but not limited to, supply chain constraints, inflationary pressures or performance or geopolitical
                conditions, including the continuing conflict in Europe or the evolving conflict in the Middle East and surrounding areas.</div>
            </td>

  </tr>


</table>
      <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">These statements may be found under the &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of
        Operations&#8221; sections of this Quarterly Report on Form 10-Q.&#160;Forward-looking statements&#160; may be identified by the use of terms such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221;
        &#8220;potential,&#8221; &#8220;predicts,&#8221; or &#8220;should&#8221; or the negative thereof or other variations thereof or comparable terminology.&#160;Our actual results could differ materially from those contained in the forward-looking statements due to the factors described in
        the sections entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 and in this Quarterly Report on Form
        10-Q for the quarter ended September 30, 2024. Any forward-looking statement included or incorporated by reference in this Quarterly Report on Form 10-Q reflects our current views with respect to future events and is subject to these and other
        risks, uncertainties and assumptions related to our operations, industry and future growth. These forward-looking statements speak only as of the dates such statements are made and we undertake no obligation to publicly update any forward-looking
        statements or to publicly announce revisions to any of the forward-looking statements, unless otherwise required by the federal securities laws.</div>

      <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
      </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="width: 100%;" class="BRPFPageFooter"></div>

        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
          </div>

        </div>

      </div>

      <!--PROfilePageNumberReset%Num%1%%%--> </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor-->PART I</div>

        <div style="text-align: center; font-weight: bold;">FINANCIAL INFORMATION</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><span style="font-weight: bold;">Item 1<!--Anchor-->.</span></td>

    <td style="width: auto; vertical-align: top;">
                <!--Anchor-->
                <div style="font-weight: bold;"><!--Anchor-->Financial Statements.</div>
              </td>

  </tr>


</table>
        <div style="text-align: center; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <!--Anchor-->
        <!--Anchor-->
        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED
          <!--Anchor--><!--Anchor--><!--Anchor--><a id="BALANCESHEETS"><!--Anchor--></a>BALANCE SHEETS<!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">September 30,</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">December 31,</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"> (Unaudited)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(In thousands, except share data)</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">ASSETS</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center;"><br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current assets:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2433aaa0f77c4c2088cd8707941d7e68" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,707</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_9cbd99f142bc49918de54d35b82c9d7f" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts receivable, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_a65a3741507a430fb1245c9c1f8d85e2" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,140</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_86347a9c044b48f19dc559a37403ea87" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,421</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Inventories</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_9142fbb79b634d9da8f751e35db17e72" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">171,801</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_c733c840f9854e208bc854b08f2bbeeb" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,906</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,545</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_9177520ab36c49ea97cd19a1c968df92" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,334</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">318,193</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_f45b3271b441455cb2105680565b129e" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">257,013</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Property and equipment, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,694</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_c7aaf9819ea84e03bf8722ce95af85af" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,835</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Intangible assets, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_f17de370315f4091b0f89c2e84d973d1" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">485</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_0514a0e23bdc4d0ea5e717bdf3754926" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">499</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Goodwill</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_769d5f0c97eb4064bdb43ac410530a21" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Goodwill" id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Right-to-use assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_bbc32b4cc98043e9a94ba4f7220fb722" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,897</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_6dd902973f4846a4bb1c1594e27f8f57" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,635</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,819</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_a50743018b6247889bc69ddeeb66ade6" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL ASSETS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_c2f9187a8f1347b180e4de1c4e0650a0" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">390,618</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Assets" id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">329,182</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Current liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_7dde0dfcef624d98a7c818296df97379" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,020</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_79f8959f51c440058a2b2ae73dcbf97b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,660</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Accrued expenses and other current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_dd0f579f43084bb2aa500ce0cc36df30" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,535</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_0e9ccf6016784da8a8b04f3a1af923c3" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,919</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of deferred revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_717f5016a22d44e788a7623ed89d02dc" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_f9a0da175433427abcd2517ac58e7ac3" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Current portion of lease obligations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_e15d10dae4084e71835cb788dda3105c" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,193</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,045</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Total current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_e040cd8f2ecf4ad193d82978ff855ac5" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">44,891</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_df082a6c52ae4c43b80203fb015af4c8" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,806</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Senior notes payable, net of discount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_5dbbafa983e447648edea5d160779986" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,326</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_a253f9727f7042bdb255854fc1f4cc07" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,594</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Deferred revenue, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c6a34d215f70489cb00ad0517bb21b35" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,583</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_c686e6297dea4e4d93efce7816cca250" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;">End of term fee<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_4d410e2a246640308a098f9cd7fdd048" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_a0a3d9326c654effa015cbfada21a58e" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Lease obligations, net of current portion</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_67604891dc8248dba7f483ed9d867778" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,865</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,779</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other non-current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_1425725201a64a6b81c6061265b988a6" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">375</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_019efd73590a4e5fb4700d5a202f9ba9" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">419</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_4b09c740ef954edab33c4b39d9ffc56e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">158,728</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:Liabilities" id="Fact_95d12ad8d1e64b189d1268bbd917203d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,976</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">COMMITMENTS AND CONTINGENCIES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_292fbadd3b6847688ba39efc961e9f13" contextRef="c20240930" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"/></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_cf251b6df5654e7c8d19f0fd75cd401e" contextRef="c20231231" unitRef="U002" xsi:nil="true" format="ixt:fixed-empty"/></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Preferred Stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_4b322bc4ff9047ada11d276fba00f032" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546" contextRef="c20240930" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_c51731a3209d45bc9c438cd58e2594ec" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_6460774f302542369b031f1439c51371" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_7357d7c8b24b4172b404e8fb73377a70" contextRef="c20231231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_6a23abbcd48d427490a73e11ae49d3bd" contextRef="c20240930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_985ef26e70de4d438886de20409f6e62" contextRef="c20231231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_65817be99e324befbc84fa32051df194" contextRef="c20240930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span>
                  shares issued and outstanding</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_32421b2e655449bc95407ba53997b2dd" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_1b0624f0760d4befb7bf3f49d8cdc325" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Common Stock - voting, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_772895fcdb8948edaa197e1a3cbda00b" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_0b9116e5ffd647cd91be96bc28d8ec95" contextRef="c20240930" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_a6da05b44012449790cf1f8fefcf0523" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_e17fd8ff3db44d0db345255c9de5d29c" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_be2280b446274185893dcebcbf2be1f3" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_a47a04445e0a40c0ac5864df134f7b0a" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">236,378,607</ix:nonFraction></ix:nonFraction></span>
                  and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6acdb1cf62784deea606e18a567d8916" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_4889dba395554041a519d29516e511d1" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at September 30, 2024 and December 31, 2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_58134c88742643e59d1016963f21fc5a" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_a9deedc4c75a4eca9914e129648a18c2" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Additional paid-in capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_c293fe47874d4c80ae1b7165eead05cc" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">652,345</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_393b6c347b684f7c93234fece20c7a2e" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">641,439</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Accumulated deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">420,479</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">506,256</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_1a6712ef74b145788070fef039c2ef2d" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">231,890</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3acf9855c6604de4b9fef2d7902b6e9c" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,206</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_b55ab3549e7148a98c2fb93694e5d4ad" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">390,618</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_cceb9a747e2849a3a60625fde7c5ccf2" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">329,182</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div style="text-align: justify;"><br/>
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%1%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <!--Anchor-->
        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED
          <!--Anchor-->STATEMENTS OF <a id="OPERATIONS"><!--Anchor--></a>OPERATIONS<!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;"> (Unaudited)<br/>
        </div>

        <div style="text-align: center; font-weight: bold;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Three Months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Nine Months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="14" style="vertical-align: bottom; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(In thousands, except share and per share data)</span><span style="font-style: italic;"> </span> </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; text-align: center;" rowspan="1"><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="font-weight: bold;">REVENUES</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8c80cfc03fa74e58958a9587696524f5" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,839</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d65c68a297bb40a6abc800115fd3e089" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,275</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_db1c99d55665420f861dc5da714d74f6" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">308,905</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5276c028bca94dea939e43baf7116995" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">184,311</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="margin-left: 9pt;">Cost of product revenue</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_c06b2a811a4141e58abf55e34e8b9578" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,180</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_062c130daa7e40ca80a137d15ac19af9" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,622</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_6fc5e6ef1ffd418fb2da7dfbe64de1f6" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,685</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_2e32c73f33694f0dbc83efa5d9e3d965" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,455</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Gross profit<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_bf0593924b5d4affaa4632a067bf5af5" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,659</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_20d2ebb3b484463d9ddd515b820cee5a" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,653</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_2bb12a99b87b41f6b0c17627480dd70d" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">156,220</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_0491e4e22b0f430f8c9b9f9a03998a7e" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">57,856</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OPERATING EXPENSES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Research and development</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_76fd52e789af4a42ada5afe548ae34ca" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">412</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_538c4a8ac16743929e2629256f082196" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">596</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_767d365ccb6e4f8a941c3e2bf80e5305" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,422</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_3978299636d3471ba982778fb79b6d7f" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,854</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Plasma center operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_2508b08896b84f05ad8886a40f7a89c2" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,021</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_52fbac27372245c1845f8f60f81b05dc" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">467</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_f95713b8e2534090b79a2181f9f873de" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,968</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_67e7731d006e4d6194d461677b19b7a7" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,581</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Amortization of intangible assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_68d14fb4cdbc4d52bef5ca7b73bae20b" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_f5817a3d25a9452f8064504e0a6ad533" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">179</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_e047b89e58ce483392bb4e610b6699ab" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">363</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_86f686ac3c8944008b56a6e12dec6117" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">537</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Selling, general and administrative</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_d15b4b179ab441fe9251ccd2c2a696fb" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,560</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_bb8adde31d404947b7945ee85af00d37" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,726</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_d1a168e6e11f401184561b77d9ad0a24" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,807</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_0ae9a0b15ed14b248b6ad733e1240f4a" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,485</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Total operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_f58f61080187486cb5d586586e7c4a2a" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,021</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_2bb5a41ed61441d79b84be8f5aa9af0e" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,968</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_829a82c7dd954db2b1c95648aa88c175" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,560</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_b791a46855dc487d86f347326cd93297" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,457</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">INCOME FROM OPERATIONS</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_9905cc735ec943c78fde9b7157776e2f" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,638</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_7ccce697ae9746d696a1b2909639981d" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,685</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3d55c702be5d4b7289ed0dfcd1bbd61c" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,660</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_e3db1982360a453da28f6cb67140efc7" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,399</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div></div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">OTHER INCOME (EXPENSE):</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest income</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_e55d7714fff74a22a9e1abdc4c73dd92" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">666</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_3665c88c4a624fd0b89c4ea358fc88d7" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">423</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_3983f011cf9c44c2b31e921ee99a3c71" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,499</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_5d0ca20aa1ca4d6f8b95e4d9dde57be9" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,005</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_a71ce3062d4b4766935dbad0677878b9" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,499</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_49f9029bdfea42409552df53f24b26c9" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,398</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_ae318561cdb542efba63f477ea144d24" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,051</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_de970281193a47b3a8597ec3af3e3f43" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,812</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Other expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_3c85d6b811a84eeebac14ccc274b24ce" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">56</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_d87fb0a9fd664540a55938448c6dc318" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">145</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_897e5502eb4941bb9bb5bc25680f05e7" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_4b207b7d0347476683916641fb38cd62" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">186</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt; font-weight: bold;">Other expense, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_b922c5a89fdd43df81e81fd831e92aee" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,889</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_e13d75cb9d9247dba7d6ebc9bbd1d554" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,120</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_c24f7f1c9c08401ca83a2922629bf451" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,659</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_15362ef7299a48d5b7e06be643481db3" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,993</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; font-weight: bold; white-space: nowrap;">INCOME (LOSS) BEFORE INCOME TAXES</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_80dda2143bd847f7b13a613ead257889" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,749</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_01866707a60e473592b11ac6b4919c0e" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;"/>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_23854e21cc5b4a05ab61a54951b5e828" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,001</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_6f2c8c3611d546a6a81c48f142af2a00" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,594</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; font-size: 10pt; white-space: nowrap;">
                <div style="margin-left: 9pt"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Provision for income taxes</span></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_8e6569998f71492dab74384d70293576" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">840</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_4c14858cf27e4b34ae3fc55a7dc8ffd5" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_5803aab4ec754b2c850a8a5ee918c45f" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,224</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_a91f9fe61cbd4aa3843932385a59de81" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">NET INCOME (LOSS)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_68a96a78aa6d416585ca6b454281fac2" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,909</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_80d68c6beb7f4bd0a0041e1773a29226" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a6c25bda09c94616b5d74178043a2d99" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,777</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_368890b0c61546a488d23fc526638660" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,594</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">BASIC EARNINGS (LOSS) PER COMMON SHARE</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_1e1f704280594d328a8f4723f86bed0e" contextRef="c20240701to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.15</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_25c5c5449fdd42ea96784f59c89d554b" contextRef="c20230701to20230930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_1ecb3d59598740ac93b30ed1b3bdf5bc" contextRef="c20240101to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.37</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_d3789ace214b48058c8095f5796eec4b" contextRef="c20230101to20230930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;"><span style="font-weight: bold;">DILUTED EARNINGS (LOSS) PER COMMON SHARE </span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_a9f9053b648c4722989cf57cb792e2e8" contextRef="c20240701to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.15</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_72a1810780c74ad7bf9ab91063ca43b9" contextRef="c20230701to20230930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"/>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_8624971930e945f89f0f87def899be15" contextRef="c20240101to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.35</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_f9ff18f2397c4f999e60eef3509b3f40" contextRef="c20230101to20230930" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-weight: bold;">Basic<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_8991ef97bf7a46a292832844b8f003d1" contextRef="c20240701to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">234,571,376</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_00d234c0ded1454f8b3d8e0367feac13" contextRef="c20230701to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">225,276,980</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_932a037ed38f4c7989e02ce067b5c10c" contextRef="c20240101to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">231,959,579</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_74b02ee36d6f402bbc6e2670889e55da" contextRef="c20230101to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">223,306,331</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="margin-left: 9pt;">Diluted <br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_9b082890588c498aab811c534efc636f" contextRef="c20240701to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">244,804,065</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_6324a640e59a47c992fc9b8a335f96d1" contextRef="c20230701to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">233,761,262</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_12e84b4fc99340f8aeef1689ba128cbb" contextRef="c20240101to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">241,772,162</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_c37c5c63292c4e8c8360785258e4a2d5" contextRef="c20230101to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">223,306,331</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div style="text-align: center;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%5%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold;"><!--Anchor-->ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;"><!--Anchor-->CONDENSED CONSOLIDATED
          <!--Anchor-->STATEMENTS OF CHANGES IN<!--Anchor--></div>

        <!--Anchor-->
        <div style="text-align: center; font-weight: bold;"><!--Anchor--><!--Anchor--><a id="STOCKHOLDERSEQUITY"><!--Anchor--></a>STOCKHOLDERS&#8217; EQUITY<!--Anchor-->
          <!--Anchor-->(Unaudited)</div>

        <div style="text-align: center; font-weight: bold;"> <br/>
        </div>

        <div style="text-align: center; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(In thousands, except share data)</span> </div>

        <div style="text-align: center; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>

        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></div>

        <div style="text-align: center; font-weight: bold;">For the Three and Nine Months Ended September 30, 2024 </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px;"> Additional</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px;"> Total</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> Common Stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;"> Paid-in</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;"> Accumulated</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom;">
                <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> Amount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> Capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;"> Deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Balance at December 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_45aeace92c144a97bbc9adb9a058133f" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_eb9f34373ad64aab81a11b5c474366ba" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_883d874dd0cf40a4b6371fceabc3d735" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">641,439</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_47ede5702e2941558c3b79247dda6613" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">506,256</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b72f0ff7e3e54fbd9b574dbe2b2f7dbb" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,206</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_e220dc61862e435b898735b5af37bf0a" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_37b0632f8ffa476087ab288fff6ce834" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,141</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_5febbfca069c4579b0270ba65ae9ef16" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_22a78821e372416ca95ac549b2169928" contextRef="c20240101to20240331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,141</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">Cashless exercise of warrants</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_2ec3ca2638e14cec8d6cbaf674c50068" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,545,503</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_561b0b5be2eb4ec5a1517e173988ce34" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_e2d96d4ffeaa492082f78fa1e2c0dbe6" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_65051f3cebb44dcaa6424caf78dc8ada" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_7ed65307901f49e4a93ccf4c858d18aa" contextRef="c20240101to20240331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -16.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0);">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_438a1e66a8e5469cbd270bbf9f94a2d1" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">774,889</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_c0298a8c52ce48e1aa0b547c3cceaa37" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_11f6727784c449618d3550770d336c2b" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,476</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_9e14f56cbaf3482db991107f1b9b506c" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_b1b55ad5f570415e8c4acc14078e0749" contextRef="c20240101to20240331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,476</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">Exercise of stock options<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_c8cff83bb3d44cc69d3f45f958adecd4" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">386,341</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_04621b982ca3400287ae4dfc66f30408" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a4f7bc6ecd8b456eaf0dfd457f9f45bb" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,029</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_52cbc67d56004d9db5f81b09c499d5e0" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_136008d781ef473ea8382ef55d68d53e" contextRef="c20240101to20240331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,029</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net income<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_af0e197eb4c44dd899ef6d511ecf63ad" contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a32c37e6782140a9bb21955cfa935697" contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_521012fcafc3468987294571e5159d02" contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,806</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6f7b361568f2407fb9e67c7415c6bcca" contextRef="c20240101to20240331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,806</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Balance at March 31, <span style="text-indent: 0pt;">2024</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_bbd05341bb6848beb625be1bc13d5aca" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">231,769,765</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4181d3b4ea8948b0a86025b2b1db23fd" contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d5d6966131214429b8af2770c0e42fcf" contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">642,133</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3dde219357404ba1acf9e15b148e4427" contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">488,450</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0f1ba5c2e512404c880103388ee441d2" contextRef="c20240331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,706</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_53fc6b4b31164e55b4bf4da5873e11d6" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_aba4b5ea5089436fa8c10466bdb852bd" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,863</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_f9d9fd8c62f04981aa57ffa6d3677bdd" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_b8a9012fe1cf42beaec81480c84b9d91" contextRef="c20240401to20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,863</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">Cashless exercise of warrants <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_59956f45939848f4906161f08e1b3f09" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">937,507</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_408b57d329924777bfb63ef70d1ccaa8" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_2e29e3505c9f43cda7d25fe89b26d08f" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_819f5ca3410242edb8d894067b9b5611" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_2a0a111ef1dc41bf88f34c173e4147a5" contextRef="c20240401to20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes <br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_33fb57e48e5c4f1abdf0578df81ab9f8" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">171,408</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_826943a2bcb34eab8cc17b875713ab0d" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_d7acab1e1feb44bf901e25ab87f98569" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">693</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_2acc5184c9fc40fda477a226bd90573b" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_04fa191a880442b4ace4489878ffbaa8" contextRef="c20240401to20240630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">693</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">Exercise of stock options <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_4c1a5d0045d04358995f60042c0b57bc" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">148,056</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_536b60ba19e04948a52f55e1a5dcc586" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_65c8166a498b41509d6f382d4b2bb5dc" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">331</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_d124087e326e4424909238e5334162ab" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_7c7bb5c1b6a249cd9034744da17bc421" contextRef="c20240401to20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">331</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net income</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_024c79f617564b07b7946a75a9442d13" contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a1b5ed11df034afd9ecbf256f1f04a3f" contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_195385e259754e63b92ae690977a4b0b" contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,062</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ed76f4618e34463eafc1945138cd996f" contextRef="c20240401to20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,062</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; background-color: #CCEEFF; white-space: nowrap;">Balance at June 30, 2024</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_47f78fb3cda94137aa9b0c1ee6310031" contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">233,026,736</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_dc8b742b940147b39d325146d9526533" contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3a0576fe3e8947229dc4a9436728dd1f" contextRef="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">644,634</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6685e82fb25140c5aab2f616680096b9" contextRef="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">456,388</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c5623f894bd142da901766d649177a17" contextRef="c20240630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">188,269</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; white-space: nowrap;"><span style="font-weight: normal;">Stock-based compensation</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;">-<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_8008db02402c4178a5ba328d85aa227b" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6efcb0ed5d5049e09e66af53e996d753" contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,179</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_01403822f2a14abfbe0513877c0fe4fb" contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_5ccc5bbca0c348208ac2378b7709f308" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,179</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: normal; width: 40%; background-color: #CCEEFF; white-space: nowrap;">Cashless exercise of warrants <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_a6994ebd0d6148a183b405b3ee895236" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,741,882</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_6319963b49284978a43cf8223377f4f6" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_2e19bba84e1d4461bfff942c64a44ecf" contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_ae48df3a76bf4046aacb8ce5c91b03a3" contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_2c0135d6fbfd406aa440b046905247c3" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; white-space: nowrap;"><span style="font-weight: normal;">Vesting of Restricted Stock Units, net of shares withheld for taxes</span>
                <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_4f939ed7fb584c19a0ccf8881dfdbd45" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">250,107</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_348feaf0d30d424188d4f8564dc75ad6" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_fa39b0ec1241400dbd7b60c8a95be2b8" contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,158</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_ad35c6231ca54ac68ddbde060e03ccfd" contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_e9bc84c294ee4ae38097ffff7109ce93" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,158</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; background-color: #CCEEFF; white-space: nowrap;"><span style="font-weight: normal;">Exercise of stock options</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_5447c2763e354328ab74ccb417542084" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,359,882</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_40cde3395ee74d5fa343dff779407326" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_326ac742c7cd41688de9819e243944c2" contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,691</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b7bd6f6cbc2b4cd0b6cc2084d7e2c900" contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0f655b16db16456faf9ee9821ffa0cae" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,691</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold; width: 40%; white-space: nowrap;"><span style="font-weight: normal;">Net income</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">-<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cee44bf1b80a41f2a7fa0e2c8f4c2ff1" contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7aa5281aa52f48ab8710dfd780e66412" contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_7233a39652c84f08bc5e4ab378d96923" contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,909</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1c565a68c0f34fd49619b947288f9433" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,909</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><span style="font-weight: bold;">Balance at September 30, 2024</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_0df2d6d7a7444de3bc8804b0691cd1d1" contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">236,378,607</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_e4eb5ce383844a95895d3bec0a1055e3" contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_d1f5097c923144b99926fb510f05b952" contextRef="c20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">652,345</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_df09458422ec494aacff8c6559575c03" contextRef="c20240930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">420,479</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_aac9b80115e346199c07ec0b3ea14b4e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">231,890</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-align: center;">
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The accompanying notes are an integral part of these
            condensed consolidated financial statements.</div>

          <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div style="text-align: left;"><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

            </div>

          </div>

          <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

            <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

            <div><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

            <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</div>

            <div><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

            <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">STOCKHOLDERS&#8217; EQUITY (Unaudited)</div>

            <div style="text-align: center; font-weight: bold;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span></div>

            <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

            <div style="text-align: center; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(In thousands, except share data)</span> </div>

            <div style="text-align: center; font-weight: bold;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
              </span></div>

          </div>

          <div style="text-align: center; font-family: 'Times New Roman', Times, serif; font-size: 10pt;">
            <div style="text-align: center; font-weight: bold;">For the Three and Nine Months Ended September 30, 2023 </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px; white-space: nowrap;"> Additional</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-top: #000000 solid 2px; white-space: nowrap;"> Total</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; border-top: #000000 solid 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Common Stock</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Paid-in</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Accumulated</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Stockholders&#8217;</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Shares</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Amount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Capital</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> Deficit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Equity</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Balance at December 31, <span style="text-indent: 0pt;">2022</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_a52eec4a457749c6ac4c79793c82969b" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,816,930</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_2854c24a59cb487592bc326ac5ae3579" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_68c9f00ebc204e8eb3b3369b6260cae9" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">629,969</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_4c805a5120eb4598beeef93762a5e4d6" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">478,017</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_5265e0b771464a5abf9d75f3cc7c2747" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,974</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">Stock-based compensation <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">-</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_7f176e8f49df4f87bd39f989ef72e41b" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_d2a3105a7ec346a481b8f59c1eb62cff" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,110</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_0ea567d153ef4120b92f99a3cedbd7e4" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_473900ca57c844f0b32f7b9fa0c43f2f" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,110</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_944d21d2d64348769e545dece668d64e" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">443,215</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_7388cb98905a484d9fdf29cc01d1512a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_53b97558b37b41369d37f91b373fe5fb" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_462f1b335dff4267bb843c4199870599" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_dc5f1ab1fc9f4ac0999880c8d6532732" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">640</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">Exercise of stock options</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_552444da3e2340b1b85a6eb7321e9ce8" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,443</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a4198d1de7a94229974be6e10f1c262a" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_ad913852b6534e01ae8e7cde82acc2b8" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_e66389d7a6294a34bfe7efe4dfe8bf33" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_c30f620a79ce451ca02cf297e7ceac60" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">-</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_c31df73c23184ca189cde51e2430a8c3" contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d3d7951020674e128766fc742113e7fe" contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_2949224209954f7bb1ca3b236d2eb5de" contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,789</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_51b9eb6dd2e54028b6b7dfb7fbb7d620" contextRef="c20230101to20230331" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,789</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Balance at March 31, <span style="text-indent: 0pt;">2023</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_f8c0f876f1bc40d687164c11a77649c7" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">222,262,588</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_24478249430547d682ba9a97fd040b7f" contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6fcdd7eba9404b7f851b316e278b4238" contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">630,439</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_cb7b0e2bb34f498daaf5c0ba4986bcb1" contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">484,806</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8361d217ee7a4a0281b76881aef68f5a" contextRef="c20230331" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">145,655</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_28c6d41c2f89484b82195450dc079156" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_ff52f16888f74895b27f4d8f8a42ff84" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,637</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_d50f9397fd1f4f0ab166e911534c5ec5" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_c1b0f51c4acf4ad3943464d7e95cb4a4" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,637</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">
                <div style="margin-left: 9pt; text-indent: -9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_c9f6944ac0e94c149ac92f9d377ab058" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">117,484</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_880872d1a3f74bed9a6fb45f1ceed0c5" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_469c105eb9364ef6982a7d4e4587acf8" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_37d3a4abd8334d0eaed1ba06ae0a3b0c" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_ee3cae81ac524f51af75c7101a36649f" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">225</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">Warrants issued in connection with note payable <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">-</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_128529ce01894b40ad8c89b5adcba995" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_3376b0646f6c45438426738d689b40a7" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,594</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_ffaea5fcdfc942c5b20b40e52a9cb44c" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_25c8f7236e694ef4974c908f70b7efa4" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,594</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%;">Cashless exercise of warrants <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_acdee564111b45329aac1b93d58181bd" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,967,847</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_a24d5c4c0edf4eadb9af74c35678034b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_5e09c79fb230463da412a2c54a80e169" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_a4198e590b034bc4933a972295567964" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_e6fb0e2168624610b172c25342ec57b4" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF;">Exercise of stock options <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_9a2dd80a83dd4d7c92d6b85d14671fa0" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">178,829</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_8abf428a6c434aeda2bf15d45fd0889b" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b322e3cfb5a146f0a52c92c8d6e2dd7d" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">472</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b21a1d92874b4796bfb65894c2db2edf" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0ca5188cc251476ea28b2a75741faee5" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">472</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net loss</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>-</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ada4ac3ce1a247acae020493bf237e5f" contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0cd513dea5d04e3f8281a5cd84d36506" contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_3d9fb9bd4ab94ad7a13d2bf16770babd" contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,371</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_b72fd947365f444582535121d6e61c46" contextRef="c20230401to20230630" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,371</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; background-color: #CCEEFF;">Balance at June 30, 2023</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_6e78a7bfe7384583ab9e608fdf3baf2b" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">224,526,748</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3523c05d462044609cb78eee29efc32f" contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_74d7cc40c30b41769eb260e7ee695dae" contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">637,917</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_dbbb39b9cbc14123b0836a25297385fb" contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">491,177</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_c6c0735d52af4ba0ba2743161bbb7d75" contextRef="c20230630" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">146,762</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%;"><span style="font-weight: normal;">Stock-based compensation</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;">-<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_782b0d09321f473ca412151cd2e7d8f9" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_72cb3e695134408b95eb4d79119a47b9" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,695</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_6b22879abf8b4a9990fbfc30d8ab835d" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_a3f23e01c5e0496fb0dd453aedbe51ad" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,695</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%; background-color: #CCEEFF;"><span style="font-weight: normal;">Vesting of Restricted Stock Units, net of shares withheld for
                  taxes</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_13e0ae4543c34bcb8933c2eca77ed391" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">171,295</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_6cdd96ca59c843c082fd988a5a08bc2b" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_b1c416d75c734288b7e428ca010cccd5" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_efb63020aae84aecb370e988da571964" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_3016c4b4b3034aee8d51e038717dc47e" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">209</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">)</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 4px; font-weight: bold; width: 40%;"><span style="font-weight: normal;">Exercise of stock options </span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_84e8d6466cac4a648fc1ad36b07bf8bf" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,260,041</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_f43e600b92a64f738b96b9383582a752" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_92da9723a3b44edf85f8e8698531458c" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">623</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_e0069ce85aec41dd8dc6087e446feea5" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">624</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-weight: bold; width: 40%; background-color: rgb(204, 238, 255);"><span style="font-weight: normal;">Net income</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">-<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0262db51ceb94e6a9f7290903df21b8f" contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="0" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_d1531ff3dcd748f5b723f41dc19b0e30" contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_74612339f56f47adb6fc13d70575cdf1" contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_56e986cdffca4370a9f2a49fd5bb19fd" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="white-space: nowrap; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-weight: bold; width: 40%; padding-bottom: 4px;"><span style="font-weight: bold;">Balance at September 30, 2023</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_139f10aee83348c3a01344c4cdc31a81" contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">225,958,084</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_f3a1b163680d416aa15a4507fdb22e64" contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9bc86241117c4805b2f00c2e014c23a8" contextRef="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">640,026</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3aa1dd6027ca4177af8cf96109160a96" contextRef="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">488,612</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_df56584b844a4f9b9fad0ca0b766b4a5" contextRef="c20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,437</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div style="text-align: center;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageFooter" style="width: 100%;"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

          <div style="page-break-after:always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <div>
        <div style="text-align: center; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

        <div style="text-align: center; font-weight: bold;">CONDENSED CONSOLIDATED STATEMENTS OF<!--Anchor--><!--Anchor--> <a id="CASHFLOWS"><!--Anchor--></a>
          <!--Anchor--><!--Anchor-->CASH FLOWS<!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--><!--Anchor--></div>

        <div style="text-align: center; font-weight: bold;">(Unaudited)</div>

        <div style="text-align: center; font-weight: bold;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Nine Months Ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2024<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;"><span style="font-style: italic;">(In thousands)</span></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Net income (loss)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_606e384999c44b89a2f45b44d9be2517" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,777</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_554cda1cba654604bbccaaebde7db98c" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,594</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Adjustments to reconcile net income (loss) to net <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">cash provided by (used in) operating activities:</span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Depreciation and amortization</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_83080cccdd6c41ebbae85287f51e38d5" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,101</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_ca7370b0b19e46f99b974659c5ad04e6" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,223</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Loss on disposal of fixed assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_515262ae94b843ba8af2bd8952c28fa5" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">32</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_68fa0d6ea69d4931b29a903cca06f2d5" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">111</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-indent: 18pt; width: 76%; background-color: #CCEEFF; white-space: nowrap;">Interest paid in kind</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_a7a703ba8e0641b5a8eb820d496f2cb7" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_d8e180512f2644cf831d6f64ad829e56" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,959</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8d5c2bb295224d419c3420694af40e45" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,183</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_670daf81ec0e4ae59184cfe715be7bcc" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,442</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of debt discount</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_fd92d9f44d34479786a5d68a3983d2af" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">732</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_f13bdc7f5a914f4084b4953436f3654d" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,896</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Amortization of license revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_3e57e53903a545c1ac13b4b75ab07fce" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_89a9d124aac042ee93e9b2e64f0875e0" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 16.2pt;">Changes in operating assets and liabilities:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts receivable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_1dd109c39b304e7c91c47847eb964c36" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,719</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_9b8f4c75f5734cdc85490f66d98fe227" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,814</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Inventories</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_264d1acc9c834f019a733c35d2177df8" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,105</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_a9b6140c5d234afdb8706bbbf1d75f35" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">164</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Prepaid expenses and other current assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_f5acef387bce4b40a96171dd2a65c78a" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,211</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_c77b61709a1d49c7b5267b2f15dde1bc" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Deposits and other assets</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_b1d73d329b954767897f8f303d9ffebf" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">411</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,221</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accounts payable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_3f886d78219940d3ae9eb541eb90c632" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">208</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_5bbf598ffc494351b32f0efe70ce5fee" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,155</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Accrued expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_40dbe8521d1446c6936e91f772fa3bf3" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,384</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,872</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Other current and non-current liabilities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_f25bbf8593734543b01b1dfd3ea1038e" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">850</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">561</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash provided by (used in) operating activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6cfe9408e8844ab9b40d95553100bcca" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,456</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_a0dea6324de24915a75e5abd788855e6" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,797</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Purchase of property and equipment</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_b1f5fe8caf7047798637405d4650fbb9" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_4e1c44f0ac144022bf9d800076d23a3a" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,574</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Acquisition of intangible assets<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" id="Fact_9a945cd4a7bf49bb8cf9ea2075a05c92" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">356</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" id="Fact_fe84717725be463e8cb7fb107a9bf55b" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in investing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_8b1af39671aa45ceb09f7ef327d9e32a" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,825</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_d8843976a13c448cafd94324f9287089" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,574</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Taxes paid on vested Restricted Stock Units</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,327</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_f2f6799b325341b3a9d32f52e87bc068" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,074</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Repayment of notes payable</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_b1e37735845f4698aa98982dc3c0eddb" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_fec7c9137cf54ce3b5258849654fa39b" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Payments on finance lease obligations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_32e891ca8de644d3b4189b5bb7913221" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="margin-left: 9pt;">
                  <div style="margin-left: 9pt;">Net proceeds from the exercise of stock options</div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_8b61fdabac4f4e9181281ffb1dcb9c5b" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,051</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_bd810014a5e14c6aab17ee58e09c53ac" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,096</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 25.2pt;">Net cash used in financing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_69272294317744fcbfbcc384392b85ee" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,276</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net increase (decrease) in cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_45c3b87b315a4c698252bde2791e3307" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,355</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_79454785ed50456da17cfe72739aa946" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,365</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - beginning of period</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_b2be9221ca3942a0b45e4f329506aeb1" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2bd75314b7494603aa085ca7d4edf16b" contextRef="c20221231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,522</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Cash and cash equivalents - end of period</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_ab8dcca17d114290a2011513bb272e45" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,707</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e" contextRef="c20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,157</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-align: center;">The accompanying notes are an integral part of these condensed consolidated financial statements.</div>

        <div><br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="width: 100%;" class="BRPFPageFooter"></div>

          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

          <div class="BRPFPageBreak" style="page-break-after:always;">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%5%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
      <div>
        <div>
          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><a id="NOTESTOCONDENSED"><!--Anchor--></a>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS<!--Anchor-->
            (UNAUDITED)<!--Anchor--></div>

          <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br/>
          </div>

          <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_014177761dc640798f373cc359e0df61" contextRef="c20240101to20240930" escape="true" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a1">
<div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                  </td>

  </tr>


</table>
          </div>
</ix:nonNumeric>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a1" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a2" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a3">
<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a3" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a4">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to
            manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include
            immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a4" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a5">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a5" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a6">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA
              BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and
              Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA&#160;</span><span style="font-size: 10pt;">BioCenters<span style="color: rgb(0, 0, 0);">&#160;is the
                Company&#8217;s source plasma collection business with <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="Fact_abebb9c3c6ec49bab36ae9dd7447b8d9" contextRef="c20240101to20240930" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> plasma collection facilities located throughout the United States, all of
                which hold an approved license with the FDA.</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a6" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a7">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a7" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a8">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;">The Company has <ix:nonFraction name="adma:NumberOfFDAApprovedProduct" id="Fact_51cddc9f5b504e638c6a379228660bc3" contextRef="c20240101to20240930" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction>
            FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary
            Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii)
            BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B
            Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin
            products, the Company generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The
            Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.</div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a8" continuedAt="Text_2f12922069184e8384bda16c3eeefc5a9">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_2f12922069184e8384bda16c3eeefc5a9">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">As of September 30, 2024, the Company had working capital of $<ix:nonFraction name="adma:WorkingCapital" id="Fact_bd038db2ee3945df9351831f4bc65506" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">273.3</ix:nonFraction> million, including $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_2a427f28541341818ed13f6a7928489b" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">86.7</ix:nonFraction> million of cash and cash
            equivalents, $<ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_038ef75b1a364d4487142492ec08c9d7" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">50.1</ix:nonFraction> million of accounts receivable and $<ix:nonFraction name="us-gaap:InventoryNet" id="Fact_b3a8d828909143df99e2c99ec1f19d03" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">171.8</ix:nonFraction> million of inventories, partially offset by $<ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_bc35362e1bb741978f6111cd60204ba6" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">44.9</ix:nonFraction> million of current liabilities. Based upon
            the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s management currently believes that its cash, cash
            equivalents and accounts receivable, along with its projected future operating cash flow, will be sufficient to fund ADMA&#8217;s operations, as currently conducted, through the end of the fourth quarter of fiscal 2025 and beyond. However, the
            Company&#8217;s current outlook on cash flows and profitability may change based upon several factors, including the success of the Company&#8217;s commercial sales of its products, whether or not the assumptions underlying the Company&#8217;s projected revenues
            and expenses are correct and the continued acceptability of ADMA&#8217;s immune globulin products by physicians, patients and payers. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries
            including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, inflationary pressures, supply chain constraints, protection
            of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</div>
</ix:continuation>
          <div>
<div><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span>   <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-size: 10pt; font-family: 'Times New Roman';"><span style="font-variant: normal; text-transform: none;"> </span></span></div>

            <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

          </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-size: 10pt; font-family: 'Times New Roman';"> <span style="font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_2ad68e1e2b064586abd48cd612418dc6" contextRef="c20240101to20240930" escape="true" continuedAt="Text_be8e872002bc44b69744b26627c8edd31">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd31" continuedAt="Text_be8e872002bc44b69744b26627c8edd32">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd32" continuedAt="Text_be8e872002bc44b69744b26627c8edd33">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd33" continuedAt="Text_be8e872002bc44b69744b26627c8edd34">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd34" continuedAt="Text_be8e872002bc44b69744b26627c8edd35"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Text_1b842d491338428ea527247b3dcb683e" contextRef="c20240101to20240930" escape="true" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd35" continuedAt="Text_be8e872002bc44b69744b26627c8edd36"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f1" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>
</ix:continuation></ix:continuation>
          <div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd36" continuedAt="Text_be8e872002bc44b69744b26627c8edd37"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f2" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f3">
<div><span style="text-decoration: underline;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd37" continuedAt="Text_be8e872002bc44b69744b26627c8edd38"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f3" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f4">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
          </div>

          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd38" continuedAt="Text_be8e872002bc44b69744b26627c8edd39"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f4" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f5">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd39" continuedAt="Text_be8e872002bc44b69744b26627c8edd310"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f5" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f6">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd310" continuedAt="Text_be8e872002bc44b69744b26627c8edd311"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f6" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f7">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd311" continuedAt="Text_be8e872002bc44b69744b26627c8edd312"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f7" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f8">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 28, 2024.&#160; The accompanying consolidated balance sheet as of December 31,
              2023 was derived from the audited financial statements as of and for the year ended December 31, 2023. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q, Article 10
              of Regulation S-X and<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <span style="font-size: 10pt;">ASC 270,&#160;</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Interim Financial Statements</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">, and </span>therefore omit or
              condense certain footnotes and other information normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the
              opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements),
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">as well as material non-recurring
                costs, gains and losses applicable to the interim period, that are</span> considered necessary to present fairly the Company&#8217;s financial position as of September 30, 2024, its results of operations and changes in stockholders&#8217; equity for
              the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span> </span> 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and
              2023.</span></div>
</ix:continuation></ix:continuation>
          <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd312" continuedAt="Text_be8e872002bc44b69744b26627c8edd313"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f8" continuedAt="Text_54e55e9ef1dc4aa3bb79394a171c0e3f9">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd313" continuedAt="Text_be8e872002bc44b69744b26627c8edd314"><ix:continuation id="Text_54e55e9ef1dc4aa3bb79394a171c0e3f9">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span></span> 30,
              2024 and 2023, comprehensive income/loss was equal to the net income/loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not
              necessarily indicative of the results that may be expected for the full fiscal year.</div>
</ix:continuation></ix:continuation>
          </div>
<ix:continuation id="Text_be8e872002bc44b69744b26627c8edd314" continuedAt="Text_be8e872002bc44b69744b26627c8edd315">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd315" continuedAt="Text_be8e872002bc44b69744b26627c8edd316">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd316" continuedAt="Text_be8e872002bc44b69744b26627c8edd317"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_8dc991838e454edf8db537076279b401" contextRef="c20240101to20240930" escape="true" continuedAt="Text_19a909014fda4122878580f72e865b391">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd317" continuedAt="Text_be8e872002bc44b69744b26627c8edd318"><ix:continuation id="Text_19a909014fda4122878580f72e865b391" continuedAt="Text_19a909014fda4122878580f72e865b392">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd318" continuedAt="Text_be8e872002bc44b69744b26627c8edd319"><ix:continuation id="Text_19a909014fda4122878580f72e865b392" continuedAt="Text_19a909014fda4122878580f72e865b393">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd319" continuedAt="Text_be8e872002bc44b69744b26627c8edd320"><ix:continuation id="Text_19a909014fda4122878580f72e865b393" continuedAt="Text_19a909014fda4122878580f72e865b394">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd320" continuedAt="Text_be8e872002bc44b69744b26627c8edd321"><ix:continuation id="Text_19a909014fda4122878580f72e865b394" continuedAt="Text_19a909014fda4122878580f72e865b395">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd321" continuedAt="Text_be8e872002bc44b69744b26627c8edd322"><ix:continuation id="Text_19a909014fda4122878580f72e865b395" continuedAt="Text_19a909014fda4122878580f72e865b396">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable
              and estimates related to the valuation allowance for the Company&#8217;s deferred tax assets and its effective tax rate.</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd322" continuedAt="Text_be8e872002bc44b69744b26627c8edd323"><ix:continuation id="Text_19a909014fda4122878580f72e865b396" continuedAt="Text_19a909014fda4122878580f72e865b397">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd323" continuedAt="Text_be8e872002bc44b69744b26627c8edd324"><ix:continuation id="Text_19a909014fda4122878580f72e865b397">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><span style="font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt; color: rgb(0, 0, 0);">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of</span> 2024, the Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to
              the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a corresponding increase to net revenues of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_95fb5e9c482c47a89c6a3c2935e7bac9" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> </span><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">million
              for the nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span> 30, 2024. This change in estimate was applied on a prospective basis as of June 30,
              2024 and increased income from operations and net income <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the nine months ended September 30, 2024</span> by approximately $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_109bd23a364546d9b12138d07820703f" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_0c3142b01490495baf9731936b11680b" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction> million, respectively, and increased basic and
              diluted earnings per share by $<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_da9f01ae185d484cb99674b8392c007e" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_5747b0de79704405a69dc9013b2ae08a" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></ix:nonFraction>. Because there was little to no historical data to rely upon at the time BIVIGAM and
              ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid
              programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally
              considered that estimates may change over the lifetime of these products due to changes in utilization and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to
              reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in the $<ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_ae7159d13e3d48bd83a588f874379933" contextRef="c20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million
              adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd324" continuedAt="Text_be8e872002bc44b69744b26627c8edd325">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd325" continuedAt="Text_be8e872002bc44b69744b26627c8edd326">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd326" continuedAt="Text_be8e872002bc44b69744b26627c8edd327"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_960edfd623ae41ecbb40cabb46d04a99" contextRef="c20240101to20240930" escape="true" continuedAt="Text_b6940f6c732b4bf9971487827e0eb5f91">
<div>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd327" continuedAt="Text_be8e872002bc44b69744b26627c8edd328"><ix:continuation id="Text_b6940f6c732b4bf9971487827e0eb5f91" continuedAt="Text_b6940f6c732b4bf9971487827e0eb5f92">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd328" continuedAt="Text_be8e872002bc44b69744b26627c8edd329"><ix:continuation id="Text_b6940f6c732b4bf9971487827e0eb5f92" continuedAt="Text_b6940f6c732b4bf9971487827e0eb5f93">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd329" continuedAt="Text_be8e872002bc44b69744b26627c8edd330"><ix:continuation id="Text_b6940f6c732b4bf9971487827e0eb5f93" continuedAt="Text_b6940f6c732b4bf9971487827e0eb5f94">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd330" continuedAt="Text_be8e872002bc44b69744b26627c8edd331"><ix:continuation id="Text_b6940f6c732b4bf9971487827e0eb5f94" continuedAt="Text_b6940f6c732b4bf9971487827e0eb5f95">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd331" continuedAt="Text_be8e872002bc44b69744b26627c8edd332"><ix:continuation id="Text_b6940f6c732b4bf9971487827e0eb5f95">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior credit facility (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd332" continuedAt="Text_be8e872002bc44b69744b26627c8edd333">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd333" continuedAt="Text_be8e872002bc44b69744b26627c8edd334">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>
<ix:continuation id="Text_be8e872002bc44b69744b26627c8edd334" continuedAt="Text_be8e872002bc44b69744b26627c8edd335"><ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" id="Text_a3f7eb2891d044c6a9ebf724175e983e" contextRef="c20240101to20240930" escape="true" continuedAt="Text_e48c07e389274847a8a6fc4fb6ec50df1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd335" continuedAt="Text_be8e872002bc44b69744b26627c8edd336"><ix:continuation id="Text_e48c07e389274847a8a6fc4fb6ec50df1" continuedAt="Text_e48c07e389274847a8a6fc4fb6ec50df2">
<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd336" continuedAt="Text_be8e872002bc44b69744b26627c8edd337"><ix:continuation id="Text_e48c07e389274847a8a6fc4fb6ec50df2" continuedAt="Text_e48c07e389274847a8a6fc4fb6ec50df3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd337" continuedAt="Text_be8e872002bc44b69744b26627c8edd338"><ix:continuation id="Text_e48c07e389274847a8a6fc4fb6ec50df3">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and credit losses in the
            amount of $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_1eca436ce3464b16afae31c81cc89a6b" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million and $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_24d359e7629a4022be1162575f50a874" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction>
            million at September 30, 2024 and December 31, 2023, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation
              of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span> Based on these evaluations, the Company has
            concluded that its credit risk is minimal. At&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span>, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_f18bf3b7315b4926aa4ea064a85b2ab7" contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction> customers accounted for an aggregate of approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_f009184774e84f2d9d95a0201caebe4d" contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">91</ix:nonFraction>% of the Company&#8217;s total accounts receivable, and at December 31, 2023, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_6308d9179df94152ba218c08b1ce0ce0" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> customers accounted
            for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_a44807e83c784578a574f831d4cd62ca" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction>% of the Company&#8217;s total accounts receivable.<span style="text-decoration: underline;"></span></div>
</ix:continuation></ix:continuation>

          <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd338" continuedAt="Text_be8e872002bc44b69744b26627c8edd339">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><span style="font-style: italic;"> <br/>
              </span></span></div>
</ix:continuation>

          <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="Text_32378de28d5544cb943aa8237e33cb6e" contextRef="c20240101to20240930" escape="true" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c1"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd339" continuedAt="Text_be8e872002bc44b69744b26627c8edd340">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><span style="font-style: italic;">Inventories</span></span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:continuation></ix:nonNumeric>
          <div>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c1" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c2"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd340" continuedAt="Text_be8e872002bc44b69744b26627c8edd341">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c2" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c3"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd341" continuedAt="Text_be8e872002bc44b69744b26627c8edd342">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c3" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c4"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd342" continuedAt="Text_be8e872002bc44b69744b26627c8edd343">
<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs
              for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance,
              consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative
              to the total square footage of the facility.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c4" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c5"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd343" continuedAt="Text_be8e872002bc44b69744b26627c8edd344">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c5" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c6"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd344" continuedAt="Text_be8e872002bc44b69744b26627c8edd345">
<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c6" continuedAt="Text_c9d13d36cacb43c6a817da5e61e3dc1c7"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd345" continuedAt="Text_be8e872002bc44b69744b26627c8edd346">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c9d13d36cacb43c6a817da5e61e3dc1c7"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd346" continuedAt="Text_be8e872002bc44b69744b26627c8edd347">
<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd347" continuedAt="Text_be8e872002bc44b69744b26627c8edd348">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd348" continuedAt="Text_be8e872002bc44b69744b26627c8edd349">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd349" continuedAt="Text_be8e872002bc44b69744b26627c8edd350"><ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Text_0213f3d0f66b495f8215943a938312e6" contextRef="c20240101to20240930" escape="true" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b1">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd350" continuedAt="Text_be8e872002bc44b69744b26627c8edd351"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b1" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd351" continuedAt="Text_be8e872002bc44b69744b26627c8edd352"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b2" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd352" continuedAt="Text_be8e872002bc44b69744b26627c8edd353"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b3" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd353" continuedAt="Text_be8e872002bc44b69744b26627c8edd354"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b4" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd354" continuedAt="Text_be8e872002bc44b69744b26627c8edd355"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b5" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at
              <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and December 31, 2023 was $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_ce40654c1a3e4f4bb1143b887aa10df6" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_005ba41ea1da4053b40eba056f889113" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction></ix:nonFraction> million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd355" continuedAt="Text_be8e872002bc44b69744b26627c8edd356"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b6" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd356" continuedAt="Text_be8e872002bc44b69744b26627c8edd357"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b7" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd357" continuedAt="Text_be8e872002bc44b69744b26627c8edd358"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b8" continuedAt="Text_9561fca69a81473ba7e46c8800a9248b9">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd358" continuedAt="Text_be8e872002bc44b69744b26627c8edd359"><ix:continuation id="Text_9561fca69a81473ba7e46c8800a9248b9">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company did <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_db10b8d357224511b2c79474ef684524" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_c918795fb95c422c90cd19826ff0510e" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_76c3ae1705a04896bb17603ca42b57c5" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_1dc20e85b1bc43b590911cc98cd8e4e4" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>t <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and nine </span>months ended September 30, 2024 and 2023.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd359" continuedAt="Text_be8e872002bc44b69744b26627c8edd360">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd360" continuedAt="Text_be8e872002bc44b69744b26627c8edd361">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd361" continuedAt="Text_be8e872002bc44b69744b26627c8edd362"><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Text_545ada14f0fa4349907835c9c9451111" contextRef="c20240101to20240930" escape="true" continuedAt="Text_1e7e87c9e98146d880abe5f16f1afa5c1">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd362" continuedAt="Text_be8e872002bc44b69744b26627c8edd363"><ix:continuation id="Text_1e7e87c9e98146d880abe5f16f1afa5c1" continuedAt="Text_1e7e87c9e98146d880abe5f16f1afa5c2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd363" continuedAt="Text_be8e872002bc44b69744b26627c8edd364"><ix:continuation id="Text_1e7e87c9e98146d880abe5f16f1afa5c2" continuedAt="Text_1e7e87c9e98146d880abe5f16f1afa5c3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd364" continuedAt="Text_be8e872002bc44b69744b26627c8edd365"><ix:continuation id="Text_1e7e87c9e98146d880abe5f16f1afa5c3" continuedAt="Text_1e7e87c9e98146d880abe5f16f1afa5c4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd365" continuedAt="Text_be8e872002bc44b69744b26627c8edd366"><ix:continuation id="Text_1e7e87c9e98146d880abe5f16f1afa5c4" continuedAt="Text_1e7e87c9e98146d880abe5f16f1afa5c5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd366" continuedAt="Text_be8e872002bc44b69744b26627c8edd367"><ix:continuation id="Text_1e7e87c9e98146d880abe5f16f1afa5c5">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three and nine months ended&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and 2023, the
              Company did not identify any impairment indicators for its long-lived assets, and as a result <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_ef734576a4574f61b139ce75a27e12b7" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_e71082104c654e9e881f4edbd57274b9" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_77369376a4ea4ea49a958cbfa40e1cd4" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_5f3fdeb7194f4e48b8675c63b1033abe" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment charges were
              recorded.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd367" continuedAt="Text_be8e872002bc44b69744b26627c8edd368">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd368" continuedAt="Text_be8e872002bc44b69744b26627c8edd369">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>
<ix:continuation id="Text_be8e872002bc44b69744b26627c8edd369" continuedAt="Text_be8e872002bc44b69744b26627c8edd370"><ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Text_3fb205bcaf1f40118c3c5793f85cc5d1" contextRef="c20240101to20240930" escape="true" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af1">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd370" continuedAt="Text_be8e872002bc44b69744b26627c8edd371"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af1" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af2">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd371" continuedAt="Text_be8e872002bc44b69744b26627c8edd372"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af2" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd372" continuedAt="Text_be8e872002bc44b69744b26627c8edd373"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af3" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af4">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd373" continuedAt="Text_be8e872002bc44b69744b26627c8edd374"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af4" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd374" continuedAt="Text_be8e872002bc44b69744b26627c8edd375"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af5" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three and nine months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span></span>
                and 2023 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ASCENIV, </span>BIVIGAM and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business
                segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG
                (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest
                license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately <ix:nonNumeric name="adma:DeferredRevenueRemainingAmortizationPeriod" id="Fact_ec8a97d93d424b2b973659e6aecb4553" contextRef="c20240101to20240930_TypeOfArrangementAxis_BiotestLicenseAgreementMember" format="ixt-sec:duryear">22</ix:nonNumeric> years.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd375" continuedAt="Text_be8e872002bc44b69744b26627c8edd376"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af6" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd376" continuedAt="Text_be8e872002bc44b69744b26627c8edd377"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af7" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd377" continuedAt="Text_be8e872002bc44b69744b26627c8edd378"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af8" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af9">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; font-style: normal; color: rgb(0, 0, 0);">Product revenue is recognized when the customer is deemed
              to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the
              Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and
              related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other
              assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. <span style="letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of&#160; </span>2024, the Company engaged a third-party
                specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a
                corresponding increase to net revenues of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b9291b6f7cd34912a2bd1ee6826f1ec7" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> </span>million for the nine months ended September 30, 2024, substantially all
              of which was related to the sale of ASCENIV and BIVIGAM. This change in estimate was applied on a prospective basis as of June 30, 2024 and increased income from operations and net income by approximately $<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c031f25db80b4dfca66a8d032429c930" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_987516fdc4a949f2a7426ea7b0ca83d6" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.9</ix:nonFraction> million,
              respectively, and increased basic and diluted earnings per share by $<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_5b7782b66e59429aa11ab10eb4894abd" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_0d3b94eccd684c43ba2e3308217a61de" contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.05</ix:nonFraction></ix:nonFraction> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for
                the nine months ending September 30, 2024. </span>Because there was little to no historical data to rely upon at the time BIVIGAM and ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial
              rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government
              payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally considered that estimates may change over the lifetime of these products due to changes in utilization
              and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in
              the $<ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_84cf3dd5440540e9b1d8ca469c239742" contextRef="c20240630_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd378" continuedAt="Text_be8e872002bc44b69744b26627c8edd379"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af9" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af10">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd379" continuedAt="Text_be8e872002bc44b69744b26627c8edd380"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af10" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af11">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd380" continuedAt="Text_be8e872002bc44b69744b26627c8edd381"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af11" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af12">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer
              and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd381" continuedAt="Text_be8e872002bc44b69744b26627c8edd382"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af12" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd382" continuedAt="Text_be8e872002bc44b69744b26627c8edd383"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af13" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af14">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd383" continuedAt="Text_be8e872002bc44b69744b26627c8edd384"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af14" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af15">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd384" continuedAt="Text_be8e872002bc44b69744b26627c8edd385"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af15" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af16">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd385" continuedAt="Text_be8e872002bc44b69744b26627c8edd386"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af16" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af17">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd386" continuedAt="Text_be8e872002bc44b69744b26627c8edd387"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af17" continuedAt="Text_890f7c786eac4f5bb1c87891f0ef15af18">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd387" continuedAt="Text_be8e872002bc44b69744b26627c8edd388"><ix:continuation id="Text_890f7c786eac4f5bb1c87891f0ef15af18">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the nine months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and 2023,</span> <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_d2e214e347314f9c81c9c42f844dc29a" contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> customers represented an aggregate of approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_5ba5a7316a55487aa349fda344355202" contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">71</ix:nonFraction>% of the Company&#8217;s consolidated revenues.<br/>
            </div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd388" continuedAt="Text_be8e872002bc44b69744b26627c8edd389">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd389" continuedAt="Text_be8e872002bc44b69744b26627c8edd390">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd390" continuedAt="Text_be8e872002bc44b69744b26627c8edd391"><ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="Text_6ca79cd1448e48568dbd38122f71c2fe" contextRef="c20240101to20240930" escape="true" continuedAt="Text_ddaf8ae34b9a4a389e459e831057ed441">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd391" continuedAt="Text_be8e872002bc44b69744b26627c8edd392"><ix:continuation id="Text_ddaf8ae34b9a4a389e459e831057ed441" continuedAt="Text_ddaf8ae34b9a4a389e459e831057ed442">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd392" continuedAt="Text_be8e872002bc44b69744b26627c8edd393"><ix:continuation id="Text_ddaf8ae34b9a4a389e459e831057ed442" continuedAt="Text_ddaf8ae34b9a4a389e459e831057ed443">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd393" continuedAt="Text_be8e872002bc44b69744b26627c8edd394"><ix:continuation id="Text_ddaf8ae34b9a4a389e459e831057ed443" continuedAt="Text_ddaf8ae34b9a4a389e459e831057ed444">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd394" continuedAt="Text_be8e872002bc44b69744b26627c8edd395"><ix:continuation id="Text_ddaf8ae34b9a4a389e459e831057ed444" continuedAt="Text_ddaf8ae34b9a4a389e459e831057ed445">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd395" continuedAt="Text_be8e872002bc44b69744b26627c8edd396"><ix:continuation id="Text_ddaf8ae34b9a4a389e459e831057ed445">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products,
              intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
              When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd396" continuedAt="Text_be8e872002bc44b69744b26627c8edd397">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd397" continuedAt="Text_be8e872002bc44b69744b26627c8edd398">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>
<ix:continuation id="Text_be8e872002bc44b69744b26627c8edd398" continuedAt="Text_be8e872002bc44b69744b26627c8edd399"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_daa896e121f44c169299ec74eac4e54f" contextRef="c20240101to20240930" escape="true" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd399" continuedAt="Text_be8e872002bc44b69744b26627c8edd3100"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f1" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f2">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Earnings/Loss Per Common Share</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3100" continuedAt="Text_be8e872002bc44b69744b26627c8edd3101"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f2" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3101" continuedAt="Text_be8e872002bc44b69744b26627c8edd3102"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f3" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f4">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3102" continuedAt="Text_be8e872002bc44b69744b26627c8edd3103"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f4" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3103" continuedAt="Text_be8e872002bc44b69744b26627c8edd3104"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f5" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic earnings/loss per common share is computed by dividing net earnings/loss attributable to common stockholders by the weighted-average number of shares of common stock
                  outstanding during the period.&#160; Diluted earnings/loss per common share is calculated by dividing net earnings/loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted-average
                  number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, as well
                  as restricted stock units (&#8220;RSUs&#8221;), using the treasury stock method. Potentially dilutive common stock is excluded from the diluted <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">earnings/</span>loss per common share computation to the extent that it would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Text_f8ad7b2eec494b5e99e65731e768668f" contextRef="c20240101to20240930" escape="true" continuedAt="Text_2dc4f694be064bddad183ce8221b1a881"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the three and nine months ended September 30, 2024 </span></ix:nonNumeric></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt;"><ix:continuation id="Text_2dc4f694be064bddad183ce8221b1a881" continuedAt="Text_2dc4f694be064bddad183ce8221b1a882"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">and the three months ended September 30, 2023,</span></ix:continuation></span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_2dc4f694be064bddad183ce8221b1a882" continuedAt="Text_2dc4f694be064bddad183ce8221b1a883"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> basic and diluted earnings per share is calculated as follows:</span></ix:continuation></span></span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3104" continuedAt="Text_be8e872002bc44b69744b26627c8edd3105"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f6" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f7"><ix:continuation id="Text_2dc4f694be064bddad183ce8221b1a883" continuedAt="Text_2dc4f694be064bddad183ce8221b1a884">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3105" continuedAt="Text_be8e872002bc44b69744b26627c8edd3106"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f7" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f8"><ix:continuation id="Text_2dc4f694be064bddad183ce8221b1a884">
<div>
              <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;">
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;"> <br/>
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2023<br/>
                      </div>
                    </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;">
                      <div style="text-align: center;">Nine Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net income available to common stockholders ($000's) (numerator)</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a45eccd4af0244cebe699b3102a84e3a" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,909</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_f763cdf0524445e68030286026668638" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4e8c4428026c42c5b70734711113d9de" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">85,777</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares (denominator)</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b49890bba1b24ae2acf0f12f3411fd40" contextRef="c20240701to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">234,571,376</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_8bd07a8e7e1641e4bba0edcbe8ed6f67" contextRef="c20230701to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">225,276,980</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_a1c761af804e41559bdd3131031fbfb3" contextRef="c20240101to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">231,959,579</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per common shares</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_c8245993d8664fb39e9890d93a8c4173" contextRef="c20240701to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.15</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_c15e9ab0d7dc49cb89ccc3069679d686" contextRef="c20230701to20230930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_cd58947e8e0f433fa13507c97ece8301" contextRef="c20240101to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.37</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_e8a4d34aed8d4428875969c6f836d601" contextRef="c20240701to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">234,571,376</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b6d7931a90454cc09a0d191865268d6e" contextRef="c20230701to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">225,276,980</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_535e42cfc1d643ff8d75dc22119335bf" contextRef="c20240101to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">231,959,579</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_022930df76244afb917d45e5559abdb0" contextRef="c20240701to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,232,689</ix:nonFraction></div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_9cfd2a4a590e429eb2dd3987b73de281" contextRef="c20230701to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">8,484,282</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_d571f73dbf6f459db24c8ab485c17512" contextRef="c20240101to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">9,812,583</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total shares - diluted (denominator)</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_3ca46cc20d884275a3e4e4affdaca8cd" contextRef="c20240701to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">244,804,065</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_4aa4bde444b34f83832c4513842e4f98" contextRef="c20230701to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">233,761,262</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_172e5e7279ff47b5bbd1c9e02db1b266" contextRef="c20240101to20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">241,772,162</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted earnings per common share</div>
                    </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_a477b8aba56e4bd88ccd2d29a363d9cc" contextRef="c20240701to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.15</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_7328cba9b09c46f684470e034e630bd3" contextRef="c20230701to20230930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.01</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_4ef5e397fbf045ef9c10f455d94203e7" contextRef="c20240101to20240930" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.35</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>

              <div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </div>

            </div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3106" continuedAt="Text_be8e872002bc44b69744b26627c8edd3107"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f8" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f9">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">For the three and nine months ended
                September 30, 2024 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and the three months ended September 30, 2023, </span>there were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f9c62b08edc94c08b04d4d2f0918c581" contextRef="c20230701to20230930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_af36fc1cf3064374bd6180b4272cbef0" contextRef="c20240101to20240930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2e3e33496436460ebd20b4a6d17e5e4f" contextRef="c20240701to20240930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>
                shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. For the&#160; nine months ended September 30, 2023 <ix:nonFraction name="adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" id="Fact_b5a31c2df98543cb835ca0988d42cbf7" contextRef="c20230101to20230930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> potentially dilutive securities were included in the computation of diluted loss per share in the accompanying condensed consolidated financial statements as the Company reported a net loss for this
                period. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_ab7f841969c94f449bf078e68e34cc98" contextRef="c20240101to20240930" escape="true" continuedAt="Text_69d2c9d124294cf9a14bbcbb794ac4cb1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the nine months ended </span></ix:nonNumeric></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><ix:continuation id="Text_69d2c9d124294cf9a14bbcbb794ac4cb1" continuedAt="Text_69d2c9d124294cf9a14bbcbb794ac4cb2"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">September 30, 2023</span></ix:continuation></span></span></span></span><ix:continuation id="Text_69d2c9d124294cf9a14bbcbb794ac4cb2" continuedAt="Text_69d2c9d124294cf9a14bbcbb794ac4cb3"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></ix:continuation></span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3107" continuedAt="Text_be8e872002bc44b69744b26627c8edd3108"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f9" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f10"><ix:continuation id="Text_69d2c9d124294cf9a14bbcbb794ac4cb3" continuedAt="Text_69d2c9d124294cf9a14bbcbb794ac4cb4">
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3108" continuedAt="Text_be8e872002bc44b69744b26627c8edd3109"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f10" continuedAt="Text_9ccec42630304d9f8d3e2b99262cb05f11"><ix:continuation id="Text_69d2c9d124294cf9a14bbcbb794ac4cb4" continuedAt="Text_69d2c9d124294cf9a14bbcbb794ac4cb5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3109" continuedAt="Text_be8e872002bc44b69744b26627c8edd3110"><ix:continuation id="Text_9ccec42630304d9f8d3e2b99262cb05f11"><ix:continuation id="Text_69d2c9d124294cf9a14bbcbb794ac4cb5">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock Options</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_13116703a1ab4e268f33f3e5b7a31236" contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,841,241</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 86.46%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_aaf1fd443adf48288f2f88140e98db23" contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,877,482</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ffb45891753d4f82965d10ebd6d6806d" contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_4cdf4326cc244f13b951e4f1aa04d066" contextRef="c20230101to20230930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">23,221,629</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3110" continuedAt="Text_be8e872002bc44b69744b26627c8edd3111">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3111" continuedAt="Text_be8e872002bc44b69744b26627c8edd3112">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></div>
</ix:continuation>

            <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_a536cdb4a1e2457ebf1b43140fa12824" contextRef="c20240101to20240930" escape="true" continuedAt="Text_136a3112a53148818ad47793f670c7dd1"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3112" continuedAt="Text_be8e872002bc44b69744b26627c8edd3113">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>
</ix:continuation></ix:nonNumeric>
            <ix:continuation id="Text_136a3112a53148818ad47793f670c7dd1" continuedAt="Text_136a3112a53148818ad47793f670c7dd2"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3113" continuedAt="Text_be8e872002bc44b69744b26627c8edd3114">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_136a3112a53148818ad47793f670c7dd2" continuedAt="Text_136a3112a53148818ad47793f670c7dd3"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3114" continuedAt="Text_be8e872002bc44b69744b26627c8edd3115">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_136a3112a53148818ad47793f670c7dd3" continuedAt="Text_136a3112a53148818ad47793f670c7dd4"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3115" continuedAt="Text_be8e872002bc44b69744b26627c8edd3116">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_136a3112a53148818ad47793f670c7dd4"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3116" continuedAt="Text_be8e872002bc44b69744b26627c8edd3117">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options and RSUs, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
              is generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_55d8058dc7eb4eeb85cb17587b80db99" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period and a term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_1865ff749dc046edb1ec1fbca915d7ff" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">10</ix:nonNumeric>
              years. RSUs granted to employees generally have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_e742963c7eab4fc8ac6234d6c770900a" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested equity awards is fully
              reversed at the time of forfeiture.</div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3117" continuedAt="Text_be8e872002bc44b69744b26627c8edd3118">
<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3118" continuedAt="Text_be8e872002bc44b69744b26627c8edd3119">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div style="width: 100%;" class="BRPFPageFooter"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>
<ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3119" continuedAt="Text_be8e872002bc44b69744b26627c8edd3120"><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_4e76a2f0cb524e40a7bd3220a1b1553c" contextRef="c20240101to20240930" escape="true" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3120" continuedAt="Text_be8e872002bc44b69744b26627c8edd3121"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef1" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef2">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3121" continuedAt="Text_be8e872002bc44b69744b26627c8edd3122"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef2" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3122" continuedAt="Text_be8e872002bc44b69744b26627c8edd3123"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef3" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef4">
<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3123" continuedAt="Text_be8e872002bc44b69744b26627c8edd3124"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef4" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3124" continuedAt="Text_be8e872002bc44b69744b26627c8edd3125"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef5" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3125" continuedAt="Text_be8e872002bc44b69744b26627c8edd3126"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef6" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef7">
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3126" continuedAt="Text_be8e872002bc44b69744b26627c8edd3127"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef7" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3127" continuedAt="Text_be8e872002bc44b69744b26627c8edd3128"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef8" continuedAt="Text_c4b0f4e17d604d069546337dbc029eef9">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3128" continuedAt="Text_be8e872002bc44b69744b26627c8edd3129"><ix:continuation id="Text_c4b0f4e17d604d069546337dbc029eef9">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination
                  by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits are recognized for an uncertain tax position when, in management&#8217;s
                  judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.&#160; For a tax position that meets the more-likely-than-not recognition threshold, the tax benefit is measured as the largest
                  amount that is judged to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority.&#160; The liability associated with unrecognized tax benefits is adjusted periodically due to changing
                  circumstances and when new information becomes available.&#160; Such adjustments are recognized entirely in the period in which they are identified.</span> Derecognition of a tax benefit previously recognized could result in the Company
                recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_3eff2cd6659c46a2842defdc15a678b3" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_0c2d183a9e7d497d94ba294a8e639b86" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t
                incurred any material liability for uncertain tax positions as of September 30, 2024 and December 31, 2023, and during the three and nine months ended September 30, 2024 and 2023 the Company recognized</span><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> <ix:nonFraction name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" id="Fact_fcb6e03885a64fb9a3e8c1f46ffa9a09" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" id="Fact_f7eeab33034d4ee28560bebdfaa26792" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" id="Fact_3602a13434bf452d9f56f1a23096ec85" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions" id="Fact_268ea81c61df408493cf6af0cbd4c55e" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>
                adjustments for uncertain tax positions.</span></div>
</ix:continuation></ix:continuation><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3129" continuedAt="Text_be8e872002bc44b69744b26627c8edd3130">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
            <ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3130" continuedAt="Text_be8e872002bc44b69744b26627c8edd3131">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
          </div>

          <div>
            <div>
              <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_9431881c9e5347df95aa3d0f4dba2711" contextRef="c20240101to20240930" escape="true" continuedAt="Text_aa8b8074640c48c48b984bbad95f295d1"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3131" continuedAt="Text_be8e872002bc44b69744b26627c8edd3132">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>
</ix:continuation></ix:nonNumeric>
              <ix:continuation id="Text_aa8b8074640c48c48b984bbad95f295d1" continuedAt="Text_aa8b8074640c48c48b984bbad95f295d2"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3132" continuedAt="Text_be8e872002bc44b69744b26627c8edd3133">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
              </div>
</ix:continuation></ix:continuation>
              <ix:continuation id="Text_aa8b8074640c48c48b984bbad95f295d2"><ix:continuation id="Text_be8e872002bc44b69744b26627c8edd3133">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic
                  280): Improvements to Reportable Segment Disclosures.&#160;</span>The amendments in this ASU are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments; however,
                the update does not change the definition of an operating segment or the method for determining reportable segments. This update becomes effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after
                December 15, 2024. The Company does not expect this ASU to have a material impact on the Company&#8217;s consolidated financial statements, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">except that its adoption will likely lead to disclosures of additional significant segment expenses.</span></div>
</ix:continuation></ix:continuation>

              </div>

            <div><br/>
            </div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" id="Text_b0ac280d826c42309d29f504917785df" contextRef="c20240101to20240930" escape="true" continuedAt="Text_669929859c13409d80f45407aace088d1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d1" continuedAt="Text_669929859c13409d80f45407aace088d2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d2" continuedAt="Text_669929859c13409d80f45407aace088d3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d3" continuedAt="Text_669929859c13409d80f45407aace088d4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_669929859c13409d80f45407aace088d4" continuedAt="Text_669929859c13409d80f45407aace088d5"><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Text_ada03ff9ca0449d783d175db4336d576" contextRef="c20240101to20240930" escape="true" continuedAt="Text_139043f27d92460494488df224cade5e1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d5" continuedAt="Text_669929859c13409d80f45407aace088d6"><ix:continuation id="Text_139043f27d92460494488df224cade5e1" continuedAt="Text_139043f27d92460494488df224cade5e2">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d6" continuedAt="Text_669929859c13409d80f45407aace088d7"><ix:continuation id="Text_139043f27d92460494488df224cade5e2" continuedAt="Text_139043f27d92460494488df224cade5e3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d7" continuedAt="Text_669929859c13409d80f45407aace088d8"><ix:continuation id="Text_139043f27d92460494488df224cade5e3" continuedAt="Text_139043f27d92460494488df224cade5e4">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d8" continuedAt="Text_669929859c13409d80f45407aace088d9"><ix:continuation id="Text_139043f27d92460494488df224cade5e4" continuedAt="Text_139043f27d92460494488df224cade5e5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d9" continuedAt="Text_669929859c13409d80f45407aace088d10"><ix:continuation id="Text_139043f27d92460494488df224cade5e5">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024 </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" rowspan="1"><br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; text-align: center; white-space: nowrap;" colspan="6" rowspan="1"><span style="font-style: italic;">(In thousands)</span><br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_1a5b580d95734897ac8d22b531ec177a" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,246</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_97c8d8f4bfe74772ad757c67f5affac1" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,999</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_5dc3f0cff84e4b27bbb010bbf66b26cc" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,482</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_220f065503184095a2a72cf3206c2a3f" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,621</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_f808c8b5a81142bca4c5032765d5c893" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">63,073</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_fd34512a85124c4590729dc4e824ee8e" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,286</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_d2169eeb75df4447b31d3b281d65f5f7" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">171,801</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_a9f02b2205134d38a500e1594cfd10e6" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,906</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_669929859c13409d80f45407aace088d10" continuedAt="Text_669929859c13409d80f45407aace088d11">
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d11" continuedAt="Text_669929859c13409d80f45407aace088d12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <ix:continuation id="Text_669929859c13409d80f45407aace088d12" continuedAt="Text_669929859c13409d80f45407aace088d13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d13" continuedAt="Text_669929859c13409d80f45407aace088d14">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.<br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d14" continuedAt="Text_669929859c13409d80f45407aace088d15">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d15" continuedAt="Text_669929859c13409d80f45407aace088d16">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s
            immunoglobulin products. </div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d16" continuedAt="Text_669929859c13409d80f45407aace088d17">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_669929859c13409d80f45407aace088d17">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          </div>

          <div><br/>
          </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Text_f46b388b3a2a480ca88f823b8eb2cec7" contextRef="c20240101to20240930" escape="true" continuedAt="Text_8b281d49ef294947a02003ee7d68971a1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a1" continuedAt="Text_8b281d49ef294947a02003ee7d68971a2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a2" continuedAt="Text_8b281d49ef294947a02003ee7d68971a3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a3" continuedAt="Text_8b281d49ef294947a02003ee7d68971a4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a4" continuedAt="Text_8b281d49ef294947a02003ee7d68971a5"><ix:nonNumeric name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="Text_198a34bb24c64972a597f9e24fef66c1" contextRef="c20240101to20240930" escape="true" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7031">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a5" continuedAt="Text_8b281d49ef294947a02003ee7d68971a6"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7031" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7032">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at September 30, 2024 and December 31, 2023 consist of the following:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a6" continuedAt="Text_8b281d49ef294947a02003ee7d68971a7"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7032" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7033">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a7" continuedAt="Text_8b281d49ef294947a02003ee7d68971a8"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7033" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7034">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a8" continuedAt="Text_8b281d49ef294947a02003ee7d68971a9"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7034" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7035">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a9" continuedAt="Text_8b281d49ef294947a02003ee7d68971a10"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7035" continuedAt="Text_7aa5db17cf0f4d0c88e989464168b7036">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="22" style="vertical-align: bottom; text-align: center; white-space: nowrap;" rowspan="1"><span style="font-style: italic;">(In thousands)</span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;Accumulated</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1">&#160;Accumulated</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_84c1b581f778436fb65753dbd43a49e0" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_2d221c0972044484a1bede04d3fd0aac" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_f1a7e039a1ec41f68d9d5eb4fffc4ba0" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_ef2a6d76582846058785cdc46965d92c" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_ae5309739fd44472a50a2dc3f8d824ff" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,856</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_e90ba21e2ecd46c196800abae575381b" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%;" rowspan="1">Internally developed software<br/>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_7486505cec4842bb9ad35b5e750ad471" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_ef93eff493c8454299c3af3b56a36a4d" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_bfcb0e0985334e8c8f6310143249baad" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">485</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_5a14d16d2fcf4c13b2df7bcf42e2ee7e" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_75b6ba85d91945dab406f58e62e5bd2c" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_95c0d6c6df2841ba9a5f97a9bc5374e1" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">201</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_429159c1de714158b077f91cc3f7b35b" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_51ee35f01bbc49ea91fc84c2427bada7" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_9e949858d4aa4da3a6b29b81717b196c" contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_790f4c6e73ad4f649f76a836527a88cb" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_2b047b417a4c4433b4b70fdbc5323d51" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">853</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_32e4aa2b22b5443483f72dcd60785180" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_c156f9254bfc4bcdabf4c849462e7922" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,566</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_51ec0b72e3eb4b69bdb1d459dae42088" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,081</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_fff6356862444b3db284ee003007fb26" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">485</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_0eb2e7fb57624d9eb07765a31e63e649" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,217</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_293e0b07af1343ffae867d68084b2eac" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,718</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_0580a8205fef498e9e58bf7239e237da" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">499</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a10" continuedAt="Text_8b281d49ef294947a02003ee7d68971a11"><ix:continuation id="Text_7aa5db17cf0f4d0c88e989464168b7036">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a11" continuedAt="Text_8b281d49ef294947a02003ee7d68971a12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation><ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a12" continuedAt="Text_8b281d49ef294947a02003ee7d68971a13"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Text_4116e731c5374a47a052e2a92e8e2c69" contextRef="c20240101to20240930" escape="true" continuedAt="Text_a2c846b26b6a48d4b7f297cb1f1847cf1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a13" continuedAt="Text_8b281d49ef294947a02003ee7d68971a14"><ix:continuation id="Text_a2c846b26b6a48d4b7f297cb1f1847cf1" continuedAt="Text_a2c846b26b6a48d4b7f297cb1f1847cf2">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the nine months ended September 30, 2024, the Company continued to develop its data intelligence and analytics programs at a
              cost of approximately $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" id="Fact_13c4ec390c3c42a9971ff4d2b1b064ce" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, and such costs are amortized over a period of <span style="-sec-ix-hidden:Fact_aabd598a3cab423c96bb46e0610cf636">three</span> to <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Fact_808a66064f944f149e35c129a81da996" contextRef="c20240930_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">five years</ix:nonNumeric> upon the projects&#8217; completion and
              placement into service.</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Amortization expense related to the
              Company&#8217;s intangible assets was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_b331fb053f5640ac920a41d71794f8b9" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction>,000 and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_b02e4bb3d51644e1aeacf03cedca59de" contextRef="c20230701to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million for the three months ended September 30, 2024 and 2023, respectively, and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_e64f959956c94cfbb0bf778b3860ef62" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction><span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_0323129500994dd5819078dc64bf2ca5" contextRef="c20230101to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million for the nine months ended September 30, 2024 and 2023, respectively</span>. Estimated future aggregate amortization expense is
              expected to be as follows (in thousands</span>):</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a14" continuedAt="Text_8b281d49ef294947a02003ee7d68971a15"><ix:continuation id="Text_a2c846b26b6a48d4b7f297cb1f1847cf2" continuedAt="Text_a2c846b26b6a48d4b7f297cb1f1847cf3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a15" continuedAt="Text_8b281d49ef294947a02003ee7d68971a16"><ix:continuation id="Text_a2c846b26b6a48d4b7f297cb1f1847cf3" continuedAt="Text_a2c846b26b6a48d4b7f297cb1f1847cf4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a16" continuedAt="Text_8b281d49ef294947a02003ee7d68971a17"><ix:continuation id="Text_a2c846b26b6a48d4b7f297cb1f1847cf4" continuedAt="Text_a2c846b26b6a48d4b7f297cb1f1847cf5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8b281d49ef294947a02003ee7d68971a17"><ix:continuation id="Text_a2c846b26b6a48d4b7f297cb1f1847cf5">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" id="Fact_07726ed57f8f4cddb565e5aff01e1d9d" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2025<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" id="Fact_f280783f34b049d1b514f8a252cfe14e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">2026<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" id="Fact_ca9aa36165e14b9782f2d8d11049f257" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; white-space: nowrap;" rowspan="1">2027<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" id="Fact_dd97dd24ef094b34ab229219e3b5784a" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">2028</span> <br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" id="Fact_7845e2d631ff473a9ef1f33e953008d7" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_c58c1d3b3a2e40808b659d66e69f3c99" contextRef="c20240101to20240930" escape="true" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a1" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a2" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a3" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a4" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a5"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_593a680e06f44efe9f78af2c2597bdb7" contextRef="c20240101to20240930" escape="true" continuedAt="Text_a585bbac8d5148be837be7950757762f1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a5" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a6"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f1" continuedAt="Text_a585bbac8d5148be837be7950757762f2">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a6" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a7"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f2" continuedAt="Text_a585bbac8d5148be837be7950757762f3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a7" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a8"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f3" continuedAt="Text_a585bbac8d5148be837be7950757762f4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a8" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a9"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f4" continuedAt="Text_a585bbac8d5148be837be7950757762f5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a9" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a10"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f5" continuedAt="Text_a585bbac8d5148be837be7950757762f6">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;">(In thousands)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_137fdb2871174efdb6121d47d1042db9" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,240</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_07d3c96195f142998857e32be8e863c0" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,093</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_eb3fca02f33341ac815947d704338ab2" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,441</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d08649a237b34b11a893dbb923269e39" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d4e884bc4ce0414b9e1208bca742cb06" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,777</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_866bd91e49924bda89e69d1b5158fcbd" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,776</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_47706243d15b46cf8bde68bb36a4efe8" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,881</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_5269d801cee945e3af84dcea2e28b848" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,273</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_61ce0a747fbe49b49e6a15b731a09359" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,051</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_0325d57f666847cc8547c8fc597d37e5" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,811</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_d7f4cedf2d494840a569e81d30e60d38" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,339</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_eac369376bb141aeaef91587aa06ce1d" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,339</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_5deb436b56014f90b73db0008ea450e0" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,416</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a3f5b802297d4832b57338e7ac4c703d" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,218</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ec51ab6b57854fcfa2a0dc98fb999c07" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,145</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_ca2a2a4395bc469695fe037edd114183" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,572</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_14f9a0ce5e7349d4a5e11524bb08913a" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,451</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_14c3dfafdaa9474f8f890b2960b4c71c" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,737</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_da24e09ce9eb44a88f609f61668c7397" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,694</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_354a2ed4b1df464e9f3869b9307764c7" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,835</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a10" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a11"><ix:continuation id="Text_a585bbac8d5148be837be7950757762f6">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a11" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a12" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a13">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a13" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a14">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_f5c230841860451e8e3a3adef9f9c4f6" contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingMember" format="ixt-sec:duryear">30</ix:nonNumeric>
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_e1bb617d16104c86ba85a63d93bd3935">three</span> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_6e2ac767798d4fd0b7932c4d75b815de" contextRef="c20240930_RangeAxis_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric> years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a14" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a15">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a15" continuedAt="Text_6a8ac9d545c34de4b8ebe02125ecfd0a16">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_6a8ac9d545c34de4b8ebe02125ecfd0a16">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal;">The
              Company recorded depreciation expense on property and equipment for the three months ended September 30, 2024 and 2023 of $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_629504a74cf04576be669a2a3485734b" contextRef="c20230701to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_4526f3e2c00d4a57820b65c8bb10abf4" contextRef="c20240701to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.9</ix:nonFraction></ix:nonFraction>
              million <span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;">and for the
                nine months ended September 30, 2024 and 2023 of $</span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_7fb91547056d4d7f8e8aa73164286f07" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_51e0840834264dec9e971e9946ab820c" contextRef="c20230101to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction></ix:nonFraction><span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;"> million.</span></span></div>
</ix:continuation>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"> </span></div>

          <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
          </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_ba86dceeeabc4c1dba19c743f8d13860" contextRef="c20240101to20240930" escape="true" continuedAt="Text_914fd4e0508e4252a97f323fe279bc561">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc561" continuedAt="Text_914fd4e0508e4252a97f323fe279bc562">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc562" continuedAt="Text_914fd4e0508e4252a97f323fe279bc563">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc563" continuedAt="Text_914fd4e0508e4252a97f323fe279bc564">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc564" continuedAt="Text_914fd4e0508e4252a97f323fe279bc565"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_6310a76925dc44908412817c735f99a4" contextRef="c20240101to20240930" escape="true" continuedAt="Text_f4867d7d2fd041eca910adb0762d758d1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc565" continuedAt="Text_914fd4e0508e4252a97f323fe279bc566"><ix:continuation id="Text_f4867d7d2fd041eca910adb0762d758d1" continuedAt="Text_f4867d7d2fd041eca910adb0762d758d2">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at September 30, 2024 and December 31, 2023 are as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc566" continuedAt="Text_914fd4e0508e4252a97f323fe279bc567"><ix:continuation id="Text_f4867d7d2fd041eca910adb0762d758d2" continuedAt="Text_f4867d7d2fd041eca910adb0762d758d3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc567" continuedAt="Text_914fd4e0508e4252a97f323fe279bc568"><ix:continuation id="Text_f4867d7d2fd041eca910adb0762d758d3" continuedAt="Text_f4867d7d2fd041eca910adb0762d758d4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_914fd4e0508e4252a97f323fe279bc568"><ix:continuation id="Text_f4867d7d2fd041eca910adb0762d758d4">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; font-style: italic;" rowspan="1" colspan="6">(In thousands)</td>

    <td valign="bottom" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_d6197eb8c8ad4978951b68110e86b1e8" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,733</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_365161aef7064f1b9dc3f6462ec7147d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,608</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_980eb0ef9be6405d8bdc0fa52a61213b" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,780</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_b9816821bf7a47ee8c464d7e3c3f5cb8" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,954</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_77c4779b7f594deca90745d46feb1e9b" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,670</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_41ba16e02ec94b6a98d504eb1e69f8a1" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" rowspan="1">Accrued interest</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_24e5c773569148b2833e175d242f3716" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,448</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_591cc75218c1470b9ad8e7b406aee60d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">546</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_214bd2f0af4242c296a707c7411dd75d" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">579</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_4481a8d05f2a4e17a95218588e419895" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_45940794ca6643c4bf524be8d2418a50" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,010</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_568f1c5ca1024478a9273285e7be2ce8" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,203</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_901252830ac24491a0f15e330a892765" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,315</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_3cefe99a75b54ca3aa84a6d3315f3b0b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_d88f3c73ede24af091e5166d9f7a2969" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,535</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_808acfe2fa284e89a3b27419b3e1908b" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,919</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div>

          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" id="Text_c8c0406143ff4d4fa3adaf8468c4a17c" contextRef="c20240101to20240930" escape="true" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8961">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8961" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8962">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8962" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8963">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8963" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8964">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8964" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8965"><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" id="Text_113038a69c3c4b0e9deb47d766fca208" contextRef="c20240101to20240930" escape="true" continuedAt="Text_5542cfebc2c74653b9f53cb8da8e7c891">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8965" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8966"><ix:continuation id="Text_5542cfebc2c74653b9f53cb8da8e7c891" continuedAt="Text_5542cfebc2c74653b9f53cb8da8e7c892">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8966" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8967"><ix:continuation id="Text_5542cfebc2c74653b9f53cb8da8e7c892" continuedAt="Text_5542cfebc2c74653b9f53cb8da8e7c893">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8967" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8968"><ix:continuation id="Text_5542cfebc2c74653b9f53cb8da8e7c893" continuedAt="Text_5542cfebc2c74653b9f53cb8da8e7c894">
<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8968" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a8969"><ix:continuation id="Text_5542cfebc2c74653b9f53cb8da8e7c894" continuedAt="Text_5542cfebc2c74653b9f53cb8da8e7c895">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a8969" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89610"><ix:continuation id="Text_5542cfebc2c74653b9f53cb8da8e7c895">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" rowspan="1" colspan="6">(In thousands)</td>

    <td valign="bottom" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Term loan<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_58a86e6330f84ebfaac9dc0d5d81d629" contextRef="c20240930_CreditFacilityAxis_TermLoanMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_9c38075e2801471890ead0a06144a443" contextRef="c20231231_CreditFacilityAxis_TermLoanMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;" rowspan="1">Revolving credit facility</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_8ffa221dcb834fc1a28b06a9089511b9" contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,500</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_3dfdc305011b46e788b03e40cc276f86" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,500</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_4bafa993b96147008ac48e4c93be2a8b" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,674</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_a5e4a6fc6df04892ad9d23c25135d65d" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,406</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_f74a5552710f4a8aab6fe4427527dd4e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,326</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_fe4971ee44b24056bfeb8242b31ab475" contextRef="c20231231" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,594</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89610" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89611">
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89611" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89612">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div class="BRPFPageFooter" style="width: 100%;"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>

            <!--PROfilePageNumberReset%Num%13%%%-->
            <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89612" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89613">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company
              and all of its subsidiaries entered into a credit agreement (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement
              provides for a total of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_2dfebf36807c41978529e946f59a9c23" contextRef="c20231218" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">135.0</ix:nonFraction> million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term
              loan in the aggregate principal amount of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_5093b6d403c04294b76f35dc27d1af82" contextRef="c20231231_CreditFacilityAxis_TermLoanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">62.5</ix:nonFraction> million and (ii) a revolving credit facility in the aggregate principal amount of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_f49075c9aca34d47baadb256616dd4b7" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">72.5</ix:nonFraction> million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity
              date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_1bbfd756e84d405d83e78f241d601d84" contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" format="ixt:date-monthname-day-year-en">December 20, 2027</ix:nonNumeric> (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, the Company used the proceeds from the Ares Loans,
              along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP (&#8220;Hayfin&#8221;)
              including the outstanding principal in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_65f5e2d3aa44455f9308eb72968d4577" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">158.6</ix:nonFraction> million. On August 14, 2024, the Company repaid $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" id="Fact_16ca0ea411b3423eada893c28e19b488" contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction> million against the revolving credit facility and the outstanding balance on the revolving credit facility as of September 30, 2024 was $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_e34c88dc260840b4afc6f7d54635db01" contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.5</ix:nonFraction> million.</div>
</ix:continuation>
            <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89613" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89614">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <br/>
            </div>
</ix:continuation>
            <div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">
              <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89614" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89615">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the term loan bear
                  interest at the adjusted Term <span style="-sec-ix-hidden:Fact_f94c3272e4024032bf1c8ec0500c05eb"><span style="-sec-ix-hidden:Fact_837d17e5cc4148dab6c5f12dca0a9d3b"><span style="-sec-ix-hidden:Fact_2d5d7cee97d843e6bdafc3e0cea93ecc">SOFR</span></span></span> for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_f95443f8526b433eaa4fa84798dc1b44" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> tenor in effect on the day that is <span style="-sec-ix-hidden:Fact_8458c263b75e47d7a0c66a15b98f6079">two</span> business days
                  prior to the first day of the applicable calendar quarter plus <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_33cecfcc6c2640ce88a99479d9bb388a" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.50</ix:nonFraction>% (the &#8220;Initial SOFR Term Loan Applicable Margin&#8221;).
                  Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_51f1831751a447468cfe31c76d77d3b2" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> tenor in effect on the day
                  that is <span style="-sec-ix-hidden:Fact_8c7034ac2c65418ea392b4cb6da4a682">two</span> business days prior to the first day of the applicable calendar quarter&#160;plus <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_8361472b81154add9f6df813ffbfc737" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.75</ix:nonFraction>% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of September 30, 2024 and December 31, 2023, the interest rate on the term loan
                  was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_5ec193f649864764a6dc4d0ec3988baa" contextRef="c20240930_CreditFacilityAxis_TermLoanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.36</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_0f7f1c7c29c4430eb4cc0979735df660" contextRef="c20231231_CreditFacilityAxis_TermLoanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.88</ix:nonFraction>%,
                  respectively, and the interest rate on the revolving facility was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_6eaf8a4524a34453b3eb4600468fbae5" contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.08</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_8880d95fec914976865b552f90224a00" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.13</ix:nonFraction>%, respectively. </span></div>
</ix:continuation>
              <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89615" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89616">
<div style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </div>
</ix:continuation>
              <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89616" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89617">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">On the Ares Maturity Date, the Company is required to pay Ares the entire
                outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are <ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" id="Fact_97979d7111454f0797c715eda8489b7e" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction>
                scheduled principal payments on the Ares Credit Facilities, and the Company is required to make <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="Fact_856910d6f6154763bfe305e516ebff42" contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">quarterly</ix:nonNumeric> interest payments to
                Ares of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" id="Fact_ec1f213702c646979b2a6fc85f3075bb" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction> million. The Company may prepay the outstanding principal under the revolving facility, together with
                any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_b6b7fa74500a4b88b6db8be11e46fee6">three</span> business days&#8217;
                prior written notice with <ix:nonFraction name="adma:PrepaymentsOfDebtPremium" id="Fact_84d0d0f638884c4d9b6de7f489c83994" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> prepayment premium. However, in the event the Company prepays an amount under the revolving credit
                facility that is greater than <ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" id="Fact_5fb8c515b8e74275af9b9a6b4c925f6b" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the original $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_80cbf36d1ed64509a4ef4837097392a8" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">72.5</ix:nonFraction> million outstanding balance (of which $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" id="Fact_bbe86f8dd39d414288f1dbd5cfc38a9e" contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction> million, or <ix:nonFraction name="adma:PercentageOfCreditFacilityRepaid" id="Fact_988477fa400a4a60b251596fc1791fcb" contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">41.4</ix:nonFraction>%, has been repaid to date), the Company will still be required to pay interest on <ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" id="Fact_ed5c559b2ea644678829afb29b74d143" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of this balance, or $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_5ac6342f408046c3aaeed656a5b28de2" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">36.3</ix:nonFraction> million, through the term
                of the Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_572da660a7754ce69aefce28a22367a6">three</span> business days&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date
                of all remaining required interest payments on the principal amount being repaid plus <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_a25b672ba67d406dac40af07beadc4a9" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction>% of the prepaid principal amount, if
                prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_e6198b4bbc1642ac86473acdd1e8be8f" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_46204a65ec5d422dba63d24c1f56816b" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction></ix:nonFraction>% of the prepaid principal amount, if prepaid
                after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_c19906bd09b146aaba2f6df4ca46e5cf" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>%
                of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.</div>
</ix:continuation>
              <div>
                <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89617" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89618">
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
                  </span></div>
</ix:continuation>
                <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89618" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89619">
<div style="display:none;"><br/></div>
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">In connection with the closing of the Ares Credit Facility, the Company
                  incurred fees and expenses related to the transaction of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" id="Fact_fca1201217c64558a1324cfc954f285f" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction> million, including a $<ix:nonFraction name="adma:OriginalDiscountPayableCreditFacility" id="Fact_ccec40cd52c84b868d9a9e8ea289539a" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is also required to pay Ares an exit
                  fee of $<ix:nonFraction name="adma:DebtInstrumentExitFee" id="Fact_7e479c5bf9414c459fab6dab11c7eea0" contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:DebtInstrumentExitFee" id="Fact_36825ed16eb54a649ead4eb2beec695c" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction></ix:nonFraction> million upon the earlier of any prepayment date or the Ares Maturity Date, and this amount has been accrued as
                  a separate liability in the Company&#8217;s consolidated balance sheets as of September 30, 2024 and December 31, 2023. As a result, the Company recognized an aggregate debt discount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_75cae3bff7564b679e26ecdc19d8b364" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction> million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans as of September 30, 2024 and December 31, 2023 was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_7d093d5f1a4543218c53dacc518df2bf" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.73</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_4c93956a32c64236ad54bf44b7a8b12c" contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.39</ix:nonFraction>%,
                  respectively. This debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. </div>
</ix:continuation>
                <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89619" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89620">
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; color: rgb(0, 0, 0);"><br/>
                  </span></div>
</ix:continuation>
                <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89620" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89621">
<div style="display:none;"><br/></div>
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; color: rgb(0, 0, 0);">All of the Company&#8217;s obligations under the Ares
                  Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s
                  subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include
                  certain financial covenants, including maximum total leverage ratios and a $<ix:nonFraction name="adma:MinimumLiquidityCovenantsCreditFacilities" id="Fact_edf841526c1a4bf5999a5346eab52f98" contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million minimum liquidity covenant, and also
                  restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage
                  in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit
                  Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of
                  September 30, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</div>
</ix:continuation>
                <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89621" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89622">
<div><br/></div>
</ix:continuation>
              </div>

            </div>

            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageFooter" style="width: 100%;"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>

            <div style="font-family: 'Times New Roman'; font-size: 10pt;">
              <div>
                <div style="color: rgb(0, 0, 0);"> <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89622" continuedAt="Text_b9ac68e4734f41e58e972ba77f45a89623">
<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span></div>
</ix:continuation>
                  <ix:continuation id="Text_b9ac68e4734f41e58e972ba77f45a89623">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;">Events of Default on the Ares Loans include, among others, non-payment
                    of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of
                    control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_7e2ba7bf3e504373977dc1778c00f10f" contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>%
                    per annum.</div>
</ix:continuation>
                </div>

              </div>

            </div>

          </div>
<div>

          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_5ecaf0c606624acda2de24059b4958ef" contextRef="c20240101to20240930" escape="true" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83201">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83201" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83202">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83202" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83203">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83203" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83204">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83204" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83205">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83205" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83206">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83206" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83207">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83207" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83208">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83208" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe83209">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe83209" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832010">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to <ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_b9b54c54c9bf41d489c65bd4a722e3ab" contextRef="c20231231" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_26c1477333a54cbcb4d8a99938f43771" contextRef="c20240930" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction> million shares of preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_bc71659805f743e7b1bf6e9af3b48f22" contextRef="c20240930" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_b2e722cfa28b45708007730b42ceb347" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>, par
            value per share. There were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_7b9e855f3516419cb237f8cfcb8cc7d5" contextRef="c20240930" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_65a9cd8eb6464e91896777fb8b439f71" contextRef="c20231231" unitRef="U001" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at September 30, 2024 and December 31, 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832010" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832011">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832011" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832012">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832012" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832013">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832013" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832014">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832014" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832015">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832015" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832016">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832016" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832017">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832017" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832018">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024 and December 31, 2023, the Company was authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_ddd782814006439eb9b3210d64e46d5a" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_b49dbf123d754146a76cb5e4876ce280" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction> shares of its common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_b2ad31e31276488db959addb7e755933" contextRef="c20240930" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_22c4c35d68ed448495d4bf8844193f39" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
            par value per share, and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_ffa31f9f144143659de1f738e1722904" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">236,378,607</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_f4d31292941747febd54735d4d6b23ea" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction> shares of common stock were outstanding as of September 30, 2024 and December 31, 2023, respectively. After giving effect to the <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_53a22a3e467548a7993906b4ed13a822" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">27,759,065</ix:nonFraction> shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of September 30, 2024
            there were <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_f7243748a774461faf9a3b4be57035f1" contextRef="c20240930" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">35,862,328</ix:nonFraction> shares of common stock available for issuance.</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832018" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832019">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832019" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832020">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832020" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832021">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"><span style="text-decoration: underline;">Warrants</span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832021" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832022">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832022" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832023">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832023" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832024">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832024" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832025">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On January 10, 2024, a former noteholder of the Company exercised a warrant to
            purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_7e170b975b354f9f9b654ba0a8985deb" contextRef="c20240110" unitRef="U001" decimals="-6" scale="6" format="ixt:num-dot-decimal">4</ix:nonFraction> million shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_64207fe26b2f47d5b935513e39b25719" contextRef="c20240110" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,977,514</ix:nonFraction> shares of common stock to this noteholder. On March 8, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_64c53d6438d64f68ac673e0acdc210a4" contextRef="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,388,681</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_5021d12fcd424f2b8e230f859d38c7e2" contextRef="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,482,205</ix:nonFraction> shares of common stock to Hayfin and its affiliates. On March 14, 2024 an entity associated with another former noteholder of the Company exercised a warrant to
            purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_e979c640d62a4c4aa7d87c5ab5db01fe" contextRef="c20240314" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">169,651</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_5a70935f1f494d57a01ea02039b59688" contextRef="c20240314" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">85,784</ix:nonFraction> shares of common stock to this entity. On May 9, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_030d0eaadbee4c9397dd427d4bed55dd" contextRef="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,787,424</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_a530a2edeeae4431ad6da20a281e109b" contextRef="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">937,507</ix:nonFraction> shares of common stock to Hayfin and its affiliates. On August 15, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_3b14d97a736b43ccb4bed06b0b522bf1" contextRef="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,962,946</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis and the Company issued an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_9d49b9da21cb468eaa1f109bf6c3de29" contextRef="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,741,882</ix:nonFraction> shares of common stock to Hayfin and its affiliates.</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832025" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832026">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832026" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832027">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-size: 10pt;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832027" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832028">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832028" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832029">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On February 24, 2024 a warrant to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_494a938c77bc41e69318648cdebcc219" contextRef="c20240224" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">34,800</ix:nonFraction> shares of the Company&#8217;s common stock held by a former noteholder of the Company expired in accordance with its terms. At September 30, 2024
            and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_6391864b8fd04963a63465fd41fb7766" contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,159,404</ix:nonFraction> and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_55e479c4c2c747d6947551c65e176d8d" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction> shares of common stock, respectively, with weighted-average exercise prices of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_5bb412b50954420a8597e015f29f107b" contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.26</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_3085135229654bdb9a8414ad8c61d55e" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.32</ix:nonFraction> per share, respectively, with expiration dates
            ranging between October 2024 and May 2030. <ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Text_78190f10556a4ac9a4719d3bb6f63024" contextRef="c20240101to20240930" escape="true" continuedAt="Text_4767526d5c6a4f6984d51acc33ca7a9e1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The







            following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:</span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832029" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832030"><ix:continuation id="Text_4767526d5c6a4f6984d51acc33ca7a9e1" continuedAt="Text_4767526d5c6a4f6984d51acc33ca7a9e2">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
          </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832030" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832031"><ix:continuation id="Text_4767526d5c6a4f6984d51acc33ca7a9e2">
<div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-transform: none;">
            <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; font-weight: bold;">Shares</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div style="text-align: center; font-weight: bold;">Weighted</div>
                    <div style="text-align: center; font-weight: bold;">Average</div>
                    <div style="text-align: center; font-weight: bold;">Exercise Price</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at December 31, 2023</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_594febf50da54e058567dca931c866fb" contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><br/>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div>$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_b6366a81059f45afa6f3bad9c2155a25" contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.32</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div>(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="Fact_fc905bf0b4d24cdd948c6715684c2a08" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">34,800</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                    <div>$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                    <div><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="Fact_c4f871f2e71d4e8581c3fffed5f21b68" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.50</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_15933775e9dc47d39192b4320a34779d" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="INF" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;"><br/>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div>$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_b19c4078dfb64134829012b40b848eba" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                    <div>(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="Fact_99db5ecb75be44bea8fd732778bb1532" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">11,308,702</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                    <div>)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                    <div>$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                    <div><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="Fact_76f8c495d79e4268a65ea95ecbff44f9" contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.31</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at September 30, 2024</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_d7fff4a1ebba44cbb74588db6c824ee7" contextRef="c20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,159,404</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;"><br/>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div>$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_52f5a3caa11e4f9893ec44d7ef8b2637" contextRef="c20240930_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.26</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
             </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832031" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832032">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832032" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832033">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832033" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832034">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832034" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832035">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832035" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832036">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832036" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832037">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under t<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">he </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company&#8217;s equity incentive plans</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> w</span>as determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was
              developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the
              expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair
              value estimate. </span><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_91b9573094e44c8f81d6558493652ebe" contextRef="c20240101to20240930" escape="true" continuedAt="Text_df86c9bd305646d3a40cbe87f23312be1"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:</span></span></ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832037" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832038"><ix:continuation id="Text_df86c9bd305646d3a40cbe87f23312be1" continuedAt="Text_df86c9bd305646d3a40cbe87f23312be2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832038" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832039"><ix:continuation id="Text_df86c9bd305646d3a40cbe87f23312be2" continuedAt="Text_df86c9bd305646d3a40cbe87f23312be3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832039" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832040"><ix:continuation id="Text_df86c9bd305646d3a40cbe87f23312be3" continuedAt="Text_df86c9bd305646d3a40cbe87f23312be4">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="4" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_12c7ba515d2748c5a007d98ce69f435b" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_9b624afe1d8c47f4aaa282755aac7aa0" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_6b9c9b97abd440209c9481dfa3cbd31e" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric> - <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_8902a860acb64624aac2832fc757c93c" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_8aa5c1e9f9014d92a38c62f1cdb79e67" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">66</ix:nonFraction>%</span></div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;"> <br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_84de2c86c8ed4adaa3ac1de2e4f91c46" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction>%</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_35fbb3c7aa984210b9f2bb19013f5e01" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction><br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_7a011900174b40e18b6a2b8886c38889" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction></span></div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_53a74d8a596848388c51606270ebc70c" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.16</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_48b2fd77b8e7491482d9785659c67237" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.34</ix:nonFraction>%</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_4b333a6995454944b0fb75439f40ff8c" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.20</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_12a3244223a047d8ae7ec0e23d08b66d" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.24</ix:nonFraction>%</div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832040" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832041"><ix:continuation id="Text_df86c9bd305646d3a40cbe87f23312be4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832041" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832042">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832042" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832043">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832043" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832044">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;During the nine months ended September 30, 2024 and 2023, the Company granted options to purchase an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_8d16cb867c634dcd8c57782ad7db5a7d" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,511,624</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_2dc9fcae917d4955a3db788f3e697ea7" contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,727,510</ix:nonFraction> shares of
            common stock, respectively, to its directors and employees. The weighted<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">-</span>average remaining contractual life of stock options outstanding and expected to vest at
            September 30, 2024 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_7a46a06fb7164b9e84caf8b70057768e" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.5</ix:nonNumeric> years. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The weighted<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">-</span>average remaining contractual life of stock options exercisable at
              September 30, 2024 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_93dd12df3e814bd58538ea3f7c4e7b96" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">6.2</ix:nonNumeric> years. During the nine months ended September 30, 2024, options to purchase an aggregate of <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_4f1c788bc92244a7818e06557c51810b" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,925,498</ix:nonFraction> shares of common stock were exercised, which included certain exercise transactions for which an aggregate of </span><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" id="Fact_9115bc33cd864eb789275a81861a21ad" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">31,219</ix:nonFraction><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> shares were withheld to cover the exercise price and income tax liabilities, and the Company received aggregate net exercise proceeds of $</span><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_39cb61c98d564c1688cb0ff340e4eaf9" contextRef="c20240701to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.1</ix:nonFraction><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million.</span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832044" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832045">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>
</ix:continuation>

          <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_076a681cd8bd47819400c863c4d20d7f" contextRef="c20240101to20240930" escape="true" continuedAt="Text_f042e24abd9744a2a10681f8228761401"><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832045" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832046">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
            follows:</div>
</ix:continuation></ix:nonNumeric>
          <ix:continuation id="Text_f042e24abd9744a2a10681f8228761401" continuedAt="Text_f042e24abd9744a2a10681f8228761402"><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832046" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832047">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f042e24abd9744a2a10681f8228761402" continuedAt="Text_f042e24abd9744a2a10681f8228761403"><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832047" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832048">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f042e24abd9744a2a10681f8228761403"><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832048" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832049">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </div>
                </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_250a2065177a4c429f08d52968095a5c" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,906,184</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_8152b7291121408aaf910859fd75a6be" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.38</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_d282f9183bd84337a46e0803993a71e8" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">15,723</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_230f8e31350843b29316323e9a49788d" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.94</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_33eb597814404b77887f9305af1dd8c1" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">221,067</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_50404ded5138423c922aba19379e676e" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.34</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_35ef16bff83342d0ad7bf65df106a2e2" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,511,624</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_9a0077af70cd4741b29e577f6394478d" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.25</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_513e07c3e15642caa00299a745cdbb46" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,925,498</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_aa54b02879254f4980627817acf3cb44" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.85</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_3e27f95168fc42d381c5f624469b0926" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,255,520</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_4f7b643a508c4bfc818eb6a8a1a19b9b" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.87</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_6cf2ca0b342d4372807ee9385792734a" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,509,884</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_a8c2fca303014785918bf4418193677b" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.10</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
           </div>

        <div>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832049" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832050">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="width: 100%;" class="BRPFPageFooter"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832050" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832051">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832051" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832052">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_2183e0f1f8704f66b62b47119a97a396" contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.4</ix:nonFraction> million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_ecb74b7ba0d544f49e5c10daf39ab80b" contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">2.9</ix:nonNumeric> years.</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832052" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832053">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832053" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832054">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; text-indent: 18pt;">
            <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832054" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832055">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the nine months ended September 30, 2024 and 2023, the Company granted RSUs representing an aggregate of
              <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_238e19f7ba244106829cde536281ffc7" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,227,188</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_ebb465465aaf46af9fa1faa819b57c1f" contextRef="c20230101to20230930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,345,760</ix:nonFraction>
              shares, respectively, to certain employees of the Company and to members of its Board of Directors. These RSUs generally vest annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_e55332d8b6bc4341aad8a051672567f1" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric> for employees and semi-annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_46e15336afda4e8a9eeb2f4d044efd88" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> for directors. During the
              nine months ended September 30, 2024, an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_c664144df99942dd8cf43afccc2a8cfc" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,701,229</ix:nonFraction> shares of common stock vested in connection with grants of RSUs.
              With respect to these vested RSUs, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_d2708ba18da74a3cb0ed1079b49e64c0" contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">504,825</ix:nonFraction> shares valued at approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_6ac0a60722ec445c9120c7c848371dcf" contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.3</ix:nonFraction> million were withheld by the Company to cover employees&#8217; tax liabilities. These shares were no longer outstanding as of September 30, 2024. <ix:nonNumeric name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="Text_0f7d8855abb74f1da2c548ef9c1047a0" contextRef="c20240101to20240930" escape="true" continuedAt="Text_906e2d62a8a94baba2e302c8ffe130341"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested
              RSU activity and related information is as follows:</span></ix:nonNumeric></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832055" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832056"><ix:continuation id="Text_906e2d62a8a94baba2e302c8ffe130341" continuedAt="Text_906e2d62a8a94baba2e302c8ffe130342">
<div><br/></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832056" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832057"><ix:continuation id="Text_906e2d62a8a94baba2e302c8ffe130342">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" rowspan="1" colspan="2">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </div>
                </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_754791977cc843ebb868c56c9f3fc0af" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">4,657,297</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_a61ac8157e3a4ea19f45c7aefc659f8b" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.81</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_8e0112ccef2d43a59caf59531fc49762" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">3,227,188</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_457272f4d59d47c899698d338d9af273" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.25</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_1fb112804b954b5ab776bae291995716" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">1,701,229</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_36945ffa76e64934bbb46c7696422283" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.59</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_ba9d6fbb81a940789dc26f0dfba2305a" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">211,688</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div>)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_14bc3c86652c4a89a3c03b2b76717b09" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.57</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_946c42005c2048a2848c0be9e56e1fad" contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">5,971,568</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_d7d161d634a141d09da4d14d75f1224b" contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.25</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832057" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832058">
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832058" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832059">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832059" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832060">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832060" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832061">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_ec4965b2d61f42afbda21c314eb14eea" contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">27.4</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_d27bb0adf9604c968b2a387e60441452" contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">3.2</ix:nonNumeric> years.</div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832061" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832062">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832062" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832063">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832063" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832064"><ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Text_0cfebe5db0554c4a8d6b82f250a91866" contextRef="c20240101to20240930" escape="true" continuedAt="Text_43ce51d9db794c868bc7f4664ff99fc61">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832064" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832065"><ix:continuation id="Text_43ce51d9db794c868bc7f4664ff99fc61" continuedAt="Text_43ce51d9db794c868bc7f4664ff99fc62">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
            and nine months ended September 30, 2024 and 2023 is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832065" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832066"><ix:continuation id="Text_43ce51d9db794c868bc7f4664ff99fc62" continuedAt="Text_43ce51d9db794c868bc7f4664ff99fc63">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832066" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832067"><ix:continuation id="Text_43ce51d9db794c868bc7f4664ff99fc63" continuedAt="Text_43ce51d9db794c868bc7f4664ff99fc64">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832067" continuedAt="Text_f11874f680ce4dd1b04ed3f41afe832068"><ix:continuation id="Text_43ce51d9db794c868bc7f4664ff99fc64" continuedAt="Text_43ce51d9db794c868bc7f4664ff99fc65">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_f11874f680ce4dd1b04ed3f41afe832068"><ix:continuation id="Text_43ce51d9db794c868bc7f4664ff99fc65">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; text-align: center; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_614cb3d802f3493896310988b88303cb" contextRef="c20240701to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_ba4eb47a9b0c4842bcf9424f9c7ea510" contextRef="c20230701to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">12</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_f7207f38a9984250b335f3dac7bb828f" contextRef="c20240101to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">65</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_af6deabdb2284d5a8e5a1375fec15412" contextRef="c20230101to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">27</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_a9230d8a86e74ffd95483f442a38d5ea" contextRef="c20240701to20240930_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">44</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_25cf26f73406406f9c9cbea1bbfd01c4" contextRef="c20230701to20230930_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">41</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_df43ad8a114c43c5912402cabf552c74" contextRef="c20240101to20240930_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">131</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b59664423d16445c8a7b5c860a2778ff" contextRef="c20230101to20230930_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">104</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_73d17c56a3e04b0ea1f3cd37313443ad" contextRef="c20240701to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,714</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_a4e1a272aff64a1b97a3415fa0d808d7" contextRef="c20230701to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,451</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_c590ce5a2ca44d3eae03f4d96e1f4033" contextRef="c20240101to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,960</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_02b5653d55914c6591ce009ad4749ae4" contextRef="c20230101to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,839</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_2a85f7e7ce42430bb72c05a63bb64a5e" contextRef="c20240701to20240930_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">397</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8019c05f9082431887608791d11f58ee" contextRef="c20230701to20230930_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">191</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_086574d078894d459fbedfb966cb4f15" contextRef="c20240101to20240930_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,027</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_69728ee16d06448e9b1c320826b5cfb2" contextRef="c20230101to20230930_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">472</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1f38784f4d374375bb85d60c27e6060d" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,179</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_c4dc7b3ffdb540dc85e2675ebe16ead5" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,695</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_320f2fb19c2c424298172bfc544ee086" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,183</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_e4d3e53c16db4cd18588642339e64952" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,442</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div><ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_c780bfd708e44e8fa86486118498f0cb" contextRef="c20240101to20240930" escape="true" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a181">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  </div>
</ix:nonNumeric>
      <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a181" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a182">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>
</ix:continuation>
      <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a182" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a183">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a183" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a184">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a184" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a185">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
      <div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
        <div style="text-indent: 36pt;">
          <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a185" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a186">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company leases office space and
            equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $<ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_9c427e4b0b334fb1bb6a840a5e877fe6" contextRef="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction>,000 through December 31, 2026. Rent expense for the nine months ended September 30, 2024 and 2023 amounted to $<ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_f2835458968540ffaf6bc7139cb0d6fb" contextRef="c20240101to20240930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_dc09406eb8d042dfbfb90a3aa7cd8b8d" contextRef="c20230101to20230930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></ix:nonFraction>,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
            Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the nine months
            ended September 30, 2024 and 2023.</div>
</ix:continuation>
          <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a186" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a187">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a187" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a188">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the nine months ended September
            30, 2024 and 2023, the Company purchased certain specialized medical equipment and services primarily related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#8220;Genesis&#8221;),
            aggregating to $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_72a91b461c464392bdedb0b7122ffa71" contextRef="c20240101to20240930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_a3b7c894548e438699625bc4efac2a3f" contextRef="c20230101to20230930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction>
            million, respectively. Genesis is owned by Dr. Grossman and Mr. Grossman.</div>
</ix:continuation>
          <div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a188" continuedAt="Text_91fd8585f2044552b41357c2fb0b8a189">
<div><br/></div>
</ix:continuation>
            <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
              <div class="BRPFPageFooter" style="width: 100%;"></div>

              <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

              <div style="page-break-after: always;" class="BRPFPageBreak">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div class="BRPFPageHeader" style="width: 100%;">
                <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
                </div>

                <div>
                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                  <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_91fd8585f2044552b41357c2fb0b8a189">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the three and nine months ended
            September 30, 2024, <ix:nonFraction name="adma:NumberOfExecutiveOfficersThatExercisedOptions" id="Fact_c0ace11f7e034a93ba86049d2e7b39c9" contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="adma:NumberOfExecutiveOfficersThatExercisedOptions" id="Fact_5d99eb01bef14477a21b937f86a55c5c" contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></ix:nonFraction> of the Company&#8217;s executive officers exercised options to purchase an aggregate of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_815dce9c77a845068cecb965122d671b" contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_216c90db18f9412cb905c45128a85fd7" contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">650,395</ix:nonFraction></ix:nonFraction> shares of common stock, for which the Company received net proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_f3807ff2824b4f7c8bd08cc26959a050" contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_a3adb71de3c942fd8bfdefc708e3664b" contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction></ix:nonFraction> million (see Note 8). During the three and nine months ended September 30, 2023, <ix:nonFraction name="adma:NumberOfExecutiveOfficersThatExercisedOptions" id="Fact_f57a769f16c94f59bfd2d16b75f96b71" contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="adma:NumberOfExecutiveOfficersThatExercisedOptions" id="Fact_e4972df233a34ab39bdb5d0e5b551c47" contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></ix:nonFraction>
            of the Company&#8217;s executive officers exercised options to purchase <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" id="Fact_a14cb0864682499ab13561da4328245a" contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" id="Fact_96bd570060054df3a30213b5d3c82f03" contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,909,721</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s common stock on a cashless
            basis, and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_73034da93fa14e5e853b52d8e109208c" contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_4b07a46c27964b0aa00f6b6011e2f0be" contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">688,657</ix:nonFraction></ix:nonFraction> shares of common stock were issued to these executive officers, net of <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_cc5a09a6eb57472fb032f8b027908404" contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_1d33ddb0177245a195a5be362d7ffa30" contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">257,867</ix:nonFraction></ix:nonFraction> shares of common stock to cover a portion of their tax liabilities. </div>
</ix:continuation>
        </div>

      </div>


      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </span></div>

      <div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
 </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_4473a060a68a403d939a6af745d8e9bf" contextRef="c20240101to20240930" escape="true" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da1" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da2">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da2" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da3" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da4" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da5" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da6">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da6" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da7" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da8">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da8" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da9">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">From time to time, the Company is or may
              become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s
              liquidity, results of operations or financial condition. </span></div>
</ix:continuation>
          <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">
            <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da9" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da10">
<div><br/>
            </div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da10" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da11">
<div style="font-style: italic;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da11" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da12">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da12" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da13">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of
              source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase
              Agreement the Company was permitted to also collect high-titer RSV plasma from up to <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilities" id="Fact_2ac00a24c78b4a569a9ea8f1904f18a3" contextRef="c20240101to20240930_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> wholly-owned ADMA plasma collection
              facilities.&#160; During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the
              Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the
              Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for <ix:nonFraction name="adma:NumberOfRenewalTerms" id="Fact_364336ee0ba3405b962f2cb037e4858a" contextRef="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional <ix:nonNumeric name="adma:PlasmaPurchaseAgreementRenewalPeriod" id="Fact_fc9e3bd9ac5248a59062599e51a87502" contextRef="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> periods
              if agreed to by the parties. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its
              successor-in-interest, effective January 1, 2019.</span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da13" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da14">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da14" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da15">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 6, 2017, the Company entered into
            a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that
            contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric name="adma:PlasmaSupplyAgreementTerm" id="Fact_a258413f0f2646849d0ce7c29a720a6c" contextRef="c20240101to20240930" format="ixt-sec:durwordsen">10-year</ix:nonNumeric> term. On July
            19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is
            unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for
            the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da15" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da16">
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;">
            </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da16" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da17">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da17" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da18">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-Marketing Commitments</span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da18" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da19">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da19" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da20">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"><br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da20" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da21">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the nine months ended September 30,
              2024 and 2023, the Company incurred expenses related to this study in the approximate amount of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_e79ad84c63e642478ee7f01482bf1042" contextRef="c20240101to20240930_ProductOrServiceAxis_ASCENIVMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_1ce748be4df743828f98a1b667b58ba2" contextRef="c20230101to20230930_ProductOrServiceAxis_ASCENIVMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million, respectively. The Company expects to incur expenses of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_2916e0a780394d25a51fb73c9c9a0fe9" contextRef="c20190401to20190401" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million to complete this study, which is required to be completed by June of 2026. </span></div>
</ix:continuation>
          <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da21" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da22">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
            </div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da22" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da23">
<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment Contracts</span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da23" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da24">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da24" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da25">
<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da25" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da26">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company previously entered into employment agreements with Mr. Grossman and with Brian Lenz, the Company&#8217;s former Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters. Effective as of April 1,
              2024, Mr. Lenz transitioned to a non-employee consulting role and entered into a consulting agreement with the Company. On April 1, 2024, the Company entered into an employment agreement with Kaitlin Kestenberg, who was promoted to Chief
              Operating Officer and Senior Vice President, Compliance. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On July 24, 2024, the Company entered into an employment agreement with Brad Tade, who was appointed Chief Financial Officer and Treasurer of the Company.</span><span style="font-family: 'Times New Roman';">
              <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da26" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da27">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>
<ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da27" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da28">
<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span>
           <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-style: italic;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da28" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da29">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: italic;"><span style="text-decoration: underline;">Other Commitments</span></span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da29" continuedAt="Text_c093f8f7a5ef47698d9b702c3f9cf8da30">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="text-decoration: underline;"> <br/>
              </span></span></div>
</ix:continuation>
          <ix:continuation id="Text_c093f8f7a5ef47698d9b702c3f9cf8da30">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and executive officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these
            arrangements is unknown as of September 30, 2024. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
</ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_8d577c5a49fb4883907c94d4289126da" contextRef="c20240101to20240930" escape="true" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced1" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced2" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced3" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced4" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced5" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">The
              Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#8217;s ADMA BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development
              operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of&#160; <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_5b964c264c87450fbf5e17497f368e3d" contextRef="c20240701to20240930" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> plasma collection facilities
              located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and
              administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive Officer. For the Company&#8217;s <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_f52bc11dad42476087d41ea74aa775ca" contextRef="c20240101to20240930" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_ace1429e22f7499c863c9704403e8a50" contextRef="c20240101to20240930" escape="true" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">Summarized









              financial information concerning reportable segments is shown in the following tables:</span></ix:nonNumeric></span></div>
</ix:continuation>
          <div><ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced6" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced7"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b1" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b2">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><br/>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced7" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced8"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b2" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b3">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2024</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"> ADMA </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">
                    <div> Plasma Collection </div>
                  </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_078c9302598340caae63c3e137fc6563" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">113,088</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_84c1e648bec4470b9230891446292a31" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,715</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_456aa1ce112745098eb161569e046920" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9f1e7bc91751486f924450d00a7c2464" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,839</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_9dd589651be6436da26a29380b6ab8a0" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,731</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_9671e27b1901441790108233d0e0051c" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,449</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_f0033ae92bab40cf9b4ea6ab97727e9e" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_68425aca8c3e4982a053847ecd39b545" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,180</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_8065e9e59c0242d4969289c81a9116a2" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,347</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_41298bec1e4f4639809a8b47c4f790c3" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,755</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_422311e8bfc14f02b48c8510db6e3a0b" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,954</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_62ffc3340cba45a79fd15a9fcab85710" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,638</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_657d21f6d8f6433b9ea2a1954bab1de5" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">54</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_097657deac124b1c8d9a99172daa17a0" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_14bbf56cbcf2483a8da2356c4d248c35" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,835</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_4cb32e29d77e46658cc78460a11e42e9" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,889</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss)
                        before taxes</span></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_2e2437fa2d5949049e1dacdddc592d81" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,293</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_fe52c2f3969440469cd6a9f37a2f9bf1" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,755</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_9163c6e3d2424c4dbcc4628b9af9fb9a" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,789</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_70c7d7333bbe4090a54383a2d38fdf4c" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36,749</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;"><br/>
                  </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense </div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_876ce33540fa4412a44e1705609da93c" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,138</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_1cd07a5831ac4bda9ad7d27722d354e7" contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">802</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_8b6d3120be4b4cf48dd09e0f5562774e" contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_6b0c9058ac064b13a2fcad62a744bcd2" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,940</ix:nonFraction></div>
                  </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                  </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_bd41babfb1fe4de3af6aa1fc70ba89e2" contextRef="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">266,456</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_bfada37cdfa64af78860b766a8723f14" contextRef="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,191</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_103bbb510a4a40c6bfdbb4688a6b720a" contextRef="c20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">90,971</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_1ea6ebbae4564edab53178c815478582" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">390,618</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          </div>

          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced8" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced9"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b3" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
            </span></div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>

          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced9" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced10"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b4" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation> </div>

        <div>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced10" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced11"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b5" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b6">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"> ADMA </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">
                  <div> Plasma Collection </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1fcae80ca8394867ba871cde3cb22c26" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">66,567</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6ac55ed13a254ba6bdeaaef90967b16f" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">672</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_36a2784280d347e092795ef16becf3d5" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_95a00577b70c4a56bb3aeaeaf6777077" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,275</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_8e5dc2817f934685b01500a557ac2559" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">41,734</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_06c7fe9991584bea8956b636a24024eb" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">888</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_ab713f9117fd4889831a0a1d8ec8c37a" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_db5e0e1c76d5483b8d2288b50775e975" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,622</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_262733d31e254f3da9c77f4fdc8f0f24" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,017</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c060cd3fd03c423f92a70e4d1e6d480a" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">683</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c38d45651e694bf9ae9ba4cd7d0366a2" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,649</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_ba04025d338644239f1a2adbc8bf966a" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,685</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other (expense) income, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_bfae18d71c074b23839a9fad43920c5f" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">141</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_d342e1f1b4de4b879b4ded5b492efd68" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_2a24fde6a0e045169bdd068260fe35d5" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,979</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_76857455e86a4c3c8ce9c138b88fe275" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,120</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss) before
                      taxes</span></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_d42f82a09ba8474eaed39e2a8d9b7a7f" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,876</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_98dbf4a147554b449c9e265d3dece405" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">683</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_668b9a9930c84bf1875c346687befdf7" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,628</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_e91072c124694e9c88f1c785efe0adf9" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,565</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_fa50dd34b1874bbbacc40d98fb2e0cfc" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,282</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_d93f0cccb3714ca893f192fb9cf68a28" contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">811</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_8ec85abf291e4f5e869d0b48830d7724" contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_42214fb9c0ad4980b993fe06cda28152" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,093</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;">Total assets </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_cb1dd7de782946ffb6022a1fc6f811f0" contextRef="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">262,554</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_40dc2ae3c8414c158210d8d406e1be9f" contextRef="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,622</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_1bffc1f4b60a4d9f9114111fbc759102" contextRef="c20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">50,821</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:Assets" id="Fact_f0f9208679f742c29cfb87c4db5cea5e" contextRef="c20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">348,997</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced11" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced12"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b6" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b7">
<div> <br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced12" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced13"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b7" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b8">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation></div>

        <div>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced13" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced14"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b8" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b9">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="16">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2024</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center;" rowspan="1" colspan="2"> ADMA </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" rowspan="1" colspan="2">
                  <div> Plasma Collection </div>
                </td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" rowspan="1" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_158c7430f6f94a4e8e213d99ae0fe521" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">299,385</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c5eeb823fb51415494320073d699465e" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,413</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_cfa1978aeebb40ffb2237b5067399f60" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e5ebf4bc395047b89c913763a8963bf4" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">308,905</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_f79086f8be8d4cfea8e5b47df1dfe6f8" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">142,193</ix:nonFraction><br/>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_a86487922aff4ea38f04d0b526bfc926" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,492</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_c2d814125584474b852446c34ed2bcd7" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_9ac50f04f4eb44878c005e3a37cb0717" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">152,685</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_80a81078b34543278e27dfcc7cd6c11d" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">123,756</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_1c321b9b987d4a6bb3bc664f7d3642f4" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,047</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_76a6f9fb9afb45bea7048e6ee8ea5bde" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">19,049</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_2d2e2f727e6f4ca8b9cefd4be7429935" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,660</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_f22938fe971e4abd994065aa3a25a301" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">95</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_3c32e2c9896a41aba20500f107276031" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_cc5aa8eb11434271a6691e7bb978be81" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,560</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_0d364d55bcec4d3b872ec972325ce8c7" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,659</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_b80ad374c06748df9dab3e1d6e89254b" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">123,661</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_c344cb45fb8640169e737d5c5a4d09e7" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,051</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_1f0b0f1511fe4de097157b31b3b79e6f" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,609</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_6de2f481b4c94ba29088307c84749030" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">91,001</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">Capital expenditures<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_c8661c74f412472fb67fbba4dce47a24" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,364</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_ed165df269e14edca7fe3afa324533c6" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">105</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_68509a8fac00464097d4277b21857304" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_6bf6c7b914a545a097545a39ba8529b6" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,469</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_b9b2d384992f48cdb610d4885a2db785" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,686</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_86f13d429dc44845ae401a2d3321edc4" contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,415</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_f09ae0ce3d4a485fa252a642baf9005f" contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_5131f34b68b34cba932c612c57139c2c" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,101</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced14" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced15"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b9" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b10">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced15" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced16"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b10" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b11">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <!--PROfilePageNumberReset%Num%21%%%--> <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced16" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced17"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b11" continuedAt="Text_65c92ba98ca444ca82c2de43a584325b12">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced17" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced18"><ix:continuation id="Text_65c92ba98ca444ca82c2de43a584325b12">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2023</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;"> ADMA</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;">
                  <div> Plasma Collection </div>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_77b9f740f0204e63b624f8509f447e12" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">175,905</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_883fef9147914816afec69cccaf7ccda" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,299</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e65e8bbe45f643f4a9c3ac9d865fd333" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_30067e22782c4d75af58158e93c94061" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">184,311</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_e281bb1fb8dd4637bb71196639b3a0ad" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,708</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_e41aeebced434a7892cf49cd228e2041" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,747</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_0db5c44322de4ea482b240de9b17d141" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_7e2f759088f04736939c62ab8edb97d3" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">126,455</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3463075f1b7c417797b0fa350952e3e5" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,577</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_28638e2886c8491cb0875768e559ba97" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,029</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_3ca61f1b4f48442aaef4c11a18006a23" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">16,149</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_7fe7dccbe8624253b1d9e841a06d1c71" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,399</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_2813223937514c6db86b62e6a06aa301" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">170</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_78dfe50362434278a3e9c2cc4c61bff9" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_0a09245ef58c4fa2b6fdbd17196fcc07" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,823</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_d10580018c56494897a1f23eef8e96eb" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,993</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_a6df1dab4b154b4ea8b301215b076a3f" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,407</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_d89cda905fdc4c3fbf6ddb963962881c" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">3,029</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_a787b6ef1a854bcfb54744369aa9c303" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">33,972</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_bdce3a42032745b7b2387a23bbacab2d" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,594</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">Capital expenditures<br/>
                </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_4eb9cf58de224912906b87354208724b" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,768</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_4f7e50cfe2bb40bf8a97fed2699db3a5" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,806</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_6d2ae148ae4741b4b55ca998aa8c4f16" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_29c773af34f640c090176db226528bda" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,574</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_345268fa878e43ad9c46678ad0a96cd4" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,857</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_04b74955a2ff4eb2a5709a4fee97dc5b" contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,366</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_9800bb34c09745bd8beb054cf5f2caff" contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_d97509c981ae4d8c87d4402f873f3d00" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,223</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced18" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced19">
<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced19" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced20">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>
<ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced20" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced21"><ix:nonNumeric name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="Text_cb3457db51a845d5ad4ccf3d19e66190" contextRef="c20240101to20240930" escape="true" continuedAt="Text_cb3ad5c80e334793be3ec5a2b86288eb1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced21" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced22"><ix:continuation id="Text_cb3ad5c80e334793be3ec5a2b86288eb1" continuedAt="Text_cb3ad5c80e334793be3ec5a2b86288eb2">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced22" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced23"><ix:continuation id="Text_cb3ad5c80e334793be3ec5a2b86288eb2" continuedAt="Text_cb3ad5c80e334793be3ec5a2b86288eb3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced23" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced24"><ix:continuation id="Text_cb3ad5c80e334793be3ec5a2b86288eb3" continuedAt="Text_cb3ad5c80e334793be3ec5a2b86288eb4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced24" continuedAt="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced25"><ix:continuation id="Text_cb3ad5c80e334793be3ec5a2b86288eb4" continuedAt="Text_cb3ad5c80e334793be3ec5a2b86288eb5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_c62dc1c7e0274cd9a73a2bcc3b8c4ced25"><ix:continuation id="Text_cb3ad5c80e334793be3ec5a2b86288eb5">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; white-space: nowrap;"><span style="display: inline; float: none; letter-spacing: normal; white-space: nowrap; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-weight: 400; text-indent: 0px; text-transform: none;">(in thousands)</span></td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_658e3c1fd6b84b04adfdf679bba1c0b6" contextRef="c20240701to20240930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">114,748</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_bc2cd4e222984ca0be0f4132ee154b9f" contextRef="c20230701to20230930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,618</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_3794e485bc0c45328ba75c3861adb9ab" contextRef="c20240101to20240930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">295,465</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_caf33e60b35449f3b36cbceb414b8566" contextRef="c20230101to20230930_StatementGeographicalAxis_US" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">173,920</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_dcf2b40f2284402ab7604d2f38d635b3" contextRef="c20240701to20240930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,091</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_20a751098dc94e1ea3aed40c588cd050" contextRef="c20230701to20230930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,657</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_da2eb3b0ad8849918bae98fd5d65acb3" contextRef="c20240101to20240930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,440</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_bdaaf33ca6ff41789cc68fb7dbe75cef" contextRef="c20230101to20230930_StatementGeographicalAxis_NonUsMember" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,391</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fb6a8063e5184879acfffbd4518d9bb7" contextRef="c20240701to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">119,839</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b45ee5ebf8f14088993d5716a352c4c3" contextRef="c20230701to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,275</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_68de6db07dea406aa61037c443a608f5" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">308,905</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_466279db437d497da14fd7b2c507f479" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">184,311</ix:nonFraction></div>
                </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_07c47f886b1349e5b405490a00370332" contextRef="c20240101to20240930" escape="true" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc1">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc1" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc2">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc2" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc3">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc3" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc4">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc4" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc5">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc5" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc6">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.</div>
</ix:continuation><ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc6" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc7">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           <br/></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc7" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc8">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The Company determines if an arrangement is an operating lease at inception. Leases with
              an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities
              representing the obligation to make lease payments arising from the lease.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span>Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
              lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease
              term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;">Aggregate lease expense for the Company&#8217;s leases <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the three months ended September 30, 2024 and 2023 was approximately</span> $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_e2b08e43259248809e050b8907d8e4db" contextRef="c20230701to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_3d60ac7ef7c5444c929bf0d6d99b181d" contextRef="c20240701to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction></ix:nonFraction> million, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">aggregate lease expense for<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></span>the









                      nine months ended&#160; <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span>
                      30, 2024 and 2023 was <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">approximately </span>$</span><ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_b9ee2ed92ec042b6b43471c1c6df72d6" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_b272b9c20b7146f198adf5167230401e" contextRef="c20230101to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction></ix:nonFraction><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million</span></span></span>. Cash paid for the
                Company&#8217;s leases for <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span> 30, 2024 and 2023 was also
                  approximately</span> $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_ef43412d8b9245e5ae67a3c042d34813" contextRef="c20230701to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_204a032e45ce4621964c91ff0deb5688" contextRef="c20240701to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction></ix:nonFraction> million, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">and









                      cash paid for the nine months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span>
                      30, 2024 and 2023 was approximately $</span><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_f915f1c66e6548a4bd95fddaecc66c43" contextRef="c20230101to20230930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_16f6f3d10b534c219d48ec9747144b32" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction></ix:nonFraction> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">million.</span></span></span> </span><br/>
            </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc8" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc9">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc9" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc10">
<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc10" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc11">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc11" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc12">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The Company has aggregate lease liabilities of $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_ab98db09dd4b434c915c9e6d155b3836" contextRef="c20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.1</ix:nonFraction> million and $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_127bb570acba409da88206e7e23fcf1e" contextRef="c20231231" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.8</ix:nonFraction> million as
                of </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> 30, 2024 and December 31, 2023,</span> respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a
                warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin manufacturing operations.&#160; The Company&#8217;s operating leases have a weighted-average remaining term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_1d2a3e6f55a641b596496d80f993d100" contextRef="c20240930" format="ixt-sec:duryear">7.0</ix:nonNumeric> years. </span><span style="font-size: 10pt;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_405210bb330f4623aeab49dce8f76c74" contextRef="c20240101to20240930" escape="true" continuedAt="Text_ff3aead621cc42acb5891b22378e51081"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; color: #000000;">Scheduled payments under the Company&#8217;s lease obligations are as follows </span></ix:nonNumeric><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><ix:continuation id="Text_ff3aead621cc42acb5891b22378e51081" continuedAt="Text_ff3aead621cc42acb5891b22378e51082"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt; font-variant: normal;">(in thousands):</span></ix:continuation></span></span></span></div>
</ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc12" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc13"><ix:continuation id="Text_ff3aead621cc42acb5891b22378e51082" continuedAt="Text_ff3aead621cc42acb5891b22378e51083">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc13" continuedAt="Text_3a5a0e8411e6490c9e4816b865b16fbc14"><ix:continuation id="Text_ff3aead621cc42acb5891b22378e51083" continuedAt="Text_ff3aead621cc42acb5891b22378e51084">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_3a5a0e8411e6490c9e4816b865b16fbc14"><ix:continuation id="Text_ff3aead621cc42acb5891b22378e51084">
<table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 54pt; margin-left: 9pt;">Remainder of <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" id="Fact_4a231363756a4e8aab7e3cb585f7e6a2" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">603</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 0pt; margin-left: 9pt;">Year ended December 31, <span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_361220d64c9a4abc806dacd28f372767" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,421</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 117pt;">&#160;<span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_7f83c8ae0c14409e949e92fb0abc968c" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2027</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_d122b9e0f656461f9fc19d02bb370d2a" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2028</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_d397dbf717f343a0a400e103d9554d43" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,088</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2029</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_f7084f6ec7904b3bb96423d99440bebe" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,109</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Thereafter</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_79dc053a7edd470b950788b78449e1ca" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,042</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Total payments</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_a9da986e5279494cafb02cca01f21eb8" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,461</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Less: imputed interest</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_0a26da9836e946668f65a5402871aa5e" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,403</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Current portion</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_485da2db41a24c45a64ddd489dcf8c62" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,193</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Balance at September 30, 2024</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_c5ee20a89db843f0b37ae18957865f6b" contextRef="c20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,865</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

          <div><br/>
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageFooter" style="width: 100%;"></div>

            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
              </div>

              <div>
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)</div>

                <a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;"> </span></a></div>

            </div>

          </div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div style="margin-left: 9pt;">
      <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_0bd3e4583a044137939c6d3a07fa6631" contextRef="c20240101to20240930" escape="true" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98711">
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold;">13.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">INCOME TAXES</span></div>
            </td>

  </tr>


</table>
</ix:nonNumeric>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98711" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98712">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98712" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98713">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company uses the estimated annual effective tax rate approach as prescribed by ASC
        740-270, Interim Reporting, to calculate its interim tax provision. For the three and nine months ended September 30, 2024, the Company recorded income tax expense of $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_1722bc37557f41628dbcc8c0011b4d2b" contextRef="c20240701to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_fad0efa5d15f42718495a1bdda6f72c4" contextRef="c20240101to20240930" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.2</ix:nonFraction> million, respectively, resulting in an effective tax rate
        of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" id="Fact_1c695f11ff8e48beaeee2715179f69ff" contextRef="c20240101to20240930" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">5.7</ix:nonFraction>% <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the nine months ended September 30, 2024.</span> The tax expense for the three and nine months ended September 30, 2024 represents federal and state tax liabilities
        that are not fully sheltered by net operating loss carryforwards (&#8220;NOLs&#8221;) due to limitations from prior ownership changes and other limitations&#160;<span style="color: rgb(0, 0, 0);">on NOLs incurred after 2017</span>. The Company&#8217;s effective tax rate
        differs from the federal statutory tax rate of <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact_3fe9f0d5f903488e88bfb04af8c9087a" contextRef="c20240101to20240930" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">21</ix:nonFraction>% due primarily to the reversal of the valuation allowance on certain federal and state
        NOLs estimated to be realized in the current year and, to a lesser extent, the tax benefit associated with the employee exercise of stock options and vesting of RSUs.</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98713" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98714">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98714" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98715">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98715" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98716">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"><span style="text-decoration: underline;">Valuation Allowance</span></div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98716" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98717">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98717" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98718">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98718" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e98719">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">A valuation allowance, if needed, reduces deferred tax assets to the amount expected
        to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings
        history, expected future earnings, carryback and carryforward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and
        negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income, exclusive of reversing taxable temporary differences, to
        outweigh objective negative evidence of recent financial reporting losses. Based on these criteria and the relative weighting of both the positive and negative evidence available, the Company continues to maintain a full valuation allowance against
        its net deferred tax assets.</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e98719" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987110">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987110" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987111">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"><span style="text-decoration: underline;">Net Operating Losses</span></div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987111" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987112">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987112" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987113">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">As of December 31, 2023, the Company had federal and state (post-apportioned basis)
        NOLs of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_c0941c58f6534d3297f7b4bec36c562c" contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">315.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_3ee59c9ee9994c20acbd236cf92e1a99" contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">216.4</ix:nonFraction>
        million, respectively. Approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_a109ff918ba740969b4f5f853ab6866b" contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">35.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_9dd4cf59586141069366b507e44a7afb" contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">95.1</ix:nonFraction> million of the foregoing federal and state NOLs, respectively, will expire at various dates from <span style="-sec-ix-hidden:Fact_04c4d72102c94fdb82f3fcd93478e6fd">2028</span> through <span style="-sec-ix-hidden:Fact_ee510cd27e5248eea4877ba277c443e7">2043</span>, if not limited by triggering events prior to such time.</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987113" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987114">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987114" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987115">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987115" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987116">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">Under the provisions of the Internal Revenue Code, changes in ownership of the Company,
        in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an entity&#8217;s
        ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully utilize its
        NOLs. As of December 31, 2023, approximately $<ix:nonFraction name="adma:OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" id="Fact_07f326f1779d49f99f0ab28c2d14e070" contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U002" decimals="-5" scale="6" format="ixt:num-dot-decimal">267.8</ix:nonFraction> million of the foregoing federal NOLs are subject to limitation under Section 382 due
        to prior ownership changes.</div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987116" continuedAt="Text_92eaa121dbfb40bb98e54d6dbb1e987117">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>
</ix:continuation>
      <ix:continuation id="Text_92eaa121dbfb40bb98e54d6dbb1e987117">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">The Company may experience ownership changes in the future as a result of subsequent
        shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control that could result in further limitations being placed on the Company&#8217;s ability to utilize its federal NOLs.<span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"><br/>
        </span></div>
</ix:continuation>

      <div><br/>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

      <div>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

        <div><ix:nonNumeric name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Text_673ec408ded04a738b2e6188e9f26692" contextRef="c20240101to20240930" escape="true" continuedAt="Text_fd76069b9f7443339009472dac421d681">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_fd76069b9f7443339009472dac421d681" continuedAt="Text_fd76069b9f7443339009472dac421d682">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>
</ix:continuation>
          <ix:continuation id="Text_fd76069b9f7443339009472dac421d682" continuedAt="Text_fd76069b9f7443339009472dac421d683">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_fd76069b9f7443339009472dac421d683" continuedAt="Text_fd76069b9f7443339009472dac421d684">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation><ix:continuation id="Text_fd76069b9f7443339009472dac421d684" continuedAt="Text_fd76069b9f7443339009472dac421d685"><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="Text_35fb1c620ab44388bdc46b9d5e9dccc2" contextRef="c20240101to20240930" escape="true" continuedAt="Text_f4053b74428e4f6ba2639ab3721591091">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:nonNumeric></ix:continuation>
          <div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">
            <div>
              <ix:continuation id="Text_fd76069b9f7443339009472dac421d685" continuedAt="Text_fd76069b9f7443339009472dac421d686"><ix:continuation id="Text_f4053b74428e4f6ba2639ab3721591091" continuedAt="Text_f4053b74428e4f6ba2639ab3721591092">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental cash flow information for the nine months ended September 30, 2024 and 2023 is as follows:</div>
</ix:continuation></ix:continuation>
            </div>

          </div>

          <ix:continuation id="Text_fd76069b9f7443339009472dac421d686" continuedAt="Text_fd76069b9f7443339009472dac421d687"><ix:continuation id="Text_f4053b74428e4f6ba2639ab3721591092" continuedAt="Text_f4053b74428e4f6ba2639ab3721591093">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_fd76069b9f7443339009472dac421d687" continuedAt="Text_fd76069b9f7443339009472dac421d688"><ix:continuation id="Text_f4053b74428e4f6ba2639ab3721591093" continuedAt="Text_f4053b74428e4f6ba2639ab3721591094">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_fd76069b9f7443339009472dac421d688"><ix:continuation id="Text_f4053b74428e4f6ba2639ab3721591094">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="2">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;" rowspan="1" colspan="6"><span style="font-style: italic;">(In thousands)</span></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_f6bd987e87e24ffdbb7596a7e70f8e20" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,417</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_b4e62d9b9ea14880a126e4084f909e54" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,896</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" rowspan="1">
                  <div style="margin-left: 9pt">Cash paid for income taxes<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" id="Fact_ff4932e349c940f394f0500792237bbd" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,895</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1">$ <br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" id="Fact_0e211900ebf74e39b892881f3117d98d" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_7971b43883b84cb49d1fa65c47e3ff4d" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">452</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_4a424ba1b1c44cddaf876f738905afc1" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">270</ix:nonFraction></div>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1">
                  <div style="margin-left: 9pt">Warrants issued in connection with notes payable<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$<br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_a5fb776b426343c79a2e42ce948cb904" contextRef="c20240101to20240930" unitRef="U002" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">$<br/>
                </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_14ce0e16f31c49deb39e6b29b3f06eb3" contextRef="c20230101to20230930" unitRef="U002" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,595</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

          <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
</div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

    <div style="width: 100%;" class="BRPFPageFooter"></div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
        </div>

      </div>

    </div>

    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; margin: 0px auto; height: 4px; width: 0%; color: #000000; text-align: center; margin-left: auto; margin-right: auto;"/>
      <div>
        <a id="ManagementsDiscussion"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt; font-style: italic;">The following discussion of our financial condition and results of operations, which refers to our historical results, should be read in conjunction with the other sections of this Quarterly
          Report on Form 10-Q, including &#8220;Risk Factors&#8221; and our unaudited consolidated financial statements and the notes thereto appearing elsewhere herein, and in conjunction with the Management&#8217;s Discussion and Analysis of Financial Condition and
          Results of Operations set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 28, 2024 (the &#8220;2023 10-K&#8221;). The various sections of this discussion contain a number of forward-looking statements, all of
          which are based on our current expectations and could be affected by the uncertainties and risk factors described throughout or referenced within this Quarterly Report on Form 10-Q. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;&#160; Our
          actual results may differ materially from our current expectations.</div>

        <div>&#160;</div>

        <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">OVERVIEW</span></div>

        <div>&#160;</div>

        <div style="font-weight: bold;">Our Business</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><a id="z_cp_text_1_218"></a>ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty
          biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune
          deficiency disorder or who may be immune-suppressed for medical reasons.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i)
          ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an Intravenous Immune Globulin (&#8220;IVIG&#8221;)&#160; product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or
          Inborn Errors of Immunity in adults and adolescents, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the
          treatment of PI, and for which we received FDA approval on May 9, 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood
          containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent No. 10,259,865 related to
          methods of treatment and prevention of <span style="font-style: italic;">S. pneumonia</span> infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of <span style="font-style: italic;">S.
            pneumoniae</span>. We have successfully completed production of a pilot-scale batch and identified a laboratory partner to conduct forthcoming animal studies for our<span style="font-style: italic;"> S. pneumoniae</span> hyperimmune globulin
          program, SG-001. Our products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><a id="z_Hlk96506219"></a>We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000
          liters (the &#8220;Boca Facility&#8221;). Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce sufficient quantities of our immune
          globulin (&#8220;IG&#8221;) products representing annual revenues greater than $415 million in 2024 and $465 million in 2025. These revenue targets translate to potential fiscal year 2024 and 2025 net income exceeding $120 million and $165 million,
          respectively, and adjusted EBITDA exceeding $160 million and $215 million, respectively.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the United States, all of which hold FDA licenses. This business unit, which we refer to as our Plasma
          Collection Centers business segment, provides us with the blood plasma required for the manufacture of our products, and also allows us to sell certain quantities of source and hyperimmune plasma to third-party customers for further
          manufacturing. In addition, three of our FDA-approved plasma collection centers also have approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. A typical plasma
          collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source and hyperimmune plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of
          purchase and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are
          approved under supply agreements or in the open &#8220;spot&#8221; market.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">We sell plasma-derived intermediate fractions to certain customers, which are generated as part of our FDA-approved manufacturing process for IG and IVIG products, through a plasma intermediates supply agreement we
          entered into in October 2019. These intermediate by-products are used as the starting raw material to produce other plasma-derived biologics. In addition, from time to time we provide contract manufacturing services for certain third-party
          clients. We also provide laboratory contracting services to certain customers and anticipate providing contract filling, labeling and packing services utilizing our FDA-approved in-house fill-finish capabilities.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Our Products</div>

        <div><br/>
        </div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">ASCENIV</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and prevent
          against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific J-code for ASCENIV.&#160; Under
          the Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and
          tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to Respiratory Syncytial Virus (&#8220;RSV&#8221;) using our proprietary microneutralization testing assay.
          With our patented testing methods and assay, we are able to identify the high-titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV. This type of high-titer plasma is typically found in less than 10% of the
          total donor collection samples we test.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><span style="color: #000000;">ASCENIV is approved for the treatment of PIDD or PI, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of
            age). Our pivotal Phase III clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections (&#8220;SBI&#8221;) reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV
            in the low incidence of infection, therapeutic antibiotic use, days missed from work, school and daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of PIDD
            better positions ADMA to potentially further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens at an appropriate time. In the future, we may elect to work
            with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population. Following FDA approval in April 2019, commercial sales of ASCENIV commenced in
            October of 2019 and in</span> 2023 ADMA commenced manufacturing ASCENIV at the 4,400-Liter production scale. This expansion has improved the product&#8217;s margin profile and increases plant production capacity as fewer batches are needed to support
          our revenue goals<span style="color: rgb(0, 0, 0);">. </span>ASCENIV&#8217;s prescriber and patient base continued to expand during 2023, which drove record utilization and pull-through for this product. These elevated demand trends have sustained
          into 2024, and ADMA currently expects that this product&#8217;s rapid growth will continue throughout 2024 and beyond.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">BIVIGAM</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients
          against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not limited to, the
          humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders. Based on recent
          estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">On May 9, 2019, the FDA approved the Prior Approval Supplement (the &#8220;PAS&#8221;) for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the United States. We
          resumed production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial
          re-launch and first commercial sales for this product commenced in August of 2019.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. This
          increased IVIG plasma pool scale, which allows us to produce BIVIGAM at an expanded capacity utilizing the same equipment, release testing assays and labor force, has had a favorable impact on our gross margins, manufacturing efficiencies and
          operating results.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM&#8217;s label in the United States to now include the pediatric setting for those two years of age and older.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Nabi-HB</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a
          Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with
          acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus, which is a major global health problem. The Hepatitis B virus can cause chronic
          infection and places people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.&#160;
          Production of Nabi-HB at the Boca Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial
          distribution in the United States and we continue to manufacture Nabi-HB under HHS License No. 2019.</div>

        <div><br/>
        </div>

        <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">RESULTS OF OPERATIONS</span></div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Critical Accounting Estimates</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our condensed consolidated financial statements, which have been prepared in accordance with accounting
          principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets,
          liabilities, revenues and expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be
          reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may
          differ materially from these estimates.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Some of the estimates and assumptions we have to make under U.S. GAAP require very difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, we have identified those
          as critical accounting estimates, which are considered critical to an understanding of our historical financial condition and results of operations and are reasonably likely to have a material impact on our future results of operations and
          financial condition. Critical accounting estimates include rebates and certain other deductions from gross revenues, valuation of inventory, impairment of long-lived assets, assumptions used in the fair value of awards granted under our equity
          incentive plans and warrants issued in connection with the issuance of notes payable, estimates related to the valuation allowance for our deferred tax assets and our effective tax rate for the current fiscal year. For a description of our
          significant accounting policies, see Note 2 to the Consolidated Financial Statements included in the 2023 10-K.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Revenue Deductions for Rebates, Chargebacks and Sales Allowances</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our gross product revenues are subject to a variety of deductions, which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates, distribution
          fees, chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while other estimates require
          complex or subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Prior to June 30, 2024, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. While we have some historical sales and rebate experience from
          our two primary immunoglobulin products, ASCENIV and BIVIGAM, since their FDA approvals in 2019, our historical experience is not extensive. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate
          estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment are those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the
          accrual and its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes. During the second quarter of 2024, we
          engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a
          corresponding increase to net revenues of $12.6 million in the three months ended June 30, 2024 (see Note 2 to the Consolidated Financial Statements). The primary driver in the adjustment to our estimated rebates accrual at June 30, 2024 relates
          to a change in the assumption around the payor mix for our products, specifically the proportion of our revenue that is attributable to providers and patients utilizing Managed Medicaid, Medicaid and Medicare Part D, relative to our total sales.
          The change in this key assumption to our standing estimation model was based on the collection of additional historical data from our direct experience with selling our primary immunoglobulin products. Additional changes in estimate assumptions
          surrounding U.S. Medicaid and other rebate obligations could materially impact our revenues and our results of operations in the future.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Valuation of Inventory</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;"><a id="z_Hlk157174935"></a>Estimates related to the valuation of inventory include net realizable value of inventory in determining whether the cost of inventory exceeds its net realizable value which, if this were
          the case, would require a charge against earnings to write down the value of the inventory to its net realizable value. Net realizable value of inventory is based on our management&#8217;s estimate of the future net selling price of the inventory,
          which is subject to market conditions and the estimation processes we use for revenues as discussed above. With respect to raw materials inventory, we are required to estimate the level and timing of usage of these materials prior to their
          expiration dates in determining whether it is appropriate to carry these materials on our balance sheet as a valid asset of the Company. Changes in either of these estimates could materially impact our cost of product revenue and results of
          operations.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Stock-Based Compensation and Valuation of Warrants</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">All equity-based payments, including grants of stock options and restricted stock units (&#8220;RSUs&#8221;) are recognized at their estimated fair value at the date of grant, and compensation expense is recognized on a
          straight-line basis over the grantee&#8217;s requisite vesting period. For the purpose of valuing stock options granted to our employees, directors and executive officers, we use the Black-Scholes option pricing model. The Black-Scholes option
          valuation model was developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. The Company&#8217;s employee stock options have characteristics significantly different from
          those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair value estimate. To determine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of the grant
          with a term consistent with the term of our awards. The expected term of the options granted is in accordance with U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletins 107 and 110 and is based on the average between vesting
          terms and contractual terms. The expected dividend yield reflects our current and expected future policy for dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining the historical
          volatility of our common stock since our common stock became publicly traded. We will continue to analyze the expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as
          appropriate. Any changes in the foregoing Black-Scholes assumptions, or our election to utilize an alternative method for valuing stock options granted to employees, directors and executive officers, could potentially impact our stock-based
          compensation expense and our results of operations.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">We also use the Black-Scholes option valuation model for the purpose of estimating the fair value of warrants we issue from time to time in connection with the issuance of notes payable. Changes in our Black-Scholes
          assumptions, or our election to utilize an alternative method for valuing warrants issued to our lenders, could impact our interest expense and results of operations.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Impairment of Long-Lived Assets</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We assess the recoverability of our long-lived assets, which include property and equipment and definite-lived intangible assets, whenever significant events or changes in circumstances indicate impairment may have
          occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is
          recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the three and nine months ended September 30, 2024 and 2023, we did not identify any impairment indicators for our
          long-lived assets, and as a result no impairment charges were recorded. Examples of events or circumstances that may be indicative of impairment that would require the use of significant judgment by management include:</div>

        <div><br/>
        </div>

        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div>A significant adverse change in legal factors or in the business climate that could affect the value of the asset.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div>Significant and continued cash flow losses.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div>A significant adverse change in the extent or manner in which an asset is used, such as a restriction imposed by the FDA or other regulatory authorities that could affect our ability to manufacture our products using a particular
                    asset.</div>
                </td>

  </tr>


</table>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
                </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                  <div>An expectation of losses or reduced profits associated with an asset. This could result, for example, from the introduction of a competitor&#8217;s product that impacts projected revenue growth, or a change in the acceptance of a product
                    by patients, physicians and payers that results in an inability to sustain projected product revenues.</div>
                </td>

  </tr>


</table>
        </div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The testing of goodwill for impairment requires us to determine whether or not the fair
          value of the reporting unit associated with the goodwill is less than its carrying amount, including goodwill and other intangible assets. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value exceeds its fair value,
          with the impairment loss recognized not to exceed the total amount of goodwill allocated to that reporting unit. In order to determine the fair value of the reporting unit, we utilize the fair value of the Company as a whole, as determined by its
          market capitalization. Determination of the fair value and carrying value of each reporting unit, relative to the fair value of the Company, requires management to employ certain estimates, assumptions and judgment, which we believe are
          reasonable. However, any changes to these estimates and assumptions could impact our determination of whether or not our goodwill is impaired. We did not recognize any impairment charges related to goodwill for the three and nine months ended
          September 30, 2024 and 2023.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Deferred Tax Assets and Effective Tax Rate</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We currently maintain a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated financial
          statements despite continued losses through December 31, 2023. This valuation allowance reflects our assessment of whether it is more likely than not that we will generate sufficient taxable income in the future to be able to utilize our deferred
          tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and negative
          evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets.&#160; We consider cumulative losses in recent years to be a significant type of negative evidence. Based on our history of losses through
          December 31, 2023, at this time we have not included future projected taxable income as a source of income to recognize our deferred tax assets, despite our achievement of positive net income for the three and nine months ended September 30,
          2024.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">After consideration of all available positive and negative evidence regarding our estimates of future taxable income, we have elected to maintain a full valuation allowance for our deferred tax assets as of September
          30, 2024. We will continue to monitor this evidence through the remainder of 2024 to determine if a reduction to the valuation allowance is warranted, which could potentially result in our recognition of an income tax benefit later in fiscal
          2024.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Our income tax expense for the nine months ended September 30, 2024 is based on our estimated effective tax rate for the full year 2024, which is a function of our projected pre-tax income under U.S. GAAP, our
          estimates and assumptions regarding certain permanent and temporary differences between U.S. GAAP income and taxable income, and the limitations to our net operating loss carryforwards and their limitations under Section 382 of the Internal
          Revenue Code of 1986, as amended (see &#8220;Risk Factors&#8221; appearing elsewhere in this report and Note 13 to the Consolidated Financial Statements).</div>

        <div><br/>
        </div>

        <div style="text-align: justify; font-weight: bold;">Three Months Ended September 30, 2024 Compared to Three Months Ended September 30, 2023</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the three months ended September 30, 2024, our third fiscal quarter, compared to the three months ended
          September 30, 2023:<a id="z_MON_1562418206"></a><a id="z_MON_1586265234"></a><a id="z_MON_1587308315"></a><a id="z_MON_1594056188"></a><a id="z_MON_1594195726"></a></div>

        <div><br/>
        </div>

        <a id="z_MON_1759728827"></a><a id="z_MON_1760279158"></a><a id="z_MON_1775457018"></a><a id="z_MON_1783684188"></a><a id="z_MON_1784046729"></a><a id="z_MON_1791545042"></a><a id="z_MON_1791874685"></a><a id="z_MON_1791976794"></a>
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Three Months Ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Increase (Decrease)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Revenues</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">119,839</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">67,275</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">52,564</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Cost of product revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">60,180</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">42,622</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">17,558</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Gross profit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">59,659</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">24,653</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">35,006</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Research and development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">412</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">596</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(184</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Plasma center operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,021</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">467</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">554</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Amortization of intangibles</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">28</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">179</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(151</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Selling, general and administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">18,560</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">14,726</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">3,834</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income from operations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">39,638</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">8,685</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">30,953</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(3,499</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(6,398</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,899</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other income, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">610</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">278</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">332</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income before taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">36,749</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,565</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">34,184</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Provision for income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">840</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">840</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net income</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">35,909</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,565</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">33,344</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Adjusted EBITDA *</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">45,367</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">12,750</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">32,617</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="color: rgb(0, 0, 0);">* - See Non-GAAP Financial Measures appearing at the end of this discussion</div>

        <div><a id="z_MON_1744464734"></a><a id="z_MON_1633505558"></a><a id="z_MON_1649409398"></a><a id="z_MON_1681130304"></a><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Revenues</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We recorded total revenues of $119.8 million for the three months ended September 30, 2024, as compared to $67.2 million for the three months ended September 30, 2023, an increase of $52.6 million, or approximately
          78%. The increase is primarily related to increased sales of our ASCENIV IG product, as we continue to experience increased physician, payer and patient acceptance and utilization of ASCENIV.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We also experienced a $6.0 million increase in third-party plasma sales by our Plasma Collection Centers business segment, mainly due to an additional spot purchase of normal source plasma (&#8220;NSP&#8221;) by our primary
          third-party customer in excess of the amount of NSP we are contractually committed to sell to this customer in fiscal 2024.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue and Gross Profit</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Cost of product revenue was $60.2 million for the three months ended September 30, 2024, as compared to $42.6 million for the three months ended September 30, 2023. This increase is primarily attributable to
          volume-driven increases in product revenue costs related to the increased sales of our IG products, including intermediates, and NSP of $13.0 million and $6.5 million, respectively, partially offset by decreases in other manufacturing costs
          totaling $1.9 million, mainly due to lower unabsorbed manufacturing expenses in 2024.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">For the three months ended September 30, 2024, we had gross profit of $59.7 million, as compared to $24.7 million for the same period of a year ago, which represents a gross margin in the third quarter of 2024 of
          49.8%, as compared to 36.6% in the third quarter of 2023. This improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the reduction in other
          manufacturing costs in the third quarter of 2024 as compared with the third quarter of 2023.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Research and development (&#8220;R&amp;D&#8221;) expenses totaled $0.4 million for the third quarter of 2024, as compared to $0.6 million for the third quarter of 2023. The decrease is primarily due to the absence of
          expenditures in 2024 related to the BIVIGAM post-marketing commitments, which were completed in June of 2023.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Plasma center operating expenses increased from approximately $0.5 million for the three months ended September 30, 2023 to $1.0 million for the three months ended September 30, 2024. The increase is primarily due to
          increases in donor fees of $0.9 million and softgoods and supplies of $0.3 million, partially offset by an increase in the capitalization of plasma center expenses into inventory of $0.4 million related to increased collections and to lower donor
          testing expenses of $0.2 million.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Amortization expense mainly pertains to the amortization of intangible assets acquired in a 2017 acquisition transaction and was $28,000 and $0.2 million for the three months ended September 30, 2024 and 2023,
          respectively. The decrease is mainly due to the intangibles acquired in 2017 becoming fully amortized in June of 2024.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $18.6 million for the three months ended September 30, 2024, an increase of $3.8 million from the three months ended September 30, 2023. The increase
          reflects increases in employee-related costs, including salaries, benefits, stock-based compensation, relocation and recruiting, in the amount of $3.0 million, temporary labor and software maintenance expense of $0.3 million each and professional
          fees in the amount of $0.2 million. SG&amp;A expenses as a percentage of net revenues fell from 21.9% in the third quarter of 2023 to 15.5% in the third quarter of 2024.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Income from Operations</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our operating income was $39.6 million for the third quarter of 2024, as compared to $8.7 million for the third quarter of 2023. The approximately $31.0 million improvement in operating income was due to the improved
          gross profit of $35.0 million, partially offset by an increase in total operating expenses of $4.1 million in 2024.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Interest expense for the three months ended September 30, 2024 was $3.5 million, as compared to $6.4 million for the three months ended September 30, 2023. The decrease is due to the refinancing of our senior debt in
          December of 2023 (see &#8220;Liquidity and Capital Resources&#8221;). This transaction reduced our stated rate of interest from approximately 13.9% in the third quarter of 2023 to approximately 10.4% in the third quarter of 2024, and also resulted in a
          reduction to our outstanding debt principal of approximately $23.6 million. We also had lower amortization of debt discount in 2024 of approximately $0.5 million. In addition, our interest expense for the third quarter of 2024 was favorably
          impacted by the $30.0 million partial paydown of our senior debt on August 14, 2024.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Other Income, Net</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Other income, net, which primarily consists of interest income on our cash balances, was $0.6 million and $0.3 million for the three months ended September 30, 2024 and 2023, respectively.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;"><a id="z_Hlk164845500"></a>Provision for Income Taxes</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We recorded income tax expense of $0.8 million for the three months ending September 30, 2024, with no comparable amount for the three months ending September 30, 2023. The provision for income taxes for the third
          quarter of 2024 represents an effective tax rate of 5.7% for the first nine months of 2024 and reflects federal and state income tax liabilities that are not fully sheltered by net operating losses due to limitations from prior ownership changes
          and other limitations on net operating loss carryforwards under the Internal Revenue Code of 1986, as amended (see &#8220;Risk Factors&#8221; appearing elsewhere in this report and Note 13 to the Consolidated Financial Statements). Our effective tax rate for
          the three months ended September 30, 2024 differs from the federal statutory tax rate of 21%, mainly due to the reversal of the valuation allowance on certain federal and state net operating loss carryforwards expected to be realized in the
          current year and, to a lesser extent, the tax benefit associated with the employee exercise of stock options and vesting of RSUs.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Net Income</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our net income was $35.9 million for the third quarter of 2024, as compared to $2.6 million for the third quarter of 2023. The $33.3 million increase was primarily due to the increase in operating income of
          approximately $31.0 million discussed above and the reduction in interest expense for the third quarter of 2024.</div>

        <div><br/>
        </div>

        <div style="text-align: justify; font-weight: bold;">Nine Months Ended September 30, 2024 Compared to Nine Months Ended September 30, 2023</div>

        <div>&#160;</div>

        <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the nine months ended September 30, 2024 compared to the nine months ended September 30, 2023:</div>

        <div><br/>
        </div>

        <a id="z_MON_1783690482"></a><a id="z_MON_1784046921"></a><a id="z_MON_1791549393"></a><a id="z_MON_1791874842"></a><a id="z_MON_1791977016"></a>
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Nine Months Ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic; text-align: center;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
                <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">Increase (Decrease)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Revenues</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">308,905</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">184,311</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">124,594</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Cost of product revenue</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">152,685</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">126,455</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">26,230</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Gross profit</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">156,220</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">57,856</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">98,364</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Research and development expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,422</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,854</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(1,432</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Plasma center operating expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,968</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">3,581</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(613</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Amortization of intangibles</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">363</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">537</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(174</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Selling, general and administrative expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">50,807</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">43,485</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">7,322</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income from operations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">100,660</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">7,399</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">93,261</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(11,051</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(18,812</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">7,761</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Other income, net</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,392</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">819</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">573</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income (loss) from before taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">91,001</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(10,594</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">101,595</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Provision for income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">5,224</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">5,224</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Net income (loss)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">85,777</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">(10,594</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">96,371</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Adjusted EBITDA *</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">116,336</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">21,653</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">94,683</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="color: rgb(0, 0, 0);">* - See Non-GAAP Financial Measures appearing at the end of this discussion</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Revenues</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We recorded total revenues of $308.9 million for the nine months ended September 30, 2024, as compared to $184.3 million for the nine months ended September 30, 2023, an increase of $124.6 million, or 68%. Excluding
          the $12.6 million adjustment we recorded in the second quarter of 2024 to decrease our accrual for U.S. Medicaid rebates (which had the effect of increasing net revenues by $12.6 million), revenue would have increased by approximately $112.0
          million, or 61%. This increase is primarily related to increased sales of ASCENIV and our other IG products, as we continue to experience increased physician, payer and patient acceptance and utilization of ASCENIV. The revenue increase also
          includes an increase in NSP sales by our Plasma Collection Centers business segment in the amount of $1.1 million.</div>

        <div style="text-indent: 36pt;"> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue and Gross Profit</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Cost of product revenue was $152.7 million for the first nine months of 2024, as compared to $126.5 million for the first nine months of 2023. This increase is primarily attributable to volume-driven increases in
          product revenue costs related to the increased sales of our IG products and NSP of $28.1 million and $2.3 million, respectively, partially offset by a reduction in other manufacturing costs, mainly unabsorbed manufacturing expenses, of $4.2
          million.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">For the nine months ended September 30, 2024, we had gross profit of $156.2 million, as compared to $57.9 million for the same period of a year ago, which represents a gross margin for the first nine months of 2024
          of 50.6%, as compared to 31.4% in the first nine months of 2023. Excluding the $12.6 million adjustment we recorded in the second quarter of 2024 to reduce our accrual for estimated U.S. Medicaid rebates, our gross profit for the first nine
          months of 2024 was approximately $143.5 million, representing a gross margin of 48.4%. The improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the
          reduction in other manufacturing costs.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">R&amp;D expenses totaled $1.4 million for the first nine months of 2024, as compared to $2.9 million for the first nine months of 2023. The decrease is primarily due to the absence of expenditures in 2024 related to
          the BIVIGAM post-marketing commitments, for which we incurred $1.7 million of expenses in 2023, partially offset by an increase in expenses associated with our ASCENIV post-marketing commitment in the amount of $0.3 million.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Plasma center operating expenses decreased from $3.6 million for the nine months ended September 30, 2023 to $3.0 million for the nine months ended September 30, 2024. The decrease is due to a 22% increase in the
          amount of plasma collected in the first nine months of 2024 as compared to the same period of a year ago, which resulted in a $7.8 million increase in the amount of plasma center costs we capitalized into inventory in 2024. This amount was
          partially offset by increases in donor fees of $4.4 million, softgoods and supplies of $1.4 million, donor testing expenses of $1.0 million, salaries, wages, benefits and temporary labor of $0.2 million and software maintenance expense of $0.2
          million.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Amortization expense mainly pertains to the amortization of intangible assets acquired in a 2017 acquisition transaction and was $0.4 million and $0.5 million for the nine months ended September 30, 2024 and 2023,
          respectively.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">SG&amp;A expenses were $50.8 million for the nine months ended September 30, 2024, an increase of $7.3 million from the nine months ended September 30, 2023. The increase reflects increases in employee-related costs,
          including salaries, benefits, stock-based compensation, relocation and recruiting, in the amount of $5.7 million, $3.1 million of which is stock-based compensation, repairs and maintenance expense of $0.6 million, software maintenance expense of
          $0.6 million and temporary labor expense of $0.5 million. SG&amp;A expenses as a percentage of net revenues decreased from 23.6% in the first nine months of 2023 to 16.4% in the first nine months of 2024, or 17.2% excluding the revenue adjustment
          described above.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Income from Operations</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our operating income was $100.7 million for the first nine months of 2024, as compared to $7.4 million for the first nine months of 2023. The $93.3 million increase in operating income was mainly due to the improved
          gross profit, partially offset by $5.1 million of higher total operating expenses. The higher gross profit reflects the foregoing change in estimate which increased our revenues for the nine months ended September 30, 2024 by $12.6 million.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Interest expense for the nine months ended September 30, 2024 was $11.1 million, as compared to $18.8 million for the nine months ended September 30, 2023. The decrease is due to the refinancing of our senior debt in
          December of 2023 (see &#8220;Liquidity and Capital Resources&#8221;). This transaction reduced our stated interest rate by approximately 360 basis points in 2024 compared to 2023, and also resulted in a reduction to our outstanding debt principal balance. In
          addition, we had lower amortization of debt discount in 2024 of approximately $1.2 million.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Other Income, Net</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Other income, net, for the nine months ended September 30, 2024 was $1.4 million, as compared to $0.8 million for the nine months ended September 30, 2023. The increase is mainly due to an increase in interest income
          of $0.5 million in 2024.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Provision for Income Taxes</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We recorded income tax expense of $5.2 million for the nine months ended September 30, 2024, with no comparable amount for the nine months ending September 30, 2023. The provision for income taxes for the first nine
          months of 2024 represents an effective tax rate of 5.7% and reflects federal and state income tax liabilities that are not fully sheltered by net operating losses due to limitations from prior ownership changes and other limitations on net
          operating loss carryforwards under the Internal Revenue Code of 1986, as amended (see &#8220;Risk Factors&#8221; appearing elsewhere in this report and Note 13 to the Consolidated Financial Statements). After consideration of all available positive and
          negative evidence regarding our estimates of future taxable income, we have elected to maintain a full valuation allowance for our deferred tax assets as of September 30, 2024. We will continue to monitor this evidence through the balance of 2024
          to determine if a reduction to the valuation allowance is required, which could potentially result in our recognition of an income tax benefit later in fiscal 2024.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Net Income/Loss</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our net income was $85.8 million for the first nine months of 2024, as compared to a net loss of $10.6 million for the first nine months of 2023. This $96.4 million improvement in our results of operations was
          primarily due to the increase in operating income of $93.3 million and lower interest expense of $7.8 million discussed above, partially offset by the provision for income taxes for the period. The foregoing change in estimate in our accrual for
          Medicaid rebates favorably impacted our net income for the first nine months of 2024 by approximately $12.0 million.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Non-GAAP Financial Measures</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;), Adjusted EBITDA</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;"><a id="Critical_Accounting_Policies_and_Estimat"></a><a id="Selling_general_and_administrative_expe"></a><a id="Labor_and_related_expenses"></a><a id="Other_operating_expenses"></a><a id="General_and_administrative_expenses"></a><a id="EBITDA_Adjusted_EBITDA_and_Adjusted_EBI"></a>EBITDA and Adjusted EBITDA are important non-GAAP financial measures used by our management and Board of Directors to assess our operating
          performance. We use EBITDA and Adjusted EBITDA as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude potential differences driven by the impact of variations of
          non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or certain one-time and non-recurring items. In addition, we believe that EBITDA, Adjusted EBITDA and similar measures are
          widely used by investors, securities analysts, ratings agencies and other parties in evaluating companies in our industry as a measure of financial performance and debt-service capabilities. See below for a reconciliation of our EBITDA and
          Adjusted EBITDA to net income/loss, the most directly comparable financial measure calculated and presented in accordance with U.S. GAAP.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">Because EBITDA and Adjusted EBITDA are measures not deemed to be in accordance with U.S. GAAP and are susceptible to varying calculations, our EBITDA and Adjusted EBITDA may not be comparable to similarly titled
          measures of other companies, including companies in our industry, because other companies may calculate EBITDA and Adjusted EBITDA in a different manner than we calculate these measurements. <span style="color: rgb(0, 0, 0);">Although we use
            Adjusted EBITDA as one of several financial measures to assess our operating performance, its use is limited as it excludes certain significant operating expenses. EBITDA and Adjusted EBITDA are not intended to represent cash flows for the
            periods presented, nor have they been presented as an alternative to operating income, net income/loss or as an indicator of operating performance and should not be considered in isolation or as a substitute for measures of performance prepared
            in accordance with U.S. GAAP. The following table presents the reconciliation of net income/loss to EBITDA and Adjusted EBITDA for the three and nine months ended September 30, 2024 and 2023:</span></div>

        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Three Months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Nine Months ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;"> 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="14" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-style: italic;">(In thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net income (loss)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>35,909</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>2,565</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>85,777</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(10,594</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Depreciation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,912</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,913</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">5,738</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">5,686</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Amortization</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">28</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">179</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">363</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">537</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Income taxes</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">840</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">5,224</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Interest expense</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">3,499</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">6,398</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">11,051</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">18,812</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 52%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">EBITDA</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">42,188</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">11,055</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">108,153</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">14,441</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">Stock-based compensation</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">3,179</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">1,695</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">8,183</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">4,442</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0);">IT systems disruption</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">-</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">2,770</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-weight: bold;">Adjusted EBITDA</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">45,367</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">12,750</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">116,336</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="color: rgb(0, 0, 0);">21,653</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Adjusted EBITDA increased for the three and nine months ended September 30, 2024 by $32.6 million and $94.7 million, respectively, as compared to the same periods of a year ago. The improvement is driven primarily by
          the increased sales and gross profit in 2024, as well as continued operational oversight and cost containment efforts at both of our business segments.</div>

        <div style="text-align: center;"><a id="z_MON_1752487959"></a><br/>
        </div>

        <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">LIQUIDITY AND CAPITAL RESOURCES</span></div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">At September 30, 2024, we had working capital of $273.3 million, primarily consisting of $171.8 million of inventory, cash and cash equivalents of $86.7 million and $50.1 million of accounts receivable, partially
          offset by current liabilities of $44.9 million, as compared to working capital at December 31, 2023 of $207.2 million, primarily consisting of $172.9 million of inventory, cash and cash equivalents of $51.4 million and accounts receivable of
          $27.4 million, partially offset by current liabilities of $49.8 million. We had positive cash flows from operations for the nine months ended September 30, 2024 and the year ended December 31, 2023 of $68.5 million and $8.8 million, respectively.
          Prior to fiscal 2023, we funded our operations primarily from the sale of our equity and debt securities. Our material cash requirements are primarily comprised of:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>The collection and procurement of raw material source plasma, which includes plasma donor fees and plasma center supplies, and other raw materials necessary to maintain and scale up our manufacturing operations;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Employee compensation and benefits;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Capital expenditures for equipment upgrades and capacity expansion at the Boca Facility and to maintain our plasma collection facilities;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Interest on our debt;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Marketing programs, medical education and continued commercialization efforts;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Boca Facility maintenance, repairs and supplies;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Conducting required post-marketing clinical trials for ASCENIV; and</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 27.35pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Continuous improvements and updates to our IT infrastructure, laboratory equipment and assays, and facilities and engineering equipment.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div>In addition, our end-to-end production cycle time from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial inventories of raw material plasma
          and other manufacturing and laboratory testing materials and single use disposables.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to
          fund our operations, as currently conducted, through the end of the fourth quarter of fiscal 2025 and beyond. Based on current operations and assuming continued market acceptance and utilization of our finished drug products, we do not anticipate
          the need to raise additional capital at this time. However, should the market for our products or political or economic conditions change, we may need to seek additional capital which may not be available due to a variety of potential factors
          beyond our control (see &#8220;Risk Factors&#8221; appearing elsewhere in this report).</div>

        <div><br/>
        </div>

        <div>
          <div style="text-indent: 36pt;">&#160;<span style="color: rgb(0, 0, 0);">ADMA continues to evaluate a variety of strategic alternatives, and the exploration of value-creating opportunities remains a top corporate priority.</span></div>

        </div>

        <div><br/>
        </div>

        <div>
          <div style="text-indent: 36pt; color: #000000;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we and all of our subsidiaries entered into a credit agreement (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds
            affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement provides for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate
            principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a
            maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, we used the proceeds from the Ares Loans, along with a portion of our existing cash on hand, to terminate and pay in full all of the outstanding
            obligations under our previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP (&#8220;Hayfin&#8221;) including the outstanding principal in the amount of $158.6 million, a prepayment penalty in the amount $11.1 million, an
            exit fee of $1.6 million, all accrued and unpaid interest outstanding on the Hayfin Credit Facility as of the Ares Closing date, as well as certain fees and expenses related thereto. On August 14, 2024 we repaid $30.0 million against the
            revolving credit facility and the outstanding balance on the revolving credit facility as of September 30, 2024 was $42.5 million.</div>

          <div style="text-indent: 36pt;"><span style="color: #000000;"> </span><br/>
          </div>

          <div style="text-indent: 36pt; color: #000000;">Borrowings under the term loan bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar
            quarter plus 6.50% (the &#8220;Initial SOFR Term Loan Applicable Margin&#8221;). Borrowings under the revolving facility initially bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the
            first day of the applicable calendar quarter<span style="font-style: italic;">&#160;</span>plus<span style="font-style: italic;">&#160;</span>3.75% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of September 30, 2024 and December 31, 2023, the
            interest rate on the term loan was approximately 11.36% and 11.88%, respectively, and the interest rate on the revolving facility was approximately 9.08% and 9.13%, respectively.</div>

        </div>

        <div>
          <div><br/>
          </div>

        </div>

        <div>
          <div style="text-indent: 36pt; color: #000000;">On the Ares Maturity Date, we are required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date,
            there are no scheduled principal payments on the Ares Credit Facility, and we are required to make quarterly interest payments during the term of the Ares Credit Facility of approximately $2.8 million. We may prepay the outstanding principal
            under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice with no prepayment premium. However, in the event that
            we prepay an amount under the revolving facility that is greater than 50% of the original $72.5 million outstanding balance (of which $30.0 million, or 41.4%, has been repaid to date), we will still be required to pay interest on 50% of this
            balance, or $36.3 million, through the term of the Ares Credit Facility. We may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time
            upon three business days&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of
            the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second
            anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.</div>

          <div><br/>
          </div>

        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div>
          <div style="text-indent: 36pt; color: rgb(0, 0, 0);">In connection with the closing of the Ares Credit Facility, we incurred fees and expenses related to the transaction of approximately $2.7 million, including a $1.7 million original issue
            discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, we are also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this amount has
            been accrued as a separate liability in our consolidated balance sheet as of September 30, 2024 and December 31, 2023. As a result, we recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average
            effective interest rate on the Ares Loans as of September 30, 2024 and December 31, 2023 was 11.73% and 11.39%, respectively.</div>

        </div>

        <div>
          <div><br/>
          </div>

        </div>

        <div>
          <div style="text-indent: 36pt; color: rgb(0, 0, 0);">All of our obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including
            intellectual property and all of the equity interests in our subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for
            similar financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million liquidity covenant, and also restrict or limit our ability and the ability of our subsidiaries to, among
            other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our
            subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
            impact of restricting our ability to make loan repayments under the Ares Credit Agreement. As of September 30, 2024, we were in compliance with all of the covenants contained in the Ares Credit Agreement.</div>

        </div>

        <div style="text-indent: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Events of default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency
          events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we will incur an increase in the rate of interest on the Ares Loans of 2% per annum.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Cash Flows</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">The following table sets forth a summary of our cash flows for the periods indicated:</div>

        <div style="text-indent: 36pt;"> <br/>
        </div>

        <div style="text-indent: 36pt;"><a id="z_MON_1586701709"></a><a id="z_MON_1562425759"></a><a id="z_MON_1563007408"></a><a id="z_MON_1643040171"></a><a id="z_MON_1617786835"></a></div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Nine Months Ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic; text-align: center;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash provided by (used in) operating activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>68,456</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(8,797</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in investing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(5,825</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(3,574</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash (used in) provided by financing activities</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(27,276</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div>6</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net change in cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>35,355</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>(12,365</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - beginning of period</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>51,352</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>86,522</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - end of period</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>86,707</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>74,157</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Net Cash Provided by (Used in) Operating Activities</div>

        <div style="font-style: italic; font-weight: bold;"> <br/>
        </div>

        <div style="text-indent: 36pt;">Cash provided by operations for the nine months ended September 30, 2024 was $68.5 million, as compared to cash used in operations of $8.8 million, for the same period of a year ago, mainly due to the increase in
          revenues, gross margin and net income in 2024, partially offset by higher unfavorable changes in accounts receivable and accounts payable and accrued expenses. The following table illustrates the primary components of and changes to our cash
          flows from operations:</div>

        <div><a id="z_MON_1563007657"></a><a id="z_MON_1594144389"></a><a id="z_MON_1562426320"></a><br/>
        </div>

        <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Nine Months Ended September 30,</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-style: italic; text-align: center;">(in thousands)</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2024</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">2023</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income (loss)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>85,777</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(10,594</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-cash expenses, gains and losses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>14,941</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>15,524</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts receivable</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(22,719</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(15,814</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in inventories</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>1,105</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div>164</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts payable and accrued expenses</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>(5,176</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div>3,717</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(5,472</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div>(1,794</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash provided by (used in) operations</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>68,456</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>(8,797</div>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>)</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;"><a id="z_MON_1643040438"></a><a id="z_MON_1617558680"></a><a id="z_MON_1625663889"></a><a id="z_MON_1633969327"></a><a id="z_MON_1759754753"></a><a id="z_MON_1775393436"></a>Net Cash
          Used in Investing Activities</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Net cash used in investing activities for the nine months ended September 30, 2024 and 2023 was $5.8 million and $3.6 million, respectively, and is mainly comprised of capital expenditures at the Boca Facility. While
          we currently have no firm commitments for capital expenditures, we expect our total capital expenditures will be between $3.0 million and $5.0 million for the remainder of fiscal 2024, mainly for additional upgrades to the Boca Facility
          manufacturing operations and related operational systems.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Net Cash (Used in) Provided by Financing Activities</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Net cash used in financing activities was $27.3 million for the nine months ended September 30, 2024, and was comprised of the $30.0 million repaid under the Ares Credit Facility and $4.3 million of taxes paid in
          connection with shares that were withheld from RSUs that vested during the period, partially offset by approximately $7.1 million in proceeds from the exercise of stock options. During the nine months ended September 30, 2023, proceeds from the
          exercise of stock options of $1.1 million was offset by $1.1 million of taxes paid in connection with shares withheld from RSUs that vested during the period.</div>

        <div><br/>
        </div>

        <div style="color: #000000; font-weight: bold;">Effect of Inflation</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Inflation impacted a number of facets of our business during the nine months ended September 30, 2024 and for the years ended December 31, 2023 and 2022 at each of our business segments. We experienced price
          increases for, among other items, certain raw materials, consumable supplies, services for repairs and maintenance of our facilities, utilities, shipping and freight charges, fuel surcharges and labor costs, among other expenses. Based upon the
          macroeconomic environment, publicly available information and reports from the U.S. government, we expect this trend to continue in 2024 and potentially longer, which could potentially have a significant impact on our future results of
          operations. In addition, some of our third-party inventory purchase agreements provide for annual price increases that are tied to various consumer price indices, which have resulted in higher than historical percentage price increases and has
          resulted in and could continue to result in higher source plasma and other raw material and supplies costs in 2024 and beyond. Also, in a higher inflationary environment, we may not be able to raise the prices of our products to keep up with the
          rate of inflation. We are unable to predict when these external drivers of inflation will subside.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Off-Balance Sheet Arrangements</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt; color: #000000;">None.</div>

        <div style="text-indent: -72pt; margin-left: 72pt;"><a id="z_Toc268701252"></a><br/>
        </div>

        <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt;">We are exposed to market risk as the result of changes in interest rates. Our senior credit facility with Ares requires quarterly payments of interest based on the adjusted Term SOFR plus the Applicable Margin. We
          currently do not utilize any derivative financial instruments, such as interest rate swaps or caps, to mitigate this risk. As of September 30, 2024, we had $105.0 million outstanding under our senior credit facility that is subject to variable
          interest rates. As a result, the effect of a hypothetical, instantaneous and unfavorable change of 100 basis points in interest rates would have an approximate $1.0 million annualized negative impact on our earnings and cash flows.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <a id="ControlsandProcedures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Controls and Procedures.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="font-weight: bold;">Evaluation of Disclosure Controls and Procedures</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">We designed our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the &#8220;Exchange Act&#8221;), to provide reasonable
          assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated
          and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosures.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Under the supervision of and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls
          and procedures as of September 30, 2024. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of September 30, 2024 were effective to provide reasonable
          assurance that the information required to be disclosed by us in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and (ii) accumulated and
          communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding disclosures.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><span style="color: #000000;">A control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide
            absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.</span> We do not expect that our disclosure controls and procedures or our internal control over financial reporting are able to
          prevent with certainty all errors and all fraud.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Changes in Internal Control Over Financial Reporting</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal
          control over financial reporting.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;"><a id="PARTII"><!--Anchor--></a>PART II</div>

        <div style="text-align: center; font-weight: bold;">OTHER INFORMATION</div>

        <div>&#160;</div>

        <a id="LegalProceedings."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 1.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Legal Proceedings.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. In the opinion of management, there are currently no material pending legal proceedings that
          would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</div>

        <div><br/>
        </div>

        <a id="RiskFactors."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 1A.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;"><!--Anchor-->Risk Factors.</div>
              </td>

  </tr>


</table>
        <div><span style="font-weight: bold;"> </span><br/>
        </div>

        <div style="font-weight: bold;">Summary of Risk Factors</div>

        <div><br/>
        </div>

        <div style="font-style: italic;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks
          summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Quarterly Report on Form 10-Q, the 2023 10-K and
          our other filings with the SEC, before making an investment decision regarding our common stock.</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Although we achieved net income on a non-GAAP basis and generated positive cash flows for the year ended December 31, 2023 and generated positive net income and cash flows for the nine months ended September 30, 2024, we may not be
                  able to maintain profitability and generate positive cash flows in the future.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We have a history of losses and we may, in the future, need to raise additional capital or seek alternative financing in order to operate, expand or maintain our business, which may not be available on favorable terms, if at all.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture, and we also obtain source plasma from certain third parties. This reliance on third parties carries the risk that the
                  services and supply upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could delay the availability of our finished drug product and could adversely affect our
                  commercialization efforts and our revenues.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could fail to
                  grow at similar rates, if at all.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Both of our business segments and our facilities are subject to periodic inspections by the FDA, which, depending on the outcome of such inspections, could result in certain FDA actions, including the issuance of observations, notices,
                  citations, warning letters or other enforcement actions.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Business interruptions could adversely affect our business.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited and FDA could require clinical trials beyond
                  what we may deem to be reasonable. Unless additional clinical trials are successfully conducted and the FDA approves a Biologics License Application (&#8220;BLA&#8221;) or other required submission for review, we may not be authorized to market
                  ASCENIV for any other indication.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>With the approval to market ASCENIV, BIVIGAM and Nabi-HB, there can be no assurance that we will be successful in further developing and expanding commercial operations or balancing our research and development activities with our
                  commercialization activities.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, some of which are single-sourced, and such parties are outside of our control.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite approval from
                  the FDA.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial penalties if we
                  fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of operations and
                  financial condition.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other assumptions.&#160; Any change in our accrual estimates could have a
                  material effect on our business, financial position and operating results.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of existing
                  products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their requirements.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our senior secured credit facility with Ares Capital Corporation and certain of its affiliates (&#8220;Ares&#8221;) is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any collateral.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be
                  materially damaged.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and reputation.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and the manufacturing processes we have in place to
                  counter transmittable diseases.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source plasma with proper specifications or other necessary raw materials.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-weight: bold;">Risk Factors</div>

        <div>&#160;</div>

        <div style="font-style: italic;">Described below are various risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. You should recognize that other significant risks and uncertainties may
          arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones that we currently deem immaterial or
          that are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial condition or results of operations could be
          materially and adversely affected. You should carefully consider the following risk factors and the section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; before you decide to invest in our securities.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Risks Relating to our Business</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">Through December 31, 2023, we have a history of losses and have historically needed to raise, and in the future may be required to raise, additional capital to operate our business.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our long-term liquidity depends upon our ability to grow our commercial programs, expand our commercial operations at the Boca Facility, improve our supply chain capabilities, improve production yields, continue to
          build out our commercial infrastructure and meet our ongoing obligations. In addition, our end-to-end production cycle from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially
          longer, requiring substantial investments in raw material plasma and other manufacturing materials.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to
          fund our operations, as currently conducted, through the end of the fourth quarter of fiscal 2025 and beyond. However, our current outlook on cash flows and profitability may change based upon our effectiveness in executing on our
          commercialization efforts and operational initiatives and whether or not the assumptions underlying our projected revenues and expenses are correct. Although we achieved net income and positive cash flows for the nine months ended September 30,
          2024 and positive cash flow from operations for the first time in our history for the year ended December 31, 2023, at present we cannot be certain that we will be able to continue to generate positive cash flows from operations during the
          remainder of 2024 or beyond and if we cannot raise additional capital or obtain alternative financing if needed, we may have to delay, curtail or eliminate our commercialization efforts and product development activities. Even if we are able to
          raise additional capital, such equity or debt financings may only be available on unattractive terms, resulting in significant dilution of stockholders&#8217; interests and, in such event, the value and potential future market price of our common stock
          may decline. In addition, if we raise additional funds through license arrangements or through the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or assets or grant
          licenses on terms that are not favorable to us.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Historically, the major source of our cash has been from proceeds from various public offerings of our common stock and debt transactions. The actual amount of additional cash that we may need, if any, is subject to
          many factors. There can be no assurances that additional financing will be available if needed or that management will be able to obtain financing on terms acceptable to us or that we will continue to be profitable and generate positive operating
          cash flow.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We may not be able to maintain profitability in 2024 and beyond.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We have a history of losses through December 31, 2023, and we may not be able to maintain profitability. Although we achieved net income of $85.8 million for the nine months ended September 30, 2024, for the years
          ended December 31, 2023, 2022 and 2021, we incurred net losses of $28.2 million, $65.9 million and $71.6 million, respectively. From our inception in 2004 through September 30, 2024, we have incurred an accumulated deficit of $420.5 million. <a id="z_Hlk54687406"></a>We may not be able to maintain profitability for the remainder of or beyond 2024, and if we are unable to continue to consistently achieve positive cash flows we may need to continue to finance our operations through
          additional equity or debt financings or corporate collaboration and licensing agreements. We also expect to continue to incur significant operating and capital expenditures and anticipate that as our business continues to grow our operating
          expenses will increase accordingly as we:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>expand commercialization and marketing efforts;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>expand our research and development programs;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>implement additional internal systems, controls and infrastructure;</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>hire additional personnel; and</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>expand production capacity at the Boca Facility.</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">As a result, we will need to generate significant revenues in order to maintain profitability. We may not be able to generate these revenues or maintain profitability in the future.</div>

        <div><br/>
        </div>

        <div>
          <div style="color: #000000; font-style: italic; font-weight: bold;">Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations.</div>

          <div>&#160;</div>

        </div>

        <div>
          <div style="text-indent: 36pt; color: rgb(0, 0, 0);">The COVID-19 pandemic negatively impacted certain aspects of our business and operations. The resurgence of the COVID-19 pandemic, or a future pandemic or health epidemic, could adversely
            affect our business, financial condition, liquidity or results of operations. These adverse effects include, but are not limited to, the potential adverse effects on the global economy, our manufacturing processes, including our supply chain,
            our submissions or applications to the FDA and our employees. The ultimate impact will depend on the severity and duration of the pandemic and actions taken by governmental authorities and other third parties in response, each of which is
            unforeseeable and difficult to predict.</div>

        </div>

        <div><br/>
        </div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">We contract with third parties for a portion of the filling, packaging, testing and labeling of the drug substance we manufacture, and also obtain plasma from certain third
          parties. This reliance on third parties carries the risk that the services and raw materials upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could delay the
          availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Third parties may not perform as agreed or in accordance with FDA requirements. Any significant problem that our third-party providers experience could delay or interrupt our supply of finished drug
          product until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed services, raw materials and
          products meeting the necessary quality standards or at all could have a material and adverse effect on our products, business, financial condition and results from operations.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><span style="color: #000000;">Although we are utilizing our FDA-approved fill/finish suite that we built at the Boca Facility for a portion of our finished drug product and although we receive our raw material plasma
            from our ADMA BioCenters plasma collection facilities, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug product and to supply raw material source and high-titer RSV plasma. Any failure by
            us, our contract fill/finishers, or other third parties involved in the process for producing our products or product candidates to comply with the applicable manufacturing and regulatory requirements, including quality requirements, could
            place us and them </span>at risk of regulatory enforcement actions, recalls and other adverse consequences, could adversely impact our products, and could adversely impact patients receiving our products, which may negatively impact our
          business and our ability to produce and supply products to meet commercial and clinical needs.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Our anticipated reliance on a limited number of third-party contractors exposes us to the following risks:</div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>we may be unable to identify contractors on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance as part
                      of our marketing application;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>a pandemic, or the resurgence of a pandemic such as the COVID-19 pandemic, or a cyberattack or data breach, could adversely affect our contractors&#8217; operations, supply chain or workforce;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, therefore they may require a significant amount of support from us in order to implement and maintain the infrastructure
                      and processes required to deliver our finished drug product;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>our third-party contractors might be unable to timely provide finished drug product or raw material plasma in sufficient quantity or in accordance with our specifications to meet our commercial needs;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>contractors may not be able to execute our inspection procedures and required tests appropriately;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>contractors are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over third-party
                      providers&#8217; compliance with these regulations;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>contractors may fail to comply with applicable regulatory requirements, placing them and us at risk of regulatory enforcement actions, recalls and other adverse consequences, and which place our patients at risk, which may
                      negatively impact our business and their ability to supply products to meet our development, clinical and commercial needs;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>our third parties could breach or terminate their agreements with us; and</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">
                    <div><br/>
                    </div>
                  </td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">&#8226;</div>
                  </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control, quality
                      assurance and qualified personnel.</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div><span style="color: #000000;">Each of these risks could delay or prevent production, the completion of our finished drug product and the release of finished drug product by us or the FDA, which could result in higher costs or adversely impact
            our revenues. These risks could also result in the delay in obtaining clinical supplies, which would delay our development programs. In addition, our contract fill/finishers and our other third-party vendors may source their materials and
            supplies globally and are therefore subject to supply disruptions in the event of </span>fire, weather related events such as hurricanes, wind and rain, international conflicts, strikes, embargos trade and sanction requirements and limits,
          other acts of God or force majeure events or global health occurrences and emergencies.</div>

        <div><br/>
        </div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete
          achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. In particular, the size and
          growth of the overall U.S. IVIG and source plasma markets and the potential market opportunity for an <span style="font-style: italic;">S. pneumoniae</span> hyperimmune globulin are subject to significant variables that can be difficult to
          measure, estimate or quantify. Our business depends on, among other things, successful commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there can be no
          assurance that we will be able to generate the revenue that we believe our products and plasma collection facilities are capable of generating. As a result, we may not be able to accurately forecast or predict revenue. For these reasons, the
          estimates and forecasts in our filings relating to revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could fail to grow at similar rates,
          if at all.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Geopolitical conditions, war, terrorism or other military actions may have a material adverse effect on our business.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Geopolitical conflicts, war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in
          disruptions to our supply chain, delays or cancellations of customer orders, a general decrease in consumer spending, our inability to effectively market and distribute our products and/or our inability to access the capital markets, our business
          and results of operations could be materially and adversely affected. For example, in response to the ongoing conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries may additionally impose,
          broad sanctions or other restrictive actions against governmental and other entities in Russia. Additionally, further escalation of geopolitical tensions, such as ongoing conflicts in the Middle East and the surrounding areas could have a broader
          impact that extends into other markets where we do business. We are unable to predict geopolitical conditions, whether acts of international terrorism or the involvement in a war or other military actions will result in any long-term commercial
          disruptions or if such involvement or responses will have any long-term material adverse effect on our business, results of operations, or financial condition.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA and other regulatory authorities, which, depending on the
          outcome of such inspections, could result in certain regulatory actions, including the issuance of observations, notices, citations or warning letters.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;"><span style="color: #000000;">We and our suppliers and contractors may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements for commercial and
            clinical supply. </span>The FDA and other regulatory authorities are authorized to perform inspections and remote regulatory assessments of our and our suppliers&#8217; facilities, including the Boca Facility. The FDA and other regulatory
          authorities also may inspect and approve our and our third-parties&#8217; facilities before they may be used for commercial production. If we or our suppliers are not able to comply with the applicable regulatory requirements, we or they may be subject
          to regulatory enforcement actions, which can materially impact our business. For instance, at the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause the FDA to not approve the use of
          the facility and cause us to modify certain activities identified during the inspection. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of
          regulatory significance of a warning letter. FDA guidelines also provide for the issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected to result
          in an enforcement action. FDA also may issue warning letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection. Depending on the seriousness of any findings, we or our suppliers may be subject to
          additional significant enforcement actions which could have a material impact on our business.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In the event of any enforcement actions, we and our third-party contractors would need to implement remedial actions which may be time-intensive or costly. We may not be able to timely resolve concerns raised by the
          applicable regulator as a result of an inspection or without expending significant resources. We are unable to control the timing of inspections, communications and actions, and will be required to respond to the regulator and make certain
          submissions within certain timeframes. We also do not know whether or not the regulator will change its requirements, guidance or expectations. If the regulator determines that we have not remediated the issues identified in a warning letter or
          any other inspection issues and deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of our commercialization efforts and could have a
          material adverse effect on our financial condition and operating results.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the
          success of our business.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and
          wastes. Our commercial manufacturing and any research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the disposal of these
          materials. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption to our commercialization efforts, research and development efforts and business operations, environmental damage resulting
          in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized internally and by
          our third-party manufacturers and service providers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of
          accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of
          certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be
          certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our commercial
          manufacturing, research and development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties, or other sanctions.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div><span style="font-weight: bold; font-style: italic;">Business interruptions could adversely affect our business</span><span style="font-weight: bold;">.</span></div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes, wind and
          rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, cyberattacks on our operations and information technology systems as well as the systems of our customers,
          suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims and events beyond our
          control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of these risks, including replacing or rebuilding a part of our facilities, these policies are subject to the insurance
          carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our inventory, infrastructure, business income or our entire facility.&#160; In addition, our disaster recovery plans for our
          facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other manufacturers in the event of a casualty to or destruction of any of our facilities. If we are required to rebuild or
          relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited amount of business interruption insurance, which may not sufficiently compensate us for losses that may occur. As a
          result, any significant business interruption could adversely affect our business and results of operations.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive results, we may be required to delay or
          abandon development of such product, which would have a material adverse impact on our business.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to design
          and implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.<span style="font-weight: bold; font-style: italic;">&#160;</span>Human clinical trials are
          very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur at any stage of the process,
          and we could encounter problems that cause us to abandon our product development programs and related Investigational New Drug (IND) applications or BLAs, or to repeat clinical trials. The commencement and completion of clinical trials or
          ultimate product approval for any current or future development product candidate may be delayed by several factors, including:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>unforeseen safety issues;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>determination of dosing issues;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>lack of safety or effectiveness, or other adverse study results during clinical trials;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>slower than expected rates of patient recruitment or noncompliance with clinical trial requirements;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>inability to monitor patients adequately during or after treatment; and</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>inability or unwillingness of medical investigators to follow our clinical protocols.</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our product
          candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase III) be demonstrated in two
          adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase III clinical trial results do not demonstrate a statistically significant, clinically meaningful benefit
          with an acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase III clinical trials in order to gain approval, we will incur significant additional development costs and commercialization of these products
          would be prevented or delayed and our business could be adversely affected.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In addition, the FDA or an IRB may not permit us to commence a clinical trial, may require amendments to our clinical trial protocols, or may suspend our clinical trials at any time if it appears that we are exposing
          participants to unacceptable health risks or if the FDA or IRB finds deficiencies in our IND submissions or the conduct of these trials. Regulatory authorities may also not accept data from clinical trials if the trials are not conducted in
          accordance with the applicable regulatory requirements. Failure to comply with the applicable regulatory requirements may also result in enforcement actions. Therefore, we cannot provide any assurance or predict with certainty the schedule for
          future clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain regulatory approval to market and sell
          our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the capital necessary to fund our operations will
          increase.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or we may be forced to abandon
          development of such product candidate altogether.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that later clinical
          trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay
          development of other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Other issues that may impact our clinical trials and that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, include:</div>

        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our contract research organizations (&#8220;CROs&#8221;);</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Regulators requiring us to perform additional or unanticipated clinical trials to obtain approval or becoming subject to additional post-marketing testing, surveillance, or Risk Evaluation and Mitigation Strategies requirements to
                  maintain regulatory approval;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Failure by our third-party contractors to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or our being required to engage in additional
                  clinical trial site monitoring;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>The cost of clinical trials of our product candidates being greater than we anticipate or our having insufficient funds for a clinical trial or to pay the substantial user fees required by FDA upon the filing of a marketing
                  application;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Insufficient supply or inadequate quality of our product candidates or other materials necessary to conduct clinical trials;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">47</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Inability to achieve sufficient study enrollment, subjects dropping out or withdrawing from our studies, delays in adding new investigators or clinical trial sites or a withdrawal of clinical trial sites;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Flaws in our clinical trial design that are not discoverable until the clinical trial has progressed;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Disagreement by the FDA or comparable foreign regulatory authorities with our intended indications or study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials, finding that a product
                  candidate&#8217;s benefits do not outweigh its safety risks or requiring that we conduct additional development or study work;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>The need to make changes to our product candidates that require additional testing or that cause our product candidates to perform differently than expected;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Global trade policies that may impact our ability to obtain raw materials and/or finished product for commercialization;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>FDA or comparable regulatory authorities taking longer than we anticipate to make decisions on our products or product candidates; and</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>Potential inability to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition, certain
          portions of our clinical trials and product testing for our product candidates may be performed outside of the United States, and therefore, may not be performed in accordance with standards normally required by the FDA and other regulatory
          agencies.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product candidate, which would make
          it difficult for us to recover the costs of researching and developing such product candidate.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">If we are not able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues, revenues
          generated from sales of our FDA-approved commercial products, revenues generated from new contract manufacturing arrangements with third parties and revenues generated from the sales of manufacturing intermediates. We cannot assure you that we
          will receive the approvals necessary to commercialize any product candidate we may acquire or develop in the future or that we will be able to maintain our current approvals. In order to obtain FDA approval of any product candidate requiring FDA
          approval, our clinical development must demonstrate that the product candidate is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally
          requires significant research and testing, referred to as preclinical studies, as well as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type, complexity
          and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe for humans and
          effective for indicated uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies or may require additional Chemistry,
          Manufacturing and Controls (&#8220;CMC&#8221;) or other data and information, and the development and provision of this data and information may be time-consuming and expensive. The approval process may also be delayed by changes in government regulation,
          future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>delay commercialization of, and our ability to derive revenues from, our product candidates;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>impose costly procedures on us; and</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">48</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>diminish any competitive advantages that we may otherwise enjoy.</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct further
          studies with more subjects. We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval of any of our product candidates will severely undermine our business by
          leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval from the appropriate
          regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the FDA review, inspection and
          approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the United States.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited, unless
          additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The FDA and other governmental authorities strictly regulate and monitor marketing, labeling and the advertising and promotion of prescription drugs. These regulations include standards and restrictions for
          direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA does not allow drugs to be promoted for &#8220;off-label&#8221; uses&#8201;-&#8201;that is, uses that
          are not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. The FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required for new
          formulations, any new indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain FDA approval for
          any desired future indications for ASCENIV.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in clinical
          studies and approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties and may constitute
          an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not regulate the behavior of physicians in their choice of treatments. Regulatory authorities do, however, restrict
          communications by pharmaceutical companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be subject to warnings from, or enforcement action
          by, these authorities. In addition, our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters, bring an enforcement action against us, suspend or withdraw an
          approved product from the market, require a recall, require payment of civil fines or could result in disgorgement of money, operating restrictions, injunctions or criminal prosecution, among other consequences, any of which could harm our
          reputation and our business.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring an adequate supply of
          high-titer antibody RSV plasma or balancing our research and development activities with our commercialization activities.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to successfully manage
          the balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently encountered by companies balancing
          development of product candidates, which can include problems such as unanticipated issues related to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with commercialization efforts, which can include problems
          related to managing manufacturing and supply, including supply chain constraints, reimbursement, marketing challenges, development of a comprehensive compliance program, and other related and additional costs. For example, the raw material plasma
          we collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors which contains high-titer antibodies to RSV. This high titer-plasma <span style="color: rgb(0, 0, 0);">which meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay </span>amounts to less than 10% of the total donor collection samples we test. As a result, we may
          experience an insufficient supply of this plasma.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">49</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the United States and other
          countries. In addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and commercialize
          any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for other pre and post-approval
          services, and such parties&#8217; performance is, to some extent, outside of our control.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, CROs, contract manufacturers, contract fill/finishers, third-party plasma centers and
          consultants to conduct our preclinical activities, clinical trials, CMC testing and other activities under agreements with us. We also depend on third-party suppliers for materials used in our operations. These collaborators are not our employees
          and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs
          ourselves. Additionally, certain of our third-party suppliers may be single-sourced or may not be able to supply sufficient materials for our operations, and it may be time-consuming, expensive or otherwise not feasible to locate an alternative
          supplier. If outside collaborators fail to devote sufficient time and resources to our products and/or development programs, or if their performance is substandard or does not comply with the applicable regulatory standards, our trials may be
          repeated, extended, delayed, or terminated, the approval of our FDA application(s), if any, and our introduction of new products, if any, will be delayed, and we may not be able to maintain existing approvals or meet our regulatory requirements
          or we may not be able to produce forecasted amounts of product. We or they may also be subject to regulatory enforcement actions, may need to take corrective actions, including initiating recalls, and we may not be able to meet commercial demand.
          These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our expense, our competitive position would be harmed. Additionally, any change in
          the regulatory compliance status of any of our vendors may impede our ability to receive and maintain approval for our product candidates.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if
          we do not obtain requisite approval from the FDA.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We currently anticipate expanding the manufacturing capacity and product output capability of our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new equipment, such as
          our fill-finish machine, we will need to validate the expanded facility and equipment, make the necessary submissions to FDA, obtain any FDA-required approvals and have it inspected by the FDA. Given the significant delays that may result during
          the validation process, we may experience a supply shortage of our products or our production capabilities may be limited until completion of and validation of our facility expansion and new manufacturing equipment.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">50</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div>
          <div style="color: rgb(0, 0, 0); font-style: italic; font-weight: bold;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the
            market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>

        </div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as withdrawal
          from the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling and advertising and promotional activities for such products, among other things, are subject to ongoing regulatory compliance
          requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, adherence
          with labeling and promotional requirements and restrictions, requirements related to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding safeguarding the drug supply
          chain as well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our application supplement to allow for the commercial relaunch of BIVIGAM, as well as the FDA&#8217;s approval of our BLA for ASCENIV,
          require us to conduct specified post-marketing studies, including pediatric and safety studies. If, during the post-marketing period (after marketing approval) previously unknown adverse events emerge, there is the discovery that the product is
          less effective than previously thought, or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to comply with the numerous regulatory requirements to which we are subject,
          those circumstances may yield various results, including:</div>

        <div style="text-align: justify;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">restrictions on such products or manufacturing processes;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">restrictions on the labeling or marketing of a product;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">restrictions on product distribution or use;</td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">clinical holds or termination of clinical trials;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div style="text-align: justify;">
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top; text-align: justify;">
                    <div>requirements to conduct further post-marketing studies or clinical trials, implement risk mitigation strategies, or to issue corrective information;</div>
                  </td>

  </tr>


</table>
          </div>

        </div>

        <div><br/></div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">warning letters or untitled letters;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">withdrawal of the products from the market;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">refusal to approve pending applications or supplements to approved applications that we submit;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">recall of products;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">restrictions on coverage by third-party payers;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">fines, restitution or disgorgement of profits or revenues;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">suspension or withdrawal of marketing approvals;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">refusal to permit the import or export of products;</td>

  </tr>


</table>
          </div>

        </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">FDA debarment, suspension and debarment from government programs, refusal of orders under existing government contracts, exclusion from participation in federal healthcare programs, consent
                    decrees, deferred or non-prosecution agreements or corporate integrity agreements;</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">product seizure or detention; or</td>

  </tr>


</table>
          </div>

        </div>

        <div style="text-indent: -36pt; margin-left: 36pt;"><span style="color: #000000;"> </span><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 36pt; vertical-align: top;"><br/>
                  </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">injunctions or the imposition of civil penalties or criminal fines.</td>

  </tr>


</table>
          </div>

        </div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">51</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">
          <div style="font-style: italic; font-weight: bold;">Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on
            our business, results of operations and financial condition.</div>

          <div><br/>
          </div>

          <div>For the nine months ended September 30, 2024, two customers, BioCARE, Inc. (&#8220;BioCare&#8221;) and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution (&#8220;Curascript&#8221;), represented an aggregate of approximately 71% of our
            consolidated revenues. For the year ended December 31, 2023, BioCare and Curascript represented an aggregate of 72% of our consolidated revenues.</div>

        </div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">As of September 30, 2024, four customers, BioCare, Reliance Life Sciences Pvt. Limited (&#8220;Reliance&#8221;), Healix Infusion Therapy, LLC (&#8220;Healix&#8221;) and BioLife Plasma Services, L.P., represented an aggregate of
          approximately 91% of our consolidated accounts receivable. As of December 31, 2023, five customers, BioCare, Healix, Curascript, Cencora, Inc. (f/k/a AmerisourceBergen Corporation) and Reliance, represented an aggregate of approximately 98% of
          our consolidated accounts receivable.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The loss of any key customers or a material change in the revenue generated by any of these customers could have a material adverse effect on our business, results of operations and financial condition. Moreover, we
          anticipate deriving increased revenue from some of these customers over the next few years. Factors that could influence our relationships with our customers include, among other things:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>our ability to sell our products at competitive prices;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>the impact of a pandemic, or the resurgence of a pandemic, and government responses thereto on our customers and their businesses, operations and financial condition;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>the impact of a cyberattack or data breach on our customers or related entities; and</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>widespread economic conditions or geopolitical conditions, including the exacerbated conflicts in Europe, the Middle East and the surrounding areas.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div>Additionally, an adverse change in the financial condition of any of our key customers could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our business and results of operations.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the safety and
          efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse inspection reports,
          warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, patient injury, refusal of a government to grant approvals and
          licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely manner may also cause negative publicity or a
          loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully commercializing our current products and launching new products.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In addition, as a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing process. As
          our biologics production levels increase, there may be normal course inventory losses or write-downs as we ensure product quality and compliance with cGMP, FDA, state and local regulations, or due to testing results not meeting specifications. As
          a result, our operating results are subject to potentially significant variability from one reporting period to the next should such normal course losses occur in any given period. However, because our products and product candidates are
          plasma-based products, not only are we subject to the FDA&#8217;s drug and biologic cGMP requirements, but we are also subject to special requirements for the collection, testing, handling, storage, and use of blood products.&#160; This adds an extra level
          of compliance and complexity to our operations, which we may not be able to successfully meet.&#160; Failure to meet any regulatory quality standards could have an adverse impact on our business.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">52</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including, but not limited to:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>cost-effectiveness of our products relative to competing products;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>availability of reimbursement for our products from government or other healthcare payers; and</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div>The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable terms, if at all.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other assumptions.&#160; These estimates
          are subject to change based on actual results and other factors. Any such change could have a material effect on our business, financial position, and operating results.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date
          of the financial statements and the reported amounts of revenues and expenses during the reporting period.&#160; Significant estimates include, among other things, accruals for U.S. Medicaid rebates related to the sale of our immunoglobulin products.
          We accrue these rebates at the time of sale based on our estimates of the sales mix of our products and the portion of the products we sell that will be prescribed to Medicaid beneficiaries. These estimates are based on historical experience and
          certain other assumptions, and while we believe that such estimates are reasonable, they are subject to change based on future experience, Medicaid utilization trends and other factors.&#160; If any of our ratios, factors, assessments, experiences or
          judgments are not indicative or accurate estimates of our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment include those associated with U.S. Medicaid rebates because of the
          extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and
          channel mixes.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">For example, during the nine months ended September 30, 2024, we engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin
          products. As a result of this evaluation, we recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 million.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In addition, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) included a significant expansion of state Medicaid programs. As more individuals become eligible for coverage under these programs, Medicaid
          utilization of our products could increase, resulting in a corresponding increase in our rebate payments. Such rebate payments may exceed what we have accrued for during the applicable period.&#160; Increases in Medicaid rebate payments could decrease
          our net revenues from product sales, which in turn could adversely affect our business, financial position, and operating results.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">53</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product
          candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our current product development portfolio consists primarily of label expansion activities for ASCENIV, as well as expanding our IP estate with patents issued for <span style="font-style: italic;">S. pneumoniae</span>
          hyperimmune IG. We have initiated small-scale preclinical activities to potentially expand our current portfolio through new product development efforts. If we are not successful in developing or acquiring additional products and product
          candidates, we will have to depend on our ability to continue to generate revenues from ASCENIV, BIVIGAM, Nabi-HB, contract manufacturing, intermediate fractions and plasma attributable to the operations of ADMA BioCenters to support our
          operations.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if
          we fail to meet their requirements.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Consumer privacy is highly protected by federal and state law. The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical
          Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose requirements with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by covered entities and business
          associates. HIPAA &#8220;covered entities&#8221; include health plans/insurers, healthcare providers engaging in HIPAA standard electronic transactions and healthcare clearinghouses. A &#8220;business associate&#8221; provides services to covered entities (directly or
          as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or transmitting PHI on a covered entity&#8217;s behalf.&#160; In order to legally provide access to PHI to service providers, covered entities and
          business associates must enter into a &#8220;business associate agreement&#8221; (&#8220;BAA&#8221;) with the service provider that receives PHI on behalf of the entity.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">While we are not a covered entity or business associate subject to HIPAA, personal information that we obtain pursuant to a clinical trial may be subject to U.S. Federal Trade Commission (the &#8220;FTC&#8221;) privacy
          regulation. Failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute an unfair act or practice violating Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data
          security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.
          Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to, but less prescriptive than, what is required by the HIPAA Security Rule. In
          addition, states impose a variety of laws protecting consumer information, with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened standards.&#160; In addition, federal and state privacy, data security,
          and breach notification laws, rules and regulations, and other laws apply to the collection, use and security of personal information, including social security number, driver&#8217;s license numbers, government identifiers, credit card and financial
          account numbers. For example, the CCPA was amended by the CPRA, effective January 1, 2023. The CCPA, among other things, imposes data privacy obligations for covered companies and provides new privacy rights to California residents, including the
          right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. We could be
          subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws. Virginia, Colorado, Connecticut and Utah have also enacted privacy laws that became effective in 2023 and are similar in many
          respects to the CCPA. Several other states have also enacted privacy laws similar to the CCPA that will become effective in the coming years, adding to potential privacy compliance obligations.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">54</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">The Ares Credit Facility is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any collateral.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we entered into a credit agreement with Ares (the &#8220;Ares Credit Agreement&#8221;) (see &#8220;Liquidity and Capital Resources&#8221;). The Ares Credit Agreement provides for a total of
          $135 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million
          (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On August 14, 2024, we repaid $30.0 million against the
          revolving credit facility. The Ares Loans are secured by substantially all of our assets, including our intellectual property. Events of default include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy
          of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we would incur an increase in the rate of
          interest on the Ares Loans of 2% per annum. The occurrence of an event of default could result in, among other things, the termination of commitments under the Ares Credit Facility, the declaration that all outstanding loans are immediately due
          and payable in whole or in part, and Ares taking immediate possession of, and selling, any collateral securing the Ares Loans.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Developments by competitors may render our products or technologies obsolete or non-competitive.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to compete
          with other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and biotechnology companies in
          the United States and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater financial resources, larger research and
          development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also compete with us to attract qualified personnel and
          parties for acquisitions, joint ventures or other collaborations.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness
          and business prospects may be materially damaged.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">As we move forward in clinical development, we continue to discover novel technologies related to our products and we may draft patent applications directed to these technologies. We rely on a combination of patent
          rights, trade secrets, intellectual property assignment agreements and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance that our patents, trade
          secret policies and practices or other agreements will adequately protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent proceedings before courts, the U.S. Patent
          and Trademark Office or foreign patent offices. Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition. The processes, systems, and/or security measures we use to preserve the
          integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies as a result of any such breaches. In addition, our trade secrets may otherwise become known or be independently discovered by
          competitors. There can be no assurance that the confidentiality, invention assignment, nondisclosure and non-competition agreements with employees, consultants and other parties with access to our proprietary information to protect our trade
          secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes and proprietary rights, will be adequate, will not be breached, that we will
          have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent
          that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We could lose market exclusivity of a product earlier than expected.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the United States and in some other countries, when
          market exclusivity expires and generic or biosimilar versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines in a product&#8217;s revenues.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">55</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on the
          availability of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, limitations on the use or loss of such rights could be material to us. In some countries, basic patent protections for
          our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent environment can be unpredictable and
          the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be approved and marketed.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing approval or
          choose to launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly, time-consuming and no assurance
          can be given that we will prevail. In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development, manufacturing and marketing activities, and
          consequently have a material and adverse effect on our business and prospects, regardless of the outcome. There is no assurance that ASCENIV, or any other of our products for which we are issued a patent, will enjoy market exclusivity for the
          full time period of the respective patent.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available on reasonable
          terms or at all.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to the
          development and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of products and
          competitors in our market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement claims. We cannot be
          certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the United States and in foreign jurisdictions. If our products, methods, processes and other technologies are
          found to infringe third-party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the applicable third-party patent and pay royalties or are
          able to design around such patent. We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid infringement. Even if we are able to redesign our products or
          processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior or more costly product and/or process. Any claim of infringement by a
          third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business. Furthermore, if any such claim is successful, a court could order us to pay
          substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the compensatory damages and award attorney fees. These damages could be substantial and could harm
          our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or permanently prohibit us, our licensees, if any, or our customers from making, using, selling, offering to sell
          or importing one or more of our products or practicing our proprietary technologies or processes, or could enter an order mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating
          results and financial condition.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to successfully manage our growth, our business may be harmed.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our success will depend on the expansion of our commercial and manufacturing activities, supply of raw material plasma and overall operations and the effective management of our growth, which will place a significant
          strain on our management and on our administrative, operational and financial resources. To manage this growth, we must expand our operational, financial and management systems and hire and train additional qualified personnel. If we are unable
          to manage our growth effectively, our business could be harmed.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">56</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">The loss of one or more key members of our management team could adversely affect our business.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss of Adam S.
          Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment agreements with each of
          our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective
          terms. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and diversion of management resources.</div>

        <div><br/>
        </div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and
          reputation.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission of and
          access to this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including e-mails and other
          electronic communications. Hackers may impersonate our vendors, suppliers or other third parties with whom we do business, which may result in financial harm to our business. Further, while many of our employees and certain suppliers with whom we
          do business operate in a remote working environment, the risk of cybersecurity attacks and data breaches, particularly through phishing attempts, may be increased as we and third parties with whom we interact leverage our IT infrastructure in
          unanticipated ways. In addition, an employee, contractor, or other third party with whom we do business may attempt to obtain such information and may purposefully or inadvertently cause a breach involving such information. While we have certain
          safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide cybersecurity policy, our information technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, such as
          the IT disruption described elsewhere in this report, or employee error or malfeasance. Any such compromise of our data security and access to, or public disclosure or loss of, confidential business or proprietary information could disrupt our
          operations, damage our reputation, provide our competitors with valuable information and subject us to additional costs which could adversely affect our business.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development, manufacturing
          operations, and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales, marketing, medical affairs,
          reimbursement, government regulation, formulation, quality control, manufacturing, finance, general and operational management and plasma collections. In particular, over the next 12-24 months, we expect to hire several new employees devoted to
          our plasma collection centers, commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, information technology, finance and general and operational management. Qualified individuals of the
          requisite caliber and number needed to fill these positions may be in short supply in some areas. We compete for qualified individuals with numerous biopharmaceutical companies, universities and other research institutions. Competition for such
          individuals is intense, and we cannot assure you that our search for such personnel will be successful. If we are unable to hire and retain personnel capable of consistently performing at a high level, our business and operations could be
          materially adversely affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect on our business, financial condition or operating results.</div>

        <div style="text-indent: 36pt;"> <br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">57</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We currently collect human blood plasma at our ADMA BioCenters facilities, and if we cannot maintain FDA licensure for these facilities or obtain FDA licensure for additional facilities that we
          may construct or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We intend to maintain FDA licensure of our current and future ADMA BioCenters collection facilities for the collection of human blood plasma and we may seek other governmental and regulatory approvals for these
          facilities. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation, including compliance with current cGMP and blood standards and FDA licensure and other governmental
          approvals, as applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our current or future facilities may result in enforcement actions, such as adverse inspection reports, warning or
          untitled letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of regulatory authority approvals and licenses, restrictions
          on operations or withdrawal of existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a material adverse effect on our ability to manufacture our products or offer
          for sale plasma collected at the affected sites. Failure to comply with applicable governmental regulations may also impact the ultimate quality and compliance of our finished biologic products, which may have a material adverse effect on our
          business.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we or our vendors cannot maintain appropriate
          FDA status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">There are no assurances we will be able to maintain compliance with all FDA or other regulations. There is also no guarantee that we will be able to fulfill our contractual requirements to our customers. Moreover, to
          the extent that we use third-party vendors to fulfill our regulatory or contractual requirements, these third-party vendors may perform activities for themselves or other clients and we may not be privy to all regulatory findings or issues
          discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely affect our ability to continue to work with these vendors, or our ability to release commercial drug product or perform necessary
          testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to commercialize our products. If we are not able to maintain manufacturing compliance at our facilities or our vendors&#8217; facilities for our
          products and product candidates, we may not be able to successfully develop and commercialize our products and product candidates and we may face potential contractual or regulatory actions, which would have an adverse impact on our business.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
          required to limit commercialization of our products. Product liability claims may also result in recalls and/or regulatory enforcement actions. Even successful defense, however, could impair our results of operations. Our inability to obtain and
          maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical products we develop, either alone or with collaborators.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal and state laws. Failure to
          comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The laws governing our conduct in the United States are enforceable on the federal, state and local levels by criminal, civil and administrative sanctions. Violations of laws such as the Federal Food, Drug, and
          Cosmetic Act, the Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of
          overpayments, other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from participation in or
          debarment from federal and state healthcare or government procurement programs, pursuant to enforcement actions by DOJ, Medicare, Medicaid, OIG and other regulatory authorities. Similarly, the violation of applicable laws, rules and regulations
          of states, including the State of Florida, with respect to the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from
          participation in applicable state healthcare programs. There can be no assurance that our activities will not come under the scrutiny of federal and/or state regulators and other government authorities or that our practices will not be found to
          violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">58</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value to induce or reward patient referrals, or in return for purchasing, leasing, ordering or
          arranging for or recommending the purchase, lease, or ordering of any item or service reimbursable in whole or in part by a federal healthcare program is prohibited.&#160; This places constraints on the marketing and promotion of products and on
          common business arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these practices can result in substantial legal
          penalties, including, among others, exclusion from participation in the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations, healthcare organizations, physicians and pharmacists
          must be structured with care to comply with applicable requirements. Legislators and regulators may seek to further restrict the scope of financial relationships that are considered appropriate. For example, HHS recently promulgated a regulation
          that is effective in two phases.&#160; First, the regulation excludes from the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care
          Organization plan reflected in point-of-sale reductions in price and (b) PBM service fees paid by a manufacturer to a PBM.&#160; Second, effective January 1, 2023, the regulation expressly provides that rebates to plan sponsors under Medicare Part D
          either directly to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager, will not be protected under the Anti-Kickback Statute discounts safe harbor. Recent legislation and a final rule promulgated on December
          29, 2023 delayed implementation of this portion of the rule until January 1, 2032.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Also, certain business practices, such as payments of consulting fees to healthcare professionals, sponsorship of educational or research grants, charitable donations, interactions with healthcare professionals who
          prescribe products for uses not approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of wrongfully influencing healthcare
          professionals to prescribe or purchase particular products or as a reward for past prescribing. Under the Healthcare Reform Law, payments and transfers of value by pharmaceutical manufacturers of drugs, devices, biologics and medical supplies for
          which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but limited to, U.S.-licensed physicians, physician assistants, nurse
          practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report
          certain ownership interests held by physicians and their immediate family members. A number of states have similar laws in place. Additional and stricter prohibitions could be implemented by federal and state authorities. Where such practices
          have been found to be improper incentives to use such products, government investigations and sanctions against manufacturers have resulted in substantial fines, penalties and damages. Many manufacturers have been required to enter into consent
          decrees or orders that prescribe allowable corporate conduct and/or Corporate Integrity Agreements that impose ongoing compliance requirements on a manufacturer.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Failure to satisfy requirements under the Federal Food, Drug, and Cosmetic Act can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct.
          In addition, while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the
          potential safety and efficacy of unapproved products in development. Companies in the United States, Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the competent
          regulatory authorities such as the FDA in the United States, nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of approved products or results of
          studies involving investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or enforcement action by, these authorities.
          Furthermore, if such activities are prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of the Federal Food, Drug, and Cosmetic Act and subjects
          us to civil and criminal sanctions. Furthermore, sanctions under the federal False Claims Act have been brought against companies accused of promoting off-label uses of drugs, because such promotion induces unapproved the use and subsequent
          claims for reimbursement under Medicare and other federal programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law significantly strengthened provisions of the federal
          False Claims Act, the federal Anti-Kickback Statute that applies to government healthcare programs, and other healthcare fraud provisions, leading to the possibility of greatly increased lawsuits by whistleblowers for perceived violations.
          Violations or allegations of violations of the foregoing restrictions could materially and adversely affect our business.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">59</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to CMS for the purpose of calculating national reimbursement levels, certain federal prices and
          certain federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in criminal and/or civil liability under the federal False Claims Act, the federal Anti-Kickback Statute and various other laws,
          rules and regulations.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We have established systems for collecting and reporting this data accurately to CMS and have instituted a compliance program to assure that the information collected is complete in all respects. If we report pricing
          information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization in the European Union or
          otherwise market and sell our products outside of the United States, we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures vary among countries in complexity and
          timing. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all, which would preclude us from commercializing products in those markets.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities can take
          considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate
          to other available therapies. Such trials may be time-consuming and expensive and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
          unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Also, under the U.S. Foreign Corrupt Practices Act, the United States has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the United States, generally prohibiting remuneration
          to foreign officials for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such as the HHS Office of
          Inspector General (the &#8220;OIG&#8221;) have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program described in Section 8B2.1 of the
          U.S. Sentencing Commission Guidelines Manual. Most U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the OIG&#8217;s recommendations and voluntary industry
          guidelines and train our employees. Such a program may be expensive and may not provide assurance that we will avoid compliance issues.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states and localities in which our business operates, including the State of Florida where our
          manufacturing facility is located.&#160; These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business.&#160; Although compliant with applicable federal requirements, we may
          be required to comply with additional state and local laws, rules, regulations and permits.&#160; Failure to appropriately comply with such state and local requirements could result in temporary or long-term cessation of our manufacturing operations,
          as well as fines and other sanctions.&#160; Any such penalties may have a material adverse effect on our business and results of operations.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">60</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">
          <div style="font-style: italic; font-weight: bold;">We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory<span style="color: rgb(0, 0, 255);">&#160;</span>approvals












            before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain necessary capital in
            order to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies.</div>

          <div style="font-style: italic; font-weight: bold;"> <br/>
          </div>

        </div>

        <div style="text-indent: 36pt;">Both before and after the approval of our products, our products, operations, facilities, suppliers and CROs are subject to extensive regulation by federal, state and local governmental authorities in the United
          States and other countries, with regulations differing from country to country. In the United States, the FDA regulates, among other things, the pre-clinical and nonclinical testing, clinical trials, manufacturing, safety, efficacy, potency,
          labeling, storage, record keeping, quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other things, one or more of the following actions:
          notices of violation, untitled letters, warning letters, CRLs, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or product candidate, product recall or seizure, interruption of
          manufacturing or clinical trials, operating restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the United States without FDA and other federal, state and local business
          regulatory approvals. Any failure to receive the marketing approvals necessary to commercialize our products or product candidates could harm our business.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors, including government
          budget and funding levels, ability to hire and retain key personnel and to accept the payment of user fees, as well as statutory, regulatory, and policy changes. Average review times at the FDA and other federal, state and local business
          regulatory agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject
          to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate submissions to be reviewed and/or approved by necessary
          government agencies, which would adversely affect our business. For example, over the last few years, including in December 2018 and January 2019, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA
          and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections at domestic and foreign manufacturing facilities from March 2020 until July
          2021. If a prolonged government shutdown or regulatory agency disruption reoccurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and other reporting requirements which could have a
          material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For instance,
          improper storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing process, it may be
          necessary to discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma products is an extremely complex
          process of fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217; specifications through a failure in one or more of these
          process steps. We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process was not collected or stored in a compliant manner consistent with our
          cGMP or other regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe replaced or withdrawn from the market and therefore should be destroyed. Once
          manufactured, our plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties that supply, test, ship or distribute our products or product components to properly care for
          our products, may require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have other issues or problems after storage which may require products to be destroyed or recalled. While we
          expect to write off certain amounts of raw materials and work-in-process inventory in the ordinary course of business due to the complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs
          materially in excess of our expectations and the reserves we have established for these purposes. Such write-offs or losses and other costs could cause material fluctuations in our results of operations. Product or component quality issues may
          also result in regulatory enforcement actions, liability, corrective actions and recalls, among other actions, as described elsewhere in this Quarterly Report on Form 10-Q.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">61</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures, which could
          adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability damages and claims from
          companies for whom we do contract manufacturing.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and
          manufacturing processes against transmittable diseases.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease-causing agents, the risk of transmissible disease through blood plasma
          products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West Nile virus, H1N1 virus or
          &#8220;swine flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs worldwide were infected with HIV through the
          use of contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the human population from time to time. If a new infectious
          disease has a period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be contaminated by that infectious agent. Typically, early in an outbreak of a new
          disease, tests for the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less
          sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the
          manufacturing process&#8217; capacity to inactivate or remove the infectious agent. To the extent our manufacturing processes are inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute our products would be
          impaired. If a new infectious disease were to emerge in the human population or if there were a reemergence of an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission of the disease
          that would impair our ability to procure plasma, manufacture our products or both. Such precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived products. In
          recent years, new testing and viral inactivation methods have been developed that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation methods
          will adequately screen for, and inactivate, infectious agents in the plasma used in the production of our products.</div>

        <div> <br/>
        </div>

        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">62</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma with proper specifications or
          other necessary raw materials.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must generally be licensed by the FDA and approved by the regulatory authorities of any
          country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory requirements. Therefore, even if
          we are able to construct new plasma collection centers to complement our current plasma collection facilities, an unsatisfactory inspection could prevent a new center from being licensed or risk the suspension or revocation of an existing
          license, among other enforcement actions. Additionally, although we achieved plasma supply self-sufficiency with the approval of our tenth plasma collection center in November 2023, we remain reliant on the purchase of plasma from third parties
          and the collection of plasma from our FDA-licensed plasma collection centers to manufacture our products. We can give no assurances that appropriate plasma will be available to us through our own plasma collection facilities or on commercially
          reasonable terms, or at all, to manufacture our products, or that third parties will be able to supply plasma to us in accordance with plasma purchase agreements. Further, the COVID-19 pandemic resulted in significant constraints in raw material
          supply across various different industries, including the supply of plasma. It is possible that in the future, pandemics and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and
          quality sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in
          compliance with cGMP and other applicable regulatory requirements, we may be unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if
          non-compliance in the plasma collection process is identified after the impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted.
          Consequently, we could experience significant inventory impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes
          through increased purchases of plasma from third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facilities. This strategy is dependent upon our ability to maintain a cGMP compliant environment at our
          plasma collection facilities and to expand production and attract donors to our facilities. There is no assurance that the FDA will inspect and license any of our current or future unlicensed plasma collection facilities in a timely manner
          consistent with our production plans. If we misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially
          hamper our operations and our ability to increase plasma collections. Our ability to expand production and increase our plasma collection facilities to more efficient production levels may be affected by changes in the economic environment and
          population in selected regions where ADMA BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the demographic potential of
          individual regions where ADMA BioCenters expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities held by us from time to time.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Additionally, our supply contract with Grifols for the purchase of normal source plasma (&#8220;NSP&#8221;) expired on December 31, 2022 and was not renewed. Although we have executed additional agreements with other third-party
          suppliers of NSP, we anticipate that the NSP used in IG production in 2024 and beyond will be sourced from our ADMA BioCenters plasma collection facilities. There can be no assurances that we will be able to obtain an adequate supply of NSP from
          other third-party suppliers or be able to collect NSP in the same quantities, or at all, through our ADMA BioCenters plasma collection facilities at a cost that is not higher than the price we paid to Grifols for NSP. If our costs to obtain NSP
          through collections at our ADMA BioCenters plasma collection facilities or from other third-party suppliers are higher than what we paid to Grifols under our supply contract, our liquidity and results of operations could be adversely impacted.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from governmental agencies, health
          administration authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other governmental authorities for our product
          candidates.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of insurance coverage. Significant uncertainty exists as to the
          reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare, are challenging the prices
          charged for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products. Even if one of our product candidates is
          approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide adequate coverage and reimbursement levels for one of our
          products, once approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain pharmaceutical products, such as plasma-derived products, are subject to
          price controls in several of the world&#8217;s principal markets, including many countries within the European Union. In the United States, where pricing levels for our products are substantially established by third-party payers, including Medicare,
          if payers reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue administration of the product, to administer lower doses, to substitute lower cost products or to seek additional
          price-related concessions. These actions could have a negative effect on our financial results, particularly in cases where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of
          treatment. The existence of direct and indirect price controls and pressures over our products could materially adversely affect our financial prospects and performance.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">63</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">The biosimilar pathway established as part of healthcare reform may make it easier for competitors to market biosimilar products.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the &#8220;Healthcare Reform Law&#8221;) introduced an abbreviated licensure pathway for biological products that are
          demonstrated to be biosimilar to an FDA-licensed biological product.&#160; A biological product may be demonstrated to be &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an already-approved biological product,
          known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be submitted as soon as four years after the reference
          product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed.&#160; Since the enactment of the law, the FDA has issued several guidance documents to assist
          sponsors of biosimilar products in preparing their approval applications. Moreover, in an effort to increase competition in the biologic product marketplace, Congress, the executive branch, and the FDA have taken certain legislative and
          regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further Consolidated Appropriations Act included provisions requiring that sponsors of approved biologic products provide
          samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities, and on commercially reasonable market-based terms. The FDA approved the first biosimilar product in 2015 and has
          since approved a number of biosimilars.&#160; As a result of the biosimilar pathway in the United States, we expect in the future to face greater competition from biosimilar products, including a possible increase in patent challenges.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">The implementation of the Healthcare Reform Law in the United States may adversely affect our business.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Through the March 2010 adoption of the Healthcare Reform Law in the United States, substantial changes are being made to the current system for paying for healthcare in the United States, including programs to extend
          medical benefits to millions of individuals who currently lack insurance coverage. This reform establishes significant cost-saving measures with respect to several government healthcare programs, including Medicaid and Medicare Parts B and D,
          that may cover the cost of our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a manufacturer&#8217;s products to be reimbursed by federal funding
          under Medicaid, the manufacturer must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data provided by each state to the manufacturer and to CMS and pricing data provided
          by the manufacturer to the federal government. The states share these savings with the federal government, and sometimes implement their own additional supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for
          most branded drug products was previously equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price, whichever is greater, plus the inflation penalty if applicable. Effective January 1, 2010, the Healthcare
          Reform Law generally increased the size of the Medicaid rebates paid by manufacturers for single source and innovator multiple source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions,
          plus the inflation penalty if applicable. For non-innovator multiple source (generic) products, the rebate percentage was increased from a minimum of 11.0% to a minimum of 13.0% of AMP, and the Bipartisan Budget Act of 2015 established a new
          inflation penalty for these drugs.&#160; In 2010, the Healthcare Reform Law also newly extended the Medicaid drug rebate obligation to prescription drugs covered by Medicaid managed care organizations. These increases in required rebates may adversely
          affect our future financial prospects and performance. In order for a pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer
          must extend discounts to entities eligible to participate in the 340B drug pricing program.&#160; The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.&#160; As the 340B drug
          pricing is determined based on AMP and Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase, and recent regulations have established a civil
          monetary penalty for failure to refund these overcharges.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">64</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-indent: 36pt;">Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities
          according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">The Healthcare Reform Law also created new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for persons 65
          years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products to be reimbursed under
          Medicare Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70% savings for the manufacturer&#8217;s brand name
          drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who have expended certain amounts for drugs). The Part D plan
          sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug manufacturers of the rebate amounts it must pay to each Part D plan
          sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a
          manner that overstates our rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative
          Effectiveness Research (&#8220;CER&#8221;). While the stated intent of CER is to develop information to guide providers to the most efficacious therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be
          less cost-effective than others. Should any of our products be determined to be less cost effective than alternative therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could
          materially impact our future financial prospects and results.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">There have been repeated legal challenges and attempts by Congress to repeal or change the Healthcare Reform Law and the possibility of future challenges or legislative changes contribute to the uncertainty of the
          ongoing implementation and impact of the law and also underscores the potential for additional reform going forward. We cannot assure that the law, as currently enacted or as amended in the future, will not adversely affect our business and
          financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.&#160; Certain provisions of enacted or proposed legislative changes may negatively impact
          coverage and reimbursement of, or rebates paid by manufacturers for, healthcare items and services. We will continue to evaluate the effect that the Healthcare Reform Law and any potential changes may have on our business.</div>

        <div>&#160;</div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">Corporate responsibility, specifically related to Environmental, Social and Governance (&#8220;ESG&#8221;) matters, may impose additional costs and expose us to new risks.</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;"><span style="color: #000000;">Public ESG and sustainability reporting is becoming more broadly expected by investors, stockholders and other third parties. Certain organizations that provide corporate governance and
            other corporate risk information to investors and stockholders have developed, and others may in the future develop, scores and ratings to evaluate companies and investment funds based upon ESG or &#8220;sustainability&#8221; metrics. Many investment funds
            focus on positive ESG business practices and sustainability scores when making investments and may consider a company&#8217;s ESG or sustainability scores as a reputational or other factor in making an investment decision. In addition, investors,
            particularly institutional investors, use these scores to benchmark companies against their peers and if a company is perceived as lagging, these investors may engage with such company to improve ESG disclosure or performance and may also make
            voting decisions, or take other actions, to hold these companies and their boards of directors accountable. Board diversity is an ESG topic that is, in particular, receiving heightened attention by investors, stockholders, lawmakers and listing
            exchanges. Certain states have passed laws requiring companies to meet certain gender and ethnic diversity requirements on their boards of directors. We may face reputational damage in the event our corporate responsibility initiatives or
            objectives, including with respect to board diversity, do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if we are unable to achieve an acceptable ESG or sustainability rating
            from third-party rating</span><span style="color: #FF0000;">&#160;</span><span style="color: #000000;">services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from
            consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to new risks.</span></div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">65</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-weight: bold;">Risks Relating to our Finances, Capital Requirements and Other Financial Matters</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">If we are unable to continue to generate positive cashflows and net income, we may require additional funding and may be unable to raise capital when needed, which would adversely affect our
          operations and could force us to delay, curtail or eliminate some of our commercialization efforts or one or more of our research and development programs.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Although we generated positive cash flow from operations of $68.5 million for the nine months ended September 30, 2024 and $8.8 million for the year ended December 31, 2023, our operations have consumed substantial
          amounts of cash since inception, and for the year ended December 31, 2022 we had negative cash flows from operations of $59.5 million. We expect to continue to spend substantial amounts for collecting plasma at our plasma collection centers,
          maintaining our plasma collection centers, procurement of raw material plasma and other raw materials necessary to scale up our manufacturing operations, commercial product launches, infrastructure upgrades and capacity expansion at the Boca
          Facility. In addition, our end-to-end production cycle from collecting and procuring raw material source plasma to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial
          investments in raw material plasma and other manufacturing materials. We had a net loss of $28.2 million for the year ended December 31, 2023 and although we achieved net income of $85.8 million for the nine months ended September 30, 2024, at
          present we cannot be certain that we will be able to maintain profitability on an ongoing basis. If we are unable to generate positive cash flow beyond fiscal 2024, we may need to continue to finance our operations through additional equity or
          debt financings or corporate collaboration and licensing agreements. We currently anticipate, based upon our projected revenue and expenditures, that our current cash, cash equivalents and accounts receivable, along with our projected future
          operating cash flow, will be sufficient to fund our operations, as currently conducted, through the end of fiscal 2025 and beyond. Our current outlook with respect to cash flows and profitability may change based upon how effective we are in
          continuing to execute on our commercialization efforts and operational initiatives and whether or not the assumptions underlying our projected revenues and expenses are correct. If we are required to raise additional capital and if such capital
          is not available due to widespread liquidity constraints or significant market instability that could result from widespread economic or geopolitical conditions or other factors beyond our control, we may have to delay, curtail or eliminate our
          commercialization efforts or our product development activities.</div>

        <div><br/>
        </div>

        <div style="color: #000000; font-style: italic; font-weight: bold;">We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">The Ares Credit Facility provides for total senior secured loans in an aggregate principal amount of up to $135.0 million, of which $105.0 million is currently outstanding. Borrowings under the Ares Credit Facility
          currently bear interest at a weighted-average rate of approximately 10.4% per annum, which reflects the three-month term SOFR rate; provided, however, that upon, and during the continuance of, an event of default, the interest rate will
          automatically increase by an additional 200 basis points. We are currently required to make quarterly payments of interest during the term of the Ares Credit Facility of approximately $2.8 million, with all principal and unpaid interest due at
          maturity. In addition, our monthly interest rate obligation is subject to rising interest rates. The Ares Credit Facility has a maturity date of December 20, 2027, subject to acceleration pursuant to the Ares Credit Agreement, including upon an
          event of default. All of our obligations under the Ares Credit Facility are secured by a first-priority lien and security interest in substantially all of our and our subsidiaries&#8217; tangible and intangible assets, including intellectual property,
          and all of the equity interests in our subsidiaries.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Our current and projected cash, cash equivalents and accounts receivable may not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to achieve sufficient positive
          cash flow to repay our outstanding debt obligations as they mature, we will need to obtain additional financing in the amounts necessary to repay our outstanding debt obligations when due. If we are unable to repay our outstanding debt
          obligations when they mature, our creditors would be able to accelerate all of the amounts due and, in the case of the Ares Credit Facility, seek to enforce their security interests, which could lead to our creditors taking immediate possession
          of and selling substantially all of our assets with no return provided to our stockholders.</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">66</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations or require us to relinquish
          proprietary rights.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among other
          restrictions, limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In addition, if we raise
          additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that are not favorable to us.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating accounts on a
          daily basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit cash fails or is subject to
          other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that access to our invested cash and cash
          equivalents will not be impacted by adverse conditions in the financial and credit markets.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could
          result in investors losing confidence in the accuracy and completeness of our financial statements, harm our operating results and negatively affect the market price of our common stock.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 and related rules (the &#8220;Sarbanes-Oxley Act&#8221;), we are required to maintain internal control over financial reporting and our management is required to report
          on the effectiveness of our internal control over financial reporting, including any material weaknesses in such internal controls. The rules governing the standards that must be met for management to assess our internal control over financial
          reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been required to upgrade, and will need to implement
          further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Because we became a large accelerated filer effective December 31, 2023, the Sarbanes-Oxley Act requires our <span style="color: rgb(0, 0, 0);">independent registered public accounting firm to attest to the
            effectiveness of our internal control over financial reporting. Our transition to large accelerated filer status and becoming subject to additional requirements of the Sarbanes-Oxley Act will be time-consuming, and there is a risk of
            noncompliance. Further, the costs associated with the compliance with and implementation of procedures under these and future laws and related rules could have a material impact on our results of operations.</span></div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">Consequently, we have incurred increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act and will continue to do so. Our Audit Committee has retained the services of BDO, a Sarbanes-Oxley
          advisor, to assist with our internal control over financial reporting and information technology related to the Sarbanes-Oxley Act. Moreover, i<span style="color: rgb(0, 0, 0);">f we have a material weakness in our internal control over financial
            reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with the
            requirements of Section 404 of the Sarbanes-Oxley Act in a timely </span>manner<span style="color: rgb(0, 0, 0);">, if we are unable to assert that our internal controls over financial reporting is effective or if our independent registered
            public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of
            our common stock could be negatively affected. In addition, we could become subject to investigations by any stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial
            and management resources, which could have an adverse impact on our business.</span></div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">67</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="font-style: italic; font-weight: bold;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We have incurred substantial losses during our history. As of December 31, 2023, we had federal and state NOLs of $315.6 million and $216.4 million, respectively. Federal and state NOLs of approximately $35.6 million
          and $95.1 million, respectively, will begin to expire at various dates beginning in 2028, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), changes in our
          ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code ("Section 382") imposes limitations on a company&#8217;s ability to
          use NOLs upon certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were able to fully utilize our NOLs. The acquisition transaction
          that we completed on June 6, 2017 resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs. On October 25, 2021, we completed a public offering of our common stock
          whereby we issued 57,500,000 shares of our common stock resulting in another change of ownership for ADMA under section 382 of the Code, resulting in an additional write-off of $3.0 million of federal NOLs, $28.1 million of state NOLs and $1.0
          million of research and development credits. Although we did not experience any ownership changes for the years ended December 31, 2023 and 2022, we may experience ownership changes in the future as a result of subsequent changes in our stock
          ownership that we cannot predict or control that could result in further limitations being placed on our ability to utilize our federal NOLs.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial
          condition or financial results.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt;">We are subject to taxes by the U.S. federal, state, and local tax authorities. We record tax expense based on our estimates of future payments, which may include the recording of, or adjustments to, liabilities for
          uncertain tax positions, and changes in the valuation allowance related to our net deferred tax assets. In addition, at any one time multiple tax years may be subject to audit by various tax authorities. The results of these audits and
          negotiations with taxing authorities may affect the ultimate settlement of these issues and impact our results of operations. We expect that during fiscal year 2024 and beyond there could be ongoing variability in our effective tax rate as events
          occur and exposures are evaluated. The volatility of our future effective tax rate could be materially impacted by a number of factors, including:</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>changes in the valuation of our deferred tax assets and liabilities;</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>expected timing and amount of the release of any valuation allowance on our deferred tax assets; or</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>changes in U.S. federal, state and local tax laws, regulations, or interpretations thereof.</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="text-indent: 36pt;">In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of factors including, but not limited to, changes in the mix and level of earnings, deductible
          expenses and availability of net operating loss carryforwards in the different states in which we operate, fluctuations in the valuation allowance on our deferred tax assets, or by changes to existing accounting rules or regulations. Further, tax
          legislation may be enacted or amended, as applicable, in the future which could materially impact our current or future tax structure and effective tax rates. We may be subject to audits of our income, sales, and other transaction taxes by U.S.
          federal, state, and local taxing authorities. Outcomes from these audits could have a material effect on our financial condition or financial results.</div>

        <div><br/>
        </div>

        <div style="font-weight: bold;">Risks Associated with our Common Stock</div>

        <div>&#160;</div>

        <div style="font-style: italic; font-weight: bold;">The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our stock price may experience substantial volatility as a result of a number of factors, including:</div>

        <div> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>sales or potential sales of substantial amounts of our common stock;</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">68</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>delay in a decision by federal, state or local business regulatory authority;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>developments concerning our licensors or third-party vendors;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>conditions in the pharmaceutical or biotechnology industries;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>governmental regulation and legislation;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>overall market volatility;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>global and economic uncertainty;</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>variations in our anticipated or actual operating results; and</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations.</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <div>Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations
          often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">As of November 1, 2024, most of our 236,390,253 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public
          market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our
          common stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of
          Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">As of September 30, 2024, BlackRock Inc., Vanguard Group and our directors and executive officers and their affiliates owned approximately 27% of the outstanding shares of our common stock. Provisions of our
          Certificate of Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our Company or changes in our management, including transactions in which our
          stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to be in their best interests. These
          provisions include:</div>

        <div> <br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">69</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>the inability of stockholders to call special meetings;</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our Company; and</div>
              </td>

  </tr>


</table>
        <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
        </div>

        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
              </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                <div>authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders.</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which
          together with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business
          combination is approved in a prescribed manner.&#160; The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter
          potential acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our
          stockholders may, from time to time, observe instances where there may be less liquidity in the public markets for our securities.</div>

        <div><br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">We have never paid cash dividends on any of our capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and
          future debt agreements may preclude us from paying dividends. For example, the Ares Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the
          foreseeable future.</div>

        <div> <br/>
        </div>

        <div style="font-style: italic; font-weight: bold;">If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be
          delisted.&#160; If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</div>

        <div> <br/>
        </div>

        <div style="text-indent: 36pt;">Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, market capitalization and
          stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity,
          but also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would
          view an investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common
          stock. Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</div>

        <div><br/>
        </div>

        <div style="text-align: justify; font-style: italic; font-weight: bold;">Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of
          holders of our common stock.</div>

        <div style="text-align: justify;"> <br/>
        </div>

        <div style="text-indent: 36pt;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board.
          Currently, our Certificate of Incorporation authorizes the issuance of up to 300,000,000 shares of common stock. As of September 30, 2024, there were 35,862,328 shares remaining available for issuance, after giving effect to 12,386,492 shares of
          our common stock that were subject to outstanding stock options, RSUs and warrants as of September 30, 2024 that may be issued by us without stockholder approval, as well as an additional 15,372,573 shares reserved for the future issuance of
          awards under our equity compensation plans.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">70</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <a id="UnregisteredSales"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Unregistered Sales of Equity Securities and Use of Proceeds.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="margin-left: 36pt;">None.</div>

        <div><br/>
        </div>

        <a id="DefaultsUponSeniorSecurit"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Defaults Upon Senior Securities.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt;">None.</div>

        <div><br/>
        </div>

        <a id="MineSafetyDisclosures."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Mine Safety Disclosures.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt;">Not applicable.</div>

        <div><br/>
        </div>

        <a id="OtherInformation."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Other Information.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt;">Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule
          10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act. During the quarter ended September 30, 2024, no such plans or other arrangements were <ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_b4ac8cf75b3c4d1486cfd90b3cb4bfdf" contextRef="c20240701to20240930" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_7cc9109802584c5dae888d86dcd3271d" contextRef="c20240701to20240930" format="ixt:fixed-false">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_e8a165cb2ac6498394472c5f6fb9b236" contextRef="c20240701to20240930" format="ixt:fixed-false"><ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_18f058bcc71d40719e42b6868cb36882" contextRef="c20240701to20240930" format="ixt:fixed-false">terminated</ix:nonNumeric></ix:nonNumeric>.</div>

        <div>&#160;</div>

        <a id="Exhibits."><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable">


  <tr>

    <td style="width: 72pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
                <div style="font-weight: bold;">Exhibits.</div>
              </td>

  </tr>


</table>
        <div>&#160;</div>

        <div style="text-indent: 36pt;">See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.</div>

        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">71</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;"><a id="SIGNATURES"><!--Anchor--></a>SIGNATURES</div>

        <div>&#160;</div>

        <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</div>

        <div><br/>
        </div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td colspan="3" style="vertical-align: top;">
                <div style="text-align: justify; font-weight: bold;">ADMA Biologics, Inc.</div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td colspan="3" style="vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Date:</div>
              </td>

    <td style="width: 45%; vertical-align: top;">November 7, 2024</td>

    <td style="width: 3%; vertical-align: top;">
                <div style="text-align: justify;">By:</div>
              </td>

    <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div style="text-align: justify;">/s/ Adam S. Grossman</div>
                </div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Name:</div>
              </td>

    <td style="width: 42%; vertical-align: top;">
                <div style="text-align: justify;">Adam S. Grossman</div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Title:</div>
              </td>

    <td style="width: 42%; vertical-align: top;">
                <div style="text-align: justify;">President and Chief Executive Officer</div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 42%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Date:<br/>
                </div>
              </td>

    <td style="width: 45%; vertical-align: top;">November 7, 2024</td>

    <td style="width: 3%; vertical-align: top;">
                <div style="text-align: justify;">By:</div>
              </td>

    <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div style="text-align: justify;">/s/ Brad Tade</div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Name:</div>
              </td>

    <td style="width: 42%; vertical-align: top;">
                <div style="text-align: justify;">Brad Tade</div>
              </td>

  </tr>

  <tr>

    <td colspan="2" style="vertical-align: top;">&#160;</td>

    <td style="width: 3%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: top;">
                <div style="text-align: justify;">Title:</div>
              </td>

    <td style="width: 42%; vertical-align: top;">
                <div style="text-align: justify;">Chief Financial Officer</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">72</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div><a href="#INDEX"><span style="font-weight: normal; font-size: 8pt; font-style: italic;">Index</span></a><br/>
            </div>

          </div>

        </div>

        <div style="text-align: center; font-weight: bold;">EXHIBIT INDEX</div>

        <div>&#160;</div>

        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 15%; vertical-align: top;">
                <div><span style="text-decoration: underline;">Exhibit Number</span></div>
              </td>

    <td style="width: 85%; vertical-align: top;">
                <div><span style="text-decoration: underline;">Description</span></div>
              </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 15%; vertical-align: top;"><br/>
              </td>

    <td rowspan="1" style="width: 85%; vertical-align: top;"><br/>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124034440/ef20033085_ex10-1.htm">10.1</a></div>
              </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Employment Agreement, dated July 24, 2024, by and between ADMA Biologics, Inc. and Brad Tade (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on July 26, 2024).</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
                <div><a href="ef20034474_ex31-1.htm">31.1*</a></div>
              </td>

    <td style="width: 85%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="ef20034474_ex31-2.htm">31.2*</a></div>
              </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
                <div><a href="ef20034474_ex32-1.htm">32.1**</a></div>
              </td>

    <td style="width: 85%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div><a href="ef20034474_ex32-2.htm">32.2**</a></div>
              </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top;">
                <div>101*</div>
              </td>

    <td style="width: 85%; vertical-align: top;">
                <div style="color: rgb(0, 0, 0);">The following materials from ADMA Biologics, Inc.&#8217;s Form 10-Q for the quarter ended September 30, 2024, formatted in Extensible Business Reporting Language (XBRL): (i) Condensed Consolidated Balance Sheets
                  as of September 30, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2024 and 2023, (iii) Condensed Consolidated Statements of
                  Changes in Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024 and 2023, and (v)
                  Notes to (Unaudited) Condensed Consolidated Financial Statements.</div>
              </td>

  </tr>

  <tr>

    <td style="width: 15%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div>104</div>
              </td>

    <td style="width: 85%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0);">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</div>
              </td>

  </tr>


</table>
        <div><br/>
        </div>

        <div>
          <hr style="height: 2px; width: 20%; color: #000000; background-color: #000000; border: none; margin-left: 0px; margin-right: auto;"/></div>

        <div>* Filed herewith.</div>

        <div><br/>
        </div>

        <div>** In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.</div>

        <div><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;"> <br/>
          </span></div>

        <div><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;"> <br/>
          </span></div>

        <div style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">73</span> </div>

        <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

    </div>

  </div>


</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ef20034474_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-align: justify;">I, Adam S. Grossman, certify that:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z4b9bd618dcd4484186233ddee799edd2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z7294e6ea8e534b5fa50228a9c99cdf78" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9937177cb77140ff94ed1894a8de0b35" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z46b3a15157cb4872be85ba64e55dd7e0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3006963840cc4a68affc528528c36d47" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd8d18c7e11224765b0cbc4c5e29c5e51" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd4aca06efa1e413a8a2e1035edaa303f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="za695b5717c3f44ebb7e613de6dfdc657" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2867f7d080da40a18afc80a7db443b93" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zd6dba12ae807465998590adb3f1341bd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9416727cc9ac4cdbb4cbc49b42a943b3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z8e8bdb21952647f6879c0acb56af07f0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: November 7, 2024</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ef20034474_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 31.2</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div>&#160;</div>
      <div style="text-align: justify;">I, Brad Tade, certify that:</div>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z3cbad7a401ee4ba88b6fed4424510e8e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>I have reviewed this Quarterly Report on Form 10-Q of ADMA Biologics, Inc.;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z36189e1112774479bb167463214ef797" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
                misleading with respect to the period covered by this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z52eeecab4fdf4a3eaeb78e1bc2ea07f9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">3.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and
                for, the periods presented in this report;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z9fd562861a7b4d52b2e99ff4fc09cabd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">4.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
                (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z2b664b1e6b7c4d0793a607387f58b1df" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 13.5pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z0da581a239c24d95ba8cd81a36128a3a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and
                the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z1ffb2b272be74091ae95da729fbb5e2d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">c)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by
                this report based on such evaluation; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z8422e9fe27104a9f9b0fb6602d515685" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">d)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report)
                that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z5a4ade565ed945838c17c8f87774275f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">5.</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors
                (or persons performing the equivalent functions):</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="zf6c95150355446b69f122cc44adccccc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">a)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                report financial information; and</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" id="z05f973d9bb744c12a8f0df7a7db15b56" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 45pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">b)</td>
            <td style="width: auto; vertical-align: top; text-align: justify;">
              <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="zc5a5e40880784d39aa2d1ca924ab951e" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: November 7, 2024</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Brad Tade</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Brad Tade</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Chief Financial Officer</div>
              <div>(Principal Financial Officer)</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ef20034474_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.1</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div><br>
      </div>
      <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the
        &#8220;Report&#8221;), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za30e2b8e0dc14afca2a38ea3e92fb7fa">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">1.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zea8a61110b70489ab0e9668f3f55e4db">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top;">2.</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3eb0d8f641fd4a0085c8961facb2b2c7">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>Date: November 7, 2024</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>By:</div>
            </td>
            <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>
                <div>/s/ Adam S. Grossman</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;"><br>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div> <br>
      </div>
      <div>
        <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ef20034474_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.9.1.5252
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; text-indent: 36pt; font-weight: bold;">Exhibit 32.2</div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
        <div style="text-align: center; font-weight: bold;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div><br>
        </div>
        <div>In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the
          &#8220;Report&#8221;), I, Brad Tade, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3805f3c8be67438394bb724bb844daac">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">1.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2ea13b72aaa2481296810752f6edf699">

            <tr>
              <td style="width: 18pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">2.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z3cd4cb42600240da8a9ed189e7bfa7fb">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>Date: November 7, 2024</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>By:</div>
              </td>
              <td style="width: 45%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>
                  <div>/s/ Brad Tade</div>
                </div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Brad Tade</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Chief Financial Officer</div>
                <div>(Principal Financial Officer)</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <br>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>adma-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<xs:schema targetNamespace="http://admabiologics.com/20240930" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:adma="http://admabiologics.com/20240930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" id="CondensedConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONDENSED CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" id="CondensedConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" id="CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>060100 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Inventories" id="Inventories">
        <link:definition>060300 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060400 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060500 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Debt" id="Debt">
        <link:definition>060700 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060800 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060900 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Segments" id="Segments">
        <link:definition>061100 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligations" id="LeaseObligations">
        <link:definition>061200 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061300 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" id="SupplementalDisclosureOfCashFlowInformation">
        <link:definition>061400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061500 - Disclosure - INSIDER TRADING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesTables" id="InventoriesTables">
        <!--Parent Role: INVENTORIES-->
        <link:definition>080300 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtTables" id="DebtTables">
        <!--Parent Role: DEBT-->
        <link:definition>080700 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsTables" id="SegmentsTables">
        <!--Parent Role: SEGMENTS-->
        <link:definition>081100 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsTables" id="LeaseObligationsTables">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" id="SupplementalDisclosureOfCashFlowInformationTables">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>081400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" id="OrganizationAndBusinessDetails">
        <!--Parent Role: ORGANIZATION AND BUSINESS-->
        <link:definition>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails" id="SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" id="SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" id="SummaryOfSignificantAccountingPoliciesGoodwillDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" id="SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" id="SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
        <link:definition>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)Default</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails" id="SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" id="SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" id="SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
        <!--Parent Role: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090214 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesDetails" id="InventoriesDetails">
        <!--Parent Role: INVENTORIES-->
        <link:definition>090300 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" id="IntangibleAssetsSummaryDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" id="IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" id="AccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES-->
        <link:definition>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/DebtDetails" id="DebtDetails">
        <!--Parent Role: DEBT-->
        <link:definition>090700 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" id="StockholdersEquityPreferredStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" id="StockholdersEquityCommonStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" id="StockholdersEquityWarrantsDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" id="StockholdersEquityEquityIncentivePlansDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsDetails" id="SegmentsDetails">
        <!--Parent Role: SEGMENTS-->
        <link:definition>091100 - Disclosure - SEGMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetails" id="LeaseObligationsDetails">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>091200 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" id="LeaseObligationsDetailsCalc2">
        <!--Parent Role: LEASE OBLIGATIONS (Details)-->
        <link:definition>091202 - Disclosure - LEASE OBLIGATIONS (Details) Calc 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails" id="IncomeTaxesIncomeTaxExpenseDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091300 - Disclosure - INCOME TAXES, Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails" id="IncomeTaxesNetOperatingLossesDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091302 - Disclosure - INCOME TAXES, Net Operating Losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" id="SupplementalDisclosureOfCashFlowInformationDetails">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>091400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="AmortizationOfLicenseRevenue" id="adma_AmortizationOfLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="TaxesPaidOnVestedRestrictedStockUnits" id="adma_TaxesPaidOnVestedRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInDepositsAndOtherAssets" id="adma_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="NetOperatingLossCarryforwardsAbstract" id="adma_NetOperatingLossCarryforwardsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" id="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TaxYear2028Through2043Member" id="adma_TaxYear2028Through2043Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OperatingAndFinancingLeaseLiability" id="adma_OperatingAndFinancingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilities" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaCollectionCentersSegmentMember" id="adma_PlasmaCollectionCentersSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ADMABioManufacturingSegmentMember" id="adma_ADMABioManufacturingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RightToIntermediatesMember" id="adma_RightToIntermediatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermLiabilityEndOfTermFeePayable" id="adma_LongTermLiabilityEndOfTermFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DepositsAndOtherNoncurrentAssets" id="adma_DepositsAndOtherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="UnvestedRestrictedStockUnitsRSUMember" id="adma_UnvestedRestrictedStockUnitsRSUMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="UseOfEstimatesAbstract" id="adma_UseOfEstimatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccrualForUSMedicaidRebatesMember" id="adma_AccrualForUSMedicaidRebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccruedTestingCurrent" id="adma_AccruedTestingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedRebatesCurrent" id="adma_AccruedRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="RelatedPartyTransactionAbstract" id="adma_RelatedPartyTransactionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfExecutiveOfficersThatExercisedOptions" id="adma_NumberOfExecutiveOfficersThatExercisedOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ArethLLCMember" id="adma_ArethLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GenesisBPSMember" id="adma_GenesisBPSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WarrantsIssuedInConnectionWithNotesPayable" id="adma_WarrantsIssuedInConnectionWithNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="TermLoanMember" id="adma_TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinCreditFacilityMember" id="adma_HayfinCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AresCreditFacilityMember" id="adma_AresCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentExitFee" id="adma_DebtInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="OriginalDiscountPayableCreditFacility" id="adma_OriginalDiscountPayableCreditFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DebtInstrumentTermOfVariableRate" id="adma_DebtInstrumentTermOfVariableRate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaymentsOfDebtPremium" id="adma_PrepaymentsOfDebtPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentApplicableMargin" id="adma_DebtInstrumentApplicableMargin" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PercentageOfCreditFacilityRepaid" id="adma_PercentageOfCreditFacilityRepaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MinimumLiquidityCovenantsCreditFacilities" id="adma_MinimumLiquidityCovenantsCreditFacilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="NumberOfBusinessDays" id="adma_NumberOfBusinessDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AresCreditAgreementMember" id="adma_AresCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeniorNotesPayableBeforeDebtDiscount" id="adma_SeniorNotesPayableBeforeDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PrepaidOnOrPriorToThirdAnniversaryMember" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidAfterTheFirstAnniversaryMember" id="adma_PrepaidAfterTheFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidOnOrPriorToSecondAnniversaryMember" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidOnOrPriorToFirstAnniversaryMember" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FourCustomersMember" id="adma_FourCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FiveCustomersMember" id="adma_FiveCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfCustomers" id="adma_NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="WorkingCapital" id="adma_WorkingCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="NumberOfFDAApprovedProduct" id="adma_NumberOfFDAApprovedProduct" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="VendorAndLicensorCommitmentsAbstract" id="adma_VendorAndLicensorCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilities" id="adma_NumberOfPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PostMarketingCommitmentsAbstract" id="adma_PostMarketingCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfRenewalTerms" id="adma_NumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaSupplyAgreementTerm" id="adma_PlasmaSupplyAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ASCENIVMember" id="adma_ASCENIVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementOneMember" id="adma_PlasmaPurchaseAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementRenewalPeriod" id="adma_PlasmaPurchaseAgreementRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TwoCustomersMember" id="adma_TwoCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BiotestLicenseAgreementMember" id="adma_BiotestLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DeferredRevenueRemainingAmortizationPeriod" id="adma_DeferredRevenueRemainingAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionsAbstract" id="adma_StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionsWeightedAverageExercisePriceAbstract" id="adma_StockOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionSharesAbstract" id="adma_StockOptionSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EmployeesMember" id="adma_EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="adma_EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockUnitsAbstract" id="adma_RestrictedStockUnitsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="Two022CompensationPlanMember" id="adma_Two022CompensationPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="HayfinWarrantsMember" id="adma_HayfinWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsAbstract" id="adma_WarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>adma-20240930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="calculation: Assets to DepositsAndOtherNoncurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesAndOtherLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SeniorLongTermNotes" xlink:title="calculation: Liabilities to SeniorLongTermNotes" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="calculation: Liabilities to LongTermLiabilityEndOfTermFeePayable" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: OperatingExpenses to AmortizationOfIntangibleAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OtherCostAndExpenseOperating" xlink:title="calculation: OperatingExpenses to OtherCostAndExpenseOperating" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: GrossProfit to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfRevenue" xlink:title="calculation: GrossProfit to CostOfRevenue" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpenseNonoperating" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="2.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireIntangibleAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to TaxesPaidOnVestedRestrictedStockUnits" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="10.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfNotesPayable" order="3.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfLicenseRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfLicenseRevenue" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDepositsAndOtherAssets" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationAndAmortization" order="12.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="9.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryWorkInProcess" xlink:title="calculation: InventoryNet to InventoryWorkInProcess" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryFinishedGoods" xlink:title="calculation: InventoryNet to InventoryFinishedGoods" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryRawMaterials" xlink:title="calculation: InventoryNet to InventoryRawMaterials" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedRebatesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedRebatesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedTestingCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedTestingCurrent" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedProfessionalFeesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to OtherAccruedLiabilitiesCurrent" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedSalariesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedSalariesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedBonusesCurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to InterestPayableCurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="calculation: SeniorLongTermNotes to DebtInstrumentUnamortizedDiscount" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="calculation: SeniorLongTermNotes to SeniorNotesPayableBeforeDebtDiscount" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityNoncurrent" order="2.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>adma-20240930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxesNetOperatingLossesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxesIncomeTaxExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20240930.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="adma-20240930.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20240930.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20240930.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20240930.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20240930.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20240930.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20240930.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20240930.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="13.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InsiderTradingArrangements" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="UseOfEstimatesAbstract" xlink:title="definition: ChangeInAccountingEstimateLineItems to UseOfEstimatesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: ChangeInAccountingEstimateLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: ChangeInAccountingEstimateLineItems to OperatingIncomeLoss" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: ChangeInAccountingEstimateLineItems to NetIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: ChangeInAccountingEstimateLineItems to EarningsPerShareBasic" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: ChangeInAccountingEstimateLineItems to EarningsPerShareDiluted" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="definition: ChangeInAccountingEstimateLineItems to AccruedLiabilitiesAndOtherLiabilities" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="ScheduleOfChangeInAccountingEstimateTable" xlink:title="definition: ChangeInAccountingEstimateLineItems to ScheduleOfChangeInAccountingEstimateTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="definition: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain_2" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain_2" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="definition: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="definition: ConcentrationRiskLineItems to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: ConcentrationRiskLineItems to NumberOfCustomers" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskPercentage1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskTable" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="definition: ConcentrationRiskTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FourCustomersMember" xlink:label="FourCustomersMember" xlink:title="FourCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FourCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FourCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to OperatingIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to EarningsPerShareBasic" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to EarningsPerShareDiluted" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to AccruedLiabilitiesAndOtherLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ChangeInAccountingEstimateByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain_2" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain_2" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="definition: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to TwoCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to OperatingIncomeLoss" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to EarningsPerShareBasic" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to EarningsPerShareDiluted" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to AccruedLiabilitiesAndOtherLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to NumberOfCustomers" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to ConcentrationRiskPercentage1" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ChangeInAccountingEstimateByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain_2" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain_2" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="definition: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to TwoCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareBasic" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDiluted" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UnvestedRestrictedStockUnitsRSUMember" xlink:label="UnvestedRestrictedStockUnitsRSUMember" xlink:title="UnvestedRestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="UnvestedRestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to UnvestedRestrictedStockUnitsRSUMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNet" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ComputerSoftwareIntangibleAssetMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to ComputerSoftwareIntangibleAssetMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LandMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NotesPayableAbstract" xlink:title="definition: DebtInstrumentLineItems to NotesPayableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfLongTermLinesOfCredit" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PercentageOfCreditFacilityRepaid" xlink:label="PercentageOfCreditFacilityRepaid" xlink:title="PercentageOfCreditFacilityRepaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PercentageOfCreditFacilityRepaid" xlink:title="definition: DebtInstrumentLineItems to PercentageOfCreditFacilityRepaid" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTermOfVariableRate" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfBusinessDays" xlink:title="definition: DebtInstrumentLineItems to NumberOfBusinessDays" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentApplicableMargin" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentApplicableMargin" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPaymentPrincipal" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFrequencyOfPeriodicPayment" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPaymentInterest" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPaymentInterest" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="definition: DebtInstrumentLineItems to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PrepaymentsOfDebtPremium" xlink:title="definition: DebtInstrumentLineItems to PrepaymentsOfDebtPremium" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="definition: DebtInstrumentLineItems to LineOfCreditFacilityCommitmentFeePercentage" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: DebtInstrumentLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFeeAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFeeAmount" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="OriginalDiscountPayableCreditFacility" xlink:title="definition: DebtInstrumentLineItems to OriginalDiscountPayableCreditFacility" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentExitFee" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentExitFee" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="MinimumLiquidityCovenantsCreditFacilities" xlink:title="definition: DebtInstrumentLineItems to MinimumLiquidityCovenantsCreditFacilities" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="definition: DebtInstrumentLineItems to SeniorNotesPayableBeforeDebtDiscount" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorLongTermNotes" xlink:title="definition: DebtInstrumentLineItems to SeniorLongTermNotes" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="29.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="AresCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to AresCreditFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="CreditFacilityAxis" xlink:title="definition: DebtInstrumentTable to CreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="TermLoanMember" xlink:title="definition: CreditFacilityDomain to TermLoanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="definition: CreditFacilityDomain to RevolvingCreditFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: DebtInstrumentTable to CounterpartyNameAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="AresCreditAgreementMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to AresCreditAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToSecondAnniversaryMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToThirdAnniversaryMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfWarrantOrRightLineItems to CommonStockSharesIssued" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="16.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="HayfinWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to HayfinWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensation" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ProceedsFromStockOptionsExercised" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionSharesAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionSharesAbstract" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsWeightedAverageExercisePriceAbstract" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="46.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="47.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="definition: PlanNameDomain to Two022CompensationPlanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to OperatingExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="OperatingCostsAndExpenses" xlink:title="definition: RelatedPartyTransactionLineItems to OperatingCostsAndExpenses" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionPurchasesFromRelatedParty" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: RelatedPartyTransactionLineItems to ProceedsFromIssuanceOfCommonStock" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfExecutiveOfficersThatExercisedOptions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: RelatedPartyTransactionLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="definition: RelatedPartyTransactionLineItems to SharesPaidForTaxWithholdingForShareBasedCompensation" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="9.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="definition: RelatedPartyDomain to RelatedPartyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="ArethLLCMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to ArethLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GenesisBPSMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to GenesisBPSMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveOfficerMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: LossContingenciesLineItems to ResearchAndDevelopmentExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionFacilities" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfRenewalTerms" xlink:title="definition: LossContingenciesLineItems to NumberOfRenewalTerms" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementRenewalPeriod" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaSupplyAgreementTerm" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="8.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: LossContingenciesTable to ProductOrServiceAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="definition: ProductsAndServicesDomain to ASCENIVMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfFDALicensedPlasmaCollectionFacilities" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfOperatingSegments" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfOperatingSegments" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: SegmentReportingInformationLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CostOfRevenue" xlink:title="definition: SegmentReportingInformationLineItems to CostOfRevenue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OperatingIncomeLoss" xlink:title="definition: SegmentReportingInformationLineItems to OperatingIncomeLoss" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: SegmentReportingInformationLineItems to NonoperatingIncomeExpense" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="definition: SegmentReportingInformationLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="definition: SegmentReportingInformationLineItems to SegmentExpenditureAdditionToLongLivedAssets" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: SegmentReportingInformationLineItems to DepreciationAndAmortization" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="Assets" xlink:title="definition: SegmentReportingInformationLineItems to Assets" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="12.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="definition: SegmentDomain to ADMABioManufacturingSegmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="definition: SegmentDomain to CorporateMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain_2" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain_2" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="definition: SegmentGeographicalDomain to US" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="definition: SegmentGeographicalDomain to NonUsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="NetOperatingLossCarryforwardsAbstract" xlink:title="definition: OperatingLossCarryforwardsLineItems to NetOperatingLossCarryforwardsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsExpirationDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardAmount" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:label="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="definition: IncomeTaxAuthorityDomain to InternalRevenueServiceIRSMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxCreditCarryforwardAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain_2" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain_2" xlink:title="definition: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="definition: TaxCreditCarryforwardNameDomain to ResearchMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="definition: OperatingLossCarryforwardsTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain_2" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain_2" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2028Through2043Member" xlink:title="definition: TaxPeriodDomain to TaxYear2028Through2043Member" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>adma-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag_lbl1">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag_lbl1">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag_lbl1">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag_lbl1">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent1" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent1">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent1" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets1">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract">Impairment of Long-lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetUnderConstructionMember" xml:lang="en-US" id="us-gaap_AssetUnderConstructionMember">Construction in Process [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember" xlink:title="label: AssetUnderConstructionMember to us-gaap_AssetUnderConstructionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic1">Basic earnings per common shares (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic2" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic2">Basic earnings per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic2" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingMember" xml:lang="en-US" id="us-gaap_BuildingMember">Building [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember" xlink:title="label: BuildingMember to us-gaap_BuildingMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue1" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InterestPaidNet" xml:lang="en-US" id="us-gaap_InterestPaidNet">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateByTypeAxis">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:title="label: ChangeInAccountingEstimateByTypeAxis to us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateTypeDomain">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:title="label: ChangeInAccountingEstimateTypeDomain to us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateLineItems" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateLineItems">Change in Accounting Estimate [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" xlink:title="label: ChangeInAccountingEstimateLineItems to us-gaap_ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xml:lang="en-US" id="us-gaap_ScheduleOfChangeInAccountingEstimateTable">Change in Accounting Estimate [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:title="label: ScheduleOfChangeInAccountingEstimateTable to us-gaap_ScheduleOfChangeInAccountingEstimateTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized1">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockValue" xml:lang="en-US" id="us-gaap_CommonStockValue">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized,236,378,607 and 226,063,032 shares issued and outstanding at September 30, 2024 and December 31, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue_lbl1" xml:lang="en-US" id="us-gaap_CommonStockValue_lbl1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl1" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">Stock-based compensation expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="label: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ComputerSoftwareIntangibleAssetMember" xml:lang="en-US" id="us-gaap_ComputerSoftwareIntangibleAssetMember">Internally Developed Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:title="label: ComputerSoftwareIntangibleAssetMember to us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl1" xml:lang="en-US" id="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl1">Computer Software, Intangible Asset [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl1" xlink:title="label: ComputerSoftwareIntangibleAssetMember to us-gaap_ComputerSoftwareIntangibleAssetMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US" id="us-gaap_ConcentrationRiskByTypeAxis">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="label: ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskLineItems" xml:lang="en-US" id="us-gaap_ConcentrationRiskLineItems">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems" xlink:title="label: ConcentrationRiskLineItems to us-gaap_ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTable" xml:lang="en-US" id="us-gaap_ConcentrationRiskTable">Concentration Risk [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable" xlink:title="label: ConcentrationRiskTable to us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US" id="us-gaap_ConcentrationRiskTypeDomain">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:title="label: ConcentrationRiskTypeDomain to us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfRevenue" xml:lang="en-US" id="us-gaap_CostOfRevenue">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CostOfRevenue1" xml:lang="en-US" id="us-gaap_CostOfRevenue1">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue1" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfRevenue_lbl2" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl2">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl2" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock">Cost of Product Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl2" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl2">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl2" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount">Outstanding principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentFeeAmount">Incurred fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount" xlink:title="label: DebtInstrumentFeeAmount to us-gaap_DebtInstrumentFeeAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US" id="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">Frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="label: DebtInstrumentFrequencyOfPeriodicPayment to us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentInterest" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPaymentInterest">Interest payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:title="label: DebtInstrumentPeriodicPaymentInterest to us-gaap_DebtInstrumentPeriodicPaymentInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPaymentPrincipal">Scheduled principal payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:title="label: DebtInstrumentPeriodicPaymentPrincipal to us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount">Less: Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable" xml:lang="en-US" id="us-gaap_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization1" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization1" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDiluted1" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted1">Diluted earnings per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted1" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted2" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted2">Diluted earnings per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted2" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateContinuingOperations">Effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:title="label: EffectiveIncomeTaxRateContinuingOperations to us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">Federal statutory tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="label: EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate to us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensation_lbl2">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl2" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">Estimated Aggregate Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit" xml:lang="en-US" id="us-gaap_GrossProfit">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit" xlink:title="label: GrossProfit to us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairmentLoss" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss">Impairment charges related to goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl1">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock_lbl1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl1" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet">Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill" xml:lang="en-US" id="us-gaap_Goodwill">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill" xlink:title="label: Goodwill to us-gaap_Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Goodwill1" xml:lang="en-US" id="us-gaap_Goodwill1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill1" xlink:title="label: Goodwill to us-gaap_Goodwill1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoods" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNet" xml:lang="en-US" id="us-gaap_InventoryNet">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet" xlink:title="label: InventoryNet to us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InventoryNet1" xml:lang="en-US" id="us-gaap_InventoryNet1">Total inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet1" xlink:title="label: InventoryNet to us-gaap_InventoryNet1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl2" xml:lang="en-US" id="us-gaap_InventoryNet_lbl2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl2" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryRawMaterials" xml:lang="en-US" id="us-gaap_InventoryRawMaterials">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWorkInProcess" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandMember" xml:lang="en-US" id="us-gaap_LandMember">Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandMember" xlink:to="us-gaap_LandMember" xlink:title="label: LandMember to us-gaap_LandMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">Aggregate principal amount revolving credit facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems">Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable" xml:lang="en-US" id="us-gaap_LossContingenciesTable">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ManufacturingFacilityMember" xml:lang="en-US" id="us-gaap_ManufacturingFacilityMember">Manufacturing and Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember" xlink:title="label: ManufacturingFacilityMember to us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash used in financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">NET INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss2" xml:lang="en-US" id="us-gaap_NetIncomeLoss2">Net income available to common stockholders (numerator)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NetIncomeLoss3" xml:lang="en-US" id="us-gaap_NetIncomeLoss3">Net income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss3" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense">Interest and other (expense) income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense1">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract">OTHER INCOME (EXPENSE):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesPayableAbstract" xml:lang="en-US" id="us-gaap_NotesPayableAbstract">Senior Notes Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract" xlink:title="label: NotesPayableAbstract to us-gaap_NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OfficeEquipmentMember" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember">Office Equipment and Computer Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">Income (loss) from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss1">INCOME FROM OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingIncomeLoss2" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss2">Income from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss2" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">ORGANIZATION AND BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1">Preferred Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding">Preferred stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding1">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare1" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare1">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare1" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">Organization and Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised">Net proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised1">Aggregate exercise proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross">Property, plant and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet1">Total property, plant and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:title="TaxAdjustmentsSettlementsAndUnusualProvisions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xml:lang="en-US" id="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">Uncertain tax positions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:title="label: TaxAdjustmentsSettlementsAndUnusualProvisions to us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US" id="us-gaap_PaymentsToAcquireIntangibleAssets">Acquisition of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="label: PaymentsToAcquireIntangibleAssets to us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1">Payments to Acquire Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xlink:title="label: PaymentsToAcquireIntangibleAssets to us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl1">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain" xml:lang="en-US" id="us-gaap_RelatedPartyDomain">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermLinesOfCredit" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermLinesOfCredit">Repayment of revolving credit facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:title="label: RepaymentsOfLongTermLinesOfCredit to us-gaap_RepaymentsOfLongTermLinesOfCredit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable">Repayment of notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl1">Repayments of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl1" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchMember" xml:lang="en-US" id="us-gaap_ResearchMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember" xlink:title="label: ResearchMember to us-gaap_ResearchMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchMember_lbl1" xml:lang="en-US" id="us-gaap_ResearchMember_lbl1">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchMember" xlink:to="us-gaap_ResearchMember_lbl1" xlink:title="label: ResearchMember to us-gaap_ResearchMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock">SEGMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">Summarized Financial Information Concerning Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeniorLongTermNotes" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes">Senior notes payable, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SeniorLongTermNotes1" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes1">Senior notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes1" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1">Beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">Vested (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Options exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl2">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl2" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding1">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding1" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Warrant to purchase shares of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract">SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAmount">Tax credit carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:title="label: TaxCreditCarryforwardAmount to us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardNameDomain">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:title="label: TaxCreditCarryforwardNameDomain to us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardAxis">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:title="label: TaxCreditCarryforwardAxis to us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaid" xml:lang="en-US" id="us-gaap_IncomeTaxesPaid">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid" xlink:title="label: IncomeTaxesPaid to us-gaap_IncomeTaxesPaid" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember" xml:lang="en-US" id="us-gaap_WarrantMember">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember" xlink:title="label: WarrantMember to us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember1" xml:lang="en-US" id="us-gaap_WarrantMember1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember1" xlink:title="label: WarrantMember to us-gaap_WarrantMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Total shares - diluted (denominator) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US" id="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="label: WeightedAverageNumberDilutedSharesOutstandingAdjustment to us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted-average number of common shares (denominator) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember">Buildings and Building Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense1">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets1" xml:lang="en-US" id="us-gaap_Assets1">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets1" xlink:title="label: Assets to us-gaap_Assets1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetAbstract" xml:lang="en-US" id="us-gaap_AccountsReceivableNetAbstract">Accounts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract" xlink:title="label: AccountsReceivableNetAbstract to us-gaap_AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US" id="us-gaap_ConcentrationRiskByBenchmarkAxis">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="label: ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US" id="us-gaap_ConcentrationRiskBenchmarkDomain">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="label: ConcentrationRiskBenchmarkDomain to us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract">Segment Reporting Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Warrants Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="label: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract" xml:lang="en-US" id="us-gaap_EquityAbstract">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_CashFlowSupplementalDisclosuresTextBlock">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:title="label: CashFlowSupplementalDisclosuresTextBlock to us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US" id="us-gaap_InternalRevenueServiceIRSMember">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:title="label: InternalRevenueServiceIRSMember to us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Warrants issued in connection with note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCostAndExpenseOperating" xml:lang="en-US" id="us-gaap_OtherCostAndExpenseOperating">Plasma center operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating" xlink:title="label: OtherCostAndExpenseOperating to us-gaap_OtherCostAndExpenseOperating" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses" xml:lang="en-US" id="us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Potentially dilutive securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Earnings/loss Per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Calculation of Diluted Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock">Earnings/Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock_lbl1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl1" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">Loss Per Common Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">Other current and non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare1">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Common stock, available for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingCostsAndExpenses" xml:lang="en-US" id="us-gaap_OperatingCostsAndExpenses">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses" xlink:title="label: OperatingCostsAndExpenses to us-gaap_OperatingCostsAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit1">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue" xml:lang="en-US" id="us-gaap_PreferredStockValue">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableMember" xml:lang="en-US" id="us-gaap_AccountsReceivableMember">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaidInKindInterest" xml:lang="en-US" id="us-gaap_PaidInKindInterest">Interest paid in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Common stock shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract">OPERATING EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Unvested RSU, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1">Warrants Outstanding [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">Stock Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Options outstanding, vested and expected to vest, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1">Options outstanding, vested and expected to vest, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Options outstanding, vested and expected to vest, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1">Options outstanding, vested and expected to vest, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract" xml:lang="en-US" id="us-gaap_LeasesAbstract">LEASE OBLIGATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent">Accrued incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Accrued distribution fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedSalariesCurrent" xml:lang="en-US" id="us-gaap_AccruedSalariesCurrent">Accrued payroll and other compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:title="label: AccruedSalariesCurrent to us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent" xml:lang="en-US" id="us-gaap_InterestPayableCurrent">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain" xml:lang="en-US" id="us-gaap_SegmentDomain">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember">Operating Segments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">Shares withheld to cover portion of tax liabilities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">ORGANIZATION AND BUSINESS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock">Components of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">INCOME TAXES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxDisclosureAbstract1" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract1">Income Taxes [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract1" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">INTANGIBLE ASSETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="label: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock to us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract">DEBT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="label: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock to us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityCommitmentFeePercentage">Revolving facility percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:title="label: LineOfCreditFacilityCommitmentFeePercentage to us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfDebtTableTextBlock">Summary of Outstanding Senior Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="label: ScheduleOfDebtTableTextBlock to us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember2" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember2">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember2" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">Intangible Asset Future Aggregate Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract">SEGMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowElementsAbstract">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" xlink:title="label: SupplementalCashFlowElementsAbstract to us-gaap_SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Number of stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract">Noncash Financing and Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_BasisOfAccountingPolicyPolicyTextBlock">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="label: BasisOfAccountingPolicyPolicyTextBlock to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">Purchased materials amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">Cost of programs during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="label: FiniteLivedIntangibleAssetsPeriodIncreaseDecrease to us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">Number of restricted stock units granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1">Warrants Outstanding, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">Forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unrecognized compensation expense, stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">Unrecognized compensation expense, non option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">Accrued Expenses and Other Current Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1">Accrued Liabilities and Other Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities1">Accrual adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities2">Total accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities3" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities3">Accrual adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities3" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US" id="us-gaap_RevolvingCreditFacilityMember">Revolving Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:title="label: RevolvingCreditFacilityMember to us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityAxis" xml:lang="en-US" id="us-gaap_CreditFacilityAxis">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis" xlink:title="label: CreditFacilityAxis to us-gaap_CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityDomain" xml:lang="en-US" id="us-gaap_CreditFacilityDomain">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain" xlink:title="label: CreditFacilityDomain to us-gaap_CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife">Estimated useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Weighted average remaining contractual life of stock options, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Weighted average remaining contractual life of stock options, expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">Equity incentive plans, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Equity incentive plans, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2">Restricted stock units vested over a period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Unrecognized compensation expense recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CorporateMember" xml:lang="en-US" id="us-gaap_CorporateMember">Corporate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember" xlink:title="label: CorporateMember to us-gaap_CorporateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateMember_lbl1" xml:lang="en-US" id="us-gaap_CorporateMember_lbl1">Corporate Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateMember" xlink:to="us-gaap_CorporateMember_lbl1" xlink:title="label: CorporateMember to us-gaap_CorporateMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1">Percentage of account receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ConcentrationRiskPercentage2" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage2">Percentage of consolidated revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage2" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">Schedule of Unvested RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="label: ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember" xml:lang="en-US" id="us-gaap_CostOfSalesMember">Cost of Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenseMember" xml:lang="en-US" id="us-gaap_OperatingExpenseMember">Plasma Center Operating Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember" xlink:title="label: OperatingExpenseMember to us-gaap_OperatingExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsExpirationDate">Net operating loss carryforwards, expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:title="label: OperatingLossCarryforwardsExpirationDate to us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xml:lang="en-US" id="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">Net Revenues According to Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="label: RevenueFromExternalCustomersByGeographicAreasTableTextBlock to us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodAxis">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:title="label: DebtInstrumentRedemptionPeriodAxis to us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodDomain">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:title="label: DebtInstrumentRedemptionPeriodDomain to us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="label: FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 to us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 to us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease">Increase applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">Percentage of prepaid principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="label: DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed to us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodAxis" xml:lang="en-US" id="us-gaap_TaxPeriodAxis">Tax Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis" xlink:title="label: TaxPeriodAxis to us-gaap_TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodDomain" xml:lang="en-US" id="us-gaap_TaxPeriodDomain">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain" xlink:title="label: TaxPeriodDomain to us-gaap_TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Warrant exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonUsMember" xml:lang="en-US" id="us-gaap_NonUsMember">International [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonUsMember" xlink:to="us-gaap_NonUsMember" xlink:title="label: NonUsMember to us-gaap_NonUsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset">Right-to-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">Payments Under Lease Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1">REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerMember" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerMember">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" xlink:title="label: RevenueFromContractWithCustomerMember to us-gaap_RevenueFromContractWithCustomerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and cash equivalents - beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">Cash and cash equivalents - end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments" xml:lang="en-US" id="us-gaap_OperatingLeasePayments">Cash payments for lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments">Payments on finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">Year ended December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">Remainder of 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear to us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">Payments Under Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseExpense" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense">Aggregate lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl1">Operating Lease, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl1" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent">Current portion of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent">Lease obligations, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent1">Balance at September 30, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock">LEASE OBLIGATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">Weighted average remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">Revenues [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1">Revenue from Contract with Customer, Product and Service Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xml:lang="en-US" id="us-gaap_SegmentExpenditureAdditionToLongLivedAssets">Capital expenditures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:title="label: SegmentExpenditureAdditionToLongLivedAssets to us-gaap_SegmentExpenditureAdditionToLongLivedAssets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyMember" xml:lang="en-US" id="us-gaap_RelatedPartyMember">Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember" xlink:title="label: RelatedPartyMember to us-gaap_RelatedPartyMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xml:lang="en-US" id="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:to="us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="label: DebtInstrumentVariableInterestRateTypeExtensibleEnumeration to us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpenseNonoperating" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseNonoperating_lbl1" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating_lbl1">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl1" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain">Title and Position [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_NameOfMajorCustomerDomain" xml:lang="en-US" id="srt_NameOfMajorCustomerDomain">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain" xlink:title="label: NameOfMajorCustomerDomain to srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_DirectorMember" xml:lang="en-US" id="srt_DirectorMember">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember" xlink:title="label: DirectorMember to srt_DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl1" xml:lang="en-US" id="srt_DirectorMember_lbl1">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl1" xlink:title="label: DirectorMember to srt_DirectorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ExecutiveOfficerMember" xml:lang="en-US" id="srt_ExecutiveOfficerMember">Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember" xlink:title="label: ExecutiveOfficerMember to srt_ExecutiveOfficerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_SegmentGeographicalDomain" xml:lang="en-US" id="srt_SegmentGeographicalDomain">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain" xlink:title="label: SegmentGeographicalDomain to srt_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementGeographicalAxis" xml:lang="en-US" id="srt_StatementGeographicalAxis">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis" xlink:title="label: StatementGeographicalAxis to srt_StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MajorCustomersAxis" xml:lang="en-US" id="srt_MajorCustomersAxis">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember" xml:lang="en-US" id="srt_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember" xlink:title="label: MinimumMember to srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis" xml:lang="en-US" id="srt_CounterpartyNameAxis">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis" xml:lang="en-US" id="srt_TitleOfIndividualAxis">Title and Position [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis" xml:lang="en-US" id="srt_ConsolidationItemsAxis">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain" xml:lang="en-US" id="srt_ConsolidationItemsDomain">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain" xml:lang="en-US" id="srt_ProductsAndServicesDomain">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis" xml:lang="en-US" id="srt_ProductOrServiceAxis">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:label xlink:type="resource" xlink:label="country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="country_US" xml:lang="en-US" id="country_US">United States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US" xlink:title="label: US to country_US" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentQuarterlyReport" xml:lang="en-US" id="dei_DocumentQuarterlyReport">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport" xlink:title="label: DocumentQuarterlyReport to dei_DocumentQuarterlyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport" xml:lang="en-US" id="dei_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus" xml:lang="en-US" id="dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany" xml:lang="en-US" id="dei_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany" xlink:title="label: EntityShellCompany to dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AmortizationOfLicenseRevenue_lbl" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl">Amount of noncash revenue related to amortization of license revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AmortizationOfLicenseRevenue_lbl1" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl1">Amortization of License Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl1" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AmortizationOfLicenseRevenue" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue">Amortization of license revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl">Amount of cash outflow related to taxes on vested Restricted Stock Units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1">Taxes Paid on Vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits">Taxes paid on vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl">Amount of increase (decrease) in deposits and operating assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xml:lang="en-US" id="adma_NetOperatingLossCarryforwardsAbstract_lbl1">Net Operating Loss Carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xlink:title="label: NetOperatingLossCarryforwardsAbstract to adma_NetOperatingLossCarryforwardsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NetOperatingLossCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NetOperatingLossCarryforwardsAbstract" xml:lang="en-US" id="adma_NetOperatingLossCarryforwardsAbstract">Net Operating Losses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="adma_NetOperatingLossCarryforwardsAbstract" xlink:title="label: NetOperatingLossCarryforwardsAbstract to adma_NetOperatingLossCarryforwardsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:label="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl" xml:lang="en-US" id="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl">Operating loss carryforwards are subject to limitation as a result of the ownership change.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:to="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl" xlink:title="label: OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges to adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl1" xml:lang="en-US" id="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl1">Operating Loss Carryforwards Subject to Limitation Ownership Changes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:to="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl1" xlink:title="label: OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges to adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xml:lang="en-US" id="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges">Operating loss carryforwards subject to limitation ownership changes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:to="adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="label: OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges to adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2028Through2043Member_lbl" xml:lang="en-US" id="adma_TaxYear2028Through2043Member_lbl">Identified as tax years 2028 through 2043.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member_lbl" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2028Through2043Member_lbl1" xml:lang="en-US" id="adma_TaxYear2028Through2043Member_lbl1">Tax Year 2028 through 2043 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member_lbl1" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2028Through2043Member" xml:lang="en-US" id="adma_TaxYear2028Through2043Member">2028 through 2043 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl">Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1">Stock Issued During Period Value Cashless Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">Cashless exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl">Number of shares issued during the period as a result of the cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1">Stock Issued During Period Shares Cashless Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">Cashless exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl">Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1">Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount">Vesting of Restricted Stock Units, net of shares withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl">Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1">Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl1" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl1">Operating and Financing Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingAndFinancingLeaseLiability" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability">Operating and financing lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl">Number of plasma collection facilities having FDA license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1">Number of FDA-Licensed Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities">Number of FDA-licensed plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl">Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl1" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl1">Plasma Collection Centers Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaCollectionCentersSegmentMember" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember">Plasma Collection Centers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl">Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl1" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl1">ADMA BioManufacturing Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ADMABioManufacturingSegmentMember" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember">ADMA BioManufacturing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RightToIntermediatesMember_lbl" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RightToIntermediatesMember_lbl1" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl1">Right to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl1" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RightToIntermediatesMember" xml:lang="en-US" id="adma_RightToIntermediatesMember">Rights to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl">Principal balance of the loans and any other obligations advanced or otherwise owed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl1">Long Term Liability, End of Term Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable">End of term fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl1">Deposits and Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DepositsAndOtherNoncurrentAssets" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UnvestedRestrictedStockUnitsRSUMember" xlink:label="UnvestedRestrictedStockUnitsRSUMember" xlink:title="UnvestedRestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="adma_UnvestedRestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_UnvestedRestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" id="adma_UnvestedRestrictedStockUnitsRSUMember_lbl">Unvested share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnvestedRestrictedStockUnitsRSUMember" xlink:to="adma_UnvestedRestrictedStockUnitsRSUMember_lbl" xlink:title="label: UnvestedRestrictedStockUnitsRSUMember to adma_UnvestedRestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_UnvestedRestrictedStockUnitsRSUMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_UnvestedRestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US" id="adma_UnvestedRestrictedStockUnitsRSUMember_lbl1">Unvested Restricted Stock Units RSU [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnvestedRestrictedStockUnitsRSUMember" xlink:to="adma_UnvestedRestrictedStockUnitsRSUMember_lbl1" xlink:title="label: UnvestedRestrictedStockUnitsRSUMember to adma_UnvestedRestrictedStockUnitsRSUMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_UnvestedRestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_UnvestedRestrictedStockUnitsRSUMember" xml:lang="en-US" id="adma_UnvestedRestrictedStockUnitsRSUMember">Unvested Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnvestedRestrictedStockUnitsRSUMember" xlink:to="adma_UnvestedRestrictedStockUnitsRSUMember" xlink:title="label: UnvestedRestrictedStockUnitsRSUMember to adma_UnvestedRestrictedStockUnitsRSUMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl">Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1">Potentially dilutive securities not included in computation of diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares">Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_UseOfEstimatesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_UseOfEstimatesAbstract_lbl1" xml:lang="en-US" id="adma_UseOfEstimatesAbstract_lbl1">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesAbstract" xlink:to="adma_UseOfEstimatesAbstract_lbl1" xlink:title="label: UseOfEstimatesAbstract to adma_UseOfEstimatesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_UseOfEstimatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_UseOfEstimatesAbstract" xml:lang="en-US" id="adma_UseOfEstimatesAbstract">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesAbstract" xlink:to="adma_UseOfEstimatesAbstract" xlink:title="label: UseOfEstimatesAbstract to adma_UseOfEstimatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccrualForUSMedicaidRebatesMember_lbl" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember_lbl">Accrual for U.S. Medicaid Rebates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember_lbl" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccrualForUSMedicaidRebatesMember_lbl1" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember_lbl1">Accrual for U.S. Medicaid Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember_lbl1" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccrualForUSMedicaidRebatesMember" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember">Accrual for U.S. Medicaid Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedTestingCurrent_lbl" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedTestingCurrent_lbl1" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl1">Accrued Testing, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl1" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedTestingCurrent" xml:lang="en-US" id="adma_AccruedTestingCurrent">Accrued testing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedRebatesCurrent_lbl" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl">Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedRebatesCurrent_lbl1" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl1">Accrued Rebates, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl1" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedRebatesCurrent" xml:lang="en-US" id="adma_AccruedRebatesCurrent">Accrued rebates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RelatedPartyTransactionAbstract_lbl1" xml:lang="en-US" id="adma_RelatedPartyTransactionAbstract_lbl1">Related Party Transaction [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAbstract" xlink:to="adma_RelatedPartyTransactionAbstract_lbl1" xlink:title="label: RelatedPartyTransactionAbstract to adma_RelatedPartyTransactionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RelatedPartyTransactionAbstract" xml:lang="en-US" id="adma_RelatedPartyTransactionAbstract">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAbstract" xlink:to="adma_RelatedPartyTransactionAbstract" xlink:title="label: RelatedPartyTransactionAbstract to adma_RelatedPartyTransactionAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl">The number of executive officers who have exercised options to purchase shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1">Number of Executive Officers that Exercised Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions">Number of executive officers that exercised options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl">Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1">Share Based Compensation Arrangement By Share Based Payment Award, Shares Purchased in Cashless Transaction for Award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward">Shares purchased in cashless transaction (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ArethLLCMember_lbl" xml:lang="en-US" id="adma_ArethLLCMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ArethLLCMember_lbl1" xml:lang="en-US" id="adma_ArethLLCMember_lbl1">Areth, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl1" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_GenesisBPSMember_lbl" xml:lang="en-US" id="adma_GenesisBPSMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_GenesisBPSMember_lbl1" xml:lang="en-US" id="adma_GenesisBPSMember_lbl1">GenesisBPS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl1" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_GenesisBPSMember" xml:lang="en-US" id="adma_GenesisBPSMember">Genesis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl">Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1">Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">Equipment acquired reflected in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl">Amount of warrants issued in connection with the issuance of notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1">Warrants Issued in Connection with Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable">Warrants Issued in connection with notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TermLoanMember_lbl" xml:lang="en-US" id="adma_TermLoanMember_lbl">A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember_lbl" xlink:title="label: TermLoanMember to adma_TermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TermLoanMember_lbl1" xml:lang="en-US" id="adma_TermLoanMember_lbl1">Term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember_lbl1" xlink:title="label: TermLoanMember to adma_TermLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TermLoanMember" xml:lang="en-US" id="adma_TermLoanMember">Term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember" xlink:title="label: TermLoanMember to adma_TermLoanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinCreditFacilityMember_lbl" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl1">Hayfin Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl1" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AresCreditFacilityMember_lbl" xml:lang="en-US" id="adma_AresCreditFacilityMember_lbl">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AresCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_AresCreditFacilityMember_lbl1">Ares Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl1" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AresCreditFacilityMember" xml:lang="en-US" id="adma_AresCreditFacilityMember">Ares Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentExitFee_lbl" xml:lang="en-US" id="adma_DebtInstrumentExitFee_lbl">Amount of expenses associated with exit fee of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee_lbl" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentExitFee_lbl1" xml:lang="en-US" id="adma_DebtInstrumentExitFee_lbl1">Debt Instrument, Exit Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee_lbl1" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentExitFee" xml:lang="en-US" id="adma_DebtInstrumentExitFee">Exit fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OriginalDiscountPayableCreditFacility_lbl" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility_lbl">Amount represent the original discount payable in related transaction in credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility_lbl" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OriginalDiscountPayableCreditFacility_lbl1" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility_lbl1">Original Discount Payable, Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility_lbl1" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OriginalDiscountPayableCreditFacility" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility">Original discount payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl">Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl1">Debt Instrument, Term of Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentTermOfVariableRate" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate">Term of variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaymentsOfDebtPremium_lbl" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium_lbl">Amount represents the payments of premium.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium_lbl" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaymentsOfDebtPremium_lbl1" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium_lbl1">Prepayments of Debt Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium_lbl1" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaymentsOfDebtPremium" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium">Prepayments of premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentApplicableMargin_lbl" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl">Percentage points added to the reference rate to compute the margin rate on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentApplicableMargin_lbl1" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl1">Debt Instrument Applicable Margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl1" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentApplicableMargin" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin">Applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PercentageOfCreditFacilityRepaid" xlink:label="PercentageOfCreditFacilityRepaid" xlink:title="PercentageOfCreditFacilityRepaid" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfCreditFacilityRepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfCreditFacilityRepaid_lbl" xml:lang="en-US" id="adma_PercentageOfCreditFacilityRepaid_lbl">The percentage of credit facility from a contractual arrangement with the lender repaid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCreditFacilityRepaid" xlink:to="adma_PercentageOfCreditFacilityRepaid_lbl" xlink:title="label: PercentageOfCreditFacilityRepaid to adma_PercentageOfCreditFacilityRepaid_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfCreditFacilityRepaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfCreditFacilityRepaid_lbl1" xml:lang="en-US" id="adma_PercentageOfCreditFacilityRepaid_lbl1">Percentage of Credit Facility Repaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCreditFacilityRepaid" xlink:to="adma_PercentageOfCreditFacilityRepaid_lbl1" xlink:title="label: PercentageOfCreditFacilityRepaid to adma_PercentageOfCreditFacilityRepaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfCreditFacilityRepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfCreditFacilityRepaid" xml:lang="en-US" id="adma_PercentageOfCreditFacilityRepaid">Percentage of credit facility repaid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfCreditFacilityRepaid" xlink:to="adma_PercentageOfCreditFacilityRepaid" xlink:title="label: PercentageOfCreditFacilityRepaid to adma_PercentageOfCreditFacilityRepaid" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl">Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1">Number of Business Days for Prior Written Notice to Prepay Outstanding Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">Number of business days for prior written notice</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities_lbl">The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1">Minimum Liquidity Covenants, Credit Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities">Minimum liquidity covenant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBusinessDays_lbl" xml:lang="en-US" id="adma_NumberOfBusinessDays_lbl">Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBusinessDays_lbl1" xml:lang="en-US" id="adma_NumberOfBusinessDays_lbl1">Number of Business Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl1" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBusinessDays" xml:lang="en-US" id="adma_NumberOfBusinessDays">Number of business days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AresCreditAgreementMember_lbl" xml:lang="en-US" id="adma_AresCreditAgreementMember_lbl">Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AresCreditAgreementMember_lbl1" xml:lang="en-US" id="adma_AresCreditAgreementMember_lbl1">Ares Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl1" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AresCreditAgreementMember" xml:lang="en-US" id="adma_AresCreditAgreementMember">Ares Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl">Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1">Senior Notes Payable Before Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount">Senior notes payable before debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl">The third anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1">Prepaid on or Prior to Third Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember">Prepaid on or Prior to Third Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl">The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1">Prepaid after the First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl">The second anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1">Prepaid on or Prior to Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember">Prepaid on or Prior to Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl">The first anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1">Prepaid on or Prior to First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FourCustomersMember" xlink:label="FourCustomersMember" xlink:title="FourCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_FourCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_FourCustomersMember_lbl" xml:lang="en-US" id="adma_FourCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FourCustomersMember" xlink:to="adma_FourCustomersMember_lbl" xlink:title="label: FourCustomersMember to adma_FourCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_FourCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_FourCustomersMember_lbl1" xml:lang="en-US" id="adma_FourCustomersMember_lbl1">Four Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FourCustomersMember" xlink:to="adma_FourCustomersMember_lbl1" xlink:title="label: FourCustomersMember to adma_FourCustomersMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_FourCustomersMember" xml:lang="en-US" id="adma_FourCustomersMember">Four Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FourCustomersMember" xlink:to="adma_FourCustomersMember" xlink:title="label: FourCustomersMember to adma_FourCustomersMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_FiveCustomersMember_lbl" xml:lang="en-US" id="adma_FiveCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_FiveCustomersMember_lbl1" xml:lang="en-US" id="adma_FiveCustomersMember_lbl1">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl1" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_FiveCustomersMember" xml:lang="en-US" id="adma_FiveCustomersMember">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl">Amount of allowance for contractual credits and doubtful accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1">Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">Accounts receivable, allowances for contractual credits and credit losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfCustomers_lbl" xml:lang="en-US" id="adma_NumberOfCustomers_lbl">Number of major customers of the organization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfCustomers_lbl1" xml:lang="en-US" id="adma_NumberOfCustomers_lbl1">Number of Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl1" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfCustomers" xml:lang="en-US" id="adma_NumberOfCustomers">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_NumberOfCustomers_lbl2" xml:lang="en-US" id="adma_NumberOfCustomers_lbl2">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl2" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl2" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WorkingCapital_lbl" xml:lang="en-US" id="adma_WorkingCapital_lbl">The amount of difference between current assets and liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WorkingCapital_lbl1" xml:lang="en-US" id="adma_WorkingCapital_lbl1">Working Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital_lbl1" xlink:title="label: WorkingCapital to adma_WorkingCapital_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WorkingCapital" xml:lang="en-US" id="adma_WorkingCapital">Working capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WorkingCapital" xlink:to="adma_WorkingCapital" xlink:title="label: WorkingCapital to adma_WorkingCapital" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDAApprovedProduct_lbl" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl">Number of products approved by FDA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDAApprovedProduct_lbl1" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl1">Number of FDA Approved Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl1" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDAApprovedProduct" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct">Number of FDA approved product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl">Number of plasma collection facilities under various stages of development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1">Number of Plasma Collection Facilities Under Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">Number of plasma collection facilities under approval and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract_lbl1">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VendorAndLicensorCommitmentsAbstract" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl">Number of wholly-owned plasma collection facilities of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl1">Number of Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilities" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities">Number of plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PostMarketingCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_PostMarketingCommitmentsAbstract_lbl1">Post-Marketing Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:title="label: PostMarketingCommitmentsAbstract to adma_PostMarketingCommitmentsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfRenewalTerms_lbl" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl">Number of renewal terms to extend purchase agreement, if agreed to by the parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfRenewalTerms_lbl1" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl1">Number of Renewal Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl1" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfRenewalTerms" xml:lang="en-US" id="adma_NumberOfRenewalTerms">Number of renewal terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl">Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl1">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaSupplyAgreementTerm" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ASCENIVMember_lbl" xml:lang="en-US" id="adma_ASCENIVMember_lbl">ASCENIV an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ASCENIVMember_lbl1" xml:lang="en-US" id="adma_ASCENIVMember_lbl1">ASCENIV [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl1" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl">Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl1">Plasma Purchase Agreement One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementOneMember" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember">2011 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl">Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1">Plasma Purchase Agreement Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod">Plasma purchase agreement renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TwoCustomersMember_lbl" xml:lang="en-US" id="adma_TwoCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TwoCustomersMember_lbl1" xml:lang="en-US" id="adma_TwoCustomersMember_lbl1">Two Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl1" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BiotestLicenseAgreementMember_lbl" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl">Name of license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BiotestLicenseAgreementMember_lbl1" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl1">Biotest License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl1" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl">Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsAbstract_lbl1">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="adma_StockOptionsAbstract_lbl1" xlink:title="label: StockOptionsAbstract to adma_StockOptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1">Stock Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: StockOptionsWeightedAverageExercisePriceAbstract to adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockOptionsWeightedAverageExercisePriceAbstract" xml:lang="en-US" id="adma_StockOptionsWeightedAverageExercisePriceAbstract">Stock Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="label: StockOptionsWeightedAverageExercisePriceAbstract to adma_StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl">The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld to Cover Aggregate Exercise Prices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices">Shares withheld to cover aggregate exercise prices (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">Forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionSharesAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionSharesAbstract_lbl1">Stock Option, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionSharesAbstract" xlink:to="adma_StockOptionSharesAbstract_lbl1" xlink:title="label: StockOptionSharesAbstract to adma_StockOptionSharesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionSharesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockOptionSharesAbstract" xml:lang="en-US" id="adma_StockOptionSharesAbstract">Stock Options, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionSharesAbstract" xlink:to="adma_StockOptionSharesAbstract" xlink:title="label: StockOptionSharesAbstract to adma_StockOptionSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl">Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EmployeesMember_lbl" xml:lang="en-US" id="adma_EmployeesMember_lbl">A group of person working with the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EmployeesMember_lbl1" xml:lang="en-US" id="adma_EmployeesMember_lbl1">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl1" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EmployeesMember" xml:lang="en-US" id="adma_EmployeesMember">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember" xlink:title="label: EmployeesMember to adma_EmployeesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl">Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">Expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl">Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl1">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquityIncentivePlanMember" xml:lang="en-US" id="adma_EquityIncentivePlanMember">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl">Number of shares under fully vested and expected to vest options that were exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RestrictedStockUnitsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RestrictedStockUnitsAbstract_lbl1" xml:lang="en-US" id="adma_RestrictedStockUnitsAbstract_lbl1">Restricted Stock Units [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsAbstract" xlink:to="adma_RestrictedStockUnitsAbstract_lbl1" xlink:title="label: RestrictedStockUnitsAbstract to adma_RestrictedStockUnitsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl">The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">Shares withheld for tax withholding obligation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl">Number of shares under fully vested and expected to vest options that were granted during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl">The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">Amount of shares withheld for tax withholding obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_Two022CompensationPlanMember_lbl" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl">Represents 2022 compensation plan of equity based compensation arrangement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_Two022CompensationPlanMember_lbl1" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl1">Two022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl1" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_Two022CompensationPlanMember" xml:lang="en-US" id="adma_Two022CompensationPlanMember">2022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl">The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Expired in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl">The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Exercised in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl">The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Expired in Period Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue">Expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl">The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Exercised in Period Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinWarrantsMember_lbl" xml:lang="en-US" id="adma_HayfinWarrantsMember_lbl">On the hayfin closing date, the Company issued the hayfin warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinWarrantsMember" xlink:to="adma_HayfinWarrantsMember_lbl" xlink:title="label: HayfinWarrantsMember to adma_HayfinWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinWarrantsMember_lbl1" xml:lang="en-US" id="adma_HayfinWarrantsMember_lbl1">Hayfin Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinWarrantsMember" xlink:to="adma_HayfinWarrantsMember_lbl1" xlink:title="label: HayfinWarrantsMember to adma_HayfinWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsAbstract_lbl1" xml:lang="en-US" id="adma_WarrantsAbstract_lbl1">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl1" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsAbstract" xml:lang="en-US" id="adma_WarrantsAbstract">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>adma-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.9.1.5252 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxesNetOperatingLossesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxesIncomeTaxExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetailsCalc2" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SegmentsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#DebtDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20240930.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/DebtTables" xlink:type="simple" xlink:href="adma-20240930.xsd#DebtTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="adma-20240930.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20240930.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="adma-20240930.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20240930.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20240930.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20240930.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20240930.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20240930.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/Debt" xlink:type="simple" xlink:href="adma-20240930.xsd#Debt" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" xlink:href="adma-20240930.xsd#AccruedExpensesAndOtherCurrentLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20240930.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20240930.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20240930.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20240930.xsd#SummaryOfSignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20240930.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20240930.xsd#CondensedConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20240930.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentQuarterlyReport" xlink:title="presentation: CoverAbstract to DocumentQuarterlyReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: CoverAbstract to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentTransitionReport" xlink:title="presentation: CoverAbstract to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: CoverAbstract to EntityCurrentReportingStatus" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: CoverAbstract to EntityInteractiveDataCurrent" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFilerCategory" xlink:title="presentation: CoverAbstract to EntityFilerCategory" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntitySmallBusiness" xlink:title="presentation: CoverAbstract to EntitySmallBusiness" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityShellCompany" xlink:title="presentation: CoverAbstract to EntityShellCompany" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: CoverAbstract to EntityCommonStockSharesOutstanding" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="presentation: AssetsAbstract to DepositsAndOtherNoncurrentAssets" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to SeniorLongTermNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermLiabilityEndOfTermFeePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: IncomeStatementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: IncomeStatementAbstract to CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: CostsAndExpensesAbstract to OtherCostAndExpenseOperating" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: CostsAndExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to CostsAndExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLicenseRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfLicenseRevenue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDepositsAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireIntangibleAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to TaxesPaidOnVestedRestrictedStockUnits" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="CashFlowSupplementalDisclosuresTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to CashFlowSupplementalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsGoodwillPolicy" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="presentation: SegmentReportingAbstract to RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDAApprovedProduct" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDAApprovedProduct" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WorkingCapital" xlink:label="WorkingCapital" xlink:title="WorkingCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="WorkingCapital" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to WorkingCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to CashAndCashEquivalentsAtCarryingValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to AccountsReceivableNetCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="InventoryNet" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to InventoryNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to LiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="presentation: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="presentation: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="presentation: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: UseOfEstimatesAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: UseOfEstimatesAbstract to OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: UseOfEstimatesAbstract to NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: UseOfEstimatesAbstract to EarningsPerShareBasic" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: UseOfEstimatesAbstract to EarningsPerShareDiluted" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: UseOfEstimatesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="UseOfEstimatesAbstract" xlink:title="presentation: ChangeInAccountingEstimateLineItems to UseOfEstimatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateLineItems" xlink:title="presentation: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfChangeInAccountingEstimateTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfChangeInAccountingEstimateTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FourCustomersMember" xlink:label="FourCustomersMember" xlink:title="FourCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="FourCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to FourCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to FiveCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: ConcentrationRiskTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="presentation: AccountsReceivableNetAbstract to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: AccountsReceivableNetAbstract to NumberOfCustomers" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: AccountsReceivableNetAbstract to ConcentrationRiskPercentage1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskLineItems" xlink:to="AccountsReceivableNetAbstract" xlink:title="presentation: ConcentrationRiskLineItems to AccountsReceivableNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskLineItems" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ConcentrationRiskTable" xlink:title="presentation: AccountingPoliciesAbstract to ConcentrationRiskTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="GoodwillImpairmentLoss" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to GoodwillImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillImpairedAccumulatedImpairmentLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AssetImpairmentChargesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AssetImpairmentChargesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="presentation: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="presentation: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ChangeInAccountingEstimateByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to TwoCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="RevenueFromContractWithCustomerMember" xlink:title="RevenueFromContractWithCustomerMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerMember" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="presentation: RevenueFromContractWithCustomerMember to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByBenchmarkAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to ConcentrationRiskByTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to DeferredRevenueRemainingAmortizationPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NetIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to EarningsPerShareBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to EarningsPerShareDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to AccruedLiabilitiesAndOtherLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to NumberOfCustomers" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to ConcentrationRiskPercentage1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_UnvestedRestrictedStockUnitsRSUMember" xlink:label="UnvestedRestrictedStockUnitsRSUMember" xlink:title="UnvestedRestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="UnvestedRestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to UnvestedRestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: EarningsPerShareAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: IncomeTaxDisclosureAbstract to UnrecognizedTaxBenefits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:label="TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:title="TaxAdjustmentsSettlementsAndUnusualProvisions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:title="presentation: IncomeTaxDisclosureAbstract to TaxAdjustmentsSettlementsAndUnusualProvisions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxDisclosureAbstract" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryRawMaterials" xlink:title="presentation: InventoryDisclosureAbstract to InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryWorkInProcess" xlink:title="presentation: InventoryDisclosureAbstract to InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoods" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryNet" xlink:title="presentation: InventoryDisclosureAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ComputerSoftwareIntangibleAssetMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:label="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRebatesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedRebatesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedTestingCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedTestingCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedSalariesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedSalariesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to OtherAccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesAndOtherLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DebtDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="AresCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to AresCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="TermLoanMember" xlink:title="presentation: CreditFacilityDomain to TermLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="presentation: CreditFacilityDomain to RevolvingCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: DebtInstrumentTable to CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="AresCreditAgreementMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to AresCreditAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: DebtInstrumentTable to CounterpartyNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToSecondAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToThirdAnniversaryMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="presentation: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="presentation: NotesPayableAbstract to SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: NotesPayableAbstract to DebtInstrumentUnamortizedDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: NotesPayableAbstract to SeniorLongTermNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NotesPayableAbstract" xlink:title="presentation: DebtInstrumentsAbstract to NotesPayableAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentCarryingAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="presentation: DebtInstrumentsAbstract to RepaymentsOfLongTermLinesOfCredit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PercentageOfCreditFacilityRepaid" xlink:label="PercentageOfCreditFacilityRepaid" xlink:title="PercentageOfCreditFacilityRepaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PercentageOfCreditFacilityRepaid" xlink:title="presentation: DebtInstrumentsAbstract to PercentageOfCreditFacilityRepaid" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:label="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentVariableInterestRateTypeExtensibleEnumeration" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTermOfVariableRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NumberOfBusinessDays" xlink:title="presentation: DebtInstrumentsAbstract to NumberOfBusinessDays" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentApplicableMargin" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentApplicableMargin" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateStatedPercentage" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodicPaymentPrincipal" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFrequencyOfPeriodicPayment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodicPaymentInterest" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodicPaymentInterest" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PrepaymentsOfDebtPremium" xlink:title="presentation: DebtInstrumentsAbstract to PrepaymentsOfDebtPremium" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="presentation: DebtInstrumentsAbstract to LineOfCreditFacilityCommitmentFeePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: DebtInstrumentsAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFeeAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFeeAmount" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="OriginalDiscountPayableCreditFacility" xlink:title="presentation: DebtInstrumentsAbstract to OriginalDiscountPayableCreditFacility" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentExitFee" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentExitFee" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateEffectivePercentage" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="MinimumLiquidityCovenantsCreditFacilities" xlink:title="presentation: DebtInstrumentsAbstract to MinimumLiquidityCovenantsCreditFacilities" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ClassOfWarrantOrRightOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="HayfinWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to HayfinWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: WarrantsAbstract to CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: EquityAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="presentation: PlanNameDomain to Two022CompensationPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to OperatingExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: StockOptionsAbstract to ProceedsFromStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionSharesAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionsWeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: RestrictedStockUnitsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="presentation: RelatedPartyDomain to RelatedPartyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="ArethLLCMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to ArethLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GenesisBPSMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to GenesisBPSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="OperatingCostsAndExpenses" xlink:title="presentation: RelatedPartyTransactionAbstract to OperatingCostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="presentation: RelatedPartyTransactionAbstract to RelatedPartyTransactionPurchasesFromRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: RelatedPartyTransactionAbstract to ProceedsFromIssuanceOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="presentation: RelatedPartyTransactionAbstract to NumberOfExecutiveOfficersThatExercisedOptions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: RelatedPartyTransactionAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RelatedPartyTransactionAbstract to SharesPaidForTaxWithholdingForShareBasedCompensation" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to RelatedPartyTransactionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="presentation: ProductsAndServicesDomain to ASCENIVMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: LossContingenciesTable to ProductOrServiceAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfRenewalTerms" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfRenewalTerms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaPurchaseAgreementRenewalPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaSupplyAgreementTerm" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: PostMarketingCommitmentsAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="presentation: SegmentDomain to ADMABioManufacturingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateMember" xlink:label="CorporateMember" xlink:title="CorporateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="CorporateMember" xlink:title="presentation: SegmentDomain to CorporateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="presentation: SegmentGeographicalDomain to US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="presentation: SegmentGeographicalDomain to NonUsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="presentation: StatementGeographicalAxis to SegmentGeographicalDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementGeographicalAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfOperatingSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to CostOfRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NonoperatingIncomeExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to SegmentExpenditureAdditionToLongLivedAssets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to DepreciationAndAmortization" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="Assets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to Assets" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseExpense" xlink:title="presentation: LeasesAbstract to OperatingLeaseExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LeasesAbstract to OperatingLeasePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingAndFinancingLeaseLiability" xlink:title="presentation: LeasesAbstract to OperatingAndFinancingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc2" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="EffectiveIncomeTaxRateContinuingOperations" xlink:title="EffectiveIncomeTaxRateContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateContinuingOperations" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateContinuingOperations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="presentation: IncomeTaxAuthorityDomain to InternalRevenueServiceIRSMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="TaxCreditCarryforwardAxis" xlink:title="TaxCreditCarryforwardAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="TaxCreditCarryforwardNameDomain" xlink:title="TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember" xlink:label="ResearchMember" xlink:title="ResearchMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardNameDomain" xlink:to="ResearchMember" xlink:title="presentation: TaxCreditCarryforwardNameDomain to ResearchMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxCreditCarryforwardAxis" xlink:to="TaxCreditCarryforwardNameDomain" xlink:title="presentation: TaxCreditCarryforwardAxis to TaxCreditCarryforwardNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxCreditCarryforwardAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxCreditCarryforwardAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2028Through2043Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2028Through2043Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="presentation: TaxPeriodAxis to TaxPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to OperatingLossCarryforwardsExpirationDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="TaxCreditCarryforwardAmount" xlink:title="TaxCreditCarryforwardAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="TaxCreditCarryforwardAmount" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to TaxCreditCarryforwardAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:label="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="NetOperatingLossCarryforwardsAbstract" xlink:title="presentation: OperatingLossCarryforwardsLineItems to NetOperatingLossCarryforwardsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="IncomeTaxesPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20240930.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to WarrantsIssuedInConnectionWithNotesPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to NoncashInvestingAndFinancingItemsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: SupplementalCashFlowElementsAbstract to SupplementalCashFlowInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076394496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,390,253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078379008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 86,707<span></span>
</td>
<td class="nump">$ 51,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">50,140<span></span>
</td>
<td class="nump">27,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">171,801<span></span>
</td>
<td class="nump">172,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">9,545<span></span>
</td>
<td class="nump">5,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">318,193<span></span>
</td>
<td class="nump">257,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">53,694<span></span>
</td>
<td class="nump">53,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">485<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">3,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-to-use assets</a></td>
<td class="nump">8,897<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DepositsAndOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="nump">5,819<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">390,618<span></span>
</td>
<td class="nump">329,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,020<span></span>
</td>
<td class="nump">15,660<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">27,535<span></span>
</td>
<td class="nump">32,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,891<span></span>
</td>
<td class="nump">49,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable, net of discount</a></td>
<td class="nump">101,326<span></span>
</td>
<td class="nump">130,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,583<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermLiabilityEndOfTermFeePayable', window );">End of term fee</a></td>
<td class="nump">1,688<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">8,865<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">375<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">158,728<span></span>
</td>
<td class="nump">193,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized,236,378,607 and 226,063,032 shares issued and outstanding at September 30, 2024 and December 31, 2023</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">652,345<span></span>
</td>
<td class="nump">641,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(420,479)<span></span>
</td>
<td class="num">(506,256)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">231,890<span></span>
</td>
<td class="nump">135,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 390,618<span></span>
</td>
<td class="nump">$ 329,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DepositsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DepositsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LongTermLiabilityEndOfTermFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal balance of the loans and any other obligations advanced or otherwise owed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LongTermLiabilityEndOfTermFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074796656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078745456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUES</a></td>
<td class="nump">$ 119,839<span></span>
</td>
<td class="nump">$ 67,275<span></span>
</td>
<td class="nump">$ 308,905<span></span>
</td>
<td class="nump">$ 184,311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">60,180<span></span>
</td>
<td class="nump">42,622<span></span>
</td>
<td class="nump">152,685<span></span>
</td>
<td class="nump">126,455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">59,659<span></span>
</td>
<td class="nump">24,653<span></span>
</td>
<td class="nump">156,220<span></span>
</td>
<td class="nump">57,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">412<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
<td class="nump">2,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">2,968<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">18,560<span></span>
</td>
<td class="nump">14,726<span></span>
</td>
<td class="nump">50,807<span></span>
</td>
<td class="nump">43,485<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">20,021<span></span>
</td>
<td class="nump">15,968<span></span>
</td>
<td class="nump">55,560<span></span>
</td>
<td class="nump">50,457<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME FROM OPERATIONS</a></td>
<td class="nump">39,638<span></span>
</td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">100,660<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">423<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3,499)<span></span>
</td>
<td class="num">(6,398)<span></span>
</td>
<td class="num">(11,051)<span></span>
</td>
<td class="num">(18,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(2,889)<span></span>
</td>
<td class="num">(6,120)<span></span>
</td>
<td class="num">(9,659)<span></span>
</td>
<td class="num">(17,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">36,749<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">91,001<span></span>
</td>
<td class="num">(10,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">840<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,224<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 35,909<span></span>
</td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="nump">$ 85,777<span></span>
</td>
<td class="num">$ (10,594)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">234,571,376<span></span>
</td>
<td class="nump">225,276,980<span></span>
</td>
<td class="nump">231,959,579<span></span>
</td>
<td class="nump">223,306,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">244,804,065<span></span>
</td>
<td class="nump">233,761,262<span></span>
</td>
<td class="nump">241,772,162<span></span>
</td>
<td class="nump">223,306,331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076969280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 629,969<span></span>
</td>
<td class="num">$ (478,017)<span></span>
</td>
<td class="nump">$ 151,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">221,816,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(640)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(640)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">443,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">2,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,789)<span></span>
</td>
<td class="num">(6,789)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">630,439<span></span>
</td>
<td class="num">(484,806)<span></span>
</td>
<td class="nump">145,655<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">629,969<span></span>
</td>
<td class="num">(478,017)<span></span>
</td>
<td class="nump">151,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">221,816,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">640,026<span></span>
</td>
<td class="num">(488,612)<span></span>
</td>
<td class="nump">151,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">225,958,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2023</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">630,439<span></span>
</td>
<td class="num">(484,806)<span></span>
</td>
<td class="nump">145,655<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">222,262,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">1,967,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(225)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">117,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with note payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">472<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">178,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,371)<span></span>
</td>
<td class="num">(6,371)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2023</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">637,917<span></span>
</td>
<td class="num">(491,177)<span></span>
</td>
<td class="nump">146,762<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">224,526,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">171,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,260,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">640,026<span></span>
</td>
<td class="num">(488,612)<span></span>
</td>
<td class="nump">151,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="nump">225,958,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">641,439<span></span>
</td>
<td class="num">(506,256)<span></span>
</td>
<td class="nump">135,206<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">4,545,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,476)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">774,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">386,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,806<span></span>
</td>
<td class="nump">17,806<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">642,133<span></span>
</td>
<td class="num">(488,450)<span></span>
</td>
<td class="nump">153,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">231,769,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">641,439<span></span>
</td>
<td class="num">(506,256)<span></span>
</td>
<td class="nump">135,206<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,777<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">652,345<span></span>
</td>
<td class="num">(420,479)<span></span>
</td>
<td class="nump">231,890<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">642,133<span></span>
</td>
<td class="num">(488,450)<span></span>
</td>
<td class="nump">153,706<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Mar. 31, 2024</a></td>
<td class="nump">231,769,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">937,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(693)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(693)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">171,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">148,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,062<span></span>
</td>
<td class="nump">32,062<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">644,634<span></span>
</td>
<td class="num">(456,388)<span></span>
</td>
<td class="nump">188,269<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2024</a></td>
<td class="nump">233,026,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">1,741,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,158)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">250,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,691<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,359,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,909<span></span>
</td>
<td class="nump">35,909<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 652,345<span></span>
</td>
<td class="num">$ (420,479)<span></span>
</td>
<td class="nump">$ 231,890<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2024</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078466304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 85,777<span></span>
</td>
<td class="num">$ (10,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,101<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">8,183<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">732<span></span>
</td>
<td class="nump">1,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(22,719)<span></span>
</td>
<td class="num">(15,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">1,105<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(4,211)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="num">(411)<span></span>
</td>
<td class="num">(1,221)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">208<span></span>
</td>
<td class="num">(1,155)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(5,384)<span></span>
</td>
<td class="nump">4,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(850)<span></span>
</td>
<td class="num">(561)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">68,456<span></span>
</td>
<td class="num">(8,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(5,469)<span></span>
</td>
<td class="num">(3,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(356)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(5,825)<span></span>
</td>
<td class="num">(3,574)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TaxesPaidOnVestedRestrictedStockUnits', window );">Taxes paid on vested Restricted Stock Units</a></td>
<td class="num">(4,327)<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="num">(30,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from the exercise of stock options</a></td>
<td class="nump">7,051<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(27,276)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">35,355<span></span>
</td>
<td class="num">(12,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">51,352<span></span>
</td>
<td class="nump">86,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">$ 86,707<span></span>
</td>
<td class="nump">$ 74,157<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash revenue related to amortization of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TaxesPaidOnVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow related to taxes on vested Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TaxesPaidOnVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078238880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text">
<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.</td>

    <td style="width: auto; vertical-align: top;">
                    <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></div>
                  </td>

  </tr>


</table>
          </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to
            manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include
            immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><span style="color: rgb(0, 0, 0); font-size: 10pt;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc. (&#8220;ADMA BioCenters&#8221;). ADMA
              BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#8220;FDA&#8221;)-licensed BIVIGAM and
              Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA&#160;</span><span style="font-size: 10pt;">BioCenters<span style="color: rgb(0, 0, 0);">&#160;is the
                Company&#8217;s source plasma collection business with ten plasma collection facilities located throughout the United States, all of
                which hold an approved license with the FDA.</span></span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;">The Company has three
            FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary
            Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii)
            BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B
            Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin
            products, the Company generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The
            Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">As of September 30, 2024, the Company had working capital of $273.3 million, including $86.7 million of cash and cash
            equivalents, $50.1 million of accounts receivable and $171.8 million of inventories, partially offset by $44.9 million of current liabilities. Based upon
            the Company&#8217;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#8217;s commercialization and expansion activities, the Company&#8217;s management currently believes that its cash, cash
            equivalents and accounts receivable, along with its projected future operating cash flow, will be sufficient to fund ADMA&#8217;s operations, as currently conducted, through the end of the fourth quarter of fiscal 2025 and beyond. However, the
            Company&#8217;s current outlook on cash flows and profitability may change based upon several factors, including the success of the Company&#8217;s commercial sales of its products, whether or not the assumptions underlying the Company&#8217;s projected revenues
            and expenses are correct and the continued acceptability of ADMA&#8217;s immune globulin products by physicians, patients and payers. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries
            including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, inflationary pressures, supply chain constraints, protection
            of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076782800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>

<div><span style="text-decoration: underline;"> </span></div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 28, 2024.&#160; The accompanying consolidated balance sheet as of December 31,
              2023 was derived from the audited financial statements as of and for the year ended December 31, 2023. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q, Article 10
              of Regulation S-X and<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <span style="font-size: 10pt;">ASC 270,&#160;</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Interim Financial Statements</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">, and </span>therefore omit or
              condense certain footnotes and other information normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the
              opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements),
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">as well as material non-recurring
                costs, gains and losses applicable to the interim period, that are</span> considered necessary to present fairly the Company&#8217;s financial position as of September 30, 2024, its results of operations and changes in stockholders&#8217; equity for
              the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span> </span> 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and
              2023.</span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span></span> 30,
              2024 and 2023, comprehensive income/loss was equal to the net income/loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not
              necessarily indicative of the results that may be expected for the full fiscal year.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable
              and estimates related to the valuation allowance for the Company&#8217;s deferred tax assets and its effective tax rate.</span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><span style="font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt; color: rgb(0, 0, 0);">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of</span> 2024, the Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to
              the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 </span><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">million
              for the nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span> 30, 2024. This change in estimate was applied on a prospective basis as of June 30,
              2024 and increased income from operations and net income <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the nine months ended September 30, 2024</span> by approximately $12.6 million and $11.9 million, respectively, and increased basic and
              diluted earnings per share by $0.05. Because there was little to no historical data to rely upon at the time BIVIGAM and
              ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid
              programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally
              considered that estimates may change over the lifetime of these products due to changes in utilization and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to
              reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in the $12.6 million
              adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior credit facility (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and credit losses in the
            amount of $0.2 million and $0.1
            million at September 30, 2024 and December 31, 2023, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation
              of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span> Based on these evaluations, the Company has
            concluded that its credit risk is minimal. At&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span>, four customers accounted for an aggregate of approximately 91% of the Company&#8217;s total accounts receivable, and at December 31, 2023, five customers accounted
            for approximately 98% of the Company&#8217;s total accounts receivable.<span style="text-decoration: underline;"></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><span style="font-style: italic;"> <br/>
              </span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><span style="font-style: italic;">Inventories</span></span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs
              for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance,
              consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative
              to the total square footage of the facility.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.</div>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at
              <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and December 31, 2023 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company did not <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and nine </span>months ended September 30, 2024 and 2023.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three and nine months ended&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and 2023, the
              Company did not identify any impairment indicators for its long-lived assets, and as a result no impairment charges were
              recorded.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three and nine months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span></span>
                and 2023 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ASCENIV, </span>BIVIGAM and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business
                segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG
                (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest
                license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; font-style: normal; color: rgb(0, 0, 0);">Product revenue is recognized when the customer is deemed
              to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the
              Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and
              related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other
              assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. <span style="letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of&#160; </span>2024, the Company engaged a third-party
                specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a
                corresponding increase to net revenues of $12.6 </span>million for the nine months ended September 30, 2024, substantially all
              of which was related to the sale of ASCENIV and BIVIGAM. This change in estimate was applied on a prospective basis as of June 30, 2024 and increased income from operations and net income by approximately $12.6 million and $11.9 million,
              respectively, and increased basic and diluted earnings per share by $0.05 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for
                the nine months ending September 30, 2024. </span>Because there was little to no historical data to rely upon at the time BIVIGAM and ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial
              rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government
              payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally considered that estimates may change over the lifetime of these products due to changes in utilization
              and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in
              the $12.6 million adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer
              and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the nine months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and 2023,</span> two customers represented an aggregate of approximately 71% of the Company&#8217;s consolidated revenues.<br/>
            </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products,
              intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
              When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Earnings/Loss Per Common Share</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic earnings/loss per common share is computed by dividing net earnings/loss attributable to common stockholders by the weighted-average number of shares of common stock
                  outstanding during the period.&#160; Diluted earnings/loss per common share is calculated by dividing net earnings/loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted-average
                  number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, as well
                  as restricted stock units (&#8220;RSUs&#8221;), using the treasury stock method. Potentially dilutive common stock is excluded from the diluted <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">earnings/</span>loss per common share computation to the extent that it would be anti-dilutive. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the three and nine months ended September 30, 2024 </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">and the three months ended September 30, 2023,</span></span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> basic and diluted earnings per share is calculated as follows:</span></span></span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
              <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <br/>
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2023<br/>
                      </div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Nine Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net income available to common stockholders ($000's) (numerator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">35,909</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,565</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">85,777</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.37</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">10,232,689</div>
                    </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">8,484,282</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">9,812,583</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total shares - diluted (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">244,804,065</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">233,761,262</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">241,772,162</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted earnings per common share</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.35</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

              <div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </div>

            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">For the three and nine months ended
                September 30, 2024 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and the three months ended September 30, 2023, </span>there were no
                shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. For the&#160; nine months ended September 30, 2023 no potentially dilutive securities were included in the computation of diluted loss per share in the accompanying condensed consolidated financial statements as the Company reported a net loss for this
                period. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the nine months ended </span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">September 30, 2023</span></span></span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock Options</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">5,841,241</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4,877,482</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">12,502,906</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">23,221,629</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options and RSUs, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
              is generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. RSUs granted to employees generally have a four-year vesting period. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested equity awards is fully
              reversed at the time of forfeiture.</div>

<div>
             <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination
                  by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits are recognized for an uncertain tax position when, in management&#8217;s
                  judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.&#160; For a tax position that meets the more-likely-than-not recognition threshold, the tax benefit is measured as the largest
                  amount that is judged to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority.&#160; The liability associated with unrecognized tax benefits is adjusted periodically due to changing
                  circumstances and when new information becomes available.&#160; Such adjustments are recognized entirely in the period in which they are identified.</span> Derecognition of a tax benefit previously recognized could result in the Company
                recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not
                incurred any material liability for uncertain tax positions as of September 30, 2024 and December 31, 2023, and during the three and nine months ended September 30, 2024 and 2023 the Company recognized</span><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> no
                adjustments for uncertain tax positions.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
              </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic
                  280): Improvements to Reportable Segment Disclosures.&#160;</span>The amendments in this ASU are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments; however,
                the update does not change the definition of an operating segment or the method for determining reportable segments. This update becomes effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after
                December 15, 2024. The Company does not expect this ASU to have a material impact on the Company&#8217;s consolidated financial statements, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">except that its adoption will likely lead to disclosures of additional significant segment expenses.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076805024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INVENTORIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"><br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; width: 1%; text-align: center; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">55,246</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,999</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,482</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">49,621</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">63,073</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">70,286</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">171,801</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">172,906</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.<br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#8217;s
            immunoglobulin products. </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers that is expected to be sold to third-party customers.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076795280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at September 30, 2024 and December 31, 2023 consist of the following:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,856</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 28%;" valign="bottom">Internally developed software<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">559</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">74</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">485</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">210</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">9</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">201</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">853</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">54</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,566</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,081</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">485</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,217</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,718</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">499</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the nine months ended September 30, 2024, the Company continued to develop its data intelligence and analytics programs at a
              cost of approximately $0.4 million, and such costs are amortized over a period of <span style="-sec-ix-hidden:Fact_aabd598a3cab423c96bb46e0610cf636">three</span> to five years upon the projects&#8217; completion and
              placement into service.</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Amortization expense related to the
              Company&#8217;s intangible assets was $28,000 and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.4<span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively</span>. Estimated future aggregate amortization expense is
              expected to be as follows (in thousands</span>):</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2025<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">140</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2026<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">140</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">2027<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">130</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">2028</span> <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448168475904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,240</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,062</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,777</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,776</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,881</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,273</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,051</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,811</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,416</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,218</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">86,145</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">80,572</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(32,451</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(26,737</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,694</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,835</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from <span style="-sec-ix-hidden:Fact_e1bb617d16104c86ba85a63d93bd3935">three</span> to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal;">The
              Company recorded depreciation expense on property and equipment for the three months ended September 30, 2024 and 2023 of $1.9
              million <span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;">and for the
                nine months ended September 30, 2024 and 2023 of $</span>5.7<span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;"> million.</span></span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448079390016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at September 30, 2024 and December 31, 2023 are as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,733</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">16,608</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,780</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,954</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,670</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,961</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3,448</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">546</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">579</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">282</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,010</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,203</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,315</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,365</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,535</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">32,919</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076383824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">DEBT</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: bold;">7.</span></td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">DEBT</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Term loan<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,500</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,500</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Revolving credit facility</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">42,500</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">72,500</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,674</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,406</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">101,326</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">130,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company
              and all of its subsidiaries entered into a credit agreement (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement
              provides for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term
              loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity
              date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, the Company used the proceeds from the Ares Loans,
              along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP (&#8220;Hayfin&#8221;)
              including the outstanding principal in the amount of $158.6 million. On August 14, 2024, the Company repaid $30.0 million against the revolving credit facility and the outstanding balance on the revolving credit facility as of September 30, 2024 was $42.5 million.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the term loan bear
                  interest at the adjusted Term <span style="-sec-ix-hidden:Fact_f94c3272e4024032bf1c8ec0500c05eb"><span style="-sec-ix-hidden:Fact_837d17e5cc4148dab6c5f12dca0a9d3b"><span style="-sec-ix-hidden:Fact_2d5d7cee97d843e6bdafc3e0cea93ecc">SOFR</span></span></span> for a three-month tenor in effect on the day that is <span style="-sec-ix-hidden:Fact_8458c263b75e47d7a0c66a15b98f6079">two</span> business days
                  prior to the first day of the applicable calendar quarter plus 6.50% (the &#8220;Initial SOFR Term Loan Applicable Margin&#8221;).
                  Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a three-month tenor in effect on the day
                  that is <span style="-sec-ix-hidden:Fact_8c7034ac2c65418ea392b4cb6da4a682">two</span> business days prior to the first day of the applicable calendar quarter&#160;plus 3.75% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). As of September 30, 2024 and December 31, 2023, the interest rate on the term loan
                  was approximately 11.36% and 11.88%,
                  respectively, and the interest rate on the revolving facility was approximately 9.08% and 9.13%, respectively. </span></div>

<div style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
              </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;">On the Ares Maturity Date, the Company is required to pay Ares the entire
                outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no
                scheduled principal payments on the Ares Credit Facilities, and the Company is required to make quarterly interest payments to
                Ares of approximately $2.8 million. The Company may prepay the outstanding principal under the revolving facility, together with
                any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_b6b7fa74500a4b88b6db8be11e46fee6">three</span> business days&#8217;
                prior written notice with no prepayment premium. However, in the event the Company prepays an amount under the revolving credit
                facility that is greater than 50% of the original $72.5 million outstanding balance (of which $30.0 million, or 41.4%, has been repaid to date), the Company will still be required to pay interest on 50% of this balance, or $36.3 million, through the term
                of the Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_572da660a7754ce69aefce28a22367a6">three</span> business days&#8217; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date
                of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if
                prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid
                after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0%
                of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.</div>

<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"><br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;">In connection with the closing of the Ares Credit Facility, the Company
                  incurred fees and expenses related to the transaction of $2.8 million, including a $1.7 million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is also required to pay Ares an exit
                  fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this amount has been accrued as
                  a separate liability in the Company&#8217;s consolidated balance sheets as of September 30, 2024 and December 31, 2023. As a result, the Company recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans as of September 30, 2024 and December 31, 2023 was 11.73% and 11.39%,
                  respectively. This debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. </div>

<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; color: rgb(0, 0, 0);"><br/>
                  </span></div>

<div style="display:none;"><br/></div>
<div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; color: rgb(0, 0, 0);">All of the Company&#8217;s obligations under the Ares
                  Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s
                  subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include
                  certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also
                  restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage
                  in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit
                  Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of
                  September 30, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</div>

<div><br/></div>

<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;">Events of Default on the Ares Loans include, among others, non-payment
                    of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of
                    control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of 2%
                    per annum.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080057232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">STOCKHOLDERS&#8217; EQUITY</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par
            value per share. There were no shares of preferred stock outstanding at September 30, 2024 and December 31, 2023.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024 and December 31, 2023, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001
            par value per share, and 236,378,607 and 226,063,032 shares of common stock were outstanding as of September 30, 2024 and December 31, 2023, respectively. After giving effect to the 27,759,065 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#8217;s equity incentive plans, as of September 30, 2024
            there were 35,862,328 shares of common stock available for issuance.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"><span style="text-decoration: underline;">Warrants</span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On January 10, 2024, a former noteholder of the Company exercised a warrant to
            purchase 4 million shares of the Company&#8217;s common stock on a cashless basis and the Company issued 1,977,514 shares of common stock to this noteholder. On March 8, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 3,388,681 shares of the Company&#8217;s common stock on a cashless basis and the Company issued 2,482,205 shares of common stock to Hayfin and its affiliates. On March 14, 2024 an entity associated with another former noteholder of the Company exercised a warrant to
            purchase 169,651 shares of the Company&#8217;s common stock on a cashless basis and the Company issued 85,784 shares of common stock to this entity. On May 9, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 1,787,424 shares of the Company&#8217;s common stock on a cashless basis and the Company issued 937,507 shares of common stock to Hayfin and its affiliates. On August 15, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 1,962,946 shares of the Company&#8217;s common stock on a cashless basis and the Company issued an aggregate of 1,741,882 shares of common stock to Hayfin and its affiliates.</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On February 24, 2024 a warrant to purchase 34,800 shares of the Company&#8217;s common stock held by a former noteholder of the Company expired in accordance with its terms. At September 30, 2024
            and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of 1,159,404 and 12,502,906 shares of common stock, respectively, with weighted-average exercise prices of $2.26 and $2.32 per share, respectively, with expiration dates
            ranging between October 2024 and May 2030. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The







            following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
          </div>

<div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-transform: none;">
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;">Weighted</div>
                    <div style="text-align: center; font-weight: bold;">Average</div>
                    <div style="text-align: center; font-weight: bold;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at December 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>12,502,906</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>2.32</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div>(34,800</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div>7.50</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div>(11,308,702</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>2.31</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at September 30, 2024</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>1,159,404</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>2.26</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
             </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Equity Incentive Plans</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The fair value of stock options granted under t<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">he </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company&#8217;s equity incentive plans</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> w</span>as determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was
              developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the
              expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair
              value estimate. </span><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:</span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="4" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">66%</span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">68%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0</span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">4.16-4.34%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">4.20-4.24%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;During the nine months ended September 30, 2024 and 2023, the Company granted options to purchase an aggregate of 1,511,624 and 1,727,510 shares of
            common stock, respectively, to its directors and employees. The weighted<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">-</span>average remaining contractual life of stock options outstanding and expected to vest at
            September 30, 2024 is 7.5 years. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The weighted<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">-</span>average remaining contractual life of stock options exercisable at
              September 30, 2024 is 6.2 years. During the nine months ended September 30, 2024, options to purchase an aggregate of 1,925,498 shares of common stock were exercised, which included certain exercise transactions for which an aggregate of </span>31,219<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> shares were withheld to cover the exercise price and income tax liabilities, and the Company received aggregate net exercise proceeds of $</span>7.1<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million.</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,906,184</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.38</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(15,723</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(221,067</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.34</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,511,624</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">(1,925,498</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.85</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,255,520</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.87</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,509,884</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.10</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024, the Company had $7.4 million of unrecognized compensation expense related to options granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.9 years.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the nine months ended September 30, 2024 and 2023, the Company granted RSUs representing an aggregate of
              3,227,188 and 3,345,760
              shares, respectively, to certain employees of the Company and to members of its Board of Directors. These RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. During the
              nine months ended September 30, 2024, an aggregate of 1,701,229 shares of common stock vested in connection with grants of RSUs.
              With respect to these vested RSUs, 504,825 shares valued at approximately $4.3 million were withheld by the Company to cover employees&#8217; tax liabilities. These shares were no longer outstanding as of September 30, 2024. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested
              RSU activity and related information is as follows:</span></div>

<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,657,297</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,227,188</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,701,229</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.59</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(211,688</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.57</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,971,568</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">As of September 30, 2024, the Company had $27.4 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.2 years.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
            and nine months ended September 30, 2024 and 2023 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; text-align: center; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">24</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">65</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">44</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">131</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">104</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,714</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,451</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,960</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,839</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">397</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">191</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,027</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">472</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,179</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,695</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,183</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,442</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075644544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span>  </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">RELATED PARTY TRANSACTIONS</span></div>
            </td>

  </tr>


</table>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> </div>

<div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company leases office space and
            equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $10,000 through December 31, 2026. Rent expense for the nine months ended September 30, 2024 and 2023 amounted to $90,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#8217;s Board of Directors, and Adam S. Grossman, the Company&#8217;s President and Chief Executive
            Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the nine months
            ended September 30, 2024 and 2023.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the nine months ended September
            30, 2024 and 2023, the Company purchased certain specialized medical equipment and services primarily related to the Company&#8217;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#8220;Genesis&#8221;),
            aggregating to $0.2 million and $0.4
            million, respectively. Genesis is owned by Dr. Grossman and Mr. Grossman.</div>

<div><br/></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the three and nine months ended
            September 30, 2024, two of the Company&#8217;s executive officers exercised options to purchase an aggregate of 650,395 shares of common stock, for which the Company received net proceeds of $3.0 million (see Note 8). During the three and nine months ended September 30, 2023, two
            of the Company&#8217;s executive officers exercised options to purchase 2,909,721 shares of the Company&#8217;s common stock on a cashless
            basis, and 688,657 shares of common stock were issued to these executive officers, net of 257,867 shares of common stock to cover a portion of their tax liabilities. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078075872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">COMMITMENTS AND CONTINGENCIES</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">General Legal Matters</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">From time to time, the Company is or may
              become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s
              liquidity, results of operations or financial condition. </span></div>

<div><br/>
            </div>

<div style="font-style: italic;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Vendor Commitments</span><br/>
            </span> </div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of
              source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase
              Agreement the Company was permitted to also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection
              facilities.&#160; During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the
              Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the
              Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods
              if agreed to by the parties. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its
              successor-in-interest, effective January 1, 2019.</span></div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 6, 2017, the Company entered into
            a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that
            contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July
            19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is
            unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for
            the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;">
            </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Post-Marketing Commitments</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"><br/>
            </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with the FDA&#8217;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the nine months ended September 30,
              2024 and 2023, the Company incurred expenses related to this study in the approximate amount of $1.0 million and $0.6 million, respectively. The Company expects to incur expenses of approximately $0.5 million to complete this study, which is required to be completed by June of 2026. </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
            </div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Employment Contracts</span></div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The Company previously entered into employment agreements with Mr. Grossman and with Brian Lenz, the Company&#8217;s former Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters. Effective as of April 1,
              2024, Mr. Lenz transitioned to a non-employee consulting role and entered into a consulting agreement with the Company. On April 1, 2024, the Company entered into an employment agreement with Kaitlin Kestenberg, who was promoted to Chief
              Operating Officer and Senior Vice President, Compliance. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On July 24, 2024, the Company entered into an employment agreement with Brad Tade, who was appointed Chief Financial Officer and Treasurer of the Company.</span><span style="font-family: 'Times New Roman';">
              <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> </div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span>
           <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-family: 'Times New Roman';"> <span style="font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </span> <span style="font-style: italic;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-style: italic;"><span style="text-decoration: underline;">Other Commitments</span></span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-style: italic;"><span style="text-decoration: underline;"> <br/>
              </span></span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and executive officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these
            arrangements is unknown as of September 30, 2024. The Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078073504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">11.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SEGMENTS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">The
              Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#8217;s ADMA BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development
              operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of&#160; ten plasma collection facilities
              located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and
              administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive Officer. For the Company&#8217;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">Summarized









              financial information concerning reportable segments is shown in the following tables:</span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><br/>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                    <div> Plasma Collection </div>
                  </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">113,088</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,715</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">119,839</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,731</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,449</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">60,180</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,347</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,755</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,954</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">39,638</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(54</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,835</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,889</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss)
                        before taxes</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,293</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,755</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,789</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36,749</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,138</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">802</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,940</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">266,456</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">33,191</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">90,971</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">390,618</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">66,567</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">672</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,275</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41,734</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">888</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">42,622</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">15,017</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,649</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,685</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other (expense) income, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(141</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,979</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,120</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss) before
                      taxes</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14,876</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,628</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,565</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,282</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">811</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">Total assets </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">262,554</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">35,622</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">50,821</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">348,997</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div> <br/>
          </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2024</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">299,385</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,413</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">107</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">142,193<br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,492</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">152,685</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">123,756</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,047</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(19,049</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">100,660</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(95</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,560</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,659</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">123,661</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,051</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(28,609</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">91,001</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,364</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">105</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,469</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,686</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,101</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">175,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,299</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">107</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">184,311</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">118,708</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,747</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">126,455</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">26,577</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(16,149</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,399</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,823</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,993</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">26,407</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(33,972</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(10,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,768</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,806</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">3,574</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,857</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,366</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,223</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
           <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; white-space: nowrap;" valign="bottom"><span style="display: inline; float: none; letter-spacing: normal; white-space: nowrap; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-weight: 400; text-indent: 0px; text-transform: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">114,748</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">64,618</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">295,465</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">173,920</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,091</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,657</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,440</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,391</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">119,839</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,275</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,905</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">184,311</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448170702304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">LEASE OBLIGATIONS</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           <br/></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The Company determines if an arrangement is an operating lease at inception. Leases with
              an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities
              representing the obligation to make lease payments arising from the lease.<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span>Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
              lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s incremental borrowing rate. The Company&#8217;s lease expense is recognized on a straight-line basis over the lease
              term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;">Aggregate lease expense for the Company&#8217;s leases <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the three months ended September 30, 2024 and 2023 was approximately</span> $0.6 million, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">and </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">aggregate lease expense for<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></span>the









                      nine months ended&#160; <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span>
                      30, 2024 and 2023 was <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">approximately </span>$</span>1.8<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million</span></span></span>. Cash paid for the
                Company&#8217;s leases for <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the three months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span> 30, 2024 and 2023 was also
                  approximately</span> $0.6 million, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">and









                      cash paid for the nine months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span>
                      30, 2024 and 2023 was approximately $</span>1.8 <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">million.</span></span></span> </span><br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The Company has aggregate lease liabilities of $10.1 million and $10.8 million as
                of </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">September</span></span></span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> 30, 2024 and December 31, 2023,</span> respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers and a
                warehouse lease for raw material storage related to the Company&#8217;s immunoglobulin manufacturing operations.&#160; The Company&#8217;s operating leases have a weighted-average remaining term of 7.0 years. </span><span style="font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; color: #000000;">Scheduled payments under the Company&#8217;s lease obligations are as follows </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt; font-variant: normal;">(in thousands):</span></span></span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 54pt; margin-left: 9pt;">Remainder of <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">603</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 0pt; margin-left: 9pt;">Year ended December 31, <span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 117pt;">&#160;<span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,157</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2027</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,041</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2028</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,088</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2029</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,109</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Thereafter</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,042</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Total payments</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">15,461</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Less: imputed interest</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,403</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Current portion</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,193</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Balance at September 30, 2024</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,865</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448168543792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold;">13.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;"><span style="text-decoration: underline;">INCOME TAXES</span></div>
            </td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">The Company uses the estimated annual effective tax rate approach as prescribed by ASC
        740-270, Interim Reporting, to calculate its interim tax provision. For the three and nine months ended September 30, 2024, the Company recorded income tax expense of $0.8 million and $5.2 million, respectively, resulting in an effective tax rate
        of 5.7% <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the nine months ended September 30, 2024.</span> The tax expense for the three and nine months ended September 30, 2024 represents federal and state tax liabilities
        that are not fully sheltered by net operating loss carryforwards (&#8220;NOLs&#8221;) due to limitations from prior ownership changes and other limitations&#160;<span style="color: rgb(0, 0, 0);">on NOLs incurred after 2017</span>. The Company&#8217;s effective tax rate
        differs from the federal statutory tax rate of 21% due primarily to the reversal of the valuation allowance on certain federal and state
        NOLs estimated to be realized in the current year and, to a lesser extent, the tax benefit associated with the employee exercise of stock options and vesting of RSUs.</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"><span style="text-decoration: underline;">Valuation Allowance</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">A valuation allowance, if needed, reduces deferred tax assets to the amount expected
        to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings
        history, expected future earnings, carryback and carryforward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and
        negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income, exclusive of reversing taxable temporary differences, to
        outweigh objective negative evidence of recent financial reporting losses. Based on these criteria and the relative weighting of both the positive and negative evidence available, the Company continues to maintain a full valuation allowance against
        its net deferred tax assets.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"><span style="text-decoration: underline;">Net Operating Losses</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">As of December 31, 2023, the Company had federal and state (post-apportioned basis)
        NOLs of $315.6 million and $216.4
        million, respectively. Approximately $35.6 million and $95.1 million of the foregoing federal and state NOLs, respectively, will expire at various dates from <span style="-sec-ix-hidden:Fact_04c4d72102c94fdb82f3fcd93478e6fd">2028</span> through <span style="-sec-ix-hidden:Fact_ee510cd27e5248eea4877ba277c443e7">2043</span>, if not limited by triggering events prior to such time.</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">Under the provisions of the Internal Revenue Code, changes in ownership of the Company,
        in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an entity&#8217;s
        ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully utilize its
        NOLs. As of December 31, 2023, approximately $267.8 million of the foregoing federal NOLs are subject to limitation under Section 382 due
        to prior ownership changes.</div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><br/>
      </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;">The Company may experience ownership changes in the future as a result of subsequent
        shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control that could result in further limitations being placed on the Company&#8217;s ability to utilize its federal NOLs.<span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"><br/>
        </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076365376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</span></div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental cash flow information for the nine months ended September 30, 2024 and 2023 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span></td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,896</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt">Cash paid for income taxes<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$ <br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">8,895</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$ <br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">452</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">270</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt">Warrants issued in connection with notes payable<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,595</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075127008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INSIDER TRADING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074755792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Basis of Presentation</span></div>

<div><span style="text-decoration: underline;"> </span></div>

<div><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#8220;U.S. GAAP&#8221;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;)
              of the Financial Accounting Standards Board (the &#8220;FASB&#8221;).</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2023 included in the Company&#8217;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;) on February 28, 2024.&#160; The accompanying consolidated balance sheet as of December 31,
              2023 was derived from the audited financial statements as of and for the year ended December 31, 2023. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q, Article 10
              of Regulation S-X and<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"> <span style="font-size: 10pt;">ASC 270,&#160;</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;">Interim Financial Statements</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">, and </span>therefore omit or
              condense certain footnotes and other information normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the
              opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements),
              <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">as well as material non-recurring
                costs, gains and losses applicable to the interim period, that are</span> considered necessary to present fairly the Company&#8217;s financial position as of September 30, 2024, its results of operations and changes in stockholders&#8217; equity for
              the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span> </span> 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and
              2023.</span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">During the three and nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span></span> 30,
              2024 and 2023, comprehensive income/loss was equal to the net income/loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not
              necessarily indicative of the results that may be expected for the full fiscal year.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Use of Estimates</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and warrants issued in connection with the issuance of notes payable
              and estimates related to the valuation allowance for the Company&#8217;s deferred tax assets and its effective tax rate.</span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"><span style="font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt; color: rgb(0, 0, 0);">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of</span> 2024, the Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to
              the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 </span><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);">million
              for the nine months ended <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September</span></span> 30, 2024. This change in estimate was applied on a prospective basis as of June 30,
              2024 and increased income from operations and net income <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for the nine months ended September 30, 2024</span> by approximately $12.6 million and $11.9 million, respectively, and increased basic and
              diluted earnings per share by $0.05. Because there was little to no historical data to rely upon at the time BIVIGAM and
              ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid
              programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally
              considered that estimates may change over the lifetime of these products due to changes in utilization and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to
              reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in the $12.6 million
              adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<div>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Fair Value of Financial Instruments</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The carrying amounts of certain of the Company&#8217;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#8217;s senior credit facility (see Note 7) approximates fair value due to the variable interest rate on this debt.</span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="font-style: italic;"><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts Receivable<br/>
              </span></span> <span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span></span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accounts receivable is reported at realizable value, net of allowances for contractual credits and credit losses in the
            amount of $0.2 million and $0.1
            million at September 30, 2024 and December 31, 2023, respectively, which are recognized in the period the related revenue is recorded. <span style="color: rgb(33, 37, 41);">The Company extends credit to its customers based upon an evaluation
              of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.</span> Based on these evaluations, the Company has
            concluded that its credit risk is minimal. At&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span>, four customers accounted for an aggregate of approximately 91% of the Company&#8217;s total accounts receivable, and at December 31, 2023, five customers accounted
            for approximately 98% of the Company&#8217;s total accounts receivable.<span style="text-decoration: underline;"></span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><span style="font-style: italic;">Inventories</span></span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> </div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs
              for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance,
              consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s FDA-approved products relative
              to the total square footage of the facility.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: -9pt; margin-left: 9pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#8217;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Goodwill</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at
              <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and December 31, 2023 was $3.5 million. All of the Company&#8217;s goodwill is attributable to its ADMA BioManufacturing business segment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#8217;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company did not <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">record any impairment charges related to goodwill for the three <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and nine </span>months ended September 30, 2024 and 2023.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Impairment of Long-Lived Assets</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three and nine months ended&#160;<span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span> and 2023, the
              Company did not identify any impairment indicators for its long-lived assets, and as a result no impairment charges were
              recorded.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Revenue Recognition</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Revenues for the three and nine months ended <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span></span>
                and 2023 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin products, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ASCENIV, </span>BIVIGAM and Nabi-HB, </span><span style="font-size: 10pt;">(ii) product revenues from the sale of human plasma collected through the Company&#8217;s Plasma Collection Centers business
                segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG
                (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest
                license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; font-style: normal; color: rgb(0, 0, 0);">Product revenue is recognized when the customer is deemed
              to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the
              Company expects to receive in exchange. Revenue from the sale of the Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, wholesaler distribution and
              related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other
              assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. <span style="letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">second quarter of&#160; </span>2024, the Company engaged a third-party
                specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a
                corresponding increase to net revenues of $12.6 </span>million for the nine months ended September 30, 2024, substantially all
              of which was related to the sale of ASCENIV and BIVIGAM. This change in estimate was applied on a prospective basis as of June 30, 2024 and increased income from operations and net income by approximately $12.6 million and $11.9 million,
              respectively, and increased basic and diluted earnings per share by $0.05 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">for
                the nine months ending September 30, 2024. </span>Because there was little to no historical data to rely upon at the time BIVIGAM and ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial
              rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government
              payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally considered that estimates may change over the lifetime of these products due to changes in utilization
              and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in
              the $12.6 million adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.</div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer
              and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the nine months ended </span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">September 30, 2024</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and 2023,</span> two customers represented an aggregate of approximately 71% of the Company&#8217;s consolidated revenues.<br/>
            </div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text">
<div>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Cost of Product Revenue</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue includes costs associated with the manufacture of the Company&#8217;s FDA-approved products,
              intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
              When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings/Loss Per Common Share</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
             </div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Earnings/Loss Per Common Share</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Basic earnings/loss per common share is computed by dividing net earnings/loss attributable to common stockholders by the weighted-average number of shares of common stock
                  outstanding during the period.&#160; Diluted earnings/loss per common share is calculated by dividing net earnings/loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted-average
                  number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, as well
                  as restricted stock units (&#8220;RSUs&#8221;), using the treasury stock method. Potentially dilutive common stock is excluded from the diluted <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">earnings/</span>loss per common share computation to the extent that it would be anti-dilutive. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the three and nine months ended September 30, 2024 </span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">and the three months ended September 30, 2023,</span></span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> basic and diluted earnings per share is calculated as follows:</span></span></span></div>

<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
              <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <br/>
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2023<br/>
                      </div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Nine Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net income available to common stockholders ($000's) (numerator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">35,909</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,565</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">85,777</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.37</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">10,232,689</div>
                    </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">8,484,282</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">9,812,583</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total shares - diluted (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">244,804,065</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">233,761,262</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">241,772,162</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted earnings per common share</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.35</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

              <div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </div>

            </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;">For the three and nine months ended
                September 30, 2024 <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and the three months ended September 30, 2023, </span>there were no
                shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. For the&#160; nine months ended September 30, 2023 no potentially dilutive securities were included in the computation of diluted loss per share in the accompanying condensed consolidated financial statements as the Company reported a net loss for this
                period. </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the nine months ended </span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">September 30, 2023</span></span></span></span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock Options</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">5,841,241</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4,877,482</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">12,502,906</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">23,221,629</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Stock-Based Compensation</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options and RSUs, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
              is generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#8217;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. RSUs granted to employees generally have a four-year vesting period. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested equity awards is fully
              reversed at the time of forfeiture.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Income Taxes</span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="color: rgb(0, 0, 0); font-style: italic;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net operating loss carryforwards.</span></div>

<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination
                  by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits are recognized for an uncertain tax position when, in management&#8217;s
                  judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.&#160; For a tax position that meets the more-likely-than-not recognition threshold, the tax benefit is measured as the largest
                  amount that is judged to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority.&#160; The liability associated with unrecognized tax benefits is adjusted periodically due to changing
                  circumstances and when new information becomes available.&#160; Such adjustments are recognized entirely in the period in which they are identified.</span> Derecognition of a tax benefit previously recognized could result in the Company
                recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not
                incurred any material liability for uncertain tax positions as of September 30, 2024 and December 31, 2023, and during the three and nine months ended September 30, 2024 and 2023 the Company recognized</span><span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"> no
                adjustments for uncertain tax positions.</span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"><span style="text-decoration: underline;">Recent Accounting Pronouncements</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
              </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic
                  280): Improvements to Reportable Segment Disclosures.&#160;</span>The amendments in this ASU are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments; however,
                the update does not change the definition of an operating segment or the method for determining reportable segments. This update becomes effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after
                December 15, 2024. The Company does not expect this ASU to have a material impact on the Company&#8217;s consolidated financial statements, <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">except that its adoption will likely lead to disclosures of additional significant segment expenses.</span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075049568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the three and nine months ended September 30, 2024 </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">and the three months ended September 30, 2023,</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> basic and diluted earnings per share is calculated as follows:</span>
<div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div>
              <table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <br/>
                      <div style="text-align: center;">Three Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2023<br/>
                      </div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: center;">Nine Months Ended <br/>
                      </div>
                      <div style="text-align: center;">September 30, 2024</div>
                    </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Net income available to common stockholders ($000's) (numerator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">35,909</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2,565</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">85,777</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Basic earnings per common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">0.37</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Weighted-average number of common shares</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">234,571,376</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">225,276,980</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">231,959,579</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                      <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">10,232,689</div>
                    </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">8,484,282</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">9,812,583</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Total shares - diluted (denominator)</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">244,804,065</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">233,761,262</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">241,772,162</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                      <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Diluted earnings per common share</div>
                    </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.15</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.01</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">0.35</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

              <div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </div>

            </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Calculation of Diluted Loss Per Common Share</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">For the nine months ended </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">September 30, 2023</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span>
<div><span style="font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
              </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Stock Options</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">5,841,241</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Restricted Stock Units</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">4,877,482</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Warrants</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">12,502,906</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">23,221,629</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074269840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following table provides the components of inventories:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30,</span></div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;">December 31,</div>
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023 </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"><br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; width: 1%; text-align: center; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Raw materials</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">55,246</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,999</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Work-in-process</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,482</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">49,621</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Finished goods</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">63,073</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">70,286</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total inventories</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">171,801</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">172,906</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075564864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Intangible assets at September 30, 2024 and December 31, 2023 consist of the following:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">&#160;Accumulated</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> Amortization</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,100</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,856</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">244</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 28%;" valign="bottom">Internally developed software<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">559</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">74</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">485</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">210</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">9</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">201</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Rights to intermediates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">907</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">853</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">54</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,566</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,081</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">485</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,217</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,718</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">499</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Intangible Asset Future Aggregate Amortization Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the nine months ended September 30, 2024, the Company continued to develop its data intelligence and analytics programs at a
              cost of approximately $0.4 million, and such costs are amortized over a period of <span style="-sec-ix-hidden:Fact_aabd598a3cab423c96bb46e0610cf636">three</span> to five years upon the projects&#8217; completion and
              placement into service.</span><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> Amortization expense related to the
              Company&#8217;s intangible assets was $28,000 and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.4<span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively</span>. Estimated future aggregate amortization expense is
              expected to be as follows (in thousands</span>):</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2025<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">140</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">2026<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">140</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom">2027<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">130</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">2028</span> <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078202544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);">Property and equipment and related accumulated depreciation are summarized as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Manufacturing and laboratory equipment</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,240</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Office equipment and computer software</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,441</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,062</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Furniture and fixtures</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,777</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,776</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Construction in process</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,881</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,273</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Leasehold improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,051</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,811</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Land</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,339</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Buildings and building improvements</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">21,416</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">20,218</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">86,145</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">80,572</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less: Accumulated depreciation</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(32,451</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(26,737</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total property and equipment, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,694</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">53,835</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080057728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued expenses and other current liabilities at September 30, 2024 and December 31, 2023 are as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued rebates</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,733</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">16,608</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued distribution fees</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,780</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,954</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued incentives</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,670</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,961</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Accrued interest</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">3,448</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">546</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued testing</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">579</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">282</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Accrued payroll and other compensation<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,010</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,203</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Other</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,315</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,365</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total accrued expenses and other current liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27,535</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">32,919</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075628496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Outstanding Senior Notes Payable</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
           </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of outstanding senior notes payable is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="margin-left: 13.5pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">December 31, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom">(In thousands)</td>

    <td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Term loan<br/>
                  </div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,500</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">62,500</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">Revolving credit facility</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">42,500</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">72,500</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Less:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Debt discount</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,674</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,406</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0);">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Senior notes payable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">101,326</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">130,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078083344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Outstanding</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;">The







            following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:</span>
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <br/>
          </div>

<div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-transform: none;">
            <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;">Shares</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-weight: bold;">Weighted</div>
                    <div style="text-align: center; font-weight: bold;">Average</div>
                    <div style="text-align: center; font-weight: bold;">Exercise Price</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at December 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>12,502,906</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>2.32</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Expired</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div>(34,800</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                    <div>7.50</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Granted</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Exercised</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div>(11,308,702</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div>2.31</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Warrants outstanding at September 30, 2024</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>1,159,404</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div>2.26</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
             </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions</a></td>
<td class="text"><span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:</span></span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="4" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expected term</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.5 - 6.3 years</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Volatility</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">66%</span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">68%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Dividend yield</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0<br/>
                    </span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">0.0</span></div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Risk-free interest rate</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">4.16-4.34%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;">4.20-4.24%</div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
                  </div>
                </td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">A summary of the Company&#8217;s option activity under the Company&#8217;s equity incentive plans and related information is as
            follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Exercise Price</div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,906,184</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.38</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(15,723</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1.94</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Expired</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(221,067</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.34</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,511,624</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Exercised</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">(1,925,498</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">3.85</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options outstanding, vested and expected to vest at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,255,520</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.87</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Options exercisable</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,509,884</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.10</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested RSU Activity</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested
              RSU activity and related information is as follows:</span>
<div><br/></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Shares</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div> Weighted
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Average Grant</div>
                    <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Date Fair Value</div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">December 31, 2023</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,657,297</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.81</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Granted</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,227,188</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Vested</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,701,229</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2.59</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Forfeited</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(211,688</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div>)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3.57</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Balance at <span style="text-indent: 0pt;">September 30, 2024</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,971,568</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5.25</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the three
            and nine months ended September 30, 2024 and 2023 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; text-align: center; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Research and development</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">24</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">12</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">65</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">27</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Plasma center operating expenses</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">44</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">131</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">104</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Selling, general and administrative</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,714</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,451</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,960</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,839</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">397</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">191</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,027</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">472</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total stock-based compensation expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,179</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,695</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,183</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,442</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080205664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Concerning Reportable Segments</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">Summarized









              financial information concerning reportable segments is shown in the following tables:</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span><br/>
            <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                    <div> Plasma Collection </div>
                  </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">113,088</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,715</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">119,839</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">52,731</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,449</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">60,180</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,347</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,755</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,954</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">39,638</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(54</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,835</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(2,889</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss)
                        before taxes</span></div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">48,293</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,755</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,789</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36,749</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"><br/>
                  </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense </div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,138</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">802</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,940</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                    <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total assets</div>
                  </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">266,456</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">33,191</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">90,971</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">390,618</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <br/>
            </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">66,567</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">672</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">36</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,275</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">41,734</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">888</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">42,622</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">15,017</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,649</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,685</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other (expense) income, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(141</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,979</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(6,120</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Income (loss) before
                      taxes</span></div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">14,876</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(683</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(11,628</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,565</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">1,282</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">811</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,093</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">Total assets </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">262,554</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">35,622</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">50,821</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">348,997</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div> <br/>
          </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2024</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">299,385</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">9,413</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">107</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">142,193<br/>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,492</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">152,685</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">123,756</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,047</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(19,049</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">100,660</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(95</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,560</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(9,659</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">123,661</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(4,051</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(28,609</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">91,001</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,364</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">105</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,469</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,686</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,415</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,101</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30, 2023</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"> ADMA</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom">
                  <div> Plasma Collection </div>
                </td>

    <td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">BioManufacturing</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Centers</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Corporate</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Consolidated</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Revenues</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">175,905</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,299</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">107</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">184,311</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cost of product revenue</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">118,708</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,747</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">126,455</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) from operations</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">26,577</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(16,149</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,399</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"></div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Interest and other expense, net</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(170</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,823</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(17,993</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Income (loss) before taxes</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">26,407</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(3,029</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(33,972</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(10,594</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">Capital expenditures<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,768</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">1,806</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">3,574</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Depreciation and amortization expense</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">3,857</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,366</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">-</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">6,223</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Net Revenues According to Geographic Area</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Three Months Ended September 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Nine Months Ended September 30,</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; white-space: nowrap;" valign="bottom"><span style="display: inline; float: none; letter-spacing: normal; white-space: nowrap; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-weight: 400; text-indent: 0px; text-transform: none;">(in thousands)</span></td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span> </div>
                </td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">United States</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">114,748</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">64,618</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">295,465</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">173,920</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">International</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">5,091</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,657</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,440</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">10,391</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Total revenues</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">119,839</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">67,275</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">308,905</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">184,311</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075552704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments Under Lease Obligations</a></td>
<td class="text"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; color: #000000;">Scheduled payments under the Company&#8217;s lease obligations are as follows </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt; font-variant: normal;">(in thousands):</span>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 54pt; margin-left: 9pt;">Remainder of <span style="text-indent: 0pt;">2024</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">603</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 0pt; margin-left: 9pt;">Year ended December 31, <span style="text-indent: 0pt;">2025</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,421</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 117pt;">&#160;<span style="text-indent: 0pt;">2026</span></div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,157</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2027</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,041</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2028</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,088</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;2029</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2,109</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Thereafter</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">4,042</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">Total payments</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">15,461</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Less: imputed interest</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(5,403</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Current portion</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">(1,193</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">)</div>
                </td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;">&#160;Balance at September 30, 2024</div>
                </td>

    <td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">8,865</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080219568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span>
          <span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental cash flow information for the nine months ended September 30, 2024 and 2023 is as follows:</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;">


  <tr>

    <td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2024<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                  <div style="text-align: center; font-weight: bold;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">2023<br/>
                    </span></div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span></td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">SUPPLEMENTAL CASH FLOW INFORMATION:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Cash paid for interest</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">7,417</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">13,896</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt">Cash paid for income taxes<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$ <br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">8,895</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$ <br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Noncash Financing and Investing Activities:</div>
                </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                  <div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">Equipment acquired reflected in accounts payable and accrued liabilities</div>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">452</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">$</div>
                </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                  <div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">270</div>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                  <div style="margin-left: 9pt">Warrants issued in connection with notes payable<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$<br/>
                </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">5,595</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076394496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Product </div>
<div>Facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of plasma collection facilities under approval and development | Facility</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDAApprovedProduct', window );">Number of FDA approved product | Product</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 273,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">86,707<span></span>
</td>
<td class="nump">$ 51,352<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">50,140<span></span>
</td>
<td class="nump">27,421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">171,801<span></span>
</td>
<td class="nump">172,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="nump">$ 44,891<span></span>
</td>
<td class="nump">$ 49,806<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAApprovedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAApprovedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of difference between current assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448081269616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_UseOfEstimatesAbstract', window );"><strong>Use of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 119,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,905<span></span>
</td>
<td class="nump">$ 184,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">39,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,660<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 35,909<span></span>
</td>
<td class="nump">$ 32,062<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="num">$ (6,371)<span></span>
</td>
<td class="num">$ (6,789)<span></span>
</td>
<td class="nump">$ 85,777<span></span>
</td>
<td class="num">$ (10,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember', window );">Accrual for U.S. Medicaid Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_UseOfEstimatesAbstract', window );"><strong>Use of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_UseOfEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_UseOfEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075457088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts', window );">Accounts receivable, allowances for contractual credits and credit losses | $</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Four Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of account receivables</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer Concentration Risk [Member] | Five Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of account receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for contractual credits and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076964496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080221040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long-lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448078522592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Customer </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 119,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 308,905<span></span>
</td>
<td class="nump">$ 184,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">39,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,660<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 35,909<span></span>
</td>
<td class="nump">$ 32,062<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="num">$ (6,371)<span></span>
</td>
<td class="num">$ (6,789)<span></span>
</td>
<td class="nump">$ 85,777<span></span>
</td>
<td class="num">$ (10,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=adma_TwoCustomersMember', window );">Two Customers [Member] | Revenues [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers | Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of consolidated revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember', window );">Accrual for U.S. Medicaid Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember', window );">Biotest License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredRevenueRemainingAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredRevenueRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredRevenueRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448077131760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings/loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income available to common stockholders (numerator)</a></td>
<td class="nump">$ 35,909<span></span>
</td>
<td class="nump">$ 32,062<span></span>
</td>
<td class="nump">$ 17,806<span></span>
</td>
<td class="nump">$ 2,565<span></span>
</td>
<td class="num">$ (6,371)<span></span>
</td>
<td class="num">$ (6,789)<span></span>
</td>
<td class="nump">$ 85,777<span></span>
</td>
<td class="num">$ (10,594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares (denominator) (in shares)</a></td>
<td class="nump">234,571,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,276,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">231,959,579<span></span>
</td>
<td class="nump">223,306,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common shares (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.37<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total shares - diluted (denominator) (in shares)</a></td>
<td class="nump">244,804,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,761,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,772,162<span></span>
</td>
<td class="nump">223,306,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,221,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares', window );">Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings/loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</a></td>
<td class="nump">10,232,689<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,484,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,812,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,841,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,877,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074993104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Equity incentive plans, term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448077604864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448080202528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 55,246<span></span>
</td>
<td class="nump">$ 52,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">53,482<span></span>
</td>
<td class="nump">49,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">63,073<span></span>
</td>
<td class="nump">70,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 171,801<span></span>
</td>
<td class="nump">$ 172,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075749152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">5,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Cost of programs during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember', window );">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Internally Developed Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember', window );">Rights to Intermediates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448081328096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated Aggregate Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024</a></td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2025</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2026</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2027</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2028</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448073501200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 86,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 86,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(32,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,451)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,737)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">53,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 21,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,776<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">21,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,811<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448170639600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">$ 4,733<span></span>
</td>
<td class="nump">$ 16,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">9,780<span></span>
</td>
<td class="nump">5,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentives</a></td>
<td class="nump">3,670<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">3,448<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedTestingCurrent', window );">Accrued testing</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other compensation</a></td>
<td class="nump">2,010<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,315<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 27,535<span></span>
</td>
<td class="nump">$ 32,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074435904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2024</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,674)<span></span>
</td>
<td class="num">$ (4,406)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,326<span></span>
</td>
<td class="nump">$ 130,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration', window );">Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
<td class="text">us-gaap:SecuredOvernightFinancingRateSofrMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_MinimumLiquidityCovenantsCreditFacilities', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid after the First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Revolving facility percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.36%<span></span>
</td>
<td class="nump">11.88%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfCreditFacilityRepaid', window );">Percentage of credit facility repaid</a></td>
<td class="nump">41.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.08%<span></span>
</td>
<td class="nump">9.13%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember', window );">Ares Credit Facility [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Scheduled principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal', window );">Number of business days for prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PrepaymentsOfDebtPremium', window );">Prepayments of premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Incurred fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OriginalDiscountPayableCreditFacility', window );">Original discount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.73%<span></span>
</td>
<td class="nump">11.39%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 158,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentApplicableMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the margin rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentApplicableMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit fee of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentTermOfVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentTermOfVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumLiquidityCovenantsCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumLiquidityCovenantsCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OriginalDiscountPayableCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represent the original discount payable in related transaction in credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OriginalDiscountPayableCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfCreditFacilityRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of credit facility from a contractual arrangement with the lender repaid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfCreditFacilityRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PrepaymentsOfDebtPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the payments of premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PrepaymentsOfDebtPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates type of variable interest rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_AresCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=adma_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448074375040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448076795808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">27,759,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="nump">35,862,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448081319472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Aug. 15, 2024</div></th>
<th class="th"><div>May 09, 2024</div></th>
<th class="th"><div>Mar. 14, 2024</div></th>
<th class="th"><div>Mar. 08, 2024</div></th>
<th class="th"><div>Feb. 24, 2024</div></th>
<th class="th"><div>Jan. 10, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,800<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">236,378,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,977,514<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">27,759,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember', window );">Hayfin Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,962,946<span></span>
</td>
<td class="nump">1,787,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,388,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741,882<span></span>
</td>
<td class="nump">937,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,482,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">12,502,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(34,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised (in shares)</a></td>
<td class="num">(11,308,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">1,159,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Warrants Outstanding, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue', window );">Expired (in dollars per share)</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">1,159,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448077056032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate exercise proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,051<span></span>
</td>
<td class="nump">$ 1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,179<span></span>
</td>
<td class="nump">$ 1,695<span></span>
</td>
<td class="nump">8,183<span></span>
</td>
<td class="nump">4,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Plasma Center Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,714<span></span>
</td>
<td class="nump">1,451<span></span>
</td>
<td class="nump">6,960<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">$ 191<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,624<span></span>
</td>
<td class="nump">1,727,510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionSharesAbstract', window );"><strong>Stock Options, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,906,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,723)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(221,067)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,511,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,925,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, ending balance (in shares)</a></td>
<td class="nump">5,255,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,255,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">2,509,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,509,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, ending balance (in dollars per share)</a></td>
<td class="nump">$ 3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.34%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices', window );">Shares withheld to cover aggregate exercise prices (in shares)</a></td>
<td class="nump">31,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate exercise proceeds</a></td>
<td class="nump">$ 7,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, stock options</a></td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,227,188<span></span>
</td>
<td class="nump">3,345,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities', window );">Shares withheld for tax withholding obligation (in shares)</a></td>
<td class="nump">504,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities', window );">Amount of shares withheld for tax withholding obligation</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Unvested RSU, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,657,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,227,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,701,229)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(211,688)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,971,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,971,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, non option</a></td>
<td class="nump">$ 27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RestrictedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RestrictedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were granted during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448081270688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Related Party [Member]<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>Officer </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>Officer </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfExecutiveOfficersThatExercisedOptions', window );">Number of executive officers that exercised options | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward', window );">Shares purchased in cashless transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,395<span></span>
</td>
<td class="nump">688,657<span></span>
</td>
<td class="nump">650,395<span></span>
</td>
<td class="nump">688,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to cover portion of tax liabilities (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Rent expense | $</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchased materials amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfExecutiveOfficersThatExercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of executive officers who have exercised options to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfExecutiveOfficersThatExercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RelatedPartyTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RelatedPartyTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_GenesisBPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_GenesisBPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448077555744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Term </div>
<div>Facility</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="nump">$ 1,422<span></span>
</td>
<td class="nump">$ 2,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_ASCENIVMember', window );">ASCENIV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned plasma collection facilities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of renewal terms to extend purchase agreement, if agreed to by the parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PostMarketingCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PostMarketingCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VendorAndLicensorCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VendorAndLicensorCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_ASCENIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_ASCENIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448072841424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 119,839<span></span>
</td>
<td class="nump">$ 67,275<span></span>
</td>
<td class="nump">$ 308,905<span></span>
</td>
<td class="nump">$ 184,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">60,180<span></span>
</td>
<td class="nump">42,622<span></span>
</td>
<td class="nump">152,685<span></span>
</td>
<td class="nump">126,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">39,638<span></span>
</td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">100,660<span></span>
</td>
<td class="nump">7,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other (expense) income, net</a></td>
<td class="num">(2,889)<span></span>
</td>
<td class="num">(6,120)<span></span>
</td>
<td class="num">(9,659)<span></span>
</td>
<td class="num">(17,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">36,749<span></span>
</td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">91,001<span></span>
</td>
<td class="num">(10,594)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,469<span></span>
</td>
<td class="nump">3,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,940<span></span>
</td>
<td class="nump">2,093<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="nump">6,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">390,618<span></span>
</td>
<td class="nump">348,997<span></span>
</td>
<td class="nump">390,618<span></span>
</td>
<td class="nump">348,997<span></span>
</td>
<td class="nump">$ 329,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">114,748<span></span>
</td>
<td class="nump">64,618<span></span>
</td>
<td class="nump">295,465<span></span>
</td>
<td class="nump">173,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,091<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">13,440<span></span>
</td>
<td class="nump">10,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember', window );">Corporate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="nump">107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(6,954)<span></span>
</td>
<td class="num">(5,649)<span></span>
</td>
<td class="num">(19,049)<span></span>
</td>
<td class="num">(16,149)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other (expense) income, net</a></td>
<td class="num">(2,835)<span></span>
</td>
<td class="num">(5,979)<span></span>
</td>
<td class="num">(9,560)<span></span>
</td>
<td class="num">(17,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="num">(9,789)<span></span>
</td>
<td class="num">(11,628)<span></span>
</td>
<td class="num">(28,609)<span></span>
</td>
<td class="num">(33,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">90,971<span></span>
</td>
<td class="nump">50,821<span></span>
</td>
<td class="nump">90,971<span></span>
</td>
<td class="nump">50,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">113,088<span></span>
</td>
<td class="nump">66,567<span></span>
</td>
<td class="nump">299,385<span></span>
</td>
<td class="nump">175,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">52,731<span></span>
</td>
<td class="nump">41,734<span></span>
</td>
<td class="nump">142,193<span></span>
</td>
<td class="nump">118,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">48,347<span></span>
</td>
<td class="nump">15,017<span></span>
</td>
<td class="nump">123,756<span></span>
</td>
<td class="nump">26,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other (expense) income, net</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">48,293<span></span>
</td>
<td class="nump">14,876<span></span>
</td>
<td class="nump">123,661<span></span>
</td>
<td class="nump">26,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,364<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">3,686<span></span>
</td>
<td class="nump">3,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">266,456<span></span>
</td>
<td class="nump">262,554<span></span>
</td>
<td class="nump">266,456<span></span>
</td>
<td class="nump">262,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,715<span></span>
</td>
<td class="nump">672<span></span>
</td>
<td class="nump">9,413<span></span>
</td>
<td class="nump">8,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">7,449<span></span>
</td>
<td class="nump">888<span></span>
</td>
<td class="nump">10,492<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(1,755)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="num">(4,047)<span></span>
</td>
<td class="num">(3,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other (expense) income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="num">(1,755)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="num">(4,051)<span></span>
</td>
<td class="num">(3,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Capital expenditures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">802<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="nump">2,415<span></span>
</td>
<td class="nump">2,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">$ 33,191<span></span>
</td>
<td class="nump">$ 35,622<span></span>
</td>
<td class="nump">$ 33,191<span></span>
</td>
<td class="nump">$ 35,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075287600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for lease</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingAndFinancingLeaseLiability', window );">Operating and financing lease liabilities</a></td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Payments Under Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2024</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2025</a></td>
<td class="nump">2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">15,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,403)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(1,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Balance at September 30, 2024</a></td>
<td class="nump">$ 8,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,779<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingAndFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingAndFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448075646368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES, Income Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 840<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,224<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448189103360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES, Net Operating Losses (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2043<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 315.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges', window );">Operating loss carryforwards subject to limitation ownership changes</a></td>
<td class="nump">267.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2028 through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">35.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">216.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | 2028 through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Losses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 95.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NetOperatingLossCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NetOperatingLossCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards are subject to limitation as a result of the ownership change.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2028Through2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2028Through2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45448164459152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 7,417<span></span>
</td>
<td class="nump">$ 13,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">8,895<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing and Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsIssuedInConnectionWithNotesPayable', window );">Warrants Issued in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsIssuedInConnectionWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued in connection with the issuance of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsIssuedInConnectionWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MB:]KCLR,U (@;!N]!4*9,PF$\DY(=EPK1=PL%8^(?D:I $4B-H7;&?$\([L
MS,'ZZB. 8.:*AT,P)41\>H)S+1AQLV)\ZZ-?QV'X"5WQZ_&$OS77:?\'O ;'
M@(IS7-L( : (F6.DW$3YZDLURMN$J<I@_@G%3&KM2)JUXWV>/<?57O$BRW<-
M#,GH%180Q)1QGJWK)@"DYQV ,$)LC72CHV.^M60DS9)QQ*?H*.L@36SNC##?
MTC,,P( , RB/N:[^50.PQ@S7 I$T"\2K?C@<(-Z?C-2"/'RK=268D(K"W7B$
MPMN^JOJ/<8KF69)$>8&4F$3%,LH%')WM>-YA6KY@I@<'0NEU'8 H:L3&1)TI
M9R>F,U)+2-(L(8/AUX=R+[3-X-!W!0="F<&!4%3?J@)03<&IE29I5IK?^?#F
MMHQ._YL2US?\*"(A&C],PVE_%*BX@>J3M*H^6_46M.J-M^7M.$^U^B3-ZO,J
M*N)95:%5519P69IZD%"U",/4U:4*!"6,N(ZO;[D&H%?L,Y_INP0<]$JIY5!Z
M8O^#U*J4-*O2($XV4LS_,0;0QJGM6;:E]^P!!*4J5)@X^H8RZ!6[+L$ZE$/0
M$S'H'IP#KD3^5!W %FB6;5*Y/?K9/]T?\O:KHTWM^14^'V#@>8#/^?8(MW:_
M/5&^B_*G."U0(A9J*.N+J]XWWQ[2;F]DMJY.(1\S*;-5=;D4T5SD)4#]?Y%E
M\NVF'&!_5-[[&U!+ P04    "  3B&=97:;,([$,  !X;   &    'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;,5=;7/;-A+^*QQ?YZZ9J6+BG<K9GDE$MLE=
MX^1BIYV;SGU@)#K65!)=D8Z3?W^@K @"L )$9>U\221K^0B[6 +[8'>ID[MZ
M^6=S755M\GD^6S2G1]=M>_/L^+@97U?SLGE:WU0+_<E5O9R7K7Z[_'C<W"RK
M<K*Z:#X[IFDJC^?E='%T=K+ZV]OEV4E]V\ZFB^KM,FENY_-R^>5%-:OO3H_(
MT=<_O)M^O&Z[/QR?G=R4'ZN+JGU_\W:IWQUO4";3>;5HIO4B6597IT?/R;,B
MX]T%*XG?IM5=L_4ZZ53Y4-=_=F]>34Z/TFY$U:P:MQU$J?_[5(VJV:Q#TN/X
M:PUZM/G.[L+MUU_1?UXIKY7Y4#;5J)[]/IVTUZ='V5$RJ:[*VUG[KKY[6:T5
M$AW>N)XUJW^3N[5L>I2,;YNVGJ\OUB.83Q?W_Y>?UX;8NH#2'1?0]074N8#)
M'1>P]07,_8;AC@OX^@+N7$#8C@O$^H*5ZL?WNJ\,EY=M>7:RK.^292>MT;H7
M*^NOKM;VFBXZ1[EHE_K3J;ZN/1N].<^+\XLB3_2KBS>_OLJ?7^HW%Y?ZO]?%
M^>5%\N;G9/3R^?DOQ47RZEQ_\&;T[Y=O?LV+=Q?_2(K_O']U^=]DD+R_R),?
M?WB2_)!,%\GE=7W;E(M)<W+<ZB%V7W0\7@_GQ?UPZ*[AU/.Y=I^+MA[_F?SQ
MNII_J);_ V!&89CGD\FT\\-REKPMIY.!'M2HO)FV^GT -(^ CL>W\]M9V5:3
M)*^NIN-I&T(KPFB7M1Z-?=FQGKO-!-+-!-(5#M^!\Z*<E8MQE92M'M3X:<+(
M3PE-*85L?X\D5TC="O+IK)/[M&U77T32X5 .;;'<%QMPE:5$V7*%+T<$&2J^
M$;-T9AN=V5XZ_ZCGM;DNEU7S9"_][U&%I3_)B!RRU#%#\/N[Q?M9<U..J],C
MO3HWU?)3=73V][\1F?X3<BM,L ()S+([W]B=K]#9#KN_6HSU9M1HPVM3KUX]
MZ>[WU=UZ7<\FU;+1:\)?M]/V2_+'NWHV2_1B?E<N)]#]\8(CFF6$"99C@A5(
M8-:$B<V$B>"-LIJ90;>13I)Q/=?115-VZR(T'<*[5=V;0GBW#R'$$<I](4>B
MB,!8BLJ-HC*HZ&]5TTX7'Y/Z*GFG7RZGXVZ5OM]&WB^F;?-3LM!1E_[X?KW0
MNVQ[?5W-)HF.M9*V_%R!FY6,VD1ZR@PD=VWB"[DVB<!8-E$;FZB'MLGV"@O9
M1WG#YIQ1(APC!<?9]^;$!"N0P*SYR3;SDP7GI_A<+<=3O9IV,[":E?JFNSE!
M3\RBGIC%G"R/2A0A"4O'X4;'X6$ZQCQKZ&_5VK4<E8/?W=>O,,$*)##+YB0U
M,7T:M/JYOJVG"[W@ZYUZ5C>PA=<8(9=:BX1\"A 92)4Y\6(1%;,UW6(O9-_H
M]W6YW$1_#%28Q,/?M<SV."5+.7/C7T!NP#.>I=)5W!<D7$@A=FANPGZR7]SO
MQ,!Q*U @"*944I%EKC&"(^A[?Z&B%5AHMO4- 2'[,9!]6,<:*NQW/C4!>1<@
M!Q,O0##$O(BA "08L![,O=:P^Y"O\ AZ^QUJ-(^%9EO?Q/-$/"(#(T'VT)>"
MH:+EJ&@%%IH];8:=D# ]V6]##F+TG@U,M!P5K2  W2&I&.Y:G SC(6'*L[4L
M7U0W>D%* QNA\I=E-\ D/L'1M"RETEV6?3D=#F224'=9]@7ULLR9VJ&YX1(D
M3"9V+,MQ*_@A/Z5B*+(TXZXQ@B/H[5&8: 46FFU]PW)(F.;T"D.'>X0#/OV!
MPU!?;D<8Z@N&PE!JJ 8-4XU#PU#J$X)=86AX!'W]#A6MP$*SK6_H#R6/& [0
M(-?JNP&AHN6H: 46FCUM6RF;,'?K<RQ+_12*&R]3G](1R1Q&D -2[O%/#,A6
MUY E&B9+H[*YGE5-DU1;IT':"Y?EH@4/NZC/F#R=?7[C'DW$18J@B*VM(4@T
M3)""VL:.O:C/DLA0JHPK5W]4CH2*5F"AV1-@.!(-)ST>*!= XPD2ZJ<V!CJ:
M<OTRGB*) =F6,32$/GB6).K ?FA/B.)>,!D>:6__1:4G6&CV+!D20\,DYO>O
M:\6T:6[U_&B#C^O%8EU9TTU)LJC;*KDIOY0?9A4X"SZW\7S59R)BFX&M#>M+
M>;X: ;*M8 @-1<R.T'AZA/I$AROJJAM/D41P;&T-@: /E">A0&"OLHP.7?51
M<R6H: 46FEU+8B@,0\B6L'BVA,6S)8#(0 =8Q/&QJ)BMJ:$+;.]LR;]N%^&#
M ;9'MH1!V1(U= ^C<T!NP(=Z7W!/K0%!PJ62.^XO9B)N=E"V)&X%*%O"!95Z
M2W.-@9HM044KL-!LZV^5:[%'I*D,LYYJA(J6HZ(56&CVM!DFP\),I@]-74,%
MUT> V\BA&QT#4NX6' .RU36\@7T7WL#BO(%!X7[J'O8!4IYE(D"V90QO8-^=
M-S" -RA"7?<8A4?:^W9%Y0U8:/8L&=[ PKRA5\3,?(9 7%,#R0\W0Y*'Q]3;
M@M!7[BH6-E2"'4@EHD[IQ_J$RC3EGJE04R.H: 46FFU\PVQ8F-GL%UW[.1%O
MC?2)CA== T5C0@IWC8Q(V971AD7P_1(A^R3=N$\FO-0C]SD F'H$Y.#4(R 8
M2CURPRKX?JRB;^J1^\'^KM1C> 2]R[M1<PE8:+;U#;/A!_5_P!8'&D \O_,9
MC^3$3ST"<@.12GTKN7X')!68H%LI2EMSPRKX-W>!P%: VD!D*EG*7((;'D%O
MOT,E!UAHMO6W6D$>M1<$MQD$MQL$MQWD(9(CW) <CM<1PN/,A?N$@Q(W/,H!
M*9>YQ(!L=0USX6'FTCOUR.,M'SS:SI''18J@B*VM80 \S "^*?7(@68.P85(
MO1T"M9T#%:W 0K,GP# -'F8:#W2$P./I#>Y3E0'ERHL6XPF.*))M&T,$>)@(
M/,(A O=#>Z5T,.PF0\(C[>W!J,D0+#2[7]#0&!&F,;T.$40\*2( UI&ZV:D<
MD/*Z!B- MKZ&O(@P>3GX;$#X[(5EDGE' ^'O[^MKJ&@%%IIM>T-=1)BZ['4T
M(.+U3R):V90#(D3Y99)1,5M30U7$WNTBVY61'%08:!=QMV !M(MP2IA[.@?(
M=8<#7'AW%]0NPM1.S0U-$ >UB\2M +2+,*+D4+D'.J/P"'K?8:C1/A::;?VM
M]N]PM-_G<$#XT;[O=WZ4#AX. '+PX0 @&#H<$";P%^' _]## >&'Y;L.!\(C
MZ.UWJ*D(+#3;^H:("/6(AP,"DR*,4-%R5+0""\V>-D-?1)B^[+<A8V8G1JAH
M.2I:(7PFE FE=AR8"\.$Q-[=(MN'Y/ ^"'2+N*?C N@6$91Q-[4.R TX3;ER
MN[4!0;WY9L-=#^DP[$(>U"T2M8($ND689"J3J5L8'1Y!7X="12NPT&SK&ZXC
M#VJ6ART.E'^YT8 $RK^@*!20@Z-00# 4A4K#-.0W-\O#5@#*OW9$H>$1]/8[
MU/(O+#3;^H;]R,<L_Y*HY5^H:#DJ6H&%9D^;H6X2K_Q+QLN_),#H,NFM%?'R
MKQB0K:[A2C+,E7JG"F0\/2*CB8\\+E($16QMMYZ7]0V)D=C9E_1)TI IX>_%
MJ P)%:W 0K/M;QB2?/"'<X$S$V_\D$"ONAQZ]V&\\2,&9%O&D!#YX#F4J/\"
M=5V*\-0MZ0Z/M+?_HI(3+#1[E@R'D0<VK(#VCI=W29]R,.;FD0$ASRG#./:#
M] QO40=F1:(/R .R%CQ+W7.P4?C[>S\B#Y6U8*'9MC>L1859RUZ'$LJG*ZZ'
M*9]<N'LQ(,)H*MU*NJB8K:EA*6KO4J[MQA20F:@]2KD45,K%)7.;_ "Y 1>2
MN4]B* !!DF54[LC"*<,0U$&E7'$K *5<C*54*N;=8:B!/BI:@85F6]\$^NHQ
M2[D4:BD7*EJ.BE9@H=G39@B+PBOE4G&NHGR6P8A[-)@#4NX6' .RU36,12&7
M<BF_E,M-SBOH052NQO%:KJ"(K>[6PWL?L)9+ 8^94KQ;JUT#X#Z:%_?9O ^1
M#%&&AZCO4LNEXK5<"JC (D1DKF/&:[FB2+9M3/2OOGLMEX+:-%+BG3&$1]K;
M@U%KN;#0[,=+&]:2(=9R9?%:KLPG,T(.W?42D/(>,QT!LO4U3"%[H%JN#,@[
M,#'TE\OP /HZ&RI:@85F&]^0EPRAF"N+%W-E\6(N0$3/EMLO6T3%;$T-6<GV
M+N:*)BXSH)C+3=\",F#Z%I"#T[?0EP;2MYDA"ME!Q5QQ*T#%7'#Z-CR"WG<8
M:KR/A79O_>.M'VWJ?I/K=;G\.-5KU:RZTO#ITRZ,7M[_S-7]F[:^6?V.TX>Z
M;>OYZN5U56IVU@GHSZ_JNOWZIOMIJ,V/C9W]'U!+ P04    "  3B&=9M<WU
MP[$&  !E&P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM;*U9;6_B.!#^
M*Q:W.K72L<1.0D*O1:*TO47:TJJPNY]#8HJOP69C0]O[]3=.*('$<5N)5;4X
MR7CRS(OG\<3GSR)[D@M*%7I9IEQ>M!9*K<XZ'1DOZ#*27\6*<G@R%]DR4G"9
M/7;D*J-1DD]:IAWB.-W.,F*\U3_/[]UG_7.Q5BGC]#Y#<KU<1MGK)4W%\T4+
MM]YN/+#'A=(W.OWS5?1()U3]6-UG<-79:4G8DG+)!$<9G5^T!OALZ+IZ0B[Q
MD]%GN3=&VI29$$_Z8I1<M!R-B*8T5EI%!#\;.J1IJC4!CM];I:W=._7$_?&;
M]IO<>#!F%DDZ%.DOEJC%12MLH83.HW6J'L3S-[HUR-?Z8I'*_'_TO)5U6BA>
M2R66V\F 8,EX\1N];!VQ-P'TF">0[012G> U3'"W$W+/=0IDN5E7D8KZYYEX
M1IF6!FUZD/LFGPW6,*[#.%$9/&4P3_6'=^.KZ_'D^@K!:'+W?70UF,+%9 H_
MM]?CZ03=W:#A8/(-W7R_^S5!;?1C<H5.OIRB+XAQ-%V(M8QX(L\["M!HG9UX
M^^;+XLVDX<T]="NX6DATS1.:',[O@!4[4\B;*9?$JG!"5U^1Z_R%B$,\ Y[A
MQZ>[%CCNSK-NKL]M\FSIM)N'NUMT=W_],)B.QO^@P7 Z^CF:CJXG9R:W%6H]
MLUJ]K,_D*HKI10O6K:39AK;Z?_Z!N\[?)IN/I.S  ][. YY->W\,58CQ6"PI
M.DF%E*<F:PL5W5R%KCF;?N@'07#>V>R;49=J8\?O>3NQ X#^#J!O#=$@^1=6
M&!0E)9$24)5BP6.64L2KR/5C?3..Y *M,K%AD+-H]HI.UA(&C)\BJ*Q9I!A_
M+$H34XQ*8WS]8\;W2,H.W-?=N:]KC>\5!:4QBXIZS!,4+46FV'_Y#9/EA3I_
M+XI=[.!*J U"1"](4Z"#'=+ BO0[Q! !R(3)E9!1BL0<S=D+1"Z2DBIC]0IJ
M.%Q2@5H7P1B;D88[I*$5Z8@K"I%2:!4QG5?HB?'$!"^LO=NIH*M+D)[?,\/K
M[>#UK/ F2L1/;<V;"8+E 9L)V1CM7NW](0[="LBZD.=YQ P2.R6I.5:8@[U$
MU+%.Z$SIX,=BS961JIP:CJ 6;H,0#GO=!K![#(P_!39E,;B50CG:4+ZF1KBX
MA@3J8;5HOB=UB)>4>(F=V!81?Z12)^=>S<O745X%4A;-6-I<_[;JCU0 CZ7M
MT!DER6,K@_8'<9Y34I,'99MHEIH#YM9#04B >]60&>2P'^(&HL,E%6,[%X\X
M)),2&03%B,\SE#+'KZ(S2'6;H)4DC*TDU;_/:%[LZ(LN)[1((J$6-(,-<)8!
M;$N5WNH^<)A'<)543&*XJ<R4_(??)4 AF=I';$%:)[:V5P=JD,*$-+ *+@D0
MVQEPEZ>KZ+4Q2>M\1IRP"K NU,;8]QL EKR'[<0' +,U+;/ "+!.:6W?#;TJ
MQ+J8%P9-T2ZI#]NY[^XP)2'D7/#VV_5>U3-"KQ-=._2KE&V2\KL-P2<E'1([
M'8X_OW,UV4#J_-<-/;];,<(@U@Z#7@/OD)(G"?Y40S4:_[R>?*2A(E;^_2SA
M'$O;H1=*]B560NO?K[-X ?LOO5. <$+HU&N>C/3WFJUT+V-T 3$DEM>MTH])
MS/6#AA)/2I8D[[$D@(-*N=WA,*Y@"\&@#%GJ)3%0H5M/MKJ4TX"VY$KR?M^:
M+Y?M"H&_#6S)/[! ZOS8]D-2I5&3F,7+)9$2>SM;72 WH_%@//S( CEJ2WHL
M;8=>*$F9V$EY&KU06;1/D&TZ<!#$!_C)6*R'>0N#?G#6D'8FFG9)=6]M$H.]
M=5,,2YXF=IY^@+W0JU[%>IUPH:B5L8F!C%T'_E71UN6:5DE)V,1.V/<%SKRO
MGC,>\9BBE.:5:9:RQ[R=,7OX_=;5(-+&#8T6*0F<V E<KVLHF3&EB43S3"P1
M,#IL.&@6LZ*@RCPWQ*H9>YV@ \>O;N(,4MAI:A3=DL;=#]+X6UTJW/Y^77(-
MC$P"$E2+J4&N"73)VJZ]N]U^!,SRS#A):#$ZU?!S6S1UY0/-7YLHU2EEM*'>
MS+J^ZU=KJT$,]L]NMV%_ZI:\Z]IY=]@$%K71C#XRSG4<-"G3C GC)QNWSJX^
M=OWJ9P:#6-CU2</^U=W['FTG89L%5#<P5NQN_3MM-ZA]<C"(!1[VJWN_SMZ!
MQ9)FC_DYCD1YBU)\\-_=W9T5#?(3DLK]2WPV+$Y\2C7% =1ME$%0))2D.:AT
MO@;@SZPXTRDNE%CEQR(SH918YL,%C1*::0%X/A=0?;<7^@6[D[7^_U!+ P04
M    "  3B&=9GK"@U50)  !0%@  &    'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;)5876_;.A)]]Z\@?+L7*>#OI$W:)@'LI&E\T:1!<]L%=K$/M$1;W%"B
M2E)QO;]^SY"4+"=N[^U+(IG#X7R<.3/4Z5J;!YL)X=CW7!7VK)LY5[X=#FV2
MB9S;@2Y%@96E-CEW>#6KH2V-X*G?E*OA9#1Z/<RY++KGI_ZW.W-^JBNG9"'N
M#+-5GG.SF0FEUV?=<;?^X;-<98Y^&)Z?EGPE[H7[4MX9O T;+:G,16&E+I@1
MR[/N=/QV=D3R7N"K%&O;>F;DR4+K!WJ9IV?=$1DDE$@<:>#X]R@NA%*D"&9\
MBSJ[S9&TL?U<:[_ROL.7!;?B0JM_RM1E9]V3+DO%DE?*?=;K:Q']>47Z$JVL
M_\O60?;PN,N2RCJ=Q\VP()=%^,^_QSBT-IR,?K!A$C=,O-WA(&_E)7?\_-3H
M-3,D#6WTX%WUNV&<+"@I]\Y@56*?.__T^</T=OZOZ9_S3[=L>GO)9E_NY[?O
M[^]/AP[J26B81%6SH&KR U5OV(TN7&;9^R(5Z>[^(<QJ;)O4MLTF/U5X+\H!
M.QSUV&0T.?J)OL/&UT.O[_!7?67_GBZL,T#(?_:Y';0>[==*5?/6ECP19UV4
MA17F473/?_]M_'KT[B<V'S4V'_U,^Z_EY^>JQH/.CR,PO;R9LIG42J]D8GML
M7B0#=O#[;R>3R>@=+?K'\3NF#7.98''E0N<E+S9Q\263EO&"B2+M.]W'/Y;H
M/!<FD5RQA=1EQE%)B:B<3/!+$G:CBE*\.Y$RISLY+ZHE4E$96:QZP+IY$ Z/
M4)Q"\A$\4M*K+06I=1M2',QFRVB= S\Y4(=C>LEDGE>%1J7*1-)/)7?T'Y8Z
M9J1]\+MDL:QY L=H*#&[ HDP#AS7"%:6I=(*$((=L#]Q9BL4X^-WECEN5H)\
MBN>Q4I>5XG2&A99$5:GH>-M$GP)A= Y]*992^2C3BBO+UID&72Z7PK EUBFV
M%8K+J U%(&QFM6?)ABS2!NN4)=J;<T1'1,&^K4I"*!U"'N4^Z@K4RBUL&@0,
M@.X-4@'[,Z.K5<:D\W8HM>GK=8&]MEI8F4IN)*1JW-SL9NWCQXL=]#P3:1!#
MX:XE+A FBOL'@2XC^7,0MH1J!<'LSE/];,T]''(?4?8'UM!SP"3C8X",04XJ
MZ>"HQPM/OE722I]_(*;.-4>LX'TF5,H6&R_Y-,O^" *=-&F_Y 9P3,""Q"5L
MBV1A>HBA3+(Z\:E7]F5P/V!76J<^"I>F6K%I"I*71$;>F-KYJ\NZ %_VE4S0
M%*%B-O\Z_S"]H<V=6[Z0_>M9!/M*Z46%^F= 55HE#@5-)P ^4+154"IN<PYH
M<0_]<.1._=6!VC"E0X5"Z0R/[#-WNNBQJX_LH,4'?NDJ[ME-43O!DN E.D^#
M:75E$E&;A=96]^Y%94%F%D"4+F-.%'MDHJ4$RMK6"&',(B'<A:1?[RGM%!&E
MD.Q.R L [N/#42+Z$5(Q2/%$[$;D=@J=9=P7B1 ="FJSL15R?T!,/#<"_=P8
M1$!M(JN)D/@M1V*%/W*I^$*)M^Q OF33^XOWM_.O[& >BOU#G=DY@>Q1%""B
M'KNND#6?@S$HVBK#V7CT#_91 M;I2TH^\M;(U\31H*1&&>&I*<SHA^>C$,Z]
M['IG)$US'9B@#=ADOL.VX*1:^=V\5DV1L9H]%. 3U%BMXOG6RT"P+167EXU]
M,&9>++0IV'MC-$ %8[P&(*_G;0V!;U4MJ"X1DI*$C,54PV2 9UH:J=B81HWQ
MFVU2BH3<EL:Z=B.S7 FB</8I<7J!ZJ=-[Y N^;)3U^3?R%?("\G_[5C/0QW_
MHG,WZ )O]KJVSZEIM<+8&7TB<?@%(-8$<W MJ*$YE/"L\\3)K6.1[.Q?><23
M"A0LOI?:@B6)F1>*^) X% Q,#-0Z#ZW'H,S!UX63*[$%[O7,3G=;BN_@*&)+
M1]?Z+1W0TC= 5AA/TT#\6*->M[\:GQ!K9UOE[13 IM@]#0:5HL*#[]LD0P'V
MXPA1(/5>:CZ+3;_6!"&:-X3%?6*[:S^?D[EX3(@2/2"\."Y+Y(3_3]F7J;#[
MNE$]3,$QE*S3*#T:6T%X=F?4292?DSSKU5P-2?'@XQA',<99*4M!PR9Y%WBY
MCQG$0Y&RP$L_[\4>1"%N7*8?:NPG>)&I#QYQ)86I\(U2TPA34;]"#RZSC04]
MH'#B_(<,D]6)%T!8$A[Z%LUTSX>K9O;SM Z9/2->9^^(-_4$@RN)$SG5?'TO
MV05 QE-_#243$EYBPO MX,7D^'!PB/N;4I*Z9I@"2.C%R>O!<;W@9P]NLU"E
M>.@($#BJF$SNL1>O1H-Q6Y8GB:[(FU#Z'J>T]<7X>#PX:4O* G!$IB4U/AI3
M KSU<HD)A^+ZXNAH\&;'CM"K4$(H_-!7!VS&*8A5J8O.OF&HWH-P_Q<1A&@L
M V\5JA 9E30.V78(ZCBUUR-/H<RQ&Z#)2R6(,W@]HNT]OJE<^3_>S/)0R\,W
M!/\%P'O2V[L?%<)7_IA6IUX VG BEJ<G""2F]RP]8<!ZGA!J=IKF40)<!'\,
MSK(B7^/$'2*!W"^57H- D0G"/4W_\=Y"8VL5I^7&YK@9\WN/6NG6;@2/RDJD
MO6:2)Y_I3A;#M\2T!9N^83!V=&58HM-9NA  UJ^\.PNQ@98!N]9KA,#T]@YM
M==+IBX_6#Z$&HQ]-A2^1X448).E.DF2\6 G_.27 ";2" W V,12:>1L?GCRK
MQ)/=7V8^]C&"?(MHJ"$)WQ%0YH4.XR"F^RHOPWVL=:O:I_\9H&VG0;2-A)5H
MQ $\1@ND8XM>H *T4?L/TW8R^'08:\BQS7:^:NMK*X64;S!'[\ZCZ&BXFI&=
M!!5BM1"8T-K"75N&'D_VX=;L1)(5='?>!*6[M_/=AH%&CK& "*33I*:'P=SY
M>"J9RW!_[Z$Q4!W3@.&Q@ D]]!DT! 3*4.;S0&BQA?B*V[U?49YB,RYQ^W=Q
MOBO$FC5&>R-E46#,B06P>_*#0  1)5T40A&@EN'V3:.FOP<'(J);L?*0I)8'
M/6B7TIN'3+APN>A09S,:0Z)PM'T;N%X]494@2CK8U[F?P)HI9(5[@2D\?=%M
M>]5\!?"440]JALC$A- ,]GTY&K:^\@'M*_\MDT($Q@D?_)I?F\^ET_"5<"L>
MOK7><-RO88 22VP=#8Y?=0$8__TRO#A=^F^&"^V<SOUC)CAJA 2POM0(37RA
M YJ/R.?_!U!+ P04    "  3B&=9(T0:R8@6   +00  &    'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;*U<6W/;QI)^QZ] Z63/L:M BJ*N3FQ7R;*=56VB
M:"4KV:VM?0"!(3DV+@P&D*S\^OVZ>P8SX$66S]D7BP3GTMW3_?5E&G[]4#=?
MS%*I-OY:%I5YL[=LV]6/^_LF6ZHR->-ZI2K\,J^;,FWQM5GLFU6CTIPGE<7^
M=#(YV2]37>V]?<W/KINWK^NN+72EKIO8=&69-H_O5%$_O-D[V',/;O1BV=*#
M_;>O5^E"W:KV;G7=X-M^OTJN2U4975=QH^9O]LX/?GQW1.-YP.]:/9C@<TR<
MS.KZ"WVYS-_L38@@5:BLI152_+E7%ZHH:"&0\:==<Z_?DB:&G]WJ'YEW\#)+
MC;JHBS]TWB[?[)WMQ;F:IUW1WM0/_ZXL/\>T7E87AO^-'V3L\=%>G'6FK4L[
M&124NI*_Z5<KAV#"V63'A*F=,&6Z92.F\GW:IF]?-_5#W-!HK$8?F%6>#>)T
M18=RVS;X56->^_;V[M=?SV_^._[M8WQ[^?/5Y<?+B_.K3_'YQ<5O=U>?+J]^
MCJ]_^^7RXO+#[>O]%OO1K/W,KOU.UI[N6/M5_&M=M4L3?ZARE0_G[X/.GMBI
M(_;=],D%;]5J'!].DG@ZF1X]L=YAS_PAKW?X+S,?_\_YS+0-=.A_M\E!MCG:
MO@W9U8]FE6;JS1X,QZCF7NV]_?O?#DXF/SW!Q%'/Q-%3J_^+)_CTVM-Q]!TR
M>I<:;>)Z'E\3EU6;LMU]6BK87E:7J[1ZU-4B[JJTRW6K\CBKH1B5D4^F+G2>
MTN.YKM(JTVD1&ZRA  &MB9?IO8IG2E4Q9+A*&XS3%<TC8-+M(^RF7?)&7=72
M-JM&8Y%5H4R\4)5JTJ)XI-_5JI6Y+0B[JYB06]K'1"#]O%2-SM+XQ=__=C:=
M3GZZ&]^.XY_/SZ_Y^\%/+V/LA]DMAI4!I;H2@ 3'X_B\>B3 4HVJ,F6W,BJN
M:FP2MW6<KE8%-ID5*EYT8)I'F;A4:=72[SR7/O2[QZG!QEW5$W[N&07Q59XV
MN8DOZES/L3#+W7%P?GO1TXZ!VV?>K4CT)IATYR:15&C'CSVO6U=X5^-/_()&
MVC4^GM^^<XN,_[_4P"SKKLBA"#&Y(*L"G[M*,)YU@$A(JZK#Q&"';ZQ+DK'G
ML\2YT2&Q*N-Y1"=.BSZJM(D585G\7F6JG.&0#@\8C0Y!259TN=>L"^&4!'!P
M^I.!3C!%-VI5-VT,6LFIQ >3T7^ H +S>MKYT&]5UC6ZU4I(^_ U6Z;5@I<M
MM6&7&,KZ]H,_9%I;S9H./C:>G@E8;I'_0":SM& ME$! 6 ]YC)C'!_R00_'O
M28I-78JHK8RWB]4),7Z.$)E*&,H.A=BTNF_B W'<B('U\M45D+QCA6%K= ?Q
MGTE\WK0Z@U4>3$CK;]2B*\28;D?_)<9S>Q%/3^&!+BTMWBIN/2T)CP7O#X@V
MZ"^  :,QJ*JK44-'"W!:1%EM6I/$"\1.<LQ%;0R=N,<'T"<TRW8K_%OG"9ZE
M.*9&04\ 9RS$]QVMR:/;9:.4J#0 /2[%"XO0_80[2!I<?C"M+MGX245$>,(T
M?MPJZD;]V6E /-BJ$+C10Z*S3+^H6/6KB0@0[*VLI)GD^1SA&!/9L"6 HK0D
M-!%% ?O6& N=SG3A+2#7)H-XND;1T4 O"']HYUUS9!?2G-@BV$[#WT5.H^Y5
MU5D"U-<5Z20LP M:)K&WX8,!]&<MF3FD@[#0@$Y"*Z R ;HUF=H$8H*EZT7%
MJ U>O/0LG$2-FO72! 0T"WS/OI 9YE!A9X>+!HK3DYO$]VG1]6>H*SQNZ^8Q
M&9Q'9SQ8S5/=\"265?K B+YH0!+&P.NH9BNFD1[ \X)6; !4B%= $:$52]!T
M,((M>U]=J36<IE_9.K&MP.\J?23%CUCDO3@:53 $6'/P_,&KUP^\@@.8=2)S
M<J8$!VWZ-506C;^*U9$HIQ^A]FH<VI%1A$3QGX!2F!_16.JBP+:]2WC*OIXS
MQ@6ST4<Z@=_="7A4N62P$E4E^\P@5X;O0$TSU;2 $*?FZP((@Y1^L<1J&'N"
MU"Q%P>@#'2KD*X-L/$4'D"D\)DABPW;/[7$E#$9PS@\XDI:!+7Y8ZFQ)6-;4
M7^TQ!GJ6=SVX85K3CB#A,J[2%A9N.3$JI%A<6*YF\)Y=:RCPD#!BEW8B!-4X
M@@QGKUMLG1$T/,8O#+#Q"KH6G[Y\#G7W*9";^&8,ADJRGI"7;9?:,$%C%Q(9
M^(Q>3N=;9*=- #0MQ3"%_HM_X7V3N(+[)1-T:FU8C0CN*/D@:!%^+"((;]9M
MB#%'HAFTR@^3\=2I+(_'@X.H?]!N440>MN&8$P*TE9A* 1RQ1]L0 F8U\.LO
MCR6"A!8>Q6HM, GWY)!5+J=ICPS8VL(RC.,'DB<.)?U5C>&\&T"T8C9BU9L_
MN0*5@A0W=(O2DPGKUDG [H"3(T0<QQ_ZM<RFF^BG)J3G[.?L1.?=:HSC %.6
M;;3YPA;94TXR@D0H.< PH;^N%C6I[HSRI?&V0[BTD$V.["9]Z.,'X\&<0R,0
MPV23CM:="<:MN@;NPC@'83H**4!08/=111D+G&&-L8S=IDR9L1L<MH:6TS:W
MCU7VV)(T?M=-YS.$F]O?^XASJ1> <TT8*:LD ^\"$\LEWMH%478$A/%'W7P9
MZ6J$)U!^T7(<B$9@FL>+NLZ]"$@XWI@/7U+:5+CH@A&(7/A >D%(QK$7XWB.
M6 :SV"=4]DN1SNHFH1RRA&B1.!H$R+0C=!\AC] U0UHY)T6E58*8396KHGY4
M-#C8,!5GE?5^N;Y7S9*2&"9EW<6]P\CXHP,M#]9=:R,<HJZ&:N%7."_Z;M-<
M0A@@F=!(=3G8%D%)$I'*="73:!7"QE8*81]I,F>OGS9V[RD-&" ;[751ASEV
M8*S$B'/B>6S(D9*CKEO(T.G"<"N.$K7Y3OWY^/Y\Q%!.F8E3)I$H$"NR(FVQ
M;[&#"N<>QJ'MA4[2F@=+DWPXG3E ,;4.<=O/[# J;-D95P6(UBE'"-W-"=DI
MZ$B@"B5@@\ ';D$XYFV0-&5+>U: X'K%8,0E3:L,Q!,%!UH\"_$$%R)1BQA#
MP\YEW>5@0?*\B%&@T(\6 !O3P@@3^PGN-BX5 E>@]M6V)0;''Z[7:T(D-@G$
M@K>V"C3 ?W(N1FH?Y"R1KBU595.?0,N0#"+[*0@9Q&HP(U<%)C1K@^V9DUZO
M-)Z)7ON(<KY+'F'$S%(5+NIJX(6)1T,R93T7KP#S+R)B!8= $2G[&Q>;45DA
MC+^3/O-P0IB!#QRNS91,1P<>Q.OB;5-35T2LUU.6BSA=(J"@TM.]5@\")4A9
M** 2LR*?ZN)'>_@U]D/@C1/(E)*@>)M4;$:;?X9CLWE30\F).'/:Z*$!_F,]
M!(!,>I!U2&4.XFLHBJ@E;I-DAF8ZJ+9VZZ*%Q*O &M&0NA>X3!?RC03U/>!L
MXV0<_0PO\H 8*.X_-&HE%4LCB/6570^19+TH.0)*4IR:#?.E2ODL-./4N#<E
M>[9COQ>BXRT.O_]9RW$@AD->25'5K&,\I/6-<<!2$L S!$A$8<M=,RG -L@V
M".$H3\<8:(2>AW/(RV7DW0VT%8(<QF+@ETFO5P[G;?R"(P1T B095"U%0L2<
M73,SP 9I$8!.D/5>,P],5:&_((0DA:R84];,39GJU@39=5?)"FSX/'6@RQ+Q
MAFC=DT-JR[87 8W3:J$Y@^'#@@D-O G9-R?=QA&E*7VU&F@455T4[1R7L()
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M;5N7_)%ZEU5# _ [-?ZZ+[1!__\?O/T_4$L#!!0    ( !.(9UE#1MQ@S0,
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M**N WS=2FN/&.CC]6YC_"U!+ P04    "  3B&=9EY0]3LD#  "-"   &0
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MFM#US]X\SYNJ*9G! HYD[U)JX\TKJ0S_A]E"]F[1O+/ZH%A!;Y9Z=(PEL5+
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MG\5GSUW_->S90O^ ?3N@PU9>L-H@OO0"X$B% !@76A7M3F=W/^&YPG8'3LX
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M2LE27\X%1P#2 CR?2JFZ&SJ@_^IZ]#]02P,$%     @ $XAG6>"K36PL!0
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M;FSL]9=@"[X.GMH0;,Z/"X74=[0 O\\LBK/Z0@J:_Q\X_A-02P,$%     @
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M891Z1X*G<>P=>T<)S^,(BS#G29A!>N0KD4DA:WK'7,XZ:;TC=_B5=Q3 -:<
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M30?P^U)A3!X?R,#T%NO\OU!+ P04    "  3B&=9#)"3J*$$  # "@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R-5FU/XS@0_IY?,<JN5JQ4M4G:
M0F&A4@OL'1+<(N#N=#K=!S>9-A9.G+4="O_^9IPTE 4JOK1^F7GFF=?X>*W-
MO<T1'3P6JK0G8>Y<=308V#3'0MB^KK"DFZ4VA7"T-:N!K0R*S"L5:I!$T?Z@
M$+(,I\?^[-I,CW7ME"SQVH"MBT*8ISDJO3X)XW!S<"-7N>.#P?2X$BN\1?=G
M=6UH-^A0,EE@::4NP>#R))S%1_,1RWN!OR2N[=8:V).%UO>\N<A.PH@)H<+4
M,8*@OP<\1:48B&C\;#'#SB0K;J\WZ-^][^3+0E@\U>IOF;G\))R$D.%2U,K=
MZ/7OV/HS9KQ4*^M_8=W()H<AI+5UNFB5B4$AR^9?/+9QV%*81.\H)*U"XGDW
MACS+,^'$]-CH-1B6)C1>>%>]-I&3)2?EUAFZE:3GII?GL]MS^#&_O/AM=G?Q
MXX_;XX$C6+X<I"W$O(%(WH$XA"M=NMS">9EA]E)_0'0Z3LF&TSS9"7B+51^&
M40^2*!GMP!MV/@X]WO"C/L*_LX5UABKBO[?<;=!&;Z-QEQS92J1X$E(;6#0/
M&$Z_?(KWHV\[N(XZKJ-=Z!_+QTZ(MPG&23]X'8>['.%4%Y4HGT A%;>%%(VC
M7H;*4.,;)^E(E!G@SUI6U(P.:!" =!9F9U<SF$M]2H=H&JG-V94HZR6%MS:R
M7%'#+ZS,I# $UH-U+M,\:*V1E0>9(3@B8KB!P&FH;7-04ST9]<00PEITC0W#
M5 PV?*$23\S*DH+1]2IOD-!6Z-N]E2*"A6TL SY6K"X</! C75O(A,-G@"0:
M#OO;D?GR:9+$!]]LBR56!K&QF6DHM8.4RI]#QE&D.8%&"L4<9%;3XD&H&F%5
M"R,H4&@#BM^VE#.RH9KJ!RQ)QKZP3B.&V5..+<@EV0!A"&GE*8#DF !G2CB.
M4TN1+LH4*YY[?;AL0KV6+@](6);2L6E&!;V$.(&BZ5\BIM 2(H6'_3*8:D,M
M#30].:P+H03!@I\V?9@I!9K.S:9T6&^GCN>PR:5!7YVEY_VA_/O2XXOGI/J*
M:+9*BH54DBLV>(6M%TJNA/\.D(%"W+^J'ZH%R])+HXMG(^3EBO)-JAL%*A_Z
M)&''Y<TBL=TU517B)L#( Q)HO#DL%A2WS8SS7M!B"&M!3"KJBD?)-:*>_)78
MP>$9[:5>(962;1)VDB #02IL3J&06<>[I()[3Z.%?EFF.3/_A>=62KC2/L=1
M/^Z(L6-\,GD^H=Y8OA>>,TS;T]B?#GMP2R^4K%;$K<NB+YGW\[)5!TVY"LZ4
MHI>)A3W)P:)Y0-;LUZ/@!OE-PW!$BFD$GX/]:!C\@\*T(?F5TSA(>J,D#FBY
M3\MX?,!+^NE%(W\ZX>5DPLM#%H@. XHA/::65,S!B,22X$X[ZLZ-1T$\[HWV
MX^"2&O,(9%'5C@Q+'KDT.H(]NB5.7X/3VA@>")4V[%VP%_?B0[Z8MPU(,^%U
M9,FE26^R/X:WOER#K5=%@6;EWT[T@=!UZ9H'1G?:/<]FS:OD6;QYVUT)LY(E
M)V%)JE'_8!PV[;[9.%WY-\I".WKQ^&5.3TPT+$#W2ZW=9L,&ND?K]']02P,$
M%     @ $XAG60N7O.+1!@  YP\  !D   !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&ULC5?;;MM&$'W75PR4M&@ E;KZTL0V8+LI&J"Y(.X-*/JP(H?B-N0N
MN[NTK'Y]SRQ)6;)EMT#@B,N=V9DS9\XLS];6??$%<Z"[JC3^?%B$4+\>CWU:
M<*5\8FLV>)-;5ZF 1[<:^]JQRJ)158YGD\GQN%+:#"_.XMHG=W%FFU!JPY\<
M^::JE-M<<6G7Y\/IL%_XK%=%D(7QQ5FM5GS#X9?ZD\/3>.LETQ4;KZTAQ_GY
M\'+Z^FHA^^.&7S6O_<YODDR6UGZ1AW?9^7 B 7'):1 /"O_=\C67I3A"&']W
M/H?;(\5P]W?O_8>8.W)9*L_7MOQ-9Z$X'YX.*>-<-67X;-<_<I?/D?A+;>GC
M7UJW>V>+(:6-#[;JC!%!I4W[O[KK<-@Q.)T\83#K#&8Q[O:@&.7W*JB+,V?7
MY&0WO,F/F&JT1G#:2%%N@L-;#;MP\>[#]<?W;^GGR]_?WIR- SS*^CCMK*]:
MZ]D3UM_1>VM"X>FMR3C;MQ\CDFTXLSZ<J]FS#F^X3F@^&=%L,EL\XV^^36\>
M_<W_1WKTQ^72!P<>_'DHT];1XK CZ8W7OE8IGP]!?L_NEH<77[^8'D_>/!/F
M8AOFXCGO_UF%YZVG\V2PE^C/!=.UK6IE-M1X]A2PP#YHL)@S4L8TJB3.<XX]
M04'=D<,K4G7MK$H+4IXDS=3I)0R6&[J\N1Z<+";?SDY0G'<FL-,5?>;:NJ#-
M:D3!4JK*M"G%C0Z>=+='?,/IK98V3@BM%*,)A6.<9S(RR(:JED8L-"*0('"U
M9+=EPBC:]"DY3JV3C=JDMFK#YSO(E&>R.;V<)*=HE;*,78\37AXELWYA!&M?
MMWF7F_B$_D4*<(;-!T 9P.51<O(5Y5WH_R?@A'#VAX\_"0YIXYR@G@,0O)R>
MT*^J;%04I<L2JJA,RG1)M]M5U:^.2.=DF'&(A)HU*8H)S>'H42)4WC/0!OP2
MFJIL8T($(T6E!UA>,@Q5J?_A+*'?"C:P1R"0$DEZQ\C*2>&P]T(%4DZRQI]2
M?P%TLFC(V$#[A^R72AS(/TF)U*W2I5J63+7U.H(<"< K%1_X5F>,K!,06/OM
MHT!8-AG[$2V;0'@CIY:ZTD+F8$?@ET9M6#G)R0]@'*Q#<7L<*&]"@\C['2-P
MU;G-4J5?8@3Q">5=*Y=1#=K:S,<7DDK.RNNE+G78"$;6K&Q$#O"(F@1>:>X@
M2FU3PH$-;()&QAOPHXC5%4<1-UU8FXD?66DQ:VN.)74 _"0V\SH.%UH!)=/7
M>A?#P2,,!28TAXS/)K;V6H>BU8$[":_]V6^NU$9J:)=_]9U!MX AUT*:2X^1
MG1;@8@1_Q89=3"[3>:[1\B&VQC:>K5>'H%PF8$$ _MJK!/*+1&@[6"J%$GNQ
M!@Z.<;CO0([;T%U0&EP:XIGLQ+T7T1G@GA'!N8_],9]:GZEDG6N#>J V6.BT
MBTHK#$WH"L,]D[X%-% 2:)\HF-H2P7'9^FVK(:9PO+0=KL]S^I[\^PV20D>T
M:3BVL%RB@A(A DYHF .*0&J%#3X,1&.?Z->$/N#%1Q!9Q2A_B@E*'1'O]P"B
ME:IIE*KY?CR%0HV@-ZAP3,0'(<\W2"Y\B^D@D%DC(P%-X5\-HL2)YLZG1\GQ
MONK.IL?)8G!0=T$JF31W<2"!22_GCZR_.TJFVY6N7T S;KOO<8@2R4-Q7\-<
M1$"#<6C/6X7.;B"@V.\I=[82 $[Q9S&G7Z#DK;YOIY7OSXWSSN"XSV FB@6T
M,M0Q16^O6"2>[!I-X0M=]R8=GJ,!7J;L8E53[=*F0K@M>]=1+:*./=#A/KN(
M;JLLT%HT:!-T%-ENA ,Y;5IDNK:R,,_!@0<-EB %JA6*)Q/:C3"QVDOQ_'3V
M;)+TS=<O3F>SR9L=@[@R??.*-)I2B!53B#SU9-LI"E*'C6R<GKSQ ]7))\+#
M=:1-JZGM#C('D$3,>U"*]O2BCWW"_P=^9:F;N3T@&TA^?%X7&M<:(%W@:O-0
M?8*,Q=VC(G%JB&(<>-C>*KR1<0P?:R@0H>_9K37.;27*QI[=]#62:&)[)$\W
MGMIO@MGQR<[-Y4G.QQ1E&OLF:IX<?5\":B*1=PN<-2PW@79*WC.U SW9NR[*
M))"QZ72KG ]W/R <P%3='4H"1D2>_VY0_@&,\O!L;_3T +EK!%^BD2T&<N3[
MGD2"[!CXN(]F&MDB!Q%-AT^EG:';Q1 K[Z0R>ZQ<<IQ")>[OO<(_BF*73/<E
MW$,].735'^]\?%7L5O$34X8OFKG]#MNN;K]B+]N/M_OM[2?P>^56$'<J.8?I
M)#DY&I)K/RO;AV#K^"F'H8,/P_BSP)<X.]F ][G%W:-[D .VW_87_P)02P,$
M%     @ $XAG66PT [(* P  Y08  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C N>&ULK551;]HP$'[G5YRR:=JDK@D!2L< B3+0D&A!95T?ICV8Y"#6'#NS
MG=+^^YT=FK8:19JTA]AG^^Z[[QS[<W^G]"^3(5JXSX4T@R"SMNB%H4DRS)DY
M505*6MDHG3-+0[T-3:&1I3XH%V$<16=ASK@,AGT_M]3#OBJMX!*7&DR9YTP_
M7*!0NT'0#!XGKODVLVXB'/8+ML45VIMBJ6D4UB@ISU$:KB1HW R"4;-WT7;^
MWN$[QYUY9H.K9*W4+S>8I8,@<H108&(= J/N#L<HA ,B&K_WF$&=T@4^MQ_1
MI[YVJF7-#(Z5N.6IS0;!>0 I;E@I[+7:?<5]/1V'ERAA? N[RO<L"B IC57Y
M/I@8Y%Q6/;O?[\.S@//7 N)]0.QY5XD\RR_,LF%?JQUHYTUHSO"E^F@BQZ7[
M*2NK:953G!VN;I;+^>1R<O5M-(<OL]5XOEC=7$]@,87Q:/45IO/%+<RNIHOK
MR]&WV>*J'UK*ZF+#9)_AHLH0OY+A$UPJ:3,#$YEB^C(^)+8UY?B1\D5\%'"%
MQ2FTHA.(H[A]!*]5;T'+X[7^TQ; C]':6$WGZ>>AW:B2M0\G<W>L9PJ6X""@
M2V10WV$P?/>F>19]/E)*NRZE?0S]O_S-HQD.\V^V3QO_O(NKLB@$TOVV3$#"
M3 8;4@C@LE(:=V7) ILA2"(!>76*T)TBH#-@,5^CK@\",)DZHP7< #,4*PC.
M]!INT36MQON9)#A5&G(U'UXR/LBQUQ@[7@7CJ>?"I44JVC;>-KHG[6:7^F;K
MY/S3V5]^B<H1++M' V_AG%PZU']L7"GI*YURR63"Y=:SGLD[ G6CD=,H;CD2
M[\GODA=N>TBYR-14-0F64S.RN-.S1)72&DK[P-8"/11-ZI+6!6=K+CP2D6QW
M8FKC;M2X95HS%\2-*2N<1$FYE\@=MQE(9?$)E%C3USGI4 6'#FCX3'IRU%LO
ML 8\M4J%ZME:PT>5=#VY5P_ )=-;+@T(W%!H=-KM!* K4:T&5A5>R-;*DBQZ
M,Z-W"+5SH/6-(NK[@4M0OVS#/U!+ P04    "  3B&=99#[N$EL"  "0!@
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MKD$CDGDNQ;*#15,K+0J9E"V^I[[XP<TN$@T3=Z4C_-PO%(@OLZ3)M+BH,K6
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M(:.2?GW@652/-((%N74B,S3H"$EM\C44%@7_)8DC4HXO0>SE.-1E+1$-Q9\
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M;ET_PF'TKWK<"WQV<L[)R&;@:$(O,MBE^9(G\ZJ),<E0 &OS)Z$A@L(90?7
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M1P"A^7#DH!X1&$1@'I)RJ2BPI,T"G>Z9-P0<2M%H2Y3"9(=1"2TQ3RAQ9E&
M6@9<<9,%/&XQ?IOCF/#,I1_Z:^SGFVB--A+H:2"60,*QC2X'T86%7XHKB)U1
M?V!G -=T.U1D3US,.U-9F/+6W,=:GL/LI%@B*,H+I^Y+E^$:SVC$=BO_.-_]
M(6TK5):IL-$/9KW[PV:*"@Z&(0(?;3"LY_.Y.6U.9RW+NP.VIA-?U9WLCBL"
M/5V(WR .&OU&Z?YS$L#! N[?&K''$P,9VAIF1"_.ICY9#<MQ@)P&8)VPH:Y)
M5GJ?EY)W@&W&$S)A0BNY]Z9RL3F1")@Z3(<^$,IBB$\5& KB4]6D78&)EI0>
M$#K)< .+Y(E+$E6*V7X,IZ\6 8[1>GQS0C5RV#]+3JEVE.WI2LPYHP1+DX-:
M@-.FP\#6U[QP&>SFD0JSV #3HC78&48\-\0VS3/:2WN22UOEQ!PSM@G1.E!S
MC&O@FW7/U;"]MLC"PLX+@:;>K 4P1'Y&X!W@=B=$@DEXC[&B0XCRK#K(<V+Z
M:7 L8KI3W&]-(N66LR[;"NG?/XJXM86 +?K_C=5AZ>KR^NI3+%XH]7+=E]*^
MGD<1"[!\!8%@:<.6M,IS%DR8M>J6J\$HZX8;7W!C)/I"8HBCP2?00*/6D99+
ME!&B LBP'G,_S.%""D;8G&) -TBE4GO/[X5Z>+F#=@JL"IFAAH!-&]F([Q<:
M^07TA5 <*RG>VOK1?$R?M&VCP)T)*W$0ZXRX,Q**)P:8K_C^K:K("IS_&MDL
MB'GD,B$@U;/)=,:UJN:+9&32F (@ZVWW!=I==@AE]CUSGZ" $AO0X!ILUDJ<
M+^C @@T6?E=9!M1>)N@E68+00\+@5V6R'U(0>-@0Q+'9@*7)L9G$FMY63[5J
M:R:+'&N7()\.?-'-F^=J:<T9C-IW90P1-GEOJT*,@\JG\@L%/E5;E9(C'K"N
M&!0!OKZS198@F>F]4A )3$@ - 9>,276;9K!\,J0'WL?FR329DTQ]>LSXR D
MLQE9=X"=F[Y.61PTR5<?K)C4HZ 4.7 HP_P#&0M2ARKW!!IQ& .;^ WU68N?
ML9AE!W?R@T<E5%WCZ\9&P!)"XTS6D@,L$V*CSF@.5TW(J5H0H#IA2USU:!Y;
M&.J!O&*7WA@7=J@HTV9<T?6P/MH1UC/LDZGUDVTH^!#ZJ*+HRFJ95_,.\-1G
M>;9L@T= $"'C<VPDJ3.,%<N$,\Q&C-VR327 AY.F4(J>1)53Z@>3AYI!Q.2W
M(ZLN"\K_>6&P!<Q^4@D67K>D+-81Z \?U&-C+,%VM0T!:8N;95+:1!%.2&MH
MI"KF7:--]1GM20U-3"%;L5MCSV($Q?0PU1'$U[L2&M%&0@.\-033W6F-_J0^
MJ4$!#2===#?_3+G<RCAFGC:#&6MT,<JCC:E067>66($ET4#9E$X\;5A6]C=\
MG7[--=MAXK:9+)0+H^_0M=0+-*%KFAC9 4Q\PA5L1ECRM   X)->J$'L:9,O
M:.JH+*6#Q*G5"J=Q:XE><X(@06O59"-P,_'H'6S(JL(DILO.8A+ZKX&LPLV/
M^ATFYMXH#/3:X4)2XW*LU;Z2EG84Y"J V?Z:T4K2"2++],;'J99Q-MSPZ4QR
M\-U9#QH?QD7P+2BKN+'B#<)Z'0U44P8DU))&MG1,: OMYD"(G_;]=U3^21BI
MBKC+!YYY'WBVTWN],/DZNW*#XH-^\ ^-)"Z&,X(V"+2YWZ$HR6OA5D,R6"R(
MHYZ&.OT-),\);Z]@UJOQN ,\06!OSK"2 H/] .'R]0P*"2D(ZJ7UT25,$; Q
M2F529+HJ"8Y-/(098:OV>,C*/R6O:<VS95\T6.XX^L-BAB\B^,,'WQBNE(_>
M_J)YX46PVQJL)#8Y(,,4BEUSM$&$6HG>7MFP?79E:Z?^$/=TY_'J-Y=) WJR
MU/N_X1FF&U -/&>)Y_[ O X+[@^<U]X]B\#CTZF0MA$>&4!PIY(/--+42&F*
M[KN6L36#G2&SA+Y(O^OZGMAAVBK] OY#1F$9H_,CW4&0V2C!X!Y,:=D1/A".
M)0UO?-@_"H^9!&?1[ FT=RHG"I^QF"1/.U:%O[T<TC0N04A_X)3/5Q&T(E7H
M8VIWN#9&F 7=C[>Q(OH6*\S!0#-R[\TWF'138>I3<4UL< #EL[MRV_1T>@UY
MXNNI7[% R <K0Q(,4;9:%!R0<Q 5L<H!I\GF<@],B89E_7MMHUFLXKLSI^BE
M=1BL4R=;#GS&(A$5S=EIYPQDZP+D[-EW9CTL3'.WW:T/8JI'I'Y+ PI(>H?$
MED[FXV$@_7/TD68)KZP,T?2<5@?1-2[O&T-%UY0HHZ V>4A4ODO97_PTF4S^
MI5^*%R#3DE(K+\5/XN H/IN<P8=9?'1\!/]/C^*3DY/HC^V@$"HQC)O)LBHP
M2L(!9P>'\=')-#XX.8;0^"B>G1S'9Z<3>#Z-SX[.X-U9U$>Z#5S00,1D/#VB
M?Y,I_3OX#H*>0X*3RZUJW2B2;1+)K6H4^T.F*#1="7$,"@5J232=Q+.#67Q\
M>B9.X\/3PWAV.A-G\>D4.'UZ$'WDTP8\_<@)W!H[#P_CT\EA/(&MF1T<Q"?'
MTWAV/(/G4]BE63P]GD7K:+L)M /\/'J.1@T5_KY3H[[##ST0[ ^P.A&O_2V(
M1TDAW3I06$4T_I=EXK"]F<LTZ;3U^U0#:VG5R,$26PI0XSO:X@\&*8_B4V V
M,#RZ]=#(3>X)&F&'3DY@@V?1'U88<(LG,U"LXPB8 & 9'\_.=I9H_%VMZ>Y;
M5C3SZ"T%N^BY@ANT];[6#P[5*\H8<.N%+/X"D+N_Q&&1.Y8/@&^.9H\X+K=9
MQ%[-DYF%MI6]BL VH0;%"&7SH2.,[O \&;G &67WR"W$N(D^-\#[[LL)&X?T
MB:9QGQUVE,!I-^?3L>)H#W,9LX''P[# 0Q&'2:D:'CQ0-FGI3RWJJ'<R)E@G
M)HL$7A=$S!OAQME:N4T-!L&-'=>G**D!DMA;.2^.E[I9V*7V8R/9=BM^^ "^
M7Q5E-A.\OM:,Z/;/&KE<T+&IV.DD,NE4E  W?X_1SQX;_ ^(S3MSK>[\[EY<
M5V-,P!^/)F>QN"HHR.,T&#2X-#.P0VX4X\:<*PUNO;WX6-5@P$ZFIR]WJ;2_
M1C/=?0OFBBWX1SRE-ZC&S^_>4UTG3]MO((3759S'3%E97X3$+IC#I<,9*=M*
M4Q:E?(^_>K5^">[;]^[P; B.@U<?),Q6PL;?&UE3.F(W,GX6^6MY%5<F [FI
M&KP,QU=@> ESV3Y*$^#BF*@FW[K^P]CASUD'*_('"&S] O@BRX1+9N9>!T6_
M)AP)K\/1<\+/:#O!21-L#.7+ 0BT'&]L.,)2,G@[I>)#*$.\Q.,VSSCQXLM&
M>4YO6!-;3,<N%HI2$CBLN11 8@FTFFS@QNR1/=82K@$3ESZW:P<!4N77I#"Y
M>(I<B^0S,C'Y2FSO0% :+\=H?[ 3\U<C.J&+,7%W$6L\!(='HADIR'3@^7""
M>)=M70<[2OF[@C-Y&53+AA')(."INXTBF;O%&_>8J-PMMFRX(I_0"NI*JX&C
MK=LWBTRFAB XH1H1Q84![R(3Z8:7#/L\? IM-(A[E7>6 !8R$_C4M<0ST\!,
M5!*3=W:IGKAO>GR""F]8M^XLOUW>&/'+GY@>4&987U?:ZD*/,YCG0IJ#RX!V
MQZ+/768JSL\1<#\D2OA./J(()ANLX\3KVL[1\(64IAZ&)(R8A!&2,++G@&RI
M'UUKO:*3K Z?F#'FFC@>V:3($U_G=%2HC<+Z&S3#A;-D&2.YA B])6"%51]-
M_HVYH%85NPQSR=N=<.*>EHMG.PI2;]FV.3M<YK#FYL)1B2UD/FWD7KLRV,XV
MW&H5)&UZQU3-32,J[]!UV=ZI&RXF 81CLC&X?H]>/D"&]@$Q^#1T5K9_.#44
M+_1<&I2(_@T9"\N^ZJ0R3KIBO;FLHG!(%-%A^=R=I/1WZZ:[[\'AQ:6^'W+3
M5&6%<VZ]6?<WAT0TNT8/R<39%*0A@_!NO[U6Z=VJV<%H<A)#8$<:9^ZZ>X<I
MFIU.7OZ\X75Q,P(BV_.=NV@+B(JG@&HKU[AWF3GH23IJ5#G'VP>(HKXGX57&
MCC8Z'<&A+G,*97<6>3_X=13 K"7]!HSF(QC\0RGNJ?N=F7/^=17?G'^DYG=0
M42S>Y'(!72?C$W#H&O[=%_[25C7]ULJ\:MNJH(]XGT(VV #>XV4$^P4G<+^^
M\^;_ %!+ P04    "  3B&=9"5 %KS8$   2"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6RE5EMOZD80?N=7C&C4)I(3[#4&DP(2(<DIT@E!(6E4
M57U8[ %6Q_;2W75(_WUGUT!(2VB.^@#>RWQSG]GIKJ7ZII>(!E[SK-"]^M*8
MU66CH9,EYEQ?R!46=#.7*N>&MFK1T"N%/'6@/&LPWV\U<BZ*>K_KSB:JWY6E
MR42!$P6ZS'.N_KK"3*Y[]:"^/7@0BZ6Q!XU^=\47.$7SM)HHVC5V7%*18Z&%
M+$#AO%<?!)=7D:5W!+\*7.N]-5A+9E)^LYM1VJO[5B',,#&6 Z?/"PXQRRPC
M4N//#<_Z3J0%[J^WW&^=[63+C&L<RNQ9I&;9J\=U2''.R\P\R/4ON+''*9C(
M3+M_6%>T4;,.2:F-S#=@TB 71?7EKQL_[ %B_P, VP"8T[L2Y+2\YH;WNTJN
M05EJXF87SE2')N5$88,R-8IN!>%,?_IT=S=X^ WN;V$Z^C(>W8Z&@_$C#(;#
M^Z?QXVC\!2;W7T?#T<T43A_Y+$-]UFT8$FSAC60CY*H2PCX0TH$[69BEAILB
MQ?0]OD$*[[1F6ZVOV%&&4UQ=0.A[P'S6/,(OW'DA=/S"_^^%WP<S;10ETQ^'
M_%"):1X68POL4J]X@KTZ59!&]8+U_H\_!"W_YR-&-'=&-(]Q[P]YEI09=\DN
MYW#%M4B %RE<BZPTF,(-5X4H%AHFJ&"ZY H/F7!4R&$3J#[ +)%^"M&))#D(
M>15TM$$'"IG!?$:2MW%SA&^PX]2A9XMO8U"Z,0BW!JV(4%N#0&A(-GX@ JYA
M+C-J//JR]NBD["?B(9T^0Q76QM:\_V!5&U-+%44B<W+)"Q>9K1XP$NB$; 4J
M[>3;4F8I*@VG)[[O_Z3/X+0H<U3<2'4&)Q!&7L?OT()Y42NB;QQY[7:[]NR:
M#:;G_(6(%PB$LK(I[%ONUAO$-\5"4MNH&+*PZ47MP O;+6 L\EB[Y75BG\X#
MKQ-UZ*Y3J]+FG6??LSP!_R*(W,</W"?\#H4^H\)$&BR,X-D6M,?%.@VX$IJT
M@[F2.=!+HPUEA3VHKN7*UH#V8,V5XH71+FG*X@6U38J'Z9.N!;['0N:UX@[$
M7C-N>BQFT/'B@#P=A[5':=[$G^\2[A_N;#:]V&]Z/H6&A:'7;@4>:S$Z#RA*
MS M:K'9]*%7W77+(GQ$<:0?1KAU$W],.MHI\E;IJ ,-*B0_[P%'NQ_O )ZH_
M!,^15N7I8H=)J801Y/ UDE_P-<E*BW51MK3)>XNV0<FL1?]RZPP37FJTA(05
MBG+ B'.'H3$ <#ZGN8#:PM2ES'V5,A!Y,06/ EA[H&11(K$"*I*G0E F4<3;
M;4H85GO>)I=-&9]1H;9JU*88"[P6ZQR,8&/OG:8J7[AIA!J6+ M3/=F[T]W
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MRBK0][649C^Q#KH7U.Q?4$L#!!0    ( !.(9UF;[A79. ,  -0&   9
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M-+P8#3RJNAG:*48V;FZMI<$IZ,0M_G9 60?<+Z4T>\4F./S(9C\ 4$L#!!0
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MVO2W"PLS4%':!'.>"U-"N[ "W8A._@%02P,$%     @ $XAG6=@5RJW-!0
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MM.@XFFF7OBIH#$,7^T&!? %W='X6=/SK$URCFFMT"GTTIV]8^UJ1)_R9DLP
M2X\\K%BVH::<U3&^)Q&/\UU@ER<E@X04^X2E3:A3(%.1%Y2_G9]UP^#J6A%F
M28AW$H1*(%21M6#8W8HT,HZ!HE24)^JB[SR"F0L&3JSM(SJ?G([?<GX"E01,
ME9 ;B"%?H4<KL._<=L)F% 8.FATT@_:5,?'3]"-[VC5FMVO,GG'P>\XR!1Q(
M:PW2B= M=)9"4U8K<H)V,^H$S@R4ZI,L+TJ-B3.._J"TT\!;Y'3A3$LIT9\4
M0AIU3B-H!CUS,:&,\AB5:H(EJ7=\=W6)DKK-;J=-CCVZ=]"9.<B-G3^*Q*+D
MNFK2^K0><>.JL]_=J_EX3^4FX^81UACJ7UZU72*KF5-MM"ALGZ^$QJEAS13'
M-$CC@/=K(?1^8Q+4@W_T%U!+ P04    "  3B&=94:6:PQ0#  "K!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RM55%OVC 0?N=7G+)JZJ2N"0':
MC@$2I: BM065=GV8]F"2@UAS[-1V2O?O=W9HVFJ4IST0G^V[[[ZS?1^]C=*_
M389HX3D7TO2#S-JB&X8FR3!GYE@5*&EGI73.+$WU.C2%1I;ZH%R$<12=A#GC
M,ACT_-I<#WJJM()+G&LP99XS_><<A=KT@V;PLG#+UYEU"^&@5[ U+M#>%W--
ML[!&27F.TG E0>.J'PR;W?.V\_<./SANS!L;7"5+I7Z[R33M!Y$CA (3ZQ 8
M#4\X0B$<$-%XW&(&=4H7^-9^09_XVJF6)3,X4N*!IS;K!V<!I+ABI;"W:G.)
MVWHZ#B]1PO@O;"K?DRB I#16Y=M@8I!S68WL>7L.;P+./@J(MP&QYUTE\BPO
MF&6#GE8;T,Z;T)SA2_711(Y+=RD+JVF74YP=+.[G\ZOQ]?CF;G@%%]/%Z&JV
MN+\=PVP"H^'B$B97LP>8WDQFM]?#N^GL!@[OV%*@^=(++:5W(&&R375>I8H_
M2/4-KI6TF8&Q3#%]'Q\2[9I[_,+]/-X+N,#B&%K1$<11W-Z#UZK/HN7Q6O_K
M+'X.E\9J>EB_=IU&E:R].YEKMJXI6(+]@+K)H'["8/#Y4_,D^KZGE'9=2GL?
M^F!1%H5 :A[+!(R8R6!"[0=36;4Q]<,NQGLQ=S-^ERAQB58N$7]-!&2!S1 D
MX4%>/0%T3P#H BWF2]3U+0*3J3-:P TP0[&"X$RWX3;=I]4XG$J"4Z4A5_.E
M\>[2=EY3M^$/H& \]5RXM$C\;>.@<7K4;I[2V&P=G7T[^<<O43F"9<]HX #.
MR*5#X]?&C9*^T@F73"9<KCWKJ7PB4#<;.J7AEB/Q'C^6O'#'0_I#IJ:J27:<
M)I'%G2HEJI364-H_KK$\%"WJDO8%9TLN/!*1;'=B^L:G4>.!:<U<$#>FK' 2
M)>56Z#;<9B"5Q5=08DV_SE&'*MCUNL(W I*C7GN9-."I55I2K]9*/*P$Z-6]
MDO%KIM=<&A"XHM#H^+03@*ZDL9I857@Y6BI+XN;-C/Y-4#L'VE\IHKZ=N 3U
M_]/@+U!+ P04    "  3B&=90'H1,'8#   ]"@  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6RM5FV/VC@0_BM6NJI:Z;1Q$B"P!Y%XZ;9\*+M:NJUT
MI_M@DH%8=>+4=J ]]<?7=D+*0C8ZK>X+V,[,,\\S'MLS/G#Q5:8 "GW/6"XG
M3JI4<>.Z,DXA(_*:%Y#K+ULN,J+T5.Q<60@@B77*F.MC/' S0G,G&MNU>Q&-
M>:D8S>%>(%EF&1$_9L#X8>)XSG'A@>Y291;<:%R0':Q!/1;W0L_<!B6A&>22
M\AP)V$Z<J7<S][!QL!:?*1SDR1@9*1O.OYK),IDXV# "!K$R$$3_[6$.C!DD
MS>-;#>HT,8WCZ?B(?FO%:S$;(F'.V1>:J'3B#!V4P):43#WPPP>H!?4-7LR9
MM+_H4-MB!\6E5#RKG36#C.;5/_E>)^+$(1@]X^#7#OZ9@^\_XQ#4#H$56C&S
MLA9$D6@L^ $)8ZW1S,#FQGIK-30WV[A60G^EVD]%=P_OIZOE7]-/R[L5FJX6
M:/:X7J[>K=?HS0(4H4R^15>(YNA3RDM)\D2.7:7C&F\WKF/,JAC^,S%&Z"//
M52K1NSR!Y*F_J_DVI/TCZ9G?";B&XAH%^ _D8[^''M<+].;J+;H7/"ECA6Y)
M3!E5/UJ(SKMQ%Q!K7,_B!D?<#KY!D^3 X@;/)5GL2$[_)57AY@F:E5*;2(G^
MGFZD$KJ6_VE+:X7::T<U!_Q&%B2&B:-/L 2Q!R=Z_<H;X#_;I/]/8$\2T&L2
MT.M"CU9EM@&!^!85C,B,(%VVQX.\K;:+@D2EK@^!2%$(OB?,9BJ!O;YJ"GUQ
M*/2S:VMG%8.^96 NKWWDX;&[/TU!)\D7IJ#?I*#_'U-PNYC6&B%!15VT/X_E
MVR:M?R$M.%/6&?N%R@:-LD&GLB_ZGJ;Y#L6DH(JP-@$5P.!$@!\& 3[?G\XX
M+U01-BK"3A5S(E-;<;$9P+>2ZA+45==ZWX47&S(<A#@\DQ->J.Y[0=]OK)[P
M'#8\AYT\IW',2TU+OZ$Q:(X;!FT,AQ<,^]CKG2?\TLH/>[[7SG#4,!QU,ESF
M>YTW+O2);F,VNCRGH3?$WAFU-C-_A ?MW#S\^[W#W?M<"F$N$T;)IKYW6E\T
M?+%YO=YP=,ZRS6PTO&#IGCS0&8B=[5LDLCM9O=7-:M,;36U'X/XVKQJKCT3L
M:"X1@ZUVQ=>A3I&H>I5JHGAAG_L-5[IYL,-4]W<@C('^ON5<'2<F0-,Q1K\
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M$&*2%^#?;[.,O9[D 8[_OS#]'U!+ P04    "  3B&=9T9^HV7L#  #U#0
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MW*A[&7)MH-ZO&)/'CA[ WO2&_P!02P,$%     @ $XAG6:WDN6'D @  .0H
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M236@S3%12QJY-E#W"\;D5M .ZK4?_ 502P,$%     @ $XAG67# PP:+!P
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MC".Q*0K,WT:0L^W :3C[A3E99U(ON$&_Q&N(02[*&5<SMT9)20%4$$81A]7
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MV%5Y+BB1 IW-XX4XM]:H%?>#!]ZM67=/4:/=$U#NU91[)ZI1.ZZE1MV#M[P
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MP)2!W%]0*G83Y:!H%YU_4$L#!!0    ( !.(9UF#>@NHBP(  ,<&   9
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;*U576^;,!3]*Q:KIE9:"YB/)!U!
M:I-6[<.Z*NG'P[0'!VZ"58.9[83NW\\&BM*$1GW8"_C:]QR?@WTO4<7%B\P
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M=3]''8Z@VSEV,V@+HX(B 56D!L4S=S!QT6W ]OK\S(*?6]EO"-O1M?U909*
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ME'U<<3;G,CU ?[\00CUMI +[%S2&_P-02P,$%     @ $XAG6;E2M*Y5 @
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MX3GO6'.0QJGU7?XC%FP#;7H#VO3>)7,QJ1=B<W-/9X/M<U#HTFVP:YQWCGR
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M0O]E"!539,7$$ESJF12"*4TJ4#7&5HKZB(-.<GX/,PON,3P9MD$P: D&+R/
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M;Z-&&(7_RLBMVEUI-X;AZFUB*6NN;5>[W>Q%5=4/Q)[8:#&X@)/LOR]@ A[
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M;4>,E^8[7?D))TFV,[,@G),H._0!+X&F'<3U%2%\>Y(Z*/<;A_\#4$L#!!0
M   ( !.(9UDG;Q&&NP0  $(?   9    >&PO=V]R:W-H965T<R]S:&5E=#4S
M+GAM;+696W/B-A3'OXK&W>GLSK3Q!4Q""LP0++>9*2P3LNG#3A\4$.");7DE
M$9*9?OA*MC&8."ITS[Z +SH_7?[2D75.;\OXDUA3*M%+$J>B;ZVES*YM6\S7
M-"'B@F4T56^6C"=$JEN^LD7&*5GD1DEL>X[3L1,2I=:@ES^;\D&/;60<I73*
MD=@D">&O-S1FV[[E6KL'=]%J+?4#>]#+R(K.J/R23;FZLRO*(DIH*B*6(DZ7
M?6OH7H=N1QOD)1XBNA4'UTAWY9&Q)WUSN^A;CFX1C>E<:@11?\]T1.-8DU0[
MOI50JZI3&QY>[^AAWGG5F4<BZ(C%?T4+N>Y;5Q9:T"79Q/*.;?^@98=\S9NS
M6.2_:%N4];L6FF^$9$EIK%J01&GQ3U[*@3@P\+QW#+S2P#O5H%4:M$XU:)<&
M[2.#5N<= [\T\$^MH5,:Y&+:Q6#E(QT0208]SK:(Z]**IB]RN7)K-<!1JF?6
M3'+U-E)V<C#Z/![?WH_QY'Z&AI, C3Y/[F\GO^/)Z!;/T,> 2A+%XA/Z@*(4
MW:_91I!T(7JV5'5K@CTOZQD5]7COU--"8Y;*M4 X7=!%@STVVW<-]K;J<]5Q
M;]?Q&\\('&;\ CGN+\ASW"[Z,@O0QP^?FOIEQLQH=H%:CL9X;0,F.!W3,F#P
M_V@-NJ<\02&91W$D7QN@X7>WK:9 JYIZK9S;>H?[0-,%XTC-)_1G-%?.2MV,
M6))$4GDN*=#7X:.07+F>OQO:?%.PV\UL[8^O14;FM&\IARLH?Z;6X.>?W([S
M6Y/&D+  $H8A82$0K*9VNU*[;:(/IC$1"5$[6);%KXBL.*5:9B35Y&S2UT@[
M5U](6  )P^9!<QWT2@EO\K<A4#-J8OJ5F+YQZ4Z9D+^."7^B,DI79ZQ:'U)5
M2%@ "<.0L! (5A.Z4PG=,4[ .T4D?+[.O71 G]67:)8O6_RBOFT%;=*X('9R
MHOZP?1[XCM.SGP^E>UNF[7KU,D$#I]NIE\%OR[AM[P@4OBWD7?GMJE!M8"ZK
M@;DT#LQP-L*3VP?T=4R31\H;)[N1<.YDAX0%D# ,"0N!8#5-KRI-KWZ,5[N"
M%!H2%D#","0L!(+5A.Y60G?!O9J1>*[&D+  $H:[;QVJ<^R]P[>%.@=E:I*X
MSOX@ZAA%4><P%Y5?B=.-4H<(BH;5=Z+)T9K)YXH#2@M :1B4%D+1ZHH?A![<
M'W@ +.%0HD/2 E :!J6%4+2ZZ-Y>=,^XS"<;O8P16R).4[HE<7X"%.B?/$S1
M*+01>+;0D+0 E(9+FG_XI7KD>J$JK*NW#]FXQAC![A2?[?SS_AR_4S.C/&)-
M ;X;,_IL'4%C-J T_!^#Z+]_J(=J1UW>?8S&-<<;3MR#U6(=DY<HV23F;1DT
MA@-*"T!I&)060M'JDV ?VW'-P9WOW)9!0SR@M "4AD%I(12M+OH^SN.: SW[
M;3DKEO^<Q;OLW[)('414[]*&/,*-N8ZSM8>D!: T7-(.=VK_>*<&JK 0U#Y(
M\264K_)DK% J;5)9I%RJIU7"=YBG.8^>C]SKP&UXCG6".$\I[O%%=GE,^"I*
M!8KI4E7E7%RJ7O,B85O<2);E"<9')B5+\LLU)0O*=0'U?LF8W-WH"JJT^>!?
M4$L#!!0    ( !.(9UGUS3?(TPD  .=*   9    >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;+5<76_C-A;]*X);+#) ,Q8_1$G9Q$!B2>T FYE!/--=H.B#
M8C.)4%MR)3F9+OKC2\F.:9$WM*VA7Q);/CS4O9>\Y"$I7;X4Y1_5$^>U\VTQ
MSZNKP5-=+R^&PVKZQ!=I];Y8\ES\\E"4B[067\O'8;4L>3IK"RWF0^RZ;+A(
MLWPPNFRO?2Y'E\6JGF<Y_UPZU6JQ2,N_;OB\>+D:H,'KA;OL\:EN+@Q'E\OT
MD4]X_77YN13?AEN66;;@>945N5/RAZO!-;I(:-@4:!&_9OREVOGL-*;<%\4?
MS9</LZN!V]P1G_-IW5"DXM\S'_/YO&$2]_'GAG2PK;,IN/OYE3UIC1?&W*<5
M'Q?S_V:S^NEJ$ R<&7](5_/ZKGCYA6\,\AJ^:3&OVK_.RQK+O($S755UL=@4
M%G>PR/+U__3;QA$[!0AZHP#>%,!* 8S?*$ V!8A:@_M& ;HI0 ^MP=L4\ XM
MP#8%6.O[M;-:3T=IG8XNR^+%*1NT8&L^M.%J2PL'9WG3LB9U*7[-1+EZ-(E_
MOHT_?IDX9Q&OTVQ>O7-^=++<^?)4K*HTGU67PUI4TX"'TPWES9H2OT%)G-LB
MKY\J)\YG? :4C\SE0T/YH3!O:R-^M?$&&PDG?/G>(>Y/#G8Q=;Y.(N?LQW=.
MDDZS>5;_!=S@^' ^\LH'V=GGMB;\473<&J"+[=Q58J:)^%30(!--)PADV]!(
MRTO>O+W6+N>.+XNRSO)'YT.^3HQ-@OGM^KZJ2Y%F?H?:VYJ9PLQ-[KVHENF4
M7PU$<JUX^<P'HW_]@)C[;RBV-LDBFV2Q3;+$$EDGUG0;:VIB'WU<+>YYZ10/
M3A)=G\^SJ1B)^,Q9SM-JD3HB9;V.*P_K/ICQROG;U"%OUO5Y;7W-8/D\0N[E
M\'DWKL9;.C:N-LEBFV2));).7+UM7+T#XRIF-F7:]N)JW:^; +Z=NFZ,O,?V
M8)MDD:>U+-QM6+'-ZA)+9)WPL6WXF#%\=_R9YRL.#NGKDFRW@Z$P(*'2R708
M\['O=5&1CB)N$+H*+ ;J#"A!J M+C$;U=)F_=9EO=-FXJ.JFO2_+8K::UF(N
MW;H0\J"O-23FHD#-4CJ*8H:5)A?I*.1A%J@.!&"844^!)483>SHPV#HP,#KP
M0SXM%MPYFQ>5F%H^E,7B-7<4.=@0 \TF$C(2*&[448'FGD@'(:&WF!*26(?Y
M)%0:?F*TLJ</PZT/PST^K+E@K1TQ'W>*^DFDX#/^;=D,JN_$7+UQ\$].SL'$
M&VK&G>,@4+LU@&((*XZ* %3(/(4K!E#(#T.B.-1H<D^'(E>J'M?LTH_C3[>Q
M<_:?3Y/).^<F3C[=Q<[FXI?K_\434/:X>MMD/E6="<"PQ]3&":!"T3R5Y!<#
ML'/D>B%5W&FVMZ\_=U0D,N?)=)G5Z=QIF^4LJU<E/,R8:8Z="%AEBS9LNZ[V
M*%.;-X BGJ^%P]*==<.!93BP,1P1%[33;*VMFJR1+AK1]?_UA4WN ..#]9P9
M4G40 U#857MX!* 8TALX@,)8S19F>_OZ4VI79)1+HR]%T[C3JN(UW*P),&JY
M#*G#%H2C01CZJNL.XXL/Y$LVN,Z,#(<HD/..KF.DT$-FI?<USVJA["9U6@L-
M]]LM;P0"J.'-1$?W?*MJSRI;;)4ML<76#;!4?,@[V;(-LJKZK+)%5MEBJVR)
M+;9NR*5*1/UEXJ9H9WQ U*=:HM-QC&KY*P)@.!2#KBITH&K%)%V=H29FR_IZ
M3HI%9%:+[40];[N&&"Z,V="2)MMXVR9;9)4MMLJ6V&+K!EB*612<+AM:DI";
MD-MDBZRRQ5;9$EMLW9!+[8W,XMN8#76MZ[DA4G.ACL+,TZ9\.@H1JDZ]8PCF
M$K7.Q&Q43Z=A*:^Q65Z/BU)T$#$G-"9!,\FQ/<(J6V25+;;*EMABZP97:GV,
M3I8$L57];Y4MLLH66V5+;+%U0R[7$[!Y/<&4!+$NX E34N !F C (%?)DO$A
MH,1L3%]GR<4";%XL.&+/ .OZ75UKV0^)]D/B_9#$;%5?K\F5!&Q>23AZHP#K
M>\+G3(@'U7\ S&/JHFT$P5#HJK@8Q#&DXA*SM7V]*64[-N_4?L^6 =:W1,]Q
M0#S5L0#,"WW-L0 L]+1-& B&_$!;"#3;W=>O4AMCLS;NM6^ =?5Z'OK:)@P$
M0XAA531#.!PP5VNJ (Z0T,>J2T\AFK$4S7C/%NN!6P=FFJ.G#E8E,]9W8K4&
MOA>2V+JG;B"DN,7FK=K>FP98WT'51K&]D&@_)-X/2<PV]O6A5(O8K!;W;11@
M7;Z%;NBKDA& >6Z D>JR@]CBP]@2LVD]74>D9B1FS?AI>Z1H\GJDZ%4\.G\[
MU]'MM7.3%;=IOGH0ZF)5-DB3NC17=_2I0:OJTBI;;)4ML<76;09279+3J4MB
M55U:98NLLL56V1);;-V02W5)^JM+ @@^1-Q W7  <(QY3%UE V X#(EVL@JJ
MUO>T(VR)V;*^GMLY4VU-:A)= 7K8)^K( \ H\@E5_:C#$,5(/0,00S@4^&Z@
M^O$4XI-(\4DLBT^BRT :$.JKW@3.+7LNTEHE ,/$]YCJ31W7K"2KZQ]F8_LZ
M4VI/<CKM22!1J4IZ"(2H.CF"4*'6ST'9J4XJS0;W=:@4G>0$HI/HZH\&6.V@
M8P"&:."KBW,0#!/&U*DF@,.,:BMT9H/[.E1*3F)'<IIICIY/6)6<1->3'F%4
MC0=P1-AG6O8]A? D4GB2$PE/ ISP1=I980B% _7(-8 B+- R,( *U+V\Q&QO
M7W]*$4J^3X02:$.2476X&8,X[*GY.#J0+SZ0+S&;U_?9)2E$Z?<(T<_KAYC&
M\B&F,6\&///I-W.5QV82JVR15;;8*EMBBZW;%*08I:<3H]2J&+7*%EEEBZVR
M);;8NB&78I3V%Z,4$)D^4C=&0)0ZW "@D")5/@$H,8=3]YK,%O7UF!2AU)H(
MI;H<]*GV  6 "E3!'P$@Y-)0?7@/JM%7=5IBMK"O!W<>E[4L/RFT"^FK#WZ-
M(1@+U'/Z$(JZJH]B"$9<K#7&4XA/*L4G/9WXI+H8U!XRW@N) ,BY.BW?3Y.8
M[>SK1ZDYZ0DT)X5V,(%F"<" 9@F@J.NIBA."0<WR%(J32L5)[2A.,\W1DP:K
MBI,"6E)[IA<"!2Y3HW$*P4FEX*0G$IP4>.[4Q6KS!D#J0\T1 ,)4G4K$$(HP
MS9NGD)M4RDWZ?7)S4[SS\!%!VC%9".;ICT8?QA8?QI:833O6=<.=]_ L>/G8
MOC&I<J;%*J_7;TK97MV^E>FZ?1>1<OT&78P1<#U"%_'ZG4N2?OT*J-NT?,SR
MRIGS!U&5^]X7;:9<OU5I_:4NENU;@.Z+NBX6[<<GGLYXV0#$[P]%4;]^:2K8
MOMMJ] ]02P,$%     @ $XAG692-IV M!0  L!\  !D   !X;"]W;W)K<VAE
M971S+W-H965T-34N>&ULK5EM;^(X&/PK%K<Z[4JW)0Y)@!Y%*I#<5>I>J]+>
MZG2Z#P8>(-J\K6WZ\N_/3M) B.L-77]I2? S$\\XM@>/GE+ZC6T!.'J.HX1=
M=+:<9^?=+EMN(2;L+,T@$=^L4QH3+B[IILLR"F25%\51U[8LKQN3,.F,1_F]
M6SH>I3L>A0G<4L1V<4SHRP2B].FB@SNO-^["S9;+&]WQ*",;F -_R&ZIN.I6
M**LPAH2%:8(HK"\ZE_@\P$-9D+?X.X0G=O 9R:XLTO2;O+A:770L^400P9)+
M""+^/<(4HD@BB>?X7H)V*DY9>/CY%3W(.R\ZLR ,IFGT-5SQ[45GT$$K6)-=
MQ._2IS^A[) K\99IQ/*_Z*EHZ_8Z:+EC/(W+8O$$<9@4_\ES*<1!@<!1%]AE
M@7U<X+Q1T"L+>FT9G++ :<O@E@5NVP*O+/!R[0NQ<J5GA)/QB*9/B,K6 DU^
MR.W*JX7 82)'UIQ3\6THZOCXVK^<^^AF<GWUQ^7]U<U?<_1Q!IR$$?N$/J.'
M^0Q]_/ )?4!A@NZWZ8Z19,5&72Z897UW6;),"A;[#98>^I(F?,N0GZQ@I:B?
MZ>N'FOJNZ''5;?NUVQ-;"SB'[ SUK-^0;=F.XGFF[<M[JN[\'+O_<^R!OGP&
M2U&.5>4U+7O5$.KE>+W60^C?RP7C5$P:_ZF&2H'FJ-'D3'K.,K*$BXZ8*AG0
M1^B,?_T%>];O*I],@LU,@ODFP0)#8#5_G<I?1X<^OMQL*&P(!Q2!F,,1/(ME
MC8'*V@+(RX'DFO8X]BQKU'T\=*Q%FUFS#1X<-_+;- JT77NG<&XEG*L5;DK8
M%F7D12S$G"&Q"R@$5 E7 +E:X=P6PC5Q%,(U@13":;OV3N&\2CA/*]Q-!I3P
M,-D@L=R@=9B09"FOBO$7A6011B$/0;D2><W>6;@AIO8!3ITW6E'Z)BD#%>6A
MB37=^Y7N?:WN7_-]&*P0>10&;$!L'>7F5$K/@<8JM?6 ??0"A*ILFFH+3S7@
MO4_AFWR*P!!8S;I!9=U NPC?ODXS#V*'1-%U_J;<+*)03-QB!\]^L"8/3*[)
M)L%F)L%\DV"!(;":W</*[J%V2-_E+Z9T.EV_M8N<#!4+1N]H'M32G.I5"T+?
M)&%@"*QF ;;VT<G2FO"/F%40R$2"Q)X:XH6PH]Q7N\J,9#569]NQ\9$C>M)3
M+6G%Z1OE#$RAU6TY2+18:XN0WU/*CYM28+=_++\6_&3YVW#Z1CD#4VAU^>V]
M_/:/Y.\KY;>;4EA.8_1KP4^6OPVG;Y0S,(56EW\?QK$V"TKY!TKY>PHI!H-C
M^8WFZ5:<OE'.P!1:7?Y]5L;ZL"SD'RKE=Q03@34\EM]07"WE;\/I&^4,3*'5
MY=\G;JR/W/=;H$#6(JTH36C&8\=R[&,3#$7?TH0VG+Y1SL 46MV$?7K'^OA^
MGW(253]\*(WPFK]3N([76 R,IO1VI+Y1TL 46MV*?:#'^NA[#8R=HS#.=C+6
MAXEX,8!QI27]ACJ?7:>1%_1\)UO2BM0W2AJ80JM;L@_J6!L,Q],=I>*]0%E*
M93)7>C%HRH+QL.&%T:#=CM0W2AHH22W'5?^.A??Q&.OS\81$)%D"(AS-(>-E
M-GO[Q&6"F]EU,/#<8\6-QN56G+Y1SD#!.>SWAT=Z=P\.%&.@F_SHEZ%ENDMX
M<3!4W:V.ER_S0]6C^Q-\/L6*^S-\[A>'QWOXXBS["Z&;,&$H@K6@LL[Z8FS0
MXGBXN.!IEA]G+E+.TSC_N 6R BH;B._7:<I?+R1!=4@__A]02P,$%     @
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MY4.>([TZDZU4GW4.8-!#P86>1KDQY7D<ZS2'@NJ.+$'8.RNI"FKLJ5K'NE1
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MW.U;.B#M^)($3FY4I&Q 'LX^_IX7^OI#X.XGGTY.6@_GU[OQ,PN<D] K>G6
MZ$7+7*BR13'Y^##Y?>*8=/<@Z3W*F'!O6]B./C4ZCG>*T1(/S=A?,Z&#D+LM
M+WF#:HEA72C#?E;(=;U$Q 6,,LU9\$C%@(RHX&/%@971G(NE"W<@,"E$H0)M
M"M6D:D.D>G)PV_6@AFN=G,M"V=PN@_L]KH?O *L>&.1"- 8[Q 6&_9)JS92\
M,1T[V 9?0$'=OE^6QN%4T66[<T76!'LS2<:%2IEJTK3)*C3L"Y:!'<6G,[CK
MH@P!U+K(32/E=%I(:CVL&'7#R$Z8$'?P@/_*MK07V<:>V1V33=,8JIM.QG5
M?U/-:6_*7KY*-RCY8Z&_SLUTI.U#8;-;Q3*^L/U%UAC U-NX.BU+L?PB^%3F
MS$W^X(3#/EWQ@EFA^)/)!J4R,0&F2/#(E.:3S<@?1<M[MM"K<EIDN.?.$7K^
MM^L\99(I*C9-F]I_SZO\:L=1]ZTLVV^57<->C_5;^[V;O#H&D_$QF#R*FNP=
M@\GD"$QVW^Q;\W"3T?M<R+ ^"6T<M[8.6TTT@$/M@/R$X[%8)PW&<RXTEW5O
MQM.4R1=G+B.OZ=C\J;:E;\:G+*-SH>\;<$#6[1\LY?,\:4;=PD+4H];M[S"]
M=MR<J$TN+E.V8.FH[JKIV#8#TS!9ZPL(N\B-O?P(QG&8'P$,RX,YP#B.A>7Y
MG^;30^?C,,Q;SXOT4$X/Y3B6#QG9#Y;'STG,Y9]IDD11'&,K.AIY'8RP=8MC
M^/&K8=Z @>6!3'^WUOANXQ6ROPZP/=U7(=A,\4K$9HJO-2#^=0-&DOAW&\L#
M#&P7L-J!_/X\4%-^3A3!KF+>L"<81Y($0Z 6_34:Q\CJQ/#Q[P_VE$11DO@1
MP/P.H@A#X&G$$<P!>,"0*++OP9WW4;AZ3X7K_U\.GP%02P,$%     @ $XAG
M69>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(
M,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5
MN %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;
M+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%
MR=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M    "  3B&=9R%!.2]H$  !?)@  #P   'AL+W=O<FMB;V]K+GAM;,6:6V^C
M.!2 _XJ5E^U*U2;<>M-D))>X*5H"64RZTWVI:.*D:+AD#)EVYM>O(9-9,Z%'
M^W*4IP2#S(>Q_9UC\^&UE)^?R_(S><NSHAH/7NIZ>S,<5LL7D2?5'^56%.K,
MNI1Y4JM#N1E66RF25?4B1)UG0W,TNACF25H,/GXXU#670_V@K,6R3LM"%38%
M#ZEXK?X[WQR2KVF5/J=96G\;#]K_F1B0/"W2//TN5N/!:$"JE_+UOI3I][*H
MDXPO99EEXX&Q/_$@9)TNCXIY QDGSU5;4B?/4:) QH.+D:IPG<JJ;J]HZT\4
MXU>A+MX?[>KR+LUJ(2=)+::RW&W38M-4HYYBJ#U&VPZ'WWTCWLC_TXSE>ITN
MQ:1<[G)1U/MVE")K (OJ)=U6 U(DN1@/#I>0I%@15M2JD8A7[*M2US9/JF[M
MK?9/72M<K0WE3:I.2&_5@N-!NF$P80%G$Z+^\=#W)C16![?4IX'+B 9I I#F
M"2&?3 W2 B"MDT#R6/W,6*!!V@"D?4+(3DLZ *1S2DA+@[P ("]P(<-H2@/O
M'QI[84!HH'KC@GL!XUS#NP3P+G'Q^&(VH]$C">\(]Z:!=^>Y-(@)==UP$<2>
M!GD%0%[A0GK! POB,/*8WFK7 - U-E!,@ZEWZS-".6>QCF6,H%EZA LVC\(Y
MB^+'MJ>QOQ;>7$TIL4X'.@19(JI710LU0MFG>3-N>4L9QO<L(NXBBG1,R"(&
MLD8F[+;39) L#&1;\#AT_[P/_0F+^&_M&XT?=3;($0:R)"+FMQ/NG#8]+HYH
MP*G;S'.=X0 )PD WQ&SFQ<T0V/<UY8G8"Z8L<+M3B0$)PD V!&?3EE#G@8Q@
M("O!9Y0S$M[ZWI0>O4W( @:Z!M3[9"2FG[HO#Q*!@6P"OIC/_29NBZE/)AYW
M_9 O(M;XU*7\7H^+(2^8R%[P NZI*:09I!,U  B-U&B=LE_[G0G9P42V QB*
M=&).$\PQD.T 8^I1IPF)PT06AQ8SD3.5]6:B^EUG@\1A(HOC*'SJ)83$82*+
MHS^.ZL6$U&$BJP,,J+I#!C**B6R4)J#J;3O()B:R3?HBJUY(2"\FMEY^Q 9]
M8!8D% M9*$=!0B\AI!,+72> F;N+09!.+&2=O+L^0,XFHDYT3'#1"CL/ :UG
MZYB062QDL\"8CHX)Z<5"U@N,>:%C0GJQL#,3$/-2QX3T8IUR#>OI2L>$A&-A
M"P?$O-8Q(>58Z!G-^YA/[>+6S_5I2$ VLH!@3$/'A"QD(UNH$X8W$WJ:=11I
M0^ZQD=US%(>?$[[+\T1^:UEU3,@]-GHJ<X1YMZMW4A"ZV4BA8X);)LCN>2]G
M^/'6=4S(/3:R>^"<0<]?;<@]-K)[]CE#WXB!5&-CJZ8G:3@G<RG60DJQTC$A
MU=@GR&W.B5OF>5D0WAG8D&IL;-7T8OZ=2)D4=:5O*CN0:AQLU?1BLB^[_4Z]
MC@FIQD%6S?O+\;_.Y@XD'0=]DQY8DR=G.B8D'0<[X?F9>??,00[D&0?9,SVI
M=Q\BN#&/[!A]I?Y<#9%EF0L2)V^$O:E:=14ZD&,<9,=T,0-UEW KI+JNV!"_
M[&!"TG'0\QMH)4,WM@-)QVFE,SQ\T+02Z[00JT#=HE+ERR1;SB5I?O8;L+;3
M;*RL=UGFJK*P\,MD=?@^ZO!MU\=_ 5!+ P04    "  3B&=9$R?LNN\!  "E
M(@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=J[3NM %(7A5XG\
M $SV+< 1H:*A1;R %287D<26/0AX>Z)0A&51G ;-JJRQY>V_^F2-??>4]VW9
M=<=QN^O'V<=A?QR7S;:4_E]*XVJ;#^UXU?7Y>+JR[H9#6T[+89/Z=O7:;G+2
M^7R1AI\SFON[GS-GSY]]_I^)W7J]6^6';O5VR,?RR^#TW@VOXS;GTLR>VV&3
MR[))'_O+Z3&=#W)UFMS,'E^6S?#X(DVJ':00I/6##(*L?I!#D-</"@B*^D$+
M"%K4#[J&H.OZ03<0=%,_Z!:";NL'R1QEG!,D3; FT%J0:R'P6A!L(1!;D&PA
M,%L0;2%06Y!M(7!;$&XAD%N0;B&P6Q!O(=!;46\ET%M1;R706R<OVP1Z*^JM
M!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z*^JM!'H;ZFT$>AOJ;01Z&^IM
M!'K;9+.$0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T.]C4!O0[V-0&]'O9U ;T>]
MG4!O1[V=0&]'O9U ;Y]L=A/H[:BW$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z!VH
M=Q#H':AW$.@=J'<0Z!VH=Q#H':AW$.@=DX^5!'H'ZAT$>@?J'01Z!^H=?ZGW
M6#[W>;ST?*_Q^7])=3G=FR^//R^_3Z*$BS/."?Y*N?\"4$L#!!0    ( !.(
M9UEB(^<8V $  $@B   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:74^#,!0&
MX+^R<&M&UZ_Y$>>->JM>^ <JG TRH$W;S?GO+4Q--$I<9N)[ X&VYSVTR7/%
MY>.+HS#9M4T7%ED5H[M@+!05M2;DUE&71I;6MR:F1[]BSA1KLR(F9K,Y*VP7
MJ8O3V-?(KBYO:&DV39S<[M+K4-MND7EJ0C:YWD_LLQ:9<:ZI"Q/3.-MVY9>4
MZ5M"GE8.<T)5NW"2)F3LVX1^Y.> MW7W6_*^+FGR8'R\,VV:Q78-"_&EH9"/
ME_BF1[M<U@65MMBT:4D>G"=3AHHHMDV^+WHRGAS3#M/^RH_.'\J,!::9#]ZZ
MD$[,T^%Q[T?2KYZZ5(A\K,<_\2,QE3[Z^Z@_[9+*7V:G[7VV?CV<1V##[?@]
M_GS&'_4/[$. ]"%!^E @?6B0/N8@?9R"]'$&TL<Y2!]\AM((BJ@<A52.8BI'
M096CJ,I16.4HKG(46#F*K )%5H$BJT"15:#(*E!D%2BR"A19!8JL D56@2*K
M1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56BR*I09%4HLBH4616*K I%5H4B
MJT*15:'(JE!D52BR:A19-8JL&D56C2*K1I%5H\BJ4635*++J_Y3UR=KU7__;
MT-_SUM3=>SX;?B"Y>@502P$"% ,4    "  3B&=9!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !.(
M9UG=]7H&[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( !.(9UF97)PC$ 8  )PG   3              "
M <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ $XAG6?U*%3?!
M!0  Q!X  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( !.(9UET6%K_B08  -,:   8              "
M@00.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  3B&=9
MJ&'C@P$#  !3"@  &               @('#%   >&PO=V]R:W-H965T<R]S
M:&5E=#,N>&UL4$L! A0#%     @ $XAG6<_,">'*!@  -A\  !@
M     ("!^A<  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    (
M !.(9UE=ILPCL0P  'AL   8              " @?H>  !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6Q02P$"% ,4    "  3B&=9M<WUP[$&  !E&P  &
M            @('A*P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#
M%     @ $XAG69ZPH-54"0  4!8  !@              ("!R#(  'AL+W=O
M<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( !.(9UDC1!K)B!8   M!
M   8              " @5(\  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q0
M2P$"% ,4    "  3B&=90T;<8,T#   Y"   &               @($04P
M>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ $XAG69>4/4[)
M P  C0@  !D              ("!$U<  'AL+W=O<FMS:&5E=',O<VAE970Q
M,"YX;6Q02P$"% ,4    "  3B&=9,7W7FP,$  #]"   &0
M@($36P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( !.(
M9UGH40O._@(  .X&   9              " @4U?  !X;"]W;W)K<VAE971S
M+W-H965T,3(N>&UL4$L! A0#%     @ $XAG6;4FKN.A"0  *!D  !D
M         ("!@F(  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
M    "  3B&=9[EN:BZ8)  "!'0  &0              @(%:;   >&PO=V]R
M:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( !.(9UG@JTUL+ 4  "D,
M   9              " @3=V  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M4$L! A0#%     @ $XAG67U=B[%C"0  *Q@  !D              ("!FGL
M 'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    "  3B&=9$>0?
MBI\'  #1$@  &0              @($TA0  >&PO=V]R:W-H965T<R]S:&5E
M=#$W+GAM;%!+ 0(4 Q0    ( !.(9UD,D).HH00  , *   9
M  " @0J-  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @
M$XAG60N7O.+1!@  YP\  !D              ("!XI$  'AL+W=O<FMS:&5E
M=',O<VAE970Q.2YX;6Q02P$"% ,4    "  3B&=9;#0#L@H#  #E!@  &0
M            @('JF   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4
M Q0    ( !.(9UED/NX26P(  ) &   9              " @2N<  !X;"]W
M;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ $XAG65A['8Q9%P
MB4<  !D              ("!O9X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6Q02P$"% ,4    "  3B&=9"5 %KS8$   2"@  &0              @(%-
MM@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !.(9UF/
M6$'"GP(  )4%   9              " @;JZ  !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL4$L! A0#%     @ $XAG66@;2L/^ P  30D  !D
M     ("!D+T  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !.(9UG2BF&?P@4  /P.   9              "
M@4_1  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ $XAG
M61>@5;7C @  ! 8  !D              ("!2-<  'AL+W=O<FMS:&5E=',O
M<VAE970S,2YX;6Q02P$"% ,4    "  3B&=94:6:PQ0#  "K!@  &0
M        @(%BV@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0
M   ( !.(9UE >A$P=@,  #T*   9              " @:W=  !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ $XAG6>UC=H<#!@  RS
M !D              ("!6N$  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q0
M2P$"% ,4    "  3B&=9T9^HV7L#  #U#0  &0              @(&4YP
M>&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( !.(9UFMY+EA
MY (  #D*   9              " @4;K  !X;"]W;W)K<VAE971S+W-H965T
M,S8N>&UL4$L! A0#%     @ $XAG6>K:4G2K @   @@  !D
M ("!8>X  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  3
MB&=9<,##!HL'   N1P  &0              @(%#\0  >&PO=V]R:W-H965T
M<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !.(9UG"(M6F/@<  *,[   9
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M970T,RYX;6Q02P$"% ,4    "  3B&=9N5*TKE4"  #N!0  &0
M    @(&L#P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    (
M !.(9UD^;+'))P<  "M#   9              " @3@2 0!X;"]W;W)K<VAE
M971S+W-H965T-#4N>&UL4$L! A0#%     @ $XAG6<)/4*A  P  N0D  !D
M             ("!EAD! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"
M% ,4    "  3B&=9<;_J3?$)  "&6P  &0              @($-'0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( !.(9UEM^T/>=0(
M )0&   9              " @34G 0!X;"]W;W)K<VAE971S+W-H965T-#@N
M>&UL4$L! A0#%     @ $XAG6<V Z][+ @  8 @  !D              ("!
MX2D! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  3B&=9
M!L9[V34'  #V2   &0              @('C+ $ >&PO=V]R:W-H965T<R]S
M:&5E=#4P+GAM;%!+ 0(4 Q0    ( !.(9UF?@:8Z!PX  /F'   9
M      " @4\T 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%
M  @ $XAG63OYJC+>!   >QP  !D              ("!C4(! 'AL+W=O<FMS
M:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  3B&=9)V\1AKL$  !"'P
M&0              @(&B1P$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+
M 0(4 Q0    ( !.(9UGUS3?(TPD  .=*   9              " @91, 0!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ $XAG692-IV M
M!0  L!\  !D              ("!GE8! 'AL+W=O<FMS:&5E=',O<VAE970U
M-2YX;6Q02P$"% ,4    "  3B&=9:Y:M7^8"  ")"@  &0
M@($"7 $ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !.(
M9UF38%U0?P,  /X/   9              " @1]? 0!X;"]W;W)K<VAE971S
M+W-H965T-3<N>&UL4$L! A0#%     @ $XAG6;Y$>6PW P  %0D  !D
M         ("!U6(! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
M    "  3B&=9!$.<G4<#  #,%   #0              @ %#9@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !.(9UF7BKL<P    !,"   +
M  "  ;5I 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( !.(9UG(4$Y+V@0  %\F
M   /              "  9YJ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  3B&=9$R?LNN\!  "E(@  &@              @ &E;P$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  3B&=98B/G&-@!  !((@
M$P              @ ',<0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..0@!"  42  #5<P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>207</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Debt</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Segments</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligations</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061500 - Disclosure - INSIDER TRADING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InsiderTradingArrangements</Role>
      <ShortName>INSIDER TRADING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>080300 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Inventories</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>080400 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssets</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080700 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Debt</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/StockholdersEquity</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>081100 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Segments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>081400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusinessDetails</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090214 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090300 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/InventoriesTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsSummaryDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090700 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DebtDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/DebtTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>091100 - Disclosure - SEGMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsDetails</Role>
      <ShortName>SEGMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SegmentsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>091200 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>091300 - Disclosure - INCOME TAXES, Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAXES, Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>091302 - Disclosure - INCOME TAXES, Net Operating Losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails</Role>
      <ShortName>INCOME TAXES, Net Operating Losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ef20034474_10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>091400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adma-20240930.xsd</File>
    <File>adma-20240930_cal.xml</File>
    <File>adma-20240930_def.xml</File>
    <File>adma-20240930_lab.xml</File>
    <File>adma-20240930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ef20034474_10q.htm">ef20034474_10q.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="812">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20034474_10q.htm": {
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20240930",
   "dts": {
    "schema": {
     "local": [
      "adma-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "adma-20240930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20240930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20240930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20034474_10q.htm"
     ]
    }
   },
   "keyStandard": 256,
   "keyCustom": 54,
   "axisStandard": 26,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 25,
   "hidden": {
    "total": 16,
    "http://admabiologics.com/20240930": 4,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 7
   },
   "contextCount": 207,
   "entityCount": 1,
   "segmentCount": 62,
   "elementCount": 525,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 812,
    "http://xbrl.sec.gov/dei/2024": 29,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://admabiologics.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
     "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
     "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20221231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://admabiologics.com/role/OrganizationAndBusiness",
     "longName": "060100 - Disclosure - ORGANIZATION AND BUSINESS",
     "shortName": "ORGANIZATION AND BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "060200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://admabiologics.com/role/Inventories",
     "longName": "060300 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://admabiologics.com/role/IntangibleAssets",
     "longName": "060400 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://admabiologics.com/role/PropertyAndEquipment",
     "longName": "060500 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "longName": "060600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://admabiologics.com/role/Debt",
     "longName": "060700 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://admabiologics.com/role/StockholdersEquity",
     "longName": "060800 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://admabiologics.com/role/RelatedPartyTransactions",
     "longName": "060900 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://admabiologics.com/role/CommitmentsAndContingencies",
     "longName": "061000 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://admabiologics.com/role/Segments",
     "longName": "061100 - Disclosure - SEGMENTS",
     "shortName": "SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://admabiologics.com/role/LeaseObligations",
     "longName": "061200 - Disclosure - LEASE OBLIGATIONS",
     "shortName": "LEASE OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://admabiologics.com/role/IncomeTaxes",
     "longName": "061300 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation",
     "longName": "061400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://admabiologics.com/role/InsiderTradingArrangements",
     "longName": "061500 - Disclosure - INSIDER TRADING ARRANGEMENTS",
     "shortName": "INSIDER TRADING ARRANGEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "080200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://admabiologics.com/role/InventoriesTables",
     "longName": "080300 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://admabiologics.com/role/IntangibleAssetsTables",
     "longName": "080400 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://admabiologics.com/role/PropertyAndEquipmentTables",
     "longName": "080500 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "longName": "080600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://admabiologics.com/role/DebtTables",
     "longName": "080700 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://admabiologics.com/role/StockholdersEquityTables",
     "longName": "080800 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://admabiologics.com/role/SegmentsTables",
     "longName": "081100 - Disclosure - SEGMENTS (Tables)",
     "shortName": "SEGMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://admabiologics.com/role/LeaseObligationsTables",
     "longName": "081200 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables",
     "longName": "081400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://admabiologics.com/role/OrganizationAndBusinessDetails",
     "longName": "090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)",
     "shortName": "ORGANIZATION AND BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails",
     "longName": "090200 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
     "longName": "090202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails",
     "longName": "090204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:Goodwill",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "us-gaap:GoodwillImpairmentLoss",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails",
     "longName": "090206 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
     "longName": "090208 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember",
      "name": "adma:NumberOfCustomers",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
     "longName": "090210 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Earnings/loss Per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails",
     "longName": "090212 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails",
     "longName": "090214 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefits",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://admabiologics.com/role/InventoriesDetails",
     "longName": "090300 - Disclosure - INVENTORIES (Details)",
     "shortName": "INVENTORIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
     "longName": "090400 - Disclosure - INTANGIBLE ASSETS, Summary (Details)",
     "shortName": "INTANGIBLE ASSETS, Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails",
     "longName": "090402 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "shortName": "INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetails",
     "longName": "090500 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "longName": "090600 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://admabiologics.com/role/DebtDetails",
     "longName": "090700 - Disclosure - DEBT (Details)",
     "shortName": "DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c20231218",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231218",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails",
     "longName": "090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
     "longName": "090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240930",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
     "longName": "090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c20240314",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240314",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
     "longName": "090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
     "longName": "090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ProceedsFromIssuanceOfCommonStock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:ProceedsFromIssuanceOfCommonStock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
     "longName": "091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "adma:PlasmaSupplyAgreementTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://admabiologics.com/role/SegmentsDetails",
     "longName": "091100 - Disclosure - SEGMENTS (Details)",
     "shortName": "SEGMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://admabiologics.com/role/LeaseObligationsDetails",
     "longName": "091200 - Disclosure - LEASE OBLIGATIONS (Details)",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:OperatingLeaseExpense",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails",
     "longName": "091300 - Disclosure - INCOME TAXES, Income Tax Expense (Details)",
     "shortName": "INCOME TAXES, Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c20240701to20240930",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails",
     "longName": "091302 - Disclosure - INCOME TAXES, Net Operating Losses (Details)",
     "shortName": "INCOME TAXES, Net Operating Losses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails",
     "longName": "091400 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20240930",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20034474_10q.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "adma_ADMABioManufacturingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ADMABioManufacturingSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "ADMA BioManufacturing Segment [Member]",
        "terseLabel": "ADMA BioManufacturing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ASCENIVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ASCENIVMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASCENIV an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "ASCENIV [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r47",
      "r52",
      "r814"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r688"
     ]
    },
    "adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for contractual credits and doubtful accounts.",
        "label": "Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts",
        "terseLabel": "Accounts receivable, allowances for contractual credits and credit losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "adma_AccrualForUSMedicaidRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AccrualForUSMedicaidRebatesMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for U.S. Medicaid Rebates.",
        "label": "Accrual for U.S. Medicaid Rebates [Member]",
        "terseLabel": "Accrual for U.S. Medicaid Rebates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued incentives",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other current liabilities",
        "label": "Accrual adjustments",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "terseLabel": "Accrual adjustments",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities [Abstract]",
        "label": "Accrued Liabilities and Other Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued distribution fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "adma_AccruedRebatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AccruedRebatesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.",
        "label": "Accrued Rebates, Current",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued payroll and other compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r644"
     ]
    },
    "adma_AccruedTestingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AccruedTestingCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Testing, Current",
        "terseLabel": "Accrued testing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r129",
      "r501"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r688",
      "r873"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r739",
      "r740",
      "r741",
      "r742",
      "r820",
      "r874"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants issued in connection with note payable",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32",
      "r93"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r72",
      "r300",
      "r826"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r246",
      "r252",
      "r664"
     ]
    },
    "adma_AmortizationOfLicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AmortizationOfLicenseRevenue",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash revenue related to amortization of license revenue.",
        "label": "Amortization of License Revenue",
        "terseLabel": "Amortization of license revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "adma_AresCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AresCreditAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Ares Credit Agreement [Member]",
        "terseLabel": "Ares Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AresCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "AresCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Ares Credit Facility [Member]",
        "terseLabel": "Ares Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ArethLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ArethLLCMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "Areth, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Process [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total assets",
        "totalLabel": "TOTAL ASSETS",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r110",
      "r132",
      "r152",
      "r183",
      "r189",
      "r207",
      "r211",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r402",
      "r404",
      "r420",
      "r493",
      "r574",
      "r657",
      "r658",
      "r688",
      "r715",
      "r781",
      "r782",
      "r832"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r136",
      "r152",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r402",
      "r404",
      "r420",
      "r688",
      "r781",
      "r782",
      "r832"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "adma_BiotestLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "BiotestLicenseAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of license agreement.",
        "label": "Biotest License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r127",
      "r642"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents - beginning of period",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r77",
      "r149"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r77"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price per share (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to purchase shares of common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants outstanding (in shares)",
        "terseLabel": "Warrants outstanding (in shares)",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r102",
      "r495",
      "r561"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r265",
      "r266",
      "r624",
      "r769",
      "r774"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, available for issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r708",
      "r710",
      "r711",
      "r712",
      "r713",
      "r739",
      "r740",
      "r742",
      "r820",
      "r871",
      "r874"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r562"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r56",
      "r562",
      "r580",
      "r874",
      "r875"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized,236,378,607 and 226,063,032 shares issued and outstanding at September 30, 2024 and December 31, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r497",
      "r688"
     ]
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internally Developed Software [Member]",
        "label": "Computer Software, Intangible Asset [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r641",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r765",
      "r766"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r37",
      "r38",
      "r218",
      "r623"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r37",
      "r38",
      "r218",
      "r537",
      "r623"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r37",
      "r38",
      "r218",
      "r623",
      "r726"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of account receivables",
        "terseLabel": "Percentage of consolidated revenues",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r37",
      "r38",
      "r218"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r22",
      "r37",
      "r98",
      "r623"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r37",
      "r38",
      "r218",
      "r623"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r158",
      "r183",
      "r191",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r657",
      "r658",
      "r781",
      "r782"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r108",
      "r158",
      "r183",
      "r191",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r274",
      "r275",
      "r276",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r657",
      "r658",
      "r781",
      "r782"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r324"
     ]
    },
    "us-gaap_CorporateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate [Member]",
        "label": "Corporate Segment [Member]",
        "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "verboseLabel": "Cost of product revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r152",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r420",
      "r657",
      "r781"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Product Revenue [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Product Revenue",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r727"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r288",
      "r307",
      "r447",
      "r451",
      "r492",
      "r645",
      "r647"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r779"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r779",
      "r780"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r218"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_DebtInstrumentApplicableMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DebtInstrumentApplicableMargin",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the margin rate on the debt instrument.",
        "label": "Debt Instrument Applicable Margin",
        "terseLabel": "Applicable margin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r46",
      "r47",
      "r100",
      "r101",
      "r158",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r686",
      "r737",
      "r770",
      "r771",
      "r772",
      "r825",
      "r827"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r101",
      "r302"
     ]
    },
    "adma_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DebtInstrumentExitFee",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit fee of debt instrument.",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incurred fees and expenses",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frequency of periodic payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r42"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r303",
      "r427",
      "r428",
      "r686"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase applicable margin",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r286"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r686",
      "r737",
      "r825",
      "r827"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r133",
      "r666",
      "r821",
      "r822"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r158",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r686",
      "r737",
      "r770",
      "r771",
      "r772",
      "r825",
      "r827"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payments",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scheduled principal payments",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of prepaid principal amount",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r33",
      "r34",
      "r41",
      "r91",
      "r92",
      "r158",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r686",
      "r737",
      "r825",
      "r827"
     ]
    },
    "adma_DebtInstrumentTermOfVariableRate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DebtInstrumentTermOfVariableRate",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term of Variable Rate",
        "terseLabel": "Term of variable rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r824",
      "r825",
      "r827"
     ]
    },
    "us-gaap_DebtInstrumentVariableInterestRateTypeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentVariableInterestRateTypeExtensibleEnumeration",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]",
        "documentation": "Indicates type of variable interest rate on debt instrument."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, net of current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r728"
     ]
    },
    "adma_DeferredRevenueRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DeferredRevenueRemainingAmortizationPeriod",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_DepositsAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DepositsAndOtherNoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.",
        "label": "Deposits and Other Noncurrent Assets",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r30"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r183",
      "r194",
      "r211",
      "r657",
      "r658"
     ]
    },
    "adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.",
        "label": "Potentially dilutive securities not included in computation of diluted net loss per share (in shares)",
        "terseLabel": "Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r872"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r719"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings/loss Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)",
        "terseLabel": "Basic earnings per common shares (in dollars per share)",
        "label": "Basic earnings per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r173",
      "r175",
      "r177",
      "r178",
      "r179",
      "r182",
      "r397",
      "r400",
      "r414",
      "r415",
      "r488",
      "r506",
      "r650"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)",
        "terseLabel": "Diluted earnings per common share (in dollars per share)",
        "label": "Diluted earnings per share (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r175",
      "r177",
      "r178",
      "r179",
      "r182",
      "r397",
      "r400",
      "r414",
      "r415",
      "r488",
      "r506",
      "r650"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings/Loss Per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r372",
      "r678"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r372",
      "r388",
      "r678"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense, non option",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense, stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "adma_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "EmployeesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A group of person working with the entity.",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.",
        "label": "Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Equipment acquired reflected in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r121",
      "r140",
      "r141",
      "r142",
      "r159",
      "r160",
      "r161",
      "r163",
      "r168",
      "r170",
      "r172",
      "r184",
      "r225",
      "r226",
      "r258",
      "r319",
      "r386",
      "r387",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r431",
      "r440",
      "r505",
      "r531",
      "r532",
      "r533",
      "r547",
      "r604"
     ]
    },
    "adma_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.",
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r436"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r230",
      "r251",
      "r664"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Three",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Two",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets By Major Class Axis",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r455",
      "r456",
      "r637"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Aggregate Amortization Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r251",
      "r456",
      "r664"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r251",
      "r253",
      "r254",
      "r256",
      "r455",
      "r637",
      "r664"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r637"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r455",
      "r762"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of programs during the period",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "adma_FiveCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "FiveCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Five Customers [Member]",
        "terseLabel": "Five Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_FourCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "FourCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Four Customers [Member]",
        "terseLabel": "Four Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r735",
      "r767",
      "r768"
     ]
    },
    "adma_GenesisBPSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "GenesisBPSMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "GenesisBPS [Member]",
        "terseLabel": "Genesis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "verboseLabel": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r232",
      "r487",
      "r658",
      "r663",
      "r680",
      "r688",
      "r755",
      "r756"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r243",
      "r663"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Abstract]",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges related to goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r233",
      "r239",
      "r243",
      "r663",
      "r680"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r67",
      "r109",
      "r152",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r420",
      "r652",
      "r657",
      "r744",
      "r747",
      "r748",
      "r749",
      "r750",
      "r781"
     ]
    },
    "adma_HayfinCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "HayfinCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "HayfinWarrantsMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the hayfin closing date, the Company issued the hayfin warrant.",
        "label": "Hayfin Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r29",
      "r87",
      "r679"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r104",
      "r109",
      "r489",
      "r503",
      "r652",
      "r657",
      "r744",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r261",
      "r262",
      "r417",
      "r418",
      "r419",
      "r528",
      "r530",
      "r589",
      "r637",
      "r681",
      "r842"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r417",
      "r418",
      "r419",
      "r528",
      "r530",
      "r589",
      "r637",
      "r681",
      "r842"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r372",
      "r373",
      "r377",
      "r383",
      "r678",
      "r818"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r372",
      "r373",
      "r377",
      "r383",
      "r678",
      "r818"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES [Abstract]",
        "terseLabel": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r367",
      "r372",
      "r374",
      "r375",
      "r376",
      "r379",
      "r382",
      "r389",
      "r391",
      "r392",
      "r393",
      "r543",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense",
        "label": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r120",
      "r171",
      "r172",
      "r183",
      "r197",
      "r211",
      "r371",
      "r372",
      "r390",
      "r508",
      "r678"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r369",
      "r370",
      "r379",
      "r380",
      "r381",
      "r385",
      "r541"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r79",
      "r736",
      "r816",
      "r817"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "adma_IncreaseDecreaseInDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "IncreaseDecreaseInDepositsAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits and operating assets classified as other.",
        "label": "Increase (Decrease) in Deposits and Other Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current and non-current liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r255",
      "r257",
      "r636",
      "r637"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r762",
      "r764"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r734"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r146",
      "r147"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/InventoriesDetails",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r643",
      "r688"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r126",
      "r134",
      "r227",
      "r228",
      "r229",
      "r453",
      "r648"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r192",
      "r211",
      "r657",
      "r733"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r439"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year ended December 31, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remainder of 2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r46",
      "r47",
      "r48",
      "r51",
      "r52",
      "r53",
      "r54",
      "r152",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r403",
      "r404",
      "r405",
      "r420",
      "r560",
      "r651",
      "r715",
      "r781",
      "r832",
      "r833"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r103",
      "r499",
      "r688",
      "r738",
      "r754",
      "r823"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r125",
      "r152",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r403",
      "r404",
      "r405",
      "r420",
      "r688",
      "r781",
      "r832",
      "r833"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving facility percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate principal amount revolving credit facility",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r50"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "adma_LongTermLiabilityEndOfTermFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "LongTermLiabilityEndOfTermFeePayable",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal balance of the loans and any other obligations advanced or otherwise owed.",
        "label": "Long Term Liability, End of Term Fee Payable",
        "terseLabel": "End of term fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r272",
      "r365",
      "r665",
      "r775",
      "r776"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r269",
      "r272",
      "r365",
      "r665",
      "r775",
      "r776"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r674",
      "r698",
      "r703",
      "r785",
      "r841",
      "r843",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Laboratory Equipment [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r327",
      "r365",
      "r416",
      "r452",
      "r527",
      "r529",
      "r536",
      "r552",
      "r553",
      "r612",
      "r614",
      "r616",
      "r617",
      "r619",
      "r634",
      "r635",
      "r662",
      "r671",
      "r675",
      "r682",
      "r683",
      "r684",
      "r685",
      "r699",
      "r783",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "adma_MinimumLiquidityCovenantsCreditFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "MinimumLiquidityCovenantsCreditFacilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.",
        "label": "Minimum Liquidity Covenants, Credit Facilities",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r327",
      "r365",
      "r416",
      "r452",
      "r527",
      "r529",
      "r536",
      "r552",
      "r553",
      "r612",
      "r614",
      "r616",
      "r617",
      "r619",
      "r634",
      "r635",
      "r662",
      "r671",
      "r675",
      "r682",
      "r683",
      "r684",
      "r699",
      "r783",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r674",
      "r698",
      "r703",
      "r785",
      "r841",
      "r843",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r80"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income available to common stockholders (numerator)",
        "terseLabel": "Net income",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r80",
      "r105",
      "r123",
      "r137",
      "r138",
      "r142",
      "r152",
      "r162",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r176",
      "r224",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r397",
      "r400",
      "r415",
      "r420",
      "r504",
      "r582",
      "r602",
      "r603",
      "r714",
      "r781"
     ]
    },
    "adma_NetOperatingLossCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NetOperatingLossCarryforwardsAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss Carryforwards [Abstract]",
        "terseLabel": "Net Operating Losses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "International [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r877",
      "r878",
      "r879"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Financing and Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest and other (expense) income, net",
        "totalLabel": "Other expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfBusinessDays",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Business Days",
        "terseLabel": "Number of business days"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Business Days for Prior Written Notice to Prepay Outstanding Principal",
        "terseLabel": "Number of business days for prior written notice"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesAccountsReceivableDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers of the organization.",
        "label": "Number of Customers",
        "terseLabel": "Number of customers",
        "verboseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfExecutiveOfficersThatExercisedOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfExecutiveOfficersThatExercisedOptions",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of executive officers who have exercised options to purchase shares.",
        "label": "Number of Executive Officers that Exercised Options",
        "terseLabel": "Number of executive officers that exercised options"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDAApprovedProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfFDAApprovedProduct",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products approved by FDA.",
        "label": "Number of FDA Approved Product",
        "terseLabel": "Number of FDA approved product"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities having FDA license.",
        "label": "Number of FDA-Licensed Plasma Collection Facilities",
        "terseLabel": "Number of FDA-licensed plasma collection facilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r746"
     ]
    },
    "adma_NumberOfPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly-owned plasma collection facilities of the entity.",
        "label": "Number of Plasma Collection Facilities",
        "terseLabel": "Number of plasma collection facilities"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities under various stages of development.",
        "label": "Number of Plasma Collection Facilities Under Development",
        "verboseLabel": "Number of plasma collection facilities under approval and development"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "NumberOfRenewalTerms",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal terms to extend purchase agreement, if agreed to by the parties.",
        "label": "Number of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment and Computer Software [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "adma_OperatingAndFinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "OperatingAndFinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Operating and Financing Lease, Liability",
        "terseLabel": "Operating and financing lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plasma Center Operating Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (loss) from operations",
        "totalLabel": "INCOME FROM OPERATIONS",
        "terseLabel": "Income from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r652",
      "r744",
      "r747",
      "r748",
      "r749",
      "r750"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of lease obligations",
        "negatedLabel": "Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease obligations, net of current portion",
        "verboseLabel": "Balance at September 30, 2024",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r433"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-to-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r687"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, expiration",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "adma_OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards are subject to limitation as a result of the ownership change.",
        "label": "Operating Loss Carryforwards Subject to Limitation Ownership Changes",
        "terseLabel": "Operating loss carryforwards subject to limitation ownership changes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r212",
      "r657",
      "r658"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r97",
      "r538",
      "r539"
     ]
    },
    "adma_OriginalDiscountPayableCreditFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "OriginalDiscountPayableCreditFacility",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represent the original discount payable in related transaction in credit facility.",
        "label": "Original Discount Payable, Credit Facility",
        "terseLabel": "Original discount payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plasma center operating expenses",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r507",
      "r657"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest paid in kind",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "adma_PercentageOfCreditFacilityRepaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PercentageOfCreditFacilityRepaid",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of credit facility from a contractual arrangement with the lender repaid.",
        "label": "Percentage of Credit Facility Repaid",
        "terseLabel": "Percentage of credit facility repaid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812"
     ]
    },
    "adma_PlasmaCollectionCentersSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PlasmaCollectionCentersSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "Plasma Collection Centers Segment [Member]",
        "terseLabel": "Plasma Collection Centers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PlasmaPurchaseAgreementOneMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.",
        "label": "Plasma Purchase Agreement One [Member]",
        "terseLabel": "2011 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PlasmaPurchaseAgreementRenewalPeriod",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Renewal Period",
        "terseLabel": "Plasma purchase agreement renewal period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PlasmaSupplyAgreementTerm",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma supply agreement term",
        "terseLabel": "Plasma supply agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PostMarketingCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PostMarketingCommitmentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Marketing Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r562"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r305"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r562",
      "r580",
      "r874",
      "r875"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r496",
      "r688"
     ]
    },
    "adma_PrepaidAfterTheFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PrepaidAfterTheFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid after the First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "adma_PrepaidOnOrPriorToFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PrepaidOnOrPriorToFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaidOnOrPriorToSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PrepaidOnOrPriorToSecondAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The second anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to Second Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to Second Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaidOnOrPriorToThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PrepaidOnOrPriorToThirdAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The third anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to Third Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to Third Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaymentsOfDebtPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "PrepaymentsOfDebtPremium",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the payments of premium.",
        "label": "Prepayments of Debt Premium",
        "terseLabel": "Prepayments of premium"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business [Abstract]",
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from the exercise of stock options",
        "terseLabel": "Aggregate exercise proceeds",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r10"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r454",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r639",
      "r672",
      "r697",
      "r699",
      "r700",
      "r704",
      "r705",
      "r777",
      "r778",
      "r785",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r214",
      "r454",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r639",
      "r672",
      "r697",
      "r699",
      "r700",
      "r704",
      "r705",
      "r777",
      "r778",
      "r785",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r439"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r115",
      "r118",
      "r119"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r128",
      "r502"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, net",
        "totalLabel": "Total property, plant and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r439",
      "r490",
      "r502",
      "r688"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r439"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r325",
      "r327",
      "r356",
      "r357",
      "r358",
      "r365",
      "r416",
      "r449",
      "r450",
      "r452",
      "r527",
      "r529",
      "r536",
      "r552",
      "r553",
      "r612",
      "r614",
      "r616",
      "r617",
      "r619",
      "r634",
      "r635",
      "r662",
      "r671",
      "r675",
      "r682",
      "r683",
      "r684",
      "r685",
      "r699",
      "r708",
      "r773",
      "r783",
      "r821",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r271",
      "r325",
      "r327",
      "r356",
      "r357",
      "r358",
      "r365",
      "r416",
      "r449",
      "r450",
      "r452",
      "r527",
      "r529",
      "r536",
      "r552",
      "r553",
      "r612",
      "r614",
      "r616",
      "r617",
      "r619",
      "r634",
      "r635",
      "r662",
      "r671",
      "r675",
      "r682",
      "r683",
      "r684",
      "r685",
      "r699",
      "r708",
      "r773",
      "r783",
      "r821",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r223",
      "r753"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r326",
      "r444",
      "r445",
      "r494",
      "r500",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r579",
      "r581",
      "r611"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r444",
      "r445",
      "r446",
      "r447",
      "r494",
      "r500",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r579",
      "r581",
      "r611"
     ]
    },
    "adma_RelatedPartyTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "RelatedPartyTransactionAbstract",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r585",
      "r586",
      "r589"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials amount",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r326",
      "r444",
      "r445",
      "r494",
      "r500",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r579",
      "r581",
      "r611",
      "r831"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r441",
      "r442",
      "r443",
      "r445",
      "r448",
      "r544",
      "r545",
      "r546",
      "r587",
      "r588",
      "r589",
      "r608",
      "r610"
     ]
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayment of revolving credit facility",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r156",
      "r157",
      "r288",
      "r307",
      "r447",
      "r451",
      "r492",
      "r646",
      "r647"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development",
        "terseLabel": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r637",
      "r657",
      "r840"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "adma_RestrictedStockUnitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "RestrictedStockUnitsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "RSUs [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r93",
      "r498",
      "r534",
      "r535",
      "r542",
      "r563",
      "r688"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r159",
      "r160",
      "r161",
      "r163",
      "r168",
      "r170",
      "r172",
      "r225",
      "r226",
      "r258",
      "r386",
      "r387",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r406",
      "r408",
      "r409",
      "r411",
      "r413",
      "r429",
      "r431",
      "r531",
      "r533",
      "r547",
      "r874"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues",
        "terseLabel": "REVENUES",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r183",
      "r190",
      "r191",
      "r205",
      "r211",
      "r214",
      "r216",
      "r218",
      "r322",
      "r323",
      "r454"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r724"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues [Member]",
        "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues According to Geographic Area",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r638",
      "r649"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "adma_RightToIntermediatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "RightToIntermediatesMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Right to Intermediates [Member]",
        "terseLabel": "Rights to Intermediates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Calculation of Diluted Loss Per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Table]",
        "documentation": "Disclosure of information about change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r167"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Outstanding Senior Notes Payable",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Calculation of Basic and Diluted Earnings Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r251",
      "r253",
      "r254",
      "r256",
      "r455",
      "r637",
      "r664"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r764"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r62",
      "r63",
      "r64"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r439"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r585",
      "r586",
      "r589"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summarized Financial Information Concerning Reportable Segments",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r94"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested RSU Activity",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset Future Aggregate Amortization Expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r763"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r718"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r183",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r218",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r256",
      "r263",
      "r264",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r654",
      "r657",
      "r658",
      "r663",
      "r702",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital expenditures",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r200",
      "r211",
      "r657",
      "r658"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r549",
      "r550",
      "r551",
      "r613",
      "r615",
      "r618",
      "r620",
      "r622",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r673",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r701",
      "r708",
      "r785",
      "r841",
      "r843",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r183",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r201",
      "r203",
      "r204",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r218",
      "r653",
      "r655",
      "r656",
      "r657",
      "r659",
      "r660",
      "r661"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorLongTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorLongTermNotes",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior notes payable, net of discount",
        "totalLabel": "Senior notes payable",
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r688"
     ]
    },
    "adma_SeniorNotesPayableBeforeDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "SeniorNotesPayableBeforeDebtDiscount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.",
        "label": "Senior Notes Payable Before Debt Discount",
        "terseLabel": "Senior notes payable before debt discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity incentive plans, term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity incentive plans, vesting period",
        "label": "Restricted stock units vested over a period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Exercised in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Exercised in Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Expired in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Expired in Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in dollars per share)",
        "terseLabel": "Granted (in dollars per share)",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested RSU, Shares [Abstract]",
        "terseLabel": "Warrants Outstanding [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r344"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Warrants Outstanding, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities",
        "terseLabel": "Amount of shares withheld for tax withholding obligation"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities",
        "terseLabel": "Shares withheld for tax withholding obligation (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock units granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r337"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld to Cover Aggregate Exercise Prices",
        "terseLabel": "Shares withheld to cover aggregate exercise prices (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were granted during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Purchased in Cashless Transaction for Award",
        "terseLabel": "Shares purchased in cashless transaction (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r328",
      "r334",
      "r353",
      "r354",
      "r355",
      "r356",
      "r359",
      "r361",
      "r362",
      "r363",
      "r364"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of stock options, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of stock options, expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares withheld to cover portion of tax liabilities (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r150"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r122",
      "r183",
      "r186",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r211",
      "r212",
      "r213",
      "r218",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r256",
      "r260",
      "r263",
      "r264",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r654",
      "r657",
      "r658",
      "r663",
      "r702",
      "r841",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r56",
      "r59",
      "r60",
      "r121",
      "r140",
      "r141",
      "r142",
      "r159",
      "r160",
      "r161",
      "r163",
      "r168",
      "r170",
      "r172",
      "r184",
      "r225",
      "r226",
      "r258",
      "r319",
      "r386",
      "r387",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r413",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r431",
      "r440",
      "r505",
      "r531",
      "r532",
      "r533",
      "r547",
      "r604"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r217",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r549",
      "r550",
      "r551",
      "r613",
      "r615",
      "r618",
      "r620",
      "r622",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r640",
      "r673",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r701",
      "r708",
      "r785",
      "r841",
      "r843",
      "r844",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r184",
      "r431",
      "r454",
      "r540",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r583",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r709"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r184",
      "r219",
      "r431",
      "r454",
      "r540",
      "r548",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r581",
      "r583",
      "r584",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r604",
      "r709"
     ]
    },
    "adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options (in shares)",
        "verboseLabel": "Common stock shares issued (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r55",
      "r56",
      "r93",
      "r340"
     ]
    },
    "adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Value Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r56",
      "r59",
      "r60",
      "r93"
     ]
    },
    "adma_StockOptionSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "StockOptionSharesAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Shares [Abstract]",
        "terseLabel": "Stock Options, Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "StockOptionsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockOptionsWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "StockOptionsWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Stock Options, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r60",
      "r84",
      "r564",
      "r580",
      "r605",
      "r606",
      "r688",
      "r715",
      "r738",
      "r754",
      "r823",
      "r874"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheets",
      "http://admabiologics.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r151",
      "r304",
      "r306",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r412",
      "r607",
      "r609",
      "r621"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxAdjustmentsSettlementsAndUnusualProvisions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Uncertain tax positions",
        "documentation": "Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax credit carryforwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r384"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "adma_TaxYear2028Through2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "TaxYear2028Through2043Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax years 2028 through 2043.",
        "label": "Tax Year 2028 through 2043 [Member]",
        "terseLabel": "2028 through 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxesPaidOnVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "TaxesPaidOnVestedRestrictedStockUnits",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow related to taxes on vested Restricted Stock Units.",
        "label": "Taxes Paid on Vested Restricted Stock Units",
        "negatedLabel": "Taxes paid on vested Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "TermLoanMember",
     "presentation": [
      "http://admabiologics.com/role/DebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r830"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]",
        "terseLabel": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "adma_Two022CompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "Two022CompensationPlanMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2022 compensation plan of equity based compensation arrangement plan.",
        "label": "Two022 Compensation Plan [Member]",
        "terseLabel": "2022 Compensation Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Two Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://admabiologics.com/role/SegmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r368",
      "r378",
      "r677"
     ]
    },
    "adma_UnvestedRestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "UnvestedRestrictedStockUnitsRSUMember",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Unvested Restricted Stock Units RSU [Member]",
        "terseLabel": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r113",
      "r114",
      "r116",
      "r117"
     ]
    },
    "adma_UseOfEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "UseOfEstimatesAbstract",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates [Abstract]",
        "terseLabel": "Use of Estimates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VendorAndLicensorCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "VendorAndLicensorCommitmentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Licensor Commitments [Abstract]",
        "terseLabel": "Vendor and Licensor Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Amount",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Shares",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "terseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r707",
      "r710",
      "r711",
      "r712",
      "r713"
     ]
    },
    "adma_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "WarrantsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_WarrantsIssuedInConnectionWithNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "WarrantsIssuedInConnectionWithNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants issued in connection with the issuance of notes payable.",
        "label": "Warrants Issued in Connection with Notes Payable",
        "terseLabel": "Warrants Issued in connection with notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total shares - diluted (denominator) (in shares)",
        "label": "Diluted (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://admabiologics.com/role/CondensedConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SummaryOfSignificantAccountingPoliciesEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average number of common shares (denominator) (in shares)",
        "label": "Basic (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r179"
     ]
    },
    "adma_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20240930",
     "localname": "WorkingCapital",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of difference between current assets and liabilities.",
        "label": "Working Capital",
        "terseLabel": "Working capital"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0001140361-24-045693-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-045693-xbrl.zip
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MM>B7&(49GDN\C;^P J]//+):VZP!^;<EQ?/K$P9Y+T;YGVN*3X'#F(2Z-A9
MPI+/((L'&LDY&^\JCHM U,R4DM$!*,1=8^H3D'JG0F<O)I:)[+IB018SL%LM
ME87G=:6"+,0A;1;*1@]UA8(LV'Y=>5@Y!D@@L1_W,U5@,3E+0]<,F)V6'4MQ
M?.)O5.BE=,75Z40BUO6)D&);>US_#K??SL&,GY]+/2DN(?D3.984%B<EROOU
M;+^0_?(##UN:\QO_O=^AH]P1B2CG7I^IGC&MEOGYHJ\Q$@T!&KB.A1VH 7YX
MKDTL-IK?()N-,/H28]\+8:I )P0+H.)@Z=">.$)KH$V&RD17ANR7KHW5H6S
M'S?R6)X,%$G_JBB&WF%V &931*$5EM@G(%95 -.9DC*#IQ<F2C.H_TLUX+B7
M)U*(B\,40OHEQ>A?.P6IIB#;AO:TN;9F;CMP).K=!1F$J%Y6[^:Z ?_=*1-
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MIN;7OZ(]ZMA)O1NTB#NH5&O>08U+UPUWR+O=;U$0H>@R\&;Q&H77NS!$0?R
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M8JM@Q&I #_VR3^$9.:@![U":?!7 MO-E7[9-L#[')&\1Y!';J$VY(P#2QDJ
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M_O6.D;VC/[W[\/'=#Q^^>\G"M[6(]+-")8S\I4=?Z_3AIY]^>E]^W9,21I&
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M@G>>V/K8/4NL/XYIK$:4C%JW%,BMTN7:Q9F1RLWU_,//]-8!"G]YFZ<%JG[
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M12#XX >PK;">F' Z(35J!@@9M2_. 7P J:>L>&IHG3I*&8\R/F1IW@ $^>L
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M!4:=EVW8H.<UN[ "M&B0F4'H[O,,,5I(ML04GXADNV('&@/\5NO4^>9H^H+
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M^[UZ/KN!?95CP?\*7HE@"C:4$]::B@@]MJ.R?JJ6%#%TG=*A+17@)/$)ZE:
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M:X-!X>$8G>+ HS)JQ8\-8":M-NYC-&H"L>='9AL3HKUKWFJ(:;8'-(49=_=
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M[-0T@\+0M0N*-W7 @IX$EYE CK_3(V\B.*Y,0PK!Q@]8N^M]YJ9$8.00GP!
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M!ON-?YMP'\2R\-<48D2_LI AM#?]&HU]%?,0F)<4N !/AA%[+W '%?P8]<?
M-K>6&:@^R[) W2D4.HE[3?-J>)!$O3,H!A?X5+$!#'M0@/06].8D@/7[Y(+Y
M6XL$-5 O]Z\=!(4N>, 7*#G)LW>#[@H"*I5 /W\5]'SY OB]X\18A)2[4 =+
M'BD!B!E$J#0!'$'(U$&/K=#)[3)*Y=B!TU!O0>K==-@$=1_Y.D(*#*47*:]2
M-OIE?4FN. ?V76.DJY )[U=*%(%H&6+,; $:>,140(ZA>/G@1O?IYSA&[QY=
M]Y '33^.BE_.T3/_X?^.MEMR#.)HZ;ZZ]SX>!;ODE_"(=S//O?=\+_9P=.-%
M6Y]$QQ!O\$M\G13DCQJ"-:WDW[&UE9:\,_0-M**W?AE8M-6UZHS&X]7=Y 9-
M_K:<S->3-1K-;]!B\\MDA<9WJ]5DOD&SZ>AZ.IMNII.U75+K@H\80T(U'K0T
M1J.%=GGL,,)(6V6H#!W0(F_O"FV4JR,WV*'< "I90&<3Z#,U@E(KEIM ^VP1
M-*'V*#. )GB%M]A[IH6>XWA\#,.D \5I9T6BM<:4+6HH/HC*8;19Y#B"D)RI
M>B9Q>'H\#%X*JY9!/@ 4:N1B:; 8U#MRC#<=/"=M8?.>B9LK%.#X[8!'$IIU
MT&,IP-YZ@1?CF?>,=],@3BK>HPU#%.$X2DI[W!]].D =[4D8>_](M\#6P-O>
M0/X-VQC0)%K[,NNRKY5G$25;&'1*#Y!;>F*7IQI (B:JMDII=3MEHAO =%_=
MJZ(P-_B0A&TO+4SR;Q_3?] >8JF0RY <<!B_+A,XQLFSR=^/WF'/[(H9-7ON
MMADRJ]]0&WT_(7E$>V0;3;NI8DEZ 6;<.#,<17]%;BD<[4H&K7<;S&*8=(>?
M1F_$B/5:S^5M4<_T=(S10O7!OO.$S8E\97M7Z&0QF\,IV;Q"A=7D7]3N52IR
M,OV-N$KHNQSVVIP(VNT\6C;77[I>TJD:NP<O=OUZQT,L5?0C>%*ZL4GLW<RD
M#]>',&APM)SS W1(GKSS K3-GEDFL:0B"?BKU]C%%JZ0I5]TF&V(Q#Y:0*1H
M)LXXH8]1@I/QV\")*!2W!HO-0%D*Y(N'^NBS'B]!PD78E CK\@-4%@A#GG%X
M3R1A5.9,2!6QLE.9%2 /"5D*">2F(I8Y ZMTHEHU-?((=2H<LHDK<Z%7ZJ8]
MI-Y_=9CB161#H+(5FZGSZ3[I:86T.SU^<L-''(WNHSATMXU)-)!P$9LEPKH<
M I5%FT(R+T(&B96=\R-*GQD)'M_Y='X6Y=CY7(C:WH, JW:B6CDU(@EU*D12
M0U9_/+H+=C@<DR IR'%+:?X)[^]QR&*11+3,(:ZH"09)RF&$/WP?4O;P5)WR
M;[3KOPS)%D<)9S*!(3!&5L5UOL @468+1Z/!%2B">F'*.G;C=+?QXN'6"]Q@
MZR4C%1*E8Q9.NZ.BDG\FF(HF@U3*I<LDH"\1HT FG/%B?D,WD=Z@Y%_KQ6QZ
M,]HD?UR/9J/Y>(+6OTPFF_5@VB8E:)!V55=E'D2SS,!62.R%B1,W#+S@,5KB
M<)VTH?C:C;QM#>I"F?S#<&0TR27T;&C,S?,A8A%;Q[D>K:=C-!FMYM/YQS7Z
M?K98KW] 2[H#>_'ITV*>$&>TFJ#OD[9J1WS?#2-T2$)U1$W\8)=#XCHFP"JI
MLH0I6J9%CZ!1&E!+I[NY+I1!DXRAL\^"\Z<I(K9DOT_Z-"DPHC>(%\XXNAU@
MFJ-F(XCY8*K5YEI7!LL')EA2.+Q!D'PP"9(/0YCVOL'W,=W(3G=;+D.\]XY[
MX<RW0)XY^<V4-SI/*2B1V9E*MB/X7"5+OS%;N4N$T"Z7&M),I:CBN9.5<K0P
MIRL9:OP92PC">B'6]='S:;HWYNP*^V'^$>H/-?G!]J5+AH95$?)KPD[Q]T F
M0CBU063?L K:JDP9H9(*[06.8S=Z&@4[^A^Z+>79]6F"QE$\=L/P-2G;KZY_
MK"-(22?_&$ =34PKE4P7ZE!G(@; ;#CT>;HG;$O_@<^2=@FB!@32LIZJ= *I
MEEDV(.0IC>4 ,P!@I]H0?/^58I SWNL&A)964:=!C!-TQW3'S1S7IZ\Y3T^Y
MCFM/-6G$\6:(+TWK(F+4I3,&T&U]Z(&$=,= ^MAV_F)V]1#I-ZUG*ZX(E;';
M<1T;W;#'L:U0S?D&O>+7='O>%9J\;/UCVC7-=Z1Y_\"[TT>[0HL#O5@CS7.]
MC;WG].3WI0%#L',/C@Z+._6FP3;$;H1O</;?:= \']H(;G"54\2#J&A3!%XN
M0X>=@"[%3 *8&-YI>"40D':55*>37+/*L8%@SG"LACO4A=TIJF<BZ/M"^ >Z
M_^($R=57 $EAF#>/2XL-POB)YH8[%2IIG2=1[.V32'C]NDG\CEZ\^@9N%95B
M9@.DHCN\5"B7]KP&S)=P3 DQX612)0+2_E,A2*\HHZ+H,Q6V/!.H! O2KMIJ
M(TR 9F6 V0:%EEE(RW5#]JY7SX&AHB)E85FE,Q8VR]4="RN^VK&P9$+,PJN<
M@YGP8%G(@ 6(A5PX25EXUH2Q4(!"RRR<<>Z[4M"0<G"F?0-6B_?HCH$SR=U8
M*A8DK>!P;LI2P0.(?#P82;DW*U^DI>3'RI;A[1/>'7V\>!!$!\;<A+)>L7D8
MKJ>[@UBUA-K;B!4<"O<2@^W(V)E*V=Y%K P4HE&'M?W$4/7*IN+6"+4TCS@-
MGG&0./)P\U)(@"QWYK B:WSZAE&2SN8*J[[49FO*ND[ICZ%-P;!J5CCWPH<"
M=[ZEI"*>:.D-.AU/^3$\M4:/>)+OC2)+:3JO#;P&M:*S##%=@+W!#S@,\6[R
M<L!!1!,O+^(G'#)S,N@9X<9NF!'CS%0I>V?1'E@(-2*#C#JY%,+9XRC=D4*H
M!-KF"6*'<'Y?$W1"\K> +S<@0&R)(\6 >=!QTZ52!/-4$#=V!4URU90EJ7)^
M//_K9H=2F]D/10;5RIYVL^2;73@GF]45N:TI7]%XY)"5T7R@$'A4BPM<0_DT
M142I3TY;D;*&,.6^?[Z0XJ]#X[X4-$*^ R''I3=/7TQI,%XM[WS*;R8!;WNJ
MR4OW/)WD.]M\4BN1L9V@<G_M]IP4^N=]3H?LEZ'1CE?EH.TD;)Q(MY$4MQB!
M]I#TAJV>=C75O&G!"[B?:?EVH==J&U,;_ VJ9S9JW"\%">T<%5%T;ZAT04).
MN3JA8-.7,@'K)IS\M]-DQ !YQJMZ&=7$D!$1K:8IY9H,:?ULCR#[O1?OTT,Y
MP6Y,TK4H'&Q!-Y*V4RXV32@JZ^Z?:%56([E'E%T+MU:H&7-H'IOIYM-DOLGN
M%QTOYIOI_.-D/K9^IVA+^!#=2JUMMU"R4=EY,60$&^W;M7-M#L9YKZ^DE [N
M*VK#O FT;XP+>H=] =WFQO<T"],Z3DJ1)I*)1L?XB83TS!JCZ9)(EMHIKJ0!
M2DM*8>K$M-"3C*D\36><I[VB3Z^*[%?N22#-<93]:CFQ$:2^B5+%-,G%4:@S
MR0*8C#8$ A\M<?3^JP22($SK(6DHP7<:14=YX*U*\8)N(66:(U7OQNEQ,J_$
MC%R+30HO?3A@0M0J5$0&9MWS>) )"SG 08D=^"^.<10GW=2DKR3C $.41X2*
MJ&DV,,IA; 0L<*1$CK(JFR'D+#%@FK#J7,05/D9XA"EI"%G3%Z2ZZX74G+3%
M$Z\?\N8!!>V*M$"4_<X(,Y,;YW$SZAK*DL7Q9SJZ@E*OU<4+T*<_H7?HF=#Q
M_17Z[S_]Z:>??GJ/#FZ(GJGD%?KYIY^N?LK^O]E)O_KP\Y^O?OZ7_WGUYY_^
M)9V?^?#ASU<__?GGJY]^_E#KO:2;%TM@<F.T3G">90K\^:<K1"LTE;K!V_S7
M]^FO/P^&=?P$6V)P-<G5S)K5-?Z,SPZRC*N L#3#5R#Q"OV:@2[KU5U>O4OF
MXJ"5;W$^K<C&C'=)H>A27YI4=N2GWK+[7L>^&T7>@Y?], U.MR6<;E#@W4O5
MC?'B,*!AX[HG!CMY5^UCA:9+)3Q[:-:9DQ+DW3TU2+/OGRP6B]+#N>RD&YR3
MKM%5._!HU$?E5&2W5.VKNWDX)AVU-7F(OR2O4[LGD)GS6DGGW#&%Z.CW%N E
M,]6%!7F4="D -K($AX'K^Z])W_(9^^20!)!"9R )N-6@05K67*-+(E>M]5.&
M@D73W5FX1VU GCN^J>P)B5?H+)Z=7?DJL"GN,W< 4*NKU<E'#N(P;=167O0'
M/SN;7/+40 @DM:DH+84^]T0NQ&3C:SJ5AX@^'5"*-4#=$J5*J-.&JU E"QPX
M=M@QX^5KD@KRN#$SEYU)6@;CS)A!<S'Q%5F\&%#>)7F]BGC!0P&/%C-F<B4X
M9.R0@I5 22S$(X.9U$ABW\9) $EZQ%%B@G\(:8TDU2?"O"!A$5M6B'6+J8B:
M9>&FS)1+<A%O,$&FO!3FL0].ARG0Y'>-AI'Y$E"[0D+(\ESR%<34L)W5DD3Q
MXF&%GW' 6-MD/#MQH/),&_4,3X;F@ZJ6Q? NRSKT3WI5X"$DN^,V1F'VP#:.
M675"))^RCM622!6=G56J\8N;ZL;!%?O^3=0L=VH#4K7ZU^96S-&9#V-7YC(M
M@RLW4SA5\.KR*K;R,=M4;F[ 7F.R=GT<+8GO;5_YY_UD@I5FABUH!,*B,IB!
M,L>#'-),Q1.TEWGL&A#$A?79P#N@]BNX9\DW20""2B]D*)W('6=YU6I Y OD
MK\\2T 0]WZ>1WA;3O CI# 4G_T<YXXY== LJBD ^;17-3;DRBGNI<Z7.6$QB
MUU>K=%E_C*7A;*B?4PK"BZ]\3@=-M?;UNVI-FT;[:WSS:@C(>VZE!U<H?W29
M !!TY%1!8+%+URP,9Q.>7)#;JAG;'"<O@WFT S>M"119#9[E%'. RA1B7[P#
MC"\OIH'EG5G'*"9['#:F\-A[LF#2Q3!')JT[UH&51GO (W4C'/5(M)U" +$6
M7(:QI058ZT2Y:FHC(K%295BD"*U>N'2#[^-ID+#Y2+=<%E=XC_8T:U@-PA#1
M_..(134I!"F'+G\D/D3D$:HZY>-6A] +MMXAZ6N[Z5.[C %5+U&KABI71!IE
MHBBAQP)+;C$&$*0AQ>1&2<HH+1K>S3*B;!Y.AK,6S?9(NQ([](#SQ/?#2#PG
MJT,N 7C5S<3^29@/>SXP;" ^Q'\_XF#[NGA8XM C.V^[=%_WS9DT534V)P1J
M9DDB+9]AUHC\*="(;\8Y/4M7U?*G-&WOWOKP71D;?*Y!<<4F'U=;P$8X)"W0
M,SW_@*-XY<9X\O" M['WC)-RTFZF^UCG0BM=)E&END;9"BRI6<K*G<)Y*[/E
MG'Y$7BZ*DE&"Y16E=G#A<E<-;TP"2TSP6:R*5\M43D_"[5KPF*<H)7%3L3,&
M\\K8'7T9'MMQMV'(F5X"7;FH '%5@BDI4>OZ,)9* 6F!HI_<^!AZ\>M-4C0A
M)5F"3 I6!8U2CE4&LQ2K>8!3JJ+H%'^AW< HQ*Q%+F4$=<ZD2%F>3PDA0"Q0
M8.[NV5NW96),^)?%C(*_Z=\L]"OVX< OJ3GT"3H_ND+TX4!V:DLKD\L";L4S
M.7"6YC- @!$+^*^- 8L62T@&B0Z3&5P=HS21E,PL9_C.X 3BV3CWP_()CT%-
M)LH P&43##E,:G%4^3R#(LX^Z9;%ZHD*ZQI*$-J5E+KD7:-LG1*O[*TU\\Y&
MG/7V">^./MZ5EK4N@(5-0$!IR(,2A(<G73 1^1BTP,2[P-V3,*8) NEE =*E
M,($\DW],>:/4$Y1("#CX3=,0?W#>L?2=&8ZB#&AHE_\X)*:):IU+,CE4F/QB
MJ/&I905>1O/9@+UI(2S/8],8HI1$T<T;!IX@<8U9]%E,6%,M&R^OHT2*&<3-
M95J4>#=+)FCN0YY6G2[18)(6RBJ12PU)&D&.,)\!EA/[50O#2,W$%V "W4@B
M)KY/L_ &I%UB*-1!/8@L2X)JXD*9GU.I*<<'L+T,2M5RS#CIDR123!3/C"5.
MDG@WB^<9,&423ZN)[-E0DB7):I$+<EZ%,Y$^8^5(@D+# N99V9$$$DRLF\F+
M)/!J%N.0C$@LC=.<#-T+-B/!X[L8AWO4[* ,(462J ZY2!<D1V((\A%N,2W2
M#7[ ="-L?GI\3H(M\XRR5.Z$=*Z<-MXE)=!'/=^!&/L\/:=X5"06N4(!3@_M
M%Z=;#W0H1@+;V)?5+5&HACH/..)5-D!!TQ,G#B'>>D6J\%$V7D[_;+!"*GGB
MA4!2FQG24A@YU"_V(Z8(7],I/TRWXKNEQ\6^?-L,D=<S4:J0.DNX"E6>6 &1
MP7E#H8^6"'HO@=!;@0YW+E 7.Y;F_B9N&'C!8[3$87IAPXWG'^/&[9X2J?Q;
M<*4T62'Q;BB'&=^+B!(\+>=F.KO;3&[09+2:3^<?U^C[V6*]_@$M)RLT7GSZ
MM)BC]2^CU22]>6Y'?-\-(WI8([M1R_(E=++Z)N#*J=*$(URF2,\@4DN^(FN<
M!4Y:@(C&U/P#X5PB1<@VO\R0BKY1^'#";'O\Z&=NX1@VEKI%8+\%=CYPL/.6
M0</)[](>-):RO)R.I4R#A.IXX[[0;?!C$L1><$R*N4BJ+.TSU.=\U16+EEM!
M49=&RF74)I:*1R'5X(9*Q[AB]V4 1T):0(/H5%J-@F#]"BO;H](B3U>85H/G
MY[W\^!;ODF*F5YH=DS*\5H1!!&YE4<AL18N=4+[56W43"U2+HAXDU#PX^6,4
M%<\''47:X5,:7G1@+XP[2H;E 4F/3!8O?*W152PDO("UHXM4#8_PN4[4[S?E
MWU,ZQ$M)69P#U79.([:L_++/CF!A=LS.]Z$.B_?R^VLO&Q^<<7E;@.B/RMEV
MC>94%;M0!TF>6S5]^"Y]BHK<(Z,P3&SA_!1@4HUN](0F;P$X@ORK;<%C,0\K
MYVYCI0O1E2XX[_C"\GXN(->Z4)QY07@%,$/98PNL;_E%WVTN[H9?Q&UU_^VM
MZX6_NOX1+QY.EWZ7MB-E5P;4,*RDDW\LH(XFJY1*IDLNJ#,1QV V'"J&4CFZ
M7>8D6=XX9I=J:I @+6NL2CR0:IE_[3#8#PV]P(OQ+!G1[FJW*$>?W/\BX=AW
MHXB;Z*&E=D%-56U=DK8KK39=E=T*B:MHS<D4WJ4:C:O'HRN4:J%4;4AI)]I"
MBVC7=XWL:D8JM-?$M^T </UZ+B;C@$P+33GQFYK=D9Y7R@X)SW#9DNP-2SG1
M$8?HZ/JU0G6J,UB&<_$#8[<$?G)FUPT 62T%KVU&SSA'A514Y!R>&3M$I%*N
M#ED[ QXO IF0-,@#.GJDA H8,WEHDE-RQCJAU J$MDEX>XR/(2[O_,SG]SBS
M1R9,R4D+,-4=F<'OT2')(65H27ZY:6<2Q=Z>9A-!H\?',$TL@BI[B'.-P<QQ
M&4$E+&BHHEP>3*06@4%&G33]!)]CF!29EBS8W7HO]%\1\U8DN6 1. 2"NF%!
M6@9MTHL\""G-5W1.S]*##L73@=Q[!*A7HE(#-6)QY2NT@4.F%U)\3(;8,Q)%
MB^#&BPXD\BA=%P\9D6O8!,GF'T4BJ\D.4$D,):N2^1)11:SKT$<H:<5VZ4/7
MI[/)#]Y+TMRYJ81=NL"JFRC62I4T0I4R;RSBR6AV*I"GUI#*LU)1&?0]E?J!
MPJLDF-_)?<!A_(J6B9,83?Y^] [9ROKD9>L?T^NW%IZ?1O"/;G26IS]LO#2B
M%;^])80*4EJ9@:G%5%8?"=E]\7P_:77JO;7B$7-M45FO"/]P/5WJJI;0T*8Y
M%;]"/H/M.,7?EDFG# FB45LU'D+5*YP<'A;--BFJ7HW L6AJ\A_3QH&QCE8\
MOT)YQ7S._[O!+S&Z3J+='Y9'!?W@6=2X= IJFXU.F+2$24_AP:M/WC&>% U'
M^8DN'9M>0#MC2>SZPM!?L2MD4TG22?] A_0ORY!G?'XB_&XUQ)X%*ICLIN[,
M!LNF76 %%@$OK<7E1=6B*/A(J])B )GN#ZX7TK')XH'FZ$IG&[,@]POV=[<D
MO(OJ %+2R;\%4$<3TDHE,[*%'^I1Q "8#><L1H>8/DVHYJ=+>4.8R5##!&E9
M955B@53+E!L0"(U&7"6/VDC,H_19]BK+[I>M*Z?25XB*OWL@X;L[V\<'ND6F
M(.YW \\!S'"<RTGG83C3&6RAVMQ%7<C0X)#MVTB\Y[J C/AJ2N6(OGURPT<<
MH1#[;IXAXG%0<Q&<^F0,U(0U7QN05659HZ]>(-+)9 ';A3I.:M, 5Z7 @NCS
MR\8'8-2N"A*;W>GTP'5Z;6B:J9N]L48B5729>5*Z_1.Q=^W."->\L.?!T7+&
MB_G-9+Z>W*#D7^O%;'HSHKG-UIOD/Y\F\\T:+6[18CE9C3;31& PVU1D=4S
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M'#=&^5#YHIV4R^NVD] 2"<'XEXR:03ISM1-V/ '^A,VE5-])'V3THW.UWDD
MN:F$Y=82# '2HI9JK:5,K=):VL>:V14^J#<MN!7K>;D<_:"Y)#J+HM&;!9YH
MO<XH^FRNSM7+QNU8RL*]5)$7]P6*IDDI+6-7+8'(L1)'^8:<9?(EGMQL$>_
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M[$XY*Y2VMZ#.]._07]\])#\C+_\=A<F#-Q3?A;SI*KH#R-I%;&>Y[2RR7V:
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MDS@:#1I!L=4WA]9QTOX]$7^'PRC+."(GDURGR2J1CCEZR4MFD&="9T#""6P
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M&>7JK!6L^FK5#)9-.(74%4KE4CZ>) =S$EL)$I#FD \E67M8T@0UB"($]L+
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MIXLAF??4L9L+B.SIPD>AK/;ECH"2:+<>$B?B2QM%NL[Y,:+/WWD!RB6&TIR
MJIHHUDC]LD6!2O5B114L]4*;%8Y=+\"[XJ \DR]BH?QC\(0T&2+VK4L-KG41
M)SA*M%-UW--T7\EPYP8_>%LO'@@+)!5(H)^[BGNV;!GP0$STDTVEVE3=D'U2
MM!KHA#)%9A2VC&[^$Y%G[2PG'./"7"9,G4;G"'W.GMA.52*L. +\SK6T(RS1
M2G(1$!+Z ??^X)-7C-.Q_>) &QEF))?*%2#GR^D"758";; +' @!S]5SLKFK
M[+=H("%=7I-$X:/7D,\3KZ ?#)%^YJK3'M5_>$'ROS%.0-B8?N8*%#/*# '=
M26*N3^UY7Y9EX51N4\$I_H4.R4-ZN?H?R6/+$[/\6B*0[UJ;/FW(569$Y17>
M"W3I8=<-#O<W^#[FI>D4RN0OS9'1Q+#0LRZ,><9%2&;K.#>3ZXU=[(KKB  _
M:17!3-$RB&&5WM]1BVFZ0>3F&";]_66Z=SU=62BU$M'D!8=;+\*[QA1F2_WR
M00TU?1,;?=N4V,@68$7'TLW!2O:<XI_T(H'TS"$BF8SM>=*V(*IO*-9 8GFK
ML8J9QDYD+33;)'VVKJC!>H !,>V%!KKA/:#,'1%?[+D%\T4&^=0?SO%B#53)
MXP <F^) (+ #B 3# KC2UNYG'-X3R<5;K4I@%NFU1%"U/;!?/=9%Y^UZ!+NM
MNVF*-=#K8^0%.(K6^'$O6YP7R=87Y]FRIA;G124QMCC/<0):G&?J.L5?PUJ3
M%U8K:TT>@(/ZFCQ+A;DF#\)-3QO4JQD N)O/Q6*GC>4\,>U-XV+_^AO"N?;%
MF[TY:LYB.5F--M/Y1S3YVW(R7T_6?[6]B5M2@P3^M>N;K]G2U8W50&#TTR[0
MENK:31HFNC*4%"B](6@4ADD]9_Q\/8LLW5?ZT^B+&^ZRY:1ID!3^F!(WW8JY
M>7*#O,6;D^ 91S'>K8COWY*0*M4;&BO.BY:K9^>Z3:&5;Z7=MO9=:F%CW6]A
MG+O\1[1:WUUEMV5$@]E3;HE[Q#:B:_V57LM0Z0!]"S_\XBH-S^6W8O=>]N%$
MH???.;^YU'8R"%F<C\!^"T.VD?UUQB%;LQ]M7S)_E5_3]\@[[=ODGQM"?^*,
M$'ORIMN/A7JSU7*H?0UK/55P,3MI%(#>JYO"KE FGZ5/SC5H4* _7W[3H$@C
M$VU!*^;JQGZ84R/!OF6LN.3@7NHM_8:]QR<J\XQ#]Q$7<_G+T&M$O6$4IMNF
M 5R88;8<BM_27(Y3VZ]CH0&"%LXIMBN7TO1<H>=S*X5+K13]^0KA;"!SG^4
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M0@?'C:,92L;8IS;T&-%+**%%BM*+',NKVZ_9__(BAYI2_H&A2IIQ0:ULNF$
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MB62J1CD%*Z=9BDE]PADG,>44/Z*[8(=#E.J4NL318&8D6Z&'RU,E]#%I*[;
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MK7HS3.KNPE[:-TO7P[%.Y96#E,T9!SQJ<&.9*]6%Y 4)LU6=']LMQ*&QJM3
MCV4GWI^AJA^H[ AB/4%%5]Y,WFQ:]#KMWHS55)Q>%-*%AO2(YYU';&:$HAK8
M;1ZEN3>OU:>9+PRVU'%$/Z%[_! GB4@C#*'P&0Q"H4RE!Z,'9L/F52$KKZH
MUE6R\J9!7CVE#WH=PO3G-^W1821$]0$X@.XB'G3S!Z0GWM1'; A!Q0UO&J9
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M%&$6_UC5"1^Z,,I_/D-<@:Z3F;=%0E 6 $_;A\8<@2?NZ(0[^M^3N]YS>=W
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M[*&Q)19#(,.\HDE; 4Q!XW&[8DG2/2FJU/,$HHLB">>"K.2NKU&+SN:%M@7
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M,G2/YXXL/&%O$MB!5D?CRSG7ZT^7YZ(V_NIF&V6[Z()LMWC)9K=/T5(,60?
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MH\KFV\I[+<_I=D[8-*X!SZ(M;[Y/R>JPG#M/5 \08CJ>4L5HDW<50\;,"^9
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MHA<F ,>\($JV(6G^$[_&FZ2\1AC_XPRM\!X7#0Y[4M06XV53EH=ME,Z]#*A
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MQHJ%O@&BZ'(8]JO<Q$ ?S38Q!%UK$\-L#P,)Z=0:HD+^F_6:4CM>E?D*=J-
M@8U9[Q(<T>GYC1?+!BWLR?$?B#T>B_+JC,FQA-PB_W2&H%LA>8*PNR<Y5)/?
MZ>A1A=[ROL]B_V5=\1A^EV<-7F< KE+K*:8<C;Y,-_%T.C')U"-]\2.R:N&'
MXHI.AV+/)@W'2P/W"@+RP*S9#$%Y(.8LX,!<@9'00_-^MT,P9MW#FB<?H =D
M85ZE<3F60+VUNM Y+LK+<UU22_(IBE.>U#?7YKEQQZ;>73?H6*CSB]U['-4B
MP:A7FW\-V:RG?(GAJ:RM4E;)6E,:<?RRN5E/6_-\\H0DHN15:TDB8MW,>(6L
M]LI"L9Z J)M/:E==OD+!LS8S]",3@Y^CW7Z+S]">TN=D)YJ(%ISRK/-;M-^G
M>!D7,47*WBH3=+0/E.>.E>Y">90^X(+!^Q->Y1AI]"9?=[<R%S,MS@_V<?K5
M>\//=CHS1O@+,./>Z4CF"K_+-W?:;(I^^2_>1\0ZB5@OB\.C;[;\*&SYW&D;
MQVK, UY?&H?/D ^)CGBG(S#D[<R2DZDR]IHLZ)OQ=%\W"73]K+/L%](*VMBN
M39\J<\2K:+9O<E3K:"-?+H0-'\BUM"KSYFTU[:C\A]$&<(9-LD!7U&Q[.<=6
MVY&OJHUYF_#7U<:^U=','9.NK?52HU[]ZMK)V?;Y<[".U[@'O,HV%J=AK[.-
M>*NC,.PG6]/_M5G4-V,*L\[BL.KV:_2RCI,_>'VO/).68M.1B)&3D[A8>QE'
M\%49C1"E(52V65PG?!EAPPG0<DLRMK+ EB/.6@76Q<I#@_:IX#9SD*\=9V(X
M+FU5EE%7*J5FY0,X,,&8CKLU9&AP4CQ"Y;- 2EHY(4'A(H^"0M]E=#!U)?OS
M>VJ+HV7>08_JL7B-_F,7E':YP2%4Q5F)3GF#10W)\L',H%2.#S'YIFTP=DDK
M("IX0 XU7.P@X6P\RJ<PP(YC6PYK\ZV_T'_1'\N?Z/^Q38/%_P=02P,$%
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MMP&E4Z;9F8*5<69VY=V&S83N6F!N%>7>%HRU\TO&1D.FEY3V#A7\L R$M!E
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M0;2UVA2T'O:_CG0J4"AXN<A2TT_*2'_Y_0KM:.#XD$[Y#J?+VA?JI!EN<E,
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MT"8B"Q1Y0+EM@$U<5<C>8R4TFM- [GT6$_EW-+UE)2@#,A!MK7$%;:!PT]&
M#<PIZG-X2F;X&CK#2X16^0WI%DA"1C!]LX96TP<*0EU-V  BH$[+SQ;ZYO\:
M^[W&_FZP #76C0VDZE0^X%V)$U@\P]=H5A;/TNJ"W">F4M+_TZCV:Y2@\DI
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M+*,.>F1,;3JDCK(]R%&C(F.S/(2&&*!\.G@1LPSYZ7;)_?7F$W=6TRZGSJ;
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M2J%_,NPDSG AZZVL7L.X<QB0NA%61>V1/> >TM$35V43.B=SE*Q/R-@*3N*
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M^B#O5#U]Q?*;-F*")CC (?#[GHU2)(UK-CQ>X1K+\P4;S^8:S0LY]F:6T[W
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M/5$H/1:=KIJ_*@V)5IE:N\ RH:#(1 5&  -65&/OKT%B3PHR*9I"A8U]?#!
M^%MXIYMU0G/8))@%U.^Q.JI?4#6GD"T$&!:6:5X80Q4=ZI?7*55_NRY_XD[G
MS%SGS%SGS%SGS%SGS%SGS%Q6YEK=O%SJ&37TK%Q"">>"G%SP JI-S[G;?%S"
M=HFS<>D444GO/!.7L&6\/%PP8I7,KG-P:?6?S#57Y]^"5"7UR$/.O=5*PW2%
M2*N7<:D5\O<$E=V<=M(S"77 [M]89GM\W-@2VV" /9(FS8: O<88S,"?JL&2
MEG>+5PY//LNTI3$-:4P_ >%50V++9GA@>J_^>V,^:;OOLBET#3H!K*Y.I?'
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M?#M $]85Y%Y3+=0%3O>Y F-\FBZT6)I@$245U@Z0V"J"O.I1/KZ)\J+V/?@
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M3:PF$65?"WU*AT].6>AFK*.'KE$<4G_UT)*DWI!7 2W!@$L C1)]2'KH_(\
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MYYH82'&?,6>F SVS!&%OV1MW <1F;,7T?<O*$%_M1<^5F13E E!5U$G.9GK
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M=?4Q"V1HB\K[G(-;XNQBO0#IOQ'W.R*MOLWS/97B$J<I*F]R_!87+W>X0(U
M#*;U"];JURD8%DZ-53( D3IUCO$"E]\SN>FD8SS':U1H.?[KN".$:T%LNG!2
M]P%;9WDQ#5K7Z#&&^@O]SW.4H__Q_P-02P,$%     @ $XAG6?75]HZV_ (
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MH6*]P(YR&]/R4CL*CJ?%=VU#R:NCY-GUA<NOK[]"._DIZVN$R_:N=-/MK2'
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MXQ/0"E.,>W:MO+59O=> H\;ZL'&8;@@<5R?/3 #E)I9LI3!IXBQ>X[#ZJHT
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M'O%QNO>/#!?.S9T"ZU-,XKZ@GZ?.GM?^N"JARU.?YK<_[6B4%T*^94]]7+"
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M<6?YD:1)N<]*6'T"0<BC<GNDC&666F/IP92?!9^IX$/C93&L:%AQY2:@W'?
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M<G\L4V-,'=<5O\Y4N<JI1M6)W;+S2M!?5]FR5-HL=GUOW-B&*PU7/BL:2B4
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M)'1HC""SW8BCP'&$BNUACL1_ZW4(N!WDZNS)TUHJ;]KX#\:1#P5.KE6-I:I
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M &T1KNK";@8P#&"\#F $OA]@R%T_<"G$'D$<,NPX#G&)PSANV:9=Y;Z3$W8
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M$8FX$S' EXLRVLQ"SQE8& ;8AA!ZS,;0)K:L#NE#85NYD >1C=?9=\?U.VZ
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MAN6[#@L/%![(K-T[P .<(88#M=X8 &>UYD# ZD@&SDK=5#DT6W=CD<=" (4
MGDH PCO.*!(*X0#*@U;4V@!6,NFPU \30,%R-O%R3PJ-P[PA-F[R87-PW*]^
M,$RU87JA^A1?]MLVE7NI1;#Z)0K!H%5U?5T?ILZ]/HAM&YZ?^XY+<U\-]9]^
ML(YRP65K)O>MF9JZQM)T$JYEJ1:E6I*._7!2]_R?8R%ZW^N?)1$:?3I[6H#*
M:+APKJ5GP)4U+FV9FJ""2N6J<)[^3"&@)67.AX;*OFD!YU/!.4K^-%M+#A$E
MM;2,6 _28ZV182!LU#*\UE1LAY.Q0'+3+<IBB%8/R3M.S2T7DQ@'+H@0$BR
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M,8R]#9QJMQU^O +I ND"Z0FD*;%4>"XDP8"T,H9@Q9@-6E'&U;,C;==_I+?
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M\%*7DAM*T;K[V#C0'3^,K:U="-' O3$@[62]#L>::^,057]$%??ZUR,E]L[
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M=S=W)D"N4>M9,DJ;N_1 W,F=)VP86*>Q-9HSX B,L59K;YP7SJCF!(%XA8G
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M)?HH/NHO:?X'9[U]&X6A[S^.Y>-C1W>'^UUW.!&1N7."@04OK0X"@1!*<BH
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M'IQ,D^Y/#O&-?#O;=8AOJTS'[(Y YW;L>2'S\X[#0>\GTMR<9U\108@"BH4
M"-8$8RU-!X:(D:RIRNUJ3P42T2(B9\,TAXS9A64*R^15S.-^DG&(2A(M,$DU
M!>^X-@Z4C7^Y@#3R*]IWNUW,8^=I)1/]+C_/>G;LE!_!O*@A*E)4I"@#HLPH
MQ7ZR@MOC0HK5-VY<2O%ULH=KXS@E/*Y?I*S'L<MI3RLC=76K--.MTCO7H54F
ME3+]=W@M6]>!W^F+_:Z;_V#FRH^^W^ZYVT5 ;><JJ52'?]ISW?WL/^FA/PS!
MV[E,L,Q2(X6AF&FP7$G"B'&>"(4]I4BL+7]@B[*<D^%D *_"!;O"!0_XL39&
M!D(! R&9=PP!XTYC88,71%"EM8*U%X_#I$7Y3K'"YH,TLLPG>%^BA+MTKVJO
M,C[>HIOV*5)EBEKP,]+(2LJQS;D",]',9K=PB?&*$&PU54 T,L \!$H40US[
MQI@W'/\LJ=0%CNH5R9A(-XJ5 ND"Z44@'0TEP2@&(R J1XAJC22S6CCP+F#>
MX-4GRX.TY"U&=AS2&]9W8!-1&0NJ0CY^O U*T&)CFA^9NMY5*DBR1!'YX>\K
MF;:ETO$*>KT>JM9&.FNC/>LP!J*0)@ACAJDQ1! /K,G-M33G5J1J@7+.@9(K
M2 O-%)K9*IHA-OY?$62$5J"(E4ZA( *GTJ>C3@W!9$N,[A#0PNSETDR#LCA]
M^9?X33H*?_WE2"CFCIZ/!VKNDJ;^VCCIOI]RP)W[2EO;NXB#\R5YH49I3W0_
M?IPJ80S]Y[[NQ&[WZZ0HPW,_\$D HO:7 FWCJ]J\T2E?W#CD-EX^&,8/ZA-S
M;YI:])A&VXX>1-EY^^GC^X_ZLW_;]_JW_?C7=/ILQ^M^/4?G4_5SV+N,TX1F
M%-+)/-4?S@%K=F@F$XS05]^]NOGH][TX)/U7/]QL9G-#CZ\NC._/M;1QX+]/
MXCBYHM:4@[YH=[Y\6WU]UKZ(4W#L_Z@^]2YT]^NQ)CUH_SO*D+RE67<3H#J3
MB](-IY]%0'W_C_2@1S:^'N5INR_C)WLF?;2G0VSUM[KSA_XRN,E/WY_WYP^C
MU:BH4&TKS0SLA"G'GZ'OJO-Q#VJS:H*<$7\V@FKRU>S4O_K'(_OVD]?QZ:\:
MI_Q&AVH1U=5Y/['9WXZ.#P[_U31AS1-P8Y;&$](>1@&P\4E'$3I_3B=%-Z2.
M:.C.38#<?/_7O;V/GTY"N^.O13!RO1]^%5]_Q;[ZZJN]O1_F?G;]^OK57^9!
M\02A'$'N-J&.)Z[_V7R#6E7Z\WHRV*MYTD1$IC/Z_=S"\?V-9>0!>JR>W+ F
MDW?_X.?]ZNW1R8>3'X_>G;:JH^-W;ZK]XX/J])>WIT<'1_N?C@Y/[Y#A5;<M
M2<Y^UY[W^E% [GFC:_W@^.3L\/3LY-U)1,3QZ>'!S=]'<:XOJ<Y.JNE%Z=7I
MR8>C@_VS^&:<(WK_0W5Z%C_X^?#X['3N)G-0^.:7X_U?#H[B#U_?>-)&1JNZ
M"=:&=HPTEP@['Q6M&RK:2?^S[K;_7><8>3==.>.;J)I][$>\=H?UVY/P?K*4
MGDY7TH/VP'9Z@ZN^/XO]>]OIV=]&6EMZ^]\( Q9"<.PL!R24#%10:RE3'KG
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M*W/8#DX=6 %3![B,FAI)5>:ZDOZ1U'V&IG\K,]U@N@<MH>EXN *#LY+-QZP
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M[!$)%BP,8C]67TT8\G<QUQ(02GSB Y0(B@"$.,8A]I,82AR%+"!]F\UAVFQ
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MG:D63GUR#,"5Q=:R.$/_9ZK6/X>A4$J1*",%QD@HVC7,R(Z1O:*+7[.GA6!
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M$(RU$YA/CJ3KX5$_KNZ@^FV<S4VBPX@#%F*0Q#%&092P*(S#0#"! HJ(]%?
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M,!#A3E)I^]:9. QZG=GKS%YG]CISY^YV *5RM"&#D(5*/R(<)#$47$1^C$.
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M3-F='O4>S4XU[>9.TUDN^5GZX^P^%4I$?['S=2@3(<$TX)0A&' 2,88BZ4?
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M1S>.VKX)MA70B!K8M0]_\+^&QI1[[/()TD9M/L$F;3[I*^JB"J)MOE?>!0]
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MV"3;%[4(S=<7/LU2A*6&FA(,N)5(0(6UHD9B23E<+'S-1:U,%-B:O'$43J]
MQ0$@6!HC'#6. ^2<<IJA1<[21HNX#?%#9VS>L)P6OX+?GXJ#34(PB^4O.5]D
MQ ?78*Y2>.F+380N*Z(W_6DE'V&OX!#X!<X&/_Q4AK;WN& AXV[O9?6Z((PW
MPQ!#_VRSL"DFOTX)I]5 ($>QX!0SZMG1:&Q2JY'@7,D(CC:J'-IT^0 X0_..
M[Y\+.N^ &JECW@IB&@KMS8'4>B'5J6"">9_)49IN*2:\ 34XGZ?&;*0I_.<G
M^_ 4OAQ[K%$>C&B)O; >M=)QB0G$$F%,D$*>WC1-O89P2MI(SM@V/-2FM!=G
M:83TNV)$SGEJ!/$Z2  L&.64*$*@$RGTY$J?PXA[H0U $;:<8L*SYZ0/;>AY
M-FJ3!^B,Y[EX9W>E<]A\YW?6N8SE8:T;&]B(AHWZS0&VW<Y_AZ=^?4-@:L]@
M.L#JK<#,_L^H&_9+O;$6XO3%+>$:/RG__1Q&QV/=59"[[&+[.(Z+/^TJE!OV
M_HU2Z\PO3?%YU"_"NQ-T][=D-L2%/]>MQP5SR+P9Z?__'!#SD-4=F*[^7(:+
M/X]'7R_(ZY6F, P @ EVWL%DF@%BC7>JN5 L<J1BSE[<X<;2XI E71"R++P(
M#WP3+Z(_F$.\N27.JW:JIK; XQ#[]*;@U-Y*U^9/*GL!A]W+?]KG[/]]##?;
MOGZ\=C.K5]<ZA J0&NH\A'IC$"GOJ*7$$D"M<@Y'/+4][@;^6CDVO<<YKVW"
M^!/B#@=SBU$0VEOMTW;-L[:29B@WUN7UJ+L&#@+$4N_J8>I%0,%P[I83AU)&
M5.2P?SO8?OU(/3R;-X.>-J)N:QQ[[T'P(>P\/2[9VUL6K @;H%]M@*ABDW%N
M1>LPJ$;#.1BL).RAVOV:!=E."'^$9PR]'BGDK=S%#9\"9(:_1P_^(2O]>T45
M<Y)ADJ82*^\W4:.XL@!83)VUM(HY1#W\:DMV;G*EX__=8_70]L/!U*ZVY5[K
M$G?^<U;;P@NLX;^X[X[NZS+NO3N3.HJ\B8F]JR?\8*W7WUQHCH18)])Y=,!<
ML6&1M/904N0L^=O@N_UFL\YX>]E_Z ^G(+>\*ZC<*;4<W>";6[^)+S6.$GFR
MR&%QMW_><M0)FZ[C/=<QA?R@[KO# LJMC;OR3G%- %'<LG!V43KA[37J?5@!
MB:/;QYXOLO^UO.:W;K][/[I?Z5/ ]7V*:-1TG.^0=;]V^UZ0M[A?RE,=4O(,
ML(9Z01826R\4'LF]\R^@C&QHMS=Y*;8Q_=,D/6F+60!*64X=-P8)@P&&G#M@
ME"'::<2EB!Z<;7T60,?SUU*0G0C?K(Q^*11-W0KV&.N=(XF#8I T5=#+I_ &
M 6 ".!VM_;--^DP)'UI?^# XFS].YQWZD)6FK-='E4KU:C+D94UG&'LMU>MY
M=1G^5';.+ZJKYUW H/7L1X@WO*RD&%/&.132*>B]#FS @E8@1PB#7J54LETP
M[ JICM'R-_DC#'>R=?1>AL['P\>Z3O'^/L+0>69,,=5(2NOQD5!)%.3&1CV"
M76<%;@4 Z-E\Q.H) +RY-AA]O9N$Z.>==[?(>7ML8 3/;@;,&+[M,70)@T92
MFDK&"-:6"FF=MI!+"!%E<AU#-VK8=L+!@_\.&VY5K&)LK?F/$[\M8L4E'EO\
M-/U5(;>\HD$>+O@F>R-;)5OE(Z_U D[%EC&D4?J'22^Z?DTF8#7O4DZ(/!.J
M4;:\L23]XOVVN$OYQ1I[_Q N^^Q=65O7+9.P2IFY&*[T,E-7+Q(214, CC*#
M4VJDQJET*5-6&HUEI/W&5FWYVM@+Q[BX^7-)B>O^=59$GVX''\.NY7F_W_76
M=BZSK2HJ$#&#)F;B8GGHNHB_55X<S*<LMNTJGV8P+?Y3:<)%4O[>&,!2(+C"
M2FE ,90Z[.$AJ8VW8KW_R5T[&.#&^E&8'7' WFB-*4R]#4>L)@9#:+S4(0.Q
M!HY0#G;@7JU/Z_-PK-9KG7U+6C/1&_\X'\]QP\J[7E_B"G46D=F\X+DUA=;?
MYN5VGX*K@1 I5285"F JI9(P)%1@+3&UWGUJA^#>WG6S7<DMB'A@?UYD9ZW#
M3C$N&(8)K,4$:^88+SHKO<%&&VNTT<:WMUFYS4S62,6.P^_A+6YI_:P-Z8U6
MF3=:9=%L.[45S!#-+K_L!S+T;0FOA7,3Q%%7DKC$K5IVB#G\YX%AE 7+W5E;
M[I+:'P^VG]NP;]8KSA"/02$,M +XYQXF^FCMW#DBIR6 J0=EIBDFA$N O%G@
MM"#804XB6'X</O*RG9Y.[>"67!J&O:YBM>.0:Q6+G1YV73-JZ[T8;0C4'"M.
MN1%26&XEY((@L3@AK>74!&=L2<!V'- >E\T?UR =.\"=\7&_ZH2I=VR--2,=
MV'KZ[&%Q8F!\+O$L\0(7:E -J[#&U'ZRG\(@GK;@'V%_1#8UDB!=JTX-3Y/V
M@W^.EYK:"C,/>$(3Y00&6&,BG R9L H S:R5BW.;6K["&Y $40Z)-6&?G7@?
M POOP&.KH+)64T'T2V+ZQ5)0Q*"*K3B9];K>%0CAF<D^7!'W*4\^9POS6<JL
MB<#;97!F$K">I,O$SC-([RYX&H9G][I239V>GSTY&TH:A+KBA489;Z[D=]8.
M\\5G^Z)IP44:<3B_GX]ZP]GSFGKPM1^*>1>;CY,#_*;>6N/9RFMYC7!&M+1(
M.<<(Q8HR82&UVGA/Q7"%:/0H^#'P((YL93P=^,R7N(7C%)S2DK+FK?1>A'?P
MJL,!WJ>()]36L[6>Q1$%KC?-)OTP'E1T5X1Y5Q,9XH#$!"/O0&J"C!<* KAQ
M4!W<2-D@)9I%<D\WRLM=3LG0N4,0*E%(\8&(2D.P<A@K)KD",(+5^U5?FZ3:
MB^<GEX?MCFX^@TR!CP.&9:: W +E@K425F$<5)6Z?J2_.&43GA$6+FQM%5'U
M"5Z%ATQDK3+LD\&W^E')^D-&^3AS<G+3O1W>#<S9VJFS&WE[HHFW!].33[^F
M3Q\]N-L*1Q\VJGX*P<MR]!>LS_E3R9)9LRI>MB0@7F0]9RMX%0G,XW)5ZM'#
M31% ?EO$ H,MYZW)LF92<5%IW56X$.I=C538E UG,'N/];HJLX/T%WWM!J^L
M *G^T\<\]^9?W2<.CR_J!X7M2>^-/=BL*AQ1>WSPO&I#R1>8G!$"U,NT+:EL
M5G!BJ&@Q*:_F+>ER@[0B=1C1=YEE8?:%E^D\Y;R."+:-]OC:]S_XK_O!_)SZ
MKBS:-NB7KF5>9KF%9="C?.@9+?/<]^1;AM.D>==SI,Q*@';>V^WK<%RU''[D
M!24QY_=LD\EDJH=X"M>&^K0&]V5Z0U7!K6<KXZTH&5?ET2_U8ZMLCD]=/PE3
MI)Y4+YG2P=VI.MC6.(X!@51[0TLY(H20!&%JI0JG=Z)E49YO9FVKJ,RR4BCW
MY>R]Z%33GQ"Y4_%Q/I]C79@&PZP;3LYF_M;[[C J2&,?:VQACS\OD+NIJH3#
M02?8!2%:6&1(>'<OG'HNI/LIB6#,(_:'M@\EBU;"4&SNSX49)Q3NE)%$SY'?
MDX!IRAO^(8?A+R'1L_00O?&1%+Y#D/J_)+;_U?-5-"3YQ*H>TV1X?,&L9>%"
MS^QW(74H[Y09"M[$N;?95YOE@7A2>[KGI705.U35Q6/[:0Y XX6>ZJ0;9V!,
MTC+"FG\K6/@OY8&"\7 O^]_\.E9Y#UGRI5I43[K/XW2(GZPLQVRL6T#4"$DF
M9/YY3+<ZE2;U'NLQ6C\V/X2B%F51B3*LO@V;?ME4<:S'BATFY2DK3+KS3EMI
M"7K"Z,+6'//HV$9<Q)WC8Q9%2.TILWI&/\UQ4'4\.#+[B!\XE3=7&+F>/^X?
M/!7ZXWSOFL9X0L?UF'GM7:V-3)Y&-<WA4TWSNG&S<OMMW:JU]5X*#>I]+ZXB
M_HHK@=/5E<!7UOR.UPH_50(_50(_50)O>R7P#6J-16$S+AK+.RENHJ@:U1:'
M:''SC4/'09[7MF1"Y.84;%AG?8<AB>@Z1"(2"X);'[Z51JY++JR3H]XP$L2O
M/-$IMR,XQ8/^V\HFC!"YR%V:Y"MU:LG:69&BT$F^=0<].<Y"F/)@I?8>B-2/
MI;&ZW&-7LO_/;/0PU(]55"(?]+Z%@[[E@39_13CIF@4O^;]'YNM]^9W.!GGN
M7<%BRGEIZ597!<X(WF"51%'2)^QZ#;O#T;#<\"]]D;B1FY1/&/3.DDM7'3#O
MEEO*Q0D[/Z?JO9%3(Z7O550##^Y6;L?F;5:5/)[->:\MTU-!Y&='_"^KMUW8
M\N^IW>H@ ,HA2U*,&!*,&0T8XSI-'4BC&R>;G(G>SK$1N$9N7?CO(7A,?7_[
M<SR%#91(#1OJ#ZY?<;"63S/MBUK1:VF.A'.?]SS2.7U3'TZ+!G/@H=36Z0_;
M*-(ZU:,D;AA-IKW]-TU\HOUW(8O+Z+\]H<C!QS+FM66U.&Z& _W/.^]!>,/A
M0Q'U#^>20Q)&;Y"/,AN,KW<]?\V;)UN,6"U=JFE**<12&PF-#;T5A<+"&V:K
M%<^;Q'IU\1"\H6QD8Z:O X S["A/M<7& )5B:Y"W_*2S',$4''+!#]OZKU9>
M9*W&?ZM)V8#^18AL6)9WM+W0!#)LF?S?-V&/T7^NNDL6GYL2:BI4LAH QH&/
MBYO/'S]U\^%M&-R,;Q?I2[FT;_U,T*3P9&=[:PX'#S%_O*%/ORYC\+,5O4*G
MARY'PT%\Z"O;O>Y]:E/B55QC0KY&P=6_5.6GNL65-[?7[__?WZX_77SX<C/>
M0?CP__U^>?M?,RIO=GI;[E&Z%3&,1@!6W;0D -#R=J2K9]: '+A-S4C7RN=I
M3J!H#?M5-Y$7RR_1PHJK;HK659R.4K8&[#YGUMGB&$EALNV%J-%*BZMN8B^6
MQZ+GX5;=%#T.-Q\)?_F %3UGMNHF\6*9*9J(N=)6GTW$W+"*Z<YH6"\TTLV3
MX@!<?QARV$;#NT%6),X.!_ZG?!0J?(1_+X^03N"O0+^JT^;-G<QL'CJ^9M^L
M^3C(/HZ&WF>]]$\-20KU<E!"$:S]_X3RU#2AIAPERF#)(+1(QH_((S =\@1K
ME7U[;B& #6<6$KHP8P@AZ:>GM,(F-)P0B#N,&%O436D[,P/S:5J+\[;R8D[E
MYL-8E^5ASIU5AT6F2?199M=96:'Z[Z&6RF>;%>2J+[=F@!+!4^(81I8IH!RU
M0CJD,'?CW;851$'Q=/5TBZN]SE2@]3RJG81<8<)2GJ9^M5.%H;8*X46M*[<R
ME?3,N]9@]1)WDH>9/D!ED9L0PR]6O4BES&S9?_(Y!"KEX/JI-E%]_T,)RPEQ
MB "*@= *(N:X=EIQK9E95*5]">=?7GU<0)NY6H[;F@0E4FC#K:*88BL %Y0Q
MYI1?;"1<3'Q7 =,S)A$I2#DOO@O%=JIDE!RN?[ILMXH51//<5]YUT(CB;@G2
M*,('X"MRIN.]W5?>]7+#+_&^@ROOFNT[V&:'.M1K]"39GS<=;SNX\JZ7&[.)
M=\-8>=<:49O7X5''.V&LO.OE!FCB%8M6WC4;HFFK4]VDMU<]@S_F>R^W8TN,
MK!FQYY-'U&Q88PSCD .<IM1;K=8[VPB&;@W88FK(HL(H2VS8=$O>UGKC5U@8
MY;Q9;1C!H>@9HUH1B[G_VT*^J.S'5L:/TK23EO]_EBW>+5+?"@VVG@]=(\5:
M7J<T"%@_3T8QYT8)(J0QBEE&B$"14L7[<J"?-P_O.6.-B*'<&HPY%L1@Y3C'
M./260_$ZI'OVGJ<TAW>D9YWGSAHE ^88/>YM.B<1<,(!/W^,*!'& L<0MX!!
M*-)%E32VPND0T0YBO$/32+FA[<T0>[Z% @H,&&;.*D-PZ)&'#56A&?PN91E"
MVDDIZJ1H/LFQ)KIUL2TC(E..]#-!?KKB05%O,_G:+?H_5)U"JV-Y*\@;LB>N
MW7^4^;O7V9>PX1\G,4$20HD\MGNXY)()@4+%2*]4 9)\S>!:4Q*S#B/"4SG2
M8Z"B<%8%38NCO77*5KG)U0%;_\GDI1(L3NQ-W>:*:&OQ:W':[>E<W>R)O,E)
MZ7"6(QP3]I9#.!:Y:!FGA'VX;E"LQOS/#A [!C%B8:$8QA0XZ81$"BM+6(J(
M:Q @?H9V(QU.80?!2+VV!0(AO\ENKT@L"@LQ7H%=QXP:;4Z!E[L[%:\3LC*'
M)7U%,:-X/8V5=S6LIQ'+K-W,W7A;E+7PF)''#[*\U?)A]J=Q'A@.)Q1[=NB5
MS=LJ]V]FG:9R]:8\I>(<9/P040A,/SVO/#!YUQW:XKO:>9OYLY&!+I 0C['5
M'S]7[WB*_DQ"!&5/\_G?JT=-?H_&%=:/+U6J--^+O,9/.J^\:TF,M_%9K@TF
MT2@*V_3DUQ8E:LEQL).4+9>R-[^6[>!WS%F-PMEP23[A(<2C4?P8DI-X/(E'
MNX4A6ICZNI_\N_3,DCUZFI9.1"?4D?(#\WY%?S"TY?&-F1(UB?UA,]W-0X6Z
ML>LSVWST893INW"4L8%O6%: N'8W9=VJKLW?RU[/FG>/8\5779A/'5D$+%6"
M$84(=L()10E6,I5<<&)LM.L8 %M*5EE2;//)%XD75JWY)Z&\3J)E?M<+=6J4
MS+MYI"-NX54^,Z!Q6=Q5SPW ,&7.0JJ@P\P0)1 A %DD%"0,1()7JZBUON<&
M.H*Q#@$1HBUPW(HP@R?&$T>>)9YW?Y.>QQ)>!3'^)A]=MRQX%B*8D[(Z>8U=
M)WYZJ/L\YM"I8K,KS]-NCV,I#N5(*4;<_^%15FK*D$VE-AJ"5$8C9BCE_XB.
MH#A?6Y)@_,K8T=JFSG8'<=ZA?#[DV%+^)MYL-0 Z;3#$#BIN(4H=)\(@KEF\
MA=N!: L[F,,.3!>'G2+BL)#9:X(!\"2\5[1C#Z7'\GR@NT45YZK'6ED_ZB@1
MWPHF-,6IH5!BC:5DAC--I")&I<!%^W"BL%.^#0RCHD/)\8B#9*D($3F'!3:$
MR118F<+4PST1E$<K]&V+5)QT&'\^UI<<6['S8R*.%>4]K)C42FF4M445968\
M)C&#E36$&!,C/4G%(9 (^(5B'0^8Q\+6DJ!4PM!H2EJ,$9"&&@G]5QQ8D(JH
MS7<@V@KD39[8]E13C#\??1WEPP208Q4,I  V@DF&J,)(Z[!O8%*J4D4@5/'-
M P[(801#4-@1F.Y+,)ZY)BL%11@LE/"R 3R9*?=P!%P0$$<U,A9&S?V#T9IA
MT.%\_7W.I:*RX[A)HS0S2-L5_&F4ZP79@8(_Z SY_T(TY6 1H$'V<"?[_E:X
M4;"T:P;?RX=$0D5^).J?77];N#<?9H-_VJEBD%L,)7E[2_\SU,9=$DYZ=NQU
M!6L?;&NM41X?Y.V2V$9[RK!A8[U3N+8]X=J/5F5%O!9.G/N:/[Y_']R[DU*$
MD I3&@-+!0*<8JZ-55K#>!P1PNTXE@AW>"2U\3DFV9WMC7LGK(Z /%0]TD-;
M+<\K3[6J@\D1JG)[P_P\=E9I"N;62*B]DR:>7;1ELWW!L3$DPAHJ[DR*!462
M(DR),Q@XQ1BEBZKY%]F21:>W(F\I3,;+E1]V82_6;-2M&HN B Y.(Q[K&FE_
MS\A+(T7[/JRA9I@9*C C!&A*+&#4\(@37[8_.@A-H'<TO;>2+O56IA-\ZYE^
MG9*IY_M_56YDJ.^IRX>LR@N.$?A#]9BB?_3DQPFV@#K5E<( *N^Q$XR]6\^)
M8#8%Q$'AO1<6=>\WYD04+SZY,HI[!B/T#DRX8R*AE!. O,LLPGZ744)R#+ T
M7%-@/-_NA#4;$RF6OEK+1H[P88&[I7T4V@].-X;)0C,:CY#*#K^'AH?7>C@(
MN#K):@VA0YBB]&R,!0M*U>D[:T8]3^IXT;K9!0CVUFSI.L:!",51":$22RTD
M9D 8I!1U%$UVV.TFI>LPHXQ :HCVKW!4<&P(\-H((2V9%!;,F-T[MMSJYE=1
ME^$/U7_U)7*#7F_PO>@Z4:1>YJ/[T"CG?T-3C[M)-Y"@5B=JKJ[[7-7BH]_M
MV\2SY/ NA(9#A[5Y/?O+Q/B>KF6W8V.\43ZC7^Y?%[]S]4(WX YX,O^/VOQ/
M9GWFA7R]G-/K:[O#)B'U]TSUAEC0-R1:I_\8&H2P)0U"MMD>I*7-039M#7+P
MQB"+.YXL;]408;J&N+C-EB!'W1#D4.U %M9LWT[!R4;I_ AL8B',*ON(6'\L
M_ENL.:/J+Z(F9Q%DR\'\*2V_IC:?547KE1.N0$R[87']VO6%U]XFV/(60&NB
M_?.@,;].43-RJ6*(52".%E6NU2;^5KPS*,A@LDQ6<+8\<?GS7Y)J]2<6#HR8
M?=\S^5#+)8^51EXR #_M@#S_]PUHTV#@RL%4%L9X+)5P)_F@US7+1A9MN+&6
M3II1,>5.]H(RR_%"R\]=B'DF;<'2G/CD>7SR'U6<<B&G-'OL>1GUW/)3QW&]
MI CLO2SFCI8Y'_^P7=BNU :C?X[Z*^_??_@0#)M-.&_L>[]E9[#F"@=*^A<7
MWSV=PYLM5S>WO[.WE<X"NRU>ZK&^;4*W[0';^JS9CO$N&EV$\-6 Q589<T79
MDD)3OI.Y-2&(;_MY8:.=!];\6D3XWST^75*U,CX/-0K*^/93<[#\.B2#WWJ;
M];KL'GTU*%HB6U.&7.I;,P([JQQ)C238IH03RHR6 @'-*76+BMXN22BKOMK/
M1EA+D'<3]HZW.#TAR@Y)OEA _[13ACKAS]C(JZRROP:DN)!#^U%VLZ(^4[V^
M%$642@Y2(D(#3R>I0TH:H2$@1,)([=X-H&F;&Z$O )1::!_NW C\4"8&M=#$
M:R7JMM-8>RXB_A2'1&GNY0[QL&*UR_YGFW4']01_IT5*E$L5-A!K8P3FFC)
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M0Y5%7#B^%6/:?E'$E1G?$86T5P=^1R<_EL'J$]-]D</ZP0XN)=' "B=2@(V
M$G%-H0/:*"8LC1[L:&1;3A_Q8/$C'F_ABC,>=/Z$QY]W%O'8+>?.-:P\2?]>
MI'^GNPIQ:&F3O&-CH>94<VNP-%(BJ8'_*ISJ AI'^M<WM*>V).\\)N_')>AM
M8])EIV37INP!+,%7&J.]Z'[K^H&9Y+%K>XOJ?K5!:^P]I+$ML=TA8YWLSU(?
MC9EX1ALAXI1"(8@I.(8@5<)!I8"W19$C-@7[L#[!V@>,T[-(#>W];\2U@>TW
M#H^>4.>$.H="'293X#$F!0PKG%K %950<>ZM8N3_C!3MVKX-O"'JO$YL.84?
M-Q?#+]W\GV]=9L,A&8\!-A\FF1>/%MN5+<3NXW#T#AZ-"+SVT;/:9<5I,SA,
MD&38<$D$Y9A[Z-7$KRF%++5*LS2RM[-]ZP^O'XO 9V ^^OBV/>3$7$%G&%/<
M,BP YM (Q@DE0E,&XS5ZMIPFL!TRH_EZ9:>@3QN"/B?D/Y+5;COR8X40DE0(
M@@D6&*O4*48P$@ZGSO'=[.I/9T)L!ZK@O&W>(HT H$008PB13#'SFM8RJU,+
MD4F]ST,C+76VGCRQ)3*?-$([-4+4(ZM]>"HSM[>SFCAM=%83;')6LY75IG9%
MWT8E^_ A3G4O/$"\VY/VN%%!.'R((]9[(DBC&FX8;ZO"U(YQM#1(+QH6A>@4
MMU05?R8E)L8E)X:#Y&&4Z3MO#?@[$OGU:V:_5C5P=F1H1'ME_34;Y'D]C\
MJA6G3%.$C3;>=V>,0VF8442R-;KU-?+=&Q?")@!T:,2,*);AD(2$1@NGI16
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M-4A#G=/RAKDEG"I_N8N5+'[,_Z,[O+NS/;^,[P=>J,['8Q@OZ.=0A;3N.PD
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MXZ7])GNC<#S6ZYN'AVSPP]\U]&IN47!L+POQ]S"F9ZT&E3J5-&406HTQT0+
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M/A[/:;WU^ZWO)+/X&>W>=YWDO&8YLA6#@^OEZ\?VZ:>VW7>\:UD:/@=*1CO
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MY_TTU1LDG%"$#D!ZR:]_NP&0 DE0I"@N(-6*8XL+@.YGZV=_8M;C]!G,X!A
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M_'CPIKYXT^L']49']]FBA5>->\I&#@_5K57&1RF^JM,_3V]27W'=!NR9C4]
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M;^]K>[2M9F%H-?OJEZNS?Y3.LRYVE5W*0&MPW0%WE5VZLS7 <51=99?N=0T
M'7!7V:4[6P,<:V;>K)9(<]"%,-<+.\6DONC@1MZT=K#J^5!:70_F/1WF(1G;
M>P_*VF/9'WZO"X.=',_+0:\J=2N[2?6D&5&;"Z.]IC:;9(@4E<X:Y3:I:J3;
M_"9E/7QVT\_4R.>DW#7OU6OTL9E=_@PT&FTJW5W>95I&G^70I[M__-3<0UUT
M^]"J*JJS?UK6[=-RG)[B_2SU'5;H7?/QP^FGTEMES4I=L7P;&Z*1^Y\S$H-$
M);&%C B68,HM-DN'3FVFC=70#N8SX!_KYC3;/-1!O$P;NG6<<'.;C2HOV>^#
MLN?)U=!]Z&?9]?M5WRB?.2]]NX(QVF2_-WF.+Q9_*'HO2V(&P_[WR ^?\G5"
MM3MPQK/F]IUXWV3IWYM#9N']9</;K+ 3'V8)M]+35]C&!>/>IWYYN;T9]67>
M]R.0OZ1E"Z.J%<W,[G69L/)P#X^"PL/K3OYA\TG+E_>7'WZ=]'LI,V1D__N?
M=ERNY!.EJBJC?@5.OY:RE9W;Z;]NT[XM/7DE69HRS\9)N+F=CAV?^;W7R'P)
M?(7W4GH/=']D'B1%J4$5D;*^PK]![I.>%Z/!>"TFNJGSY]P*9[;O&" =N$O]
M0KP3U6FQMU8VRIC*/E9U]YKQNPN:TKIME+EDQJIA8W O>]/N1O4@]2+08W*2
M>58^KTHB>D@5K).('LJV9F_U>$7+F+\G"7"U13X]R]<=9A ::7S%% 6<&0*M
M9$1*QF*]BMG=X&7?IG5SG:;F.:(F% _ 45$V\O)=AO_F/<".(MP#/'U\LS7G
M^/YE9>)5>6[4$O(^SY*T[%@PZ7U85:951%-/,)M0<=FQI&QE5M_@;7L'DHG3
M0]]:,_)3W&;='^</1/WN>_UAFR-$:@L)$A:AQ,E4H3G%6C! ","6RQ6FBB]W
MA-!8"Z2DX%H20K3D2"-C"98Q)QC%"K[:1]+CXR4DSC ;W3G-P-W0_##YF6;J
MAU;/30GB]N^8:% )RC)'T'L8)D+65T?=^NA$+6"2;-+JKA0U/TUTSVD_R1,+
MHWY97R]MSY-;<A%[]<@3EQ/ &E2#]FD8S%M0NU_$'L,X\^3W*$$^QTIJ3[)9
M<A%_#C6VNC66782?/+Q*)\/A\^96+74H1H^FY;7YW5I]B0V/W)?R<3X]T2>,
M>D#YK;HW?'^5>A^S'KKJN\X*K%(:Q[FF]2*C(NNGILQ4;'7C+<]W6WQ<[-+C
M=WV;.TWLUZRL<3^;KW$O(\\+O'OM_KT5 =^:(EN1PR),U-0X005JR:[_FDOO
M6*W,NH5^VGD'Y)J$E&=?9_>S:/5;=54\'0HK(JEE@RTTVD;?"^#P_%6AIX-]
MZ6K=45$Z/78,J\?I_7"0NJ6E;@/3"Y:Z4(3_TN)9VHX\/&3RZ0:S;VMW >;'
M!?--:@#[//7;Q-L3E*1->2]:FB#LI$)S'!@"SRG'+&&QRT++UZ4')1L5<F"*
M-Q,#]?F*]%/4YHT(B1=M.,V&QX[+1@J4UUW*J^.:@> "P>V(X,8AQT!R@>1V
M17*#<B<^/GU<5'<LML>V^6VKB]^FZ;Q'I!P,_#O@4 ED%L@LD%D@LT!F@<P.
M _Y'XA&ODSMB]&-K3Z?W[\_./GY\<IBNM6+@A+U%C79A'F@_1?5[&\S66Y7.
M/OM!8R.[.\]-.:GJ$3*ITVS60<3F>.8)9/V,]2XEG#W0PU^W2@B+H-A"(#5@
MQ;$ =MD(@Y(-/^;9W;@[]K_2X>W[4>'@8_,S/S#26_JGOF%&8<VU_-9(!0>,
M:X$!B@7'!&@I+<4:6XA9HFE,6X>=3Y5U_/O!M^'6=CZT=T4Y+F(N_[R>@5Z6
M6/@WWM7E#>//JR$3'WX]G0U%U%]8/G@"3Q+/\;)1'!#W .=SV><=\<UT3Y(%
MT=MI"1%$[P&*7DXTM-1/ZM&$,* $PH +2 A% DD,=RQZ9ZL Z[C<%J0O[3$X
M/\<FR-X@>P]11 39>X"RE\142J@MA,A7,PMN%:0PIL("0@5JK;>;EKV/"]-)
MC'F3<A//3TL+0C,(S4/D[2 T#U!HB@1:IK2 +(:$TT0@XF2G 4 RC0@E3VP!
ML;[Q+GH<BY<F"X\FTZ+A,#_H -)ZQ\W1;'EE+CCH':]WE!STEE\>D@,GOX =
M!TY^ 4@.G/P"=APX^04@.7#R"]AQX.1M(3EDP.W V?8^*\KVM/=Y9D;:-Y M
MW6LA(:Y;GK/@/-Z(\]A3^V52NY";;F%C8BYH#)6E!%,_XU<B@3E05"HN5XBE
M'6(*68QZ#,.7YH0.LJI3ZPVRZJFRBC)H$5-0 $@(9.X?P!'&!E@ 8JB/-N>*
M]0AY<2&S(*TZM=X@K9XHK1( ,);6M[Q5!.A$*&*E4ZH$8XA98;N0I92DWZPY
M^=/FV:M?3H* "0(F")C#$3"4$Q1++;G&E@B.)(@Q)\QJ@X6*2;RCC!X*>I"#
MER8\0D+/T[$60@X'Z8WNT(Y#R.$%(#EP\@O8<>#D%X#DP,DO8,>!DU\ D@,G
MOX =!TX."3TM/X>2T'->CA:-7OO9HF^B),_N&@.;0UI/M_QGP3>\$=_P)')=
M$?\G1_K-)B6 QE;86&B "#)$4(&XT!Q* 2&5Z#B3>PCO8<)>FD,Z2*Q.K?<%
M2ZS7SQ%9!"+AFRI!2Q)"L>! 2*X(TR1A NA=M[3;:(Y/41+-R;(*^1Z+C[+!
M4A=I]4W0"X.4/4C*?9Z410A#:+E*-"0)0(IPS6,(C*(62Z#VE9NTFH2D/1&3
M("&#A P2,DC([5C.%"6)QKZILI(DEDPD!L92)%HJ'C.XO"QF0TWC1(_B%]?I
M..16/1UK(?ISD(&!#NTX1']> )(#)[^ '0=.?@%(#IS\ G8<./D%(#EP\@O8
M<>#DD%O5\G,XN55#F]MB&,F!B;+AK<TC^^W>#@K;BP9V&'S$W?*@!1_Q9J)H
M%]D@F_83GU54WW05Q\P@F%##$THP5L)*)*&(B9(*&KN\#+>K25:K!>-")"Y$
MXH*4#5)V_4C<*D(6".;EK)4:(J*@YD9((2!#1DK(=MZF;FNMGXZ^(4LGR3/(
MU2!7#Y%P-Z"]0J)4$E.M=(((QY(;B;![38Q[J?$*VNL^,\%0C^.0*QOTSR G
M@YS<KIPD6F%DD3",64)IS+5FG% @(;0$6;&YA+"5)1\_RI:@7:2?ITJ^3;JD
M\^SKJIQ\^,EL+9M]2:&W?6Y__V&X7>^^8R&Y@/S ^0'Y@?,#\@/G!^0'S@_(
M#YP?D!\X_Z"0W[EDO //N_O9$\G&/%_X+78_]]_&[_K;/BRAN; 3!VLY'.6V
M6/"YEO>S'WVUGGU^B@@ ?W<T-AS:O*2=='#S\,TLO[]UF_PI0FTT.8T*\9;Z
MM2[T1SD6*N_S-<O-PY. O\8M1OV1NLO\M<4PS_ZP)S7!E)^W47;U(&-U5O6,
M.QG>IOH/']'Z*4H'Z3"=X*GQG1J&"S^O<3;YW*3%?5]^]^_TTX&-_I+>W6?Y
MT('40;&?R6$CY;+1SJZ5B/V/L@XH-AK*;[;X^6^>6D(X.X1I#M/-_GB4YJ%.
M_V.>W;UW-TX'(\?QEY,>C^]*7JB^=^T9XNR;>X@3#NE YM_+G)^+;.#C-'G6
M[Y?!GBJKN1'G0181S!*)3"R( $18:*0VQNA8(,/AP69S+FN9AP0^QG!2:)EW
M, !^P9)O28!Z-Z(OL3'2*,&""D( H4(;*D6"F42)4,FN15]HO1>"ZIN!:Y#6
M05H?G;06D&)-+3:((**)45H3BK@2,A&)^[O;B9NBQT+Z4I"T0=(&2=MUCP #
MFAF&,5;*.L$)9$PPQQ(9S!.3D.53YS?4"I#VV,L; K_#>,*NLB<=5:O\;]M"
MV4L*H!Y1W*Q#.^Y8H#0@.7!R0'+@Y(#DP,DO%LF!DU\ D@,GOX =!TY^,:F'
MQ]@'\(.]SZU.2^]:V0M0WF4.1G]6;]0M :/@;^Z6%RWXFS?B;VX2_^G G#9(
MOSETE5%M,8X)2"0A$+F_+&0@ID 8*?!R?_%!9I#!'GQY@VJ"X.K4>H/@>I;@
M@MH )F..H=1$.5DE#3.(,82,DV:6'7+^UZ.RBP,4)%>07$%R':KDXHH:#!%0
MEBBB$\*- <*")(ZIDU_$[BL7ZD5U]@SBYF  ',3-L\0-54 +$'.I 24*8HD2
M+0U%DA&BM$$[R@B"/4' 2Y,DF_3R/:&UVO+N9P?MUKO.AK(?R:*PPV([!-0"
MZX[%.Y:L</_AB2>0ZSK1A,<EXVE)&PTAJ R!2JI$P<028[%,J)0PT0PHR85M
M%8*'ZMQ"E/9(3%MD[0NCM\"R!\VRB302,VT228E,&.<4*$:IY SA!)*=L.SN
MW#H8]Z" @6D#TQXRTT* E5(Q!))( C15B5&*4,XE50R!UCJOW7@TYHNZ0$^P
MP'"!X0Z;X:RD5BEIG<9'K)$JQI!QS6%,&(_Y(L5V0V>6XR$*VP*I!TD "ZSU
MJ9<_N&](U;>__%#N6E=E7++>]NP[C4MK0[7YSLRW2Z1>NZW^6U-D--3, L2(
M-D(R+)'2&BNNB;:&5UAU%UIS.ESQ(E'15OL3::P%4E)P+0DA6G*DD;$$RY@3
MC&*%VYZX["+RRD')[WJJ+]AV?0/1?+G2=*.IIZ*MZ0#L6YF7M'8[\84,L_OQ
M.NMW*E*LWW1@<QJDXZIWGW_[^)N\L>]R*_\X=7_-^&#*Y\Q\]V.6#?UI5S]^
M3-L _/@P!FKI32Y&_L@LG]C&3KI4:&=[MST!1WR"HG%'M:DV:]-=VYQQ"J?1
M,;_^>@GW;NTGRD/K1"9NB3]%LO]5?B\6@'3.I?7S;3Z^E<IR8_.ICFHMJ/PI
M(O??ZGYK#4A'M_6V4'E=[1($Y4^KM[#^Z-7?5D;1/ZTT"_$\NZV2GV1TFWO9
M_1_G%Q_._KL->>W(F,'8N!W<T!&#+INX&?MM@A_96OK7MJEZ67,"=<ZA.$UT
M:[H)QUM36=^X17NO2O3N_/+3Y3_.WU_UHO.+]V^CTXL/T=7O[Z[./YR??CX_
MNVI?]8Y6>'%Y?78575]&[R\=NBZNSC[XWZXN/YU_.+UV+SZ>7YQ>O#\__11=
M7;LW?CV[N+Z*7O]^<?K[AW/W^9N%B]\2&41-$FBCX?FC;(.'FUCG<(/@.:<;
M6>=TB_=RNCWY+)O#S2RKKH\I"-9"%7P.JN)U4$4]JDJUS3%VWZN:OOGF?[[R
MZW>O[Z4QD]>5:-;)L/S^^CGG\SKK[-GQB)R?UT!;HT4KZ--TJ9%2GXYCM:5>
M7E3ZT,I#KS5:M$QP+@X+30G';4>*G'RTT:_NDMLB.G.GFXFN[/VP]")$V*W*
MV4-X00AIH8VPA?AC38$3)*!%75\?,V 6FR]/(Y[.S'!:QX!;R[YLH<LVFEYH
M=&YAH>CI>%BZ 7=^E,K23H&WQ%X/.-XLCE>/]Y=Z0%0%.**'",>B<I@7232=
MI8;M;#>@X(A1L"GU8)\J09O >X+NM*GY!%/V\FXF$4SE8X%'!@W,3Q=8:7K
MLR<#1 M' [Q.!]'P-AL5<F"*-Q,+]KG:]59UZ16EQ0LVK683F8[%B@I$>$!$
M6*?C!-H+M+=[VALGI03J"]2W!^H;9SE:<RP$> P6RG:9;A_-?K;/I]OEE(.
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MIW7#"Q;\OQOP_WH:OTQJ+W!S\IB-C48<LD1@0GFL (P!D'',I$9Q+(XSI8O
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MB27& L%@S!2&"BLF+$VZG?& >(^"$ @,HC6(UB!:.V;G4V-10CA41 NB)!*
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MURZ+;.!LG.\3Y<+=3UEW2YOKU"VW.F+G%ONPL,F"G:292"+CF'+,/;/'L]M
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MWD&EDLMU_O<(MO")T;!:";TIN0H$2F? ?81D6OOXGZ 6XRP[.@[]!$5 NHE
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MG7NX+)(= (P5B,\,_X)!$:] L(3;1'A9+D)8,)#Q*L@4G:0R#/%_2>[8PRY
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M*+JQ5MR,ZXLY4*75IA8P\!S%RD*A>+GR/FXUDK)-UCN;QY;UE,4R58UEYQ_
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M'R<@Q6"J4&2,JF**5(1,"<=G)Z_?GOY)5SSB]F/J)WKZ"PP0^[F7I81O "<
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M6I!<0<=&E>U1@1'1;*LOF6:D0?QZ1>;2!R7@;T/")IL23$@.5-74<% PM5M
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MNMW[!7,FM_ #%)\^GPTL1K>-C-HU:@^P,/25R^A;F+-=V7JC&QBOQ&K*0^0
M^;85R4M5+Y4<92-=:*O@?9['9)$O05NQ/:]\;\W-)I"$]KQA@%OIGFH8^;Z4
M^75GXP9M-J[-QNV0Q.HBWM>EBWCW(8.K=_S>3@"PL+8R$W6YN+L98C7A%4O6
M K:Y9 !$G J!IS(*8'A?SK-R7/V5]'ADK:Y?I%(Z__7W:;_?_>&W "QU/\@V
M9%F<L*?H?) I#.G)E-[J_?"M<A!M6YY#G"P^TTRPKZJ F:"<W4J:#<9=X)04
M T4@F[,B!%03](/%8):IX@<7(3]XDY)C>09S1V1'T,[7"0CV8 U[F(.Q"#95
M!WPHVX_W_8 M-A7J#N-+S(Q5O!P:"ZLLR$#4ZT1/O1)?+;S+QS)+^'[!4W6_
MX%NYSPS3UMV%[EWXP7;LJ^QP1[>DZDL$50.D$KPSE,A[*:<+2LZFCH \5D2N
MU)=6F9@?K;ZT^RXU*%K?EOR$D146N9U[2#'0*%9HI>B^\J-VC(.\N0NAZYUM
M>F^5^; S29'*_Z/#C;LF681)HL[D&^4(*DMQ(7WCJ9,$LX$5!F(>A" K,+R^
M%)F#OEH4PRYSM&#3I0R1Q*@V %VHPE;%EBS22.LP6 $]D.O K@1(* Q-748R
M29?!6EFH[#ER%L/^!" #H]OT6YK'\422; !4X$KZJ0,&B&2HD5Z+2)2S9W42
M^P2&WFPZ)K84*\:QK0T^!.DGYPT(^#C1HM\J1)-A*B^7&%X@/R_ Y"PXHAEG
M7&. 7V^@%=0)+!X;$Y%>*,K;SA#,%+L'E7*\X#!EE :^<J](Q(: D@L1A$1;
MZQCC2!>46+? $,ESCJG("_@8?6>P^ $&I!#S(M-&-++(,>6 :*4AM7PC#8!#
MJ$ N+)V<<4&Z!O&,M8RY"B&$H"G(24?"Q"E\N9"4;D!RT;$PFJ\N[@P\>0G\
M5JK: "H.,B)S@*792+8$2_*<LEU:B=6D/:E*!N"W0F8+%E7EB!_7+9Z0QO$Z
M'6KVJ.)E#?B+E'O&2I=</_*-O/@\"@QZ(IM-5"#&P=@-,C"P:^H!HA]3IF(_
M)):DW_T&/+%G#STJNBV1>IN.:E38S5US00,2[U)TNUN3!KFNZ.+Y;&SY]Y54
M+:,,$<C5$29R48WKUR7KKG3[<;VE( 'R/=M/0=6,YL!A 2A5L:IC./7!@.QF
M&H'S)JQ KO3T%32L#+RU_ZTJ,IVMWB!$!4F$N(S_:[%=5RC6+_(7C\80N^N*
M[\@<-YWYM4@ +.>I\Y+O1]3NE<LVC@O."&AJS*9J^BGE(EXH/<0'(+7SX3J5
MDY%[Y'!PG0/_IV<G24 %Z7\=>V3RPQ[^>@_ZRP/U_Q<L\Z_73%//V _FCU3(
M_Z]SCOC3>Z(4\?\+V:'TS6\8L:4W5;S[+QW:*KU&AOA?A@/K7_KEZGFWWF?@
M_:6!^9?Z&S^W?^-OU!E4SF*4SZ6B)11@"!H\+V #36P+0VPK7<2>J^))Y*.5
MB,0Y2RD<]&4,VAKYYA7H(C(X2#JBZ92R:Z<W;\LLF2PP@$%^'6A4&-^Y:J&I
M\TEN[*^*I<VE)_!S, +F,@PD6HM++K7?@"CPT/8CR]%(07L8ENA!6EAUG,N%
M+>A_X6 <Y):%<@4Y",9I@GH^M:IG5/A4<-7J!8RLS3\[$8"0]D2Z! Z4J]1)
M<ZPVP9A]A:5L9U85BZ))E9J\AZ=2.Q5X[4ZF8-C>X\0@6*3R"'B!*QUQ23!Y
MGI"!2.M"A[OL9I?@JZ?:PA4:X6#XAB(ID 249NW_$@PDK+!31(59[!0)Q\5"
MK#QA6QVH+-Q001ZC#7X!_O2"DH5-RD?EGY25Q-4;:Q&IWY$$05; &I,-ITW4
MJLB@-*1N$P6.CX&#HU0F%X%'B7?C1'3HQ > (KXD/2+(KHJ0SHSEBW,6X+!V
M7@46D%FAEKY#8\(EQ*ZP0M0GA@) 61[:%F_"VD(OYXP;E06S_Z0"+1XZC[0G
M\O:H6 UYO UPWR? /6P#W%]9@+O.XGBI%,\U"M;(0(PY^!(4)VF7N;R205G^
MP^=IGF)]?Z +L$6R(1&GN!Z5BUN1-UO+6(D-S3Z7MBB!T92<!A&3!5E8ROB9
M9:,X(UEKI*IK9?)WBEK7*.;*U[0:([2N6C9Y[UK/9FAW1!04 8*YM.0>"LS4
MP)EB$AVG1%<[NG2$V9+\\TNR/TK44F. @+I$6*2@ #'65&,D[3![;-4"H,O(
MFD+_G<)#*+8!>,;$2(U^MNIP:Q.HU] =(IP*$OB<4A%:<\CT6(#^,IY8:>]L
M]Z2%)G&1%SG"0D;57(*Q4^@90;$Z$5*<BJ-U\9;/Z5;U'%HB0ITT0?\MXS*O
M>BN-;(HEA3<,'7.PB?4<V&^AL6](QZ?Y' S]+,_8V;.IV1YXC>4>28GPG:L5
MIW)6,0Y#-0\<V])!2T[I5,V!ZM8!/E<@3SNG&4A*99S=IG[J^QW*Z28:GG?C
M@96)AVYA?S\]ZSZCO]4I7OZ;I;VWR.C]9W?0N&PFV/H=V^ILJZN2FJD]V:O^
MV&/;H<;TN7^DA8RO74CE7+O"CFI8?\6J*DNYUKBKC41\)#;X?2?U/^JY]I8V
M&D4;;U$P?CFD\;?M#@:M<+O?0OK-)F!2W4^-3)_40AI. &BQM?C_JO'?\O_7
MC?\GQ_^/8*8<I-?9_N<<WG'2NY%6-2CZXA2S1'&>BLA_H+NE]@/+?1#4[9N3
MC?JU5Z[^_>3D]>LW;QZV;_"NZI>FW@9V:S =\%[CNR"P66T$][.EP<B==6?-
MN<OX42BF)>^OA;S[[F@\:JF[N8MMJ?L>6SKL58@M>;?D_:#D?>"K O>TBYM:
MZ ?T;Q[_\A.[,+A!'LR3NESG<+<-74D9.V[W<&>]_J$XN7GJJ"6TAR2T@[6Q
M;PFM =,_$J&![3V8MH36$MK#$]IX>K!KL=H8_9WN]K/.Y#3(O/V"G.!#<O9^
M26W';5H'4RUM6.<I@[&Y%-V;M&FFEJ2_*)(>C _F:;8D_93!V%R2'@V>?C[I
MJXJDGUH]4QKD:K3A@(<*!TR'W:<1#&C)["F3V5%+9"V1/7QHL__()QM:0FO6
M]*TTJTQ^*,NU]LA'HX+JU>;=#;)V]P.\Q_-ZKSW,U+"U7^,7[W\[=PD&N</9
MP2*<32+ EH6:N/:GP$)C=S [6-ZK2038LE 3U_X46*C7<[NC7LM#+0^U/'1G
M'IJZT\,5*S\L!>[#PVQP/J2^3;G=1GR_^&SC/,V*\PS[;F_:5N6VE/;@E$:&
MUL&.%K>4UH#I'XO2NE.W-VK/M+2D]O"D-G2'PX-YCT\F5]*HM,C9CEL\&F3O
M-LP';>[*#E__-W#;.NV6J+\PHNZYXUG;!:@EZB^*J,$IF+;'#UJB_J*(&OV/
M@T7>&Q5DWV<9UP%JM3XZZ2:EBPO]($WR=<,\DL8TN-Z=RX,EJ<17.</10,'0
MW(4?$N4M93YMRKR#^CI8F7%+W"UQM\3=$G=+W'?MM^).)@<[5]F0ZS;VY'(,
M&W9RI+8FJ'*?9H-=D[N!\] 5B'Z<XRVA#T +]?S;J/;'S0#)<.0.Q@?KYM D
M,FX9L67$ X*D!\;%J#'&1<N(+2-^K8S8&[N#P<%ZJ3:)CEM.;#GQ@"#I]]SQ
MX4I:'Y:,:UQQ\\^_P1,!D"X>TATA/\Z3[ZR?&"RE5VH]X<$8?-XM7Q;O!TPD
MU0,NXL3)EA+^/Y'2$9'O1'@9^FKG9>ATU;0SWSC/!_W.V%D%81C$$7WY?#;L
M3/0OKI/(="V]++B0X<9U1$JUAR*! ;.8YDS%2CIKF02QGSKQPA'.1HK$$>=Q
MQ_D(SX/5.HDOY IVX@2IXR<P5.2LDP#\^B#<P"(L .* Q;92$<J4%@4(2U/X
M*%X$>"\B+9]6<RG#D%<594&4PT<QK(4*(T7HP+Q)BKQ!@WAQFM&+(HAH.7(!
M@,M@A@RI9XFKC_/$F><I0 _F2^4YOI=VKL64HD%U ^>SGW\43N#_].P_?_W^
M[NU?O<FH/YQ.9J,9//A.W)8*RF/71CE^1.8H?>1++V8P?.\ J<LDA"W!F[^=
M_M\_3E^=?OS_G>.WKYR3X_>G'X]_<SZ\/GOWQX>3UV<_?H<C_5RWIOL2;U9#
M@2[@SUD*W[F,DT_ J8XGUGAC*6+B>7\RZ P*0BPH!E"8!FF&[^-[O4FO,S4D
M#+\$$5!8%B= KYY(EXQ[_(?\=QZ 9$&4TI?3<4'I3/NC;J=G#R4\#R0%O)Y(
M3\*WP-*P$@&21X2A3;CQ8I'*##G*RY,$B2L,Q#P(@RR0/-EPV)D5NZDP4G7_
M0)&O8$8&5H^ -6"@=">=_HV TB^FNQ501KW.L 24&AC B];> 5/%)Q9X;@*4
M68&ZCO-/)H9UG 8H<'A]BS"^3)U%$J\*UDZ-Q+N1G,-=X,LDF/BM>NB.IYU1
MF2"FQ?K*LK!C > ]"+\$T;@(4M!(-!Z1]B*GR5"H6&LOD$:[8B%*0*4W$2'9
MAJ;WY3P#*030(Y!UG'?P?"5 #@" &3P)OIZ0> 5!EL@228#H#5"0QHOO:UE:
MJ[;*(U)=('!"5+H>D-1/S[K/Z&^E4>EOQ>PDCQ8"@+3YWOG'QV %J'TK+YT/
M\4I$_]"W$0?_ 97:ZZX+*Z77[7Y3MF(PPFM"N\IB^0'F#46:_O3LU=G[-[\!
MA7_$Q3VKU;KJCZMBX6K1:@W]"<FFLF33\NT*\Z0\2F^ZKC&KLYB-AVF_/[[:
M""Z/)O(LWC5:K07V,VI9@%J(I*GH%C0E$ TK72"K1%P69),"D7E )P#6E7#1
MZ/&6J'3#W ?4\<]@*$9 T@NI]*_ZE760D^;K=0CTZ-(ST)SPFSU%ZD3 7FDJ
MD@URQ0KT+>I<>AL91#KYFD@=*"1?""\#^D:Y95CDAQM:C'<PP5J2[PQ&7P+5
MOUZMPW@C9>DP#)'87$82[,26BEHJNI:*3I3!1;WF_  DD63C M7JFN1GOCY/
MA*\$(1AH@%A0S_"! (L+22XC%?XR]H3S!AZ&6GO;H@^EG1:BA:A>\.L@2EM:
M;6GU.EHUC1%CIB>T#ENZ:>GF.KKY722?)'F&8!:"+%N!X;:2/G[N2#_W"LU9
M1%% J:YDXH$QIZZWTL&2EN!:@KN.X,JJD'2@C$3D272AUR)(6)=J-Z(EJ9:D
MKK73X@@D%0DQ%?&@.%%VM#+"S0N#B&1:QCXH6G''9R>OWY[^^0/26TME+95=
M3V6H_^(\M=,6+*WRM2\R0 I8]6A\G7YT@FB1B#1+<@Q@@&P+Q1QC[G&RL;P'
MBJ"FJ=BH:$EA\M.?,CH/(BDI_F$^ZCP<J=X\B.^%4B245EN:&DR G28_]8M.
MK=&/ALA>?GC_YKTXER\3*3X=PW]* +\N>U(=Y6V.D5H>II3IN 7/$&&54B=1
MG*Q$J%_" <UOSWX>C'9D0LJK7\/JCN:XR2.Q@+4#S867@.H=D*B0W8_+1 _$
MT*0,I=.EJF";NU4R5_W6_<%9JCU0 7&%T^L2G/J1C=-GWUVS.7L)6_OY58)+
MG%0W1!0FG&4B%S\]^_OIVU>O_[<.9?4HJ.!)H02]\\##HX:1+S\;K%2S:'74
M7$/?=4'P4[!]01QG%.*G #Q +HN/),=12>V _>MM 'I.!D3&8?LK0JPD) H+
M&C16B E-?&T!.BI=2C.RXP%L,O%).G.974H)@)*8'T79T.OKS 9HLG4,-I3*
MJX1Q="X35VE"%!UI/D\S0<]-ID?E6$JQ7PY!6! J KCE6"S^;LDS$'RD8XL=
MD@$'/V$P%[;F!RFH8Q0X]=G2>V8/_REU"BG$V H(]& -2W$=[H>3KY5+#%#]
ME_0P1YX@&'-.AMO!'=?)EB*CEW52"O,H[G8R;$?N"\0XPA\X%#/&I3D7.4ZA
MX]B4SE,)+!=>#T/ ,6!JL8#5X[Q9;"$"4T651!%G"<VV/3:!I(]; /X^7U+<
M"<D4T(S_7,#WL*A_YR+!,#V1FTY(C51H= .C=)R7!#:D:@4#*SVE-%:^HAT8
MCY -+82(7&=HS+-6S +C(:K\E2%Q/\G/-9VGE _S8^#YS$*@!0#*YDE.AR8B
M )K27$FI+I,7S99!2FS8<7Z-+P'+P CI,LY#SO&I9:+QIY!#TS,+H>)%>&!\
M#W86KP*/P!KPSKVE ,:BE:[$QJPFE?)3W6(X<T)OPJ8 M^)"!"$9?3Y0'GPI
MG L!?)AA*K3@8+0!@*M2:_.,%Z9*@'@2A\X+F-8AHZ?[PX<@_80.%7Y%/_7
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M$:!KJBBVBGP;*+^*#:CAG91*NU'OG,GD(O!PO[^]=UZ4OC?O<W4 ;K2R;(O
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M>*$\_KJ4H<^GOC^<_:$>(O/#,GVFFN*.]/H3[V(-?L_G *^YA]^?3SH]LS@
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MO@2\N#-:&ZYD'"L\<;5K;N [58-YUAY_FP:%)!21$=\K&]<:G2!;$4]YT=S
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MG4VMIGBL.J=1I-$\4^6@BI!VA<.S:GEN%,UHMN%\7Z;;]-7247R^(O[84_[
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M-*)6-&U%E\@Z<#)^/OT_G],_E+./1.A'4O3N.8I,T>(PAB/,#L;?OE@E47F
M]:%1BK+59Y2=:J.H%1/>"6,<5+8]K4< -5Z%J?)C;%%DH,05BYR"$>JPSKNK
MU0;=$WUG@:42S#6LE5;*EV0(&?)J!F7>C=@_?(:;/.AU8GIZ:_C"&\!)^JO@
M4_)S6DQD3;MWSFZ1 /,RR[E*/<^=I,<JMN.-AC$+N6ZPH-4^0D>R<)EGMWQW
M>Q?HSN:2BF?O!24R:Q6;77? BCD,N2$I.[KRL<<1[<#IZI44-R(JP8$V!%'"
M:*Z\K:;F>-$$-B2EBQ.-&C/V423<:LN7]!A$<]LXU^,ZQ,>-Q"U]>O),1!.6
MZT@::M_9D:D]N6JI!' RW?NP/XX -7S_&V^3COE6_18;\RJ5AR%(12!WZ@/0
M'Y#Q@/'70\<\XZ6!D,5>F\-EY',G0&!'=, .GQ_.T<RI^K-Z;Q3FF6^;P79E
M-JM%:%,CC;D+7'K;-!Q<):1(5:6N?S?:]7O8Y>=<F<ZEX88T=#PP<Q+H:I(G
M[/:C6>M]S7<AG4R]W9KV3FNB )(P#Q]98JG_3K'4)XSN(IL*:5^(^K'U)#'T
M^RRVK"'>[^@UC#26(IB9H>6 DR,MP=N&Z1FNQ8:'BUJ/9-)JP,KAFO82?.O?
MQ,IY(.PWCU\^[X3JYJ/[2XDM<O]O)??F@"K:%C4EWW%*O.:"'Y1G0$0[^L[]
M-$[E7!.O;:EDELFK#+#IG@K6?W\2];28%DBJV5X'N-88P0[/>8F5TM_"0X?(
MZ_VL5*3CZA49 Y=E2"E94H8B_<\*5F9\J.7T+*?G3J='@R(7^Z/$4*.8R:$@
MB0:+YF\+CH@)#UN9UL@T%Y4<@DYJC8@=2*BB0!IJ#!TWK9#)9UH4=!&XHB$&
M)D)]245(M3N@,Z=G-$:\L#1!#D]<SL]R?NYT?AA6WO6S^/&#3CM+[25B+!19
M1.QL>BVI=%_EE"C"*B@M=Z(P42<UA2,AY@33+I< HBO> K\/Z2WBO4)X<PP(
M#SMAT>-.%%QY9E?9S,%QX/OEE"RGY$ZGY-P+L%#>4\ABTB+O:/V9EDTJJ4H2
M/M4,Q7N#A2X$&7=$@WRYH$$^!#3(HI/_8CHYZ>7!/,%>31/F/M2(Y^ J1O%]
MNU71-KL=4X#TRK5:M#FQ.U,:C>AVN6[3R@[%((>/(.HEQ?1-(TP<0"(C1Y_.
MQ&YSGUOLD$7F[^;M$H.6(!U&DB25NQ2@5P1"47;,:H&[S "I&?\6&\90&2L8
M(Z%8A'$1QKL%[,LNAN)=3Q).[NSR5HD.#R'BC)&&^52$X$_R@ K>837.PNW)
M9N##NZ8D1B-K[@16UZX-D0PY G;N6-R?*?&Z'*,9S*3^9Y:]9*<[Q=@9G  N
M%S)NB*%:L'4&:8JA7@5*S6#HDGRE+L5-T[Y>SNAR1N\<WE$B(^9H%_Y+ ?_-
M^*DDCX<).SA&:B0)AQX2DQ=(+Q%:)KI):M 6(5Z$^$Y"_!W3KW$?<R,+FT,L
M.(] \7GYS93%=J-X-I7<33/#-KW(YR*?=[/*)T;/ 6.GSU\3BWT#*G@V;*Y:
MN@CK4N#+"?.,=H$8J=O[K7%<I/7?2EI?& 0X*:Z=@/DBL&Y.YA023DVM\@++
M0XAXZ1K1CD(D%%G<,>Z!/FG3SK ,<5-O1A]C@#S?"9S?F;_W6!3Y#DLUYD!S
MVN\AEQ;IU+6VV^959:7WNV8G;-BGJV^$84O)P^B#'?6*I6;GV1@LRBCO\5L=
M':3Z4]?T4%ES[:N2LD].&_@@*E=;?!V"!*ILJ(%X&(NO&&<Q#8G,ON^PL$"F
MFS2RS11NKO4(;E+Q"=3'+2VHB'+'0>58@%;<UCO335TK\MXG5CW6/2B&AY"L
M@I/IKQPGY>JGTU>GTW[1,UB:6!YD<,L9T&PL,QAUN\+Z!2.(G7S',1CBS>76
MK^P=LQS*!&.:A-14BG(Z%F+%U1F/'Y]\Z[8W>?.](-LC]Z1OU#A?:#'N,#U?
MTX%A9&G40+/D!U#[!1" $O]!_0SXF7%7MN6OU F[%)<+24<1&#[AF^8& 17E
MQ1DIG-E/;B]T#@6_B+\A1QJ.PHFT5/15=*YP1!\X?@S&P0T:.>J(,Z&,31O0
M,%G>_&.UAH5KZ)/'DJQ+5ZZD+PT5)875OADTGN)F+VA[1B-+N92<C%$&-CDC
M]7[FVI-"C7S-_C$5#9*L*O^M*%CUDEWMC@J4G6?FMN;KT(9$*MGJ(T4-^%)<
MY<Z=CBW&E.#S7I-9?66BPGUT:3MT_=0$F*_)+;N[H/G[+H;T!FTYCJN';TI*
MEZ6@)FBOQ&]^.!/^T-/5<R-]G2S!S,BLX-A-WBI51^WS8EL+0SO"/1-:06%1
M2'P2,TPZ.3/#.'Z[FWQW4M[V"@MV-_G:5:;BE"QX> B1%DN>P7F@&Q2V?H\5
MEMK3N8L0&"Q(UP*E7\&N\S( $ZWAB%?&X'V@;B*NEX/?Q'XS&^[O3:N7I3VN
MXE+.]6*Q?GY#FRZ_+17M;KZ^"I/.Y*9H32JYR6S=<=NA&7%T4[^MS(2?ADD0
M/V5,G;1!2)R3]3(IU)J8,<OMP9IH+U%I]-G%UF+D;(3*U;BUE.7.A.@>7X4M
M7!GMWC.>/INT*GO,5>X.M_[LL<+6(TQ%.'@3[GXSR28[3^Y 9\*-Y8LSWT\Z
M;J;4O<9)RULR662K7TTI1S6>"7O$?;:DWZ?VE_$KH;UQPF795=;.*2^HO!'5
M'C'B6@=.]V@4$ H\[:70B2AG=TJ)@+> \ \-[6I"@XPM7S6%?)3%FF:Y4*6Z
MC_R[.N%<.S7'69!9U4GBG+=<^2P6$]I)V0$G:^%B6V3V#D_['617VQUVXY2F
MB*Z=(,CM<,\QR'<M>@NV4;"-7RW8Q@7;N*C:/YFJ5<H-YN5W\7&+M$>"'6H/
M@Q;[38D-H>M?FOV?@T)P+L3V+1@PTE_)UV-AD!MM;&ELWD76(YQ=P@'SB_:L
MF5@^YDM_\\/9*+ =748N7!<>KKB&&)1 )\Q[4P87E:RQ.EQCP,Z&>U2X151/
MC>;&;4KE6>094QP;N<2.D<AH5P9Q6B)QR]1MQWY!^46HT(<"]Y?B@MQP>I^P
M!AT))MW&SX&C#=2NI)"E2_BQDL;!H'NOI885%P QMA1TB^:LA53=:N=K<K>=
ME2M<1$S^-F[JJW$U6D877--H'*Z>QN@.TCR C"@\[1?PWSH,5%@S89()C1K&
M;=$()?T&/$!X4A)MFDW\1N(^;%AR,,YX(+UK61)*D6#8_^D,J&[D, ??7UEH
M%.B<2?0G]JN)G>PH,MMUS;JD (G12_'11%<6$7A<*L_!YYDHH[<,"VO>G%\T
MZ-H?B]B^TS@M'A\F0O)KY]-+[RVOXYMS4Y<GF6(Q(U6XTI$^ZNS5XV__<?Y/
M;D<8N]CCW%Z</WF2C=U$^1HUR FO4UVBSR*]XEK >;BET=Q)>[,,9*."=?>[
M'$_L3*,A1WF6A'@U:A15#TH:17HMWF0INLC>)M%&BJ'<1\+GQTDF,,:04"6Y
M$XQ]IM<]W4!TY(1D1ABI+4B7L2;6H!8)<4$W?Z>_@]EO&PT#2WMS;M"&3)K6
MT]FW2-;C&Q.;TF>*!L7=.A.2M0(6<MV#&R-!-FU%P,/ 0UP,&"<\Z7;P]X96
MG:HF,$#.X3C8QMQ4,UTFVK"21Y_\7K+<RHEU3BE)X3]K-IL3OI[LNS'J:HQ,
M.3$BTPI(2HP_C4DA6& )5-JS)%Q),5S\^9.'?S^1_R5M4L)0!^V@Y\57@?&F
MF-+@KMD0HVW,>\$QZE%M.KN(6E5427HYSI$.4Q<_P^-JY"%L*] W<X80U7MJ
M4-C/9!&<4:,-,I/;W,X0KED=;GSP$WP0%2CN&,AE+'KZQ>"(P[1P-Y,&2E8@
M)86]1]4VI=?2#,),2FW.LDE/1%XSB)P6ATTJK_F<AKP?TC3JTKJ[VG<EW%NU
M=<M,;B1.#%\UC:;+4%KC)<YTGZ26,4G0B@C+H>$,N_H%;RSG_,+T(3,2#RJ'
MGS7#E^9Q]>,#,6\732XP.?-I=AWMO[QMFQM8 ^V[:<?';Z+-'"T42O71W3-W
M-D6?/)_3)W*1;;=D1[<-)A^$R9T>S'WH+>N#&A:\LR&Q _4@L8$X$O .F\):
M$P-83&JM6ZS69;L>MJCDU^$P,^FLY$0I$?R(75/XV8N A?AXTVZF,HA$%E=-
MN680C@[T\/N+)D/":^9"UCO(37W41AI6?7>5M]M\'0;MAXQ*KN3 H13ZLU>W
M<9<%[ 11;JKJF"-//G 9*3_=F"5U)M^J52:7 ]B(55FG?*&.+.<F;S%K8Z'W
M=H8]U2W"Q5Z;&[NE&SFEW*[6O#-I"D"V]E I(9R-RWH+VC%1_(<W,$@@M46C
MJERB>-,9@'O64[=S8A("P46R:_E=MKJ0).',[%8YDC5WR#><14[@6#P)WYIX
M QYBK?< 7P!9S%_BI4&4*/J;7;Y7BKXU[&F%>&W.>[*!&A/#1=E=-NUET(_#
MD<6N[4) 2DFV:".AV?,+.#NVZ: 9MR7G94&5K ?)<,)#+L4<Q+.-(0D\D)DZ
MRHQY6DO7UG8[:LK,[;5M=V[OVOKN/8Z?'2^PN?ERO66,J-.FJG7C"'W'B)6T
M :_$.3PX2Q*W.==,.?!0I(#-#*X4[=^UYJ(C!;N2*FS<2F*+U!.04+1>05(O
MFF*_>OGJGPJ#0EJK'*FI8N+5P0J2!'74#59O-LV]Q4_=!]OBJQ)7F.VC"9[%
MF1^9V5(7V$C1#Y/-Z[*S,W5#5@49:((G>X.ET/#*703!L(#>J=OF=7[I+SVZ
M:FA'@@:4#HXCX0B^RY:L/&X9:Z^Q[IK@;WVS?GT%@D](D"MC:K\AP+%!7:B]
MJQ9S9P(W$"UK.$6Z/2@(2>5*UA]6L 9V<9G<>9\K)1>=9:)FS9'7YM'IP!CF
M",9P2NXFY)Q.]<\!<$FH=MQTW2(FB=TMMMTX9@0G2EI.('OW9/7#!K[3'QUW
MHO=LD"09?!V-L2=\SGTAIYS\]15:\&L&H'%=)XQW>S&TG30ACD@8^"RH% 1G
M9.-E9Q^J#5?:KCHV,=MQI]XL ?[RF/D:C9$-Q*52E WDA+#7 KMVQ42BA3S,
M,*BJ<WI.$'^Z#,$<GZ'3LXI;31T(V%X,/8:YMB58GC683*T[#5V'Y4X=3['L
M$#\]!H4JB+)H:CP@>E<1X+";T:@E^Z*@5H5Q%S^RHH^<R).3O);D<MK+BP>?
M9"O\OX] N4EO^Q PA#D8)KF*EGATL]@&B L2KZ:D9X"JG+*@L,0^J@E;+R-\
MIG61E!E<WX/T%,#0%5?9//SD/U45] V&=FAY/)"6(?8([J/'@FO;D66"EH::
MA!Y3!NJC+;G?0IWR6]E-)KJ:%O%M;Y0/.TG]]9*D_A"2U+=84,^/)*C4=3C0
M,F8><*HU_X),YN('*9;&./ :_?04-AROS@&DH.XB!G!Z?<XZZG;W)!XS:*QV
MZB#.-ZY@Q\L/BQGUX(T70UD5QFN36%3.X+K5\),.BE>!K208CNAICX_EEPKP
M6\R$H&S^SDK4A-RX1T\:+3F2@<Q<NK#>C_9#\'!X46,B4&F DK*9/!EWA>/A
M[KVN"$*#3>\M*?1S$/@V!T$B:ZF*:FBC<1/$U(79%L)F*G_)_%6:Z=T3"YZI
M%JOEU/:=2E8<OGUCJ9E=RTM*@&0U,7WD+[37Y5HKMKABAPL]M'6#0)I)QC V
MCW*,IPN..=EVK@[,"+>;ZK[Z5\25Q[_ASWAQIY1.+*]5E8.^I]]DSD8OL0M4
M&<. UNB1(X'J]TIIC#V#C&TD"7=_=/O7^M]OX"1]+(7J+0$BHHRHR4=7]!CN
M3AF?JM?&2M;XB';?X<]=4F>B$1\_>YRTTY!NUM&-)AQ 9&(7)VY@? ,YI//2
M30):XJ WC6="'#H.*Z?M8S07ENR#Q;;QLP&LMF8?DF*GM#F'B!*'0\@VI -1
M;H4L-)8V:'$!Z:R&J['ES*#?8*-)*YFT*!%T*'I7(!Y$BTKU*27W?1L]AY+\
MX-8,%*3;XE>*$HPN]CGI $I%'0-E*,-$"R[UXUH21T]S$V_05ZJNJ8&%W7WH
M;&F7%CE=\QMB+6KJRRJ<\*(46FPPK@ED/>.LWI'*2;:1U4+9SZ/_LPC]MV0P
M09GPG9N0=Z6\M&K6? GX_+770C(5"ANK0DE%)W8NH0UVXZ<.9I)557EH)BKS
MXUCO10ZG;H*V;^)P>JKL]/;!Q"U5"FC*\VY-O"SGRP%C5]][D0)/=DC&6V2L
M4@O\R1I(N08FE#T:10:E"M SXS[H/J)&AW#C1D!ZB2<)UT*2UYA C%6"^FEK
M&Z5OU\*OJ1C9%1U^E4K'&+]0JNU)144LCO*BWQYX!8^/::C6.66OU$.,01K2
M6NR:[I-"$Y< <&.8Z9LFQ<EB//;$M-.TK=0=Y3$ K5$/4+A@CDB,&L/?W=&%
MPI5PQEP10+J*4[< <XK29B*I6<EW7)4[#;I)D-N>BZXV7PET.U.PN]E*F@M1
MB"$J^G.]JA/=W&'-JMJ>!%ND7XNVYJ!;EOP=%XB[CX%465]&#*R'8JS(" Y)
M93EI2[U1BM$%?;!3YM"-8&YJ1PE[3"C"H=XUJ2%Y>[>Y]Q;A-]<@=H1+S&Z.
MRM,HTR!<A(=1R[9JPUV+MIK^';.-:,LV_P?<J76^X_5B+IZ68 ",=Q& @F@(
M/+ [CN Y\?=Q_DG5.QUR8K2?A1'<1W@>@6E<BDMP)6-DB=F--&Y%8<@<L=3]
M/C&FX>+9#7U<'A.Z;^#Z6CV%+U2,RZ1TGSXX(C=323VT=Q)'.[+68JRFY@%9
ME2=L5<*SL>#>%_Z+^H+U9A"=C0R+>#<R=/;YXHN(L":E)O#]-^%YW %9"0V(
MMOW$/-JH\?&YI*G*7E&&HZS]=]@OF%/&S@L4?E;C@Y+T(%?DC92$3 V73!;3
MW&P?TC,#YPH\6^(UV4P.QK'S(&=3T0K,O*F- W63"S\:>8$MLH/R8N5NN!F)
M@FW $EE\B\CBYY\LD<4/)+)X2#+G$AIS(YN]AEU(4NPWZI#K*[Y%8>#5*F0I
M4K+!^G"F.5Y"))%%4*XS1D>5X0D2U$$RW+V9K*#K3DM)J^D+?,0,;#:!/)5)
M!]P[-M3A+SGMFJ8X+0,:\SMQS?2*-,3AG7;Z+0-$?\)-S>@&0!\- 4'6C6O,
M7A0=#0U514GP4- 4BD,-5:_\E&,,<&KTF V2'>(GX(A8CIC-;H2'/HB%'@&X
M$"0W&I-#Y?3($X2_:Y/U@P\TH\+ZZ @DKG(44'%N*9P'!SNS,@<F+K!2AUMH
MHU*4EP*XW3DP!+?O3+Y15N#XR-&2>NH$#D[L.-3>(H=!W\:_5.) CR978*0_
MG3Z=LV17_"XDHQZCS+/TSVG&/\I(9MU0)/@6?Q$S#1Q?!8L;(>@%@P6(,$;A
M(T@4I5#WHED/,J71""[SEE$$L))8(F2F.J)BQ8SSP5%"&8P$O,"E+"\&-<0T
M%XQG,J(E!6D!8WH=PHY83B8  8\P'$=87'2%Q\4!!.2+(>"?YL:=.XX+/-38
M;G*S^N;\G^??G3V;G,YCK\3Z"@\MFAZ"$5>)I.M#<>!L>Q=N1S1,K=0+B"3+
MYS ZD"DG!@%PTL?A7= 4JP><:9JJRX^HIVS9#!W5G+VNFYN:E4<G+>*[%2Q?
M>QD4SE;:5A*]V'Y*8%1Z7XB@ 9$8AD "[I6,:N^=DHWU=[!6Z]#67OC&K@&'
M 0_Y;CIPCED12ND",RA"9@=WS4W.#=4/X%AK+.B @1XF#6KBM>249)8X0U3+
M[Q''=(/MRU 5!$CF%Q!-H-OV67:2.2O_EZ%#V,;?1X;AN!;XOQ2W<?N=/;;@
M1E;AGZK$>;8R>/2+F:)F^^BTB)BY#N:+B.>JG7D5IS7*1U[Q.ZN>CSSQ6.5S
M:K36Z87/>8?9\W-@##.US).%G]8TOP4JX0C[Q"+QB\3?0>)1EYLAYJL($WZ[
M1=[U-XN\3_[[2\F[6F*IO4T59W^ D"_RF'ST Y!'@[E@M4#GL^+B^$U;;WXH
MFO>X!;\<@W^?8["Z=8M'FSWV+$>T-T=82B>PLG*K40]D'UEMRUYZIJ^8=?B2
M:X+;6+3H0!0N%C9/<7AXX>__&EENCW_S8_,?_W6'^MD/Z,)8A/O?2[B3'K4N
M;-J-LT6+C.MO%AF?_/>GEO$V;(8NIXBZL!.LJ+J%\PZ:F^&FHY:?Z=S'B_1S
M6JU(.;WE7-AOEG,Q^>]/?B[6P@NH.G^19?W-(LN3__[DLIR&'+G[^65@ (>K
MH,KWB[WN?K/(^>2_/[6<;YBJ"L5="@ZIM&A$AP3ZG!J2,XLFE<HN(J^_641^
M\M^?6N29<JP344\=UBF":!%T^\TBZ)/__M2"[OQ4IORDZ MV7VFI=CG\RC_]
MH?;Z(I;)1S\ L602S@NLR^3Z,E/'S.TF?^%XH>O%%FND5; 1G=H271O3"%CU
MK_N6\B 05=NZ&I@.'!]-A?=4/2 D*YM0(/?IZBKD57]%?:;C.XG!L>YGE@ 9
MV]9M8 XQ:=Z(K,E-?>+X(#W' 3%&M;N&N$@0JWQ)Y?WQ$\N=H[]9#O?DOS_U
MX59H3A?*WP;M:TN(YZ;^._QK$6SYS2+8D__^U((]HOQ52ZJSLFEF&(XU;IX7
MF+SLTS_ N%K:U]VQ?O?A4K_[@=3O'JO8/+ R=ZWB_;Y$-F%N%Y"M<C H;U;K
M 7ZW11N5* GR-3,!,T=&GO(,"JN4D"L1OZB$V[CHD;_;":D(72#:'*;"[@*1
M\H$IX^.[E60<1Q"99ZT0BNJ75@GQ_"HA',^T@H=&%RF7B>RCQ%([J6CBVM9)
M>>VLKS>[@_B+IZ)@:^P/MH6%ONI6W #^5=CU ;7#ZM-/LM6C3QY]EJWZFR;.
M-%M]4S:/SUY^FZW.Z_6I=:;&WX)!;]VI<> OE%?K^VCP/W&08GE$\?'%Q_GJ
M\=#FKZC#SNK5D]4KZ=^P3[X0^V##A[D=C[X0%Q [;3#A+%)/75YBW5<?C&WY
M5^U-]^7#_Q0A2/8#/9"&"34*U]M,%PM[N<LJ/0'YX$5Z2(OT*:]*+NQ[<71'
M!_7E(QW&@5>_(_?^V($\(X&;V_4-C2O=]APKHE\&8>SYH=R$U:LUU8IWJQ?7
M_2G\BGDT=)_TLW&74!3*7V'C-^PI(L-EOH/3_,,/C^UK_*%$EN#U]+X7S*CW
MRH@,?SA]<7IT\]T>IV+P]</Y]9]1 \0R#)^=V?@-D5?/K!-/(G/2 #\C47F;
MZ]G9?/P:)/\,OE@RE]DW6'!8KQZ+\PH+Q+/7=7P3*?_ZJ_],9W^GB=Y7]RZO
M/U^'O5.=I*9-91IIE%!%L7968E'NOO16*OBMU.[J6=.&AAJJW*2\J,9#1!W
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M YE"J2RQ%C2F:K$\.]%)6\8>:,Z43K/$!HL#-IG37A16!>>%BIESL?M<*KW
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MVG0S@AJH1Y\"V?LV\*D-\R\E$YC@"F#!-VT=]@0U58R,?LS4T3ADNS92XE$
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MV]PF\2S4J;PG1G+*Z" ;7DY9-FH,/8I0DHFI;)B9T3DRA4W#55-S>$;O_Q]
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M%!=!K2$F,EZ,DPM1RR^(,D0\*BR^2*])F^.&])R8,'1E+J5R;Y,V_FHIE?O
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M+9"-G.I6_%5BNQE]TF_73?<%#Q9HH%LQK8J %01JV50+8-D)+8RIQ(-,S+:
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M-W\9KJ,5W3@D/&%'O-D=B#4 +T10'4+9=VH] N(X-'TX2^!LX65'2+8]VL6
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M2L>T84]TF@KIU;H;!3^(V2FO"Z;U;1H/IL%QTY;[#$@HJ T$RA5LB>\0C.'
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MN;V.?HV9S.2?;]Z\<1XE+@ZK$P)Q,W^G$;FG@D"ML(RW*9@")^-V.V5!5^0
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MPEB_FM=S#>=3XE'%V\B V'^EA1N@X6\A/#%,:ARY=8L>3V!HZ&;VU*K%YP^
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MU*-A0.QR0?Z3U""&1Q8J%;1J3^Y,6V@Y+KAO#4RT=K=2O%!=!Y<=%+]9Y(W
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M/$A@/1(.BG)W1>S0^N!27BZD@:V,JC<1-7Q*Q7.B\AB\WU!A<QEIK";E"VR
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M&@AH19#S@!0#"!CE_^_O?7S>Z973?7KE,TNO#'G;WFBC\,QHVRU+R!^4#:B
MM#@%DR0OL$Z52%4+ZLA=DP9?B[>GNI"R[1B&:]4V$F-XX"K&DE>)GPD(F;.+
M@ <!220H3,\.(M\:]GK%ID!?HU0VDM<A5Z+TD<GM'J_<\D!ILSDR<H<K_*%R
M2%L,I D:]3E6F_=LH8':#>NHBF7P,@5S VYBV'[/_=S;.XENZ%OY8D1#H>^J
MP0WH=J:<,R,,QSJ?G)G-I+ ]6!X8K'1?)>>0!J:6.[)(0Q^X%F"@-<@0:HT
MH7"M)+7'!:7GSH\]=*Z1TU<5P]3?=C*\\\)W)3\WBB+@".\82L!-,(O0VXZ=
MPP?N.Q=2>O5MM@02'[K(W_&:[1!5B$K(*# 0#8GZS3@4CLJ"W."JOO$N[5/G
M2X@'+R7^@ROC?3.;0^PIA]: '0P-8Y:U/J(!EHM;ZWC<)+'NW%)!U*Q.3*B/
MO>F\KE9.0=3S0A)]CW!KK]R"ND_&C]1:-\(<BY_/'09+\EAB3&[X#L[T<2#G
M,*]^NBC! "#^@W0Q9+39F)5:7EH [721_;=V?(G@YW:<S,1CV&=(V\HHI;K<
MG1K=-#E/M;:< FO@%![7.P.:](@L:D%M@!@6N 0@:5M7X)"M?7R*997=TCW9
M5]A>1<>%4%.=%@>=S&@LGN4TNZX;9_"NL:ODRDT\8]:"#<+9*CE$!@1#3/\M
MCHBPJA&B.HA'B*16%=PU#Z+&<3*"Q(TT_*'36%<9W89"UE,/8(D,J[C B%=9
M*@(.I(#6-7-3Q=+H VIP<!]]N^H (Z9USV4"LS>5%,)AN2GAR3.)&YK]%U &
MT6"^T$S[59#%UJ=)R.OBU7L)>0D@OH8\B?&$DK;N<W!LD,8%<VH0E(#=E^
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M)M/PA_3H38JQ$,+]*HGA$N^4I(4 /I*9*UEE6.4UU<VR5F$L_'T9#P2;@[P
M.HR6C[!JKL,+3I&+@:<C-$A$?(,X.=;[(;\<2F_4Z&'1Q2%@TX _P$!W5"Z$
MR(':?@!FH72U<$SBWN?A+C0/%!2I\KXQ.\!#H>1&)5DTOF;;U-RA>:Z<M%AM
M5F]]$73H/(@.^$DX !MDVN(8/+Y_G,V)BT4H,;E,9_., &6DU8:JUUQZ_K)
MV8)F&P:.DJ)CKJ;AW^))E8:9&TPZ@,DF-J(9$/LV/MJL#D4=]B?E&71T,B\O
M.![YOU94M&AFUUJ>4JE-U#\/-()P(6!3F/WO(T&%.-=2:IHJX+Y/.V\1$S0L
M55!R7DER29 &@3KO!M':N:R1AV,BH5*[JZ^LQ4 6H/;#Q-T-.2Z')R(2/L$<
M+%U*1S4$"08J(^CH(N7'3B ^/A+H/_M8$66)M+:YSSBW[=%R6&QXP!P;[;(P
M^X>^_@Z+@H\.5^674CKDM4E7GLV,+:7BTC3.8U_47&+8!"EN.T6T7#WL0(FN
M1-+-A?8 DI03 Y]_&A:,+D+=1T22FSND?/&>KWUSXD/5I=44+ED/VDZOGZRY
MZ@-Z?+I"*/M"Y',_EC0! )I()]@6&=-.DDGCAH!*,D#[0"GA@RC<=R8 =LGI
M_].C4]$#EUDSSMQ\#]Y^G#N'6]&,CHZYW87Z,)H5P'4^,IW!_2]*XT4ZE.51
MH=I=?B2P95C>RC9,'>%G@UXMTRPC_9*\TCN_.$"ZK-9>T]XXUZU"4E *R$UF
MO8=R,).6BYHEE.U8BWD))8(IVA<%-0Z:61)*+@[]]G$'@J]+UQ0LS!]Y&\D'
ML(DO0>7-R+YSQI&O?!!T3Z@,R4M!D&6>=D-)&=9=3QEB,C,CD:)Z'QM]Q37)
M(#)>W7/KH-];+O^@VR\(9FDCGNU48U!;*1I)17WK.J5!+XK)@H*O@/B7<%<J
M8EX_5,8JVG(.\IZG9K[\*"T@*?*5-*C,HJHV-B)DT:4*P,G)=/H0H=,7!;F4
M-[#:$Z":R]QU"A3(/GX&PY@#>;WJ^X%RK UZ0[$@8-V'ZK:;J_&CHS2!_SYV
MXX'A"4\M$$LR=,62NJ',ZDQ+(K:&BL96(OEAJ\&]#CPE\='W*<77WK0PS#Q%
M%0#<BV5S#[:Q,SP;&U9-7%.X^@ZHJ UUD#?Z2FS8@6ZJ@!<$*:@] W7$\L[=
M;6T+[7*=\$C37T*R;FYDC<!SC>SJT6VE41W]9FS<Z-\1PW"E(4SI(,G>SU1$
M/B3Y/<IJ'!XZY4WA26=S7C73?"BU^';!=KM%56W92I\<:.9)W)ZOP-*[<-<_
MX,<7F.H"[!'J38?[@GL;X!TO7KX%()KP-8$;?EVVT&:J .N^?.9N%V[0L%=,
M9A7@C03]F,/S#=#7=SC\4]V&K'_!BL.U^]67V.O[QF=WH-_?;4;1- A3;EB>
MO9.VR<J3 (3IN%^4+:$J2*:#*=TW&@EW-3P&RZF#.S>:=*AC=A--2W;-AXZ
M-7;8M^$Q@KG2=+[RJV<6;?$26G/94#.2E&ST+X>PP7#XHBA;,S#G13;4UYX
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M']## Z&C>\510/$TEZMF,D,6%^XJ&NQR 0\X0Q37CGHML%W(Q_2@3 '7\KI
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MMW:+718%:V@<8(+AFZ1<8$8/6[ZF-7#QB,*FH#GQ<UYQ15?9)O\@/>X^_KZ
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MSY\_W'A?(NX"-DS<;;"?<L\W]0W=\Z,O=M^1.X/';'[+EG7<[2WW=Y\V3G1
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MHIK"C/6,4^NQ,30#7R6#><,JPRJ1Q?JZ[![8TM2/W3BF)([=P,DR@!YSDS3
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ME^445FQFG#J+K:(9V*H8K!N\#%XBBW6_[![8HH!S3C$)!1,A[G/,29QPG]"
M8R\6Z0^P;8*MOQ-@XTC( L+9(F,5OEU &HA#MU[KEX4 'L"EA'ED0;.*P9P
MD;70[ *\I.6.&02T!:<%;9:MT-?$N7FB&@#.I)VX:R6J# 0 <@I@X-099P_%
M9HI$IN9FB4?-)Q!,&H,B;!N=W9M@ [.[:[ R2^LVS-\]9*6"18,@&?@X)B&+
M A+P-!4B%-1+ 7#L![(VD16^)K+&C\+PIS=)X,='IL%.DV';75X) 36O=H%\
MB;#F#@H0VM+& D0HXL;&A313*V[%<J \2WOVGDE#,V4J&&?)4*NLQL1,*\H9
M-!NT!Q!@'#!5A_7Y/9WB @K=$=#*;96!A-_'/3_:X_MNJ!^Q^JZ^E;9P*6HL
MVOF1Y9XUB-8( 5LV\;6U9O%(LP#-=N%/D0P2-B\=[AP8 S(8A,3G Q+3D'EQ
MVL<#+^XGL8@2XC/Q_8(QC+X(C/V#Z'DXXOU7A"-ZQPW(02"ZC.R/8=.UR2+%
ME=E^B$W2"(>(;S35>:"J-$P #',GC2,RD.*%F\<6V"L*7*=1S3-L,;7,^U8P
MZ#84:SLET"'88E0FF3T+VT2@J8B13&(M[8IDG;\ZIB_LU)6Q*:3;DXS+-QWM
M*</!PA)XUPZ:8>OY*L.6OF&=SJI5*@HCZDQW/4&'*\*M(! JC.=L]PC48SA*
M?!ST4QJ$+(T(3BB#!J@/@P3W\?\M9C]!H.0U$?L8L%NST 9NMQZY/7P!\G>2
M651BHPH7<Q JE;;EGX4JUFR)$@"RQ$1FLES8Y+1-;6MJZA#FP%-O"(_&KM63
M+D&X;U8XJ_0,P&M<=DVITLQ9Y K)"2\@:<X P]##9S;'M2)0-=<XA5U%SH"2
M=P^IOA $\MLX(#P.O=3'/(T8CH-4$!+QX#M.=;\=4NEK(O7\#F>5>Q=CHY8+
M 86<O(-X,RT%V4,FO 6?UK?M)9D#)@P$+C1U)4A453YOP3:,CQ^DN2US1?N1
M2QM85V:1947M-A]>NP8,/++:=@Y;21A X2AX$/M>B%.1$D] ,NL%+/*C01+]
MP-8FMMBKLF =MIOA;X\\FW+*];1B[ 7<9U-116FE;9"OI7DML^;*E-!N7VG!
M7 96AWZK7PZ@O6>&"$ KD- 3Z<9P"I!QI[7V(+>H'NS:;T,:F#G%YB%KMGSF
MX,Z98W[GH(:5%RB3'WG6G.4^D>]^L<]V$]$1#B'%CP819VD8)?V$^C%-1!+'
M<1C$T7=<BWZ[@Z%H]P^&W LYMMP,NBN:L32X#L@5XUA(O2!MWJ@T'TS#4&V6
M2M=\:65< TR9Y[(L.?\$R1,%N;#M9Q+LLY.TG!(!;(%DC25Q^&N+X.7FPW^K
M)*S';3150=V1[_[NG?^( 4V!+[U^%(7A@ Q2X0<!I2$@D=K?]XNY;\>BKWKZ
M,\J@: )!"9"R1XGV4))*#AAHLLR'0Y@YQQ]MVE@742YQ=/6@>W6X?.WP(F0U
MQR/UR6X+,V$& PU_(*9G4=A4D3 $H 2U7;?.70TDKJ;*<ZPA0MJ+R29E:'UC
MLYLLYD4BC?LL)20.0^H'.!$>$S&.&?$C$@U^(.I//IT90?HI-!!!%^*;.^X"
MA-AW\DLH=>MD319W*KOC-F,K\*1Y,Z\;NN/Y+%,+#KWSJ:HY#C\"*@#KJ^2W
M![L4X?4'<ZM@IQ&.>.@EB1<G(>NG& ?,IS@-0DR 5[Y66-=J[9=_&9X9D%E>
M?>.(CZSR]I!M+WD@@(;H"AYE3N!IQEWWB>96#[!5_<NTGRZVRR_:L?V,KJ7O
MB2I+E0]1,+M'[M0>Z0G9\[K(_MM_SJ3-#=TU'YK#U5=[;39;JU\>]5_\4#]S
M:WOA<[K"^99O E_TI)Z+BD_Y^7_$HV/[,?;KN?1L*KE %P][]75=[SP3R+9Q
M[Z8^I0;AC6'[7WV#1^M>;_D*]H_Z5VH^Y_OMX$_[?OO16E;7RZOC0_L]O+MH
MONW_+U!+ P04    "  3B&=9&R",P0T%   <$@  %0   &5F,C P,S0T-S1?
M97@S,BTQ+FAT;=U86V_:2!1^7VG_PUE'VR82$-M<PBV1""&[2%E(@:RZCV//
M&$:U/>[,$$)__9[Q)9"$J"1I=ZM:2,SU?.?RG3-C=Q<Z"L]^_06@NV"$IBUL
M:ZY#=M8]SO[SP=_*9;CB/HL5HZ!%&\ZE(%1R.F?9BO2Y$/XR8K$&7S*B<>52
M\7B^M1:N)^. APS<6J55<2IUM^YN[>^+9"WY?*'!:;7J4 ;7=FO;V\OE3-_C
M7.&N)^@:O+DO0B%/K8,@?2Q0>AVR4RL0L2X').+AN@WO9SQB"D9L!1,1D?A]
M!])YQ;^P-CAVHCN@V9TNDY#/XS:$+,"15'(;#NSTZ5@9/N6WA6<6$F*A%H0B
M7MZP(!5Q:J&_-)/WZBR8L:T-M>3NB6#PB/]I+L4RIN7'4]M:92([$!$YYW'9
M*-D&LM3B?DAF(-F8)R1E*"L6,<N5?Z!^UBD4W 9*Q>38/*8(VX9JPS@I]=HJ
MM\43(47!@[L%][B&JEMQNL>/Y9^].W :=N?IQ"[@PL)=,/W!9#:\'/9[L^%X
M!.-+F/TY0$X-1_WA=>\*!A\'_9O9\.\!3N&JP>3MB-<WD^E-;S2#V1BF@WZ*
MV[(;!?:T-SGOC0;3\OCCU> ?Z/5G9L:U;7>'%[J>W P\G1[&2(HX9K[F(H85
MUPO0"P8?ED2B>N$:)BP14H,(H'?Q5P_..?)DSGU5@F'L5TI X(*%9$4D0T$2
MUY)4TJ&1\NZ@Z;IVIR^BA,3KM.=TCDJ \Y="1LC_\@=T@$PA/V>0P##N%*8L
MT2SRL%^U2VE*(I0"D\=TH^:4^4O)-<<4(S&%P9V_(#&F+")&7"FC"/[,2HJE
M 19,,C3$Z+8I +F2F9T;'8<EZ%$2P;0"?TBA%"9O":XE4]S0,H7K+S@+$!25
MT/R6P3@(L%I)XRL#F9M=2F&]-49<:AY@/UE*M20H1 MPFG!3F5;Z%3!T/>F
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M,#(T,#DS,%]C86PN>&UL4$L! A0#%     @ $XAG60.EA<B>.P  +DH$ !4
M             ( ! R,  &%D;6$M,C R-# Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( !.(9UF+T#>H\;X  )(D"P 5              "  =1>  !A9&UA+3(P
M,C0P.3,P7VQA8BYX;6Q02P$"% ,4    "  3B&=9U.[<#VQ@  "PM08 %0
M            @ 'X'0$ 861M82TR,#(T,#DS,%]P<F4N>&UL4$L! A0#%
M  @ $XAG6?75]HZV_ ( B^0@ !(              ( !EWX! &5F,C P,S0T
M-S1?,3!Q+FAT;5!+ 0(4 Q0    ( !.(9UG7T(W&4PD   0P   5
M      "  7U[! !E9C(P,#,T-#<T7V5X,S$M,2YH=&U02P$"% ,4    "  3
MB&=99BRP\$H)  #D+P  %0              @ $#A00 968R,# S-#0W-%]E
M>#,Q+3(N:'1M4$L! A0#%     @ $XAG61L@C,$-!0  '!(  !4
M     ( !@(X$ &5F,C P,S0T-S1?97@S,BTQ+FAT;5!+ 0(4 Q0    ( !.(
M9UF#41E;_ 0  '@2   5              "  <"3! !E9C(P,#,T-#<T7V5X
>,S(M,BYH=&U02P4&      H "@"7 @  [Y@$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>ef20034474_10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20240930"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adma-20240930.xsd" xlink:type="simple"/>
    <context id="c20240101to20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20241101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-11-01</instant>
        </period>
    </context>
    <context id="c20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240701to20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20240930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230331_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20240930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_TypeOfArrangementAxis_BiotestLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240630_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="c20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231218to20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_CounterpartyNameAxis_AresCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-03-14</instant>
        </period>
    </context>
    <context id="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-09</instant>
        </period>
    </context>
    <context id="c20240110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-01-10</instant>
        </period>
    </context>
    <context id="c20240224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-02-24</instant>
        </period>
    </context>
    <context id="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-08</instant>
        </period>
    </context>
    <context id="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-15</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240930_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240701to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240701to20240930_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20190401to20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20230101to20230930_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230930_StatementBusinessSegmentsAxis_CorporateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:CorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="U001">
        <measure>shares</measure>
    </unit>
    <unit id="U002">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>adma:Facility</measure>
    </unit>
    <unit id="U005">
        <measure>adma:Product</measure>
    </unit>
    <unit id="U006">
        <measure>adma:Customer</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>adma:Officer</measure>
    </unit>
    <unit id="U009">
        <measure>adma:Term</measure>
    </unit>
    <unit id="U010">
        <measure>adma:Segment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20240101to20240930"
      id="Fact_bc34a0819aa14c55b88748319002a33f">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20240101to20240930"
      id="Fact_c1f44fcffab749dda721d1e5b746ce94">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20240101to20240930"
      id="Fact_a4839fbe616246d3a08857ac06e2e7d7">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20240101to20240930"
      id="Fact_08a4081ba0214061a447aff0c26db396">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20240101to20240930"
      id="Fact_9fd1153128b74fd7b74acd19d68737d3">0001368514</dei:EntityCentralIndexKey>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="c20240930_RangeAxis_MinimumMember"
      id="Fact_aabd598a3cab423c96bb46e0610cf636">P3Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20240930_RangeAxis_MinimumMember"
      id="Fact_e1bb617d16104c86ba85a63d93bd3935">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="c20240101to20240930"
      id="Fact_837d17e5cc4148dab6c5f12dca0a9d3b">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="c20230101to20231231"
      id="Fact_2d5d7cee97d843e6bdafc3e0cea93ecc">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration
      contextRef="c20231218to20231218"
      id="Fact_f94c3272e4024032bf1c8ec0500c05eb">http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember</us-gaap:DebtInstrumentVariableInterestRateTypeExtensibleEnumeration>
    <adma:NumberOfBusinessDays
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember"
      id="Fact_8458c263b75e47d7a0c66a15b98f6079">P2D</adma:NumberOfBusinessDays>
    <adma:NumberOfBusinessDays
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember"
      id="Fact_8c7034ac2c65418ea392b4cb6da4a682">P2D</adma:NumberOfBusinessDays>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal
      contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_572da660a7754ce69aefce28a22367a6">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal
      contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_b6b7fa74500a4b88b6db8be11e46fee6">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="c20230101to20231231_RangeAxis_MinimumMember"
      id="Fact_04c4d72102c94fdb82f3fcd93478e6fd">2028-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="c20230101to20231231_RangeAxis_MaximumMember"
      id="Fact_ee510cd27e5248eea4877ba277c443e7">2043-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:DocumentType
      contextRef="c20240101to20240930"
      id="Fact_8838a0557939413aa4d1579953df83a0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="c20240101to20240930"
      id="Fact_3a3ef01f8157491cad9c9ad8e377e496">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20240101to20240930"
      id="Fact_a73d7046e4a8407bae525f39de634c57">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20240101to20240930"
      id="Fact_4e37d04973334da79c233499264b6521">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20240101to20240930"
      id="Fact_a582f70da2b545caabf21705bd560b2a">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20240101to20240930"
      id="Fact_66c888673190405084a95a15da08b4ea">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240101to20240930"
      id="Fact_23bbfb9951c343a094cf661a0e13e89e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240101to20240930"
      id="Fact_53c9fd7c701d422d89a56c3831f77d33">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240101to20240930"
      id="Fact_e3a3adfd9f9e469fac63dd1b004d26ce">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240101to20240930"
      id="Fact_c200eb049f51448d8face15792f9555d">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240101to20240930"
      id="Fact_c95efbad89ac4b3cb3eb6b84c66f922f">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240101to20240930"
      id="Fact_2eb3f31080d84ecf98d52ae9b7431a97">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240101to20240930"
      id="Fact_72e89c8005ea4e4f84cb8460fdebc4ab">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240101to20240930"
      id="Fact_8f186fe0b6724826af2e6d6d22d2a822">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20240101to20240930"
      id="Fact_69673173e3c9420c931b7611929ac609">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240101to20240930"
      id="Fact_07ec329ff92c43018f7bba1b424c723e">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240101to20240930"
      id="Fact_49b1bc0b736b4a74be1935da670e8868">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="c20240101to20240930"
      id="Fact_b412f81e364e47518dd0b5629f2d4731">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20240101to20240930"
      id="Fact_09b03c6f545340fc8318795d70f49675">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20240101to20240930"
      id="Fact_cdcd47892b0646169803253de81b9ae2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20240101to20240930"
      id="Fact_9c4fa56f2045498ca2904c830d4cac3b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240101to20240930"
      id="Fact_0d12894aec8d4f14b8decd8e86a3030f">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="c20240101to20240930"
      id="Fact_d4880ec764e64a0387bb9fa8c124a63e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20241101"
      decimals="INF"
      id="Fact_2357357af3cf4d788b3f1a1f17c5d3a2"
      unitRef="U001">236390253</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20240930"
      decimals="-3"
      id="Fact_2433aaa0f77c4c2088cd8707941d7e68"
      unitRef="U002">86707000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_9cbd99f142bc49918de54d35b82c9d7f"
      unitRef="U002">51352000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_a65a3741507a430fb1245c9c1f8d85e2"
      unitRef="U002">50140000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_86347a9c044b48f19dc559a37403ea87"
      unitRef="U002">27421000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20240930"
      decimals="-3"
      id="Fact_9142fbb79b634d9da8f751e35db17e72"
      unitRef="U002">171801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c733c840f9854e208bc854b08f2bbeeb"
      unitRef="U002">172906000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_a5421b8588ca4ecfadbf6cbaacc9c7b6"
      unitRef="U002">9545000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_9177520ab36c49ea97cd19a1c968df92"
      unitRef="U002">5334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f0a49f8ce9bd4d899b3db3c19e04efdd"
      unitRef="U002">318193000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f45b3271b441455cb2105680565b129e"
      unitRef="U002">257013000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d8c833d9f27b421dbaa3e2b268ca0bab"
      unitRef="U002">53694000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c7aaf9819ea84e03bf8722ce95af85af"
      unitRef="U002">53835000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f17de370315f4091b0f89c2e84d973d1"
      unitRef="U002">485000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0514a0e23bdc4d0ea5e717bdf3754926"
      unitRef="U002">499000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="c20240930"
      decimals="-3"
      id="Fact_769d5f0c97eb4064bdb43ac410530a21"
      unitRef="U002">3530000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_146dfcca9c3e49fa9b8a31f975e6acc2"
      unitRef="U002">3530000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20240930"
      decimals="-3"
      id="Fact_bbc32b4cc98043e9a94ba4f7220fb722"
      unitRef="U002">8897000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6dd902973f4846a4bb1c1594e27f8f57"
      unitRef="U002">9635000</us-gaap:OperatingLeaseRightOfUseAsset>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20240930"
      decimals="-3"
      id="Fact_fdb7387d5b0a4d048c2f6366a42a0e3e"
      unitRef="U002">5819000</adma:DepositsAndOtherNoncurrentAssets>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a50743018b6247889bc69ddeeb66ade6"
      unitRef="U002">4670000</adma:DepositsAndOtherNoncurrentAssets>
    <us-gaap:Assets
      contextRef="c20240930"
      decimals="-3"
      id="Fact_c2f9187a8f1347b180e4de1c4e0650a0"
      unitRef="U002">390618000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_7667a4f3673d4a5c8f4ea222c3c2efa1"
      unitRef="U002">329182000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_7dde0dfcef624d98a7c818296df97379"
      unitRef="U002">16020000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_79f8959f51c440058a2b2ae73dcbf97b"
      unitRef="U002">15660000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20240930"
      decimals="-3"
      id="Fact_dd0f579f43084bb2aa500ce0cc36df30"
      unitRef="U002">27535000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0e9ccf6016784da8a8b04f3a1af923c3"
      unitRef="U002">32919000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_717f5016a22d44e788a7623ed89d02dc"
      unitRef="U002">143000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f9a0da175433427abcd2517ac58e7ac3"
      unitRef="U002">182000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_e15d10dae4084e71835cb788dda3105c"
      unitRef="U002">1193000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_133ea3e3d3ae4a4c84dea5f17daf07ff"
      unitRef="U002">1045000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_e040cd8f2ecf4ad193d82978ff855ac5"
      unitRef="U002">44891000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_df082a6c52ae4c43b80203fb015af4c8"
      unitRef="U002">49806000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20240930"
      decimals="-3"
      id="Fact_5dbbafa983e447648edea5d160779986"
      unitRef="U002">101326000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a253f9727f7042bdb255854fc1f4cc07"
      unitRef="U002">130594000</us-gaap:SeniorLongTermNotes>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_c6a34d215f70489cb00ad0517bb21b35"
      unitRef="U002">1583000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c686e6297dea4e4d93efce7816cca250"
      unitRef="U002">1690000</us-gaap:DeferredRevenueNoncurrent>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20240930"
      decimals="-3"
      id="Fact_4d410e2a246640308a098f9cd7fdd048"
      unitRef="U002">1688000</adma:LongTermLiabilityEndOfTermFeePayable>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a0a3d9326c654effa015cbfada21a58e"
      unitRef="U002">1688000</adma:LongTermLiabilityEndOfTermFeePayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_67604891dc8248dba7f483ed9d867778"
      unitRef="U002">8865000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c7f10b40133643d19d8ee5f69eb7ddd7"
      unitRef="U002">9779000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_1425725201a64a6b81c6061265b988a6"
      unitRef="U002">375000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_019efd73590a4e5fb4700d5a202f9ba9"
      unitRef="U002">419000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20240930"
      decimals="-3"
      id="Fact_4b09c740ef954edab33c4b39d9ffc56e"
      unitRef="U002">158728000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_95d12ad8d1e64b189d1268bbd917203d"
      unitRef="U002">193976000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20240930"
      id="Fact_292fbadd3b6847688ba39efc961e9f13"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20231231"
      id="Fact_cf251b6df5654e7c8d19f0fd75cd401e"
      unitRef="U002"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_4b322bc4ff9047ada11d276fba00f032"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20240930"
      decimals="4"
      id="Fact_6fc4cd5d6f0b44aba187135f7f5f2546"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_c51731a3209d45bc9c438cd58e2594ec"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20240930"
      decimals="0"
      id="Fact_6460774f302542369b031f1439c51371"
      unitRef="U001">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20231231"
      decimals="INF"
      id="Fact_7357d7c8b24b4172b404e8fb73377a70"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20240930"
      decimals="INF"
      id="Fact_6a23abbcd48d427490a73e11ae49d3bd"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20231231"
      decimals="INF"
      id="Fact_985ef26e70de4d438886de20409f6e62"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20240930"
      decimals="INF"
      id="Fact_65817be99e324befbc84fa32051df194"
      unitRef="U001">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="c20240930"
      decimals="-3"
      id="Fact_32421b2e655449bc95407ba53997b2dd"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_1b0624f0760d4befb7bf3f49d8cdc325"
      unitRef="U002">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_772895fcdb8948edaa197e1a3cbda00b"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20240930"
      decimals="4"
      id="Fact_0b9116e5ffd647cd91be96bc28d8ec95"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_a6da05b44012449790cf1f8fefcf0523"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20240930"
      decimals="0"
      id="Fact_e17fd8ff3db44d0db345255c9de5d29c"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20240930"
      decimals="0"
      id="Fact_be2280b446274185893dcebcbf2be1f3"
      unitRef="U001">236378607</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240930"
      decimals="0"
      id="Fact_a47a04445e0a40c0ac5864df134f7b0a"
      unitRef="U001">236378607</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_6acdb1cf62784deea606e18a567d8916"
      unitRef="U001">226063032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_4889dba395554041a519d29516e511d1"
      unitRef="U001">226063032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20240930"
      decimals="-3"
      id="Fact_58134c88742643e59d1016963f21fc5a"
      unitRef="U002">24000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a9deedc4c75a4eca9914e129648a18c2"
      unitRef="U002">23000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20240930"
      decimals="-3"
      id="Fact_c293fe47874d4c80ae1b7165eead05cc"
      unitRef="U002">652345000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20231231"
      decimals="-3"
      id="Fact_393b6c347b684f7c93234fece20c7a2e"
      unitRef="U002">641439000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20240930"
      decimals="-3"
      id="Fact_670ee4f1c7ce4252ae8b84b63c0b3e46"
      unitRef="U002">-420479000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4f86c6a8492a4d20b20ca60fb4d5913a"
      unitRef="U002">-506256000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20240930"
      decimals="-3"
      id="Fact_1a6712ef74b145788070fef039c2ef2d"
      unitRef="U002">231890000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3acf9855c6604de4b9fef2d7902b6e9c"
      unitRef="U002">135206000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20240930"
      decimals="-3"
      id="Fact_b55ab3549e7148a98c2fb93694e5d4ad"
      unitRef="U002">390618000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_cceb9a747e2849a3a60625fde7c5ccf2"
      unitRef="U002">329182000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_8c80cfc03fa74e58958a9587696524f5"
      unitRef="U002">119839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_d65c68a297bb40a6abc800115fd3e089"
      unitRef="U002">67275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_db1c99d55665420f861dc5da714d74f6"
      unitRef="U002">308905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_5276c028bca94dea939e43baf7116995"
      unitRef="U002">184311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_c06b2a811a4141e58abf55e34e8b9578"
      unitRef="U002">60180000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_062c130daa7e40ca80a137d15ac19af9"
      unitRef="U002">42622000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_6fc5e6ef1ffd418fb2da7dfbe64de1f6"
      unitRef="U002">152685000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_2e32c73f33694f0dbc83efa5d9e3d965"
      unitRef="U002">126455000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_bf0593924b5d4affaa4632a067bf5af5"
      unitRef="U002">59659000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_20d2ebb3b484463d9ddd515b820cee5a"
      unitRef="U002">24653000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_2bb12a99b87b41f6b0c17627480dd70d"
      unitRef="U002">156220000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_0491e4e22b0f430f8c9b9f9a03998a7e"
      unitRef="U002">57856000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_76fd52e789af4a42ada5afe548ae34ca"
      unitRef="U002">412000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_538c4a8ac16743929e2629256f082196"
      unitRef="U002">596000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_767d365ccb6e4f8a941c3e2bf80e5305"
      unitRef="U002">1422000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_3978299636d3471ba982778fb79b6d7f"
      unitRef="U002">2854000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_2508b08896b84f05ad8886a40f7a89c2"
      unitRef="U002">1021000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_52fbac27372245c1845f8f60f81b05dc"
      unitRef="U002">467000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_f95713b8e2534090b79a2181f9f873de"
      unitRef="U002">2968000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_67e7731d006e4d6194d461677b19b7a7"
      unitRef="U002">3581000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_68d14fb4cdbc4d52bef5ca7b73bae20b"
      unitRef="U002">28000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_f5817a3d25a9452f8064504e0a6ad533"
      unitRef="U002">179000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_e047b89e58ce483392bb4e610b6699ab"
      unitRef="U002">363000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_86f686ac3c8944008b56a6e12dec6117"
      unitRef="U002">537000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_d15b4b179ab441fe9251ccd2c2a696fb"
      unitRef="U002">18560000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_bb8adde31d404947b7945ee85af00d37"
      unitRef="U002">14726000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_d1a168e6e11f401184561b77d9ad0a24"
      unitRef="U002">50807000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_0ae9a0b15ed14b248b6ad733e1240f4a"
      unitRef="U002">43485000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_f58f61080187486cb5d586586e7c4a2a"
      unitRef="U002">20021000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_2bb5a41ed61441d79b84be8f5aa9af0e"
      unitRef="U002">15968000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_829a82c7dd954db2b1c95648aa88c175"
      unitRef="U002">55560000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_b791a46855dc487d86f347326cd93297"
      unitRef="U002">50457000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_9905cc735ec943c78fde9b7157776e2f"
      unitRef="U002">39638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_7ccce697ae9746d696a1b2909639981d"
      unitRef="U002">8685000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_3d55c702be5d4b7289ed0dfcd1bbd61c"
      unitRef="U002">100660000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_e3db1982360a453da28f6cb67140efc7"
      unitRef="U002">7399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_e55d7714fff74a22a9e1abdc4c73dd92"
      unitRef="U002">666000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_3665c88c4a624fd0b89c4ea358fc88d7"
      unitRef="U002">423000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_3983f011cf9c44c2b31e921ee99a3c71"
      unitRef="U002">1499000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_5d0ca20aa1ca4d6f8b95e4d9dde57be9"
      unitRef="U002">1005000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_a71ce3062d4b4766935dbad0677878b9"
      unitRef="U002">3499000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_49f9029bdfea42409552df53f24b26c9"
      unitRef="U002">6398000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_ae318561cdb542efba63f477ea144d24"
      unitRef="U002">11051000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_de970281193a47b3a8597ec3af3e3f43"
      unitRef="U002">18812000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_3c85d6b811a84eeebac14ccc274b24ce"
      unitRef="U002">-56000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_d87fb0a9fd664540a55938448c6dc318"
      unitRef="U002">-145000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_897e5502eb4941bb9bb5bc25680f05e7"
      unitRef="U002">-107000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_4b207b7d0347476683916641fb38cd62"
      unitRef="U002">-186000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_b922c5a89fdd43df81e81fd831e92aee"
      unitRef="U002">-2889000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_e13d75cb9d9247dba7d6ebc9bbd1d554"
      unitRef="U002">-6120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_c24f7f1c9c08401ca83a2922629bf451"
      unitRef="U002">-9659000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_15362ef7299a48d5b7e06be643481db3"
      unitRef="U002">-17993000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_80dda2143bd847f7b13a613ead257889"
      unitRef="U002">36749000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_01866707a60e473592b11ac6b4919c0e"
      unitRef="U002">2565000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_23854e21cc5b4a05ab61a54951b5e828"
      unitRef="U002">91001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_6f2c8c3611d546a6a81c48f142af2a00"
      unitRef="U002">-10594000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_8e6569998f71492dab74384d70293576"
      unitRef="U002">840000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_4c14858cf27e4b34ae3fc55a7dc8ffd5"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_5803aab4ec754b2c850a8a5ee918c45f"
      unitRef="U002">5224000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_a91f9fe61cbd4aa3843932385a59de81"
      unitRef="U002">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_68a96a78aa6d416585ca6b454281fac2"
      unitRef="U002">35909000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_80d68c6beb7f4bd0a0041e1773a29226"
      unitRef="U002">2565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_a6c25bda09c94616b5d74178043a2d99"
      unitRef="U002">85777000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_368890b0c61546a488d23fc526638660"
      unitRef="U002">-10594000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240701to20240930"
      decimals="2"
      id="Fact_1e1f704280594d328a8f4723f86bed0e"
      unitRef="U003">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230701to20230930"
      decimals="2"
      id="Fact_25c5c5449fdd42ea96784f59c89d554b"
      unitRef="U003">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240930"
      decimals="2"
      id="Fact_1ecb3d59598740ac93b30ed1b3bdf5bc"
      unitRef="U003">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20230930"
      decimals="2"
      id="Fact_d3789ace214b48058c8095f5796eec4b"
      unitRef="U003">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240701to20240930"
      decimals="2"
      id="Fact_a9f9053b648c4722989cf57cb792e2e8"
      unitRef="U003">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230701to20230930"
      decimals="2"
      id="Fact_72a1810780c74ad7bf9ab91063ca43b9"
      unitRef="U003">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240930"
      decimals="2"
      id="Fact_8624971930e945f89f0f87def899be15"
      unitRef="U003">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20230930"
      decimals="2"
      id="Fact_f9ff18f2397c4f999e60eef3509b3f40"
      unitRef="U003">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240701to20240930"
      decimals="0"
      id="Fact_8991ef97bf7a46a292832844b8f003d1"
      unitRef="U001">234571376</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230701to20230930"
      decimals="0"
      id="Fact_00d234c0ded1454f8b3d8e0367feac13"
      unitRef="U001">225276980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20240930"
      decimals="0"
      id="Fact_932a037ed38f4c7989e02ce067b5c10c"
      unitRef="U001">231959579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20230930"
      decimals="0"
      id="Fact_74b02ee36d6f402bbc6e2670889e55da"
      unitRef="U001">223306331</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240701to20240930"
      decimals="0"
      id="Fact_9b082890588c498aab811c534efc636f"
      unitRef="U001">244804065</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230701to20230930"
      decimals="0"
      id="Fact_6324a640e59a47c992fc9b8a335f96d1"
      unitRef="U001">233761262</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20240930"
      decimals="0"
      id="Fact_12e84b4fc99340f8aeef1689ba128cbb"
      unitRef="U001">241772162</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20230930"
      decimals="0"
      id="Fact_c37c5c63292c4e8c8360785258e4a2d5"
      unitRef="U001">223306331</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_45aeace92c144a97bbc9adb9a058133f"
      unitRef="U001">226063032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_eb9f34373ad64aab81a11b5c474366ba"
      unitRef="U002">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_883d874dd0cf40a4b6371fceabc3d735"
      unitRef="U002">641439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_47ede5702e2941558c3b79247dda6613"
      unitRef="U002">-506256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b72f0ff7e3e54fbd9b574dbe2b2f7dbb"
      unitRef="U002">135206000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e220dc61862e435b898735b5af37bf0a"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_37b0632f8ffa476087ab288fff6ce834"
      unitRef="U002">2141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_5febbfca069c4579b0270ba65ae9ef16"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20240331"
      decimals="-3"
      id="Fact_22a78821e372416ca95ac549b2169928"
      unitRef="U002">2141000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2ec3ca2638e14cec8d6cbaf674c50068"
      unitRef="U001">4545503</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_561b0b5be2eb4ec5a1517e173988ce34"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_e2d96d4ffeaa492082f78fa1e2c0dbe6"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_65051f3cebb44dcaa6424caf78dc8ada"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20240331"
      decimals="-3"
      id="Fact_7ed65307901f49e4a93ccf4c858d18aa"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_438a1e66a8e5469cbd270bbf9f94a2d1"
      unitRef="U001">774889</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c0298a8c52ce48e1aa0b547c3cceaa37"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_11f6727784c449618d3550770d336c2b"
      unitRef="U002">-2476000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9e14f56cbaf3482db991107f1b9b506c"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20240331"
      decimals="-3"
      id="Fact_b1b55ad5f570415e8c4acc14078e0749"
      unitRef="U002">-2476000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c8cff83bb3d44cc69d3f45f958adecd4"
      unitRef="U001">386341</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_04621b982ca3400287ae4dfc66f30408"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a4f7bc6ecd8b456eaf0dfd457f9f45bb"
      unitRef="U002">1029000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_52cbc67d56004d9db5f81b09c499d5e0"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20240331"
      decimals="-3"
      id="Fact_136008d781ef473ea8382ef55d68d53e"
      unitRef="U002">1029000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_af0e197eb4c44dd899ef6d511ecf63ad"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a32c37e6782140a9bb21955cfa935697"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_521012fcafc3468987294571e5159d02"
      unitRef="U002">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240331"
      decimals="-3"
      id="Fact_6f7b361568f2407fb9e67c7415c6bcca"
      unitRef="U002">17806000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bbd05341bb6848beb625be1bc13d5aca"
      unitRef="U001">231769765</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_4181d3b4ea8948b0a86025b2b1db23fd"
      unitRef="U002">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d5d6966131214429b8af2770c0e42fcf"
      unitRef="U002">642133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3dde219357404ba1acf9e15b148e4427"
      unitRef="U002">-488450000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240331"
      decimals="-3"
      id="Fact_0f1ba5c2e512404c880103388ee441d2"
      unitRef="U002">153706000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_53fc6b4b31164e55b4bf4da5873e11d6"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_aba4b5ea5089436fa8c10466bdb852bd"
      unitRef="U002">2863000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f9d9fd8c62f04981aa57ffa6d3677bdd"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240401to20240630"
      decimals="-3"
      id="Fact_b8a9012fe1cf42beaec81480c84b9d91"
      unitRef="U002">2863000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_59956f45939848f4906161f08e1b3f09"
      unitRef="U001">937507</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_408b57d329924777bfb63ef70d1ccaa8"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2e29e3505c9f43cda7d25fe89b26d08f"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_819f5ca3410242edb8d894067b9b5611"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240401to20240630"
      decimals="-3"
      id="Fact_2a0a111ef1dc41bf88f34c173e4147a5"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_33fb57e48e5c4f1abdf0578df81ab9f8"
      unitRef="U001">171408</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_826943a2bcb34eab8cc17b875713ab0d"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d7acab1e1feb44bf901e25ab87f98569"
      unitRef="U002">-693000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2acc5184c9fc40fda477a226bd90573b"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240401to20240630"
      decimals="-3"
      id="Fact_04fa191a880442b4ace4489878ffbaa8"
      unitRef="U002">-693000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4c1a5d0045d04358995f60042c0b57bc"
      unitRef="U001">148056</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_536b60ba19e04948a52f55e1a5dcc586"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_65c8166a498b41509d6f382d4b2bb5dc"
      unitRef="U002">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d124087e326e4424909238e5334162ab"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240401to20240630"
      decimals="-3"
      id="Fact_7c7bb5c1b6a249cd9034744da17bc421"
      unitRef="U002">331000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_024c79f617564b07b7946a75a9442d13"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a1b5ed11df034afd9ecbf256f1f04a3f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_195385e259754e63b92ae690977a4b0b"
      unitRef="U002">32062000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240401to20240630"
      decimals="-3"
      id="Fact_ed76f4618e34463eafc1945138cd996f"
      unitRef="U002">32062000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_47f78fb3cda94137aa9b0c1ee6310031"
      unitRef="U001">233026736</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_dc8b742b940147b39d325146d9526533"
      unitRef="U002">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3a0576fe3e8947229dc4a9436728dd1f"
      unitRef="U002">644634000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6685e82fb25140c5aab2f616680096b9"
      unitRef="U002">-456388000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240630"
      decimals="-3"
      id="Fact_c5623f894bd142da901766d649177a17"
      unitRef="U002">188269000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8008db02402c4178a5ba328d85aa227b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6efcb0ed5d5049e09e66af53e996d753"
      unitRef="U002">3179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_01403822f2a14abfbe0513877c0fe4fb"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_5ccc5bbca0c348208ac2378b7709f308"
      unitRef="U002">3179000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a6994ebd0d6148a183b405b3ee895236"
      unitRef="U001">1741882</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6319963b49284978a43cf8223377f4f6"
      unitRef="U002">1000</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2e19bba84e1d4461bfff942c64a44ecf"
      unitRef="U002">-1000</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ae48df3a76bf4046aacb8ce5c91b03a3"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_2c0135d6fbfd406aa440b046905247c3"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4f939ed7fb584c19a0ccf8881dfdbd45"
      unitRef="U001">250107</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_348feaf0d30d424188d4f8564dc75ad6"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_fa39b0ec1241400dbd7b60c8a95be2b8"
      unitRef="U002">-1158000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ad35c6231ca54ac68ddbde060e03ccfd"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_e9bc84c294ee4ae38097ffff7109ce93"
      unitRef="U002">-1158000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5447c2763e354328ab74ccb417542084"
      unitRef="U001">1359882</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_40cde3395ee74d5fa343dff779407326"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_326ac742c7cd41688de9819e243944c2"
      unitRef="U002">5691000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b7bd6f6cbc2b4cd0b6cc2084d7e2c900"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_0f655b16db16456faf9ee9821ffa0cae"
      unitRef="U002">5691000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_cee44bf1b80a41f2a7fa0e2c8f4c2ff1"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_7aa5281aa52f48ab8710dfd780e66412"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_7233a39652c84f08bc5e4ab378d96923"
      unitRef="U002">35909000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_1c565a68c0f34fd49619b947288f9433"
      unitRef="U002">35909000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0df2d6d7a7444de3bc8804b0691cd1d1"
      unitRef="U001">236378607</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e4eb5ce383844a95895d3bec0a1055e3"
      unitRef="U002">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d1f5097c923144b99926fb510f05b952"
      unitRef="U002">652345000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_df09458422ec494aacff8c6559575c03"
      unitRef="U002">-420479000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20240930"
      decimals="-3"
      id="Fact_aac9b80115e346199c07ec0b3ea14b4e"
      unitRef="U002">231890000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_a52eec4a457749c6ac4c79793c82969b"
      unitRef="U001">221816930</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_2854c24a59cb487592bc326ac5ae3579"
      unitRef="U002">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_68c9f00ebc204e8eb3b3369b6260cae9"
      unitRef="U002">629969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_4c805a5120eb4598beeef93762a5e4d6"
      unitRef="U002">-478017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_5265e0b771464a5abf9d75f3cc7c2747"
      unitRef="U002">151974000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7f176e8f49df4f87bd39f989ef72e41b"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d2a3105a7ec346a481b8f59c1eb62cff"
      unitRef="U002">1110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0ea567d153ef4120b92f99a3cedbd7e4"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_473900ca57c844f0b32f7b9fa0c43f2f"
      unitRef="U002">1110000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_944d21d2d64348769e545dece668d64e"
      unitRef="U001">443215</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_7388cb98905a484d9fdf29cc01d1512a"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_53b97558b37b41369d37f91b373fe5fb"
      unitRef="U002">-640000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_462f1b335dff4267bb843c4199870599"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_dc5f1ab1fc9f4ac0999880c8d6532732"
      unitRef="U002">-640000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_552444da3e2340b1b85a6eb7321e9ce8"
      unitRef="U001">2443</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a4198d1de7a94229974be6e10f1c262a"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ad913852b6534e01ae8e7cde82acc2b8"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_e66389d7a6294a34bfe7efe4dfe8bf33"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_c30f620a79ce451ca02cf297e7ceac60"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_c31df73c23184ca189cde51e2430a8c3"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d3d7951020674e128766fc742113e7fe"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2949224209954f7bb1ca3b236d2eb5de"
      unitRef="U002">-6789000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230331"
      decimals="-3"
      id="Fact_51b9eb6dd2e54028b6b7dfb7fbb7d620"
      unitRef="U002">-6789000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_f8c0f876f1bc40d687164c11a77649c7"
      unitRef="U001">222262588</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_24478249430547d682ba9a97fd040b7f"
      unitRef="U002">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6fcdd7eba9404b7f851b316e278b4238"
      unitRef="U002">630439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_cb7b0e2bb34f498daaf5c0ba4986bcb1"
      unitRef="U002">-484806000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230331"
      decimals="-3"
      id="Fact_8361d217ee7a4a0281b76881aef68f5a"
      unitRef="U002">145655000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_28c6d41c2f89484b82195450dc079156"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_ff52f16888f74895b27f4d8f8a42ff84"
      unitRef="U002">1637000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_d50f9397fd1f4f0ab166e911534c5ec5"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_c1b0f51c4acf4ad3943464d7e95cb4a4"
      unitRef="U002">1637000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c9f6944ac0e94c149ac92f9d377ab058"
      unitRef="U001">117484</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_880872d1a3f74bed9a6fb45f1ceed0c5"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_469c105eb9364ef6982a7d4e4587acf8"
      unitRef="U002">-225000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_37d3a4abd8334d0eaed1ba06ae0a3b0c"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_ee3cae81ac524f51af75c7101a36649f"
      unitRef="U002">-225000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_128529ce01894b40ad8c89b5adcba995"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_3376b0646f6c45438426738d689b40a7"
      unitRef="U002">5594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_ffaea5fcdfc942c5b20b40e52a9cb44c"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_25c8f7236e694ef4974c908f70b7efa4"
      unitRef="U002">5594000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_acdee564111b45329aac1b93d58181bd"
      unitRef="U001">1967847</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_a24d5c4c0edf4eadb9af74c35678034b"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5e09c79fb230463da412a2c54a80e169"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a4198e590b034bc4933a972295567964"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_e6fb0e2168624610b172c25342ec57b4"
      unitRef="U002">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_9a2dd80a83dd4d7c92d6b85d14671fa0"
      unitRef="U001">178829</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_8abf428a6c434aeda2bf15d45fd0889b"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b322e3cfb5a146f0a52c92c8d6e2dd7d"
      unitRef="U002">472000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b21a1d92874b4796bfb65894c2db2edf"
      unitRef="U002">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_0ca5188cc251476ea28b2a75741faee5"
      unitRef="U002">472000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ada4ac3ce1a247acae020493bf237e5f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_0cd513dea5d04e3f8281a5cd84d36506"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3d9fb9bd4ab94ad7a13d2bf16770babd"
      unitRef="U002">-6371000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230401to20230630"
      decimals="-3"
      id="Fact_b72fd947365f444582535121d6e61c46"
      unitRef="U002">-6371000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6e78a7bfe7384583ab9e608fdf3baf2b"
      unitRef="U001">224526748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_3523c05d462044609cb78eee29efc32f"
      unitRef="U002">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_74d7cc40c30b41769eb260e7ee695dae"
      unitRef="U002">637917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_dbbb39b9cbc14123b0836a25297385fb"
      unitRef="U002">-491177000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230630"
      decimals="-3"
      id="Fact_c6c0735d52af4ba0ba2743161bbb7d75"
      unitRef="U002">146762000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_782b0d09321f473ca412151cd2e7d8f9"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_72cb3e695134408b95eb4d79119a47b9"
      unitRef="U002">1695000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6b22879abf8b4a9990fbfc30d8ab835d"
      unitRef="U002">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_a3f23e01c5e0496fb0dd453aedbe51ad"
      unitRef="U002">1695000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_13e0ae4543c34bcb8933c2eca77ed391"
      unitRef="U001">171295</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6cdd96ca59c843c082fd988a5a08bc2b"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b1c416d75c734288b7e428ca010cccd5"
      unitRef="U002">-209000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_efb63020aae84aecb370e988da571964"
      unitRef="U002">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_3016c4b4b3034aee8d51e038717dc47e"
      unitRef="U002">-209000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_84e8d6466cac4a648fc1ad36b07bf8bf"
      unitRef="U001">1260041</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f43e600b92a64f738b96b9383582a752"
      unitRef="U002">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_92da9723a3b44edf85f8e8698531458c"
      unitRef="U002">623000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_e0069ce85aec41dd8dc6087e446feea5"
      unitRef="U002">624000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0262db51ceb94e6a9f7290903df21b8f"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d1531ff3dcd748f5b723f41dc19b0e30"
      unitRef="U002">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_74612339f56f47adb6fc13d70575cdf1"
      unitRef="U002">2565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_56e986cdffca4370a9f2a49fd5bb19fd"
      unitRef="U002">2565000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_139f10aee83348c3a01344c4cdc31a81"
      unitRef="U001">225958084</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20230930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f3a1b163680d416aa15a4507fdb22e64"
      unitRef="U002">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230930_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_9bc86241117c4805b2f00c2e014c23a8"
      unitRef="U002">640026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230930_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3aa1dd6027ca4177af8cf96109160a96"
      unitRef="U002">-488612000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20230930"
      decimals="-3"
      id="Fact_df56584b844a4f9b9fad0ca0b766b4a5"
      unitRef="U002">151437000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_606e384999c44b89a2f45b44d9be2517"
      unitRef="U002">85777000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_554cda1cba654604bbccaaebde7db98c"
      unitRef="U002">-10594000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_83080cccdd6c41ebbae85287f51e38d5"
      unitRef="U002">6101000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_ca7370b0b19e46f99b974659c5ad04e6"
      unitRef="U002">6223000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_515262ae94b843ba8af2bd8952c28fa5"
      unitRef="U002">-32000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_68fa0d6ea69d4931b29a903cca06f2d5"
      unitRef="U002">-111000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:PaidInKindInterest
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_a7a703ba8e0641b5a8eb820d496f2cb7"
      unitRef="U002">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_d8e180512f2644cf831d6f64ad829e56"
      unitRef="U002">2959000</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_8d5c2bb295224d419c3420694af40e45"
      unitRef="U002">8183000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_670daf81ec0e4ae59184cfe715be7bcc"
      unitRef="U002">4442000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_fd92d9f44d34479786a5d68a3983d2af"
      unitRef="U002">732000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_f13bdc7f5a914f4084b4953436f3654d"
      unitRef="U002">1896000</us-gaap:AmortizationOfDebtDiscountPremium>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_3e57e53903a545c1ac13b4b75ab07fce"
      unitRef="U002">-107000</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_89a9d124aac042ee93e9b2e64f0875e0"
      unitRef="U002">-107000</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_1dd109c39b304e7c91c47847eb964c36"
      unitRef="U002">22719000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_9b8f4c75f5734cdc85490f66d98fe227"
      unitRef="U002">15814000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_264d1acc9c834f019a733c35d2177df8"
      unitRef="U002">-1105000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_a9b6140c5d234afdb8706bbbf1d75f35"
      unitRef="U002">-164000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_f5acef387bce4b40a96171dd2a65c78a"
      unitRef="U002">4211000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_c77b61709a1d49c7b5267b2f15dde1bc"
      unitRef="U002">12000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_b1d73d329b954767897f8f303d9ffebf"
      unitRef="U002">411000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_bf9008a7b96d42e0a6fa92a97ab7c4a8"
      unitRef="U002">1221000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_3f886d78219940d3ae9eb541eb90c632"
      unitRef="U002">208000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_5bbf598ffc494351b32f0efe70ce5fee"
      unitRef="U002">-1155000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_40dbe8521d1446c6936e91f772fa3bf3"
      unitRef="U002">-5384000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_fd95dbec2e6c4bf48dfad93fd19f3ed9"
      unitRef="U002">4872000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_f25bbf8593734543b01b1dfd3ea1038e"
      unitRef="U002">-850000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_973d5a4d2ef14b7abe9ed0af9a9d952f"
      unitRef="U002">-561000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_6cfe9408e8844ab9b40d95553100bcca"
      unitRef="U002">68456000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_a0dea6324de24915a75e5abd788855e6"
      unitRef="U002">-8797000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_b1f5fe8caf7047798637405d4650fbb9"
      unitRef="U002">5469000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_4e1c44f0ac144022bf9d800076d23a3a"
      unitRef="U002">3574000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_9a945cd4a7bf49bb8cf9ea2075a05c92"
      unitRef="U002">356000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_fe84717725be463e8cb7fb107a9bf55b"
      unitRef="U002">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_8b1af39671aa45ceb09f7ef327d9e32a"
      unitRef="U002">-5825000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_d8843976a13c448cafd94324f9287089"
      unitRef="U002">-3574000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_d32a8fddbec241f5ab3ae2c5cfadb6a4"
      unitRef="U002">4327000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_f2f6799b325341b3a9d32f52e87bc068"
      unitRef="U002">1074000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_b1e37735845f4698aa98982dc3c0eddb"
      unitRef="U002">30000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_fec7c9137cf54ce3b5258849654fa39b"
      unitRef="U002">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_32e891ca8de644d3b4189b5bb7913221"
      unitRef="U002">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_ae409d8f4bc74c5ebf7a79249c40adb1"
      unitRef="U002">16000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_8b61fdabac4f4e9181281ffb1dcb9c5b"
      unitRef="U002">7051000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_bd810014a5e14c6aab17ee58e09c53ac"
      unitRef="U002">1096000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_69272294317744fcbfbcc384392b85ee"
      unitRef="U002">-27276000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_d0382ac483a34ed6abd49cbd4df0a0eb"
      unitRef="U002">6000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_45c3b87b315a4c698252bde2791e3307"
      unitRef="U002">35355000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_79454785ed50456da17cfe72739aa946"
      unitRef="U002">-12365000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b2be9221ca3942a0b45e4f329506aeb1"
      unitRef="U002">51352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_2bd75314b7494603aa085ca7d4edf16b"
      unitRef="U002">86522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20240930"
      decimals="-3"
      id="Fact_ab8dcca17d114290a2011513bb272e45"
      unitRef="U002">86707000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20230930"
      decimals="-3"
      id="Fact_2c2c2920b7a9492c8d90f7f638ebc74e"
      unitRef="U002">74157000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_014177761dc640798f373cc359e0df61">
&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                    &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is an end-to-end commercial biopharmaceutical company dedicated to
            manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#x2019;s targeted patient populations include
            immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-size: 10pt;"&gt;ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA BioManufacturing&#x201d;) and ADMA BioCenters Georgia Inc. (&#x201c;ADMA BioCenters&#x201d;). ADMA
              BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#x2019;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;)-licensed BIVIGAM and
              Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;). ADMA&#160;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;BioCenters&lt;span style="color: rgb(0, 0, 0);"&gt;&#160;is the
                Company&#x2019;s source plasma collection business with ten plasma collection facilities located throughout the United States, all of
                which hold an approved license with the FDA.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;The Company has three
            FDA-approved products, all of which are currently marketed and commercially available: (i) ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an intravenous immune globulin (&#x201c;IVIG&#x201d;) product indicated for the treatment of Primary
            Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary Immunodeficiency Disease (&#x201c;PIDD&#x201d;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii)
            BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B
            Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin
            products, the Company generates revenues from the sale of intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The
            Company seeks to develop a pipeline of plasma-derived therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain
            infectious diseases.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 33.75pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;As of September 30, 2024, the Company had working capital of $273.3 million, including $86.7 million of cash and cash
            equivalents, $50.1 million of accounts receivable and $171.8 million of inventories, partially offset by $44.9 million of current liabilities. Based upon
            the Company&#x2019;s current projected revenue and expenditures, including capital expenditures and continued implementation of the Company&#x2019;s commercialization and expansion activities, the Company&#x2019;s management currently believes that its cash, cash
            equivalents and accounts receivable, along with its projected future operating cash flow, will be sufficient to fund ADMA&#x2019;s operations, as currently conducted, through the end of the fourth quarter of fiscal 2025 and beyond. However, the
            Company&#x2019;s current outlook on cash flows and profitability may change based upon several factors, including the success of the Company&#x2019;s commercial sales of its products, whether or not the assumptions underlying the Company&#x2019;s projected revenues
            and expenses are correct and the continued acceptability of ADMA&#x2019;s immune globulin products by physicians, patients and payers. The Company is subject to risks common to companies in the biotechnology and pharmaceutical manufacturing industries
            including, but not limited to, dependence on collaborative arrangements, development by the Company or its competitors of new technological innovations, dependence on key personnel, inflationary pressures, supply chain constraints, protection
            of proprietary technology, and compliance with FDA and other governmental regulations and approval requirements.&lt;/div&gt;
</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c20240101to20240930"
      decimals="INF"
      id="Fact_abebb9c3c6ec49bab36ae9dd7447b8d9"
      unitRef="U004">10</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <adma:NumberOfFDAApprovedProduct
      contextRef="c20240101to20240930"
      decimals="INF"
      id="Fact_51cddc9f5b504e638c6a379228660bc3"
      unitRef="U005">3</adma:NumberOfFDAApprovedProduct>
    <adma:WorkingCapital
      contextRef="c20240930"
      decimals="-5"
      id="Fact_bd038db2ee3945df9351831f4bc65506"
      unitRef="U002">273300000</adma:WorkingCapital>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20240930"
      decimals="-5"
      id="Fact_2a427f28541341818ed13f6a7928489b"
      unitRef="U002">86700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20240930"
      decimals="-5"
      id="Fact_038ef75b1a364d4487142492ec08c9d7"
      unitRef="U002">50100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20240930"
      decimals="-5"
      id="Fact_b3a8d828909143df99e2c99ec1f19d03"
      unitRef="U002">171800000</us-gaap:InventoryNet>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20240930"
      decimals="-5"
      id="Fact_bc35362e1bb741978f6111cd60204ba6"
      unitRef="U002">44900000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20240101to20240930"
      id="Text_2ad68e1e2b064586abd48cd612418dc6">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;)
              of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2023 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on February 28, 2024.&#160; The accompanying consolidated balance sheet as of December 31,
              2023 was derived from the audited financial statements as of and for the year ended December 31, 2023. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q, Article 10
              of Regulation S-X and&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt; &lt;span style="font-size: 10pt;"&gt;ASC 270,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;Interim Financial Statements&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;, and &lt;/span&gt;therefore omit or
              condense certain footnotes and other information normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the
              opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements),
              &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;as well as material non-recurring
                costs, gains and losses applicable to the interim period, that are&lt;/span&gt; considered necessary to present fairly the Company&#x2019;s financial position as of September 30, 2024, its results of operations and changes in stockholders&#x2019; equity for
              the three and nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt; &lt;/span&gt; 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and
              2023.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the three and nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; 30,
              2024 and 2023, comprehensive income/loss was equal to the net income/loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not
              necessarily indicative of the results that may be expected for the full fiscal year.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable
              and estimates related to the valuation allowance for the Company&#x2019;s deferred tax assets and its effective tax rate.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt; color: rgb(0, 0, 0);"&gt;During the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;second quarter of&lt;/span&gt; 2024, the Company engaged a third-party specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to
              the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 &lt;/span&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt;million
              for the nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt;&lt;/span&gt; 30, 2024. This change in estimate was applied on a prospective basis as of June 30,
              2024 and increased income from operations and net income &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for the nine months ended September 30, 2024&lt;/span&gt; by approximately $12.6 million and $11.9 million, respectively, and increased basic and
              diluted earnings per share by $0.05. Because there was little to no historical data to rely upon at the time BIVIGAM and
              ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid
              programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally
              considered that estimates may change over the lifetime of these products due to changes in utilization and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to
              reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in the $12.6 million
              adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior credit facility (see Note 7) approximates fair value due to the variable interest rate on this debt.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts Receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and credit losses in the
            amount of $0.2 million and $0.1
            million at September 30, 2024 and December 31, 2023, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The Company extends credit to its customers based upon an evaluation
              of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt; Based on these evaluations, the Company has
            concluded that its credit risk is minimal. At&#160;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;, four customers accounted for an aggregate of approximately 91% of the Company&#x2019;s total accounts receivable, and at December 31, 2023, five customers accounted
            for approximately 98% of the Company&#x2019;s total accounts receivable.&lt;span style="text-decoration: underline;"&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-style: italic;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-style: italic;"&gt;Inventories&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs
              for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance,
              consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s FDA-approved products relative
              to the total square footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.&lt;/div&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at
              &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt; and December 31, 2023 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company did not &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;record any impairment charges related to goodwill for the three &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and nine &lt;/span&gt;months ended September 30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three and nine months ended&#160;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt; and 2023, the
              Company did not identify any impairment indicators for its long-lived assets, and as a result no impairment charges were
              recorded.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Revenues for the three and nine months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/span&gt;
                and 2023 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;ASCENIV, &lt;/span&gt;BIVIGAM and Nabi-HB, &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;(ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business
                segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG
                (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest
                license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; font-style: normal; color: rgb(0, 0, 0);"&gt;Product revenue is recognized when the customer is deemed
              to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the
              Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, wholesaler distribution and
              related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other
              assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. &lt;span style="letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;second quarter of&#160; &lt;/span&gt;2024, the Company engaged a third-party
                specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a
                corresponding increase to net revenues of $12.6 &lt;/span&gt;million for the nine months ended September 30, 2024, substantially all
              of which was related to the sale of ASCENIV and BIVIGAM. This change in estimate was applied on a prospective basis as of June 30, 2024 and increased income from operations and net income by approximately $12.6 million and $11.9 million,
              respectively, and increased basic and diluted earnings per share by $0.05 &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for
                the nine months ending September 30, 2024. &lt;/span&gt;Because there was little to no historical data to rely upon at the time BIVIGAM and ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial
              rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government
              payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally considered that estimates may change over the lifetime of these products due to changes in utilization
              and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in
              the $12.6 million adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer
              and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the nine months ended &lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; and 2023,&lt;/span&gt; two customers represented an aggregate of approximately 71% of the Company&#x2019;s consolidated revenues.&lt;br/&gt;
            &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA-approved products,
              intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
              When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings/Loss Per Common Share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic earnings/loss per common share is computed by dividing net earnings/loss attributable to common stockholders by the weighted-average number of shares of common stock
                  outstanding during the period.&#160; Diluted earnings/loss per common share is calculated by dividing net earnings/loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted-average
                  number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, as well
                  as restricted stock units (&#x201c;RSUs&#x201d;), using the treasury stock method. Potentially dilutive common stock is excluded from the diluted &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;earnings/&lt;/span&gt;loss per common share computation to the extent that it would be anti-dilutive. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the three and nine months ended September 30, 2024 &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;and the three months ended September 30, 2023,&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; basic and diluted earnings per share is calculated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2023&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Nine Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net income available to common stockholders ($000's) (numerator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;35,909&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,565&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;85,777&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic earnings per common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.37&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;10,232,689&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;8,484,282&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;9,812,583&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total shares - diluted (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;244,804,065&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;233,761,262&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;241,772,162&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Diluted earnings per common share&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.35&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

              &lt;div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/div&gt;

            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"&gt;For the three and nine months ended
                September 30, 2024 &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and the three months ended September 30, 2023, &lt;/span&gt;there were no
                shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. For the&#160; nine months ended September 30, 2023 no potentially dilutive securities were included in the computation of diluted loss per share in the accompanying condensed consolidated financial statements as the Company reported a net loss for this
                period. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the nine months ended &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;September 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock Options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;5,841,241&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4,877,482&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;12,502,906&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;23,221,629&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options and RSUs, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
              is generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. RSUs granted to employees generally have a four-year vesting period. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested equity awards is fully
              reversed at the time of forfeiture.&lt;/div&gt;

&lt;div&gt;
             &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination
                  by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits are recognized for an uncertain tax position when, in management&#x2019;s
                  judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.&#160; For a tax position that meets the more-likely-than-not recognition threshold, the tax benefit is measured as the largest
                  amount that is judged to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority.&#160; The liability associated with unrecognized tax benefits is adjusted periodically due to changing
                  circumstances and when new information becomes available.&#160; Such adjustments are recognized entirely in the period in which they are identified.&lt;/span&gt; Derecognition of a tax benefit previously recognized could result in the Company
                recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not
                incurred any material liability for uncertain tax positions as of September 30, 2024 and December 31, 2023, and during the three and nine months ended September 30, 2024 and 2023 the Company recognized&lt;/span&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; no
                adjustments for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2023 the FASB issued ASU No. 2023-07,&#160;&lt;span style="font-style: italic;"&gt;Segment Reporting (Topic
                  280): Improvements to Reportable Segment Disclosures.&#160;&lt;/span&gt;The amendments in this ASU are intended to provide financial statement users with more disaggregated expense information about a public entity&#x2019;s reportable segments; however,
                the update does not change the definition of an operating segment or the method for determining reportable segments. This update becomes effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after
                December 15, 2024. The Company does not expect this ASU to have a material impact on the Company&#x2019;s consolidated financial statements, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;except that its adoption will likely lead to disclosures of additional significant segment expenses.&lt;/span&gt;&lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_1b842d491338428ea527247b3dcb683e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States
              of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;)
              of the Financial Accounting Standards Board (the &#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and notes thereto as of and
              for the year ended December 31, 2023 included in the Company&#x2019;s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on February 28, 2024.&#160; The accompanying consolidated balance sheet as of December 31,
              2023 was derived from the audited financial statements as of and for the year ended December 31, 2023. These condensed consolidated interim financial statements have been prepared in accordance with the instructions to Form 10-Q, Article 10
              of Regulation S-X and&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt; &lt;span style="font-size: 10pt;"&gt;ASC 270,&#160;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;Interim Financial Statements&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;, and &lt;/span&gt;therefore omit or
              condense certain footnotes and other information normally included in annual consolidated financial statements prepared in accordance with U.S. GAAP. All intercompany balances and transactions have been eliminated in consolidation.&#160; In the
              opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements),
              &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;as well as material non-recurring
                costs, gains and losses applicable to the interim period, that are&lt;/span&gt; considered necessary to present fairly the Company&#x2019;s financial position as of September 30, 2024, its results of operations and changes in stockholders&#x2019; equity for
              the three and nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt; &lt;/span&gt; 30, 2024 and 2023 and cash flows for the nine months ended September 30, 2024 and
              2023.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the three and nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; 30,
              2024 and 2023, comprehensive income/loss was equal to the net income/loss amounts presented for the respective periods in the accompanying condensed consolidated statements of operations. Operating results for interim periods are not
              necessarily indicative of the results that may be expected for the full fiscal year.&lt;/div&gt;
</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20240101to20240930"
      id="Text_8dc991838e454edf8db537076279b401">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
              of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include
              rebates and chargebacks deducted from gross revenues, valuation of inventory, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and warrants issued in connection with the issuance of notes payable
              and estimates related to the valuation allowance for the Company&#x2019;s deferred tax assets and its effective tax rate.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt; color: rgb(0, 0, 0);"&gt;During the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;second quarter of&lt;/span&gt; 2024, the Company engaged a third-party specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to
              the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6 &lt;/span&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; color: rgb(0, 0, 0);"&gt;million
              for the nine months ended &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September&lt;/span&gt;&lt;/span&gt; 30, 2024. This change in estimate was applied on a prospective basis as of June 30,
              2024 and increased income from operations and net income &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for the nine months ended September 30, 2024&lt;/span&gt; by approximately $12.6 million and $11.9 million, respectively, and increased basic and
              diluted earnings per share by $0.05. Because there was little to no historical data to rely upon at the time BIVIGAM and
              ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid
              programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally
              considered that estimates may change over the lifetime of these products due to changes in utilization and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to
              reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in the $12.6 million
              adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.&lt;/span&gt;&lt;/div&gt;
</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_95fb5e9c482c47a89c6a3c2935e7bac9"
      unitRef="U002">12600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_109bd23a364546d9b12138d07820703f"
      unitRef="U002">12600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_0c3142b01490495baf9731936b11680b"
      unitRef="U002">11900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="2"
      id="Fact_da9f01ae185d484cb99674b8392c007e"
      unitRef="U003">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="2"
      id="Fact_5747b0de79704405a69dc9013b2ae08a"
      unitRef="U003">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_ae7159d13e3d48bd83a588f874379933"
      unitRef="U002">12600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20240101to20240930"
      id="Text_960edfd623ae41ecbb40cabb46d04a99">
&lt;div&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments, including cash and cash equivalents, accounts receivable and accounts payable, are shown at
              cost which approximates fair value due to the short-term nature of these instruments.&#160; The debt outstanding under the Company&#x2019;s senior credit facility (see Note 7) approximates fair value due to the variable interest rate on this debt.&lt;/span&gt;&lt;/div&gt;
</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_a3f7eb2891d044c6a9ebf724175e983e">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts Receivable&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accounts receivable is reported at realizable value, net of allowances for contractual credits and credit losses in the
            amount of $0.2 million and $0.1
            million at September 30, 2024 and December 31, 2023, respectively, which are recognized in the period the related revenue is recorded. &lt;span style="color: rgb(33, 37, 41);"&gt;The Company extends credit to its customers based upon an evaluation
              of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition, payment history and associated credit risk of customers are performed on an ongoing basis.&lt;/span&gt; Based on these evaluations, the Company has
            concluded that its credit risk is minimal. At&#160;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;, four customers accounted for an aggregate of approximately 91% of the Company&#x2019;s total accounts receivable, and at December 31, 2023, five customers accounted
            for approximately 98% of the Company&#x2019;s total accounts receivable.&lt;span style="text-decoration: underline;"&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:ReceivablesPolicyTextBlock>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20240930"
      decimals="-5"
      id="Fact_1eca436ce3464b16afae31c81cc89a6b"
      unitRef="U002">200000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20231231"
      decimals="-5"
      id="Fact_24d359e7629a4022be1162575f50a874"
      unitRef="U002">100000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:NumberOfCustomers
      contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember"
      decimals="INF"
      id="Fact_f18bf3b7315b4926aa4ea064a85b2ab7"
      unitRef="U006">4</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FourCustomersMember"
      decimals="2"
      id="Fact_f009184774e84f2d9d95a0201caebe4d"
      unitRef="U007">0.91</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="INF"
      id="Fact_6308d9179df94152ba218c08b1ce0ce0"
      unitRef="U006">5</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="2"
      id="Fact_a44807e83c784578a574f831d4cd62ca"
      unitRef="U007">0.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_32378de28d5544cb943aa8237e33cb6e">
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-style: italic;"&gt;Inventories&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials inventory consists of various materials purchased from suppliers, including
              normal source plasma and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost of raw materials as well as costs
              for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general repairs and maintenance,
              consumable supplies and depreciation. The Boca Facility overhead allocation to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s FDA-approved products relative
              to the total square footage of the facility.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 33.75pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the
              Company&#x2019;s manufacturing, commercialization or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. Net realizable value is generally determined based upon
              the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based on contractual terms or upon historical
              experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net realizable value, and adjustments are
              recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value.&lt;/div&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="c20240101to20240930"
      id="Text_0213f3d0f66b495f8215943a938312e6">
&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at
              &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt; and December 31, 2023 was $3.5 million. All of the Company&#x2019;s goodwill is attributable to its ADMA BioManufacturing business segment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators
              exist. The Company has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other
              intangible assets. If the Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the
              reporting unit&#x2019;s carrying value exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment test as of October 1 of each year. The Company did not &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;record any impairment charges related to goodwill for the three &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and nine &lt;/span&gt;months ended September 30, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;
</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="c20231231"
      decimals="-5"
      id="Fact_ce40654c1a3e4f4bb1143b887aa10df6"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20240930"
      decimals="-5"
      id="Fact_005ba41ea1da4053b40eba056f889113"
      unitRef="U002">3500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_db10b8d357224511b2c79474ef684524"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_c918795fb95c422c90cd19826ff0510e"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_76c3ae1705a04896bb17603ca42b57c5"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_1dc20e85b1bc43b590911cc98cd8e4e4"
      unitRef="U002">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_545ada14f0fa4349907835c9c9451111">
&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived
              intangible assets, whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its
              carrying amount to determine whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the
              three and nine months ended&#160;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt; and 2023, the
              Company did not identify any impairment indicators for its long-lived assets, and as a result no impairment charges were
              recorded.&lt;/div&gt;
</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_ef734576a4574f61b139ce75a27e12b7"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_e71082104c654e9e881f4edbd57274b9"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_77369376a4ea4ea49a958cbfa40e1cd4"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_5f3fdeb7194f4e48b8675c63b1033abe"
      unitRef="U002">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_3fb205bcaf1f40118c3c5793f85cc5d1">
&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Revenues for the three and nine months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/span&gt;
                and 2023 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin products, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;ASCENIV, &lt;/span&gt;BIVIGAM and Nabi-HB, &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;(ii) product revenues from the sale of human plasma collected through the Company&#x2019;s Plasma Collection Centers business
                segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from the sale of intermediate by-products; and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG
                (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest
                license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; font-style: normal; color: rgb(0, 0, 0);"&gt;Product revenue is recognized when the customer is deemed
              to have control over the product. Control is determined based on when the product is shipped or delivered, depending on the sales terms, and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the
              Company expects to receive in exchange. Revenue from the sale of the Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, wholesaler distribution and
              related fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on historical experience and certain other
              assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future experience and other factors. &lt;span style="letter-spacing: normal; text-align: left; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;second quarter of&#160; &lt;/span&gt;2024, the Company engaged a third-party
                specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a reduction in this accrual and a
                corresponding increase to net revenues of $12.6 &lt;/span&gt;million for the nine months ended September 30, 2024, substantially all
              of which was related to the sale of ASCENIV and BIVIGAM. This change in estimate was applied on a prospective basis as of June 30, 2024 and increased income from operations and net income by approximately $12.6 million and $11.9 million,
              respectively, and increased basic and diluted earnings per share by $0.05 &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for
                the nine months ending September 30, 2024. &lt;/span&gt;Because there was little to no historical data to rely upon at the time BIVIGAM and ASCENIV were launched, the Company had considered several qualitative factors when evaluating the initial
              rate to accrue for rebates, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government
              payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. The Company additionally considered that estimates may change over the lifetime of these products due to changes in utilization
              and payor mixes. There was additional new information that arose during the three months ended June 30, 2024 that suggested the need to reevaluate the underlying assumption of historical payer mix for BIVIGAM and ASCENIV, which resulted in
              the $12.6 million adjustment to the accrual for U.S. Medicaid rebates at June 30, 2024.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;For revenues associated with contract manufacturing and the sale of intermediates, control transfers to the customer
              and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility or from a third-party warehouse that is utilized by the Company.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at
              the time control of the product has been transferred to the customer, which generally occurs at the time of shipment. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the nine months ended &lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; and 2023,&lt;/span&gt; two customers represented an aggregate of approximately 71% of the Company&#x2019;s consolidated revenues.&lt;br/&gt;
            &lt;/div&gt;
</us-gaap:RevenueRecognitionPolicyTextBlock>
    <adma:DeferredRevenueRemainingAmortizationPeriod
      contextRef="c20240101to20240930_TypeOfArrangementAxis_BiotestLicenseAgreementMember"
      id="Fact_ec8a97d93d424b2b973659e6aecb4553">P22Y</adma:DeferredRevenueRemainingAmortizationPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_b9291b6f7cd34912a2bd1ee6826f1ec7"
      unitRef="U002">12600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_c031f25db80b4dfca66a8d032429c930"
      unitRef="U002">12600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_987516fdc4a949f2a7426ea7b0ca83d6"
      unitRef="U002">11900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="2"
      id="Fact_5b7782b66e59429aa11ab10eb4894abd"
      unitRef="U003">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240930_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="2"
      id="Fact_0d3b94eccd684c43ba2e3308217a61de"
      unitRef="U003">0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20240630_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_84cf3dd5440540e9b1d8ca469c239742"
      unitRef="U002">12600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <adma:NumberOfCustomers
      contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="INF"
      id="Fact_d2e214e347314f9c81c9c42f844dc29a"
      unitRef="U006">2</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20240101to20240930_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="2"
      id="Fact_5ba5a7316a55487aa349fda344355202"
      unitRef="U007">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_6ca79cd1448e48568dbd38122f71c2fe">
&lt;div&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of Product Revenue&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue includes costs associated with the manufacture of the Company&#x2019;s FDA-approved products,
              intermediates and the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations are attributable to marketed products.
              When the activities of these operations are attributable to new products or processes in development, the expenses are classified as research and development expenses.&lt;/div&gt;
</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_daa896e121f44c169299ec74eac4e54f">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
             &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings/Loss Per Common Share&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Basic earnings/loss per common share is computed by dividing net earnings/loss attributable to common stockholders by the weighted-average number of shares of common stock
                  outstanding during the period.&#160; Diluted earnings/loss per common share is calculated by dividing net earnings/loss attributable to common stockholders, as adjusted for the effect of dilutive securities, if any, by the weighted-average
                  number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants, as well
                  as restricted stock units (&#x201c;RSUs&#x201d;), using the treasury stock method. Potentially dilutive common stock is excluded from the diluted &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;earnings/&lt;/span&gt;loss per common share computation to the extent that it would be anti-dilutive. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the three and nine months ended September 30, 2024 &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none; font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;and the three months ended September 30, 2023,&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; basic and diluted earnings per share is calculated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2023&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Nine Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net income available to common stockholders ($000's) (numerator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;35,909&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,565&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;85,777&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic earnings per common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.37&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;10,232,689&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;8,484,282&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;9,812,583&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total shares - diluted (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;244,804,065&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;233,761,262&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;241,772,162&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Diluted earnings per common share&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.35&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

              &lt;div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/div&gt;

            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"&gt;For the three and nine months ended
                September 30, 2024 &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and the three months ended September 30, 2023, &lt;/span&gt;there were no
                shares with an anti-dilutive effect that needed to be excluded from the earnings per share computation. For the&#160; nine months ended September 30, 2023 no potentially dilutive securities were included in the computation of diluted loss per share in the accompanying condensed consolidated financial statements as the Company reported a net loss for this
                period. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the nine months ended &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;September 30, 2023&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock Options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;5,841,241&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4,877,482&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;12,502,906&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;23,221,629&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_f8ad7b2eec494b5e99e65731e768668f">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the three and nine months ended September 30, 2024 &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;and the three months ended September 30, 2023,&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; basic and diluted earnings per share is calculated as follows:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;
              &lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
                      &lt;div style="text-align: center;"&gt;Three Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2023&lt;br/&gt;
                      &lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: center;"&gt;Nine Months Ended &lt;br/&gt;
                      &lt;/div&gt;
                      &lt;div style="text-align: center;"&gt;September 30, 2024&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net income available to common stockholders ($000's) (numerator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;35,909&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2,565&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;85,777&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Basic earnings per common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;0.37&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Weighted-average number of common shares&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;234,571,376&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;225,276,980&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;231,959,579&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;10,232,689&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;8,484,282&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;9,812,583&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total shares - diluted (denominator)&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;244,804,065&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;233,761,262&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;241,772,162&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                      &lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"&gt;Diluted earnings per common share&lt;/div&gt;
                    &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.15&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.01&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;0.35&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

              &lt;div style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/div&gt;

            &lt;/div&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_a45eccd4af0244cebe699b3102a84e3a"
      unitRef="U002">35909000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_f763cdf0524445e68030286026668638"
      unitRef="U002">2565000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_4e8c4428026c42c5b70734711113d9de"
      unitRef="U002">85777000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240701to20240930"
      decimals="0"
      id="Fact_b49890bba1b24ae2acf0f12f3411fd40"
      unitRef="U001">234571376</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230701to20230930"
      decimals="0"
      id="Fact_8bd07a8e7e1641e4bba0edcbe8ed6f67"
      unitRef="U001">225276980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20240930"
      decimals="0"
      id="Fact_a1c761af804e41559bdd3131031fbfb3"
      unitRef="U001">231959579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240701to20240930"
      decimals="2"
      id="Fact_c8245993d8664fb39e9890d93a8c4173"
      unitRef="U003">0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230701to20230930"
      decimals="2"
      id="Fact_c15e9ab0d7dc49cb89ccc3069679d686"
      unitRef="U003">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20240930"
      decimals="2"
      id="Fact_cd58947e8e0f433fa13507c97ece8301"
      unitRef="U003">0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240701to20240930"
      decimals="0"
      id="Fact_e8a4d34aed8d4428875969c6f836d601"
      unitRef="U001">234571376</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230701to20230930"
      decimals="0"
      id="Fact_b6d7931a90454cc09a0d191865268d6e"
      unitRef="U001">225276980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20240930"
      decimals="0"
      id="Fact_535e42cfc1d643ff8d75dc22119335bf"
      unitRef="U001">231959579</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20240701to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_022930df76244afb917d45e5559abdb0"
      unitRef="U001">10232689</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20230701to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_9cfd2a4a590e429eb2dd3987b73de281"
      unitRef="U001">8484282</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20240101to20240930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_d571f73dbf6f459db24c8ab485c17512"
      unitRef="U001">9812583</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240701to20240930"
      decimals="0"
      id="Fact_3ca46cc20d884275a3e4e4affdaca8cd"
      unitRef="U001">244804065</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230701to20230930"
      decimals="0"
      id="Fact_4aa4bde444b34f83832c4513842e4f98"
      unitRef="U001">233761262</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20240930"
      decimals="0"
      id="Fact_172e5e7279ff47b5bbd1c9e02db1b266"
      unitRef="U001">241772162</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240701to20240930"
      decimals="2"
      id="Fact_a477b8aba56e4bd88ccd2d29a363d9cc"
      unitRef="U003">0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230701to20230930"
      decimals="2"
      id="Fact_7328cba9b09c46f684470e034e630bd3"
      unitRef="U003">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20240930"
      decimals="2"
      id="Fact_4ef5e397fbf045ef9c10f455d94203e7"
      unitRef="U003">0.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230701to20230930"
      decimals="INF"
      id="Fact_f9c62b08edc94c08b04d4d2f0918c581"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20240930"
      decimals="INF"
      id="Fact_af36fc1cf3064374bd6180b4272cbef0"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240701to20240930"
      decimals="INF"
      id="Fact_2e3e33496436460ebd20b4a6d17e5e4f"
      unitRef="U001">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
      contextRef="c20230101to20230930"
      decimals="INF"
      id="Fact_b5a31c2df98543cb835ca0988d42cbf7"
      unitRef="U001">0</adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20240101to20240930"
      id="Text_ab7f841969c94f449bf078e68e34cc98">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;For the nine months ended &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;September 30, 2023&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Stock Options&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;5,841,241&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Restricted Stock Units&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;4,877,482&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 86.46%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;12,502,906&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 86.46%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;23,221,629&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_13116703a1ab4e268f33f3e5b7a31236"
      unitRef="U001">5841241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_aaf1fd443adf48288f2f88140e98db23"
      unitRef="U001">4877482</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230930_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_ffb45891753d4f82965d10ebd6d6806d"
      unitRef="U001">12502906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20230930"
      decimals="0"
      id="Fact_4cdf4326cc244f13b951e4f1aa04d066"
      unitRef="U001">23221629</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20240101to20240930"
      id="Text_a536cdb4a1e2457ebf1b43140fa12824">
&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock
              options and RSUs, to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based vesting conditions
              is generally recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted under the Company&#x2019;s equity incentive plans generally have a four-year vesting period and a term of 10
              years. RSUs granted to employees generally have a four-year vesting period. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based compensation expense related to forfeitures of unvested equity awards is fully
              reversed at the time of forfeiture.&lt;/div&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_55d8058dc7eb4eeb85cb17587b80db99">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_1865ff749dc046edb1ec1fbca915d7ff">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_e742963c7eab4fc8ac6234d6c770900a">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_4e76a2f0cb524e40a7bd3220a1b1553c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or its tax returns. Under this
                method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting amounts at enacted tax rates in effect for the years in which
                the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate sufficient taxable income to utilize its deferred tax
                assets. The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#x2019;s net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination
                  by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Tax benefits are recognized for an uncertain tax position when, in management&#x2019;s
                  judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority.&#160; For a tax position that meets the more-likely-than-not recognition threshold, the tax benefit is measured as the largest
                  amount that is judged to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority.&#160; The liability associated with unrecognized tax benefits is adjusted periodically due to changing
                  circumstances and when new information becomes available.&#160; Such adjustments are recognized entirely in the period in which they are identified.&lt;/span&gt; Derecognition of a tax benefit previously recognized could result in the Company
                recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not
                incurred any material liability for uncertain tax positions as of September 30, 2024 and December 31, 2023, and during the three and nine months ended September 30, 2024 and 2023 the Company recognized&lt;/span&gt;&lt;span style="font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt; no
                adjustments for uncertain tax positions.&lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20240930"
      decimals="-3"
      id="Fact_3eff2cd6659c46a2842defdc15a678b3"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0c2d183a9e7d497d94ba294a8e639b86"
      unitRef="U002">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_fcb6e03885a64fb9a3e8c1f46ffa9a09"
      unitRef="U002">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_f7eeab33034d4ee28560bebdfaa26792"
      unitRef="U002">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_3602a13434bf452d9f56f1a23096ec85"
      unitRef="U002">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_268ea81c61df408493cf6af0cbd4c55e"
      unitRef="U002">0</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20240101to20240930"
      id="Text_9431881c9e5347df95aa3d0f4dba2711">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2023 the FASB issued ASU No. 2023-07,&#160;&lt;span style="font-style: italic;"&gt;Segment Reporting (Topic
                  280): Improvements to Reportable Segment Disclosures.&#160;&lt;/span&gt;The amendments in this ASU are intended to provide financial statement users with more disaggregated expense information about a public entity&#x2019;s reportable segments; however,
                the update does not change the definition of an operating segment or the method for determining reportable segments. This update becomes effective for fiscal years beginning after December 15, 2023 and for interim periods beginning after
                December 15, 2024. The Company does not expect this ASU to have a material impact on the Company&#x2019;s consolidated financial statements, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;except that its adoption will likely lead to disclosures of additional significant segment expenses.&lt;/span&gt;&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_b0ac280d826c42309d29f504917785df">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INVENTORIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; width: 1%; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;55,246&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,999&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,482&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,621&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;63,073&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;70,286&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;171,801&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;172,906&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB.
            These materials will be consumed in the production of goods expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process inventory primarily consists of bulk drug substance and unlabeled filled vials of the Company&#x2019;s
            immunoglobulin products. &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods inventory is comprised of immunoglobulin product inventory and related intermediates that are available
            for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection centers that is expected to be sold to third-party customers.&lt;/div&gt;
</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_ada03ff9ca0449d783d175db4336d576">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following table provides the components of inventories:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30,&lt;/span&gt;&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;December 31,&lt;/div&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023 &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; width: 1%; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Raw materials&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;55,246&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,999&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Work-in-process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,482&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;49,621&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Finished goods&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;63,073&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;70,286&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total inventories&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;171,801&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;172,906&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="c20240930"
      decimals="-3"
      id="Fact_1a5b580d95734897ac8d22b531ec177a"
      unitRef="U002">55246000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20231231"
      decimals="-3"
      id="Fact_97c8d8f4bfe74772ad757c67f5affac1"
      unitRef="U002">52999000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20240930"
      decimals="-3"
      id="Fact_5dc3f0cff84e4b27bbb010bbf66b26cc"
      unitRef="U002">53482000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20231231"
      decimals="-3"
      id="Fact_220f065503184095a2a72cf3206c2a3f"
      unitRef="U002">49621000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f808c8b5a81142bca4c5032765d5c893"
      unitRef="U002">63073000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fd34512a85124c4590729dc4e824ee8e"
      unitRef="U002">70286000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d2169eeb75df4447b31d3b281d65f5f7"
      unitRef="U002">171801000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a9f02b2205134d38a500e1594cfd10e6"
      unitRef="U002">172906000</us-gaap:InventoryNet>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_f46b388b3a2a480ca88f823b8eb2cec7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at September 30, 2024 and December 31, 2023 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: -9pt; margin-left: 9pt;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,856&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 28%;" valign="bottom"&gt;Internally developed software&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;559&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;74&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;485&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;210&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;201&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;853&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;54&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,566&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,081&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;485&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,217&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,718&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;499&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the nine months ended September 30, 2024, the Company continued to develop its data intelligence and analytics programs at a
              cost of approximately $0.4 million, and such costs are amortized over a period of &lt;span style="-sec-ix-hidden:Fact_aabd598a3cab423c96bb46e0610cf636"&gt;three&lt;/span&gt; to five years upon the projects&#x2019; completion and
              placement into service.&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Amortization expense related to the
              Company&#x2019;s intangible assets was $28,000 and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.4&lt;span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively&lt;/span&gt;. Estimated future aggregate amortization expense is
              expected to be as follows (in thousands&lt;/span&gt;):&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2025&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;140&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2026&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;2027&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;2028&lt;/span&gt; &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_198a34bb24c64972a597f9e24fef66c1">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Intangible assets at September 30, 2024 and December 31, 2023 consist of the following:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; margin-left: auto; margin-right: auto;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; font-weight: bold; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;&#160;Accumulated&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; Amortization&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: -9pt; margin-left: 9pt;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,100&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,856&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;244&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 28%;" valign="bottom"&gt;Internally developed software&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;559&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;74&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;485&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;210&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;9&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;201&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Rights to intermediates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;907&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;853&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;54&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 28%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,566&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,081&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;485&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,217&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,718&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;499&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_84c1b581f778436fb65753dbd43a49e0"
      unitRef="U002">4100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_2d221c0972044484a1bede04d3fd0aac"
      unitRef="U002">4100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_f1a7e039a1ec41f68d9d5eb4fffc4ba0"
      unitRef="U002">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_ef2a6d76582846058785cdc46965d92c"
      unitRef="U002">4100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_ae5309739fd44472a50a2dc3f8d824ff"
      unitRef="U002">3856000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_e90ba21e2ecd46c196800abae575381b"
      unitRef="U002">244000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_7486505cec4842bb9ad35b5e750ad471"
      unitRef="U002">559000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_ef93eff493c8454299c3af3b56a36a4d"
      unitRef="U002">74000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_bfcb0e0985334e8c8f6310143249baad"
      unitRef="U002">485000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_5a14d16d2fcf4c13b2df7bcf42e2ee7e"
      unitRef="U002">210000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_75b6ba85d91945dab406f58e62e5bd2c"
      unitRef="U002">9000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_95c0d6c6df2841ba9a5f97a9bc5374e1"
      unitRef="U002">201000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_429159c1de714158b077f91cc3f7b35b"
      unitRef="U002">907000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_51ee35f01bbc49ea91fc84c2427bada7"
      unitRef="U002">907000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20240930_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_9e949858d4aa4da3a6b29b81717b196c"
      unitRef="U002">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_790f4c6e73ad4f649f76a836527a88cb"
      unitRef="U002">907000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_2b047b417a4c4433b4b70fdbc5323d51"
      unitRef="U002">853000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_32e4aa2b22b5443483f72dcd60785180"
      unitRef="U002">54000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20240930"
      decimals="-3"
      id="Fact_c156f9254bfc4bcdabf4c849462e7922"
      unitRef="U002">5566000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20240930"
      decimals="-3"
      id="Fact_51ec0b72e3eb4b69bdb1d459dae42088"
      unitRef="U002">5081000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20240930"
      decimals="-3"
      id="Fact_fff6356862444b3db284ee003007fb26"
      unitRef="U002">485000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0eb2e7fb57624d9eb07765a31e63e649"
      unitRef="U002">5217000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231"
      decimals="-3"
      id="Fact_293e0b07af1343ffae867d68084b2eac"
      unitRef="U002">4718000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_0580a8205fef498e9e58bf7239e237da"
      unitRef="U002">499000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_4116e731c5374a47a052e2a92e8e2c69">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;During the nine months ended September 30, 2024, the Company continued to develop its data intelligence and analytics programs at a
              cost of approximately $0.4 million, and such costs are amortized over a period of &lt;span style="-sec-ix-hidden:Fact_aabd598a3cab423c96bb46e0610cf636"&gt;three&lt;/span&gt; to five years upon the projects&#x2019; completion and
              placement into service.&lt;/span&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; Amortization expense related to the
              Company&#x2019;s intangible assets was $28,000 and $0.2 million for the three months ended September 30, 2024 and 2023, respectively, and $0.4&lt;span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; million and $0.5 million for the nine months ended September 30, 2024 and 2023, respectively&lt;/span&gt;. Estimated future aggregate amortization expense is
              expected to be as follows (in thousands&lt;/span&gt;):&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2025&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;140&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;2026&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; white-space: nowrap;" valign="bottom"&gt;2027&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;2028&lt;/span&gt; &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_13c4ec390c3c42a9971ff4d2b1b064ce"
      unitRef="U002">400000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="c20240930_RangeAxis_MaximumMember"
      id="Fact_808a66064f944f149e35c129a81da996">P5Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_b331fb053f5640ac920a41d71794f8b9"
      unitRef="U002">28000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230701to20230930"
      decimals="-5"
      id="Fact_b02e4bb3d51644e1aeacf03cedca59de"
      unitRef="U002">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_e64f959956c94cfbb0bf778b3860ef62"
      unitRef="U002">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20230930"
      decimals="-5"
      id="Fact_0323129500994dd5819078dc64bf2ca5"
      unitRef="U002">500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="c20240930"
      decimals="-3"
      id="Fact_07726ed57f8f4cddb565e5aff01e1d9d"
      unitRef="U002">25000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f280783f34b049d1b514f8a252cfe14e"
      unitRef="U002">140000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="c20240930"
      decimals="-3"
      id="Fact_ca9aa36165e14b9782f2d8d11049f257"
      unitRef="U002">140000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="c20240930"
      decimals="-3"
      id="Fact_dd97dd24ef094b34ab229219e3b5784a"
      unitRef="U002">130000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="c20240930"
      decimals="-3"
      id="Fact_7845e2d631ff473a9ef1f33e953008d7"
      unitRef="U002">50000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_c58c1d3b3a2e40808b659d66e69f3c99">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;Property and equipment and related accumulated depreciation are summarized as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,240&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,062&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,777&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,776&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,881&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,273&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,051&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,811&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,416&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,218&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;86,145&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;80,572&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(32,451&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(26,737&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,694&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,835&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the
            straight-line method over the asset&#x2019;s estimated useful life. Land is not depreciated. The buildings were assigned a useful life of 30
            years. Property and equipment other than land and buildings have useful lives ranging from &lt;span style="-sec-ix-hidden:Fact_e1bb617d16104c86ba85a63d93bd3935"&gt;three&lt;/span&gt; to 10 years. Leasehold improvements are amortized over the lesser of the lease term or their estimated useful lives.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal;"&gt;The
              Company recorded depreciation expense on property and equipment for the three months ended September 30, 2024 and 2023 of $1.9
              million &lt;span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;"&gt;and for the
                nine months ended September 30, 2024 and 2023 of $&lt;/span&gt;5.7&lt;span style="letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline ! important;"&gt; million.&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20240101to20240930"
      id="Text_593a680e06f44efe9f78af2c2597bdb7">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255);"&gt;Property and equipment and related accumulated depreciation are summarized as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Manufacturing and laboratory equipment&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,240&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Office equipment and computer software&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,441&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,062&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Furniture and fixtures&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,777&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,776&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Construction in process&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,881&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,273&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Leasehold improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,051&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,811&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Land&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,339&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Buildings and building improvements&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;21,416&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;20,218&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;86,145&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;80,572&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less: Accumulated depreciation&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(32,451&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(26,737&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total property and equipment, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,694&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;53,835&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="-3"
      id="Fact_137fdb2871174efdb6121d47d1042db9"
      unitRef="U002">21240000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="-3"
      id="Fact_07d3c96195f142998857e32be8e863c0"
      unitRef="U002">21093000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_eb3fca02f33341ac815947d704338ab2"
      unitRef="U002">6441000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_d08649a237b34b11a893dbb923269e39"
      unitRef="U002">6062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_d4e884bc4ce0414b9e1208bca742cb06"
      unitRef="U002">5777000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_866bd91e49924bda89e69d1b5158fcbd"
      unitRef="U002">5776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="-3"
      id="Fact_47706243d15b46cf8bde68bb36a4efe8"
      unitRef="U002">5881000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="-3"
      id="Fact_5269d801cee945e3af84dcea2e28b848"
      unitRef="U002">2273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_61ce0a747fbe49b49e6a15b731a09359"
      unitRef="U002">21051000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_0325d57f666847cc8547c8fc597d37e5"
      unitRef="U002">20811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_d7f4cedf2d494840a569e81d30e60d38"
      unitRef="U002">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_eac369376bb141aeaef91587aa06ce1d"
      unitRef="U002">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_5deb436b56014f90b73db0008ea450e0"
      unitRef="U002">21416000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_a3f5b802297d4832b57338e7ac4c703d"
      unitRef="U002">20218000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20240930"
      decimals="-3"
      id="Fact_ec51ab6b57854fcfa2a0dc98fb999c07"
      unitRef="U002">86145000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ca2a2a4395bc469695fe037edd114183"
      unitRef="U002">80572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20240930"
      decimals="-3"
      id="Fact_14f9a0ce5e7349d4a5e11524bb08913a"
      unitRef="U002">32451000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20231231"
      decimals="-3"
      id="Fact_14c3dfafdaa9474f8f890b2960b4c71c"
      unitRef="U002">26737000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20240930"
      decimals="-3"
      id="Fact_da24e09ce9eb44a88f609f61668c7397"
      unitRef="U002">53694000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_354a2ed4b1df464e9f3869b9307764c7"
      unitRef="U002">53835000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20240930_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"
      id="Fact_f5c230841860451e8e3a3adef9f9c4f6">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20240930_RangeAxis_MaximumMember"
      id="Fact_6e2ac767798d4fd0b7932c4d75b815de">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20230701to20230930"
      decimals="-5"
      id="Fact_629504a74cf04576be669a2a3485734b"
      unitRef="U002">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20240701to20240930"
      decimals="-5"
      id="Fact_4526f3e2c00d4a57820b65c8bb10abf4"
      unitRef="U002">1900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_7fb91547056d4d7f8e8aa73164286f07"
      unitRef="U002">5700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20230101to20230930"
      decimals="-5"
      id="Fact_51e0840834264dec9e971e9946ab820c"
      unitRef="U002">5700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_ba86dceeeabc4c1dba19c743f8d13860">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at September 30, 2024 and December 31, 2023 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,733&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;16,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,780&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,954&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,670&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,961&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Accrued interest&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3,448&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;546&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;579&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;282&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll and other compensation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,010&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,203&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,315&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,365&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,535&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,919&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_6310a76925dc44908412817c735f99a4">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued expenses and other current liabilities at September 30, 2024 and December 31, 2023 are as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued rebates&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,733&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;16,608&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued distribution fees&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,780&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,954&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued incentives&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,670&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,961&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Accrued interest&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;3,448&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;546&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued testing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;579&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;282&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Accrued payroll and other compensation&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,010&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,203&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Other&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,315&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,365&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total accrued expenses and other current liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27,535&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;32,919&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <adma:AccruedRebatesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d6197eb8c8ad4978951b68110e86b1e8"
      unitRef="U002">4733000</adma:AccruedRebatesCurrent>
    <adma:AccruedRebatesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_365161aef7064f1b9dc3f6462ec7147d"
      unitRef="U002">16608000</adma:AccruedRebatesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_980eb0ef9be6405d8bdc0fa52a61213b"
      unitRef="U002">9780000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b9816821bf7a47ee8c464d7e3c3f5cb8"
      unitRef="U002">5954000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_77c4779b7f594deca90745d46feb1e9b"
      unitRef="U002">3670000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_41ba16e02ec94b6a98d504eb1e69f8a1"
      unitRef="U002">4961000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_24e5c773569148b2833e175d242f3716"
      unitRef="U002">3448000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_591cc75218c1470b9ad8e7b406aee60d"
      unitRef="U002">546000</us-gaap:InterestPayableCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_214bd2f0af4242c296a707c7411dd75d"
      unitRef="U002">579000</adma:AccruedTestingCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4481a8d05f2a4e17a95218588e419895"
      unitRef="U002">282000</adma:AccruedTestingCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_45940794ca6643c4bf524be8d2418a50"
      unitRef="U002">2010000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_568f1c5ca1024478a9273285e7be2ce8"
      unitRef="U002">2203000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_901252830ac24491a0f15e330a892765"
      unitRef="U002">3315000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3cefe99a75b54ca3aa84a6d3315f3b0b"
      unitRef="U002">2365000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d88f3c73ede24af091e5166d9f7a2969"
      unitRef="U002">27535000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_808acfe2fa284e89a3b27419b3e1908b"
      unitRef="U002">32919000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="c20240101to20240930"
      id="Text_c8c0406143ff4d4fa3adaf8468c4a17c">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: bold;"&gt;7.&lt;/span&gt;&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;DEBT&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Term loan&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,500&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,500&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Revolving credit facility&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;42,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;72,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,406&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;101,326&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;130,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;On December 18, 2023 (the &#x201c;Ares Closing Date&#x201d;), the Company
              and all of its subsidiaries entered into a credit agreement (the &#x201c;Ares Credit Agreement&#x201d;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#x201c;Ares&#x201d;). The Ares Credit Agreement
              provides for a total of $135.0 million in senior secured credit facilities (the &#x201c;Ares Credit Facility&#x201d;) consisting of (i) a term
              loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#x201c;Ares Loans&#x201d;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity
              date of December 20, 2027 (the &#x201c;Ares Maturity Date&#x201d;). On the Ares Closing Date, the Company used the proceeds from the Ares Loans,
              along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#x2019;s previous senior credit facility (the &#x201c;Hayfin Credit Facility&#x201d;) with Hayfin Services LLP (&#x201c;Hayfin&#x201d;)
              including the outstanding principal in the amount of $158.6 million. On August 14, 2024, the Company repaid $30.0 million against the revolving credit facility and the outstanding balance on the revolving credit facility as of September 30, 2024 was $42.5 million.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Borrowings under the term loan bear
                  interest at the adjusted Term &lt;span style="-sec-ix-hidden:Fact_f94c3272e4024032bf1c8ec0500c05eb"&gt;&lt;span style="-sec-ix-hidden:Fact_837d17e5cc4148dab6c5f12dca0a9d3b"&gt;&lt;span style="-sec-ix-hidden:Fact_2d5d7cee97d843e6bdafc3e0cea93ecc"&gt;SOFR&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; for a three-month tenor in effect on the day that is &lt;span style="-sec-ix-hidden:Fact_8458c263b75e47d7a0c66a15b98f6079"&gt;two&lt;/span&gt; business days
                  prior to the first day of the applicable calendar quarter plus 6.50% (the &#x201c;Initial SOFR Term Loan Applicable Margin&#x201d;).
                  Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a three-month tenor in effect on the day
                  that is &lt;span style="-sec-ix-hidden:Fact_8c7034ac2c65418ea392b4cb6da4a682"&gt;two&lt;/span&gt; business days prior to the first day of the applicable calendar quarter&#160;plus 3.75% (the &#x201c;SOFR Revolving Facility Applicable Margin&#x201d;). As of September 30, 2024 and December 31, 2023, the interest rate on the term loan
                  was approximately 11.36% and 11.88%,
                  respectively, and the interest rate on the revolving facility was approximately 9.08% and 9.13%, respectively. &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;On the Ares Maturity Date, the Company is required to pay Ares the entire
                outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no
                scheduled principal payments on the Ares Credit Facilities, and the Company is required to make quarterly interest payments to
                Ares of approximately $2.8 million. The Company may prepay the outstanding principal under the revolving facility, together with
                any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon &lt;span style="-sec-ix-hidden:Fact_b6b7fa74500a4b88b6db8be11e46fee6"&gt;three&lt;/span&gt; business days&#x2019;
                prior written notice with no prepayment premium. However, in the event the Company prepays an amount under the revolving credit
                facility that is greater than 50% of the original $72.5 million outstanding balance (of which $30.0 million, or 41.4%, has been repaid to date), the Company will still be required to pay interest on 50% of this balance, or $36.3 million, through the term
                of the Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon &lt;span style="-sec-ix-hidden:Fact_572da660a7754ce69aefce28a22367a6"&gt;three&lt;/span&gt; business days&#x2019; prior written notice, subject to the payment to Ares of a prepayment premium equal to (i) the present value as of such date
                of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if
                prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid
                after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0%
                of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.&lt;/div&gt;

&lt;div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;In connection with the closing of the Ares Credit Facility, the Company
                  incurred fees and expenses related to the transaction of $2.8 million, including a $1.7 million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is also required to pay Ares an exit
                  fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this amount has been accrued as
                  a separate liability in the Company&#x2019;s consolidated balance sheets as of September 30, 2024 and December 31, 2023. As a result, the Company recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans as of September 30, 2024 and December 31, 2023 was 11.73% and 11.39%,
                  respectively. This debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. &lt;/div&gt;

&lt;div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt; color: rgb(0, 0, 0);"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt; color: rgb(0, 0, 0);"&gt;All of the Company&#x2019;s obligations under the Ares
                  Credit Agreement are secured by a first-priority lien and security interest in substantially all of the Company&#x2019;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s
                  subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include
                  certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also
                  restrict or limit the Company&#x2019;s ability and the ability of the Company&#x2019;s subsidiaries to, among other things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage
                  in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or the Company&#x2019;s subsidiaries&#x2019; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit
                  Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting the Company&#x2019;s ability to make loan repayments under the Ares Credit Agreement. As of
                  September 30, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-indent: 36pt; text-transform: none;"&gt;Events of Default on the Ares Loans include, among others, non-payment
                    of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of
                    control. If there is an event of default, the Company will incur an increase in the rate of interest on the Ares Loans of 2%
                    per annum.&lt;/div&gt;
</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_113038a69c3c4b0e9deb47d766fca208">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="margin-left: 13.5pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;December 31, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-style: italic; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-style: italic; white-space: nowrap;" valign="bottom"&gt;(In thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-style: italic; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Term loan&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,500&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;62,500&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;Revolving credit facility&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;42,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;72,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Less:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Debt discount&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,674&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,406&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0);"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Senior notes payable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;101,326&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;130,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20240930_CreditFacilityAxis_TermLoanMember"
      decimals="-3"
      id="Fact_58a86e6330f84ebfaac9dc0d5d81d629"
      unitRef="U002">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember"
      decimals="-3"
      id="Fact_9c38075e2801471890ead0a06144a443"
      unitRef="U002">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-3"
      id="Fact_8ffa221dcb834fc1a28b06a9089511b9"
      unitRef="U002">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-3"
      id="Fact_3dfdc305011b46e788b03e40cc276f86"
      unitRef="U002">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20240930"
      decimals="-3"
      id="Fact_4bafa993b96147008ac48e4c93be2a8b"
      unitRef="U002">3674000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a5e4a6fc6df04892ad9d23c25135d65d"
      unitRef="U002">4406000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f74a5552710f4a8aab6fe4427527dd4e"
      unitRef="U002">101326000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fe4971ee44b24056bfeb8242b31ab475"
      unitRef="U002">130594000</us-gaap:SeniorLongTermNotes>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231218"
      decimals="-5"
      id="Fact_2dfebf36807c41978529e946f59a9c23"
      unitRef="U002">135000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_5093b6d403c04294b76f35dc27d1af82"
      unitRef="U002">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_f49075c9aca34d47baadb256616dd4b7"
      unitRef="U002">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_1bbfd756e84d405d83e78f241d601d84">2027-12-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_65f5e2d3aa44455f9308eb72968d4577"
      unitRef="U002">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_16ca0ea411b3423eada893c28e19b488"
      unitRef="U002">30000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_e34c88dc260840b4afc6f7d54635db01"
      unitRef="U002">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember"
      id="Fact_f95443f8526b433eaa4fa84798dc1b44">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember"
      decimals="4"
      id="Fact_33cecfcc6c2640ce88a99479d9bb388a"
      unitRef="U007">0.065</adma:DebtInstrumentApplicableMargin>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember"
      id="Fact_51f1831751a447468cfe31c76d77d3b2">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="4"
      id="Fact_8361472b81154add9f6df813ffbfc737"
      unitRef="U007">0.0375</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240930_CreditFacilityAxis_TermLoanMember"
      decimals="4"
      id="Fact_5ec193f649864764a6dc4d0ec3988baa"
      unitRef="U007">0.1136</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember"
      decimals="4"
      id="Fact_0f7f1c7c29c4430eb4cc0979735df660"
      unitRef="U007">0.1188</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20240930_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="4"
      id="Fact_6eaf8a4524a34453b3eb4600468fbae5"
      unitRef="U007">0.0908</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="4"
      id="Fact_8880d95fec914976865b552f90224a00"
      unitRef="U007">0.0913</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-6"
      id="Fact_97979d7111454f0797c715eda8489b7e"
      unitRef="U002">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_856910d6f6154763bfe305e516ebff42">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_ec1f213702c646979b2a6fc85f3075bb"
      unitRef="U002">2800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <adma:PrepaymentsOfDebtPremium
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-6"
      id="Fact_84d0d0f638884c4d9b6de7f489c83994"
      unitRef="U002">0</adma:PrepaymentsOfDebtPremium>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_5fb8c515b8e74275af9b9a6b4c925f6b"
      unitRef="U007">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_80cbf36d1ed64509a4ef4837097392a8"
      unitRef="U002">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_bbe86f8dd39d414288f1dbd5cfc38a9e"
      unitRef="U002">30000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <adma:PercentageOfCreditFacilityRepaid
      contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="3"
      id="Fact_988477fa400a4a60b251596fc1791fcb"
      unitRef="U007">0.414</adma:PercentageOfCreditFacilityRepaid>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_ed5c559b2ea644678829afb29b74d143"
      unitRef="U007">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_5ac6342f408046c3aaeed656a5b28de2"
      unitRef="U002">36300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"
      decimals="3"
      id="Fact_a25b672ba67d406dac40af07beadc4a9"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember"
      decimals="3"
      id="Fact_e6198b4bbc1642ac86473acdd1e8be8f"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"
      decimals="3"
      id="Fact_46204a65ec5d422dba63d24c1f56816b"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember"
      decimals="3"
      id="Fact_c19906bd09b146aaba2f6df4ca46e5cf"
      unitRef="U007">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_fca1201217c64558a1324cfc954f285f"
      unitRef="U002">2800000</us-gaap:DebtInstrumentFeeAmount>
    <adma:OriginalDiscountPayableCreditFacility
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_ccec40cd52c84b868d9a9e8ea289539a"
      unitRef="U002">1700000</adma:OriginalDiscountPayableCreditFacility>
    <adma:DebtInstrumentExitFee
      contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_7e479c5bf9414c459fab6dab11c7eea0"
      unitRef="U002">1700000</adma:DebtInstrumentExitFee>
    <adma:DebtInstrumentExitFee
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_36825ed16eb54a649ead4eb2beec695c"
      unitRef="U002">1700000</adma:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_75cae3bff7564b679e26ecdc19d8b364"
      unitRef="U002">4400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="4"
      id="Fact_7d093d5f1a4543218c53dacc518df2bf"
      unitRef="U007">0.1173</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="4"
      id="Fact_4c93956a32c64236ad54bf44b7a8b12c"
      unitRef="U007">0.1139</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adma:MinimumLiquidityCovenantsCreditFacilities
      contextRef="c20240930_CounterpartyNameAxis_AresCreditAgreementMember"
      decimals="-5"
      id="Fact_edf841526c1a4bf5999a5346eab52f98"
      unitRef="U002">15000000</adma:MinimumLiquidityCovenantsCreditFacilities>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240101to20240930_CounterpartyNameAxis_AresCreditAgreementMember"
      decimals="2"
      id="Fact_7e2ba7bf3e504373977dc1778c00f10f"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_5ecaf0c606624acda2de24059b4958ef">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001, par
            value per share. There were no shares of preferred stock outstanding at September 30, 2024 and December 31, 2023.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of September 30, 2024 and December 31, 2023, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001
            par value per share, and 236,378,607 and 226,063,032 shares of common stock were outstanding as of September 30, 2024 and December 31, 2023, respectively. After giving effect to the 27,759,065 shares reserved for outstanding warrants and awards issued or reserved for future issuance under the Company&#x2019;s equity incentive plans, as of September 30, 2024
            there were 35,862,328 shares of common stock available for issuance.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Warrants&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;On January 10, 2024, a former noteholder of the Company exercised a warrant to
            purchase 4 million shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 1,977,514 shares of common stock to this noteholder. On March 8, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 3,388,681 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 2,482,205 shares of common stock to Hayfin and its affiliates. On March 14, 2024 an entity associated with another former noteholder of the Company exercised a warrant to
            purchase 169,651 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 85,784 shares of common stock to this entity. On May 9, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 1,787,424 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued 937,507 shares of common stock to Hayfin and its affiliates. On August 15, 2024 Hayfin and its affiliates exercised warrants to purchase an aggregate of 1,962,946 shares of the Company&#x2019;s common stock on a cashless basis and the Company issued an aggregate of 1,741,882 shares of common stock to Hayfin and its affiliates.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;On February 24, 2024 a warrant to purchase 34,800 shares of the Company&#x2019;s common stock held by a former noteholder of the Company expired in accordance with its terms. At September 30, 2024
            and December 31, 2023, the Company had outstanding warrants to purchase an aggregate of 1,159,404 and 12,502,906 shares of common stock, respectively, with weighted-average exercise prices of $2.26 and $2.32 per share, respectively, with expiration dates
            ranging between October 2024 and May 2030. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;The







            following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-transform: none;"&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants outstanding at December 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;12,502,906&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.32&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;(34,800&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;7.50&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;(11,308,702&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.31&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants outstanding at September 30, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;1,159,404&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.26&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
             &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The fair value of stock options granted under t&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;he &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Company&#x2019;s equity incentive plans&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; w&lt;/span&gt;as determined on the date of grant using the Black-Scholes option valuation model. The Black-Scholes model was
              developed for use in estimating the fair value of publicly traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of certain subjective assumptions including the
              expected stock price volatility. The stock options granted to employees and directors have characteristics significantly different from those of traded options, and changes in the subjective input assumptions can materially affect the fair
              value estimate. &lt;/span&gt;&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="4" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;66%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;68%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;4.16-4.34%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;4.20-4.24%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&#160;During the nine months ended September 30, 2024 and 2023, the Company granted options to purchase an aggregate of 1,511,624 and 1,727,510 shares of
            common stock, respectively, to its directors and employees. The weighted&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;-&lt;/span&gt;average remaining contractual life of stock options outstanding and expected to vest at
            September 30, 2024 is 7.5 years. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The weighted&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;-&lt;/span&gt;average remaining contractual life of stock options exercisable at
              September 30, 2024 is 6.2 years. During the nine months ended September 30, 2024, options to purchase an aggregate of 1,925,498 shares of common stock were exercised, which included certain exercise transactions for which an aggregate of &lt;/span&gt;31,219&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; shares were withheld to cover the exercise price and income tax liabilities, and the Company received aggregate net exercise proceeds of $&lt;/span&gt;7.1&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; million.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Weighted
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,906,184&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.38&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,723&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(221,067&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.34&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,511,624&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;(1,925,498&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.85&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,255,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.87&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,509,884&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.10&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of September 30, 2024, the Company had $7.4 million of unrecognized compensation expense related to options granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 2.9 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;During the nine months ended September 30, 2024 and 2023, the Company granted RSUs representing an aggregate of
              3,227,188 and 3,345,760
              shares, respectively, to certain employees of the Company and to members of its Board of Directors. These RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. During the
              nine months ended September 30, 2024, an aggregate of 1,701,229 shares of common stock vested in connection with grants of RSUs.
              With respect to these vested RSUs, 504,825 shares valued at approximately $4.3 million were withheld by the Company to cover employees&#x2019; tax liabilities. These shares were no longer outstanding as of September 30, 2024. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;A summary of the Company&#x2019;s unvested
              RSU activity and related information is as follows:&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Weighted
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average Grant&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,657,297&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,227,188&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,701,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.59&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(211,688&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.57&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,971,568&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;As of September 30, 2024, the Company had $27.4 million of unrecognized compensation expense related to unvested RSUs granted under the Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.2 years.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three
            and nine months ended September 30, 2024 and 2023 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;65&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;44&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;131&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;104&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,714&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,451&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,960&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;191&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;472&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,179&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,695&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,183&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,442&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20231231"
      decimals="-6"
      id="Fact_b9b54c54c9bf41d489c65bd4a722e3ab"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20240930"
      decimals="-6"
      id="Fact_26c1477333a54cbcb4d8a99938f43771"
      unitRef="U001">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20240930"
      decimals="4"
      id="Fact_bc71659805f743e7b1bf6e9af3b48f22"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_b2e722cfa28b45708007730b42ceb347"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20240930"
      decimals="INF"
      id="Fact_7b9e855f3516419cb237f8cfcb8cc7d5"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20231231"
      decimals="INF"
      id="Fact_65a9cd8eb6464e91896777fb8b439f71"
      unitRef="U001">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20240930"
      decimals="0"
      id="Fact_ddd782814006439eb9b3210d64e46d5a"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_b49dbf123d754146a76cb5e4876ce280"
      unitRef="U001">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20240930"
      decimals="4"
      id="Fact_b2ad31e31276488db959addb7e755933"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_22c4c35d68ed448495d4bf8844193f39"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20240930"
      decimals="0"
      id="Fact_ffa31f9f144143659de1f738e1722904"
      unitRef="U001">236378607</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_f4d31292941747febd54735d4d6b23ea"
      unitRef="U001">226063032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20240930"
      decimals="0"
      id="Fact_53a22a3e467548a7993906b4ed13a822"
      unitRef="U001">27759065</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20240930"
      decimals="0"
      id="Fact_f7243748a774461faf9a3b4be57035f1"
      unitRef="U001">35862328</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240110"
      decimals="-6"
      id="Fact_7e170b975b354f9f9b654ba0a8985deb"
      unitRef="U001">4000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240110"
      decimals="0"
      id="Fact_64207fe26b2f47d5b935513e39b25719"
      unitRef="U001">1977514</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_64c53d6438d64f68ac673e0acdc210a4"
      unitRef="U001">3388681</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240308_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_5021d12fcd424f2b8e230f859d38c7e2"
      unitRef="U001">2482205</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240314"
      decimals="0"
      id="Fact_e979c640d62a4c4aa7d87c5ab5db01fe"
      unitRef="U001">169651</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240314"
      decimals="0"
      id="Fact_5a70935f1f494d57a01ea02039b59688"
      unitRef="U001">85784</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_030d0eaadbee4c9397dd427d4bed55dd"
      unitRef="U001">1787424</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240509_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_a530a2edeeae4431ad6da20a281e109b"
      unitRef="U001">937507</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_3b14d97a736b43ccb4bed06b0b522bf1"
      unitRef="U001">1962946</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20240815_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_9d49b9da21cb468eaa1f109bf6c3de29"
      unitRef="U001">1741882</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20240224"
      decimals="0"
      id="Fact_494a938c77bc41e69318648cdebcc219"
      unitRef="U001">34800</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_6391864b8fd04963a63465fd41fb7766"
      unitRef="U001">1159404</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_55e479c4c2c747d6947551c65e176d8d"
      unitRef="U001">12502906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20240930_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_5bb412b50954420a8597e015f29f107b"
      unitRef="U003">2.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_3085135229654bdb9a8414ad8c61d55e"
      unitRef="U003">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="c20240101to20240930"
      id="Text_78190f10556a4ac9a4719d3bb6f63024">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400;"&gt;The







            following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024:&lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-weight: 400; text-align: left; text-transform: none;"&gt;
            &lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; orphans: 2; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Shares&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Weighted&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants outstanding at December 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;12,502,906&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.32&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Expired&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;(34,800&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;7.50&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Granted&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Exercised&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;(11,308,702&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.31&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt;"&gt;Warrants outstanding at September 30, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;1,159,404&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt;2.26&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
             &lt;/div&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_594febf50da54e058567dca931c866fb"
      unitRef="U001">12502906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_b6366a81059f45afa6f3bad9c2155a25"
      unitRef="U003">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_fc905bf0b4d24cdd948c6715684c2a08"
      unitRef="U001">34800</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_c4f871f2e71d4e8581c3fffed5f21b68"
      unitRef="U003">7.5</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="INF"
      id="Fact_15933775e9dc47d39192b4320a34779d"
      unitRef="U001">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_b19c4078dfb64134829012b40b848eba"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_99db5ecb75be44bea8fd732778bb1532"
      unitRef="U001">11308702</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_76f8c495d79e4268a65ea95ecbff44f9"
      unitRef="U003">2.31</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_d7fff4a1ebba44cbb74588db6c824ee7"
      unitRef="U001">1159404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20240930_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_52f5a3caa11e4f9893ec44d7ef8b2637"
      unitRef="U003">2.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_91b9573094e44c8f81d6558493652ebe">&lt;span style="color: #000000; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The following assumptions were used to determine the fair value of options granted during the nine months ended September 30, 2024 and 2023:&lt;/span&gt;&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="4" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.5 - 6.3 years&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;66%&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt; &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;68%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); text-align: center;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;0.0&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;4.16-4.34%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;"&gt;4.20-4.24%&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_12c7ba515d2748c5a007d98ce69f435b">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_9b624afe1d8c47f4aaa282755aac7aa0">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_6b9c9b97abd440209c9481dfa3cbd31e">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_8902a860acb64624aac2832fc757c93c">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_8aa5c1e9f9014d92a38c62f1cdb79e67"
      unitRef="U007">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_84de2c86c8ed4adaa3ac1de2e4f91c46"
      unitRef="U007">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_35fbb3c7aa984210b9f2bb19013f5e01"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_7a011900174b40e18b6a2b8886c38889"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="4"
      id="Fact_53a74d8a596848388c51606270ebc70c"
      unitRef="U007">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_48b2fd77b8e7491482d9785659c67237"
      unitRef="U007">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_4b333a6995454944b0fb75439f40ff8c"
      unitRef="U007">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_12a3244223a047d8ae7ec0e23d08b66d"
      unitRef="U007">0.0424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_8d16cb867c634dcd8c57782ad7db5a7d"
      unitRef="U001">1511624</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20230930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_2dc9fcae917d4955a3db788f3e697ea7"
      unitRef="U001">1727510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_7a46a06fb7164b9e84caf8b70057768e">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_93dd12df3e814bd58538ea3f7c4e7b96">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_4f1c788bc92244a7818e06557c51810b"
      unitRef="U001">1925498</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_9115bc33cd864eb789275a81861a21ad"
      unitRef="U001">31219</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240701to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_39cb61c98d564c1688cb0ff340e4eaf9"
      unitRef="U002">7100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_076a681cd8bd47819400c863c4d20d7f">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;A summary of the Company&#x2019;s option activity under the Company&#x2019;s equity incentive plans and related information is as
            follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Weighted
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,906,184&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.38&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(15,723&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1.94&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(221,067&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.34&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,511,624&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; white-space: nowrap; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Exercised&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;(1,925,498&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;3.85&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and expected to vest at &lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,255,520&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.87&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,509,884&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.10&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_250a2065177a4c429f08d52968095a5c"
      unitRef="U001">5906184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_8152b7291121408aaf910859fd75a6be"
      unitRef="U003">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_d282f9183bd84337a46e0803993a71e8"
      unitRef="U001">15723</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_230f8e31350843b29316323e9a49788d"
      unitRef="U003">1.94</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_33eb597814404b77887f9305af1dd8c1"
      unitRef="U001">221067</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_50404ded5138423c922aba19379e676e"
      unitRef="U003">7.34</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_35ef16bff83342d0ad7bf65df106a2e2"
      unitRef="U001">1511624</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_9a0077af70cd4741b29e577f6394478d"
      unitRef="U003">6.25</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_513e07c3e15642caa00299a745cdbb46"
      unitRef="U001">1925498</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_aa54b02879254f4980627817acf3cb44"
      unitRef="U003">3.85</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_3e27f95168fc42d381c5f624469b0926"
      unitRef="U001">5255520</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_4f7b643a508c4bfc818eb6a8a1a19b9b"
      unitRef="U003">3.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_6cf2ca0b342d4372807ee9385792734a"
      unitRef="U001">2509884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_a8c2fca303014785918bf4418193677b"
      unitRef="U003">3.1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_2183e0f1f8704f66b62b47119a97a396"
      unitRef="U002">7400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20240930_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_ecb74b7ba0d544f49e5c10daf39ab80b">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_238e19f7ba244106829cde536281ffc7"
      unitRef="U001">3227188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20230101to20230930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ebb465465aaf46af9fa1faa819b57c1f"
      unitRef="U001">3345760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"
      id="Fact_e55332d8b6bc4341aad8a051672567f1">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_46e15336afda4e8a9eeb2f4d044efd88">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_c664144df99942dd8cf43afccc2a8cfc"
      unitRef="U001">1701229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_d2708ba18da74a3cb0ed1079b49e64c0"
      unitRef="U001">504825</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_6ac0a60722ec445c9120c7c848371dcf"
      unitRef="U002">4300000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_0f7d8855abb74f1da2c548ef9c1047a0">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;A summary of the Company&#x2019;s unvested
              RSU activity and related information is as follows:&lt;/span&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Shares&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Weighted
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Average Grant&lt;/div&gt;
                    &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Date Fair Value&lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;December 31, 2023&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,657,297&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.81&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,227,188&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Vested&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,701,229&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2.59&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(211,688&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3.57&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Balance at &lt;span style="text-indent: 0pt;"&gt;September 30, 2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,971,568&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5.25&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_754791977cc843ebb868c56c9f3fc0af"
      unitRef="U001">4657297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_a61ac8157e3a4ea19f45c7aefc659f8b"
      unitRef="U003">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_8e0112ccef2d43a59caf59531fc49762"
      unitRef="U001">3227188</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_457272f4d59d47c899698d338d9af273"
      unitRef="U003">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_1fb112804b954b5ab776bae291995716"
      unitRef="U001">1701229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_36945ffa76e64934bbb46c7696422283"
      unitRef="U003">2.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ba9d6fbb81a940789dc26f0dfba2305a"
      unitRef="U001">211688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_14bc3c86652c4a89a3c03b2b76717b09"
      unitRef="U003">3.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_946c42005c2048a2848c0be9e56e1fad"
      unitRef="U001">5971568</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_d7d161d634a141d09da4d14d75f1224b"
      unitRef="U003">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_ec4965b2d61f42afbda21c314eb14eea"
      unitRef="U002">27400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20240930_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_d27bb0adf9604c968b2a387e60441452">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_0cfebe5db0554c4a8d6b82f250a91866">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the three
            and nine months ended September 30, 2024 and 2023 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;24&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;65&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;27&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;44&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;131&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;104&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,714&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,451&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,960&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;397&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;191&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;472&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,179&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,695&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,183&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,442&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240701to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_614cb3d802f3493896310988b88303cb"
      unitRef="U002">24000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230701to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_ba4eb47a9b0c4842bcf9424f9c7ea510"
      unitRef="U002">12000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_f7207f38a9984250b335f3dac7bb828f"
      unitRef="U002">65000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_af6deabdb2284d5a8e5a1375fec15412"
      unitRef="U002">27000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240701to20240930_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_a9230d8a86e74ffd95483f442a38d5ea"
      unitRef="U002">44000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230701to20230930_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_25cf26f73406406f9c9cbea1bbfd01c4"
      unitRef="U002">41000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_df43ad8a114c43c5912402cabf552c74"
      unitRef="U002">131000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_b59664423d16445c8a7b5c860a2778ff"
      unitRef="U002">104000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240701to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_73d17c56a3e04b0ea1f3cd37313443ad"
      unitRef="U002">2714000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230701to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_a4e1a272aff64a1b97a3415fa0d808d7"
      unitRef="U002">1451000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_c590ce5a2ca44d3eae03f4d96e1f4033"
      unitRef="U002">6960000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_02b5653d55914c6591ce009ad4749ae4"
      unitRef="U002">3839000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240701to20240930_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_2a85f7e7ce42430bb72c05a63bb64a5e"
      unitRef="U002">397000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230701to20230930_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_8019c05f9082431887608791d11f58ee"
      unitRef="U002">191000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_086574d078894d459fbedfb966cb4f15"
      unitRef="U002">1027000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_69728ee16d06448e9b1c320826b5cfb2"
      unitRef="U002">472000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_1f38784f4d374375bb85d60c27e6060d"
      unitRef="U002">3179000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_c4dc7b3ffdb540dc85e2675ebe16ead5"
      unitRef="U002">1695000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_320f2fb19c2c424298172bfc544ee086"
      unitRef="U002">8183000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_e4d3e53c16db4cd18588642339e64952"
      unitRef="U002">4442000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_c780bfd708e44e8fa86486118498f0cb">
&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;  &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;&lt;span style="text-decoration: underline;"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company leases office space and
            equipment from Areth, LLC (&#x201c;Areth&#x201d;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time to time, and pays monthly rent on this facility in the amount of $10,000 through December 31, 2026. Rent expense for the nine months ended September 30, 2024 and 2023 amounted to $90,000. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Company&#x2019;s Board of Directors, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive
            Officer. The Company also reimburses Areth for office and building-related (common area) expenses, equipment and certain other operational expenses, which were not material to the condensed consolidated financial statements for the nine months
            ended September 30, 2024 and 2023.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;During the nine months ended September
            30, 2024 and 2023, the Company purchased certain specialized medical equipment and services primarily related to the Company&#x2019;s plasma collection centers, as well as personal protective equipment, from GenesisBPS and its affiliates (&#x201c;Genesis&#x201d;),
            aggregating to $0.2 million and $0.4
            million, respectively. Genesis is owned by Dr. Grossman and Mr. Grossman.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;During the three and nine months ended
            September 30, 2024, two of the Company&#x2019;s executive officers exercised options to purchase an aggregate of 650,395 shares of common stock, for which the Company received net proceeds of $3.0 million (see Note 8). During the three and nine months ended September 30, 2023, two
            of the Company&#x2019;s executive officers exercised options to purchase 2,909,721 shares of the Company&#x2019;s common stock on a cashless
            basis, and 688,657 shares of common stock were issued to these executive officers, net of 257,867 shares of common stock to cover a portion of their tax liabilities. &lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-3"
      id="Fact_9c427e4b0b334fb1bb6a840a5e877fe6"
      unitRef="U002">10000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20240101to20240930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-3"
      id="Fact_f2835458968540ffaf6bc7139cb0d6fb"
      unitRef="U002">90000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20230101to20230930_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-3"
      id="Fact_dc09406eb8d042dfbfb90a3aa7cd8b8d"
      unitRef="U002">90000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20240101to20240930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_72a91b461c464392bdedb0b7122ffa71"
      unitRef="U002">200000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20230101to20230930_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_a3b7c894548e438699625bc4efac2a3f"
      unitRef="U002">400000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <adma:NumberOfExecutiveOfficersThatExercisedOptions
      contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="INF"
      id="Fact_c0ace11f7e034a93ba86049d2e7b39c9"
      unitRef="U008">2</adma:NumberOfExecutiveOfficersThatExercisedOptions>
    <adma:NumberOfExecutiveOfficersThatExercisedOptions
      contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="INF"
      id="Fact_5d99eb01bef14477a21b937f86a55c5c"
      unitRef="U008">2</adma:NumberOfExecutiveOfficersThatExercisedOptions>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_815dce9c77a845068cecb965122d671b"
      unitRef="U001">650395</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_216c90db18f9412cb905c45128a85fd7"
      unitRef="U001">650395</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="-5"
      id="Fact_f3807ff2824b4f7c8bd08cc26959a050"
      unitRef="U002">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="-5"
      id="Fact_a3adb71de3c942fd8bfdefc708e3664b"
      unitRef="U002">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <adma:NumberOfExecutiveOfficersThatExercisedOptions
      contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="INF"
      id="Fact_f57a769f16c94f59bfd2d16b75f96b71"
      unitRef="U008">2</adma:NumberOfExecutiveOfficersThatExercisedOptions>
    <adma:NumberOfExecutiveOfficersThatExercisedOptions
      contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="INF"
      id="Fact_e4972df233a34ab39bdb5d0e5b551c47"
      unitRef="U008">2</adma:NumberOfExecutiveOfficersThatExercisedOptions>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward
      contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_a14cb0864682499ab13561da4328245a"
      unitRef="U001">2909721</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward
      contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_96bd570060054df3a30213b5d3c82f03"
      unitRef="U001">2909721</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_73034da93fa14e5e853b52d8e109208c"
      unitRef="U001">688657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230701to20230930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_4b07a46c27964b0aa00f6b6011e2f0be"
      unitRef="U001">688657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20240701to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_cc5a09a6eb57472fb032f8b027908404"
      unitRef="U001">257867</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20240101to20240930_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_1d33ddb0177245a195a5be362d7ffa30"
      unitRef="U001">257867</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_4473a060a68a403d939a6af745d8e9bf">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;General Legal Matters&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;From time to time, the Company is or may
              become subject to certain legal proceedings and claims arising in connection with the normal course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s
              liquidity, results of operations or financial condition. &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;div style="font-style: italic;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Vendor Commitments&lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Pursuant to the terms of a plasma purchase agreement dated as of November 17, 2011 (the &#x201c;2011 Plasma Purchase Agreement&#x201d;), the Company agreed to purchase from its former contract manufacturer an annual minimum volume of
              source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase
              Agreement the Company was permitted to also collect high-titer RSV plasma from up to five wholly-owned ADMA plasma collection
              facilities.&#160; During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material RSV high-titer plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the
              Company to purchase its raw material RSV high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes from the Company&#x2019;s former contract manufacturer were met, thus allowing the
              Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. Unless terminated earlier, the 2011 Plasma Purchase Agreement expires in June 2027, after which it may be renewed for two additional five-year periods
              if agreed to by the parties. On December 10, 2018, the Company&#x2019;s former contract manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#x201c;Grifols&#x201d;) as its
              successor-in-interest, effective January 1, 2019.&lt;/span&gt;&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company entered into
            a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual minimum volume of hyperimmune plasma that
            contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year term. On July
            19, 2018, the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#x2019;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is
            unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for
            the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#x2019;s former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt;
            &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Post-Marketing Commitments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with the FDA&#x2019;s approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the safety and efficacy of ASCENIV in children and adolescents. For the nine months ended September 30,
              2024 and 2023, the Company incurred expenses related to this study in the approximate amount of $1.0 million and $0.6 million, respectively. The Company expects to incur expenses of approximately $0.5 million to complete this study, which is required to be completed by June of 2026. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="font-style: italic; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Employment Contracts&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-style: italic;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company previously entered into employment agreements with Mr. Grossman and with Brian Lenz, the Company&#x2019;s former Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters. Effective as of April 1,
              2024, Mr. Lenz transitioned to a non-employee consulting role and entered into a consulting agreement with the Company. On April 1, 2024, the Company entered into an employment agreement with Kaitlin Kestenberg, who was promoted to Chief
              Operating Officer and Senior Vice President, Compliance. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On July 24, 2024, the Company entered into an employment agreement with Brad Tade, who was appointed Chief Financial Officer and Treasurer of the Company.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;
              &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt; &lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;
           &lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt; &lt;span style="font-family: 'Times New Roman';"&gt; &lt;span style="font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt; &lt;span style="font-style: italic;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Other Commitments&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its
            employees, licensors, suppliers and service providers. Further, the Company indemnifies its directors and executive officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these
            arrangements is unknown as of September 30, 2024. The Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c20240101to20240930_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_2ac00a24c78b4a569a9ea8f1904f18a3"
      unitRef="U004">5</adma:NumberOfPlasmaCollectionFacilities>
    <adma:NumberOfRenewalTerms
      contextRef="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_364336ee0ba3405b962f2cb037e4858a"
      unitRef="U009">2</adma:NumberOfRenewalTerms>
    <adma:PlasmaPurchaseAgreementRenewalPeriod
      contextRef="c20240101to20240930_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      id="Fact_fc9e3bd9ac5248a59062599e51a87502">P5Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <adma:PlasmaSupplyAgreementTerm
      contextRef="c20240101to20240930"
      id="Fact_a258413f0f2646849d0ce7c29a720a6c">P10Y</adma:PlasmaSupplyAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20240930_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_e79ad84c63e642478ee7f01482bf1042"
      unitRef="U002">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20230930_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_1ce748be4df743828f98a1b667b58ba2"
      unitRef="U002">600000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20190401to20190401"
      decimals="-5"
      id="Fact_2916e0a780394d25a51fb73c9c9a0fe9"
      unitRef="U002">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_8d577c5a49fb4883907c94d4289126da">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;11.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SEGMENTS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal;"&gt;The
              Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#x2019;s ADMA BioManufacturing operating segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development
              operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of&#160; ten plasma collection facilities
              located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the
              chief operating decision maker (&#x201c;CODM&#x201d;) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and
              administrative overhead expenses and interest expense on the Company&#x2019;s senior debt (see Note 7). The Company&#x2019;s CODM is its President and Chief Executive Officer. For the Company&#x2019;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;Summarized









              financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt; Plasma Collection &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;113,088&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,715&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;119,839&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,731&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,449&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;60,180&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,347&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,755&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,954&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;39,638&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(54&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,835&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,889&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Income (loss)
                        before taxes&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,293&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,755&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,789&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36,749&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,138&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;802&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,940&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;266,456&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;33,191&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;90,971&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;390,618&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;66,567&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;672&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,275&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41,734&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;888&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,622&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,017&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,649&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,685&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other (expense) income, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(141&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,979&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Income (loss) before
                      taxes&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,876&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,628&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,565&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,282&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;811&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;Total assets &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;262,554&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;35,622&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;50,821&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;348,997&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30, 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;299,385&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,413&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;142,193&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,492&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;152,685&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;123,756&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(19,049&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(95&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,560&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,659&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) before taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;123,661&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,051&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(28,609&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;91,001&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,364&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;105&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,469&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,686&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,101&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;175,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,299&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;184,311&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;118,708&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,747&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;126,455&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,577&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(16,149&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,399&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,823&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,993&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) before taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,407&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33,972&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(10,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,768&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,806&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;3,574&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,857&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,366&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,223&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
           &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="display: inline; float: none; letter-spacing: normal; white-space: nowrap; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-weight: 400; text-indent: 0px; text-transform: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;114,748&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;64,618&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;295,465&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;173,920&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,091&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,657&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,440&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,391&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;119,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,275&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;184,311&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20240701to20240930"
      decimals="INF"
      id="Fact_5b964c264c87450fbf5e17497f368e3d"
      unitRef="U004">10</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20240101to20240930"
      decimals="INF"
      id="Fact_f52bc11dad42476087d41ea74aa775ca"
      unitRef="U010">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20240101to20240930"
      id="Text_ace1429e22f7499c863c9704403e8a50">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;Summarized









              financial information concerning reportable segments is shown in the following tables:&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;br/&gt;
            &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div&gt; Plasma Collection &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;113,088&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,715&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;119,839&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;52,731&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,449&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;60,180&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,347&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,755&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,954&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;39,638&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(54&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,835&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(2,889&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Income (loss)
                        before taxes&lt;/span&gt;&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;48,293&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,755&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,789&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36,749&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&lt;br/&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense &lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,138&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;802&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,940&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total assets&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;266,456&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;33,191&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;90,971&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;390,618&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;66,567&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;672&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;36&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,275&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;41,734&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;888&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;42,622&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,017&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,649&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,685&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other (expense) income, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(141&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,979&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(6,120&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: -9.6px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Income (loss) before
                      taxes&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14,876&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(683&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(11,628&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,565&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;1,282&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;811&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,093&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;Total assets &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;262,554&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;35,622&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;50,821&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;348,997&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30, 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;299,385&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;9,413&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;142,193&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,492&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;152,685&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;123,756&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,047&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(19,049&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;100,660&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(95&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,560&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(9,659&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) before taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;123,661&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(4,051&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(28,609&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;91,001&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,364&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;105&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,469&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,686&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,415&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,101&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td colspan="16" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30, 2023&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center;" valign="bottom"&gt; ADMA&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: center; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div&gt; Plasma Collection &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: nowrap; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;BioManufacturing&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Centers&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Corporate&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; color: rgb(0, 0, 0); font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Consolidated&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;175,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,299&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;107&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;184,311&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;118,708&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,747&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;126,455&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) from operations&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,577&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(16,149&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,399&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Interest and other expense, net&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(170&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,823&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(17,993&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Income (loss) before taxes&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;26,407&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(3,029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(33,972&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(10,594&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; width: 52%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;Capital expenditures&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,768&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;1,806&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;3,574&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Depreciation and amortization expense&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;3,857&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,366&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;6,223&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_078c9302598340caae63c3e137fc6563"
      unitRef="U002">113088000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_84c1e648bec4470b9230891446292a31"
      unitRef="U002">6715000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_456aa1ce112745098eb161569e046920"
      unitRef="U002">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_9f1e7bc91751486f924450d00a7c2464"
      unitRef="U002">119839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_9dd589651be6436da26a29380b6ab8a0"
      unitRef="U002">52731000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_9671e27b1901441790108233d0e0051c"
      unitRef="U002">7449000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_f0033ae92bab40cf9b4ea6ab97727e9e"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_68425aca8c3e4982a053847ecd39b545"
      unitRef="U002">60180000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_8065e9e59c0242d4969289c81a9116a2"
      unitRef="U002">48347000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_41298bec1e4f4639809a8b47c4f790c3"
      unitRef="U002">-1755000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_422311e8bfc14f02b48c8510db6e3a0b"
      unitRef="U002">-6954000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_62ffc3340cba45a79fd15a9fcab85710"
      unitRef="U002">39638000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_657d21f6d8f6433b9ea2a1954bab1de5"
      unitRef="U002">-54000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_097657deac124b1c8d9a99172daa17a0"
      unitRef="U002">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_14bbf56cbcf2483a8da2356c4d248c35"
      unitRef="U002">-2835000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_4cb32e29d77e46658cc78460a11e42e9"
      unitRef="U002">-2889000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_2e2437fa2d5949049e1dacdddc592d81"
      unitRef="U002">48293000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_fe52c2f3969440469cd6a9f37a2f9bf1"
      unitRef="U002">-1755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_9163c6e3d2424c4dbcc4628b9af9fb9a"
      unitRef="U002">-9789000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_70c7d7333bbe4090a54383a2d38fdf4c"
      unitRef="U002">36749000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_876ce33540fa4412a44e1705609da93c"
      unitRef="U002">1138000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240701to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_1cd07a5831ac4bda9ad7d27722d354e7"
      unitRef="U002">802000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240701to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_8b6d3120be4b4cf48dd09e0f5562774e"
      unitRef="U002">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_6b0c9058ac064b13a2fcad62a744bcd2"
      unitRef="U002">1940000</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_bd41babfb1fe4de3af6aa1fc70ba89e2"
      unitRef="U002">266456000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_bfada37cdfa64af78860b766a8723f14"
      unitRef="U002">33191000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_103bbb510a4a40c6bfdbb4688a6b720a"
      unitRef="U002">90971000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20240930"
      decimals="-3"
      id="Fact_1ea6ebbae4564edab53178c815478582"
      unitRef="U002">390618000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_1fcae80ca8394867ba871cde3cb22c26"
      unitRef="U002">66567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_6ac55ed13a254ba6bdeaaef90967b16f"
      unitRef="U002">672000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_36a2784280d347e092795ef16becf3d5"
      unitRef="U002">36000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_95a00577b70c4a56bb3aeaeaf6777077"
      unitRef="U002">67275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_8e5dc2817f934685b01500a557ac2559"
      unitRef="U002">41734000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_06c7fe9991584bea8956b636a24024eb"
      unitRef="U002">888000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_ab713f9117fd4889831a0a1d8ec8c37a"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_db5e0e1c76d5483b8d2288b50775e975"
      unitRef="U002">42622000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_262733d31e254f3da9c77f4fdc8f0f24"
      unitRef="U002">15017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_c060cd3fd03c423f92a70e4d1e6d480a"
      unitRef="U002">-683000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_c38d45651e694bf9ae9ba4cd7d0366a2"
      unitRef="U002">-5649000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_ba04025d338644239f1a2adbc8bf966a"
      unitRef="U002">8685000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_bfae18d71c074b23839a9fad43920c5f"
      unitRef="U002">-141000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d342e1f1b4de4b879b4ded5b492efd68"
      unitRef="U002">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_2a24fde6a0e045169bdd068260fe35d5"
      unitRef="U002">-5979000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_76857455e86a4c3c8ce9c138b88fe275"
      unitRef="U002">-6120000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_d42f82a09ba8474eaed39e2a8d9b7a7f"
      unitRef="U002">14876000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_98dbf4a147554b449c9e265d3dece405"
      unitRef="U002">-683000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_668b9a9930c84bf1875c346687befdf7"
      unitRef="U002">-11628000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_e91072c124694e9c88f1c785efe0adf9"
      unitRef="U002">2565000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_fa50dd34b1874bbbacc40d98fb2e0cfc"
      unitRef="U002">1282000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230701to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d93f0cccb3714ca893f192fb9cf68a28"
      unitRef="U002">811000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230701to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_8ec85abf291e4f5e869d0b48830d7724"
      unitRef="U002">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_42214fb9c0ad4980b993fe06cda28152"
      unitRef="U002">2093000</us-gaap:DepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_cb1dd7de782946ffb6022a1fc6f811f0"
      unitRef="U002">262554000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_40dc2ae3c8414c158210d8d406e1be9f"
      unitRef="U002">35622000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_1bffc1f4b60a4d9f9114111fbc759102"
      unitRef="U002">50821000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20230930"
      decimals="-3"
      id="Fact_f0f9208679f742c29cfb87c4db5cea5e"
      unitRef="U002">348997000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_158c7430f6f94a4e8e213d99ae0fe521"
      unitRef="U002">299385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_c5eeb823fb51415494320073d699465e"
      unitRef="U002">9413000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_cfa1978aeebb40ffb2237b5067399f60"
      unitRef="U002">107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_e5ebf4bc395047b89c913763a8963bf4"
      unitRef="U002">308905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_f79086f8be8d4cfea8e5b47df1dfe6f8"
      unitRef="U002">142193000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_a86487922aff4ea38f04d0b526bfc926"
      unitRef="U002">10492000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_c2d814125584474b852446c34ed2bcd7"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_9ac50f04f4eb44878c005e3a37cb0717"
      unitRef="U002">152685000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_80a81078b34543278e27dfcc7cd6c11d"
      unitRef="U002">123756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_1c321b9b987d4a6bb3bc664f7d3642f4"
      unitRef="U002">-4047000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_76a6f9fb9afb45bea7048e6ee8ea5bde"
      unitRef="U002">-19049000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_2d2e2f727e6f4ca8b9cefd4be7429935"
      unitRef="U002">100660000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_f22938fe971e4abd994065aa3a25a301"
      unitRef="U002">-95000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_3c32e2c9896a41aba20500f107276031"
      unitRef="U002">-4000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_cc5aa8eb11434271a6691e7bb978be81"
      unitRef="U002">-9560000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_0d364d55bcec4d3b872ec972325ce8c7"
      unitRef="U002">-9659000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_b80ad374c06748df9dab3e1d6e89254b"
      unitRef="U002">123661000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_c344cb45fb8640169e737d5c5a4d09e7"
      unitRef="U002">-4051000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_1f0b0f1511fe4de097157b31b3b79e6f"
      unitRef="U002">-28609000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_6de2f481b4c94ba29088307c84749030"
      unitRef="U002">91001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_c8661c74f412472fb67fbba4dce47a24"
      unitRef="U002">5364000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_ed165df269e14edca7fe3afa324533c6"
      unitRef="U002">105000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_68509a8fac00464097d4277b21857304"
      unitRef="U002">0</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_6bf6c7b914a545a097545a39ba8529b6"
      unitRef="U002">5469000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_b9b2d384992f48cdb610d4885a2db785"
      unitRef="U002">3686000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20240930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_86f13d429dc44845ae401a2d3321edc4"
      unitRef="U002">2415000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20240930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_f09ae0ce3d4a485fa252a642baf9005f"
      unitRef="U002">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_5131f34b68b34cba932c612c57139c2c"
      unitRef="U002">6101000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_77b9f740f0204e63b624f8509f447e12"
      unitRef="U002">175905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_883fef9147914816afec69cccaf7ccda"
      unitRef="U002">8299000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_e65e8bbe45f643f4a9c3ac9d865fd333"
      unitRef="U002">107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_30067e22782c4d75af58158e93c94061"
      unitRef="U002">184311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_e281bb1fb8dd4637bb71196639b3a0ad"
      unitRef="U002">118708000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_e41aeebced434a7892cf49cd228e2041"
      unitRef="U002">7747000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_0db5c44322de4ea482b240de9b17d141"
      unitRef="U002">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_7e2f759088f04736939c62ab8edb97d3"
      unitRef="U002">126455000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_3463075f1b7c417797b0fa350952e3e5"
      unitRef="U002">26577000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_28638e2886c8491cb0875768e559ba97"
      unitRef="U002">-3029000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_3ca61f1b4f48442aaef4c11a18006a23"
      unitRef="U002">-16149000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_7fe7dccbe8624253b1d9e841a06d1c71"
      unitRef="U002">7399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_2813223937514c6db86b62e6a06aa301"
      unitRef="U002">-170000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_78dfe50362434278a3e9c2cc4c61bff9"
      unitRef="U002">0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_0a09245ef58c4fa2b6fdbd17196fcc07"
      unitRef="U002">-17823000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_d10580018c56494897a1f23eef8e96eb"
      unitRef="U002">-17993000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_a6df1dab4b154b4ea8b301215b076a3f"
      unitRef="U002">26407000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d89cda905fdc4c3fbf6ddb963962881c"
      unitRef="U002">-3029000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_a787b6ef1a854bcfb54744369aa9c303"
      unitRef="U002">-33972000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_bdce3a42032745b7b2387a23bbacab2d"
      unitRef="U002">-10594000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_4eb9cf58de224912906b87354208724b"
      unitRef="U002">1768000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_4f7e50cfe2bb40bf8a97fed2699db3a5"
      unitRef="U002">1806000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_6d2ae148ae4741b4b55ca998aa8c4f16"
      unitRef="U002">0</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_29c773af34f640c090176db226528bda"
      unitRef="U002">3574000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_345268fa878e43ad9c46678ad0a96cd4"
      unitRef="U002">3857000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230930_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_04b74955a2ff4eb2a5709a4fee97dc5b"
      unitRef="U002">2366000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230930_StatementBusinessSegmentsAxis_CorporateMember"
      decimals="-3"
      id="Fact_9800bb34c09745bd8beb054cf5f2caff"
      unitRef="U002">0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_d97509c981ae4d8c87d4402f873f3d00"
      unitRef="U002">6223000</us-gaap:DepreciationAndAmortization>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_cb3457db51a845d5ad4ccf3d19e66190">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Three Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Nine Months Ended September 30,&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; white-space: nowrap;" valign="bottom"&gt;&lt;span style="display: inline; float: none; letter-spacing: normal; white-space: nowrap; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: italic; font-weight: 400; text-indent: 0px; text-transform: none;"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt; &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;United States&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;114,748&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;64,618&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;295,465&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;173,920&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;International&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;5,091&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,657&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,440&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;10,391&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Total revenues&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;119,839&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;67,275&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;308,905&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;184,311&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_658e3c1fd6b84b04adfdf679bba1c0b6"
      unitRef="U002">114748000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_bc2cd4e222984ca0be0f4132ee154b9f"
      unitRef="U002">64618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_3794e485bc0c45328ba75c3861adb9ab"
      unitRef="U002">295465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_caf33e60b35449f3b36cbceb414b8566"
      unitRef="U002">173920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_dcf2b40f2284402ab7604d2f38d635b3"
      unitRef="U002">5091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_20a751098dc94e1ea3aed40c588cd050"
      unitRef="U002">2657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_da2eb3b0ad8849918bae98fd5d65acb3"
      unitRef="U002">13440000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_bdaaf33ca6ff41789cc68fb7dbe75cef"
      unitRef="U002">10391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240701to20240930"
      decimals="-3"
      id="Fact_fb6a8063e5184879acfffbd4518d9bb7"
      unitRef="U002">119839000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930"
      decimals="-3"
      id="Fact_b45ee5ebf8f14088993d5716a352c4c3"
      unitRef="U002">67275000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_68de6db07dea406aa61037c443a608f5"
      unitRef="U002">308905000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_466279db437d497da14fd7b2c507f479"
      unitRef="U002">184311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20240101to20240930"
      id="Text_07c47f886b1349e5b405490a00370332">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;12.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;LEASE OBLIGATIONS&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which
            leases provide the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#x2019;s lease agreements do not contain any material residual value guarantees
            or material restrictive covenants.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
           &lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company determines if an arrangement is an operating lease at inception. Leases with
              an initial term of 12 months or less are not recorded on the balance sheet. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease term and lease liabilities
              representing the obligation to make lease payments arising from the lease.&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;Right-to-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term and include options to extend or terminate the
              lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s incremental borrowing rate. The Company&#x2019;s lease expense is recognized on a straight-line basis over the lease
              term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses. &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;Aggregate lease expense for the Company&#x2019;s leases &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for the three months ended September 30, 2024 and 2023 was approximately&lt;/span&gt; $0.6 million, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;and &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;aggregate lease expense for&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;the









                      nine months ended&#160; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                      30, 2024 and 2023 was &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;approximately &lt;/span&gt;$&lt;/span&gt;1.8&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; million&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;. Cash paid for the
                Company&#x2019;s leases for &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;the three months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; 30, 2024 and 2023 was also
                  approximately&lt;/span&gt; $0.6 million, &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;and









                      cash paid for the nine months ended &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;
                      30, 2024 and 2023 was approximately $&lt;/span&gt;1.8 &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;million.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;br/&gt;
            &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt;The Company has aggregate lease liabilities of $10.1 million and $10.8 million as
                of &lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;September&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; 30, 2024 and December 31, 2023,&lt;/span&gt; respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers and a
                warehouse lease for raw material storage related to the Company&#x2019;s immunoglobulin manufacturing operations.&#160; The Company&#x2019;s operating leases have a weighted-average remaining term of 7.0 years. &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; color: #000000;"&gt;Scheduled payments under the Company&#x2019;s lease obligations are as follows &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt; font-variant: normal;"&gt;(in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 54pt; margin-left: 9pt;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;603&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 0pt; margin-left: 9pt;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 117pt;"&gt;&#160;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,157&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,041&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,088&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,109&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,042&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,461&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,403&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,193&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Balance at September 30, 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,865&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20230701to20230930"
      decimals="-5"
      id="Fact_e2b08e43259248809e050b8907d8e4db"
      unitRef="U002">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20240701to20240930"
      decimals="-5"
      id="Fact_3d60ac7ef7c5444c929bf0d6d99b181d"
      unitRef="U002">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_b9ee2ed92ec042b6b43471c1c6df72d6"
      unitRef="U002">1800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20230101to20230930"
      decimals="-5"
      id="Fact_b272b9c20b7146f198adf5167230401e"
      unitRef="U002">1800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230701to20230930"
      decimals="-5"
      id="Fact_ef43412d8b9245e5ae67a3c042d34813"
      unitRef="U002">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20240701to20240930"
      decimals="-5"
      id="Fact_204a032e45ce4621964c91ff0deb5688"
      unitRef="U002">600000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230101to20230930"
      decimals="-5"
      id="Fact_f915f1c66e6548a4bd95fddaecc66c43"
      unitRef="U002">1800000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_16f6f3d10b534c219d48ec9747144b32"
      unitRef="U002">1800000</us-gaap:OperatingLeasePayments>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20240930"
      decimals="-5"
      id="Fact_ab98db09dd4b434c915c9e6d155b3836"
      unitRef="U002">10100000</adma:OperatingAndFinancingLeaseLiability>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20231231"
      decimals="-5"
      id="Fact_127bb570acba409da88206e7e23fcf1e"
      unitRef="U002">10800000</adma:OperatingAndFinancingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20240930"
      id="Fact_1d2a3e6f55a641b596496d80f993d100">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_405210bb330f4623aeab49dce8f76c74">&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; font-variant: normal; color: #000000;"&gt;Scheduled payments under the Company&#x2019;s lease obligations are as follows &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400; font-size: 10pt; font-variant: normal;"&gt;(in thousands):&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 54pt; margin-left: 9pt;"&gt;Remainder of &lt;span style="text-indent: 0pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;603&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 0pt; margin-left: 9pt;"&gt;Year ended December 31, &lt;span style="text-indent: 0pt;"&gt;2025&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,421&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; text-indent: 117pt;"&gt;&#160;&lt;span style="text-indent: 0pt;"&gt;2026&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,157&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2027&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,041&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2028&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,088&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;2029&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2,109&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;Thereafter&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;4,042&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;Total payments&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;15,461&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Less: imputed interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(5,403&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Current portion&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;(1,193&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 22%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; margin-left: 9pt;"&gt;&#160;Balance at September 30, 2024&lt;/div&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: bottom; text-align: right; width: 66%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;8,865&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="c20240930"
      decimals="-3"
      id="Fact_4a231363756a4e8aab7e3cb585f7e6a2"
      unitRef="U002">603000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20240930"
      decimals="-3"
      id="Fact_361220d64c9a4abc806dacd28f372767"
      unitRef="U002">2421000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20240930"
      decimals="-3"
      id="Fact_7f83c8ae0c14409e949e92fb0abc968c"
      unitRef="U002">2157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d122b9e0f656461f9fc19d02bb370d2a"
      unitRef="U002">2041000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20240930"
      decimals="-3"
      id="Fact_d397dbf717f343a0a400e103d9554d43"
      unitRef="U002">2088000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20240930"
      decimals="-3"
      id="Fact_f7084f6ec7904b3bb96423d99440bebe"
      unitRef="U002">2109000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20240930"
      decimals="-3"
      id="Fact_79dc053a7edd470b950788b78449e1ca"
      unitRef="U002">4042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20240930"
      decimals="-3"
      id="Fact_a9da986e5279494cafb02cca01f21eb8"
      unitRef="U002">15461000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20240930"
      decimals="-3"
      id="Fact_0a26da9836e946668f65a5402871aa5e"
      unitRef="U002">5403000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_485da2db41a24c45a64ddd489dcf8c62"
      unitRef="U002">1193000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20240930"
      decimals="-3"
      id="Fact_c5ee20a89db843f0b37ae18957865f6b"
      unitRef="U002">8865000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20240101to20240930"
      id="Text_0bd3e4583a044137939c6d3a07fa6631">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold;"&gt;13.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
              &lt;div style="font-weight: bold;"&gt;&lt;span style="text-decoration: underline;"&gt;INCOME TAXES&lt;/span&gt;&lt;/div&gt;
            &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;The Company uses the estimated annual effective tax rate approach as prescribed by ASC
        740-270, Interim Reporting, to calculate its interim tax provision. For the three and nine months ended September 30, 2024, the Company recorded income tax expense of $0.8 million and $5.2 million, respectively, resulting in an effective tax rate
        of 5.7% &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;for the nine months ended September 30, 2024.&lt;/span&gt; The tax expense for the three and nine months ended September 30, 2024 represents federal and state tax liabilities
        that are not fully sheltered by net operating loss carryforwards (&#x201c;NOLs&#x201d;) due to limitations from prior ownership changes and other limitations&#160;&lt;span style="color: rgb(0, 0, 0);"&gt;on NOLs incurred after 2017&lt;/span&gt;. The Company&#x2019;s effective tax rate
        differs from the federal statutory tax rate of 21% due primarily to the reversal of the valuation allowance on certain federal and state
        NOLs estimated to be realized in the current year and, to a lesser extent, the tax benefit associated with the employee exercise of stock options and vesting of RSUs.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Valuation Allowance&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;A valuation allowance, if needed, reduces deferred tax assets to the amount expected
        to be realized. When determining the amount of net deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings
        history, expected future earnings, carryback and carryforward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and
        negative evidence is commensurate with the extent the evidence may be objectively verified. As such, it is generally difficult for positive evidence regarding projected future taxable income, exclusive of reversing taxable temporary differences, to
        outweigh objective negative evidence of recent financial reporting losses. Based on these criteria and the relative weighting of both the positive and negative evidence available, the Company continues to maintain a full valuation allowance against
        its net deferred tax assets.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-style: italic;"&gt;&lt;span style="text-decoration: underline;"&gt;Net Operating Losses&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&#160;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;"&gt;As of December 31, 2023, the Company had federal and state (post-apportioned basis)
        NOLs of $315.6 million and $216.4
        million, respectively. Approximately $35.6 million and $95.1 million of the foregoing federal and state NOLs, respectively, will expire at various dates from &lt;span style="-sec-ix-hidden:Fact_04c4d72102c94fdb82f3fcd93478e6fd"&gt;2028&lt;/span&gt; through &lt;span style="-sec-ix-hidden:Fact_ee510cd27e5248eea4877ba277c443e7"&gt;2043&lt;/span&gt;, if not limited by triggering events prior to such time.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;"&gt;Under the provisions of the Internal Revenue Code, changes in ownership of the Company,
        in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#x201c;Section 382&#x201d;) imposes limitations on an entity&#x2019;s
        ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully utilize its
        NOLs. As of December 31, 2023, approximately $267.8 million of the foregoing federal NOLs are subject to limitation under Section 382 due
        to prior ownership changes.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
      &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; text-indent: 36pt;"&gt;The Company may experience ownership changes in the future as a result of subsequent
        shifts in ownership of the Company&#x2019;s capital stock that the Company cannot predict or control that could result in further limitations being placed on the Company&#x2019;s ability to utilize its federal NOLs.&lt;span class="HorizontalTab" style="width: 9pt; font-size: 1px; display: inline-block;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;
</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240701to20240930"
      decimals="-5"
      id="Fact_1722bc37557f41628dbcc8c0011b4d2b"
      unitRef="U002">800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20240930"
      decimals="-5"
      id="Fact_fad0efa5d15f42718495a1bdda6f72c4"
      unitRef="U002">5200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="c20240101to20240930"
      decimals="3"
      id="Fact_1c695f11ff8e48beaeee2715179f69ff"
      unitRef="U007">0.057</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20240930"
      decimals="2"
      id="Fact_3fe9f0d5f903488e88bfb04af8c9087a"
      unitRef="U007">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact_c0941c58f6534d3297f7b4bec36c562c"
      unitRef="U002">315600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact_3ee59c9ee9994c20acbd236cf92e1a99"
      unitRef="U002">216400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member"
      decimals="-5"
      id="Fact_a109ff918ba740969b4f5f853ab6866b"
      unitRef="U002">35600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member"
      decimals="-5"
      id="Fact_9dd4cf59586141069366b507e44a7afb"
      unitRef="U002">95100000</us-gaap:OperatingLossCarryforwards>
    <adma:OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges
      contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact_07f326f1779d49f99f0ab28c2d14e070"
      unitRef="U002">267800000</adma:OperatingLossCarryforwardsSubjectToLimitationOwnershipChanges>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="c20240101to20240930"
      id="Text_673ec408ded04a738b2e6188e9f26692">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"&gt;


  &lt;tr&gt;

    &lt;td style="width: 18pt; vertical-align: top; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;14.&lt;/td&gt;

    &lt;td style="width: auto; vertical-align: top;"&gt;
                  &lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Supplemental cash flow information for the nine months ended September 30, 2024 and 2023 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,896&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;Cash paid for income taxes&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;8,895&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Noncash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;452&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;270&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;Warrants issued in connection with notes payable&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,595&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="c20240101to20240930"
      id="Text_35fb1c620ab44388bdc46b9d5e9dccc2">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
          &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Supplemental cash flow information for the nine months ended September 30, 2024 and 2023 is as follows:&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2024&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;div style="text-align: center; font-weight: bold;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;2023&lt;br/&gt;
                    &lt;/span&gt;&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Cash paid for interest&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;7,417&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;13,896&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;Cash paid for income taxes&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;8,895&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Noncash Financing and Investing Activities:&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="text-indent: -7.2pt; margin-left: 16.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;452&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"&gt;270&lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;Warrants issued in connection with notes payable&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;5,595&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_f6bd987e87e24ffdbb7596a7e70f8e20"
      unitRef="U002">7417000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_b4e62d9b9ea14880a126e4084f909e54"
      unitRef="U002">13896000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_ff4932e349c940f394f0500792237bbd"
      unitRef="U002">8895000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_0e211900ebf74e39b892881f3117d98d"
      unitRef="U002">0</us-gaap:IncomeTaxesPaid>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_7971b43883b84cb49d1fa65c47e3ff4d"
      unitRef="U002">452000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_4a424ba1b1c44cddaf876f738905afc1"
      unitRef="U002">270000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20240101to20240930"
      decimals="-3"
      id="Fact_a5fb776b426343c79a2e42ce948cb904"
      unitRef="U002">0</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20230101to20230930"
      decimals="-3"
      id="Fact_14ce0e16f31c49deb39e6b29b3f06eb3"
      unitRef="U002">5595000</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20240701to20240930"
      id="Fact_b4ac8cf75b3c4d1486cfd90b3cb4bfdf">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20240701to20240930"
      id="Fact_7cc9109802584c5dae888d86dcd3271d">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20240701to20240930"
      id="Fact_e8a165cb2ac6498394472c5f6fb9b236">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20240701to20240930"
      id="Fact_18f058bcc71d40719e42b6868cb36882">false</ecd:NonRule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
